Modul 4 B – Anhang 4-G

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Belantamab-Mafodotin (BLENREP)

GlaxoSmithKline GmbH & Co. KG

Modul 4 B – Anhang 4-G

Ergänzende Analysen

Stand: 20.03.2026

1 Ergebnisse Interimsanalyse 3 – Lenalidomid- und Anti-CD38-refraktäre Patienten

1.1 Charakterisierung der Studienteilpopulation

1.1.1 Tabellen – Ergebnisse zur Charakterisierung der Studienteilpopulation

1.2 Endpunkte zur Wirksamkeit

1.2.1 Tabellen – Ergebnisse für Endpunkte zur Wirksamkeit

1.2.1.1 PFS

1.2.1.2 OS

1.2.1.3 DoR

1.2.1.4 PFS2

1.2.1.5 Ansprechraten

1.2.1.6 MRD-Negativität

1.2.1.7 Beobachtungsdauern

1.2.2 Graphische Darstellungen – Ergebnisse für Endpunkte zur Wirksamkeit

1.2.2.1 PFS

1.2.2.2 OS

1.2.2.3 DoR

1.2.2.4 PFS2

1.3 Patient Reported Outcomes

1.3.1 Tabellen – Ergebnisse für Patient Reported Outcomes

1.3.1.1 OSDI

1.3.1.2 EORTC QLQ-C30

1.3.1.3 EORTC-IL52

1.3.1.4 EQ-5D VAS

1.3.1.5 FACT-GP5

1.3.1.6 PGIC

1.3.1.7 PGIS

1.3.1.8 PRO-CTCAE

1.3.1.9 Beobachtungsdauern

1.3.1.10 Rücklaufquoten

1.3.2 Graphische Darstellungen – Ergebnisse für Patient Reported Outcomes

1.3.2.1 OSDI

1.3.2.2 EORTC QLQ-C30

1.3.2.3 EORTC-IL52

1.3.2.4 EQ-5D VAS

1.3.2.5 FACT-GP5

1.3.2.6 PGIC

1.3.2.7 PGIS

1.3.2.8 PRO-CTCAE

1.4 Endpunkte zur Sicherheit

1.4.1 Tabellen – Ergebnisse für Endpunkte zur Sicherheit

1.4.1.1 UE jeglichen Schweregrades – Gesamtraten

1.4.1.2 UE jeglichen Schweregrades nach SOC und PT

1.4.1.3 Schwere UE (CTCAE-Grad ≥ 3) – Gesamtraten

1.4.1.4 Schwere UE (CTCAE-Grad ≥ 3) nach SOC und PT

1.4.1.5 SUE – Gesamtraten

1.4.1.6 SUE nach SOC und PT

1.4.1.7 UE, die zum Therapieabbruch führen – Gesamtraten

1.4.1.8 UE, die zum Therapieabbruch führen, nach SOC und PT

1.4.1.9 Beobachtungsdauer

1.4.1.10 Behandlungsdauer

1.4.1.11 Dosisanpassungen

1.4.2 Graphische Darstellungen – Ergebnisse für Endpunkte zur Sicherheit

1.4.2.1 UE jeglichen Schweregrades – Gesamtraten

1.4.2.2 UE jeglichen Schweregrades nach SOC und PT

1.4.2.3 Schwere UE (CTCAE-Grad ≥3) – Gesamtraten

1.4.2.4 Schwere UE (CTCAE-Grad ≥3) nach SOC und PT

1.4.2.5 SUE – Gesamtraten

1.4.2.6 SUE nach SOC und PT

1.4.2.7 UE, die zum Therapieabbruch führen – Gesamtraten

1 Ergebnisse Interimsanalyse 3 – Lenalidomid- und Anti-CD38-refraktäre Patienten

1.1 Charakterisierung der Studienteilpopulation

1.1.1 Tabellen – Ergebnisse zur Charakterisierung der Studienteilpopulation

Protocol: 207499 Page 1 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0000705
Summary of Demographic Characteristics -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Sex			
n	30	33	63
Female	13 (43%)	16 (48%)	29 (46%)
Male	17 (57%)	17 (52%)	34 (54%)
Age (years) [1]			
n	30	33	63
Mean	66.5	69.4	68.0
SD	8.32	9.94	9.25
Median	68.5	69.0	69.0
Min.	45	42	42
Max.	79	83	83
Age Group (years) [1]			
<=18	0	0	0
19-64	11 (37%)	7 (21%)	18 (29%)
>=65	19 (63%)	26 (79%)	45 (71%)
65-<75	15 (50%)	15 (45%)	30 (48%)
>=75	4 (13%)	11 (33%)	15 (24%)
Ethnicity			
n	30	32	62
HISPANIC OR LATINO	4 (13%)	3 (9%)	7 (11%)
NOT HISPANIC OR LATINO	26 (87%)	29 (91%)	55 (89%)

[1] Age is imputed when full date of birth is not provided.
North America: United States.
Europe: Czech Republic, France, Germany, Greece, Italy, Poland, Russian Federation, Spain, Turkey, United Kingdom.
North East Asia: China, Japan, Republic of Korea.
Rest of the World: Australia, Brazil, Israel, New Zealand.
/mnt/code/prod/tfls/t_sp_dm_2ref.sas 19AUG2025 08:26

Protocol: 207499 Page 2 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0000705
Summary of Demographic Characteristics -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
High Level Race			
n	30	32	62
AMERICAN INDIAN OR ALASKA NATIVE	0	0	0
ASIAN	5 (17%)	2 (6%)	7 (11%)
BLACK OR AFRICAN AMERICAN	0	0	0
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0	0	0
WHITE	25 (83%)	30 (94%)	55 (89%)
MIXED RACE	0	0	0
Race Detail			
n	30	32	62
AMERICAN INDIAN OR ALASKA NATIVE	0	0	0
ASIAN - CENTRAL/SOUTH ASIAN HERITAGE	1 (3%)	1 (3%)	2 (3%)
ASIAN - EAST ASIAN HERITAGE	2 (7%)	0	2 (3%)
ASIAN - JAPANESE HERITAGE	2 (7%)	1 (3%)	3 (5%)
ASIAN - SOUTH EAST ASIAN HERITAGE	0	0	0
BLACK OR AFRICAN AMERICAN	0	0	0
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0	0	0
WHITE - ARABIC/NORTH AFRICAN HERITAGE	2 (7%)	3 (9%)	5 (8%)
WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE	23 (77%)	27 (84%)	50 (81%)
MIXED ASIAN RACE	0	0	0
MIXED WHITE RACE	0	0	0
MIXED RACE	0	0	0

[1] Age is imputed when full date of birth is not provided.
North America: United States.
Europe: Czech Republic, France, Germany, Greece, Italy, Poland, Russian Federation, Spain, Turkey, United Kingdom.
North East Asia: China, Japan, Republic of Korea.
Rest of the World: Australia, Brazil, Israel, New Zealand.
/mnt/code/prod/tfls/t_sp_dm_2ref.sas 19AUG2025 08:26

Protocol: 207499 Page 3 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0000705
Summary of Demographic Characteristics -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Geographical Region			
n	30	33	63
North America	1 (3%)	0	1 (2%)
Europe	20 (67%)	24 (73%)	44 (70%)
North East Asia	3 (10%)	1 (3%)	4 (6%)
Rest of the World	6 (20%)	8 (24%)	14 (22%)
Height (cm)			
n	30	33	63
Mean	166.09	165.32	165.68
SD	9.735	9.757	9.675
Median	167.45	164.00	164.40
Min.	151.0	148.0	148.0
Max.	184.0	182.0	184.0
Weight (kg)			
n	30	33	63
Mean	75.40	72.93	74.11
SD	15.521	17.919	16.732
Median	76.75	73.00	75.00
Min.	46.0	45.0	45.0
Max.	108.0	118.0	118.0

[1] Age is imputed when full date of birth is not provided.
North America: United States.
Europe: Czech Republic, France, Germany, Greece, Italy, Poland, Russian Federation, Spain, Turkey, United Kingdom.
North East Asia: China, Japan, Republic of Korea.
Rest of the World: Australia, Brazil, Israel, New Zealand.
/mnt/code/prod/tfls/t_sp_dm_2ref.sas 19AUG2025 08:26

Protocol: 207499 Page 4 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0000705
Summary of Demographic Characteristics -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
BMI (kg/m2)			
n	30	33	63
Mean	27.319	26.598	26.941
SD	5.0909	6.0351	5.5725
Median	27.082	24.772	26.685
Min.	18.10	17.58	17.58
Max.	37.88	46.09	46.09

[1] Age is imputed when full date of birth is not provided.
North America: United States.
Europe: Czech Republic, France, Germany, Greece, Italy, Poland, Russian Federation, Spain, Turkey, United Kingdom.
North East Asia: China, Japan, Republic of Korea.
Rest of the World: Australia, Brazil, Israel, New Zealand.
/mnt/code/prod/tfls/t_sp_dm_2ref.sas 19AUG2025 08:26

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001105
Summary of Disease Characteristics at Initial Diagnosis -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Actual Time Since Initial Diagnosis at Randomization (Years)			
n	30	33	63
Min.	0.8	0.4	0.4
1st Quartile	2.77	2.80	2.77
Median	3.62	3.49	3.52
3rd Quartile	7.61	5.99	6.36
Max.	16.7	15.1	16.7
International Staging System (ISS) at Initial Diagnosis			
I	10 (33%)	12 (36%)	22 (35%)
II	9 (30%)	6 (18%)	15 (24%)
III	4 (13%)	9 (27%)	13 (21%)
Unknown	7 (23%)	6 (18%)	13 (21%)

/mnt/code/prod/tfls/t_sp_dc_init_2ref.sas 19AUG2025 08:27

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
International Staging System (ISS) at Screening			
n	30	33	63
I	18 (60%)	15 (45%)	33 (52%)
II	8 (27%)	10 (30%)	18 (29%)
III	4 (13%)	8 (24%)	12 (19%)
Type of Multiple Myeloma			
n	30	33	63
Nonsecretory	0	0	0
Secretory	30 (100%)	33 (100%)	63 (100%)
Myeloma Light Chain			
n	30	33	63
No	2 (7%)	0	2 (3%)
Yes: Kappa Light Chain	13 (43%)	22 (67%)	35 (56%)
Yes: Lambda Light Chain	15 (50%)	11 (33%)	26 (41%)

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Protocol: 207499 Page 2 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)		Total (N=63)	
Myeloma Immunoglobulin						
IgA	10	(33%)	6	(18%)	16	(25%)
IgD	0		1	(3%)	1	(2%)
IgE	0		0		0	
IgG	12	(40%)	23	(70%)	35	(56%)
IgM	1	(3%)	1	(3%)	2	(3%)
Not Present	7	(23%)	2	(6%)	9	(14%)
Missing	0		0		0	
Extramedullary Disease						
n	30		33		63	
No	24	(80%)	28	(85%)	52	(83%)
Yes	6	(20%)	5	(15%)	11	(17%)

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)		Total (N=63)	
Extramedullary Disease, Location [1]						
Abdominal Cavity	0		1	(3%)	1	(2%)
Back	0		1	(3%)	1	(2%)
Bone	3	(10%)	1	(3%)	4	(6%)
Chest Wall	0		1	(3%)	1	(2%)
Femoral Condyle	1	(3%)	0		1	(2%)
Head And Neck	0		1	(3%)	1	(2%)
Ileum	1	(3%)	0		1	(2%)
Intertrochanteric Region	0		1	(3%)	1	(2%)
Lymph Node	1	(3%)	0		1	(2%)
Scapula	1	(3%)	0		1	(2%)
Thoracic Cavity	1	(3%)	0		1	(2%)
Thoracic Spine	1	(3%)	0		1	(2%)
Lytic Bone Lesions						
n	30		33		63	
No	6	(20%)	8	(24%)	14	(22%)
Yes	24	(80%)	25	(76%)	49	(78%)

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Protocol: 207499 Page 4 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Lines of Therapy Completed at Screening			
1 Line	8 (27%)	6 (18%)	14 (22%)
2 Lines	4 (13%)	8 (24%)	12 (19%)
3 Lines	9 (30%)	6 (18%)	15 (24%)
4 Lines	5 (17%)	7 (21%)	12 (19%)
5 Lines	3 (10%)	4 (12%)	7 (11%)
6 Lines	1 (3%)	1 (3%)	2 (3%)
7 Lines	0	1 (3%)	1 (2%)
8 Lines	0	0	0
9 Lines	0	0	0
10 Lines	0	0	0
More Than 10 Lines	0	0	0
Lines of Therapy Completed at Screening			
n	30	33	63
Mean	2.8	3.1	2.9
SD	1.45	1.58	1.51
Median	3.0	3.0	3.0
Min.	1	1	1
Max.	6	7	7

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
High Risk Cytogenetic Profile by FISH [1]			
T(4;14)	4 (13%)	5 (15%)	9 (14%)
T(14;16)	1 (3%)	3 (9%)	4 (6%)
17p13del	6 (20%)	6 (18%)	12 (19%)
High Risk Cytogenetic Profile Categories			
High Risk [2]	9 (30%)	11 (33%)	20 (32%)
Double Hit Multiple Myeloma [3]	2 (7%)	2 (6%)	4 (6%)
Standard Risk [4]	14 (47%)	13 (39%)	27 (43%)
Missing or Not Evaluable	7 (23%)	9 (27%)	16 (25%)
Other Cytogenetic Abnormalities by FISH [1][5]			
Amp(1q)	4 (13%)	10 (30%)	14 (22%)
1pdel	3 (10%)	4 (12%)	7 (11%)
Other	1 (3%)	3 (9%)	4 (6%)

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Protocol: 207499 Page 6 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)		Total (N=63)	
Best Response to the Most Recent Prior Anti-MM Therapy						
Stringent Complete Response	1	(3%)	2	(6%)	3	(5%)
Complete Response	3	(10%)	3	(9%)	6	(10%)
Very Good Partial Response	9	(30%)	7	(21%)	16	(25%)
Partial Response	13	(43%)	11	(33%)	24	(38%)
Minimal Response	3	(10%)	3	(9%)	6	(10%)
Stable Disease	1	(3%)	3	(9%)	4	(6%)
Progressive Disease	0		2	(6%)	2	(3%)
Not Evaluable	0		2	(6%)	2	(3%)
Baseline Renal Impairment Status per eGFR (mL/min/1.73 m^2)						
Normal (>=90)	6	(20%)	4	(12%)	10	(16%)
Mild (>=60, <90)	16	(53%)	17	(52%)	33	(52%)
Moderate (>=30, <60)	8	(27%)	12	(36%)	20	(32%)
Severe (>=15, <30)	0		0		0	

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Baseline Renal Impairment Status per eGFR (mL/min/1.73 m^2)			
n	30	33	63
Mean	76.07	66.51	71.06
SD	26.009	19.316	23.069
Median	68.00	64.00	66.00
Min.	38.6	31.0	31.0
Max.	165.0	115.0	165.0
Time to Relapse after Initiation of Latest Treatment [6]			
<=12 months	8 (27%)	15 (45%)	23 (37%)
>12 months	22 (73%)	18 (55%)	40 (63%)

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Time to Relapse after Initiation of Latest Treatment (months) [6]			
n	30	33	63
Mean	19.31	16.81	18.00
SD	12.199	14.536	13.426
Median	15.77	12.98	14.59
Min.	2.6	2.7	2.6
Max.	43.6	74.9	74.9
Time to Relapse after Initiation of 1 Line Treatment [7]			
<=12 months	5 (17%)	6 (18%)	11 (17%)
>12 months	25 (83%)	27 (82%)	52 (83%)

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Table 1.0001205
Summary of Disease Characteristics at Screening -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Time to Relapse after Initiation of 1 Line Treatment (months) [7]			
n	30	33	63
Mean	28.26	26.31	27.24
SD	21.149	18.600	19.716
Median	24.54	23.49	23.49
Min.	2.0	3.4	2.0
Max.	89.0	104.0	104.0
Prior Stem Cell Transplant			
No	12 (40%)	21 (64%)	33 (52%)
Yes	18 (60%)	12 (36%)	30 (48%)

[1] Subjects may be included in more than one category. Only positive results are summarised.
[2] If the subject has at least one high risk abnormality: T(4;14), T(14;16) or 17p13del.
[3] If the subject has at least two high risk abnormalities: T(4;14), T(14;16) or 17p13del.
[4] If the subject has negative results for all high risk abnormalities: T(4;14), T(14;16) and 17p13del.
[5] Results may not be collected or reported for all subjects.
[6] Relapse is defined as time from the start date of the latest prior line of the therapy to the date of randomization. [7] Relapse is defined as time from the start date of the first prior line of the therapy to the date of randomization for subjects with 1 prior line or to the start date of the second prior line of the therapy for subjects with >1 prior line.
/mnt/code/prod/tfls/t_sp_dc_scrn_2ref.sas 19AUG2025 08:27

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001605
Summary of Prior Anti-Myeloma Therapy by Drug Class of Agents -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Drug Class Base Component	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Immunomodulator	30 (100%)	33 (100%)	63 (100%)
LENALIDOMIDE	30 (100%)	33 (100%)	63 (100%)
THALIDOMIDE	10 (33%)	11 (33%)	21 (33%)
POMALIDOMIDE	0	1 (3%)	1 (2%)
Monoclonal Antibody	30 (100%)	33 (100%)	63 (100%)
Anti-CD38 antibodies	30 (100%)	33 (100%)	63 (100%)
DARATUMUMAB	28 (93%)	31 (94%)	59 (94%)
ISATUXIMAB	2 (7%)	2 (6%)	4 (6%)
CD38 (CLUSTERS OF DIFFERENTIATION 38) INHIBITORS	0	1 (3%)	1 (2%)
Other monoclonal antibodies	1 (3%)	1 (3%)	2 (3%)
ELOTUZUMAB	0	1 (3%)	1 (2%)
MDX-1097	1 (3%)	0	1 (2%)
Steroids	30 (100%)	32 (97%)	62 (98%)
Proteasome Inhibitor	27 (90%)	30 (91%)	57 (90%)
BORTEZOMIB	26 (87%)	29 (88%)	55 (87%)
CARFILZOMIB	8 (27%)	15 (45%)	23 (37%)
IXAZOMIB	3 (10%)	3 (9%)	6 (10%)
Chemotherapy	23 (77%)	20 (61%)	43 (68%)
Other	2 (7%)	4 (12%)	6 (10%)
Small Molecular Kinase Inhibitor	1 (3%)	1 (3%)	2 (3%)
HDAC Inhibitor	0	1 (3%)	1 (2%)

Note: Multiple categories per subject possible, total may add to more than 100%.
/mnt/code/prod/tfls/t_sp_ctx_class_2ref.sas 19AUG2025 08:27

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0001905
Summary of Follow-Up Anti-Myeloma Therapy by Drug Class of Agents -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Drug Class Base Component	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Steroids	12 (40%)	18 (55%)
Proteasome Inhibitor	11 (37%)	14 (42%)
CARFILZOMIB	6 (20%)	12 (36%)
BORTEZOMIB	7 (23%)	3 (9%)
IXAZOMIB	0	2 (6%)
Chemotherapy	8 (27%)	9 (27%)
Monoclonal Antibody	5 (17%)	10 (30%)
Anti-CD38 antibodies	4 (13%)	9 (27%)
ISATUXIMAB	2 (7%)	7 (21%)
DARATUMUMAB	3 (10%)	2 (6%)
Other monoclonal antibodies	2 (7%)	1 (3%)
ELOTUZUMAB	2 (7%)	1 (3%)
Bi-Specific Antibody (BiTE)	6 (20%)	8 (24%)
Immunomodulator	2 (7%)	6 (18%)
POMALIDOMIDE	2 (7%)	3 (9%)
LENALIDOMIDE	0	4 (12%)
THALIDOMIDE	2 (7%)	1 (3%)
Other	5 (17%)	2 (6%)
Antibody Drug Conjugate	0	4 (12%)
Engineered T/NK Cell Therapy	1 (3%)	3 (9%)

Note: Multiple categories per subject possible, total may add to more than 100%.
/mnt/code/prod/tfls/t_sp_ctx_class_post_2ref.sas 19AUG2025 08:28

Table 1.0001905
Summary of Follow-Up Anti-Myeloma Therapy by Drug Class of Agents -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Drug Class Base Component	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Stem Cell Transplant	1 (3%)	3 (9%)

Note: Multiple categories per subject possible, total may add to more than 100%.
/mnt/code/prod/tfls/t_sp_ctx_class_post_2ref.sas 19AUG2025 08:28

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0002005
Summary of Follow-Up Anti-Myeloma Therapy
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)	Total (N=63)
Any Anti-Myeloma Therapy			
Yes	15 (50%)	21 (64%)	36 (57%)
No	15 (50%)	12 (36%)	27 (43%)
Type of Anti-Myeloma Therapy			
Steroids	12 (40%)	18 (55%)	30 (48%)
Proteasome Inhibitor	11 (37%)	14 (42%)	25 (40%)
Chemotherapy	8 (27%)	9 (27%)	17 (27%)
Monoclonal Antibody	5 (17%)	10 (30%)	15 (24%)
Bi-Specific Antibody (BiTE)	6 (20%)	8 (24%)	14 (22%)
Immunomodulator	2 (7%)	6 (18%)	8 (13%)
Other	5 (17%)	2 (6%)	7 (11%)
Antibody Drug Conjugate	0	4 (12%)	4 (6%)
Engineered T/NK Cell Therapy	1 (3%)	3 (9%)	4 (6%)
Stem Cell Transplant	1 (3%)	3 (9%)	4 (6%)
Time from Study Treatment Discontinuation to Start of Subsequent Anti-Myeloma Therapy (days)[1]			
n	15	21	36
Min.	2	2	2
1st Quartile	14.0	8.0	9.0
Median	35.0	16.0	23.5
3rd Quartile	160.0	35.0	47.5
Max.	399	310	399

[1] Time from Study Treatment Discontinuation to Start of Subsequent Systemic Anti-Myeloma Therapy (radiotherapy and surgeries are not considered as systemic anti-myeloma therapy). Only subjects with treatment discontinuation of all 3 components are included.
/mnt/code/prod/tfls/t_sp_ctx_post_2ref.sas 19AUG2025 08:28

1.2 Endpunkte zur Wirksamkeit

1.2.1 Tabellen – Ergebnisse für Endpunkte zur Wirksamkeit

1.2.1.1 PFS

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001005
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Number of Subjects				
Progressed or Died (event)	20	(67%)	23	(70%)
Censored, follow-up ended	6	(20%)	9	(27%)
No adequate baseline assessments	0		1	(3%)
No adequate post-baseline assessments: randomized, not dosed, withdrawn	1	(3%)	0	
No adequate post-baseline assessments before start of new anti-myeloma therapy	0		1	(3%)
No adequate post-baseline assessments: other	0		0	
With adequate post-baseline assessment and new anti-myeloma treatment started	2	(7%)	4	(12%)
Progression after extended loss-to-follow-up	1	(3%)	0	
Death after extended loss-to-follow-up	2	(7%)	3	(9%)
Post-baseline assessment but no progression (or death)	0		0	
Censored, follow-up ongoing	4	(13%)	1	(3%)
Event Summary				
Disease Progression	16	(53%)	19	(58%)
Death	4	(13%)	4	(12%)

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using the Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata with a covariate of treatment.
[3] P-Value from two-sided stratified Log-Rank test.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref.sas 30SEP2025 12:17

Table 2.0001005

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.5	2.9
95% CI	(0.5,6.5)	(1.4,4.7)
Median	11.1	6.5
95% CI	(3.7,24.0)	(3.8,12.5)
3rd Quartile	26.2	14.8
95% CI	(11.8,-)	(6.7,-)
Hazard Ratio [2]		
Estimate	0.82	
95% CI	(0.44,1.55)	
Stratified Log-Rank [3]		
P-Value	0.54765	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.62	0.55
95% CI	(0.41,0.78)	(0.35,0.71)
Time-to-Event Endpoint at 12 Months	0.41	0.35
95% CI	(0.22,0.60)	(0.18,0.53)
Time-to-Event Endpoint at 18 Months	0.33	0.22
95% CI	(0.16,0.51)	(0.08,0.40)
Time-to-Event Endpoint at 24 Months	0.28	0.22
95% CI	(0.12,0.47)	(0.08,0.40)

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using the Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata with a covariate of treatment.
[3] P-Value from two-sided stratified Log-Rank test.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref.sas 30SEP2025 12:17

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001015
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	11 (37%)	7 (21%)
Number of Subjects		
Progressed or Died (event)	10 (91%)	2 (29%)
Censored, follow-up ended	0	5 (71%)
No adequate baseline assessments	0	1 (14%)
No adequate post-baseline assessments: randomized, not dosed, withdrawn	0	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	1 (14%)
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	0	2 (29%)
Progression after extended loss-to-follow-up	0	0
Death after extended loss-to-follow-up	0	1 (14%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	1 (9%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Table 2.0001015

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	8 (73%)	2 (29%)
Death	2 (18%)	0
Estimates for Time Variable (Months) [1]		
1st Quartile	2.8	6.4
95% CI	(0.5,5.6)	(2.8,-)
Median	5.6	-
95% CI	(1.8,11.8)	(2.8,-)
3rd Quartile	11.8	-
95% CI	(3.7,-)	(2.8,-)
Hazard Ratio [2]		
Estimate	2.37	
95% CI	(0.49,11.50)	
Stratified Log-Rank [3]		
P-Value	0.27142	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Protocol: 207499 Page 3 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001015
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.45	0.80
95% CI	(0.17,0.71)	(0.20,0.97)
Time-to-Event Endpoint at 12 Months	0.18	0.53
95% CI	(0.03,0.44)	(0.07,0.86)
Time-to-Event Endpoint at 18 Months	0.18	0.53
95% CI	(0.03,0.44)	(0.07,0.86)
Time-to-Event Endpoint at 24 Months	0.18	0.53
95% CI	(0.03,0.44)	(0.07,0.86)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Table 2.0001015

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	15 (50%)	15 (45%)
Number of Subjects		
Progressed or Died (event)	8 (53%)	12 (80%)
Censored, follow-up ended	6 (40%)	2 (13%)
No adequate baseline assessments	0	0
No adequate post-baseline assessments: randomized, not dosed, withdrawn	1 (7%)	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	0
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	2 (13%)	2 (13%)
Progression after extended loss-to-follow-up	1 (7%)	0
Death after extended loss-to-follow-up	2 (13%)	0
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	1 (7%)	1 (7%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001015
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	7 (47%)	10 (67%)
Death	1 (7%)	2 (13%)
Estimates for Time Variable (Months) [1]		
1st Quartile	4.0	2.8
95% CI	(1.9,17.6)	(1.2,4.5)
Median	17.6	4.9
95% CI	(3.5,26.2)	(2.6,12.5)
3rd Quartile	26.2	12.5
95% CI	(16.7,-)	(4.5,-)
Hazard Ratio [2]		
Estimate	0.43	
95% CI	(0.15,1.26)	
Stratified Log-Rank [3]		
P-Value	0.11437	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Table 2.0001015

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.73	0.44
95% CI	(0.38,0.91)	(0.19,0.67)
Time-to-Event Endpoint at 12 Months	0.63	0.30
95% CI	(0.28,0.84)	(0.09,0.54)
Time-to-Event Endpoint at 18 Months	0.42	0.10
95% CI	(0.13,0.69)	(0.01,0.34)
Time-to-Event Endpoint at 24 Months	0.28	0.10
95% CI	(0.05,0.58)	(0.01,0.34)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001015
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	4 (13%)	11 (33%)
Number of Subjects		
Progressed or Died (event)	2 (50%)	9 (82%)
Censored, follow-up ended	0	2 (18%)
No adequate baseline assessments	0	0
No adequate post-baseline assessments: randomized, not dosed, withdrawn	0	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	0
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	0	0
Progression after extended loss-to-follow-up	0	0
Death after extended loss-to-follow-up	0	2 (18%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	2 (50%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001015
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	1 (25%)	7 (64%)
Death	1 (25%)	2 (18%)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.3	3.7
95% CI	(0.0,-)	(0.1,6.5)
Median	-	6.5
95% CI	(0.0,-)	(2.9,28.6)
3rd Quartile	-	12.7
95% CI	(0.0,-)	(4.7,-)
Hazard Ratio [2]		
Estimate	0.49	
95% CI	(0.09,2.63)	
Stratified Log-Rank [3]		
P-Value	0.39694	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001015
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.75	0.59
95% CI	(0.13,0.96)	(0.23,0.82)
Time-to-Event Endpoint at 12 Months	0.50	0.35
95% CI	(0.06,0.84)	(0.09,0.64)
Time-to-Event Endpoint at 18 Months	0.50	0.24
95% CI	(0.06,0.84)	(0.04,0.53)
Time-to-Event Endpoint at 24 Months	0.50	0.24
95% CI	(0.06,0.84)	(0.04,0.53)
Interaction Test [4]		
P-Value	0.14419	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_age.sas 30SEP2025 12:17

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001025
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	16 (48%)
Number of Subjects		
Progressed or Died (event)	8 (62%)	12 (75%)
Censored, follow-up ended	3 (23%)	3 (19%)
No adequate baseline assessments	0	1 (6%)
No adequate post-baseline assessments: randomized, not dosed, withdrawn	1 (8%)	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	0
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	0	1 (6%)
Progression after extended loss-to-follow-up	1 (8%)	0
Death after extended loss-to-follow-up	1 (8%)	1 (6%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	2 (15%)	1 (6%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_gen.sas 30SEP2025 12:17

Table 2.0001025

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	7 (54%)	10 (63%)
Death	1 (8%)	2 (13%)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.7	2.9
95% CI	(1.9,11.8)	(0.1,4.5)
Median	9.1	4.5
95% CI	(1.9,26.2)	(2.8,6.5)
3rd Quartile	26.2	6.5
95% CI	(6.5,-)	(4.5,-)
Hazard Ratio [2]		
Estimate	0.57	
95% CI	(0.20,1.60)	
Stratified Log-Rank [3]		
P-Value	0.27984	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_gen.sas 30SEP2025 12:17

Table 2.0001025

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.60	0.40
95% CI	(0.25,0.83)	(0.15,0.65)
Time-to-Event Endpoint at 12 Months	0.40	0.16
95% CI	(0.12,0.67)	(0.03,0.40)
Time-to-Event Endpoint at 18 Months	0.30	0.16
95% CI	(0.07,0.58)	(0.03,0.40)
Time-to-Event Endpoint at 24 Months	0.30	0.16
95% CI	(0.07,0.58)	(0.03,0.40)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_gen.sas 30SEP2025 12:17

Table 2.0001025

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	17 (57%)	17 (52%)
Number of Subjects		
Progressed or Died (event)	12 (71%)	11 (65%)
Censored, follow-up ended	3 (18%)	6 (35%)
No adequate baseline assessments	0	0
No adequate post-baseline assessments: randomized, not dosed, withdrawn	0	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	1 (6%)
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	2 (12%)	3 (18%)
Progression after extended loss-to-follow-up	0	0
Death after extended loss-to-follow-up	1 (6%)	2 (12%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	2 (12%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_gen.sas 30SEP2025 12:17

Table 2.0001025

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	9 (53%)	9 (53%)
Death	3 (18%)	2 (12%)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.5	3.8
95% CI	(0.0,11.1)	(1.2,9.7)
Median	11.1	12.5
95% CI	(2.8,39.0)	(3.8,28.6)
3rd Quartile	39.0	28.6
95% CI	(11.1,-)	(9.7,-)
Hazard Ratio [2]		
Estimate	1.00	
95% CI	(0.41,2.47)	
Stratified Log-Rank [3]		
P-Value	0.99252	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_gen.sas 30SEP2025 12:17

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001025

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.64	0.67
95% CI	(0.36,0.82)	(0.38,0.85)
Time-to-Event Endpoint at 12 Months	0.42	0.52
95% CI	(0.18,0.65)	(0.25,0.74)
Time-to-Event Endpoint at 18 Months	0.35	0.26
95% CI	(0.13,0.59)	(0.07,0.51)
Time-to-Event Endpoint at 24 Months	0.27	0.26
95% CI	(0.07,0.51)	(0.07,0.51)
Interaction Test [4]		
P-Value	0.63081	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_gen.sas 30SEP2025 12:17

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001035
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	20 (67%)	24 (73%)
Number of Subjects		
Progressed or Died (event)	12 (60%)	16 (67%)
Censored, follow-up ended	6 (30%)	7 (29%)
No adequate baseline assessments	0	1 (4%)
No adequate post-baseline assessments: randomized, not dosed, withdrawn	1 (5%)	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	0
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	2 (10%)	4 (17%)
Progression after extended loss-to-follow-up	1 (5%)	0
Death after extended loss-to-follow-up	2 (10%)	2 (8%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	2 (10%)	1 (4%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_reg.sas 30SEP2025 12:18

Protocol: 207499 Page 2 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001035
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	9 (45%)	13 (54%)
Death	3 (15%)	3 (13%)
Estimates for Time Variable (Months) [1]		
1st Quartile	2.9	2.8
95% CI	(0.0,5.6)	(0.1,4.5)
Median	10.6	4.7
95% CI	(2.8,26.2)	(2.8,12.5)
3rd Quartile	26.2	12.5
95% CI	(10.6,-)	(4.7,-)
Hazard Ratio [2]		
Estimate	0.84	
95% CI	(0.38,1.88)	
Stratified Log-Rank [3]		
P-Value	0.67764	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_reg.sas 30SEP2025 12:18

Protocol: 207499 Page 3 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001035

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.51	0.46
95% CI	(0.25,0.72)	(0.24,0.66)
Time-to-Event Endpoint at 12 Months	0.36	0.29
95% CI	(0.14,0.60)	(0.11,0.50)
Time-to-Event Endpoint at 18 Months	0.36	0.22
95% CI	(0.14,0.60)	(0.06,0.43)
Time-to-Event Endpoint at 24 Months	0.27	0.22
95% CI	(0.08,0.52)	(0.06,0.43)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_reg.sas 30SEP2025 12:18

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001035
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	10 (33%)	9 (27%)
Number of Subjects		
Progressed or Died (event)	8 (80%)	7 (78%)
Censored, follow-up ended	0	2 (22%)
No adequate baseline assessments	0	0
No adequate post-baseline assessments: randomized, not dosed, withdrawn	0	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	1 (11%)
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	0	0
Progression after extended loss-to-follow-up	0	0
Death after extended loss-to-follow-up	0	1 (11%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	2 (20%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_reg.sas 30SEP2025 12:18

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001035

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	7 (70%)	6 (67%)
Death	1 (10%)	1 (11%)
Estimates for Time Variable (Months) [1]		
1st Quartile	6.5	5.7
95% CI	(1.9,16.7)	(2.9,12.7)
Median	14.1	11.2
95% CI	(1.9,39.0)	(2.9,-)
3rd Quartile	39.0	21.7
95% CI	(11.5,-)	(6.5,-)
Hazard Ratio [2]		
Estimate	0.92	
95% CI	(0.30,2.78)	
Stratified Log-Rank [3]		
P-Value	0.87979	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_reg.sas 30SEP2025 12:18

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001035

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.80	0.75
95% CI	(0.41,0.95)	(0.31,0.93)
Time-to-Event Endpoint at 12 Months	0.50	0.50
95% CI	(0.18,0.75)	(0.15,0.77)
Time-to-Event Endpoint at 18 Months	0.30	0.25
95% CI	(0.07,0.58)	(0.04,0.56)
Time-to-Event Endpoint at 24 Months	0.30	0.25
95% CI	(0.07,0.58)	(0.04,0.56)
Interaction Test [4]		
P-Value	0.98104	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_reg.sas 30SEP2025 12:18

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001045
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	18 (60%)	15 (45%)
Number of Subjects		
Progressed or Died (event)	12 (67%)	11 (73%)
Censored, follow-up ended	3 (17%)	4 (27%)
No adequate baseline assessments	0	1 (7%)
No adequate post-baseline assessments: randomized, not dosed, withdrawn	0	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	0
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	1 (6%)	2 (13%)
Progression after extended loss-to-follow-up	0	0
Death after extended loss-to-follow-up	2 (11%)	1 (7%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	3 (17%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_iss.sas 30SEP2025 12:17

Table 2.0001045

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	10 (56%)	10 (67%)
Death	2 (11%)	1 (7%)
Estimates for Time Variable (Months) [1]		
1st Quartile	6.5	4.5
95% CI	(1.8,11.5)	(1.2,6.7)
Median	11.8	6.7
95% CI	(3.7,39.0)	(2.9,14.8)
3rd Quartile	39.0	14.8
95% CI	(11.5,-)	(6.7,-)
Hazard Ratio [2]		
Estimate	0.78	
95% CI	(0.32,1.92)	
Stratified Log-Rank [3]		
P-Value	0.59561	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_iss.sas 30SEP2025 12:17

Table 2.0001045

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.76	0.63
95% CI	(0.47,0.90)	(0.32,0.83)
Time-to-Event Endpoint at 12 Months	0.44	0.39
95% CI	(0.20,0.66)	(0.15,0.64)
Time-to-Event Endpoint at 18 Months	0.38	0.24
95% CI	(0.16,0.60)	(0.06,0.48)
Time-to-Event Endpoint at 24 Months	0.30	0.24
95% CI	(0.10,0.53)	(0.06,0.48)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_iss.sas 30SEP2025 12:17

Table 2.0001045

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	12 (40%)	18 (55%)
Number of Subjects		
Progressed or Died (event)	8 (67%)	12 (67%)
Censored, follow-up ended	3 (25%)	5 (28%)
No adequate baseline assessments	0	0
No adequate post-baseline assessments: randomized, not dosed, withdrawn	1 (8%)	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	1 (6%)
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	1 (8%)	2 (11%)
Progression after extended loss-to-follow-up	1 (8%)	0
Death after extended loss-to-follow-up	0	2 (11%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	1 (8%)	1 (6%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_iss.sas 30SEP2025 12:17

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001045
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	6 (50%)	9 (50%)
Death	2 (17%)	3 (17%)
Estimates for Time Variable (Months) [1]		
1st Quartile	2.8	2.9
95% CI	(0.0,5.6)	(0.1,4.9)
Median	5.6	4.9
95% CI	(0.5,26.2)	(2.8,12.7)
3rd Quartile	26.2	12.7
95% CI	(4.0,-)	(4.9,-)
Hazard Ratio [2]		
Estimate	0.94	
95% CI	(0.35,2.48)	
Stratified Log-Rank [3]		
P-Value	0.89552	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_iss.sas 30SEP2025 12:17

Table 2.0001045

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.38	0.48
95% CI	(0.10,0.67)	(0.21,0.70)
Time-to-Event Endpoint at 12 Months	0.38	0.32
95% CI	(0.10,0.67)	(0.10,0.56)
Time-to-Event Endpoint at 18 Months	0.25	0.21
95% CI	(0.04,0.56)	(0.04,0.47)
Time-to-Event Endpoint at 24 Months	0.25	0.21
95% CI	(0.04,0.56)	(0.04,0.47)
Interaction Test [4]		
P-Value	0.88616	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_iss.sas 30SEP2025 12:17

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	8 (27%)	6 (18%)
Number of Subjects		
Progressed or Died (event)	5 (63%)	5 (83%)
Censored, follow-up ended	1 (13%)	1 (17%)
No adequate baseline assessments	0	0
No adequate post-baseline assessments: randomized, not dosed, withdrawn	1 (13%)	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	0
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	0	0
Progression after extended loss-to-follow-up	0	0
Death after extended loss-to-follow-up	0	1 (17%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	2 (25%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	5 (63%)	5 (83%)
Death	0	0
Estimates for Time Variable (Months) [1]		
1st Quartile	4.0	6.7
95% CI	(3.7,11.8)	(6.5,12.5)
Median	11.8	8.4
95% CI	(3.7,-)	(6.5,-)
3rd Quartile	-	12.5
95% CI	(11.1,-)	(6.5,-)
Hazard Ratio [2]		
Estimate	0.53	
95% CI	(0.14,2.03)	
Stratified Log-Rank [3]		
P-Value	0.35064	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Protocol: 207499 Page 3 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.71	1.00
95% CI	(0.26,0.92)	(1.00,1.00)
Time-to-Event Endpoint at 12 Months	0.43	0.40
95% CI	(0.10,0.73)	(0.05,0.75)
Time-to-Event Endpoint at 18 Months	0.43	0.00
95% CI	(0.10,0.73)	(-,-)
Time-to-Event Endpoint at 24 Months	0.43	0.00
95% CI	(0.10,0.73)	(-,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	14 (42%)
Number of Subjects		
Progressed or Died (event)	8 (62%)	10 (71%)
Censored, follow-up ended	3 (23%)	4 (29%)
No adequate baseline assessments	0	0
No adequate post-baseline assessments: randomized, not dosed, withdrawn	0	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	1 (7%)
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	0	2 (14%)
Progression after extended loss-to-follow-up	1 (8%)	0
Death after extended loss-to-follow-up	2 (15%)	1 (7%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	2 (15%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	7 (54%)	9 (64%)
Death	1 (8%)	1 (7%)
Estimates for Time Variable (Months) [1]		
1st Quartile	2.9	3.7
95% CI	(1.9,11.5)	(0.1,4.7)
Median	11.5	4.7
95% CI	(2.8,24.0)	(2.8,28.6)
3rd Quartile	24.0	28.6
95% CI	(10.6,-)	(3.8,-)
Hazard Ratio [2]		
Estimate	0.75	
95% CI	(0.28,1.96)	
Stratified Log-Rank [3]		
P-Value	0.55117	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Protocol: 207499 Page 6 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.62	0.38
95% CI	(0.28,0.84)	(0.12,0.64)
Time-to-Event Endpoint at 12 Months	0.42	0.28
95% CI	(0.13,0.68)	(0.07,0.55)
Time-to-Event Endpoint at 18 Months	0.31	0.28
95% CI	(0.08,0.59)	(0.07,0.55)
Time-to-Event Endpoint at 24 Months	0.21	0.28
95% CI	(0.03,0.49)	(0.07,0.55)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
Progressed or Died (event)	7 (78%)	8 (62%)
Censored, follow-up ended	2 (22%)	4 (31%)
No adequate baseline assessments	0	1 (8%)
No adequate post-baseline assessments: randomized, not dosed, withdrawn	0	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	0
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	2 (22%)	2 (15%)
Progression after extended loss-to-follow-up	0	0
Death after extended loss-to-follow-up	0	1 (8%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	0	1 (8%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	4 (44%)	5 (38%)
Death	3 (33%)	3 (23%)
Estimates for Time Variable (Months) [1]		
1st Quartile	1.8	2.7
95% CI	(0.0,6.5)	(1.2,4.5)
Median	6.5	4.5
95% CI	(0.0,-)	(1.4,-)
3rd Quartile	39.0	-
95% CI	(3.5,-)	(4.5,-)
Hazard Ratio [2]		
Estimate	1.18	
95% CI	(0.41,3.39)	
Stratified Log-Rank [3]		
P-Value	0.75528	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001055

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.56	0.49
95% CI	(0.20,0.80)	(0.19,0.73)
Time-to-Event Endpoint at 12 Months	0.42	0.39
95% CI	(0.11,0.71)	(0.13,0.65)
Time-to-Event Endpoint at 18 Months	0.28	0.26
95% CI	(0.04,0.59)	(0.05,0.55)
Time-to-Event Endpoint at 24 Months	0.28	0.26
95% CI	(0.04,0.59)	(0.05,0.55)
Interaction Test [4]		
P-Value	0.67495	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line.sas 30SEP2025 12:18

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001145

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	21 (70%)	20 (61%)
Number of Subjects		
Progressed or Died (event)	13 (62%)	15 (75%)
Censored, follow-up ended	4 (19%)	5 (25%)
No adequate baseline assessments	0	0
No adequate post-baseline assessments: randomized, not dosed, withdrawn	1 (5%)	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	1 (5%)
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	0	2 (10%)
Progression after extended loss-to-follow-up	1 (5%)	0
Death after extended loss-to-follow-up	2 (10%)	2 (10%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	4 (19%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line2.sas 30SEP2025 12:18

Table 2.0001145

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	12 (57%)	14 (70%)
Death	1 (5%)	1 (5%)
Estimates for Time Variable (Months) [1]		
1st Quartile	4.0	3.8
95% CI	(1.9,11.1)	(0.1,6.4)
Median	11.5	6.5
95% CI	(4.0,26.2)	(3.8,12.5)
3rd Quartile	26.2	14.8
95% CI	(11.5,-)	(6.5,-)
Hazard Ratio [2]		
Estimate	0.65	
95% CI	(0.31,1.39)	
Stratified Log-Rank [3]		
P-Value	0.26612	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line2.sas 30SEP2025 12:18

Protocol: 207499 Page 3 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001145

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.65	0.59
95% CI	(0.39,0.83)	(0.32,0.78)
Time-to-Event Endpoint at 12 Months	0.42	0.33
95% CI	(0.19,0.63)	(0.12,0.55)
Time-to-Event Endpoint at 18 Months	0.36	0.20
95% CI	(0.15,0.57)	(0.05,0.41)
Time-to-Event Endpoint at 24 Months	0.30	0.20
95% CI	(0.11,0.52)	(0.05,0.41)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line2.sas 30SEP2025 12:18

Table 2.0001145

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
Progressed or Died (event)	7 (78%)	8 (62%)
Censored, follow-up ended	2 (22%)	4 (31%)
No adequate baseline assessments	0	1 (8%)
No adequate post-baseline assessments: randomized, not dosed, withdrawn	0	0
No adequate post-baseline assessments before start of new anti-myeloma therapy	0	0
No adequate post-baseline assessments: other	0	0
With adequate post-baseline assessment and new anti-myeloma treatment started	2 (22%)	2 (15%)
Progression after extended loss-to-follow-up	0	0
Death after extended loss-to-follow-up	0	1 (8%)
Post-baseline assessment but no progression (or death)	0	0
Censored, follow-up ongoing	0	1 (8%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line2.sas 30SEP2025 12:18

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001145
Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Event Summary		
Disease Progression	4 (44%)	5 (38%)
Death	3 (33%)	3 (23%)
Estimates for Time Variable (Months) [1]		
1st Quartile	1.8	2.7
95% CI	(0.0,6.5)	(1.2,4.5)
Median	6.5	4.5
95% CI	(0.0,-)	(1.4,-)
3rd Quartile	39.0	-
95% CI	(3.5,-)	(4.5,-)
Hazard Ratio [2]		
Estimate	1.18	
95% CI	(0.41,3.39)	
Stratified Log-Rank [3]		
P-Value	0.75528	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line2.sas 30SEP2025 12:18

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0001145

Summary of Progression-Free Survival Based on Independent Reviewer - Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.56	0.49
95% CI	(0.20,0.80)	(0.19,0.73)
Time-to-Event Endpoint at 12 Months	0.42	0.39
95% CI	(0.11,0.71)	(0.13,0.65)
Time-to-Event Endpoint at 18 Months	0.28	0.26
95% CI	(0.04,0.59)	(0.05,0.55)
Time-to-Event Endpoint at 24 Months	0.28	0.26
95% CI	(0.04,0.59)	(0.05,0.55)
Interaction Test [4]		
P-Value	0.37350	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratio is estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs_irc_2ref_line2.sas 30SEP2025 12:18

1.2.1.2 OS

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006005
Summary of Overall Survival -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Died (event)	19 (63%)	21 (64%)
Censored, follow-up ended	2 (7%)	2 (6%)
Censored, follow-up ongoing	9 (30%)	10 (30%)
Event Summary		
Death	19 (63%)	21 (64%)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	6.4
95% CI	(1.8,16.3)	(2.6,12.7)
Median	18.4	15.9
95% CI	(10.2,-)	(8.6,-)
3rd Quartile	-	-
95% CI	(27.9,-)	(25.4,-)
Hazard Ratios [2]		
Estimate [4]	0.99	
95% CI	(0.53,1.87)	
Estimate [5]	1.07	
95% CI	(0.56,2.03)	

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes.
[3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes.
[4] Stratification factor: Number of lines of prior therapy (1 vs. 2/3 vs. >=4) and Prior bortezomib use (yes or no) assessed according to IVRS strata; Covariate: Treatment.
[5] Stratification factor: Number of lines of prior therapy (1 vs. 2/3 vs. >=4) and Prior bortezomib use (yes or no) assessed according to IVRS strata; Covariate: Treatment.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref.sas 30SEP2025 12:26

Table 2.0006005
Summary of Overall Survival -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Stratified Log-Rank [3]		
P-Value [4]	0.97829	
P-Value [5]	0.84200	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.86	0.79
95% CI	(0.68,0.95)	(0.61,0.89)
Time-to-Event Endpoint at 12 Months	0.66	0.63
95% CI	(0.45,0.80)	(0.44,0.77)
Time-to-Event Endpoint at 18 Months	0.52	0.47
95% CI	(0.33,0.68)	(0.30,0.63)
Time-to-Event Endpoint at 24 Months	0.45	0.44
95% CI	(0.27,0.62)	(0.27,0.60)

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes.
[3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes.
[4] Stratification factor: Number of lines of prior therapy (1 vs. 2/3 vs. >=4) and Prior bortezomib use (yes or no) assessed according to IVRS strata; Covariate: Treatment.
[5] Stratification factor: Number of lines of prior therapy (1 vs. 2/3 vs. >=4) and Prior bortezomib use (yes or no) assessed according to IVRS strata; Covariate: Treatment.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006015
Summary of Overall Survival by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	11 (37%)	7 (21%)
Number of Subjects		
Died (event)	8 (73%)	4 (57%)
Censored, follow-up ended	1 (9%)	1 (14%)
Censored, follow-up ongoing	2 (18%)	2 (29%)
Event Summary		
Death	8 (73%)	4 (57%)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.9	15.8
95% CI	(0.5,18.4)	(3.6,30.9)
Median	18.4	30.9
95% CI	(1.8,-)	(3.6,-)
3rd Quartile	29.9	-
95% CI	(16.4,-)	(15.8,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_age.sas 30SEP2025 12:26

Table 2.0006015
Summary of Overall Survival by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	1.71	
95% CI	(0.48,6.01)	
Estimate [5]	1.93	
95% CI	(0.54,6.84)	
Stratified Log-Rank [3]		
P-Value [4]	0.40089	
P-Value [5]	0.30337	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.82	0.86
95% CI	(0.45,0.95)	(0.33,0.98)
Time-to-Event Endpoint at 12 Months	0.64	0.86
95% CI	(0.30,0.85)	(0.33,0.98)
Time-to-Event Endpoint at 18 Months	0.55	0.69
95% CI	(0.23,0.78)	(0.21,0.91)
Time-to-Event Endpoint at 24 Months	0.36	0.69
95% CI	(0.11,0.63)	(0.21,0.91)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_age.sas 30SEP2025 12:26

Table 2.0006015
Summary of Overall Survival by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	15 (50%)	15 (45%)
Number of Subjects		
Died (event)	9 (60%)	10 (67%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	5 (33%)	5 (33%)
Event Summary		
Death	9 (60%)	10 (67%)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	6.4
95% CI	(3.0,17.6)	(1.2,9.7)
Median	22.7	12.9
95% CI	(9.3,-)	(3.3,-)
3rd Quartile	-	-
95% CI	(17.6,-)	(12.9,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_age.sas 30SEP2025 12:26

Table 2.0006015
Summary of Overall Survival by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	0.53	
95% CI	(0.19,1.54)	
Estimate [5]	0.53	
95% CI	(0.19,1.54)	
Stratified Log-Rank [3]		
P-Value [4]	0.24064	
P-Value [5]	0.24064	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.93	0.80
95% CI	(0.59,0.99)	(0.50,0.93)
Time-to-Event Endpoint at 12 Months	0.71	0.53
95% CI	(0.41,0.88)	(0.26,0.74)
Time-to-Event Endpoint at 18 Months	0.50	0.40
95% CI	(0.23,0.72)	(0.16,0.63)
Time-to-Event Endpoint at 24 Months	0.50	0.33
95% CI	(0.23,0.72)	(0.12,0.56)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_age.sas 30SEP2025 12:26

Protocol: 207499 Page 5 of 7
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006015
Summary of Overall Survival by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	4 (13%)	11 (33%)
Number of Subjects		
Died (event)	2 (50%)	7 (64%)
Censored, follow-up ended	0	1 (9%)
Censored, follow-up ongoing	2 (50%)	3 (27%)
Event Summary		
Death	2 (50%)	7 (64%)
Estimates for Time Variable (Months) [1]		
1st Quartile	5.3	4.9
95% CI	(0.0,-)	(0.1,15.9)
Median	-	15.9
95% CI	(0.0,-)	(4.3,-)
3rd Quartile	-	-
95% CI	(0.0,-)	(12.7,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_age.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006015
Summary of Overall Survival by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	0.77	
95% CI	(0.13,4.47)	
Estimate [5]	0.99	
95% CI	(0.18,5.42)	
Stratified Log-Rank [3]		
P-Value [4]	0.76692	
P-Value [5]	0.99343	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_age.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006015
Summary of Overall Survival by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.75	0.73
95% CI	(0.13,0.96)	(0.37,0.90)
Time-to-Event Endpoint at 12 Months	0.50	0.64
95% CI	(0.06,0.84)	(0.30,0.85)
Time-to-Event Endpoint at 18 Months	0.50	0.45
95% CI	(0.06,0.84)	(0.17,0.71)
Time-to-Event Endpoint at 24 Months	0.50	0.45
95% CI	(0.06,0.84)	(0.17,0.71)
Interaction Test [6]		
P-Value	0.53158	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_age.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006025
Summary of Overall Survival by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	16 (48%)
Number of Subjects		
Died (event)	8 (62%)	11 (69%)
Censored, follow-up ended	2 (15%)	1 (6%)
Censored, follow-up ongoing	3 (23%)	4 (25%)
Event Summary		
Death	8 (62%)	11 (69%)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.6	6.7
95% CI	(3.0,17.6)	(0.1,15.9)
Median	22.7	15.9
95% CI	(8.1,-)	(4.9,43.9)
3rd Quartile	-	43.9
95% CI	(17.6,-)	(15.9,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_gen.sas 30SEP2025 12:26

Table 2.0006025
Summary of Overall Survival by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	1.17	
95% CI	(0.42,3.28)	
Estimate [5]	1.17	
95% CI	(0.42,3.28)	
Stratified Log-Rank [3]		
P-Value [4]	0.76390	
P-Value [5]	0.76390	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.92	0.75
95% CI	(0.54,0.99)	(0.46,0.90)
Time-to-Event Endpoint at 12 Months	0.58	0.61
95% CI	(0.27,0.80)	(0.33,0.81)
Time-to-Event Endpoint at 18 Months	0.50	0.48
95% CI	(0.21,0.74)	(0.22,0.70)
Time-to-Event Endpoint at 24 Months	0.50	0.41
95% CI	(0.21,0.74)	(0.17,0.64)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI’s for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_gen.sas 30SEP2025 12:26

Protocol: 207499 Page 3 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006025
Summary of Overall Survival by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	17 (57%)	17 (52%)
Number of Subjects		
Died (event)	11 (65%)	10 (59%)
Censored, follow-up ended	0	1 (6%)
Censored, follow-up ongoing	6 (35%)	6 (35%)
Event Summary		
Death	11 (65%)	10 (59%)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	6.4
95% CI	(0.0,16.4)	(1.2,12.9)
Median	18.4	15.8
95% CI	(9.3,-)	(6.3,-)
3rd Quartile	-	-
95% CI	(18.4,-)	(15.8,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_gen.sas 30SEP2025 12:26

Protocol: 207499 Page 4 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006025
Summary of Overall Survival by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	0.90	
95% CI	(0.38,2.14)	
Estimate [5]	1.06	
95% CI	(0.44,2.52)	
Stratified Log-Rank [3]		
P-Value [4]	0.81117	
P-Value [5]	0.89647	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_gen.sas 30SEP2025 12:26

Protocol: 207499 Page 5 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006025
Summary of Overall Survival by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.82	0.82
95% CI	(0.55,0.94)	(0.55,0.94)
Time-to-Event Endpoint at 12 Months	0.71	0.65
95% CI	(0.43,0.87)	(0.38,0.82)
Time-to-Event Endpoint at 18 Months	0.53	0.47
95% CI	(0.28,0.73)	(0.23,0.68)
Time-to-Event Endpoint at 24 Months	0.41	0.47
95% CI	(0.19,0.63)	(0.23,0.68)
Interaction Test [6]		
P-Value	0.73780	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_gen.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006035
Summary of Overall Survival by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	20 (67%)	24 (73%)
Number of Subjects		
Died (event)	13 (65%)	16 (67%)
Censored, follow-up ended	2 (10%)	1 (4%)
Censored, follow-up ongoing	5 (25%)	7 (29%)
Event Summary		
Death	13 (65%)	16 (67%)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.1	5.6
95% CI	(0.0,10.2)	(0.1,9.7)
Median	12.2	13.3
95% CI	(8.1,-)	(6.3,25.4)
3rd Quartile	-	-
95% CI	(12.2,-)	(15.8,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_reg.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006035
Summary of Overall Survival by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	1.31	
95% CI	(0.60,2.88)	
Estimate [5]	1.31	
95% CI	(0.60,2.88)	
Stratified Log-Rank [3]		
P-Value [4]	0.49700	
P-Value [5]	0.49700	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.79	0.75
95% CI	(0.54,0.92)	(0.53,0.88)
Time-to-Event Endpoint at 12 Months	0.53	0.58
95% CI	(0.29,0.72)	(0.35,0.75)
Time-to-Event Endpoint at 18 Months	0.48	0.40
95% CI	(0.25,0.67)	(0.20,0.59)
Time-to-Event Endpoint at 24 Months	0.37	0.35
95% CI	(0.17,0.58)	(0.17,0.54)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_reg.sas 30SEP2025 12:26

Table 2.0006035
Summary of Overall Survival by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	10 (33%)	9 (27%)
Number of Subjects		
Died (event)	6 (60%)	5 (56%)
Censored, follow-up ended	0	1 (11%)
Censored, follow-up ongoing	4 (40%)	3 (33%)
Event Summary		
Death	6 (60%)	5 (56%)
Estimates for Time Variable (Months) [1]		
1st Quartile	16.4	12.7
95% CI	(10.6,32.1)	(3.6,43.9)
Median	30.0	43.9
95% CI	(10.6,-)	(3.6,-)
3rd Quartile	-	-
95% CI	(27.9,-)	(30.9,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_reg.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006035
Summary of Overall Survival by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	0.83	
95% CI	(0.25,2.79)	
Estimate [5]	1.00	
95% CI	(0.30,3.32)	
Stratified Log-Rank [3]		
P-Value [4]	0.76526	
P-Value [5]	0.99767	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_reg.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006035
Summary of Overall Survival by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	1.00	0.89
95% CI	(1.00,1.00)	(0.43,0.98)
Time-to-Event Endpoint at 12 Months	0.90	0.78
95% CI	(0.47,0.99)	(0.36,0.94)
Time-to-Event Endpoint at 18 Months	0.60	0.67
95% CI	(0.25,0.83)	(0.28,0.88)
Time-to-Event Endpoint at 24 Months	0.60	0.67
95% CI	(0.25,0.83)	(0.28,0.88)
Interaction Test [6]		
P-Value	0.48236	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI’s for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_reg.sas 30SEP2025 12:26

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006045
Summary of Overall Survival by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	18 (60%)	15 (45%)
Number of Subjects		
Died (event)	11 (61%)	8 (53%)
Censored, follow-up ended	1 (6%)	1 (7%)
Censored, follow-up ongoing	6 (33%)	6 (40%)
Event Summary		
Death	11 (61%)	8 (53%)
Estimates for Time Variable (Months) [1]		
1st Quartile	12.2	15.8
95% CI	(1.8,21.5)	(1.2,30.9)
Median	27.9	43.9
95% CI	(12.2,-)	(13.3,-)
3rd Quartile	-	-
95% CI	(29.9,-)	(30.9,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_iss.sas 30SEP2025 12:26

Protocol: 207499 Page 2 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006045
Summary of Overall Survival by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	1.32	
95% CI	(0.49,3.51)	
Estimate [5]	1.71	
95% CI	(0.65,4.55)	
Stratified Log-Rank [3]		
P-Value [4]	0.57996	
P-Value [5]	0.27357	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.89	0.93
95% CI	(0.62,0.97)	(0.61,0.99)
Time-to-Event Endpoint at 12 Months	0.78	0.93
95% CI	(0.51,0.91)	(0.61,0.99)
Time-to-Event Endpoint at 18 Months	0.61	0.65
95% CI	(0.35,0.79)	(0.35,0.84)
Time-to-Event Endpoint at 24 Months	0.56	0.65
95% CI	(0.31,0.75)	(0.35,0.84)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_iss.sas 30SEP2025 12:26

Table 2.0006045
Summary of Overall Survival by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	12 (40%)	18 (55%)
Number of Subjects		
Died (event)	8 (67%)	13 (72%)
Censored, follow-up ended	1 (8%)	1 (6%)
Censored, follow-up ongoing	3 (25%)	4 (22%)
Event Summary		
Death	8 (67%)	13 (72%)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.1	4.3
95% CI	(0.0,10.2)	(0.1,6.4)
Median	10.2	8.6
95% CI	(0.5,-)	(4.3,21.9)
3rd Quartile	-	-
95% CI	(9.3,-)	(8.6,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_iss.sas 30SEP2025 12:26

Protocol: 207499 Page 4 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006045
Summary of Overall Survival by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	0.76	
95% CI	(0.30,1.93)	
Estimate [5]	0.76	
95% CI	(0.30,1.93)	
Stratified Log-Rank [3]		
P-Value [4]	0.56750	
P-Value [5]	0.56750	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_iss.sas 30SEP2025 12:26

Protocol: 207499 Page 5 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006045
Summary of Overall Survival by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.83	0.67
95% CI	(0.46,0.95)	(0.40,0.83)
Time-to-Event Endpoint at 12 Months	0.46	0.39
95% CI	(0.17,0.71)	(0.17,0.60)
Time-to-Event Endpoint at 18 Months	0.37	0.33
95% CI	(0.11,0.63)	(0.14,0.55)
Time-to-Event Endpoint at 24 Months	0.28	0.28
95% CI	(0.07,0.54)	(0.10,0.49)
Interaction Test [6]		
P-Value	0.55194	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] CI's for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correctionas applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B & L assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B & L assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B & L with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use. L: Number of lines of prior therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_iss.sas 30SEP2025 12:26

Protocol: 207499 Page 1 of 7
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006055
Summary of Overall Survival by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	8 (27%)	6 (18%)
Number of Subjects		
Died (event)	3 (38%)	2 (33%)
Censored, follow-up ended	2 (25%)	0
Censored, follow-up ongoing	3 (38%)	4 (67%)
Event Summary		
Death	3 (38%)	2 (33%)
Estimates for Time Variable (Months) [1]		
1st Quartile	29.9	12.9
95% CI	(16.3,-)	(6.3,-)
Median	-	-
95% CI	(16.3,-)	(6.3,-)
3rd Quartile	-	-
95% CI	(29.9,-)	(12.9,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line.sas 30SEP2025 12:26

Table 2.0006055
Summary of Overall Survival by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	1.05	
95% CI	(0.17,6.37)	
Estimate [5]	1.05	
95% CI	(0.17,6.37)	
Stratified Log-Rank [3]		
P-Value [4]	0.95488	
P-Value [5]	0.95488	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	1.00	1.00
95% CI	(1.00,1.00)	(1.00,1.00)
Time-to-Event Endpoint at 12 Months	1.00	0.83
95% CI	(1.00,1.00)	(0.27,0.97)
Time-to-Event Endpoint at 18 Months	0.86	0.67
95% CI	(0.33,0.98)	(0.19,0.90)
Time-to-Event Endpoint at 24 Months	0.86	0.67
95% CI	(0.33,0.98)	(0.19,0.90)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line.sas 30SEP2025 12:26

Table 2.0006055
Summary of Overall Survival by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	14 (42%)
Number of Subjects		
Died (event)	10 (77%)	10 (71%)
Censored, follow-up ended	0	1 (7%)
Censored, follow-up ongoing	3 (23%)	3 (21%)
Event Summary		
Death	10 (77%)	10 (71%)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	4.9
95% CI	(3.0,17.6)	(0.1,9.7)
Median	17.6	12.8
95% CI	(8.9,27.9)	(4.3,-)
3rd Quartile	27.9	-
95% CI	(16.4,-)	(9.7,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line.sas 30SEP2025 12:26

Protocol: 207499 Page 4 of 7
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006055
Summary of Overall Survival by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	1.00	
95% CI	(0.40,2.48)	
Estimate [5]	1.00	
95% CI	(0.40,2.48)	
Stratified Log-Rank [3]		
P-Value [4]	0.99847	
P-Value [5]	0.99847	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.92	0.71
95% CI	(0.57,0.99)	(0.41,0.88)
Time-to-Event Endpoint at 12 Months	0.62	0.50
95% CI	(0.31,0.82)	(0.23,0.72)
Time-to-Event Endpoint at 18 Months	0.46	0.43
95% CI	(0.19,0.70)	(0.18,0.66)
Time-to-Event Endpoint at 24 Months	0.31	0.43
95% CI	(0.09,0.55)	(0.18,0.66)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line.sas 30SEP2025 12:26

Protocol: 207499 Page 5 of 7
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006055
Summary of Overall Survival by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
Died (event)	6 (67%)	9 (69%)
Censored, follow-up ended	0	1 (8%)
Censored, follow-up ongoing	3 (33%)	3 (23%)
Event Summary		
Death	6 (67%)	9 (69%)
Estimates for Time Variable (Months) [1]		
1st Quartile	1.8	8.6
95% CI	(0.0,10.6)	(1.2,13.3)
Median	10.6	15.8
95% CI	(0.0,-)	(3.3,-)
3rd Quartile	-	-
95% CI	(9.3,-)	(13.3,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line.sas 30SEP2025 12:26

Protocol: 207499 Page 6 of 7
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006055
Summary of Overall Survival by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	1.02	
95% CI	(0.36,2.89)	
Estimate [5]	1.17	
95% CI	(0.41,3.30)	
Stratified Log-Rank [3]		
P-Value [4]	0.96660	
P-Value [5]	0.76725	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line.sas 30SEP2025 12:26

Protocol: 207499 Page 7 of 7
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006055
Summary of Overall Survival by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.67	0.77
95% CI	(0.28,0.88)	(0.44,0.92)
Time-to-Event Endpoint at 12 Months	0.44	0.68
95% CI	(0.14,0.72)	(0.36,0.87)
Time-to-Event Endpoint at 18 Months	0.33	0.43
95% CI	(0.08,0.62)	(0.16,0.67)
Time-to-Event Endpoint at 24 Months	0.33	0.34
95% CI	(0.08,0.62)	(0.11,0.60)
Interaction Test [6]		
P-Value	0.98323	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line.sas 30SEP2025 12:26

Protocol: 207499 Page 1 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006075
Summary of Overall Survival by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	21 (70%)	20 (61%)
Number of Subjects		
Died (event)	13 (62%)	12 (60%)
Censored, follow-up ended	2 (10%)	1 (5%)
Censored, follow-up ongoing	6 (29%)	7 (35%)
Event Summary		
Death	13 (62%)	12 (60%)
Estimates for Time Variable (Months) [1]		
1st Quartile	13.3	6.4
95% CI	(3.0,18.4)	(0.1,12.9)
Median	24.7	20.7
95% CI	(10.2,-)	(6.3,-)
3rd Quartile	-	-
95% CI	(27.9,-)	(25.4,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line2.sas 30SEP2025 12:27

Protocol: 207499 Page 2 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006075
Summary of Overall Survival by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	0.92	
95% CI	(0.42,2.03)	
Estimate [5]	0.92	
95% CI	(0.42,2.03)	
Stratified Log-Rank [3]		
P-Value [4]	0.83414	
P-Value [5]	0.83414	
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.95	0.80
95% CI	(0.69,0.99)	(0.55,0.92)
Time-to-Event Endpoint at 12 Months	0.75	0.60
95% CI	(0.50,0.89)	(0.36,0.78)
Time-to-Event Endpoint at 18 Months	0.60	0.50
95% CI	(0.36,0.78)	(0.27,0.69)
Time-to-Event Endpoint at 24 Months	0.50	0.50
95% CI	(0.27,0.69)	(0.27,0.69)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line2.sas 30SEP2025 12:27

Table 2.0006075
Summary of Overall Survival by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
Died (event)	6 (67%)	9 (69%)
Censored, follow-up ended	0	1 (8%)
Censored, follow-up ongoing	3 (33%)	3 (23%)
Event Summary		
Death	6 (67%)	9 (69%)
Estimates for Time Variable (Months) [1]		
1st Quartile	1.8	8.6
95% CI	(0.0,10.6)	(1.2,13.3)
Median	10.6	15.8
95% CI	(0.0,-)	(3.3,-)
3rd Quartile	-	-
95% CI	(9.3,-)	(13.3,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line2.sas 30SEP2025 12:27

Protocol: 207499 Page 4 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006075
Summary of Overall Survival by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratios [2]		
Estimate [4]	1.02	
95% CI	(0.36,2.89)	
Estimate [5]	1.17	
95% CI	(0.41,3.30)	
Stratified Log-Rank [3]		
P-Value [4]	0.96660	
P-Value [5]	0.76725	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line2.sas 30SEP2025 12:27

Protocol: 207499 Page 5 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0006075
Summary of Overall Survival by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Survival Rate		
Time-to-Event Endpoint at 6 Months	0.67	0.77
95% CI	(0.28,0.88)	(0.44,0.92)
Time-to-Event Endpoint at 12 Months	0.44	0.68
95% CI	(0.14,0.72)	(0.36,0.87)
Time-to-Event Endpoint at 18 Months	0.33	0.43
95% CI	(0.08,0.62)	(0.16,0.67)
Time-to-Event Endpoint at 24 Months	0.33	0.34
95% CI	(0.08,0.62)	(0.11,0.60)
Interaction Test [6]		
P-Value	0.86432	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) according to the corresponding footnotes. [3] P-value from two-sided stratified Log-Rank test according to the corresponding footnotes. [4] Stratification factor: B assessed according to IVRS strata; Covariate: Treatment. [5] Stratification factor: B assessed according to eCRF strata; Covariate: Treatment. [6] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by B with treatment arm, subgroup and treatment by subgroup interaction included as independent variables. Note: B: Prior bortezomib use.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_os_2ref_line2.sas 30SEP2025 12:27

1.2.1.3 DoR

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009005
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
n	18	18
Progressed or Died (event)	12 (67%)	12 (67%)
Censored, follow-up ended	2 (11%)	5 (28%)
Censored, follow-up ongoing	4 (22%)	1 (6%)
Event Summary		
Disease Progression	11 (61%)	12 (67%)
Death	1 (6%)	0
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	3.2
95% CI	(1.2,10.8)	(1.9,5.6)
Median	15.6	6.8
95% CI	(3.7,38.0)	(2.8,31.5)
3rd Quartile	-	31.5
95% CI	(15.6,-)	(5.6,-)
Hazard Ratio [2]		
Estimate	0.80	
95% CI	(0.33,1.94)	

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata with a covariate of treatment.
[3] P-Value from two-sided stratified Log-Rank test.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref.sas 30SEP2025 12:28

Table 2.0009005
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Stratified Log-Rank [3]		
P-Value	0.62687	
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.77	0.50
95% CI	(0.50,0.91)	(0.25,0.71)
Time-to-Event Endpoint at 12 Months	0.53	0.44
95% CI	(0.28,0.73)	(0.20,0.66)
Time-to-Event Endpoint at 18 Months	0.41	0.36
95% CI	(0.19,0.63)	(0.14,0.59)
Time-to-Event Endpoint at 24 Months	0.41	0.36
95% CI	(0.19,0.63)	(0.14,0.59)

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata with a covariate of treatment.
[3] P-Value from two-sided stratified Log-Rank test.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref.sas 30SEP2025 12:28

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	11 (37%)	7 (21%)
Number of Subjects		
n	6	3
Progressed or Died (event)	5 (83%)	1 (33%)
Censored, follow-up ended	0	2 (67%)
Censored, follow-up ongoing	1 (17%)	0
Event Summary		
Disease Progression	5 (83%)	1 (33%)
Death	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	1.9
95% CI	(1.9,10.8)	(1.9,-)
Median	10.3	-
95% CI	(1.9,-)	(1.9,-)
3rd Quartile	38.0	-
95% CI	(8.8,-)	(1.9,-)
Hazard Ratio [2]		
Estimate	1.67	
95% CI	(0.17,16.68)	
Stratified Log-Rank [3]		
P-Value	0.65728	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.83	0.67
95% CI	(0.27,0.97)	(0.05,0.95)
Time-to-Event Endpoint at 12 Months	0.33	0.67
95% CI	(0.05,0.68)	(0.05,0.95)
Time-to-Event Endpoint at 18 Months	0.33	0.67
95% CI	(0.05,0.68)	(0.05,0.95)
Time-to-Event Endpoint at 24 Months	0.33	0.67
95% CI	(0.05,0.68)	(0.05,0.95)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	15 (50%)	15 (45%)
Number of Subjects		
n	9	8
Progressed or Died (event)	6 (67%)	5 (63%)
Censored, follow-up ended	2 (22%)	2 (25%)
Censored, follow-up ongoing	1 (11%)	1 (13%)
Event Summary		
Disease Progression	5 (56%)	5 (63%)
Death	1 (11%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	10.3	2.8
95% CI	(1.2,15.7)	(1.9,5.0)
Median	15.7	5.0
95% CI	(1.2,-)	(1.9,-)
3rd Quartile	25.1	13.8
95% CI	(10.3,-)	(3.6,-)
Hazard Ratio [2]		
Estimate	0.81	
95% CI	(0.20,3.33)	
Stratified Log-Rank [3]		
P-Value	0.77206	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Protocol: 207499 Page 6 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.76	0.43
95% CI	(0.33,0.94)	(0.10,0.73)
Time-to-Event Endpoint at 12 Months	0.63	0.43
95% CI	(0.24,0.87)	(0.10,0.73)
Time-to-Event Endpoint at 18 Months	0.38	0.21
95% CI	(0.09,0.68)	(0.01,0.59)
Time-to-Event Endpoint at 24 Months	0.38	0.21
95% CI	(0.09,0.68)	(0.01,0.59)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	4 (13%)	11 (33%)
Number of Subjects		
n	3	7
Progressed or Died (event)	1 (33%)	6 (86%)
Censored, follow-up ended	0	1 (14%)
Censored, follow-up ongoing	2 (67%)	0
Event Summary		
Disease Progression	1 (33%)	6 (86%)
Death	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.7	3.8
95% CI	(3.7,-)	(1.9,8.1)
Median	-	6.8
95% CI	(3.7,-)	(1.9,-)
3rd Quartile	-	25.9
95% CI	(3.7,-)	(3.8,-)
Hazard Ratio [2]		
Estimate	0.00	
95% CI	(0.00,)	
Stratified Log-Rank [3]		
P-Value	0.09691	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.67	0.50
95% CI	(0.05,0.95)	(0.11,0.80)
Time-to-Event Endpoint at 12 Months	0.67	0.33
95% CI	(0.05,0.95)	(0.05,0.68)
Time-to-Event Endpoint at 18 Months	0.67	0.33
95% CI	(0.05,0.95)	(0.05,0.68)
Time-to-Event Endpoint at 24 Months	0.67	0.33
95% CI	(0.05,0.95)	(0.05,0.68)
Interaction Test [4]		
P-Value	0.38170	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_age.sas 30SEP2025 12:27

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	16 (48%)
Number of Subjects		
n	7	8
Progressed or Died (event)	5 (71%)	6 (75%)
Censored, follow-up ended	0	1 (13%)
Censored, follow-up ongoing	2 (29%)	1 (13%)
Event Summary		
Disease Progression	4 (57%)	6 (75%)
Death	1 (14%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_gen.sas 30SEP2025 12:28

Protocol: 207499 Page 2 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.7	1.9
95% CI	(1.9,15.6)	(1.9,3.8)
Median	15.6	3.8
95% CI	(1.9,-)	(1.9,31.5)
3rd Quartile	-	31.5
95% CI	(10.8,-)	(3.6,-)
Hazard Ratio [2]		
Estimate	0.56	
95% CI	(0.13,2.38)	
Stratified Log-Rank [3]		
P-Value	0.43550	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_gen.sas 30SEP2025 12:28

Table 2.0009025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.71	0.29
95% CI	(0.26,0.92)	(0.04,0.61)
Time-to-Event Endpoint at 12 Months	0.57	0.29
95% CI	(0.17,0.84)	(0.04,0.61)
Time-to-Event Endpoint at 18 Months	0.43	0.29
95% CI	(0.10,0.73)	(0.04,0.61)
Time-to-Event Endpoint at 24 Months	0.43	0.29
95% CI	(0.10,0.73)	(0.04,0.61)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_gen.sas 30SEP2025 12:28

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	17 (57%)	17 (52%)
Number of Subjects		
n	11	10
Progressed or Died (event)	7 (64%)	6 (60%)
Censored, follow-up ended	2 (18%)	4 (40%)
Censored, follow-up ongoing	2 (18%)	0
Event Summary		
Disease Progression	7 (64%)	6 (60%)
Death	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_gen.sas 30SEP2025 12:28

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	5.0
95% CI	(1.2,15.7)	(1.9,13.8)
Median	15.7	13.8
95% CI	(2.6,-)	(1.9,-)
3rd Quartile	38.0	-
95% CI	(10.3,-)	(8.1,-)
Hazard Ratio [2]		
Estimate	1.25	
95% CI	(0.34,4.63)	
Stratified Log-Rank [3]		
P-Value	0.73687	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_gen.sas 30SEP2025 12:28

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.81	0.67
95% CI	(0.42,0.95)	(0.28,0.88)
Time-to-Event Endpoint at 12 Months	0.51	0.56
95% CI	(0.19,0.76)	(0.20,0.80)
Time-to-Event Endpoint at 18 Months	0.40	0.42
95% CI	(0.12,0.67)	(0.11,0.71)
Time-to-Event Endpoint at 24 Months	0.40	0.42
95% CI	(0.12,0.67)	(0.11,0.71)
Interaction Test [4]		
P-Value	0.60351	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_gen.sas 30SEP2025 12:28

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	20 (67%)	24 (73%)
Number of Subjects		
n	9	12
Progressed or Died (event)	5 (56%)	7 (58%)
Censored, follow-up ended	2 (22%)	4 (33%)
Censored, follow-up ongoing	2 (22%)	1 (8%)
Event Summary		
Disease Progression	5 (56%)	7 (58%)
Death	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_reg.sas 30SEP2025 12:28

Protocol: 207499 Page 2 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	1.9
95% CI	(1.9,25.1)	(1.9,5.0)
Median	25.1	4.4
95% CI	(1.9,-)	(1.9,-)
3rd Quartile	-	31.5
95% CI	(9.7,-)	(3.8,-)
Hazard Ratio [2]		
Estimate	0.52	
95% CI	(0.12,2.18)	
Stratified Log-Rank [3]		
P-Value	0.36748	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_reg.sas 30SEP2025 12:28

Table 2.0009035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.76	0.40
95% CI	(0.33,0.94)	(0.12,0.67)
Time-to-Event Endpoint at 12 Months	0.51	0.40
95% CI	(0.16,0.78)	(0.12,0.67)
Time-to-Event Endpoint at 18 Months	0.51	0.40
95% CI	(0.16,0.78)	(0.12,0.67)
Time-to-Event Endpoint at 24 Months	0.51	0.40
95% CI	(0.16,0.78)	(0.12,0.67)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_reg.sas 30SEP2025 12:28

Table 2.0009035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	10 (33%)	9 (27%)
Number of Subjects		
n	9	6
Progressed or Died (event)	7 (78%)	5 (83%)
Censored, follow-up ended	0	1 (17%)
Censored, follow-up ongoing	2 (22%)	0
Event Summary		
Disease Progression	6 (67%)	5 (83%)
Death	1 (11%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_reg.sas 30SEP2025 12:28

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	5.6
95% CI	(1.2,15.6)	(2.8,13.8)
Median	15.6	11.0
95% CI	(1.2,-)	(2.8,-)
3rd Quartile	38.0	25.9
95% CI	(10.3,-)	(5.6,-)
Hazard Ratio [2]		
Estimate	0.94	
95% CI	(0.26,3.43)	
Stratified Log-Rank [3]		
P-Value	0.92042	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_reg.sas 30SEP2025 12:28

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.78	0.67
95% CI	(0.36,0.94)	(0.19,0.90)
Time-to-Event Endpoint at 12 Months	0.56	0.50
95% CI	(0.20,0.80)	(0.11,0.80)
Time-to-Event Endpoint at 18 Months	0.33	0.33
95% CI	(0.08,0.62)	(0.05,0.68)
Time-to-Event Endpoint at 24 Months	0.33	0.33
95% CI	(0.08,0.62)	(0.05,0.68)
Interaction Test [4]		
P-Value	0.70041	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_reg.sas 30SEP2025 12:28

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	18 (60%)	15 (45%)
Number of Subjects		
n	13	9
Progressed or Died (event)	8 (62%)	7 (78%)
Censored, follow-up ended	2 (15%)	2 (22%)
Censored, follow-up ongoing	3 (23%)	0
Event Summary		
Disease Progression	7 (54%)	7 (78%)
Death	1 (8%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_iss.sas 30SEP2025 12:29

Table 2.0009045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.2	3.8
95% CI	(2.6,10.8)	(1.9,8.1)
Median	13.2	8.1
95% CI	(3.7,-)	(1.9,-)
3rd Quartile	-	31.5
95% CI	(10.8,-)	(5.0,-)
Hazard Ratio [2]		
Estimate	0.68	
95% CI	(0.20,2.28)	
Stratified Log-Rank [3]		
P-Value	0.52674	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_iss.sas 30SEP2025 12:29

Table 2.0009045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.83	0.56
95% CI	(0.48,0.96)	(0.20,0.80)
Time-to-Event Endpoint at 12 Months	0.50	0.44
95% CI	(0.21,0.74)	(0.14,0.72)
Time-to-Event Endpoint at 18 Months	0.42	0.33
95% CI	(0.15,0.67)	(0.08,0.62)
Time-to-Event Endpoint at 24 Months	0.42	0.33
95% CI	(0.15,0.67)	(0.08,0.62)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_iss.sas 30SEP2025 12:29

Table 2.0009045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	12 (40%)	18 (55%)
Number of Subjects		
n	5	9
Progressed or Died (event)	4 (80%)	5 (56%)
Censored, follow-up ended	0	3 (33%)
Censored, follow-up ongoing	1 (20%)	1 (11%)
Event Summary		
Disease Progression	4 (80%)	5 (56%)
Death	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_iss.sas 30SEP2025 12:29

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	1.9	1.9
95% CI	(1.2,25.1)	(1.9,5.6)
Median	15.7	5.6
95% CI	(1.2,-)	(1.9,-)
3rd Quartile	25.1	25.9
95% CI	(1.2,-)	(2.8,-)
Hazard Ratio [2]		
Estimate	1.22	
95% CI	(0.27,5.57)	
Stratified Log-Rank [3]		
P-Value	0.77374	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_iss.sas 30SEP2025 12:29

Table 2.0009045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.60	0.43
95% CI	(0.13,0.88)	(0.10,0.73)
Time-to-Event Endpoint at 12 Months	0.60	0.43
95% CI	(0.13,0.88)	(0.10,0.73)
Time-to-Event Endpoint at 18 Months	0.40	0.43
95% CI	(0.05,0.75)	(0.10,0.73)
Time-to-Event Endpoint at 24 Months	0.40	0.43
95% CI	(0.05,0.75)	(0.10,0.73)
Interaction Test [4]		
P-Value	0.86356	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_iss.sas 30SEP2025 12:29

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009055
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to any cause) - by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	8 (27%)	6 (18%)
Number of Subjects		
n	6	4
Progressed or Died (event)	4 (67%)	3 (75%)
Censored, follow-up ended	0	1 (25%)
Censored, follow-up ongoing	2 (33%)	0
Event Summary		
Disease Progression	4 (67%)	3 (75%)
Death	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Table 2.0009055

Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	10.3	5.0
95% CI	(1.2,25.1)	(5.0,-)
Median	18.0	5.6
95% CI	(1.2,-)	(5.0,-)
3rd Quartile	-	13.8
95% CI	(10.3,-)	(5.0,-)
Hazard Ratio [2]		
Estimate	0.46	
95% CI	(0.07,2.87)	
Stratified Log-Rank [3]		
P-Value	0.39466	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Protocol: 207499 Page 3 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009055
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to any cause) - by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.83	0.33
95% CI	(0.27,0.97)	(0.01,0.77)
Time-to-Event Endpoint at 12 Months	0.50	0.33
95% CI	(0.11,0.80)	(0.01,0.77)
Time-to-Event Endpoint at 18 Months	0.50	0.00
95% CI	(0.11,0.80)	(-,-)
Time-to-Event Endpoint at 24 Months	0.50	0.00
95% CI	(0.11,0.80)	(-,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Protocol: 207499 Page 4 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009055
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to any cause) - by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	14 (42%)
Number of Subjects		
n	7	7
Progressed or Died (event)	4 (57%)	6 (86%)
Censored, follow-up ended	1 (14%)	1 (14%)
Censored, follow-up ongoing	2 (29%)	0
Event Summary		
Disease Progression	3 (43%)	6 (86%)
Death	1 (14%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009055
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to any cause) - by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	1.9
95% CI	(1.9,15.6)	(1.9,3.8)
Median	15.6	3.8
95% CI	(1.9,-)	(1.9,-)
3rd Quartile	-	31.5
95% CI	(8.8,-)	(2.8,-)
Hazard Ratio [2]		
Estimate	0.64	
95% CI	(0.17,2.41)	
Stratified Log-Rank [3]		
P-Value	0.51516	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Protocol: 207499 Page 6 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009055
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to any cause) - by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.86	0.43
95% CI	(0.33,0.98)	(0.10,0.73)
Time-to-Event Endpoint at 12 Months	0.51	0.43
95% CI	(0.12,0.81)	(0.10,0.73)
Time-to-Event Endpoint at 18 Months	0.34	0.43
95% CI	(0.05,0.69)	(0.10,0.73)
Time-to-Event Endpoint at 24 Months	0.34	0.43
95% CI	(0.05,0.69)	(0.10,0.73)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009055
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to any cause) - by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
n	5	7
Progressed or Died (event)	4 (80%)	3 (43%)
Censored, follow-up ended	1 (20%)	3 (43%)
Censored, follow-up ongoing	0	1 (14%)
Event Summary		
Disease Progression	4 (80%)	3 (43%)
Death	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009055
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to any cause) - by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.7	3.6
95% CI	(2.6,-)	(1.9,-)
Median	15.7	-
95% CI	(2.6,-)	(1.9,-)
3rd Quartile	38.0	-
95% CI	(2.6,-)	(3.6,-)
Hazard Ratio [2]		
Estimate	1.72	
95% CI	(0.31,9.46)	
Stratified Log-Rank [3]		
P-Value	0.52541	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009055

Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.60	0.67
95% CI	(0.13,0.88)	(0.19,0.90)
Time-to-Event Endpoint at 12 Months	0.60	0.50
95% CI	(0.13,0.88)	(0.11,0.80)
Time-to-Event Endpoint at 18 Months	0.40	0.50
95% CI	(0.05,0.75)	(0.11,0.80)
Time-to-Event Endpoint at 24 Months	0.40	0.50
95% CI	(0.05,0.75)	(0.11,0.80)
Interaction Test [4]		
P-Value	0.55310	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line.sas 30SEP2025 12:29

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	21 (70%)	20 (61%)
Number of Subjects		
n	13	11
Progressed or Died (event)	8 (62%)	9 (82%)
Censored, follow-up ended	1 (8%)	2 (18%)
Censored, follow-up ongoing	4 (31%)	0
Event Summary		
Disease Progression	7 (54%)	9 (82%)
Death	1 (8%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line2.sas 30SEP2025 12:29

Protocol: 207499 Page 2 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	2.8
95% CI	(1.2,10.8)	(1.9,5.6)
Median	15.6	5.3
95% CI	(8.8,-)	(1.9,25.9)
3rd Quartile	-	25.9
95% CI	(10.8,-)	(5.0,-)
Hazard Ratio [2]		
Estimate	0.59	
95% CI	(0.22,1.56)	
Stratified Log-Rank [3]		
P-Value	0.28852	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line2.sas 30SEP2025 12:29

Protocol: 207499 Page 3 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.85	0.40
95% CI	(0.51,0.96)	(0.12,0.67)
Time-to-Event Endpoint at 12 Months	0.51	0.40
95% CI	(0.21,0.74)	(0.12,0.67)
Time-to-Event Endpoint at 18 Months	0.42	0.30
95% CI	(0.16,0.67)	(0.07,0.58)
Time-to-Event Endpoint at 24 Months	0.42	0.30
95% CI	(0.16,0.67)	(0.07,0.58)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line2.sas 30SEP2025 12:29

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
n	5	7
Progressed or Died (event)	4 (80%)	3 (43%)
Censored, follow-up ended	1 (20%)	3 (43%)
Censored, follow-up ongoing	0	1 (14%)
Event Summary		
Disease Progression	4 (80%)	3 (43%)
Death	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line2.sas 30SEP2025 12:29

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.7	3.6
95% CI	(2.6,-)	(1.9,-)
Median	15.7	-
95% CI	(2.6,-)	(1.9,-)
3rd Quartile	38.0	-
95% CI	(2.6,-)	(3.6,-)
Hazard Ratio [2]		
Estimate	1.72	
95% CI	(0.31,9.46)	
Stratified Log-Rank [3]		
P-Value	0.52541	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line2.sas 30SEP2025 12:29

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0009075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.60	0.67
95% CI	(0.13,0.88)	(0.19,0.90)
Time-to-Event Endpoint at 12 Months	0.60	0.50
95% CI	(0.13,0.88)	(0.11,0.80)
Time-to-Event Endpoint at 18 Months	0.40	0.50
95% CI	(0.05,0.75)	(0.11,0.80)
Time-to-Event Endpoint at 24 Months	0.40	0.50
95% CI	(0.05,0.75)	(0.11,0.80)
Interaction Test [4]		
P-Value	0.26142	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm,subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_any_2ref_line2.sas 30SEP2025 12:29

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010005
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
n	18	18
Progressed or Died due to PD (event)	11 (61%)	12 (67%)
Censored, follow-up ended	3 (17%)	5 (28%)
Censored, follow-up ongoing	4 (22%)	1 (6%)
Event Summary		
Disease Progression	11 (61%)	12 (67%)
Death due to PD	0	0
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	3.2
95% CI	(1.2,10.8)	(1.9,5.6)
Median	15.7	6.8
95% CI	(3.7,-)	(2.8,31.5)
3rd Quartile	-	31.5
95% CI	(15.7,-)	(5.6,-)
Hazard Ratio [2]		
Estimate	0.71	
95% CI	(0.28,1.76)	

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata with a covariate of treatment.
[3] P-Value from two-sided stratified Log-Rank test.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref.sas 30SEP2025 12:29

Table 2.0010005
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Stratified Log-Rank [3]		
P-Value	0.46107	
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.77	0.50
95% CI	(0.50,0.91)	(0.25,0.71)
Time-to-Event Endpoint at 12 Months	0.53	0.44
95% CI	(0.28,0.73)	(0.20,0.66)
Time-to-Event Endpoint at 18 Months	0.47	0.36
95% CI	(0.22,0.68)	(0.14,0.59)
Time-to-Event Endpoint at 24 Months	0.47	0.36
95% CI	(0.22,0.68)	(0.14,0.59)

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata with a covariate of treatment.
[3] P-Value from two-sided stratified Log-Rank test.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref.sas 30SEP2025 12:29

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	11 (37%)	7 (21%)
Number of Subjects		
n	6	3
Progressed or Died due to PD (event)	5 (83%)	1 (33%)
Censored, follow-up ended	0	2 (67%)
Censored, follow-up ongoing	1 (17%)	0
Event Summary		
Disease Progression	5 (83%)	1 (33%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Table 2.0010015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	1.9
95% CI	(1.9,10.8)	(1.9,-)
Median	10.3	-
95% CI	(1.9,-)	(1.9,-)
3rd Quartile	38.0	-
95% CI	(8.8,-)	(1.9,-)
Hazard Ratio [2]		
Estimate	1.67	
95% CI	(0.17,16.68)	
Stratified Log-Rank [3]		
P-Value	0.65728	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Protocol: 207499 Page 3 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.83	0.67
95% CI	(0.27,0.97)	(0.05,0.95)
Time-to-Event Endpoint at 12 Months	0.33	0.67
95% CI	(0.05,0.68)	(0.05,0.95)
Time-to-Event Endpoint at 18 Months	0.33	0.67
95% CI	(0.05,0.68)	(0.05,0.95)
Time-to-Event Endpoint at 24 Months	0.33	0.67
95% CI	(0.05,0.68)	(0.05,0.95)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Protocol: 207499 Page 4 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	15 (50%)	15 (45%)
Number of Subjects		
n	9	8
Progressed or Died due to PD (event)	5 (56%)	5 (63%)
Censored, follow-up ended	3 (33%)	2 (25%)
Censored, follow-up ongoing	1 (11%)	1 (13%)
Event Summary		
Disease Progression	5 (56%)	5 (63%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	10.3	2.8
95% CI	(1.2,25.1)	(1.9,5.0)
Median	15.7	5.0
95% CI	(1.2,-)	(1.9,-)
3rd Quartile	25.1	13.8
95% CI	(10.3,-)	(3.6,-)
Hazard Ratio [2]		
Estimate	0.81	
95% CI	(0.20,3.33)	
Stratified Log-Rank [3]		
P-Value	0.77206	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Protocol: 207499 Page 6 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.76	0.43
95% CI	(0.33,0.94)	(0.10,0.73)
Time-to-Event Endpoint at 12 Months	0.63	0.43
95% CI	(0.24,0.87)	(0.10,0.73)
Time-to-Event Endpoint at 18 Months	0.48	0.21
95% CI	(0.12,0.77)	(0.01,0.59)
Time-to-Event Endpoint at 24 Months	0.48	0.21
95% CI	(0.12,0.77)	(0.01,0.59)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	4 (13%)	11 (33%)
Number of Subjects		
n	3	7
Progressed or Died due to PD (event)	1 (33%)	6 (86%)
Censored, follow-up ended	0	1 (14%)
Censored, follow-up ongoing	2 (67%)	0
Event Summary		
Disease Progression	1 (33%)	6 (86%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010015
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.7	3.8
95% CI	(3.7,-)	(1.9,8.1)
Median	-	6.8
95% CI	(3.7,-)	(1.9,-)
3rd Quartile	-	25.9
95% CI	(3.7,-)	(3.8,-)
Hazard Ratio [2]		
Estimate	0.00	
95% CI	(0.00,)	
Stratified Log-Rank [3]		
P-Value	0.09691	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010015

Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.67	0.50
95% CI	(0.05,0.95)	(0.11,0.80)
Time-to-Event Endpoint at 12 Months	0.67	0.33
95% CI	(0.05,0.95)	(0.05,0.68)
Time-to-Event Endpoint at 18 Months	0.67	0.33
95% CI	(0.05,0.95)	(0.05,0.68)
Time-to-Event Endpoint at 24 Months	0.67	0.33
95% CI	(0.05,0.95)	(0.05,0.68)
Interaction Test [4]		
P-Value	0.37421	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_age.sas 30SEP2025 12:29

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	16 (48%)
Number of Subjects		
n	7	8
Progressed or Died due to PD (event)	4 (57%)	6 (75%)
Censored, follow-up ended	1 (14%)	1 (13%)
Censored, follow-up ongoing	2 (29%)	1 (13%)
Event Summary		
Disease Progression	4 (57%)	6 (75%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_gen.sas 30SEP2025 12:30

Protocol: 207499 Page 2 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.7	1.9
95% CI	(1.9,25.1)	(1.9,3.8)
Median	25.1	3.8
95% CI	(1.9,-)	(1.9,31.5)
3rd Quartile	-	31.5
95% CI	(10.8,-)	(3.6,-)
Hazard Ratio [2]		
Estimate	0.41	
95% CI	(0.08,2.11)	
Stratified Log-Rank [3]		
P-Value	0.26355	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_gen.sas 30SEP2025 12:30

Table 2.0010025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.71	0.29
95% CI	(0.26,0.92)	(0.04,0.61)
Time-to-Event Endpoint at 12 Months	0.57	0.29
95% CI	(0.17,0.84)	(0.04,0.61)
Time-to-Event Endpoint at 18 Months	0.57	0.29
95% CI	(0.17,0.84)	(0.04,0.61)
Time-to-Event Endpoint at 24 Months	0.57	0.29
95% CI	(0.17,0.84)	(0.04,0.61)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_gen.sas 30SEP2025 12:30

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	17 (57%)	17 (52%)
Number of Subjects		
n	11	10
Progressed or Died due to PD (event)	7 (64%)	6 (60%)
Censored, follow-up ended	2 (18%)	4 (40%)
Censored, follow-up ongoing	2 (18%)	0
Event Summary		
Disease Progression	7 (64%)	6 (60%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_gen.sas 30SEP2025 12:30

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	5.0
95% CI	(1.2,15.7)	(1.9,13.8)
Median	15.7	13.8
95% CI	(2.6,-)	(1.9,-)
3rd Quartile	38.0	-
95% CI	(10.3,-)	(8.1,-)
Hazard Ratio [2]		
Estimate	1.25	
95% CI	(0.34,4.63)	
Stratified Log-Rank [3]		
P-Value	0.73687	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_gen.sas 30SEP2025 12:30

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010025
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.81	0.67
95% CI	(0.42,0.95)	(0.28,0.88)
Time-to-Event Endpoint at 12 Months	0.51	0.56
95% CI	(0.19,0.76)	(0.20,0.80)
Time-to-Event Endpoint at 18 Months	0.40	0.42
95% CI	(0.12,0.67)	(0.11,0.71)
Time-to-Event Endpoint at 24 Months	0.40	0.42
95% CI	(0.12,0.67)	(0.11,0.71)
Interaction Test [4]		
P-Value	0.46520	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_gen.sas 30SEP2025 12:30

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	20 (67%)	24 (73%)
Number of Subjects		
n	9	12
Progressed or Died due to PD (event)	5 (56%)	7 (58%)
Censored, follow-up ended	2 (22%)	4 (33%)
Censored, follow-up ongoing	2 (22%)	1 (8%)
Event Summary		
Disease Progression	5 (56%)	7 (58%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_reg.sas 30SEP2025 12:30

Table 2.0010035

Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	1.9
95% CI	(1.9,25.1)	(1.9,5.0)
Median	25.1	4.4
95% CI	(1.9,-)	(1.9,-)
3rd Quartile	-	31.5
95% CI	(9.7,-)	(3.8,-)
Hazard Ratio [2]		
Estimate	0.52	
95% CI	(0.12,2.18)	
Stratified Log-Rank [3]		
P-Value	0.36748	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_reg.sas 30SEP2025 12:30

Protocol: 207499 Page 3 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.76	0.40
95% CI	(0.33,0.94)	(0.12,0.67)
Time-to-Event Endpoint at 12 Months	0.51	0.40
95% CI	(0.16,0.78)	(0.12,0.67)
Time-to-Event Endpoint at 18 Months	0.51	0.40
95% CI	(0.16,0.78)	(0.12,0.67)
Time-to-Event Endpoint at 24 Months	0.51	0.40
95% CI	(0.16,0.78)	(0.12,0.67)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_reg.sas 30SEP2025 12:30

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	10 (33%)	9 (27%)
Number of Subjects		
n	9	6
Progressed or Died due to PD (event)	6 (67%)	5 (83%)
Censored, follow-up ended	1 (11%)	1 (17%)
Censored, follow-up ongoing	2 (22%)	0
Event Summary		
Disease Progression	6 (67%)	5 (83%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_reg.sas 30SEP2025 12:30

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.8	5.6
95% CI	(1.2,15.7)	(2.8,13.8)
Median	15.7	11.0
95% CI	(1.2,-)	(2.8,-)
3rd Quartile	-	25.9
95% CI	(10.3,-)	(5.6,-)
Hazard Ratio [2]		
Estimate	0.79	
95% CI	(0.20,3.06)	
Stratified Log-Rank [3]		
P-Value	0.73456	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_reg.sas 30SEP2025 12:30

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010035
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.78	0.67
95% CI	(0.36,0.94)	(0.19,0.90)
Time-to-Event Endpoint at 12 Months	0.56	0.50
95% CI	(0.20,0.80)	(0.11,0.80)
Time-to-Event Endpoint at 18 Months	0.42	0.33
95% CI	(0.11,0.71)	(0.05,0.68)
Time-to-Event Endpoint at 24 Months	0.42	0.33
95% CI	(0.11,0.71)	(0.05,0.68)
Interaction Test [4]		
P-Value	0.81223	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_reg.sas 30SEP2025 12:30

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	18 (60%)	15 (45%)
Number of Subjects		
n	13	9
Progressed or Died due to PD (event)	7 (54%)	7 (78%)
Censored, follow-up ended	3 (23%)	2 (22%)
Censored, follow-up ongoing	3 (23%)	0
Event Summary		
Disease Progression	7 (54%)	7 (78%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_iss.sas 30SEP2025 12:30

Table 2.0010045

Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.2	3.8
95% CI	(2.6,10.8)	(1.9,8.1)
Median	24.4	8.1
95% CI	(3.7,-)	(1.9,-)
3rd Quartile	-	31.5
95% CI	(10.8,-)	(5.0,-)
Hazard Ratio [2]		
Estimate	0.53	
95% CI	(0.15,1.87)	
Stratified Log-Rank [3]		
P-Value	0.31453	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_iss.sas 30SEP2025 12:30

Protocol: 207499 Page 3 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.83	0.56
95% CI	(0.48,0.96)	(0.20,0.80)
Time-to-Event Endpoint at 12 Months	0.50	0.44
95% CI	(0.21,0.74)	(0.14,0.72)
Time-to-Event Endpoint at 18 Months	0.50	0.33
95% CI	(0.21,0.74)	(0.08,0.62)
Time-to-Event Endpoint at 24 Months	0.50	0.33
95% CI	(0.21,0.74)	(0.08,0.62)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_iss.sas 30SEP2025 12:30

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	12 (40%)	18 (55%)
Number of Subjects		
n	5	9
Progressed or Died due to PD (event)	4 (80%)	5 (56%)
Censored, follow-up ended	0	3 (33%)
Censored, follow-up ongoing	1 (20%)	1 (11%)
Event Summary		
Disease Progression	4 (80%)	5 (56%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_iss.sas 30SEP2025 12:30

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	1.9	1.9
95% CI	(1.2,25.1)	(1.9,5.6)
Median	15.7	5.6
95% CI	(1.2,-)	(1.9,-)
3rd Quartile	25.1	25.9
95% CI	(1.2,-)	(2.8,-)
Hazard Ratio [2]		
Estimate	1.22	
95% CI	(0.27,5.57)	
Stratified Log-Rank [3]		
P-Value	0.77374	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_iss.sas 30SEP2025 12:30

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010045
Summary of Duration of Response Based on Independent Reviewer - Assessed Response
(considering death due to disease progression) - by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.60	0.43
95% CI	(0.13,0.88)	(0.10,0.73)
Time-to-Event Endpoint at 12 Months	0.60	0.43
95% CI	(0.13,0.88)	(0.10,0.73)
Time-to-Event Endpoint at 18 Months	0.40	0.43
95% CI	(0.05,0.75)	(0.10,0.73)
Time-to-Event Endpoint at 24 Months	0.40	0.43
95% CI	(0.05,0.75)	(0.10,0.73)
Interaction Test [4]		
P-Value	0.72016	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use according to IVRS strata with a covariate of treatment.[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_iss.sas 30SEP2025 12:30

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010055

Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	8 (27%)	6 (18%)
Number of Subjects		
n	6	4
Progressed or Died due to PD (event)	4 (67%)	3 (75%)
Censored, follow-up ended	0	1 (25%)
Censored, follow-up ongoing	2 (33%)	0
Event Summary		
Disease Progression	4 (67%)	3 (75%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line.sas 30SEP2025 12:30

Table 2.0010055

Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	14 (42%)
Number of Subjects		
n	7	7
Progressed or Died due to PD (event)	3 (43%)	6 (86%)
Censored, follow-up ended	2 (29%)	1 (14%)
Censored, follow-up ongoing	2 (29%)	0
Event Summary		
Disease Progression	3 (43%)	6 (86%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line.sas 30SEP2025 12:30

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010055

Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
n	5	7
Progressed or Died due to PD (event)	4 (80%)	3 (43%)
Censored, follow-up ended	1 (20%)	3 (43%)
Censored, follow-up ongoing	0	1 (14%)
Event Summary		
Disease Progression	4 (80%)	3 (43%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line.sas 30SEP2025 12:30

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	21 (70%)	20 (61%)
Number of Subjects		
n	13	11
Progressed or Died due to PD (event)	7 (54%)	9 (82%)
Censored, follow-up ended	2 (15%)	2 (18%)
Censored, follow-up ongoing	4 (31%)	0
Event Summary		
Disease Progression	7 (54%)	9 (82%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line2.sas 30SEP2025 12:30

Table 2.0010075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	2.8
95% CI	(1.2,10.8)	(1.9,5.6)
Median	25.1	5.3
95% CI	(8.8,-)	(1.9,25.9)
3rd Quartile	-	25.9
95% CI	(10.8,-)	(5.0,-)
Hazard Ratio [2]		
Estimate	0.52	
95% CI	(0.19,1.42)	
Stratified Log-Rank [3]		
P-Value	0.19619	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line2.sas 30SEP2025 12:30

Protocol: 207499 Page 3 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.85	0.40
95% CI	(0.51,0.96)	(0.12,0.67)
Time-to-Event Endpoint at 12 Months	0.51	0.40
95% CI	(0.21,0.74)	(0.12,0.67)
Time-to-Event Endpoint at 18 Months	0.51	0.30
95% CI	(0.21,0.74)	(0.07,0.58)
Time-to-Event Endpoint at 24 Months	0.51	0.30
95% CI	(0.21,0.74)	(0.07,0.58)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line2.sas 30SEP2025 12:30

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
n	5	7
Progressed or Died due to PD (event)	4 (80%)	3 (43%)
Censored, follow-up ended	1 (20%)	3 (43%)
Censored, follow-up ongoing	0	1 (14%)
Event Summary		
Disease Progression	4 (80%)	3 (43%)
Death due to PD	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line2.sas 30SEP2025 12:30

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.7	3.6
95% CI	(2.6,-)	(1.9,-)
Median	15.7	-
95% CI	(2.6,-)	(1.9,-)
3rd Quartile	38.0	-
95% CI	(2.6,-)	(3.6,-)
Hazard Ratio [2]		
Estimate	1.72	
95% CI	(0.31,9.46)	
Stratified Log-Rank [3]		
P-Value	0.52541	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line2.sas 30SEP2025 12:30

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0010075
Summary of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Response Rate		
Time-to-Event Endpoint at 6 Months	0.60	0.67
95% CI	(0.13,0.88)	(0.19,0.90)
Time-to-Event Endpoint at 12 Months	0.60	0.50
95% CI	(0.13,0.88)	(0.11,0.80)
Time-to-Event Endpoint at 18 Months	0.40	0.50
95% CI	(0.05,0.75)	(0.11,0.80)
Time-to-Event Endpoint at 24 Months	0.40	0.50
95% CI	(0.05,0.75)	(0.11,0.80)
Interaction Test [4]		
P-Value	0.19742	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib use with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_dor_pd_2ref_line2.sas 30SEP2025 12:30

1.2.1.4 PFS2

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012005
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Progressed or Died (event)	21 (70%)	29 (88%)
Censored, follow-up ended	2 (7%)	2 (6%)
Censored, follow-up ongoing	7 (23%)	2 (6%)
Event Summary		
Disease Progression	10 (33%)	18 (55%)
Death	11 (37%)	11 (33%)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.1	5.4
95% CI	(1.8,10.6)	(2.6,7.1)
Median	17.5	10.4
95% CI	(8.6,22.2)	(6.3,12.9)
3rd Quartile	47.1	26.8
95% CI	(18.4,-)	(11.3,44.2)
Hazard Ratio [2]		
Estimate	0.68	
95% CI	(0.38,1.22)	

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
Note: Disease Progression includes all events due to PD2, end of first new line of anti-myeloma therapy (treated until PD) without PD2 and start of second new line of anti-myeloma therapy-1 day following end of first new line of anti-myeloma therapy (treated for a fixed number of doses) without PD2. Death includes deaths on or prior to the end of new line of anti-myeloma therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref.sas 30SEP2025 12:32

Table 2.0012005

Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Stratified Log-Rank [3]		
P-Value	0.18945	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.86	0.73
95% CI	(0.68,0.95)	(0.54,0.85)
Time-to-Event Endpoint at 12 Months	0.58	0.41
95% CI	(0.38,0.74)	(0.24,0.57)
Time-to-Event Endpoint at 18 Months	0.43	0.32
95% CI	(0.25,0.60)	(0.17,0.48)
Time-to-Event Endpoint at 24 Months	0.33	0.29
95% CI	(0.16,0.50)	(0.14,0.45)

[1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method.
[2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata with a covariate of treatment.
[3] P-value from two-sided stratified Log-Rank test.
Note: Disease Progression includes all events due to PD2, end of first new line of anti-myeloma therapy (treated until PD) without PD2 and start of second new line of anti-myeloma therapy-1 day following end of first new line of anti-myeloma therapy (treated for a fixed number of doses) without PD2. Death includes deaths on or prior to the end of new line of anti-myeloma therapy.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref.sas 30SEP2025 12:32

Protocol: 207499 Page 1 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012015
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	11 (37%)	7 (21%)
Number of Subjects		
Progressed or Died (event)	10 (91%)	6 (86%)
Censored, follow-up ended	0	1 (14%)
Censored, follow-up ongoing	1 (9%)	0
Event Summary		
Disease Progression	5 (45%)	5 (71%)
Death	5 (45%)	1 (14%)
Estimates for Time Variable (Months) [1]		
1st Quartile	6.7	11.3
95% CI	(0.5,16.5)	(2.6,26.8)
Median	16.5	26.8
95% CI	(1.8,22.2)	(2.6,-)
3rd Quartile	22.2	30.9
95% CI	(16.4,-)	(11.3,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_age.sas 30SEP2025 12:32

Table 2.0012015

Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	1.02	
95% CI	(0.34,3.09)	
Stratified Log-Rank [3]		
P-Value	0.96561	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.82	0.86
95% CI	(0.45,0.95)	(0.33,0.98)
Time-to-Event Endpoint at 12 Months	0.64	0.69
95% CI	(0.30,0.85)	(0.21,0.91)
Time-to-Event Endpoint at 18 Months	0.36	0.51
95% CI	(0.11,0.63)	(0.12,0.81)
Time-to-Event Endpoint at 24 Months	0.18	0.51
95% CI	(0.03,0.44)	(0.12,0.81)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_age.sas 30SEP2025 12:32

Protocol: 207499 Page 3 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012015
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	15 (50%)	15 (45%)
Number of Subjects		
Progressed or Died (event)	9 (60%)	13 (87%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	4 (27%)	2 (13%)
Event Summary		
Disease Progression	5 (33%)	8 (53%)
Death	4 (27%)	5 (33%)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.1	3.8
95% CI	(3.0,17.6)	(1.2,6.4)
Median	17.6	7.6
95% CI	(7.2,-)	(3.3,12.8)
3rd Quartile	-	23.4
95% CI	(17.6,-)	(7.6,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_age.sas 30SEP2025 12:32

Table 2.0012015

Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	0.40	
95% CI	(0.15,1.03)	
Stratified Log-Rank [3]		
P-Value	0.05168	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.93	0.67
95% CI	(0.59,0.99)	(0.38,0.85)
Time-to-Event Endpoint at 12 Months	0.55	0.33
95% CI	(0.26,0.77)	(0.12,0.56)
Time-to-Event Endpoint at 18 Months	0.47	0.27
95% CI	(0.20,0.70)	(0.08,0.50)
Time-to-Event Endpoint at 24 Months	0.39	0.20
95% CI	(0.15,0.64)	(0.05,0.42)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_age.sas 30SEP2025 12:32

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012015
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	4 (13%)	11 (33%)
Number of Subjects		
Progressed or Died (event)	2 (50%)	10 (91%)
Censored, follow-up ended	0	1 (9%)
Censored, follow-up ongoing	2 (50%)	0
Event Summary		
Disease Progression	0	5 (45%)
Death	2 (50%)	5 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile	5.3	4.9
95% CI	(0.0,-)	(0.1,10.4)
Median	-	10.4
95% CI	(0.0,-)	(4.3,26.0)
3rd Quartile	-	26.0
95% CI	(0.0,-)	(7.1,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_age.sas 30SEP2025 12:32

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012015
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	0.59	
95% CI	(0.11,3.26)	
Stratified Log-Rank [3]		
P-Value	0.54225	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.75	0.73
95% CI	(0.13,0.96)	(0.37,0.90)
Time-to-Event Endpoint at 12 Months	0.50	0.36
95% CI	(0.06,0.84)	(0.11,0.63)
Time-to-Event Endpoint at 18 Months	0.50	0.27
95% CI	(0.06,0.84)	(0.07,0.54)
Time-to-Event Endpoint at 24 Months	0.50	0.27
95% CI	(0.06,0.84)	(0.07,0.54)
Interaction Test [4]		
P-Value	0.42268	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_age.sas 30SEP2025 12:32

Protocol: 207499 Page 1 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012025
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	16 (48%)
Number of Subjects		
Progressed or Died (event)	8 (62%)	14 (88%)
Censored, follow-up ended	2 (15%)	1 (6%)
Censored, follow-up ongoing	3 (23%)	1 (6%)
Event Summary		
Disease Progression	3 (23%)	10 (63%)
Death	5 (38%)	4 (25%)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.1	4.6
95% CI	(3.0,16.5)	(0.1,7.1)
Median	16.5	7.1
95% CI	(6.7,-)	(4.3,12.9)
3rd Quartile	-	12.9
95% CI	(10.6,-)	(7.1,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_gen.sas 30SEP2025 12:32

Protocol: 207499 Page 2 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012025
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	0.67	
95% CI	(0.26,1.72)	
Stratified Log-Rank [3]		
P-Value	0.40826	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.92	0.63
95% CI	(0.54,0.99)	(0.35,0.81)
Time-to-Event Endpoint at 12 Months	0.56	0.28
95% CI	(0.24,0.79)	(0.09,0.51)
Time-to-Event Endpoint at 18 Months	0.37	0.21
95% CI	(0.11,0.63)	(0.05,0.44)
Time-to-Event Endpoint at 24 Months	0.28	0.14
95% CI	(0.07,0.55)	(0.02,0.36)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_gen.sas 30SEP2025 12:32

Table 2.0012025

Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	17 (57%)	17 (52%)
Number of Subjects		
Progressed or Died (event)	13 (76%)	15 (88%)
Censored, follow-up ended	0	1 (6%)
Censored, follow-up ongoing	4 (24%)	1 (6%)
Event Summary		
Disease Progression	7 (41%)	8 (47%)
Death	6 (35%)	7 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile	7.2	6.4
95% CI	(0.0,16.4)	(1.2,11.3)
Median	17.5	12.7
95% CI	(6.2,47.1)	(6.3,28.6)
3rd Quartile	47.1	28.6
95% CI	(17.5,-)	(12.7,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_gen.sas 30SEP2025 12:32

Protocol: 207499 Page 4 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012025

Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	0.70	
95% CI	(0.32,1.54)	
Stratified Log-Rank [3]		
P-Value	0.37047	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.82	0.82
95% CI	(0.55,0.94)	(0.55,0.94)
Time-to-Event Endpoint at 12 Months	0.59	0.53
95% CI	(0.33,0.78)	(0.28,0.73)
Time-to-Event Endpoint at 18 Months	0.47	0.41
95% CI	(0.23,0.68)	(0.19,0.63)
Time-to-Event Endpoint at 24 Months	0.35	0.41
95% CI	(0.14,0.57)	(0.19,0.63)
Interaction Test [4]		
P-Value	0.93649	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_gen.sas 30SEP2025 12:32

Protocol: 207499 Page 1 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012035
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	20 (67%)	24 (73%)
Number of Subjects		
Progressed or Died (event)	14 (70%)	22 (92%)
Censored, follow-up ended	1 (5%)	1 (4%)
Censored, follow-up ongoing	5 (25%)	1 (4%)
Event Summary		
Disease Progression	6 (30%)	14 (58%)
Death	8 (40%)	8 (33%)
Estimates for Time Variable (Months) [1]		
1st Quartile	6.7	4.6
95% CI	(0.0,9.7)	(0.1,6.3)
Median	10.2	8.8
95% CI	(6.7,22.2)	(4.9,12.9)
3rd Quartile	-	23.4
95% CI	(10.2,-)	(9.7,33.7)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_reg.sas 30SEP2025 12:33

Table 2.0012035

Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	0.80	
95% CI	(0.40,1.63)	
Stratified Log-Rank [3]		
P-Value	0.54296	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.79	0.67
95% CI	(0.54,0.92)	(0.44,0.82)
Time-to-Event Endpoint at 12 Months	0.48	0.36
95% CI	(0.25,0.67)	(0.17,0.55)
Time-to-Event Endpoint at 18 Months	0.37	0.27
95% CI	(0.17,0.58)	(0.11,0.46)
Time-to-Event Endpoint at 24 Months	0.26	0.22
95% CI	(0.10,0.47)	(0.08,0.41)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_reg.sas 30SEP2025 12:33

Table 2.0012035
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	10 (33%)	9 (27%)
Number of Subjects		
Progressed or Died (event)	7 (70%)	7 (78%)
Censored, follow-up ended	1 (10%)	1 (11%)
Censored, follow-up ongoing	2 (20%)	1 (11%)
Event Summary		
Disease Progression	4 (40%)	4 (44%)
Death	3 (30%)	3 (33%)
Estimates for Time Variable (Months) [1]		
1st Quartile	16.4	7.1
95% CI	(6.2,18.9)	(2.6,12.7)
Median	18.9	12.7
95% CI	(6.2,-)	(2.6,-)
3rd Quartile	47.1	30.9
95% CI	(17.6,-)	(11.3,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_reg.sas 30SEP2025 12:33

Protocol: 207499 Page 4 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012035
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	0.69	
95% CI	(0.22,2.20)	
Stratified Log-Rank [3]		
P-Value	0.53230	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	1.00	0.89
95% CI	(1.00,1.00)	(0.43,0.98)
Time-to-Event Endpoint at 12 Months	0.79	0.56
95% CI	(0.38,0.94)	(0.20,0.80)
Time-to-Event Endpoint at 18 Months	0.56	0.44
95% CI	(0.21,0.81)	(0.14,0.72)
Time-to-Event Endpoint at 24 Months	0.45	0.44
95% CI	(0.14,0.72)	(0.14,0.72)
Interaction Test [4]		
P-Value	0.96488	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_reg.sas 30SEP2025 12:33

Protocol: 207499 Page 1 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012045
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	18 (60%)	15 (45%)
Number of Subjects		
Progressed or Died (event)	12 (67%)	13 (87%)
Censored, follow-up ended	1 (6%)	1 (7%)
Censored, follow-up ongoing	5 (28%)	1 (7%)
Event Summary		
Disease Progression	6 (33%)	11 (73%)
Death	6 (33%)	2 (13%)
Estimates for Time Variable (Months) [1]		
1st Quartile	10.6	10.4
95% CI	(1.8,17.5)	(1.2,12.9)
Median	17.6	26.0
95% CI	(9.7,47.1)	(8.8,30.9)
3rd Quartile	47.1	30.9
95% CI	(17.6,-)	(12.9,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_iss.sas 30SEP2025 12:33

Protocol: 207499 Page 2 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012045
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	0.77	
95% CI	(0.32,1.85)	
Stratified Log-Rank [3]		
P-Value	0.56305	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.89	0.87
95% CI	(0.62,0.97)	(0.56,0.96)
Time-to-Event Endpoint at 12 Months	0.71	0.58
95% CI	(0.44,0.87)	(0.29,0.78)
Time-to-Event Endpoint at 18 Months	0.47	0.51
95% CI	(0.23,0.68)	(0.23,0.73)
Time-to-Event Endpoint at 24 Months	0.41	0.51
95% CI	(0.19,0.63)	(0.23,0.73)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_iss.sas 30SEP2025 12:33

Table 2.0012045

Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	12 (40%)	18 (55%)
Number of Subjects		
Progressed or Died (event)	9 (75%)	16 (89%)
Censored, follow-up ended	1 (8%)	1 (6%)
Censored, follow-up ongoing	2 (17%)	1 (6%)
Event Summary		
Disease Progression	4 (33%)	7 (39%)
Death	5 (42%)	9 (50%)
Estimates for Time Variable (Months) [1]		
1st Quartile	6.2	3.8
95% CI	(0.0,8.1)	(0.1,6.3)
Median	8.1	6.4
95% CI	(0.5,18.9)	(3.8,9.7)
3rd Quartile	18.9	12.7
95% CI	(7.2,-)	(6.4,-)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_iss.sas 30SEP2025 12:33

Protocol: 207499 Page 4 of 4
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012045
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Hazard Ratio [2]		
Estimate	0.78	
95% CI	(0.32,1.90)	
Stratified Log-Rank [3]		
P-Value	0.59181	
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.83	0.61
95% CI	(0.46,0.95)	(0.35,0.79)
Time-to-Event Endpoint at 12 Months	0.37	0.28
95% CI	(0.11,0.63)	(0.10,0.49)
Time-to-Event Endpoint at 18 Months	0.37	0.17
95% CI	(0.11,0.63)	(0.04,0.37)
Time-to-Event Endpoint at 24 Months	0.18	0.11
95% CI	(0.03,0.44)	(0.02,0.30)
Interaction Test [4]		
P-Value	0.90946	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by number of lines of prior therapy (1 vs. 2/3 vs.>=4) and prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_iss.sas 30SEP2025 12:33

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	8 (27%)	6 (18%)
Number of Subjects		
Progressed or Died (event)	4 (50%)	5 (83%)
Censored, follow-up ended	1 (13%)	0
Censored, follow-up ongoing	3 (38%)	1 (17%)
Event Summary		
Disease Progression	4 (50%)	4 (67%)
Death	0	1 (17%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	16.5	7.1
95% CI	(6.2,24.4)	(6.3,23.4)
Median	24.4	16.1
95% CI	(6.2,-)	(6.3,-)
3rd Quartile	-	28.6
95% CI	(22.2,-)	(7.1,-)
Hazard Ratio [2]		
Estimate	0.61	
95% CI	(0.16,2.32)	
Stratified Log-Rank [3]		
P-Value	0.46408	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Protocol: 207499 Page 3 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	1.00	1.00
95% CI	(1.00,1.00)	(1.00,1.00)
Time-to-Event Endpoint at 12 Months	0.86	0.50
95% CI	(0.33,0.98)	(0.11,0.80)
Time-to-Event Endpoint at 18 Months	0.71	0.50
95% CI	(0.26,0.92)	(0.11,0.80)
Time-to-Event Endpoint at 24 Months	0.57	0.33
95% CI	(0.17,0.84)	(0.05,0.68)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Protocol: 207499 Page 4 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	14 (42%)
Number of Subjects		
Progressed or Died (event)	9 (69%)	13 (93%)
Censored, follow-up ended	1 (8%)	1 (7%)
Censored, follow-up ongoing	3 (23%)	0
Event Summary		
Disease Progression	2 (15%)	8 (57%)
Death	7 (54%)	5 (36%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	4.9
95% CI	(3.0,16.4)	(0.1,9.7)
Median	17.5	10.1
95% CI	(8.1,-)	(4.3,26.8)
3rd Quartile	-	26.8
95% CI	(16.4,-)	(9.7,-)
Hazard Ratio [2]		
Estimate	0.61	
95% CI	(0.25,1.44)	
Stratified Log-Rank [3]		
P-Value	0.25217	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Protocol: 207499 Page 6 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.92	0.71
95% CI	(0.57,0.99)	(0.41,0.88)
Time-to-Event Endpoint at 12 Months	0.59	0.36
95% CI	(0.28,0.81)	(0.13,0.59)
Time-to-Event Endpoint at 18 Months	0.34	0.29
95% CI	(0.10,0.59)	(0.09,0.52)
Time-to-Event Endpoint at 24 Months	0.25	0.29
95% CI	(0.06,0.51)	(0.09,0.52)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
Progressed or Died (event)	8 (89%)	11 (85%)
Censored, follow-up ended	0	1 (8%)
Censored, follow-up ongoing	1 (11%)	1 (8%)
Event Summary		
Disease Progression	4 (44%)	6 (46%)
Death	4 (44%)	5 (38%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	1.8	3.8
95% CI	(0.0,8.6)	(1.2,11.3)
Median	8.6	11.3
95% CI	(0.0,47.1)	(3.3,26.0)
3rd Quartile	18.9	26.0
95% CI	(7.2,-)	(7.6,-)
Hazard Ratio [2]		
Estimate	0.90	
95% CI	(0.34,2.37)	
Stratified Log-Rank [3]		
P-Value	0.82642	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012055
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.67	0.62
95% CI	(0.28,0.88)	(0.31,0.82)
Time-to-Event Endpoint at 12 Months	0.33	0.44
95% CI	(0.08,0.62)	(0.17,0.68)
Time-to-Event Endpoint at 18 Months	0.33	0.26
95% CI	(0.08,0.62)	(0.07,0.52)
Time-to-Event Endpoint at 24 Months	0.22	0.26
95% CI	(0.03,0.51)	(0.07,0.52)
Interaction Test [4]		
P-Value	0.84376	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line.sas 30SEP2025 13:05

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012075
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	21 (70%)	20 (61%)
Number of Subjects		
Progressed or Died (event)	13 (62%)	18 (90%)
Censored, follow-up ended	2 (10%)	1 (5%)
Censored, follow-up ongoing	6 (29%)	1 (5%)
Event Summary		
Disease Progression	6 (29%)	12 (60%)
Death	7 (33%)	6 (30%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line2.sas 30SEP2025 13:10

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012075
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	9.7	6.3
95% CI	(3.0,17.5)	(0.1,8.8)
Median	17.6	10.1
95% CI	(9.7,-)	(6.3,26.8)
3rd Quartile	-	27.7
95% CI	(17.6,-)	(10.4,-)
Hazard Ratio [2]		
Estimate	0.58	
95% CI	(0.28,1.20)	
Stratified Log-Rank [3]		
P-Value	0.13906	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line2.sas 30SEP2025 13:10

Protocol: 207499 Page 3 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012075
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.95	0.80
95% CI	(0.69,0.99)	(0.55,0.92)
Time-to-Event Endpoint at 12 Months	0.69	0.40
95% CI	(0.44,0.85)	(0.19,0.60)
Time-to-Event Endpoint at 18 Months	0.48	0.35
95% CI	(0.25,0.68)	(0.16,0.55)
Time-to-Event Endpoint at 24 Months	0.37	0.30
95% CI	(0.17,0.58)	(0.12,0.50)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line2.sas 30SEP2025 13:10

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012075
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Number of Subjects		
Progressed or Died (event)	8 (89%)	11 (85%)
Censored, follow-up ended	0	1 (8%)
Censored, follow-up ongoing	1 (11%)	1 (8%)
Event Summary		
Disease Progression	4 (44%)	6 (46%)
Death	4 (44%)	5 (38%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line2.sas 30SEP2025 13:10

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012075
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Estimates for Time Variable (Months) [1]		
1st Quartile	1.8	3.8
95% CI	(0.0,8.6)	(1.2,11.3)
Median	8.6	11.3
95% CI	(0.0,47.1)	(3.3,26.0)
3rd Quartile	18.9	26.0
95% CI	(7.2,-)	(7.6,-)
Hazard Ratio [2]		
Estimate	0.90	
95% CI	(0.34,2.37)	
Stratified Log-Rank [3]		
P-Value	0.82642	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line2.sas 30SEP2025 13:10

Protocol: 207499 Page 6 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0012075
Summary of Progression-Free Survival 2 (PFS2) Based on Investigator-Assessed Response by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Progression-Free Survival Rate		
Time-to-Event Endpoint at 6 Months	0.67	0.62
95% CI	(0.28,0.88)	(0.31,0.82)
Time-to-Event Endpoint at 12 Months	0.33	0.44
95% CI	(0.08,0.62)	(0.17,0.68)
Time-to-Event Endpoint at 18 Months	0.33	0.26
95% CI	(0.08,0.62)	(0.07,0.52)
Time-to-Event Endpoint at 24 Months	0.22	0.26
95% CI	(0.03,0.51)	(0.07,0.52)
Interaction Test [4]		
P-Value	0.56938	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Confidence intervals for Time Variables estimated using the Brookmeyer Crowley method. [2] Hazard ratios are estimated using a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) according to IVRS strata; Covariate: Treatment.
[3] P-value from two-sided stratified Log-Rank test.
[4] Interaction test P-Value is from a Cox Proportional Hazards model (Firth correction as applicable) stratified by prior bortezomib (yes or no) with treatment arm, subgroup and treatment by subgroup interaction included as independent variables.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_tte1_pfs2_inv_2ref_line2.sas 30SEP2025 13:10

1.2.1.5 Ansprechraten

Protocol: 207499 Page 1 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013005
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Best Response		
Stringent Complete Response (sCR)	3 (10.0%)	0
Complete Response (CR)	2 (6.7%)	3 (9.1%)
Very Good Partial Response (VGPR)	7 (23.3%)	3 (9.1%)
Partial Response (PR)	6 (20.0%)	12 (36.4%)
Minimal Response (MR)	1 (3.3%)	3 (9.1%)
Stable Disease (SD)	6 (20.0%)	8 (24.2%)
Progressive Disease (PD)	1 (3.3%)	0
Not Evaluable (NE)	4 (13.3%)	4 (12.1%)

[1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor.
Note: Randomization factor is prior bortezomib (no, yes).
All p-values presented are of two-sided.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref.sas 30SEP2025 12:33

Table 2.0013005

Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Complete Response Rate (CRR)		
sCR+CR	5 (16.7%)	3 (9.1%)
Inverse Odds Ratio (OR) of CRR [1]		
Estimate	0.50	
95% CI	(0.11,2.30)	
p-value	0.37351	
Inverse Relative Risk (RR) of CRR [2]		
Estimate	0.55	
95% CI	(0.14,2.09)	
p-value	0.37647	
Absolute Risk Difference (ARD) of CRR [2]		
Estimate	0.08	
95% CI	(-0.09,0.24)	

[1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor.
Note: Randomization factor is prior bortezomib (no, yes).
All p-values presented are of two-sided.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref.sas 30SEP2025 12:33

Table 2.0013005

Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	18 (60.0%)	18 (54.5%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.80	
95% CI	(0.29,2.18)	
p-value	0.66234	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.91	
95% CI	(0.59,1.39)	
p-value	0.66180	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.05	
95% CI	(-0.19,0.30)	

[1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor.
Note: Randomization factor is prior bortezomib (no, yes).
All p-values presented are of two-sided.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref.sas 30SEP2025 12:33

Table 2.0013005

Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	12 (40.0%)	6 (18.2%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	0.33	
95% CI	(0.11,1.05)	
p-value	0.06052	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	0.45	
95% CI	(0.20,1.06)	
p-value	0.06779	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.22	
95% CI	(0.00,0.44)	

[1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor.
Note: Randomization factor is prior bortezomib (no, yes).
All p-values presented are of two-sided.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref.sas 30SEP2025 12:33

Protocol: 207499 Page 5 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013005
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	19 (63.3%)	21 (63.6%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	1.01	
95% CI	(0.36,2.83)	
p-value	0.98009	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.00	
95% CI	(0.69,1.46)	
p-value	0.98010	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.00	
95% CI	(-0.24,0.24)	

[1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor.
Note: Randomization factor is prior bortezomib (no, yes).
All p-values presented are of two-sided.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	11 (37%)	7 (21%)
Best Response		
Stringent Complete Response (sCR)	0	0
Complete Response (CR)	0	1 (14.3%)
Very Good Partial Response (VGPR)	3 (27.3%)	1 (14.3%)
Partial Response (PR)	3 (27.3%)	1 (14.3%)
Minimal Response (MR)	0	0
Stable Disease (SD)	4 (36.4%)	2 (28.6%)
Progressive Disease (PD)	0	0
Not Evaluable (NE)	1 (9.1%)	2 (28.6%)
Complete Response Rate (CRR)		
sCR+CR	0	1 (14.3%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	6 (54.5%)	3 (42.9%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.63	
95% CI	(0.09,4.22)	
p-value	0.62965	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.79	
95% CI	(0.29,2.16)	
p-value	0.64022	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.12	
95% CI	(-0.35,0.59)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+ sCR+CR+VGPR	3 (27.3%)	2 (28.6%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	6 (54.5%)	3 (42.9%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	0.63	
95% CI	(0.09,4.22)	
p-value	0.62965	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	0.79	
95% CI	(0.29,2.16)	
p-value	0.64022	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.12	
95% CI	(-0.35,0.59)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	15 (50%)	15 (45%)
Best Response		
Stringent Complete Response (sCR)	2 (13.3%)	0
Complete Response (CR)	2 (13.3%)	2 (13.3%)
Very Good Partial Response (VGPR)	3 (20.0%)	0
Partial Response (PR)	2 (13.3%)	6 (40.0%)
Minimal Response (MR)	1 (6.7%)	2 (13.3%)
Stable Disease (SD)	2 (13.3%)	4 (26.7%)
Progressive Disease (PD)	1 (6.7%)	0
Not Evaluable (NE)	2 (13.3%)	1 (6.7%)
Complete Response Rate (CRR)		
sCR+CR	4 (26.7%)	2 (13.3%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	9 (60.0%)	8 (53.3%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.76	
95% CI	(0.18,3.24)	
p-value	0.71277	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.89	
95% CI	(0.47,1.67)	
p-value	0.71332	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.07	
95% CI	(-0.29,0.42)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Protocol: 207499 Page 7 of 13
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+ sCR+CR+VGPR	7 (46.7%)	2 (13.3%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	10 (66.7%)	10 (66.7%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	1.00	
95% CI	(0.22,4.56)	
p-value	>0.99999	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.00	
95% CI	(0.60,1.66)	
p-value	>0.99999	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.00	
95% CI	(-0.34,0.34)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	4 (13%)	11 (33%)
Best Response		
Stringent Complete Response (sCR)	1 (25.0%)	0
Complete Response (CR)	0	0
Very Good Partial Response (VGPR)	1 (25.0%)	2 (18.2%)
Partial Response (PR)	1 (25.0%)	5 (45.5%)
Minimal Response (MR)	0	1 (9.1%)
Stable Disease (SD)	0	2 (18.2%)
Progressive Disease (PD)	0	0
Not Evaluable (NE)	1 (25.0%)	1 (9.1%)
Complete Response Rate (CRR)		
sCR+CR	1 (25.0%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	3 (75.0%)	7 (63.6%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.58	
95% CI	(0.04,7.66)	
p-value	0.68174	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.85	
95% CI	(0.41,1.74)	
p-value	0.65508	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.11	
95% CI	(-0.40,0.62)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+ sCR+CR+VGPR	2 (50.0%)	2 (18.2%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	3 (75.0%)	8 (72.7%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	0.89	
95% CI	(0.06,12.25)	
p-value	0.92988	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	0.97	
95% CI	(0.50,1.90)	
p-value	0.92845	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.02	
95% CI	(-0.48,0.52)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Table 2.0013015
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Interaction Test [3]		
ORR	0.97886	
CBR	0.91132	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_age.sas 30SEP2025 12:33

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	16 (48%)
Best Response		
Stringent Complete Response (sCR)	2 (15.4%)	0
Complete Response (CR)	0	1 (6.3%)
Very Good Partial Response (VGPR)	3 (23.1%)	1 (6.3%)
Partial Response (PR)	2 (15.4%)	6 (37.5%)
Minimal Response (MR)	0	1 (6.3%)
Stable Disease (SD)	3 (23.1%)	5 (31.3%)
Progressive Disease (PD)	1 (7.7%)	0
Not Evaluable (NE)	2 (15.4%)	2 (12.5%)
Complete Response Rate (CRR)		
sCR+CR	2 (15.4%)	1 (6.3%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	7 (53.8%)	8 (50.0%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.86	
95% CI	(0.20,3.71)	
p-value	0.83685	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.93	
95% CI	(0.46,1.87)	
p-value	0.83618	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.04	
95% CI	(-0.33,0.40)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Protocol: 207499 Page 3 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	5 (38.5%)	2 (12.5%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	0.23	
95% CI	(0.04,1.46)	
p-value	0.11904	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	0.33	
95% CI	(0.07,1.41)	
p-value	0.13332	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.26	
95% CI	(-0.05,0.57)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	7 (53.8%)	9 (56.3%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	1.10	
95% CI	(0.25,4.80)	
p-value	0.89698	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.04	
95% CI	(0.54,2.03)	
p-value	0.89732	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	-0.02	
95% CI	(-0.39,0.34)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	17 (57%)	17 (52%)
Best Response		
Stringent Complete Response (sCR)	1 (5.9%)	0
Complete Response (CR)	2 (11.8%)	2 (11.8%)
Very Good Partial Response (VGPR)	4 (23.5%)	2 (11.8%)
Partial Response (PR)	4 (23.5%)	6 (35.3%)
Minimal Response (MR)	1 (5.9%)	2 (11.8%)
Stable Disease (SD)	3 (17.6%)	3 (17.6%)
Progressive Disease (PD)	0	0
Not Evaluable (NE)	2 (11.8%)	2 (11.8%)
Complete Response Rate (CRR)		
sCR+CR	3 (17.6%)	2 (11.8%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Protocol: 207499 Page 6 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	11 (64.7%)	10 (58.8%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.78	
95% CI	(0.19,3.12)	
p-value	0.72436	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.91	
95% CI	(0.53,1.55)	
p-value	0.72474	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.06	
95% CI	(-0.27,0.38)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	7 (41.2%)	4 (23.5%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	0.44	
95% CI	(0.10,1.93)	
p-value	0.27618	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	0.57	
95% CI	(0.20,1.60)	
p-value	0.28609	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.18	
95% CI	(-0.13,0.49)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	12 (70.6%)	12 (70.6%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	1.00	
95% CI	(0.23,4.37)	
p-value	>0.99999	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.00	
95% CI	(0.65,1.54)	
p-value	>0.99999	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.00	
95% CI	(-0.31,0.31)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013025
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Interaction Test [3]		
ORR	0.96234	
VGPR+	0.52558	
CBR	0.91389	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_gen.sas 30SEP2025 12:33

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	20 (67%)	24 (73%)
Best Response		
Stringent Complete Response (sCR)	1 (5.0%)	0
Complete Response (CR)	1 (5.0%)	3 (12.5%)
Very Good Partial Response (VGPR)	4 (20.0%)	2 (8.3%)
Partial Response (PR)	3 (15.0%)	7 (29.2%)
Minimal Response (MR)	1 (5.0%)	2 (8.3%)
Stable Disease (SD)	5 (25.0%)	7 (29.2%)
Progressive Disease (PD)	1 (5.0%)	0
Not Evaluable (NE)	4 (20.0%)	3 (12.5%)
Complete Response Rate (CRR)		
sCR+CR	2 (10.0%)	3 (12.5%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	9 (45.0%)	12 (50.0%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	1.22	
95% CI	(0.37,4.02)	
p-value	0.74103	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	1.11	
95% CI	(0.59,2.08)	
p-value	0.74242	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	-0.05	
95% CI	(-0.35,0.25)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Protocol: 207499 Page 3 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	6 (30.0%)	5 (20.8%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	0.61	
95% CI	(0.16,2.42)	
p-value	0.48631	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	0.69	
95% CI	(0.25,1.94)	
p-value	0.48684	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.09	
95% CI	(-0.17,0.35)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Protocol: 207499 Page 4 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	10 (50.0%)	14 (58.3%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	1.40	
95% CI	(0.42,4.62)	
p-value	0.58089	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.17	
95% CI	(0.67,2.03)	
p-value	0.58519	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	-0.08	
95% CI	(-0.38,0.21)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	10 (33%)	9 (27%)
Best Response		
Stringent Complete Response (sCR)	2 (20.0%)	0
Complete Response (CR)	1 (10.0%)	0
Very Good Partial Response (VGPR)	3 (30.0%)	1 (11.1%)
Partial Response (PR)	3 (30.0%)	5 (55.6%)
Minimal Response (MR)	0	1 (11.1%)
Stable Disease (SD)	1 (10.0%)	1 (11.1%)
Progressive Disease (PD)	0	0
Not Evaluable (NE)	0	1 (11.1%)
Complete Response Rate (CRR)		
sCR+CR	3 (30.0%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	9 (90.0%)	6 (66.7%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.22	
95% CI	(0.02,2.67)	
p-value	0.23605	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.74	
95% CI	(0.45,1.23)	
p-value	0.24511	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.23	
95% CI	(-0.13,0.59)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	6 (60.0%)	1 (11.1%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	0.08	
95% CI	(0.01,0.95)	
p-value	0.04536	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	0.19	
95% CI	(0.03,1.26)	
p-value	0.08450	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.49	
95% CI	(0.12,0.86)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	9 (90.0%)	7 (77.8%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	0.39	
95% CI	(0.03,5.21)	
p-value	0.47576	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	0.86	
95% CI	(0.58,1.30)	
p-value	0.48080	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.12	
95% CI	(-0.21,0.45)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013035
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Interaction Test [3]		
ORR	0.31452	
VGPR+	0.16420	
CBR	0.38524	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_reg.sas 30SEP2025 12:34

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	18 (60%)	15 (45%)
Best Response		
Stringent Complete Response (sCR)	3 (16.7%)	0
Complete Response (CR)	2 (11.1%)	1 (6.7%)
Very Good Partial Response (VGPR)	5 (27.8%)	2 (13.3%)
Partial Response (PR)	3 (16.7%)	6 (40.0%)
Minimal Response (MR)	1 (5.6%)	1 (6.7%)
Stable Disease (SD)	3 (16.7%)	3 (20.0%)
Progressive Disease (PD)	0	0
Not Evaluable (NE)	1 (5.6%)	2 (13.3%)
Complete Response Rate (CRR)		
sCR+CR	5 (27.8%)	1 (6.7%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	13 (72.2%)	9 (60.0%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.58	
95% CI	(0.13,2.48)	
p-value	0.46020	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.83	
95% CI	(0.50,1.37)	
p-value	0.46986	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.12	
95% CI	(-0.20,0.45)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	10 (55.6%)	3 (20.0%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	0.20	
95% CI	(0.04,0.96)	
p-value	0.04452	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	0.36	
95% CI	(0.12,1.07)	
p-value	0.06700	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.36	
95% CI	(0.05,0.66)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Protocol: 207499 Page 4 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	14 (77.8%)	10 (66.7%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	0.57	
95% CI	(0.12,2.68)	
p-value	0.47779	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	0.86	
95% CI	(0.55,1.32)	
p-value	0.48711	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.11	
95% CI	(-0.20,0.42)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	12 (40%)	18 (55%)
Best Response		
Stringent Complete Response (sCR)	0	0
Complete Response (CR)	0	2 (11.1%)
Very Good Partial Response (VGPR)	2 (16.7%)	1 (5.6%)
Partial Response (PR)	3 (25.0%)	6 (33.3%)
Minimal Response (MR)	0	2 (11.1%)
Stable Disease (SD)	3 (25.0%)	5 (27.8%)
Progressive Disease (PD)	1 (8.3%)	0
Not Evaluable (NE)	3 (25.0%)	2 (11.1%)
Complete Response Rate (CRR)		
sCR+CR	0	2 (11.1%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	5 (41.7%)	9 (50.0%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	1.40	
95% CI	(0.32,6.11)	
p-value	0.65444	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	1.20	
95% CI	(0.53,2.71)	
p-value	0.66042	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	-0.08	
95% CI	(-0.45,0.28)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	2 (16.7%)	3 (16.7%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	1.00	
95% CI	(0.14,7.10)	
p-value	>0.99999	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	1.00	
95% CI	(0.20,5.12)	
p-value	>0.99999	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.00	
95% CI	(-0.27,0.27)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	5 (41.7%)	11 (61.1%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	2.20	
95% CI	(0.50,9.75)	
p-value	0.29912	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.47	
95% CI	(0.68,3.15)	
p-value	0.32596	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	-0.19	
95% CI	(-0.55,0.16)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013045
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Interaction Test [3]		
ORR	0.44025	
VGPR+	0.31081	
CBR	0.20847	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_iss.sas 30SEP2025 12:34

Protocol: 207499 Page 1 of 13
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	8 (27%)	6 (18%)
Best Response		
Stringent Complete Response (sCR)	1 (12.5%)	0
Complete Response (CR)	1 (12.5%)	0
Very Good Partial Response (VGPR)	3 (37.5%)	0
Partial Response (PR)	1 (12.5%)	4 (66.7%)
Minimal Response (MR)	0	2 (33.3%)
Stable Disease (SD)	1 (12.5%)	0
Progressive Disease (PD)	0	0
Not Evaluable (NE)	1 (12.5%)	0
Complete Response Rate (CRR)		
sCR+CR	2 (25.0%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	6 (75.0%)	4 (66.7%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.67	
95% CI	(0.06,6.87)	
p-value	0.73336	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.89	
95% CI	(0.44,1.78)	
p-value	0.73903	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.08	
95% CI	(-0.40,0.57)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+ sCR+CR+VGPR	5 (62.5%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	6 (75.0%)	6 (100.0%)
Inverse Odds Ratio (OR) of CBR [4]		
Estimate	5.00	
95% CI	(0.20,125.78)	
p-value	0.32803	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.33	
95% CI	(0.89,1.99)	
p-value	0.15873	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	-0.25	
95% CI	(-0.55,0.05)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Protocol: 207499 Page 5 of 13
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	13 (43%)	14 (42%)
Best Response		
Stringent Complete Response (sCR)	2 (15.4%)	0
Complete Response (CR)	0	1 (7.1%)
Very Good Partial Response (VGPR)	2 (15.4%)	2 (14.3%)
Partial Response (PR)	3 (23.1%)	4 (28.6%)
Minimal Response (MR)	1 (7.7%)	0
Stable Disease (SD)	3 (23.1%)	5 (35.7%)
Progressive Disease (PD)	1 (7.7%)	0
Not Evaluable (NE)	1 (7.7%)	2 (14.3%)
Complete Response Rate (CRR)		
sCR+CR	2 (15.4%)	1 (7.1%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	7 (53.8%)	7 (50.0%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.86	
95% CI	(0.19,3.89)	
p-value	0.84173	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.93	
95% CI	(0.45,1.92)	
p-value	0.84152	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.04	
95% CI	(-0.34,0.42)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+ sCR+CR+VGPR	4 (30.8%)	3 (21.4%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	8 (61.5%)	7 (50.0%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	0.63	
95% CI	(0.14,2.89)	
p-value	0.54756	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	0.81	
95% CI	(0.41,1.60)	
p-value	0.54808	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.12	
95% CI	(-0.26,0.49)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Best Response		
Stringent Complete Response (sCR)	0	0
Complete Response (CR)	1 (11.1%)	2 (15.4%)
Very Good Partial Response (VGPR)	2 (22.2%)	1 (7.7%)
Partial Response (PR)	2 (22.2%)	4 (30.8%)
Minimal Response (MR)	0	1 (7.7%)
Stable Disease (SD)	2 (22.2%)	3 (23.1%)
Progressive Disease (PD)	0	0
Not Evaluable (NE)	2 (22.2%)	2 (15.4%)
Complete Response Rate (CRR)		
sCR+CR	1 (11.1%)	2 (15.4%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	5 (55.6%)	7 (53.8%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.93	
95% CI	(0.17,5.15)	
p-value	0.93694	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.97	
95% CI	(0.45,2.10)	
p-value	0.93669	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.02	
95% CI	(-0.41,0.44)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction. All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+ sCR+CR+VGPR	3 (33.3%)	3 (23.1%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Protocol: 207499 Page 12 of 13
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	5 (55.6%)	8 (61.5%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	1.28	
95% CI	(0.23,7.19)	
p-value	0.77916	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.11	
95% CI	(0.54,2.29)	
p-value	0.78227	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	-0.06	
95% CI	(-0.48,0.36)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Table 2.0013055
Summary of Independent Reviewer - Assessed Best Response with Confirmation (IMWG Criteria) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Interaction Test [3]		
ORR	0.98653	
CBR	0.44766	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. [4] Inverse OR (95% CI) and associated p-value are derived from cell frequencies of the fourfold table including zero-count correction.
All p-values are two-sided. Subgroup analysis was not performed when the subgroup analysis rules were not met. Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line.sas 30SEP2025 12:34

Protocol: 207499 Page 1 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	21 (70%)	20 (61%)
Best Response		
Stringent Complete Response (sCR)	3 (14.3%)	0
Complete Response (CR)	1 (4.8%)	1 (5.0%)
Very Good Partial Response (VGPR)	5 (23.8%)	2 (10.0%)
Partial Response (PR)	4 (19.0%)	8 (40.0%)
Minimal Response (MR)	1 (4.8%)	2 (10.0%)
Stable Disease (SD)	4 (19.0%)	5 (25.0%)
Progressive Disease (PD)	1 (4.8%)	0
Not Evaluable (NE)	2 (9.5%)	2 (10.0%)
Complete Response Rate (CRR)		
sCR+CR	4 (19.0%)	1 (5.0%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	13 (61.9%)	11 (55.0%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.75	
95% CI	(0.22,2.61)	
p-value	0.65404	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.89	
95% CI	(0.53,1.49)	
p-value	0.65537	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.07	
95% CI	(-0.23,0.37)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

Protocol: 207499 Page 3 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	9 (42.9%)	3 (15.0%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	0.24	
95% CI	(0.05,1.06)	
p-value	0.05887	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	0.35	
95% CI	(0.11,1.11)	
p-value	0.07465	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.28	
95% CI	(0.02,0.54)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

Protocol: 207499 Page 4 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1/2/3

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	14 (66.7%)	13 (65.0%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	0.93	
95% CI	(0.26,3.38)	
p-value	0.91044	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	0.98	
95% CI	(0.63,1.52)	
p-value	0.91050	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	0.02	
95% CI	(-0.27,0.31)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

Protocol: 207499 Page 5 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)	9 (30%)	13 (39%)
Best Response		
Stringent Complete Response (sCR)	0	0
Complete Response (CR)	1 (11.1%)	2 (15.4%)
Very Good Partial Response (VGPR)	2 (22.2%)	1 (7.7%)
Partial Response (PR)	2 (22.2%)	4 (30.8%)
Minimal Response (MR)	0	1 (7.7%)
Stable Disease (SD)	2 (22.2%)	3 (23.1%)
Progressive Disease (PD)	0	0
Not Evaluable (NE)	2 (22.2%)	2 (15.4%)
Complete Response Rate (CRR)		
sCR+CR	1 (11.1%)	2 (15.4%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

Protocol: 207499 Page 6 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Overall Response Rate (ORR)		
sCR+CR+VGPR+PR	5 (55.6%)	7 (53.8%)
Inverse Odds Ratio (OR) of ORR [1]		
Estimate	0.93	
95% CI	(0.17,5.15)	
p-value	0.93694	
Inverse Relative Risk (RR) of ORR [2]		
Estimate	0.97	
95% CI	(0.45,2.10)	
p-value	0.93669	
Absolute Risk Difference (ARD) of ORR [2]		
Estimate	0.02	
95% CI	(-0.41,0.44)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
VGPR+		
sCR+CR+VGPR	3 (33.3%)	3 (23.1%)
Inverse Odds Ratio (OR) of VGPR+ [1]		
Estimate	0.60	
95% CI	(0.09,3.99)	
p-value	0.59696	
Inverse Relative Risk (RR) of VGPR+ [2]		
Estimate	0.69	
95% CI	(0.18,2.69)	
p-value	0.59506	
Absolute Risk Difference (ARD) of VGPR+ [2]		
Estimate	0.10	
95% CI	(-0.28,0.49)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

Protocol: 207499 Page 8 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Clinical Benefit Rate (CBR)		
sCR+CR+VGPR+PR+MR	5 (55.6%)	8 (61.5%)
Inverse Odds Ratio (OR) of CBR [1]		
Estimate	1.28	
95% CI	(0.23,7.19)	
p-value	0.77916	
Inverse Relative Risk (RR) of CBR [2]		
Estimate	1.11	
95% CI	(0.54,2.29)	
p-value	0.78227	
Absolute Risk Difference (ARD) of CBR [2]		
Estimate	-0.06	
95% CI	(-0.48,0.36)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0013085
Summary of Independent Reviewer - Assessed Best Response
with Confirmation (IMWG Criteria) by Prior Lines of Therapy 2
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Interaction Test [3]		
ORR	0.85406	
VGPR+	0.45738	
CBR	0.76660	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used for percentage calculation. [1] Inverse OR (95% CI) and associated p-value are from a logistic regression model without adjustment for randomization factor. [2] Inverse RR (95% CI), associated p-value and ARD (95% CI) are from a modified Poisson regression model without adjustment for randomization factor. [3] Interaction test p-value is from a modified Poisson regression model with treatment, subgroup and treatment by subgroup interaction included as independent variables. All p-values are two-sided.
Note: Randomization factor is prior bortezomib (no, yes).
Subgroup analysis was not performed when the subgroup analysis rules were not met.
Randomization factor was not adjusted for due to convergence issues.
/mnt/code/sSAP/sSAP02/prod/tfls/t_e_re1ac_irc_2ref_line2.sas 30SEP2025 12:36

1.2.1.6 MRD-Negativität

Protocol: 207499 Page 1 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015005
Summary of MRD Negativity -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Best Response			
sCR/CR	MRD Negativity Rate	3 (10.0%)	1 (3.0%)
	95% Confidence Interval	(2.1%,26.5%)	(0.1%,15.8%)
	P-Value [1]	0.30565	
	P-Value [2]	0.33963	
Difference in sCR/CR	Difference	7.0%	
	95% CI for Difference	(-18.1%,30.9%)	
Inverse Odds Ratio (OR) [3]	Estimate	0.28	
	95% Confidence Interval	(0.03,2.86)	
	P-Value	0.28400	
Inverse Relative Risk (RR) [4]	Estimate	0.30	
	95% Confidence Interval	(0.03,2.76)	
	P-Value	0.28934	
Absolute Risk Difference (ARD) [4]	Estimate	0.07	

Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5. MRD negativity rate compared between treatment arms using [1] CMH test, adjusting for prior bortezomib use and [2] Unadjusted Fisher's exact test. Confidence intervals are based on the exact method. [3] Inv. OR (95% CI) and associated p-value are from a logistic regression model without adjustment for prior bortezomib use due to convergence issues. [4] Inv. RR (95% CI), associated p-value, ARD (95% CI) are from a modified Poisson regression model without adjustment for prior bortezomib use due to convergence issues.
[5] Estimates are derived from cell frequencies of the fourfold table including zero-count correction.
Subjects without MRD assessment are assumed to be Non-Negative.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref.sas 30SEP2025 12:35

Table 2.0015005
Summary of MRD Negativity -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Response: Independent Reviewer-Assessed

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Absolute Risk Difference (ARD) [4] 95% Confidence Interval	(-0.05,0.19)	

Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5. MRD negativity rate compared between treatment arms using [1] CMH test, adjusting for prior bortezomib use and [2] Unadjusted Fisher's exact test. Confidence intervals are based on the exact method. [3] Inv. OR (95% CI) and associated p-value are from a logistic regression model without adjustment for prior bortezomib use due to convergence issues. [4] Inv. RR (95% CI), associated p-value, ARD (95% CI) are from a modified Poisson regression model without adjustment for prior bortezomib use due to convergence issues.
[5] Estimates are derived from cell frequencies of the fourfold table including zero-count correction. Subjects without MRD assessment are assumed to be Non-Negative.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref.sas 30SEP2025 12:35

Protocol: 207499 Page 3 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015005
Summary of MRD Negativity -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
sCR/CR/VGPR	MRD Negativity Rate	5 (16.7%)	2 (6.1%)
	95% Confidence Interval	(5.6%,34.7%)	(0.7%,20.2%)
	P-Value [1]	0.20360	
	P-Value [2]	0.24287	
Difference in sCR/CR/VGPR	Difference	10.6%	
	95% CI for Difference	(-14.7%,34.7%)	
Inverse Odds Ratio (OR) [3]	Estimate	0.32	
	95% Confidence Interval	(0.06,1.81)	
	P-Value	0.19794	
Inverse Relative Risk (RR) [4]	Estimate	0.36	
	95% Confidence Interval	(0.08,1.74)	
	P-Value	0.20476	
Absolute Risk Difference (ARD) [4]	Estimate	0.11	
	95% Confidence Interval	(-0.05,0.26)	

Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5. MRD negativity rate compared between treatment arms using [1] CMH test, adjusting for prior bortezomib use and [2] Unadjusted Fisher's exact test. Confidence intervals are based on the exact method. [3] Inv. OR (95% CI) and associated p-value are from a logistic regression model without adjustment for prior bortezomib use due to convergence issues. [4] Inv. RR (95% CI), associated p-value, ARD (95% CI) are from a modified Poisson regression model without adjustment for prior bortezomib use due to convergence issues.
[5] Estimates are derived from cell frequencies of the fourfold table including zero-count correction. Subjects without MRD assessment are assumed to be Non-Negative.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref.sas 30SEP2025 12:35

Protocol: 207499 Page 4 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015005
Summary of MRD Negativity -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	1 (3.3%)	0
	95% Confidence Interval	(0.1%,17.2%)	(0.0%,10.6%)
Difference in MRD Negativity Sustained for >=12 Months (sCR/CR)	Difference	3.3%	
	95% CI for Difference	(-21.5%,27.6%)	
Inverse Odds Ratio (OR) [5]	Estimate	0.29	
	95% Confidence Interval	(0.01,7.48)	
	P-Value	0.45824	
Inverse Relative Risk (RR) [5]	Estimate	0.30	
	95% Confidence Interval	(0.01,7.19)	
	P-Value	0.46057	
Absolute Risk Difference (ARD) [5]	Estimate	0.03	
	95% Confidence Interval	(-0.05,0.12)	

Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5. MRD negativity rate compared between treatment arms using [1] CMH test, adjusting for prior bortezomib use and [2] Unadjusted Fisher's exact test. Confidence intervals are based on the exact method. [3] Inv. OR (95% CI) and associated p-value are from a logistic regression model without adjustment for prior bortezomib use due to convergence issues. [4] Inv. RR (95% CI), associated p-value, ARD (95% CI) are from a modified Poisson regression model without adjustment for prior bortezomib use due to convergence issues.
[5] Estimates are derived from cell frequencies of the fourfold table including zero-count correction. Subjects without MRD assessment are assumed to be Non-Negative.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref.sas 30SEP2025 12:35

Protocol: 207499 Page 5 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015005
Summary of MRD Negativity -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	3	1
	Imaging plus MRD Negativity Rate	3 (10.0%)	0
	95% Confidence Interval	(2.1%,26.5%)	(0.0%,10.6%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	10.0%	
	95% CI for Difference	(-15.1%,33.6%)	
Inverse Odds Ratio (OR) [5]	Estimate	0.12	
	95% Confidence Interval	(0.01,2.37)	
	P-Value	0.16225	
Inverse Relative Risk (RR) [5]	Estimate	0.13	
	95% Confidence Interval	(0.01,2.42)	
	P-Value	0.17170	
Absolute Risk Difference (ARD) [5]	Estimate	0.10	
	95% Confidence Interval	(-0.02,0.22)	

Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5. MRD negativity rate compared between treatment arms using [1] CMH test, adjusting for prior bortezomib use and [2] Unadjusted Fisher's exact test. Confidence intervals are based on the exact method. [3] Inv. OR (95% CI) and associated p-value are from a logistic regression model without adjustment for prior bortezomib use due to convergence issues. [4] Inv. RR (95% CI), associated p-value, ARD (95% CI) are from a modified Poisson regression model without adjustment for prior bortezomib use due to convergence issues.
[5] Estimates are derived from cell frequencies of the fourfold table including zero-count correction. Subjects without MRD assessment are assumed to be Non-Negative.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref.sas 30SEP2025 12:35

Protocol: 207499 Page 6 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015005
Summary of MRD Negativity -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Best Response			
sCR/CR	MRD Negativity Rate	3 (10.0%)	2 (6.1%)
	95% Confidence Interval	(2.1%,26.5%)	(0.7%,20.2%)
	P-Value [1]	0.63060	
	P-Value [2]	0.66234	
Difference in sCR/CR	Difference	3.9%	
	95% CI for Difference	(-21.1%,28.2%)	
Inverse Odds Ratio (OR) [3]	Estimate	0.58	
	95% Confidence Interval	(0.09,3.74)	
	P-Value	0.56720	
Inverse Relative Risk (RR) [4]	Estimate	0.61	
	95% Confidence Interval	(0.11,3.38)	
	P-Value	0.56814	
Absolute Risk Difference (ARD) [4]	Estimate	0.04	

Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5. MRD negativity rate compared between treatment arms using [1] CMH test, adjusting for prior bortezomib use and [2] Unadjusted Fisher's exact test. Confidence intervals are based on the exact method. [3] Inv. OR (95% CI) and associated p-value are from a logistic regression model without adjustment for prior bortezomib use due to convergence issues. [4] Inv. RR (95% CI), associated p-value, ARD (95% CI) are from a modified Poisson regression model without adjustment for prior bortezomib use due to convergence issues.
[5] Estimates are derived from cell frequencies of the fourfold table including zero-count correction.
Subjects without MRD assessment are assumed to be Non-Negative.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref.sas 30SEP2025 12:35

Protocol: 207499 Page 7 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015005
Summary of MRD Negativity -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Response: Investigator-Assessed

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Absolute Risk Difference (ARD) [4] 95% Confidence Interval	(-0.10,0.17)	

Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5. MRD negativity rate compared between treatment arms using [1] CMH test, adjusting for prior bortezomib use and [2] Unadjusted Fisher's exact test. Confidence intervals are based on the exact method. [3] Inv. OR (95% CI) and associated p-value are from a logistic regression model without adjustment for prior bortezomib use due to convergence issues. [4] Inv. RR (95% CI), associated p-value, ARD (95% CI) are from a modified Poisson regression model without adjustment for prior bortezomib use due to convergence issues.
[5] Estimates are derived from cell frequencies of the fourfold table including zero-count correction. Subjects without MRD assessment are assumed to be Non-Negative.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref.sas 30SEP2025 12:35

Protocol: 207499 Page 8 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015005
Summary of MRD Negativity -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
sCR/CR/VGPR	MRD Negativity Rate	5 (16.7%)	2 (6.1%)
	95% Confidence Interval	(5.6%,34.7%)	(0.7%,20.2%)
	P-Value [1]	0.20360	
	P-Value [2]	0.24287	
Difference in sCR/CR/VGPR	Difference	10.6%	
	95% CI for Difference	(-14.7%,34.7%)	
Inverse Odds Ratio (OR) [3]	Estimate	0.32	
	95% Confidence Interval	(0.06,1.81)	
	P-Value	0.19794	
Inverse Relative Risk (RR) [4]	Estimate	0.36	
	95% Confidence Interval	(0.08,1.74)	
	P-Value	0.20476	
Absolute Risk Difference (ARD) [4]	Estimate	0.11	
	95% Confidence Interval	(-0.05,0.26)	

Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5. MRD negativity rate compared between treatment arms using [1] CMH test, adjusting for prior bortezomib use and [2] Unadjusted Fisher's exact test. Confidence intervals are based on the exact method. [3] Inv. OR (95% CI) and associated p-value are from a logistic regression model without adjustment for prior bortezomib use due to convergence issues. [4] Inv. RR (95% CI), associated p-value, ARD (95% CI) are from a modified Poisson regression model without adjustment for prior bortezomib use due to convergence issues.
[5] Estimates are derived from cell frequencies of the fourfold table including zero-count correction.
Subjects without MRD assessment are assumed to be Non-Negative.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref.sas 30SEP2025 12:35

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		11 (37%)	7 (21%)
Best Response			
sCR/CR	MRD Negativity Rate	0	1 (14.3%)
	95% Confidence Interval	(0.0%,28.5%)	(0.4%,57.9%)
Difference in sCR/CR	Difference	-14.3%	
	95% CI for Difference	(-57.9%,32.2%)	
sCR/CR/VGPR	MRD Negativity Rate	0	1 (14.3%)
	95% Confidence Interval	(0.0%,28.5%)	(0.4%,57.9%)
Difference in sCR/CR/VGPR	Difference	-14.3%	
	95% CI for Difference	(-57.9%,32.2%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	0	1
	Imaging plus MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 18 to <65
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		11 (37%)	7 (21%)
Best Response			
sCR/CR	MRD Negativity Rate	0	1 (14.3%)
	95% Confidence Interval	(0.0%,28.5%)	(0.4%,57.9%)
Difference in sCR/CR	Difference	-14.3%	
	95% CI for Difference	(-57.9%,32.2%)	
sCR/CR/VGPR	MRD Negativity Rate	0	1 (14.3%)
	95% Confidence Interval	(0.0%,28.5%)	(0.4%,57.9%)
Difference in sCR/CR/VGPR	Difference	-14.3%	
	95% CI for Difference	(-57.9%,32.2%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		15 (50%)	15 (45%)
Best Response			
sCR/CR	MRD Negativity Rate	2 (13.3%)	0
	95% Confidence Interval	(1.7%,40.5%)	(0.0%,21.8%)
Difference in sCR/CR	Difference	13.3%	
	95% CI for Difference	(-25.1%,49.1%)	
sCR/CR/VGPR	MRD Negativity Rate	4 (26.7%)	0
	95% Confidence Interval	(7.8%,55.1%)	(0.0%,21.8%)
Difference in sCR/CR/VGPR	Difference	26.7%	
	95% CI for Difference	(-12.3%,60.1%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	2	0
	Imaging plus MRD Negativity Rate	2 (13.3%)	0
	95% Confidence Interval	(1.7%,40.5%)	(0.0%,21.8%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	13.3%	
	95% CI for Difference	(-25.1%,49.1%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): 65 to <75
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		15 (50%)	15 (45%)
Best Response			
sCR/CR	MRD Negativity Rate	2 (13.3%)	0
	95% Confidence Interval	(1.7%,40.5%)	(0.0%,21.8%)
Difference in sCR/CR	Difference	13.3%	
	95% CI for Difference	(-25.1%,49.1%)	
sCR/CR/VGPR	MRD Negativity Rate	4 (26.7%)	0
	95% Confidence Interval	(7.8%,55.1%)	(0.0%,21.8%)
Difference in sCR/CR/VGPR	Difference	26.7%	
	95% CI for Difference	(-12.3%,60.1%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Protocol: 207499 Page 7 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		4 (13%)	11 (33%)
Best Response			
sCR/CR	MRD Negativity Rate	1 (25.0%)	0
	95% Confidence Interval	(0.6%,80.6%)	(0.0%,28.5%)
Difference in sCR/CR	Difference	25.0%	
	95% CI for Difference	(-32.1%,80.6%)	
sCR/CR/VGPR	MRD Negativity Rate	1 (25.0%)	1 (9.1%)
	95% Confidence Interval	(0.6%,80.6%)	(0.2%,41.3%)
Difference in sCR/CR/VGPR	Difference	15.9%	
	95% CI for Difference	(-40.1%,69.9%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	1 (25.0%)	0
	95% Confidence Interval	(0.6%,80.6%)	(0.0%,28.5%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Difference in MRD Negativity Sustained for >=12 Months (sCR/CR)	Difference	25.0%	
	95% CI for Difference	(-32.1%,80.6%)	
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	1	0
	Imaging plus MRD Negativity Rate	1 (25.0%)	0
	95% Confidence Interval	(0.6%,80.6%)	(0.0%,28.5%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	25.0%	
	95% CI for Difference	(-32.1%,80.6%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Protocol: 207499 Page 9 of 9
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015015
Summary of MRD Negativity by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Age Group (years): >=75
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		4 (13%)	11 (33%)
Best Response			
sCR/CR	MRD Negativity Rate	1 (25.0%)	1 (9.1%)
	95% Confidence Interval	(0.6%,80.6%)	(0.2%,41.3%)
Difference in sCR/CR	Difference	15.9%	
	95% CI for Difference	(-40.1%,69.9%)	
sCR/CR/VGPR	MRD Negativity Rate	1 (25.0%)	1 (9.1%)
	95% Confidence Interval	(0.6%,80.6%)	(0.2%,41.3%)
Difference in sCR/CR/VGPR	Difference	15.9%	
	95% CI for Difference	(-40.1%,69.9%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_age.sas 30SEP2025 12:35

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015025
Summary of MRD Negativity by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		13 (43%)	16 (48%)
Best Response			
sCR/CR	MRD Negativity Rate	2 (15.4%)	0
	95% Confidence Interval	(1.9%,45.4%)	(0.0%,20.6%)
Difference in sCR/CR	Difference	15.4%	
	95% CI for Difference	(-21.2%,49.2%)	
sCR/CR/VGPR	MRD Negativity Rate	2 (15.4%)	0
	95% Confidence Interval	(1.9%,45.4%)	(0.0%,20.6%)
Difference in sCR/CR/VGPR	Difference	15.4%	
	95% CI for Difference	(-21.2%,49.2%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	1 (7.7%)	0
	95% Confidence Interval	(0.2%,36.0%)	(0.0%,20.6%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_gen.sas 30SEP2025 12:36

Table 2.0015025
Summary of MRD Negativity by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Difference in MRD Negativity Sustained for >=12 Months (sCR/CR)	Difference	7.7%	
	95% CI for Difference	(-28.4%,42.1%)	
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	2	0
	Imaging plus MRD Negativity Rate	2 (15.4%)	0
	95% Confidence Interval	(1.9%,45.4%)	(0.0%,20.6%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	15.4%	
	95% CI for Difference	(-21.2%,49.2%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_gen.sas 30SEP2025 12:36

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015025
Summary of MRD Negativity by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Female
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		13 (43%)	16 (48%)
Best Response			
sCR/CR	MRD Negativity Rate	2 (15.4%)	0
	95% Confidence Interval	(1.9%,45.4%)	(0.0%,20.6%)
Difference in sCR/CR	Difference	15.4%	
	95% CI for Difference	(-21.2%,49.2%)	
sCR/CR/VGPR	MRD Negativity Rate	2 (15.4%)	0
	95% Confidence Interval	(1.9%,45.4%)	(0.0%,20.6%)
Difference in sCR/CR/VGPR	Difference	15.4%	
	95% CI for Difference	(-21.2%,49.2%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_gen.sas 30SEP2025 12:36

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015025
Summary of MRD Negativity by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		17 (57%)	17 (52%)
Best Response			
sCR/CR	MRD Negativity Rate	1 (5.9%)	1 (5.9%)
	95% Confidence Interval	(0.1%,28.7%)	(0.1%,28.7%)
Difference in sCR/CR	Difference	0.0%	
	95% CI for Difference	(-35.1%,35.1%)	
sCR/CR/VGPR	MRD Negativity Rate	3 (17.6%)	2 (11.8%)
	95% Confidence Interval	(3.8%,43.4%)	(1.5%,36.4%)
Difference in sCR/CR/VGPR	Difference	5.9%	
	95% CI for Difference	(-29.7%,40.4%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_gen.sas 30SEP2025 12:36

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015025
Summary of MRD Negativity by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	1	1
	Imaging plus MRD Negativity Rate	1 (5.9%)	0
	95% Confidence Interval	(0.1%,28.7%)	(0.0%,19.5%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	5.9%	
	95% CI for Difference	(-29.7%,40.4%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_gen.sas 30SEP2025 12:36

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015025
Summary of MRD Negativity by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Gender: Male
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		17 (57%)	17 (52%)
Best Response			
sCR/CR	MRD Negativity Rate	1 (5.9%)	2 (11.8%)
	95% Confidence Interval	(0.1%,28.7%)	(1.5%,36.4%)
Difference in sCR/CR	Difference	-5.9%	
	95% CI for Difference	(-40.4%,29.7%)	
sCR/CR/VGPR	MRD Negativity Rate	3 (17.6%)	2 (11.8%)
	95% Confidence Interval	(3.8%,43.4%)	(1.5%,36.4%)
Difference in sCR/CR/VGPR	Difference	5.9%	
	95% CI for Difference	(-29.7%,40.4%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_gen.sas 30SEP2025 12:36

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015035
Summary of MRD Negativity by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		20 (67%)	24 (73%)
Best Response			
sCR/CR	MRD Negativity Rate	1 (5.0%)	1 (4.2%)
	95% Confidence Interval	(0.1%,24.9%)	(0.1%,21.1%)
Difference in sCR/CR	Difference	0.8%	
	95% CI for Difference	(-28.7%,30.3%)	
sCR/CR/VGPR	MRD Negativity Rate	2 (10.0%)	1 (4.2%)
	95% Confidence Interval	(1.2%,31.7%)	(0.1%,21.1%)
Difference in sCR/CR/VGPR	Difference	5.8%	
	95% CI for Difference	(-23.9%,34.9%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_reg.sas 30SEP2025 12:36

Table 2.0015035
Summary of MRD Negativity by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	1	1
	Imaging plus MRD Negativity Rate	1 (5.0%)	0
	95% Confidence Interval	(0.1%,24.9%)	(0.0%,14.2%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	5.0%	
	95% CI for Difference	(-24.8%,34.2%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_reg.sas 30SEP2025 12:36

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015035
Summary of MRD Negativity by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Europe
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		20 (67%)	24 (73%)
Best Response			
sCR/CR	MRD Negativity Rate	1 (5.0%)	1 (4.2%)
	95% Confidence Interval	(0.1%,24.9%)	(0.1%,21.1%)
Difference in sCR/CR	Difference	0.8%	
	95% CI for Difference	(-28.7%,30.3%)	
sCR/CR/VGPR	MRD Negativity Rate	2 (10.0%)	1 (4.2%)
	95% Confidence Interval	(1.2%,31.7%)	(0.1%,21.1%)
Difference in sCR/CR/VGPR	Difference	5.8%	
	95% CI for Difference	(-23.9%,34.9%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_reg.sas 30SEP2025 12:36

Protocol: 207499 Page 4 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015035
Summary of MRD Negativity by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		10 (33%)	9 (27%)
Best Response			
sCR/CR	MRD Negativity Rate	2 (20.0%)	0
	95% Confidence Interval	(2.5%,55.6%)	(0.0%,33.6%)
Difference in sCR/CR	Difference	20.0%	
	95% CI for Difference	(-23.6%,59.7%)	
sCR/CR/VGPR	MRD Negativity Rate	3 (30.0%)	1 (11.1%)
	95% Confidence Interval	(6.7%,65.2%)	(0.3%,48.2%)
Difference in sCR/CR/VGPR	Difference	18.9%	
	95% CI for Difference	(-23.6%,59.7%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	1 (10.0%)	0
	95% Confidence Interval	(0.3%,44.5%)	(0.0%,33.6%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_reg.sas 30SEP2025 12:36

Protocol: 207499 Page 5 of 6
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015035
Summary of MRD Negativity by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Difference in MRD Negativity Sustained for >=12 Months (sCR/CR)	Difference	10.0%	
	95% CI for Difference	(-33.3%,51.4%)	
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	2	0
	Imaging plus MRD Negativity Rate	2 (20.0%)	0
	95% Confidence Interval	(2.5%,55.6%)	(0.0%,33.6%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	20.0%	
	95% CI for Difference	(-23.6%,59.7%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_reg.sas 30SEP2025 12:36

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015035
Summary of MRD Negativity by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Region: Non-Europe
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		10 (33%)	9 (27%)
Best Response			
sCR/CR	MRD Negativity Rate	2 (20.0%)	1 (11.1%)
	95% Confidence Interval	(2.5%,55.6%)	(0.3%,48.2%)
Difference in sCR/CR	Difference	8.9%	
	95% CI for Difference	(-33.3%,51.4%)	
sCR/CR/VGPR	MRD Negativity Rate	3 (30.0%)	1 (11.1%)
	95% Confidence Interval	(6.7%,65.2%)	(0.3%,48.2%)
Difference in sCR/CR/VGPR	Difference	18.9%	
	95% CI for Difference	(-23.6%,59.7%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_reg.sas 30SEP2025 12:36

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015045
Summary of MRD Negativity by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		18 (60%)	15 (45%)
Best Response			
sCR/CR	MRD Negativity Rate	3 (16.7%)	1 (6.7%)
	95% Confidence Interval	(3.6%,41.4%)	(0.2%,31.9%)
Difference in sCR/CR	Difference	10.0%	
	95% CI for Difference	(-24.7%,43.1%)	
sCR/CR/VGPR	MRD Negativity Rate	4 (22.2%)	1 (6.7%)
	95% Confidence Interval	(6.4%,47.6%)	(0.2%,31.9%)
Difference in sCR/CR/VGPR	Difference	15.6%	
	95% CI for Difference	(-19.5%,48.0%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	1 (5.6%)	0
	95% Confidence Interval	(0.1%,27.3%)	(0.0%,21.8%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_iss.sas 30SEP2025 12:36

Table 2.0015045
Summary of MRD Negativity by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Difference in MRD Negativity Sustained for >=12 Months (sCR/CR)	Difference	5.6%	
	95% CI for Difference	(-28.2%,38.8%)	
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	3	1
	Imaging plus MRD Negativity Rate	3 (16.7%)	0
	95% Confidence Interval	(3.6%,41.4%)	(0.0%,21.8%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	16.7%	
	95% CI for Difference	(-18.1%,48.8%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_iss.sas 30SEP2025 12:36

Protocol: 207499 Page 3 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015045
Summary of MRD Negativity by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: I
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		18 (60%)	15 (45%)
Best Response			
sCR/CR	MRD Negativity Rate	3 (16.7%)	1 (6.7%)
	95% Confidence Interval	(3.6%,41.4%)	(0.2%,31.9%)
Difference in sCR/CR	Difference	10.0%	
	95% CI for Difference	(-24.7%,43.1%)	
sCR/CR/VGPR	MRD Negativity Rate	4 (22.2%)	1 (6.7%)
	95% Confidence Interval	(6.4%,47.6%)	(0.2%,31.9%)
Difference in sCR/CR/VGPR	Difference	15.6%	
	95% CI for Difference	(-19.5%,48.0%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_iss.sas 30SEP2025 12:36

Protocol: 207499 Page 4 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015045
Summary of MRD Negativity by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		12 (40%)	18 (55%)
Best Response			
sCR/CR	MRD Negativity Rate	0	0
sCR/CR/VGPR	MRD Negativity Rate	1 (8.3%)	1 (5.6%)
	95% Confidence Interval	(0.2%,38.5%)	(0.1%,27.3%)
Difference in sCR/CR/VGPR	Difference	2.8%	
	95% CI for Difference	(-34.0%,39.0%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	0	0
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	0	0
	Imaging plus MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_iss.sas 30SEP2025 12:36

Protocol: 207499 Page 5 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015045
Summary of MRD Negativity by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage at Screening: II/III
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		12 (40%)	18 (55%)
Best Response			
sCR/CR	MRD Negativity Rate	0	1 (5.6%)
	95% Confidence Interval	(0.0%,26.5%)	(0.1%,27.3%)
Difference in sCR/CR	Difference	-5.6%	
	95% CI for Difference	(-41.5%,31.5%)	
sCR/CR/VGPR	MRD Negativity Rate	1 (8.3%)	1 (5.6%)
	95% Confidence Interval	(0.2%,38.5%)	(0.1%,27.3%)
Difference in sCR/CR/VGPR	Difference	2.8%	
	95% CI for Difference	(-34.0%,39.0%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_iss.sas 30SEP2025 12:36

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015055
Summary of MRD Negativity by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		8 (27%)	6 (18%)
Best Response			
sCR/CR	MRD Negativity Rate	1 (12.5%)	0
	95% Confidence Interval	(0.3%,52.7%)	(0.0%,45.9%)
Difference in sCR/CR	Difference	12.5%	
	95% CI for Difference	(-41.2%,61.5%)	
sCR/CR/VGPR	MRD Negativity Rate	1 (12.5%)	0
	95% Confidence Interval	(0.3%,52.7%)	(0.0%,45.9%)
Difference in sCR/CR/VGPR	Difference	12.5%	
	95% CI for Difference	(-41.2%,61.5%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line.sas 30SEP2025 12:37

Protocol: 207499 Page 2 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015055
Summary of MRD Negativity by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	1	0
	Imaging plus MRD Negativity Rate	1 (12.5%)	0
	95% Confidence Interval	(0.3%,52.7%)	(0.0%,45.9%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	12.5%	
	95% CI for Difference	(-41.2%,61.5%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line.sas 30SEP2025 12:37

Table 2.0015055
Summary of MRD Negativity by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 1
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		8 (27%)	6 (18%)
Best Response			
sCR/CR	MRD Negativity Rate	1 (12.5%)	0
	95% Confidence Interval	(0.3%,52.7%)	(0.0%,45.9%)
Difference in sCR/CR	Difference	12.5%	
	95% CI for Difference	(-41.2%,61.5%)	
sCR/CR/VGPR	MRD Negativity Rate	1 (12.5%)	0
	95% Confidence Interval	(0.3%,52.7%)	(0.0%,45.9%)
Difference in sCR/CR/VGPR	Difference	12.5%	
	95% CI for Difference	(-41.2%,61.5%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line.sas 30SEP2025 12:37

Protocol: 207499 Page 4 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015055
Summary of MRD Negativity by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		13 (43%)	14 (42%)
Best Response			
sCR/CR	MRD Negativity Rate	2 (15.4%)	1 (7.1%)
	95% Confidence Interval	(1.9%,45.4%)	(0.2%,33.9%)
Difference in sCR/CR	Difference	8.2%	
	95% CI for Difference	(-29.5%,42.8%)	
sCR/CR/VGPR	MRD Negativity Rate	3 (23.1%)	2 (14.3%)
	95% Confidence Interval	(5.0%,53.8%)	(1.8%,42.8%)
Difference in sCR/CR/VGPR	Difference	8.8%	
	95% CI for Difference	(-29.5%,42.8%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	1 (7.7%)	0
	95% Confidence Interval	(0.2%,36.0%)	(0.0%,23.2%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line.sas 30SEP2025 12:37

Protocol: 207499 Page 5 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015055
Summary of MRD Negativity by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Difference in MRD Negativity Sustained for >=12 Months (sCR/CR)	Difference	7.7%	
	95% CI for Difference	(-29.5%,42.8%)	
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	2	1
	Imaging plus MRD Negativity Rate	2 (15.4%)	0
	95% Confidence Interval	(1.9%,45.4%)	(0.0%,23.2%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	15.4%	
	95% CI for Difference	(-22.6%,49.2%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line.sas 30SEP2025 12:37

Protocol: 207499 Page 6 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015055
Summary of MRD Negativity by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: 2 or 3
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		13 (43%)	14 (42%)
Best Response			
sCR/CR	MRD Negativity Rate	2 (15.4%)	2 (14.3%)
	95% Confidence Interval	(1.9%,45.4%)	(1.8%,42.8%)
Difference in sCR/CR	Difference	1.1%	
	95% CI for Difference	(-36.3%,36.3%)	
sCR/CR/VGPR	MRD Negativity Rate	3 (23.1%)	2 (14.3%)
	95% Confidence Interval	(5.0%,53.8%)	(1.8%,42.8%)
Difference in sCR/CR/VGPR	Difference	8.8%	
	95% CI for Difference	(-29.5%,42.8%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line.sas 30SEP2025 12:37

Protocol: 207499 Page 7 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015055
Summary of MRD Negativity by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		9 (30%)	13 (39%)
Best Response			
sCR/CR	MRD Negativity Rate	0	0
sCR/CR/VGPR	MRD Negativity Rate	1 (11.1%)	0
	95% Confidence Interval	(0.3%,48.2%)	(0.0%,24.7%)
Difference in sCR/CR/VGPR	Difference	11.1%	
	95% CI for Difference	(-30.6%,50.5%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	0	0
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	0	0
	Imaging plus MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line.sas 30SEP2025 12:37

Protocol: 207499 Page 8 of 8
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015055
Summary of MRD Negativity by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy: >=4
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		9 (30%)	13 (39%)
Best Response			
sCR/CR	MRD Negativity Rate	0	0
sCR/CR/VGPR	MRD Negativity Rate	1 (11.1%)	0
	95% Confidence Interval	(0.3%,48.2%)	(0.0%,24.7%)
Difference in sCR/CR/VGPR	Difference	11.1%	
	95% CI for Difference	(-30.6%,50.5%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line.sas 30SEP2025 12:37

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015075
Summary of MRD Negativity by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy 2: 1/2/3
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		21 (70%)	20 (61%)
Best Response			
sCR/CR	MRD Negativity Rate	3 (14.3%)	1 (5.0%)
	95% Confidence Interval	(3.0%,36.3%)	(0.1%,24.9%)
Difference in sCR/CR	Difference	9.3%	
	95% CI for Difference	(-20.6%,38.8%)	
sCR/CR/VGPR	MRD Negativity Rate	4 (19.0%)	2 (10.0%)
	95% Confidence Interval	(5.4%,41.9%)	(1.2%,31.7%)
Difference in sCR/CR/VGPR	Difference	9.0%	
	95% CI for Difference	(-20.6%,38.8%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	1 (4.8%)	0
	95% Confidence Interval	(0.1%,23.8%)	(0.0%,16.8%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line2.sas 30SEP2025 12:37

Table 2.0015075
Summary of MRD Negativity by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy 2: 1/2/3
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Difference in MRD Negativity Sustained for >=12 Months (sCR/CR)	Difference	4.8%	
	95% CI for Difference	(-25.2%,34.3%)	
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	3	1
	Imaging plus MRD Negativity Rate	3 (14.3%)	0
	95% Confidence Interval	(3.0%,36.3%)	(0.0%,16.8%)
Difference in Imaging plus MRD Negativity Rate (sCR/CR)	Difference	14.3%	
	95% CI for Difference	(-15.9%,43.1%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line2.sas 30SEP2025 12:37

Protocol: 207499 Page 3 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015075
Summary of MRD Negativity by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy 2: 1/2/3
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		21 (70%)	20 (61%)
Best Response			
sCR/CR	MRD Negativity Rate	3 (14.3%)	2 (10.0%)
	95% Confidence Interval	(3.0%,36.3%)	(1.2%,31.7%)
Difference in sCR/CR	Difference	4.3%	
	95% CI for Difference	(-25.2%,34.3%)	
sCR/CR/VGPR	MRD Negativity Rate	4 (19.0%)	2 (10.0%)
	95% Confidence Interval	(5.4%,41.9%)	(1.2%,31.7%)
Difference in sCR/CR/VGPR	Difference	9.0%	
	95% CI for Difference	(-20.6%,38.8%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line2.sas 30SEP2025 12:37

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015075
Summary of MRD Negativity by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy 2: >=4
Response: Independent Reviewer-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		9 (30%)	13 (39%)
Best Response			
sCR/CR	MRD Negativity Rate	0	0
sCR/CR/VGPR	MRD Negativity Rate	1 (11.1%)	0
	95% Confidence Interval	(0.3%,48.2%)	(0.0%,24.7%)
Difference in sCR/CR/VGPR	Difference	11.1%	
	95% CI for Difference	(-30.6%,50.5%)	
MRD Negativity Sustained for >=12 Months (sCR/CR)	Sustained MRD Negativity Rate	0	0
Imaging plus MRD Negativity Rate (sCR/CR)	Number of CR+ Subjects With MRD Negativity + PET-CT Interpretation	0	0
	Imaging plus MRD Negativity Rate	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line2.sas 30SEP2025 12:37

Protocol: 207499 Page 5 of 5
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 2.0015075
Summary of MRD Negativity by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Prior Lines of Therapy 2: >=4
Response: Investigator-Assessed

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects, n*(%)		9 (30%)	13 (39%)
Best Response			
sCR/CR	MRD Negativity Rate	0	0
sCR/CR/VGPR	MRD Negativity Rate	1 (11.1%)	0
	95% Confidence Interval	(0.3%,48.2%)	(0.0%,24.7%)
Difference in sCR/CR/VGPR	Difference	11.1%	
	95% CI for Difference	(-30.6%,50.5%)	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n is used for percentage calculation.
Note: Minimal Residual Disease (MRD) negativity rate is defined as: the percentage of subjects who are MRD negative by Next Generation Sequencing (NGS) based on sensitivity of 10^-5.
Subjects without MRD assessment are assumed to be Non-Negative.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_e_mrd_neg_summ_2ref_line2.sas 30SEP2025 12:37

1.2.1.7 Beobachtungsdauern

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0002705
Summary of Duration of Observation of Progression-Free Survival -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Survival Time (Months) [1]	n	30	33
	Mean	13.32	9.48
	SD	14.758	11.670
	Median	6.03	4.53
	Min.	0.0	0.0
	Max.	46.1	46.0

[1] Survival times are calculated from the date of randomization to death or progression, whichever occurs first, or the date of last adequate assessment if death or progression do not occur.
Note: These are descriptive summary of survival times and no KM analysis applied.
/mnt/code/prod/tfls/t_doo_pfs_2ref.sas 19AUG2025 08:28

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0002605
Summary of Duration of Observation of Overall Survival -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Survival Time (Months) [1]	n	30	33
	Mean	22.72	22.60
	SD	16.849	18.316
	Median	18.02	15.84
	Min.	0.0	0.1
	Max.	49.6	56.4

[1] Survival times are calculated from date of randomization to death or date of last contact.
These are descriptive summary of survival times and no KM analysis applied.
/mnt/code/prod/tfls/t_sp_doo_os_2ref.sas 19AUG2025 08:28

1.2.2 Graphische Darstellungen – Ergebnisse für Endpunkte zur Wirksamkeit

1.2.2.1 PFS

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 2.0001005

Graph of Kaplan Meier Curves of Progression-Free Survival Based on Independent Reviewer - Assessed Response - Lenalidomide and Anti-CD38 Refractory Subpopulation



/mnt/code/sSAP/sSAP02/prod/tfls/f_e_pfs_irc_2ref.sas 14OCT2025 13:49

1.2.2.2 OS

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.)

Data as of 07JUL2025

Figure 2.0006005
Graph of Kaplan Meier Curves of Overall Survival - Lenalidomide and Anti-CD38 Refractory Subpopulation



/mnt/code/sSAP/sSAP02/prod/tfls/f_e_osurv_2ref.sas 14OCT2025 13:52

1.2.2.3 DoR

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 2.0008005

Graph of Kaplan Meier Curves of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to any cause) - Lenalidomide and Anti-CD38 Refractory Subpopulation



/mnt/code/sSAP/sSAP02/prod/tfls/f_e_dor_irc_any_2ref.sas 14OCT2025 13:52

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 2.0010005

Graph of Kaplan Meier Curves of Duration of Response Based on Independent Reviewer - Assessed Response (considering death due to disease progression) - Lenalidomide and Anti-CD38 Refractory Subpopulation



Number at Risk (Number of Events)

| | | |

1.2.2.4 PFS2

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 2.0011005

Graph of Kaplan Meier Curves of Progression-Free Survival 2 Based on Investigator - Assessed Response - Lenalidomide and Anti-CD38 Refractory Subpopulation



/mnt/code/sSAP/sSAP02/prod/tfls/f_e_pfs2_inv_2ref.sas 14OCT2025 13:53

1.3 Patient Reported Outcomes

1.3.1 Tabellen – Ergebnisse für Patient Reported Outcomes

1.3.1.1 OSDI

Protocol: 207499 Page 1 of 30
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	12.38	10.70
		SD	20.979	19.552
		Median	5.00	2.92
		Min.	0.0	0.0
		Max.	79.2	100.0
Week 5	Actual Score	n	25	29
		Mean	18.04	6.03
		SD	20.564	8.728
		Median	11.11	2.08
		Min.	0.0	0.0
		Max.	57.5	40.9
	Change from Baseline	n	24	28
		Mean	3.24	-4.34
		SD	20.843	20.074
		Median	0.00	0.00
		Min.	-54.2	-100.0
		Max.	50.0	12.5
	Worsening Score of >=15 from Baseline	n (%)	5 (21%)	0
	Improving Score of >=15 from Baseline	n (%)	2 (8%)	2 (7%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	26
		Mean	26.60	9.64
		SD	29.374	21.249
		Median	13.16	1.04
		Min.	0.0	0.0
		Max.	90.0	100.0
	Change from Baseline	n	23	25
		Mean	11.99	-0.55
		SD	23.819	7.208
		Median	6.82	0.00
		Min.	-14.2	-16.7
		Max.	71.0	14.6
	Worsening Score of >=15 from Baseline	n (%)	5 (22%)	0
	Improving Score of >=15 from Baseline	n (%)	0	1 (4%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	27
		Mean	21.70	6.19
		SD	21.963	9.731
		Median	15.91	3.13
		Min.	0.0	0.0
		Max.	65.6	45.0
	Change from Baseline	n	22	27
		Mean	5.31	-4.94
		SD	20.030	20.912
		Median	0.00	0.00
		Min.	-25.0	-100.0
		Max.	45.8	25.0
	Worsening Score of >=15 from Baseline	n (%)	6 (27%)	1 (4%)
	Improving Score of >=15 from Baseline	n (%)	4 (18%)	3 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	24
		Mean	23.75	8.78
		SD	24.609	11.347
		Median	21.67	1.14
		Min.	0.0	0.0
		Max.	77.3	42.5
	Change from Baseline	n	21	24
		Mean	7.87	-2.78
		SD	28.245	23.158
		Median	2.08	0.00
		Min.	-43.1	-100.0
		Max.	66.9	22.9
	Worsening Score of >=15 from Baseline	n (%)	9 (43%)	2 (8%)
	Improving Score of >=15 from Baseline	n (%)	3 (14%)	2 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	16	18
		Mean	26.30	5.70
		SD	25.121	6.958
		Median	22.22	2.43
		Min.	0.0	0.0
		Max.	72.9	20.0
	Change from Baseline	n	15	18
		Mean	12.03	-5.66
		SD	29.069	25.061
		Median	4.55	0.00
		Min.	-54.2	-100.0
		Max.	70.8	16.7
	Worsening Score of >=15 from Baseline	n (%)	5 (33%)	1 (6%)
	Improving Score of >=15 from Baseline	n (%)	1 (7%)	2 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	17	15
		Mean	36.10	7.22
		SD	28.082	7.782
		Median	29.17	6.25
		Min.	0.0	0.0
		Max.	88.6	22.7
	Change from Baseline	n	16	15
		Mean	23.52	-5.18
		SD	32.318	27.680
		Median	12.93	-0.95
		Min.	-29.2	-100.0
		Max.	88.6	22.7
	Worsening Score of >=15 from Baseline	n (%)	7 (44%)	2 (13%)
	Improving Score of >=15 from Baseline	n (%)	1 (6%)	1 (7%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	16	10
		Mean	24.36	13.22
		SD	18.289	13.049
		Median	27.08	11.93
		Min.	0.0	0.0
		Max.	53.6	33.3
	Change from Baseline	n	15	10
		Mean	11.08	0.23
		SD	21.302	37.471
		Median	10.00	8.81
		Min.	-40.3	-100.0
		Max.	41.7	31.3
	Worsening Score of >=15 from Baseline	n (%)	5 (33%)	4 (40%)
	Improving Score of >=15 from Baseline	n (%)	1 (7%)	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	13	9
		Mean	30.75	8.30
		SD	30.787	9.367
		Median	21.43	2.08
		Min.	0.0	0.0
		Max.	97.9	22.5
	Change from Baseline	n	13	9
		Mean	16.19	-6.13
		SD	39.150	36.547
		Median	10.42	0.00
		Min.	-59.7	-100.0
		Max.	86.6	22.5
	Worsening Score of >=15 from Baseline	n (%)	5 (38%)	2 (22%)
	Improving Score of >=15 from Baseline	n (%)	2 (15%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	11	8
		Mean	28.38	7.42
		SD	25.463	10.527
		Median	15.63	1.04
		Min.	0.0	0.0
		Max.	83.3	25.0
	Change from Baseline	n	10	8
		Mean	16.75	-8.81
		SD	35.180	38.177
		Median	11.98	0.00
		Min.	-51.4	-100.0
		Max.	77.1	21.9
	Worsening Score of >=15 from Baseline	n (%)	5 (50%)	1 (13%)
	Improving Score of >=15 from Baseline	n (%)	1 (10%)	1 (13%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	10	6
		Mean	38.52	7.87
		SD	23.652	6.771
		Median	35.07	7.29
		Min.	10.4	0.0
		Max.	81.3	16.7
	Change from Baseline	n	10	6
		Mean	22.60	5.09
		SD	32.114	9.798
		Median	20.00	5.21
		Min.	-40.3	-10.4
		Max.	75.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	6 (60%)	1 (17%)
	Improving Score of >=15 from Baseline	n (%)	1 (10%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	11	6
		Mean	26.48	18.54
		SD	18.104	40.003
		Median	25.00	2.50
		Min.	0.0	0.0
		Max.	65.6	100.0
	Change from Baseline	n	11	6
		Mean	11.80	15.76
		SD	27.962	36.272
		Median	8.33	0.42
		Min.	-51.0	-2.1
		Max.	51.3	89.6
	Worsening Score of >=15 from Baseline	n (%)	5 (45%)	1 (17%)
	Improving Score of >=15 from Baseline	n (%)	1 (9%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	8	5
		Mean	25.12	5.64
		SD	11.029	7.736
		Median	23.75	0.00
		Min.	8.3	0.0
		Max.	47.2	14.6
	Change from Baseline	n	8	5
		Mean	5.51	2.31
		SD	19.202	9.855
		Median	7.44	0.00
		Min.	-31.9	-10.4
		Max.	25.0	14.6
	Worsening Score of >=15 from Baseline	n (%)	3 (38%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	7	4
		Mean	26.50	3.13
		SD	22.029	6.250
		Median	19.44	0.00
		Min.	6.8	0.0
		Max.	61.4	12.5
	Change from Baseline	n	7	4
		Mean	9.28	-1.04
		SD	35.456	7.702
		Median	7.20	-1.04
		Min.	-59.7	-10.4
		Max.	47.1	8.3
	Worsening Score of >=15 from Baseline	n (%)	2 (29%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	21.58	5.58
		SD	14.810	5.786
		Median	23.26	5.00
		Min.	0.0	0.0
		Max.	38.9	12.5
	Change from Baseline	n	8	5
		Mean	6.51	2.25
		SD	21.799	8.471
		Median	8.96	2.92
		Min.	-40.3	-10.4
		Max.	35.4	12.5
	Worsening Score of >=15 from Baseline	n (%)	2 (25%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	6	5
		Mean	30.10	5.83
		SD	19.643	5.393
		Median	34.75	4.17
		Min.	4.2	0.0
		Max.	58.3	12.5
	Change from Baseline	n	6	5
		Mean	10.01	2.50
		SD	42.008	7.126
		Median	20.32	0.00
		Min.	-68.1	-6.3
		Max.	52.1	12.5
	Worsening Score of >=15 from Baseline	n (%)	4 (67%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	5
		Mean	29.40	5.00
		SD	26.492	5.229
		Median	29.17	4.17
		Min.	4.2	0.0
		Max.	75.0	10.4
	Change from Baseline	n	7	5
		Mean	12.18	1.67
		SD	37.378	7.424
		Median	6.82	4.17
		Min.	-44.8	-10.4
		Max.	75.0	8.3
	Worsening Score of >=15 from Baseline	n (%)	3 (43%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	46.35	5.73
		SD	18.752	7.090
		Median	50.69	4.17
		Min.	14.6	0.0
		Max.	66.7	14.6
	Change from Baseline	n	6	4
		Mean	26.26	4.17
		SD	38.403	6.133
		Median	37.82	4.17
		Min.	-43.1	-2.1
		Max.	60.4	10.4
	Worsening Score of >=15 from Baseline	n (%)	4 (67%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	6	5
		Mean	34.14	6.67
		SD	16.733	4.517
		Median	39.93	8.33
		Min.	12.5	0.0
		Max.	50.0	10.4
	Change from Baseline	n	6	5
		Mean	27.25	3.33
		SD	18.621	3.785
		Median	34.38	2.08
		Min.	-1.8	0.0
		Max.	44.4	8.3
	Worsening Score of >=15 from Baseline	n (%)	4 (67%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	5	4
		Mean	31.67	7.29
		SD	10.765	10.555
		Median	29.17	3.13
		Min.	18.8	0.0
		Max.	43.8	22.9
	Change from Baseline	n	5	4
		Mean	10.89	4.17
		SD	37.283	5.642
		Median	27.38	2.08
		Min.	-54.2	0.0
		Max.	37.5	12.5
	Worsening Score of >=15 from Baseline	n (%)	3 (60%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	29.68	11.46
		SD	15.947	16.205
		Median	31.25	11.46
		Min.	4.5	0.0
		Max.	46.4	22.9
	Change from Baseline	n	6	2
		Mean	9.59	5.21
		SD	26.838	10.312
		Median	17.71	5.21
		Min.	-41.7	-2.1
		Max.	32.1	12.5
	Worsening Score of >=15 from Baseline	n (%)	4 (67%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	5	2
		Mean	34.70	11.46
		SD	20.423	16.205
		Median	31.82	11.46
		Min.	12.5	0.0
		Max.	64.6	22.9
	Change from Baseline	n	5	2
		Mean	26.42	6.25
		SD	17.163	8.839
		Median	20.83	6.25
		Min.	8.3	0.0
		Max.	50.3	12.5
	Worsening Score of >=15 from Baseline	n (%)	4 (80%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	2
		Mean	47.58	12.50
		SD	17.053	14.731
		Median	54.55	12.50
		Min.	22.9	2.1
		Max.	64.6	22.9
	Change from Baseline	n	5	2
		Mean	39.30	7.29
		SD	13.012	7.366
		Median	37.88	7.29
		Min.	22.9	2.1
		Max.	54.2	12.5
	Worsening Score of >=15 from Baseline	n (%)	5 (100%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	7	2
		Mean	32.24	12.50
		SD	29.188	17.678
		Median	28.13	12.50
		Min.	0.0	0.0
		Max.	70.8	25.0
	Change from Baseline	n	7	2
		Mean	15.02	7.29
		SD	41.220	10.312
		Median	9.09	7.29
		Min.	-51.0	0.0
		Max.	64.6	14.6
	Worsening Score of >=15 from Baseline	n (%)	3 (43%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	4	1
		Mean	18.94	25.00
		SD	10.923	
		Median	17.71	25.00
		Min.	9.1	25.0
		Max.	31.3	25.0
	Change from Baseline	n	4	1
		Mean	12.76	14.58
		SD	8.364	
		Median	9.90	14.58
		Min.	6.3	14.6
		Max.	25.0	14.6
	Worsening Score of >=15 from Baseline	n (%)	1 (25%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 25 of 30
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	26.20	25.00
		SD	24.601	
		Median	13.64	25.00
		Min.	10.4	25.0
		Max.	54.5	25.0
	Change from Baseline	n	3	1
		Mean	19.26	14.58
		SD	16.546	
		Median	13.64	14.58
		Min.	6.3	14.6
		Max.	37.9	14.6
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 26 of 30
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	3	1
		Mean	26.00	25.00
		SD	22.783	
		Median	15.91	25.00
		Min.	10.0	25.0
		Max.	52.1	25.0
	Change from Baseline	n	3	1
		Mean	22.53	14.58
		SD	20.805	
		Median	15.91	14.58
		Min.	5.8	14.6
		Max.	45.8	14.6
	Worsening Score of >=15 from Baseline	n (%)	2 (67%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	2	1
		Mean	19.79	25.00
		SD	7.366	
		Median	19.79	25.00
		Min.	14.6	25.0
		Max.	25.0	25.0
	Change from Baseline	n	2	1
		Mean	14.58	14.58
		SD	5.893	
		Median	14.58	14.58
		Min.	10.4	14.6
		Max.	18.8	14.6
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	20
		Mean	20.85	7.97
		SD	21.536	10.816
		Median	14.44	2.95
		Min.	0.0	0.0
		Max.	71.4	42.5
	Change from Baseline	n	17	20
		Mean	5.88	-3.67
		SD	24.142	23.861
		Median	5.56	1.04
		Min.	-43.1	-100.0
		Max.	45.8	13.6
	Worsening Score of >=15 from Baseline	n (%)	6 (35%)	0
	Improving Score of >=15 from Baseline	n (%)	2 (12%)	2 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Table 4.0000105

Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	6	0
		Mean	20.13	
		SD	19.125	
		Median	17.50	
		Min.	0.0	
		Max.	52.1	
	Change from Baseline	n	6	0
		Mean	4.12	
		SD	33.571	
		Median	3.86	
		Min.	-51.0	
		Max.	52.1	
	Worsening Score of >=15 from Baseline	n (%)	2 (33%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 30 of 30
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000105
Summary of Change in OSDI Total Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	46.66	19.85
		SD	32.492	24.073
		Median	52.53	14.58
		Min.	0.0	0.0
		Max.	97.9	100.0
	Change from Baseline	n	25	30
		Mean	32.24	10.42
		SD	32.364	17.996
		Median	26.04	7.16
		Min.	-6.3	-16.7
		Max.	88.6	89.6
	Worsening Score of >=15 from Baseline	n (%)	14 (56%)	6 (20%)
	Improving Score of >=15 from Baseline	n (%)	0	1 (3%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_tot_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 1 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	6.48	9.90
		SD	16.879	21.837
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	83.3	100.0
Week 5	Actual Score	n	25	29
		Mean	12.67	4.02
		SD	20.850	7.258
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	58.3	16.7
	Change from Baseline	n	24	28
		Mean	3.82	-7.14
		SD	23.310	24.079
		Median	0.00	0.00
		Min.	-58.3	-100.0
		Max.	50.0	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	4 (17%)	0
	Improving Score of >=16.67 from Baseline	n (%)	2 (8%)	3 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205

Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	26
		Mean	21.88	7.69
		SD	26.100	19.989
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	83.3	100.0
	Change from Baseline	n	23	25
		Mean	13.41	-2.67
		SD	20.216	15.161
		Median	8.33	0.00
		Min.	-8.3	-66.7
		Max.	58.3	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	5 (22%)	1 (4%)
	Improving Score of >=16.67 from Baseline	n (%)	0	1 (4%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	27
		Mean	19.93	4.63
		SD	20.983	7.061
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	58.3	25.0
	Change from Baseline	n	22	27
		Mean	11.36	-7.10
		SD	22.937	23.875
		Median	0.00	0.00
		Min.	-41.7	-100.0
		Max.	58.3	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	7 (32%)	1 (4%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (5%)	3 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	24
		Mean	19.70	5.21
		SD	23.647	8.446
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	83.3	25.0
	Change from Baseline	n	21	24
		Mean	11.11	-6.60
		SD	31.106	26.235
		Median	8.33	0.00
		Min.	-83.3	-100.0
		Max.	75.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	5 (24%)	1 (4%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (5%)	2 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	16	18
		Mean	21.35	8.33
		SD	25.453	9.480
		Median	16.67	4.17
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	15	18
		Mean	12.22	-6.94
		SD	33.313	29.463
		Median	8.33	0.00
		Min.	-66.7	-100.0
		Max.	100.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	4 (27%)	1 (6%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (7%)	2 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	17	15
		Mean	33.33	5.56
		SD	28.868	8.133
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	91.7	25.0
	Change from Baseline	n	16	15
		Mean	22.92	-7.78
		SD	32.844	27.362
		Median	16.67	0.00
		Min.	-33.3	-100.0
		Max.	91.7	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	7 (44%)	1 (7%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (6%)	1 (7%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	16	10
		Mean	22.40	8.33
		SD	18.439	13.608
		Median	20.83	0.00
		Min.	0.0	0.0
		Max.	58.3	33.3
	Change from Baseline	n	15	10
		Mean	12.22	-5.83
		SD	22.242	36.015
		Median	16.67	0.00
		Min.	-41.7	-100.0
		Max.	50.0	33.3
	Worsening Score of >=16.67 from Baseline	n (%)	6 (40%)	2 (20%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (7%)	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	13	9
		Mean	25.00	7.41
		SD	32.454	10.577
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	13	9
		Mean	13.46	-8.33
		SD	41.463	35.600
		Median	8.33	0.00
		Min.	-75.0	-100.0
		Max.	100.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	5 (38%)	1 (11%)
	Improving Score of >=16.67 from Baseline	n (%)	2 (15%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	11	8
		Mean	23.48	7.29
		SD	21.350	8.259
		Median	16.67	4.17
		Min.	0.0	0.0
		Max.	58.3	16.7
	Change from Baseline	n	10	8
		Mean	13.33	-10.42
		SD	29.969	36.934
		Median	16.67	0.00
		Min.	-58.3	-100.0
		Max.	50.0	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	3 (30%)	0
	Improving Score of >=16.67 from Baseline	n (%)	1 (10%)	1 (13%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205

Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	10	6
		Mean	25.00	8.33
		SD	20.787	10.541
		Median	20.83	4.17
		Min.	0.0	0.0
		Max.	66.7	25.0
	Change from Baseline	n	10	6
		Mean	13.33	4.17
		SD	28.109	10.206
		Median	16.67	0.00
		Min.	-50.0	0.0
		Max.	50.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	4 (40%)	1 (17%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (10%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	11	6
		Mean	21.21	20.83
		SD	18.769	39.352
		Median	25.00	4.17
		Min.	0.0	0.0
		Max.	50.0	100.0
	Change from Baseline	n	11	6
		Mean	9.85	16.67
		SD	29.538	41.164
		Median	8.33	0.00
		Min.	-58.3	-8.3
		Max.	50.0	100.0
	Worsening Score of >=16.67 from Baseline	n (%)	4 (36%)	1 (17%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (9%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	8	5
		Mean	26.04	5.00
		SD	12.148	7.454
		Median	25.00	0.00
		Min.	8.3	0.0
		Max.	50.0	16.7
	Change from Baseline	n	8	5
		Mean	12.50	0.00
		SD	29.547	5.893
		Median	25.00	0.00
		Min.	-58.3	-8.3
		Max.	33.3	8.3
	Worsening Score of >=16.67 from Baseline	n (%)	5 (63%)	0
	Improving Score of >=16.67 from Baseline	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	7	4
		Mean	25.00	4.17
		SD	29.266	8.333
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	75.0	16.7
	Change from Baseline	n	7	4
		Mean	9.52	-2.08
		SD	43.416	4.167
		Median	8.33	0.00
		Min.	-75.0	-8.3
		Max.	58.3	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	2 (29%)	0
	Improving Score of >=16.67 from Baseline	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	26.04	8.33
		SD	28.325	8.333
		Median	12.50	8.33
		Min.	0.0	0.0
		Max.	75.0	16.7
	Change from Baseline	n	8	5
		Mean	12.50	3.33
		SD	27.458	7.454
		Median	8.33	0.00
		Min.	-33.3	0.0
		Max.	50.0	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	2 (25%)	0
	Improving Score of >=16.67 from Baseline	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	6	5
		Mean	30.56	10.00
		SD	19.484	6.972
		Median	33.33	8.33
		Min.	8.3	0.0
		Max.	50.0	16.7
	Change from Baseline	n	6	5
		Mean	12.50	5.00
		SD	45.262	7.454
		Median	25.00	0.00
		Min.	-75.0	0.0
		Max.	50.0	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	4 (67%)	0
	Improving Score of >=16.67 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	5
		Mean	25.00	10.00
		SD	26.788	10.865
		Median	25.00	8.33
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	7	5
		Mean	9.52	5.00
		SD	39.508	7.454
		Median	8.33	0.00
		Min.	-58.3	0.0
		Max.	75.0	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	2 (29%)	0
	Improving Score of >=16.67 from Baseline	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	33.33	12.50
		SD	23.570	15.957
		Median	25.00	8.33
		Min.	8.3	0.0
		Max.	66.7	33.3
	Change from Baseline	n	6	4
		Mean	15.28	6.25
		SD	41.304	12.500
		Median	20.83	8.33
		Min.	-58.3	-8.3
		Max.	66.7	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	3 (50%)	0
	Improving Score of >=16.67 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	6	5
		Mean	26.39	11.67
		SD	21.355	11.180
		Median	25.00	16.67
		Min.	0.0	0.0
		Max.	50.0	25.0
	Change from Baseline	n	6	5
		Mean	22.22	6.67
		SD	18.002	13.693
		Median	20.83	0.00
		Min.	0.0	-8.3
		Max.	50.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	3 (50%)	1 (20%)
	Improving Score of >=16.67 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	5	4
		Mean	23.33	6.25
		SD	16.029	12.500
		Median	16.67	0.00
		Min.	8.3	0.0
		Max.	50.0	25.0
	Change from Baseline	n	5	4
		Mean	1.67	4.17
		SD	38.819	14.434
		Median	16.67	0.00
		Min.	-66.7	-8.3
		Max.	25.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	2 (40%)	1 (25%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205

Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	37.50	12.50
		SD	27.259	17.678
		Median	37.50	12.50
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	6	2
		Mean	19.44	8.33
		SD	20.184	23.570
		Median	25.00	8.33
		Min.	-8.3	-8.3
		Max.	41.7	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	3 (50%)	1 (50%)
	Improving Score of >=16.67 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	5	2
		Mean	30.00	12.50
		SD	19.185	17.678
		Median	25.00	12.50
		Min.	8.3	0.0
		Max.	50.0	25.0
	Change from Baseline	n	5	2
		Mean	25.00	12.50
		SD	15.590	17.678
		Median	25.00	12.50
		Min.	8.3	0.0
		Max.	50.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	3 (60%)	1 (50%)
	Improving Score of >=16.67 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	2
		Mean	40.00	12.50
		SD	14.907	17.678
		Median	41.67	12.50
		Min.	16.7	0.0
		Max.	58.3	25.0
	Change from Baseline	n	5	2
		Mean	35.00	12.50
		SD	18.066	17.678
		Median	41.67	12.50
		Min.	16.7	0.0
		Max.	58.3	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	3 (60%)	1 (50%)
	Improving Score of >=16.67 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	7	2
		Mean	27.38	12.50
		SD	25.781	17.678
		Median	25.00	12.50
		Min.	0.0	0.0
		Max.	66.7	25.0
	Change from Baseline	n	7	2
		Mean	11.90	12.50
		SD	37.223	17.678
		Median	8.33	12.50
		Min.	-58.3	0.0
		Max.	58.3	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	3 (43%)	1 (50%)
	Improving Score of >=16.67 from Baseline	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	4	1
		Mean	20.83	25.00
		SD	25.000	
		Median	8.33	25.00
		Min.	8.3	25.0
		Max.	58.3	25.0
	Change from Baseline	n	4	1
		Mean	14.58	25.00
		SD	12.500	
		Median	8.33	25.00
		Min.	8.3	25.0
		Max.	33.3	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	1 (25%)	1 (100%)
	Improving Score of >=16.67 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205

Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	25.00	25.00
		SD	8.333	
		Median	25.00	25.00
		Min.	16.7	25.0
		Max.	33.3	25.0
	Change from Baseline	n	3	1
		Mean	25.00	25.00
		SD	8.333	
		Median	25.00	25.00
		Min.	16.7	25.0
		Max.	33.3	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	2 (67%)	1 (100%)
	Improving Score of >=16.67 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	3	1
		Mean	22.22	25.00
		SD	17.347	
		Median	16.67	25.00
		Min.	8.3	25.0
		Max.	41.7	25.0
	Change from Baseline	n	3	1
		Mean	13.89	25.00
		SD	4.811	
		Median	16.67	25.00
		Min.	8.3	25.0
		Max.	16.7	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (100%)
	Improving Score of >=16.67 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	2	1
		Mean	20.83	25.00
		SD	5.893	
		Median	20.83	25.00
		Min.	16.7	25.0
		Max.	25.0	25.0
	Change from Baseline	n	2	1
		Mean	8.33	25.00
		SD	11.785	
		Median	8.33	25.00
		Min.	0.0	25.0
		Max.	16.7	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (100%)
	Improving Score of >=16.67 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 28 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	20
		Mean	19.91	4.58
		SD	21.416	6.880
		Median	12.50	0.00
		Min.	0.0	0.0
		Max.	58.3	16.7
	Change from Baseline	n	17	20
		Mean	11.76	-8.75
		SD	26.526	26.693
		Median	8.33	0.00
		Min.	-58.3	-100.0
		Max.	50.0	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	6 (35%)	0
	Improving Score of >=16.67 from Baseline	n (%)	1 (6%)	2 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205

Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	6	0
		Mean	18.06	
		SD	23.224	
		Median	12.50	
		Min.	0.0	
		Max.	58.3	
	Change from Baseline	n	6	0
		Mean	-5.56	
		SD	38.249	
		Median	-4.17	
		Min.	-58.3	
		Max.	58.3	
	Worsening Score of >=16.67 from Baseline	n (%)	1 (17%)	0
	Improving Score of >=16.67 from Baseline	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 30 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Ocular Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	40.71	16.13
		SD	33.110	24.715
		Median	37.50	8.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	30
		Mean	33.33	6.11
		SD	33.593	23.866
		Median	25.00	0.00
		Min.	-8.3	-66.7
		Max.	100.0	100.0
	Worsening Score of >=16.67 from Baseline	n (%)	13 (52%)	3 (10%)
	Improving Score of >=16.67 from Baseline	n (%)	0	1 (3%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 31 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	17.16	13.55
		SD	29.425	24.474
		Median	0.00	2.08
		Min.	0.0	0.0
		Max.	100.0	100.0
Week 5	Actual Score	n	25	29
		Mean	23.57	7.84
		SD	27.683	13.995
		Median	12.50	0.00
		Min.	0.0	0.0
		Max.	85.0	70.8
	Change from Baseline	n	24	28
		Mean	3.85	-4.24
		SD	22.952	20.757
		Median	0.00	0.00
		Min.	-58.3	-100.0
		Max.	50.0	15.0
	Worsening Score of >=15 from Baseline	n (%)	4 (17%)	1 (4%)
	Improving Score of >=15 from Baseline	n (%)	4 (17%)	4 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 32 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	26
		Mean	32.71	12.02
		SD	35.022	24.362
		Median	18.75	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	23	25
		Mean	14.20	-0.08
		SD	30.023	10.018
		Median	6.25	0.00
		Min.	-28.3	-25.0
		Max.	91.7	16.7
	Worsening Score of >=15 from Baseline	n (%)	8 (35%)	2 (8%)
	Improving Score of >=15 from Baseline	n (%)	4 (17%)	3 (12%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205

Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	27
		Mean	25.83	7.72
		SD	28.596	14.593
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	81.3	66.7
	Change from Baseline	n	22	27
		Mean	2.54	-5.23
		SD	29.190	21.908
		Median	0.00	0.00
		Min.	-70.0	-100.0
		Max.	66.7	25.0
	Worsening Score of >=15 from Baseline	n (%)	6 (27%)	1 (4%)
	Improving Score of >=15 from Baseline	n (%)	6 (27%)	4 (15%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 34 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	24
		Mean	29.20	11.46
		SD	31.757	16.230
		Median	22.92	0.00
		Min.	0.0	0.0
		Max.	100.0	58.3
	Change from Baseline	n	21	24
		Mean	7.54	-2.31
		SD	36.305	25.556
		Median	0.00	0.00
		Min.	-80.0	-100.0
		Max.	75.0	30.0
	Worsening Score of >=15 from Baseline	n (%)	9 (43%)	5 (21%)
	Improving Score of >=15 from Baseline	n (%)	5 (24%)	5 (21%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 35 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	16	18
		Mean	33.93	5.02
		SD	33.367	7.531
		Median	27.50	0.00
		Min.	0.0	0.0
		Max.	100.0	20.8
	Change from Baseline	n	15	18
		Mean	13.36	-6.18
		SD	32.467	25.236
		Median	0.00	0.00
		Min.	-52.1	-100.0
		Max.	66.7	20.8
	Worsening Score of >=15 from Baseline	n (%)	6 (40%)	1 (6%)
	Improving Score of >=15 from Baseline	n (%)	2 (13%)	2 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	17	15
		Mean	40.54	8.19
		SD	28.106	10.578
		Median	37.50	0.00
		Min.	0.0	0.0
		Max.	87.5	25.0
	Change from Baseline	n	16	15
		Mean	24.27	-4.42
		SD	36.098	28.734
		Median	24.58	0.00
		Min.	-33.3	-100.0
		Max.	87.5	25.0
	Worsening Score of >=15 from Baseline	n (%)	9 (56%)	2 (13%)
	Improving Score of >=15 from Baseline	n (%)	2 (13%)	2 (13%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	16	10
		Mean	29.48	19.58
		SD	27.006	25.764
		Median	28.33	10.42
		Min.	0.0	0.0
		Max.	70.8	75.0
	Change from Baseline	n	15	10
		Mean	11.94	6.04
		SD	27.857	43.794
		Median	6.25	10.42
		Min.	-33.3	-100.0
		Max.	60.8	56.3
	Worsening Score of >=15 from Baseline	n (%)	5 (33%)	5 (50%)
	Improving Score of >=15 from Baseline	n (%)	2 (13%)	2 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205

Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	13	9
		Mean	35.64	10.88
		SD	30.929	16.264
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	100.0	43.8
	Change from Baseline	n	13	9
		Mean	16.99	-4.17
		SD	46.445	38.752
		Median	12.50	0.00
		Min.	-70.0	-100.0
		Max.	100.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	6 (46%)	3 (33%)
	Improving Score of >=15 from Baseline	n (%)	2 (15%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	11	8
		Mean	32.54	8.59
		SD	31.730	16.683
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	87.5	43.8
	Change from Baseline	n	10	8
		Mean	19.54	-8.33
		SD	42.232	39.591
		Median	6.25	0.00
		Min.	-52.1	-100.0
		Max.	87.5	25.0
	Worsening Score of >=15 from Baseline	n (%)	4 (40%)	2 (25%)
	Improving Score of >=15 from Baseline	n (%)	1 (10%)	2 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	10	6
		Mean	47.54	7.64
		SD	33.258	9.286
		Median	38.54	4.17
		Min.	8.3	0.0
		Max.	100.0	20.8
	Change from Baseline	n	10	6
		Mean	24.96	4.86
		SD	46.981	13.544
		Median	18.75	4.17
		Min.	-39.6	-16.7
		Max.	90.0	20.8
	Worsening Score of >=15 from Baseline	n (%)	5 (50%)	2 (33%)
	Improving Score of >=15 from Baseline	n (%)	2 (20%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 41 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	11	6
		Mean	35.45	18.06
		SD	28.820	40.283
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	90.0	100.0
	Change from Baseline	n	11	6
		Mean	14.92	15.28
		SD	42.463	33.506
		Median	25.00	0.00
		Min.	-55.0	0.0
		Max.	90.0	83.3
	Worsening Score of >=15 from Baseline	n (%)	6 (55%)	1 (17%)
	Improving Score of >=15 from Baseline	n (%)	2 (18%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 42 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	8	5
		Mean	21.82	6.00
		SD	22.443	10.840
		Median	22.92	0.00
		Min.	0.0	0.0
		Max.	68.8	25.0
	Change from Baseline	n	8	5
		Mean	-6.41	2.67
		SD	30.210	14.935
		Median	0.00	0.00
		Min.	-75.0	-16.7
		Max.	20.8	25.0
	Worsening Score of >=15 from Baseline	n (%)	2 (25%)	1 (20%)
	Improving Score of >=15 from Baseline	n (%)	1 (13%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 43 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	7	4
		Mean	30.60	1.04
		SD	28.563	2.083
		Median	29.17	0.00
		Min.	0.0	0.0
		Max.	80.0	4.2
	Change from Baseline	n	7	4
		Mean	9.76	-3.13
		SD	32.912	9.239
		Median	8.33	0.00
		Min.	-52.1	-16.7
		Max.	55.0	4.2
	Worsening Score of >=15 from Baseline	n (%)	3 (43%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (14%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	25.68	3.33
		SD	27.954	7.454
		Median	20.83	0.00
		Min.	0.0	0.0
		Max.	75.0	16.7
	Change from Baseline	n	8	5
		Mean	7.45	0.00
		SD	26.424	11.785
		Median	2.08	0.00
		Min.	-39.6	-16.7
		Max.	50.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	2 (25%)	1 (20%)
	Improving Score of >=15 from Baseline	n (%)	1 (13%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	6	5
		Mean	34.58	4.17
		SD	22.539	7.217
		Median	39.17	0.00
		Min.	4.2	0.0
		Max.	62.5	16.7
	Change from Baseline	n	6	5
		Mean	10.28	0.83
		SD	43.001	10.375
		Median	24.58	0.00
		Min.	-70.8	-12.5
		Max.	50.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	4 (67%)	1 (20%)
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	5
		Mean	31.85	1.67
		SD	29.184	3.727
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	75.0	8.3
	Change from Baseline	n	7	5
		Mean	11.01	-1.67
		SD	36.774	9.129
		Median	4.17	0.00
		Min.	-39.6	-16.7
		Max.	75.0	8.3
	Worsening Score of >=15 from Baseline	n (%)	3 (43%)	0
	Improving Score of >=15 from Baseline	n (%)	2 (29%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	58.06	2.08
		SD	22.649	4.167
		Median	60.42	0.00
		Min.	20.8	0.0
		Max.	90.0	8.3
	Change from Baseline	n	6	4
		Mean	33.75	2.08
		SD	39.383	4.167
		Median	43.75	0.00
		Min.	-33.3	0.0
		Max.	66.7	8.3
	Worsening Score of >=15 from Baseline	n (%)	5 (83%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	6	5
		Mean	40.83	3.33
		SD	27.234	4.564
		Median	33.33	0.00
		Min.	20.8	0.0
		Max.	95.0	8.3
	Change from Baseline	n	6	5
		Mean	30.42	0.00
		SD	20.775	5.893
		Median	33.33	0.00
		Min.	0.0	-8.3
		Max.	61.7	8.3
	Worsening Score of >=15 from Baseline	n (%)	5 (83%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	5	4
		Mean	40.42	8.33
		SD	33.515	9.001
		Median	25.00	6.25
		Min.	20.8	0.0
		Max.	100.0	20.8
	Change from Baseline	n	5	4
		Mean	17.92	4.17
		SD	45.443	3.402
		Median	25.00	4.17
		Min.	-52.1	0.0
		Max.	75.0	8.3
	Worsening Score of >=15 from Baseline	n (%)	4 (80%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	37.85	10.42
		SD	39.229	14.731
		Median	23.96	10.42
		Min.	0.0	0.0
		Max.	100.0	20.8
	Change from Baseline	n	6	2
		Mean	13.54	2.08
		SD	46.468	2.946
		Median	16.67	2.08
		Min.	-64.6	0.0
		Max.	75.0	4.2
	Worsening Score of >=15 from Baseline	n (%)	3 (50%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	5	2
		Mean	41.33	10.42
		SD	29.853	14.731
		Median	33.33	10.42
		Min.	8.3	0.0
		Max.	79.2	20.8
	Change from Baseline	n	5	2
		Mean	28.83	2.08
		SD	18.320	2.946
		Median	31.67	2.08
		Min.	4.2	0.0
		Max.	54.2	4.2
	Worsening Score of >=15 from Baseline	n (%)	4 (80%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	2
		Mean	55.00	12.50
		SD	31.375	11.785
		Median	75.00	12.50
		Min.	16.7	4.2
		Max.	79.2	20.8
	Change from Baseline	n	5	2
		Mean	42.50	4.17
		SD	22.898	0.000
		Median	45.83	4.17
		Min.	16.7	4.2
		Max.	75.0	4.2
	Worsening Score of >=15 from Baseline	n (%)	5 (100%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 53 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	7	2
		Mean	37.50	12.50
		SD	38.938	17.678
		Median	37.50	12.50
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	7	2
		Mean	16.67	4.17
		SD	46.085	5.893
		Median	0.00	4.17
		Min.	-45.8	0.0
		Max.	70.8	8.3
	Worsening Score of >=15 from Baseline	n (%)	3 (43%)	0
	Improving Score of >=15 from Baseline	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	4	1
		Mean	23.96	25.00
		SD	22.146	
		Median	22.92	25.00
		Min.	0.0	25.0
		Max.	50.0	25.0
	Change from Baseline	n	4	1
		Mean	16.67	8.33
		SD	15.215	
		Median	16.67	8.33
		Min.	0.0	8.3
		Max.	33.3	8.3
	Worsening Score of >=15 from Baseline	n (%)	2 (50%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 55 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	37.50	25.00
		SD	54.486	
		Median	12.50	25.00
		Min.	0.0	25.0
		Max.	100.0	25.0
	Change from Baseline	n	3	1
		Mean	25.00	8.33
		SD	36.324	
		Median	8.33	8.33
		Min.	0.0	8.3
		Max.	66.7	8.3
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 56 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	3	1
		Mean	28.61	25.00
		SD	29.537	
		Median	15.00	25.00
		Min.	8.3	25.0
		Max.	62.5	25.0
	Change from Baseline	n	3	1
		Mean	27.22	8.33
		SD	31.028	
		Median	15.00	8.33
		Min.	4.2	8.3
		Max.	62.5	8.3
	Worsening Score of >=15 from Baseline	n (%)	2 (67%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 57 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	2	1
		Mean	22.92	25.00
		SD	2.946	
		Median	22.92	25.00
		Min.	20.8	25.0
		Max.	25.0	25.0
	Change from Baseline	n	2	1
		Mean	20.83	8.33
		SD	5.893	
		Median	20.83	8.33
		Min.	16.7	8.3
		Max.	25.0	8.3
	Worsening Score of >=15 from Baseline	n (%)	2 (100%)	0
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	20
		Mean	23.89	10.29
		SD	28.355	15.242
		Median	13.75	2.08
		Min.	0.0	0.0
		Max.	100.0	58.3
	Change from Baseline	n	17	20
		Mean	2.70	-3.00
		SD	35.038	24.960
		Median	0.00	0.00
		Min.	-75.0	-100.0
		Max.	50.0	30.0
	Worsening Score of >=15 from Baseline	n (%)	6 (35%)	1 (5%)
	Improving Score of >=15 from Baseline	n (%)	4 (24%)	2 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 59 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	6	0
		Mean	24.31	
		SD	18.336	
		Median	25.00	
		Min.	0.0	
		Max.	50.0	
	Change from Baseline	n	6	0
		Mean	10.42	
		SD	32.463	
		Median	16.67	
		Min.	-45.8	
		Max.	50.0	
	Worsening Score of >=15 from Baseline	n (%)	3 (50%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 60 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Vision-Related Function

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	58.22	25.16
		SD	39.738	27.974
		Median	72.92	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	30
		Mean	38.02	14.18
		SD	39.385	20.938
		Median	35.00	10.42
		Min.	-16.7	-18.8
		Max.	100.0	83.3
	Worsening Score of >=15 from Baseline	n (%)	14 (56%)	11 (37%)
	Improving Score of >=15 from Baseline	n (%)	2 (8%)	2 (7%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	18	28
		Mean	12.04	6.85
		SD	28.328	19.909
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
Week 5	Actual Score	n	17	24
		Mean	12.25	4.69
		SD	15.343	8.271
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	50.0	25.0
	Change from Baseline	n	13	22
		Mean	1.28	1.33
		SD	17.953	11.457
		Median	0.00	0.00
		Min.	-41.7	-25.0
		Max.	25.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	3 (23%)	3 (14%)
	Improving Score of >=15 from Baseline	n (%)	2 (15%)	2 (9%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	18	17
		Mean	22.69	9.31
		SD	32.534	24.805
		Median	6.25	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	13	17
		Mean	7.05	0.00
		SD	16.872	9.317
		Median	0.00	0.00
		Min.	-16.7	-25.0
		Max.	50.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	3 (23%)	1 (6%)
	Improving Score of >=15 from Baseline	n (%)	1 (8%)	1 (6%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	21	16
		Mean	18.85	5.73
		SD	26.274	10.417
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	13	16
		Mean	8.01	0.52
		SD	19.725	11.575
		Median	0.00	0.00
		Min.	-16.7	-25.0
		Max.	50.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	4 (31%)	2 (13%)
	Improving Score of >=15 from Baseline	n (%)	1 (8%)	1 (6%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	18	17
		Mean	18.75	9.80
		SD	26.747	11.500
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	13	16
		Mean	2.24	6.77
		SD	17.063	13.340
		Median	0.00	0.00
		Min.	-29.2	-16.7
		Max.	33.3	25.0
	Worsening Score of >=15 from Baseline	n (%)	3 (23%)	6 (38%)
	Improving Score of >=15 from Baseline	n (%)	2 (15%)	1 (6%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 65 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	14	14
		Mean	13.99	3.57
		SD	18.316	7.813
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	50.0	25.0
	Change from Baseline	n	9	13
		Mean	-0.46	0.00
		SD	18.215	10.758
		Median	0.00	0.00
		Min.	-41.7	-25.0
		Max.	25.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (11%)	1 (8%)
	Improving Score of >=15 from Baseline	n (%)	1 (11%)	1 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 66 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	12	11
		Mean	34.72	10.98
		SD	37.366	11.825
		Median	25.00	8.33
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	8	10
		Mean	33.33	3.75
		SD	38.768	13.387
		Median	18.75	0.00
		Min.	0.0	-16.7
		Max.	87.5	25.0
	Worsening Score of >=15 from Baseline	n (%)	4 (50%)	2 (20%)
	Improving Score of >=15 from Baseline	n (%)	0	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 67 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	8
		Mean	10.42	6.25
		SD	10.933	9.708
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	25.0	25.0
	Change from Baseline	n	10	8
		Mean	-1.25	-7.29
		SD	23.078	38.944
		Median	0.00	0.00
		Min.	-54.2	-100.0
		Max.	25.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	3 (30%)	2 (25%)
	Improving Score of >=15 from Baseline	n (%)	2 (20%)	1 (13%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 68 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	10	6
		Mean	30.83	4.86
		SD	36.015	7.645
		Median	20.83	0.00
		Min.	0.0	0.0
		Max.	91.7	16.7
	Change from Baseline	n	8	6
		Mean	20.83	-11.81
		SD	41.547	43.813
		Median	4.17	0.00
		Min.	-41.7	-100.0
		Max.	75.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	3 (38%)	1 (17%)
	Improving Score of >=15 from Baseline	n (%)	1 (13%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	5
		Mean	24.07	5.00
		SD	32.125	11.180
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	6	5
		Mean	12.50	-15.00
		SD	49.089	48.734
		Median	-4.17	0.00
		Min.	-41.7	-100.0
		Max.	100.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	2 (33%)	1 (20%)
	Improving Score of >=15 from Baseline	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	7	4
		Mean	35.12	8.33
		SD	27.832	11.785
		Median	37.50	4.17
		Min.	0.0	0.0
		Max.	83.3	25.0
	Change from Baseline	n	5	3
		Mean	20.83	11.11
		SD	45.069	12.729
		Median	0.00	8.33
		Min.	-29.2	0.0
		Max.	83.3	25.0
	Worsening Score of >=15 from Baseline	n (%)	2 (40%)	1 (33%)
	Improving Score of >=15 from Baseline	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 71 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	10	4
		Mean	10.83	25.00
		SD	12.454	50.000
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	25.0	100.0
	Change from Baseline	n	7	4
		Mean	-2.38	22.92
		SD	20.250	45.833
		Median	0.00	0.00
		Min.	-41.7	0.0
		Max.	25.0	91.7
	Worsening Score of >=15 from Baseline	n (%)	1 (14%)	1 (25%)
	Improving Score of >=15 from Baseline	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205

Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	5
		Mean	32.74	5.00
		SD	26.618	11.180
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	4	4
		Mean	26.04	4.17
		SD	48.873	14.434
		Median	29.17	0.00
		Min.	-29.2	-8.3
		Max.	75.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	2 (50%)	1 (25%)
	Improving Score of >=15 from Baseline	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	6	4
		Mean	24.31	6.25
		SD	28.188	12.500
		Median	18.75	0.00
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	3	3
		Mean	4.17	5.56
		SD	65.484	17.347
		Median	-8.33	0.00
		Min.	-54.2	-8.3
		Max.	75.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	1 (33%)
	Improving Score of >=15 from Baseline	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	7	4
		Mean	8.93	6.25
		SD	11.890	12.500
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	25.0	25.0
	Change from Baseline	n	4	3
		Mean	-15.63	5.56
		SD	25.993	17.347
		Median	-4.17	0.00
		Min.	-54.2	-8.3
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (33%)
	Improving Score of >=15 from Baseline	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	6	5
		Mean	21.53	5.00
		SD	31.668	11.180
		Median	10.42	0.00
		Min.	0.0	0.0
		Max.	83.3	25.0
	Change from Baseline	n	3	4
		Mean	6.94	4.17
		SD	70.012	14.434
		Median	-8.33	0.00
		Min.	-54.2	-8.3
		Max.	83.3	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	1 (25%)
	Improving Score of >=15 from Baseline	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	6	5
		Mean	25.00	6.67
		SD	27.386	10.865
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	3	4
		Mean	-8.33	6.25
		SD	33.333	14.232
		Median	-8.33	4.17
		Min.	-41.7	-8.3
		Max.	25.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	1 (25%)
	Improving Score of >=15 from Baseline	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	4	4
		Mean	31.25	6.25
		SD	31.458	12.500
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	3	3
		Mean	8.33	8.33
		SD	60.093	14.434
		Median	-8.33	0.00
		Min.	-41.7	0.0
		Max.	75.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	1 (33%)
	Improving Score of >=15 from Baseline	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 78 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	6	5
		Mean	29.17	8.33
		SD	36.799	11.785
		Median	12.50	0.00
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	2	4
		Mean	33.33	8.33
		SD	58.926	15.215
		Median	33.33	8.33
		Min.	-8.3	-8.3
		Max.	75.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	2 (50%)
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	5	4
		Mean	36.67	6.25
		SD	23.274	12.500
		Median	25.00	0.00
		Min.	16.7	0.0
		Max.	75.0	25.0
	Change from Baseline	n	3	3
		Mean	13.89	5.56
		SD	58.531	9.623
		Median	8.33	0.00
		Min.	-41.7	0.0
		Max.	75.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	1 (33%)
	Improving Score of >=15 from Baseline	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 80 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	8.33	12.50
		SD	10.541	17.678
		Median	4.17	12.50
		Min.	0.0	0.0
		Max.	25.0	25.0
	Change from Baseline	n	3	2
		Mean	-13.89	8.33
		SD	47.385	11.785
		Median	0.00	8.33
		Min.	-66.7	0.0
		Max.	25.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	1 (50%)
	Improving Score of >=15 from Baseline	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 81 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	5	2
		Mean	28.33	12.50
		SD	25.413	17.678
		Median	25.00	12.50
		Min.	0.0	0.0
		Max.	58.3	25.0
	Change from Baseline	n	2	1
		Mean	29.17	16.67
		SD	41.248	
		Median	29.17	16.67
		Min.	0.0	16.7
		Max.	58.3	16.7
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (100%)
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 82 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	2
		Mean	36.67	12.50
		SD	28.013	17.678
		Median	33.33	12.50
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	2	1
		Mean	50.00	16.67
		SD	35.355	
		Median	50.00	16.67
		Min.	25.0	16.7
		Max.	75.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	2 (100%)	1 (100%)
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	7	2
		Mean	21.43	12.50
		SD	30.375	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	3	1
		Mean	0.00	16.67
		SD	71.200	
		Median	-8.33	16.67
		Min.	-66.7	16.7
		Max.	75.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	1 (33%)	1 (100%)
	Improving Score of >=15 from Baseline	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	3	1
		Mean	11.11	25.00
		SD	12.729	
		Median	8.33	25.00
		Min.	0.0	25.0
		Max.	25.0	25.0
	Change from Baseline	n	2	1
		Mean	0.00	16.67
		SD	0.000	
		Median	0.00	16.67
		Min.	0.0	16.7
		Max.	0.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 85 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	8.33	25.00
		SD	14.434	
		Median	0.00	25.00
		Min.	0.0	25.0
		Max.	25.0	25.0
	Change from Baseline	n	1	1
		Mean	-8.33	16.67
		SD		
		Median	-8.33	16.67
		Min.	-8.3	16.7
		Max.	-8.3	16.7
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 86 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	3	1
		Mean	22.22	25.00
		SD	20.972	
		Median	25.00	25.00
		Min.	0.0	25.0
		Max.	41.7	25.0
	Change from Baseline	n	2	1
		Mean	16.67	16.67
		SD	35.355	
		Median	16.67	16.67
		Min.	-8.3	16.7
		Max.	41.7	16.7
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (100%)
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	2	1
		Mean	12.50	25.00
		SD	17.678	
		Median	12.50	25.00
		Min.	0.0	25.0
		Max.	25.0	25.0
	Change from Baseline	n	2	1
		Mean	8.33	16.67
		SD	23.570	
		Median	8.33	16.67
		Min.	-8.3	16.7
		Max.	25.0	16.7
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (100%)
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	12	16
		Mean	24.31	7.29
		SD	29.614	10.486
		Median	20.83	0.00
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	9	13
		Mean	10.19	6.41
		SD	27.882	10.293
		Median	0.00	0.00
		Min.	-41.7	0.0
		Max.	58.3	25.0
	Worsening Score of >=15 from Baseline	n (%)	4 (44%)	4 (31%)
	Improving Score of >=15 from Baseline	n (%)	1 (11%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 89 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	5	0
		Mean	15.00	
		SD	22.361	
		Median	0.00	
		Min.	0.0	
		Max.	50.0	
	Change from Baseline	n	4	0
		Mean	-10.42	
		SD	39.308	
		Median	0.00	
		Min.	-66.7	
		Max.	25.0	
	Worsening Score of >=15 from Baseline	n (%)	1 (25%)	0
	Improving Score of >=15 from Baseline	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 90 of 90
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000205
Summary of Change in OSDI Subscale Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subscale: Environmental Triggers

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Worst Case Post Actual Score Baseline		n	26	29
		Mean	38.78	18.39
		SD	37.431	25.038
		Median	29.17	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	17	25
		Mean	30.39	12.67
		SD	33.617	20.571
		Median	16.67	8.33
		Min.	0.0	-8.3
		Max.	100.0	91.7
	Worsening Score of >=15 from Baseline	n (%)	10 (59%)	12 (48%)
	Improving Score of >=15 from Baseline	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_osdi_sub_2ref.sas 09OCT2025 10:01

Protocol: 207499 Page 1 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000305
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	14 (50%)	6 (18%)
Censored, follow-up ended	12 (43%)	21 (64%)
Censored, follow-up ongoing	2 (7%)	6 (18%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.0 (1.0, 3.8)	8.4 (3.8, 15.7)
Median (95% CI)	4.4 (2.0, -)	15.7 (8.4, -)
3rd Quartile (95% CI)	- (4.4, -)	- (15.7, -)
Log-Rank P-value [2]	0.00283	
Hazard Ratio (95% CI) [3]	3.85 (1.47, 10.07)	
P-value [3]	0.00604	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_osdi_ttd_fu_2ref.sas 09OCT2025 10:02

Protocol: 207499 Page 2 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000305
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	13 (46%)	3 (9%)
Censored, follow-up ended	13 (46%)	22 (67%)
Censored, follow-up ongoing	2 (7%)	8 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.8 (1.0, 4.7)	15.7 (8.4, -)
Median (95% CI)	7.4 (2.8, -)	- (8.4, -)
3rd Quartile (95% CI)	- (7.4, -)	- (15.7, -)
Log-Rank P-value [2]	0.00115	
Hazard Ratio (95% CI) [3]	6.23 (1.77, 21.95)	
P-value [3]	0.00439	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_osdi_ttd_fu_2ref.sas 09OCT2025 10:02

Protocol: 207499 Page 3 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000305
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	14 (50%)	11 (33%)
Censored, follow-up ended	12 (43%)	19 (58%)
Censored, follow-up ongoing	2 (7%)	3 (9%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.0 (1.0, 3.7)	6.5 (1.9, 8.4)
Median (95% CI)	4.4 (2.0, -)	8.4 (6.5, -)
3rd Quartile (95% CI)	- (4.4, -)	- (8.4, -)
Log-Rank P-value [2]	0.06471	
Hazard Ratio (95% CI) [3]	2.06 (0.93, 4.56)	
P-value [3]	0.07492	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_osdi_ttd_fu_2ref.sas 09OCT2025 10:02

Protocol: 207499 Page 4 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000305
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	10 (36%)	12 (36%)
Censored, follow-up ended	13 (46%)	14 (42%)
Censored, follow-up ongoing	5 (18%)	7 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.8 (1.0, 5.6)	3.7 (0.7, 7.0)
Median (95% CI)	7.3 (2.0, -)	7.0 (3.8, -)
3rd Quartile (95% CI)	36.0 (5.6, -)	15.7 (7.0, -)
Log-Rank P-value [2]	0.89311	
Hazard Ratio (95% CI) [3]	1.06 (0.44, 2.58)	
P-value [3]	0.89259	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_osdi_ttd_fu_2ref.sas 09OCT2025 10:02

Protocol: 207499 Page 1 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	5 (45%)	1 (14%)
	Censored, follow-up ended	6 (55%)	5 (71%)
	Censored, follow-up ongoing	0	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 6.8)	- (3.8, -)
	Median (95% CI)	6.8 (1.0, -)	- (3.8, -)
	3rd Quartile (95% CI)	- (4.4, -)	- (3.8, -)
	Log-Rank P-value [2]	0.17904	
	Hazard Ratio (95% CI) [3]	3.94 (0.46, 34.10)	
	P-value [3]	0.21244	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	7 (50%)	3 (20%)
	Censored, follow-up ended	5 (36%)	10 (67%)
	Censored, follow-up ongoing	2 (14%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.3 (1.0, 3.8)	8.4 (6.5, -)
	Median (95% CI)	3.8 (1.0, -)	15.7 (6.5, -)
	3rd Quartile (95% CI)	- (3.8, -)	15.7 (8.4, -)
	Log-Rank P-value [2]	0.07796	
	Hazard Ratio (95% CI) [3]	3.19 (0.82, 12.41)	
	P-value [3]	0.09478	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 3 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (67%)	2 (18%)
	Censored, follow-up ended	1 (33%)	6 (55%)
	Censored, follow-up ongoing	0	3 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.9, -)	8.4 (2.8, -)
	Median (95% CI)	2.0 (1.9, -)	8.4 (2.8, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (8.4, -)
	Log-Rank P-value [2]	0.02716	
	Hazard Ratio (95% CI) [3]	9.78 (0.85, 112.64)	
	P-value [3]	0.06750	
Interaction Test	P-value [4]	0.85150	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	5 (45%)	0
	Censored, follow-up ended	6 (55%)	5 (71%)
	Censored, follow-up ongoing	0	2 (29%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 5 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (43%)	2 (13%)
	Censored, follow-up ended	6 (43%)	10 (67%)
	Censored, follow-up ongoing	2 (14%)	3 (20%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 6 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (67%)	1 (9%)
	Censored, follow-up ended	1 (33%)	7 (64%)
	Censored, follow-up ongoing	0	3 (27%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 7 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	5 (45%)	2 (29%)
	Censored, follow-up ended	6 (55%)	5 (71%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 6.8)	3.8 (3.8, -)
	Median (95% CI)	6.8 (1.0, -)	- (3.8, -)
	3rd Quartile (95% CI)	- (4.4, -)	- (3.8, -)
	Log-Rank P-value [2]	0.39071	
	Hazard Ratio (95% CI) [3]	2.03 (0.39, 10.57)	
	P-value [3]	0.40017	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 8 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	7 (50%)	5 (33%)
	Censored, follow-up ended	5 (36%)	9 (60%)
	Censored, follow-up ongoing	2 (14%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.5 (1.0, 3.7)	8.3 (1.9, 8.4)
	Median (95% CI)	3.7 (2.0, -)	8.4 (6.5, -)
	3rd Quartile (95% CI)	- (3.7, -)	15.7 (8.3, -)
	Log-Rank P-value [2]	0.27854	
	Hazard Ratio (95% CI) [3]	1.88 (0.59, 5.97)	
	P-value [3]	0.28190	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 9 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (67%)	4 (36%)
	Censored, follow-up ended	1 (33%)	5 (45%)
	Censored, follow-up ongoing	0	2 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.9, -)	3.8 (1.0, 8.4)
	Median (95% CI)	2.0 (1.9, -)	8.4 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (3.8, -)
	Log-Rank P-value [2]	0.25235	
	Hazard Ratio (95% CI) [3]	2.77 (0.45, 17.11)	
	P-value [3]	0.27155	
Interaction Test	P-value [4]	0.90237	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	5 (45%)	3 (43%)
	Censored, follow-up ended	6 (55%)	3 (43%)
	Censored, follow-up ongoing	0	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 7.3)	3.7 (0.7, -)
	Median (95% CI)	5.6 (1.0, -)	3.8 (0.7, -)
	3rd Quartile (95% CI)	7.3 (5.6, -)	- (0.7, -)
	Log-Rank P-value [2]	0.63336	
	Hazard Ratio (95% CI) [3]	0.67 (0.13, 3.47)	
	P-value [3]	0.63528	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 11 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	5 (36%)	7 (47%)
	Censored, follow-up ended	6 (43%)	5 (33%)
	Censored, follow-up ongoing	3 (21%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.4 (1.0, 14.0)	1.9 (0.7, 8.4)
	Median (95% CI)	8.5 (1.0, -)	8.4 (1.4, -)
	3rd Quartile (95% CI)	- (2.8, -)	15.7 (6.7, -)
	Log-Rank P-value [2]	0.88107	
	Hazard Ratio (95% CI) [3]	0.92 (0.29, 2.93)	
	P-value [3]	0.88110	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 12 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000315
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	0	2 (18%)
	Censored, follow-up ended	1 (33%)	6 (55%)
	Censored, follow-up ongoing	2 (67%)	3 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (-, -)	7.0 (3.8, -)
	Median (95% CI)	- (-, -)	7.0 (3.8, -)
	3rd Quartile (95% CI)	- (-, -)	- (7.0, -)
	Log-Rank P-value [2]	0.70546	
	Hazard Ratio (95% CI) [3]#	2.33 (0.02, 43.74)	
	P-value [3]#	0.71425	
Interaction Test	P-value [4]	0.86299	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_age.sas 09OCT2025 12:54

Protocol: 207499 Page 1 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000325
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	5 (42%)	2 (13%)
	Censored, follow-up ended	6 (50%)	12 (75%)
	Censored, follow-up ongoing	1 (8%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.9, 7.4)	8.4 (8.4, -)
	Median (95% CI)	7.4 (2.0, -)	15.7 (8.4, -)
	3rd Quartile (95% CI)	- (4.4, -)	- (8.4, -)
	Log-Rank P-value [2]	0.14300	
	Hazard Ratio (95% CI) [3]	3.22 (0.62, 16.81)	
	P-value [3]	0.16511	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_gen.sas 09OCT2025 10:03

Table 4.0000325
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	9 (56%)	4 (24%)
	Censored, follow-up ended	6 (38%)	9 (53%)
	Censored, follow-up ongoing	1 (6%)	4 (24%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 3.7)	6.5 (2.8, -)
	Median (95% CI)	3.7 (1.0, -)	- (6.5, -)
	3rd Quartile (95% CI)	6.8 (3.7, -)	- (8.4, -)
	Log-Rank P-value [2]	0.00799	
	Hazard Ratio (95% CI) [3]	4.45 (1.34, 14.76)	
	P-value [3]	0.01461	
Interaction Test	P-value [4]	0.64782	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 3 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000325
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	4 (33%)	2 (13%)
	Censored, follow-up ended	7 (58%)	12 (75%)
	Censored, follow-up ongoing	1 (8%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (1.9, -)	8.4 (8.4, -)
	Median (95% CI)	- (4.4, -)	15.7 (8.4, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (8.4, -)
	Log-Rank P-value [2]	0.45156	
	Hazard Ratio (95% CI) [3]	1.90 (0.35, 10.47)	
	P-value [3]	0.45918	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_gen.sas 09OCT2025 10:03

Table 4.0000325
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	9 (56%)	1 (6%)
	Censored, follow-up ended	6 (38%)	10 (59%)
	Censored, follow-up ongoing	1 (6%)	6 (35%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 2.8)	- (1.9, -)
	Median (95% CI)	2.8 (1.0, -)	- (-, -)
	3rd Quartile (95% CI)	8.5 (2.8, -)	- (-, -)
	Log-Rank P-value [2]	0.00087	
	Hazard Ratio (95% CI) [3]	14.45 (1.82, 114.51)	
	P-value [3]	0.01145	
Interaction Test	P-value [4]	0.11918	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 5 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000325
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	6 (50%)	5 (31%)
	Censored, follow-up ended	6 (50%)	10 (63%)
	Censored, follow-up ongoing	0	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.9, 7.4)	3.8 (1.9, 15.7)
	Median (95% CI)	7.4 (2.0, -)	8.4 (3.7, -)
	3rd Quartile (95% CI)	- (4.4, -)	15.7 (8.4, -)
	Log-Rank P-value [2]	0.21880	
	Hazard Ratio (95% CI) [3]	2.21 (0.61, 7.92)	
	P-value [3]	0.22512	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 6 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000325
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	8 (50%)	6 (35%)
	Censored, follow-up ended	6 (38%)	9 (53%)
	Censored, follow-up ongoing	2 (13%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 3.7)	6.5 (1.0, 8.4)
	Median (95% CI)	3.7 (1.0, -)	8.4 (3.8, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (8.3, -)
	Log-Rank P-value [2]	0.15225	
	Hazard Ratio (95% CI) [3]	2.15 (0.74, 6.26)	
	P-value [3]	0.15994	
Interaction Test	P-value [4]	0.87799	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 7 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000325
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	3 (25%)	5 (31%)
	Censored, follow-up ended	7 (58%)	9 (56%)
	Censored, follow-up ongoing	2 (17%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, -)	7.0 (1.9, 8.4)
	Median (95% CI)	7.3 (1.0, -)	8.4 (3.3, -)
	3rd Quartile (95% CI)	- (2.0, -)	15.7 (7.0, -)
	Log-Rank P-value [2]	0.98940	
	Hazard Ratio (95% CI) [3]	1.01 (0.24, 4.32)	
	P-value [3]	0.98939	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 8 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000325
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	7 (44%)	7 (41%)
	Censored, follow-up ended	6 (38%)	5 (29%)
	Censored, follow-up ongoing	3 (19%)	5 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (1.0, 5.6)	3.7 (0.7, 6.7)
	Median (95% CI)	5.6 (1.1, -)	6.7 (1.4, -)
	3rd Quartile (95% CI)	14.0 (3.0, -)	- (6.7, -)
	Log-Rank P-value [2]	0.95654	
	Hazard Ratio (95% CI) [3]	1.03 (0.33, 3.27)	
	P-value [3]	0.95642	
Interaction Test	P-value [4]	0.90614	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 1 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000335
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	6 (33%)	3 (13%)
	Censored, follow-up ended	10 (56%)	17 (71%)
	Censored, follow-up ongoing	2 (11%)	4 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 6.8)	8.4 (3.8, -)
	Median (95% CI)	6.8 (3.7, -)	15.7 (8.4, -)
	3rd Quartile (95% CI)	- (4.4, -)	- (8.4, -)
	Log-Rank P-value [2]	0.05173	
	Hazard Ratio (95% CI) [3]	3.65 (0.91, 14.65)	
	P-value [3]	0.06808	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_reg.sas 09OCT2025 10:02

Table 4.0000335
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	8 (80%)	3 (33%)
	Censored, follow-up ended	2 (20%)	4 (44%)
	Censored, follow-up ongoing	0	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 2.8)	6.5 (2.8, -)
	Median (95% CI)	2.4 (1.0, 7.4)	8.4 (2.8, -)
	3rd Quartile (95% CI)	7.4 (2.0, -)	- (6.5, -)
	Log-Rank P-value [2]	0.05224	
	Hazard Ratio (95% CI) [3]	3.46 (0.91, 13.19)	
	P-value [3]	0.06868	
Interaction Test	P-value [4]	0.92220	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_reg.sas 09OCT2025 10:02

Protocol: 207499 Page 3 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000335
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	6 (33%)	2 (8%)
	Censored, follow-up ended	10 (56%)	17 (71%)
	Censored, follow-up ongoing	2 (11%)	5 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_reg.sas 09OCT2025 10:02

Table 4.0000335
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	1 (11%)
	Censored, follow-up ended	3 (30%)	5 (56%)
	Censored, follow-up ongoing	0	3 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_reg.sas 09OCT2025 10:02

Table 4.0000335
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	7 (39%)	6 (25%)
	Censored, follow-up ended	10 (56%)	16 (67%)
	Censored, follow-up ongoing	1 (6%)	2 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, 4.4)	8.3 (1.9, 15.7)
	Median (95% CI)	4.4 (2.0, -)	8.4 (8.3, -)
	3rd Quartile (95% CI)	- (4.4, -)	15.7 (8.4, -)
	Log-Rank P-value [2]	0.04870	
	Hazard Ratio (95% CI) [3]	3.07 (0.96, 9.87)	
	P-value [3]	0.05941	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_reg.sas 09OCT2025 10:02

Table 4.0000335
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	5 (56%)
	Censored, follow-up ended	2 (20%)	3 (33%)
	Censored, follow-up ongoing	1 (10%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.7)	3.7 (1.0, 8.4)
	Median (95% CI)	2.9 (1.0, -)	6.5 (1.0, -)
	3rd Quartile (95% CI)	- (2.0, -)	8.4 (3.8, -)
	Log-Rank P-value [2]	0.58937	
	Hazard Ratio (95% CI) [3]	1.37 (0.43, 4.36)	
	P-value [3]	0.59086	
Interaction Test	P-value [4]	0.47520	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_reg.sas 09OCT2025 10:02

Protocol: 207499 Page 7 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000335
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	5 (28%)	9 (38%)
	Censored, follow-up ended	10 (56%)	11 (46%)
	Censored, follow-up ongoing	3 (17%)	4 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 7.3)	3.8 (1.4, 7.0)
	Median (95% CI)	7.3 (1.0, -)	7.0 (3.7, -)
	3rd Quartile (95% CI)	36.0 (3.0, -)	15.7 (7.0, -)
	Log-Rank P-value [2]	0.78352	
	Hazard Ratio (95% CI) [3]	1.18 (0.36, 3.92)	
	P-value [3]	0.78374	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_reg.sas 09OCT2025 10:02

Protocol: 207499 Page 8 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000335
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	5 (50%)	3 (33%)
	Censored, follow-up ended	3 (30%)	3 (33%)
	Censored, follow-up ongoing	2 (20%)	3 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 14.0)	0.7 (0.7, -)
	Median (95% CI)	5.6 (1.0, -)	- (0.7, -)
	3rd Quartile (95% CI)	14.0 (2.8, -)	- (3.8, -)
	Log-Rank P-value [2]	0.95153	
	Hazard Ratio (95% CI) [3]	1.05 (0.23, 4.70)	
	P-value [3]	0.95167	
Interaction Test	P-value [4]	0.90227	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_reg.sas 09OCT2025 10:02

Protocol: 207499 Page 1 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000345
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	11 (61%)	2 (13%)
	Censored, follow-up ended	6 (33%)	9 (60%)
	Censored, follow-up ongoing	1 (6%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 3.8)	- (3.8, -)
	Median (95% CI)	3.8 (1.1, 7.4)	- (6.5, -)
	3rd Quartile (95% CI)	7.4 (3.8, -)	- (-, -)
	Log-Rank P-value [2]	0.00223	
	Hazard Ratio (95% CI) [3]	7.50 (1.65, 34.08)	
	P-value [3]	0.00903	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_iss.sas 09OCT2025 10:02

Table 4.0000345
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	3 (30%)	4 (22%)
	Censored, follow-up ended	6 (60%)	12 (67%)
	Censored, follow-up ongoing	1 (10%)	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.8 (1.0, -)	8.4 (2.8, -)
	Median (95% CI)	- (1.0, -)	8.4 (8.4, -)
	3rd Quartile (95% CI)	- (6.8, -)	15.7 (8.4, -)
	Log-Rank P-value [2]	0.85309	
	Hazard Ratio (95% CI) [3]	1.11 (0.25, 4.97)	
	P-value [3]	0.89640	
Interaction Test	P-value [4]	0.06651	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_iss.sas 09OCT2025 10:02

Protocol: 207499 Page 3 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000345
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	9 (50%)	0
	Censored, follow-up ended	8 (44%)	9 (60%)
	Censored, follow-up ongoing	1 (6%)	6 (40%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_iss.sas 09OCT2025 10:02

Protocol: 207499 Page 4 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000345
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	4 (40%)	3 (17%)
	Censored, follow-up ended	5 (50%)	13 (72%)
	Censored, follow-up ongoing	1 (10%)	2 (11%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_iss.sas 09OCT2025 10:02

Protocol: 207499 Page 5 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000345
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	11 (61%)	4 (27%)
	Censored, follow-up ended	6 (33%)	8 (53%)
	Censored, follow-up ongoing	1 (6%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 2.9)	6.5 (3.8, -)
	Median (95% CI)	2.9 (1.1, 7.4)	- (3.8, -)
	3rd Quartile (95% CI)	7.4 (2.9, -)	- (-, -)
	Log-Rank P-value [2]	0.00981	
	Hazard Ratio (95% CI) [3]	4.05 (1.28, 12.85)	
	P-value [3]	0.01746	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_iss.sas 09OCT2025 10:02

Protocol: 207499 Page 6 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000345
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	3 (30%)	7 (39%)
	Censored, follow-up ended	6 (60%)	11 (61%)
	Censored, follow-up ongoing	1 (10%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (2.0, -)	8.3 (1.0, 8.4)
	Median (95% CI)	6.8 (2.0, -)	8.4 (3.7, -)
	3rd Quartile (95% CI)	- (3.7, -)	8.4 (8.3, -)
	Log-Rank P-value [2]	0.47595	
	Hazard Ratio (95% CI) [3]	0.59 (0.15, 2.31)	
	P-value [3]	0.45368	
Interaction Test	P-value [4]	0.02505	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_iss.sas 09OCT2025 10:02

Table 4.0000345
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (33%)	5 (33%)
	Censored, follow-up ended	7 (39%)	5 (33%)
	Censored, follow-up ongoing	5 (28%)	5 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 5.6)	3.8 (0.7, 7.0)
	Median (95% CI)	5.6 (1.0, -)	7.0 (3.7, -)
	3rd Quartile (95% CI)	- (3.0, -)	- (6.7, -)
	Log-Rank P-value [2]	0.59790	
	Hazard Ratio (95% CI) [3]	1.39 (0.41, 4.67)	
	P-value [3]	0.59931	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_iss.sas 09OCT2025 10:02

Protocol: 207499 Page 8 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000345
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	4 (40%)	7 (39%)
	Censored, follow-up ended	6 (60%)	9 (50%)
	Censored, follow-up ongoing	0	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (2.0, -)	3.3 (0.7, 8.4)
	Median (95% CI)	14.0 (2.0, -)	8.4 (1.9, -)
	3rd Quartile (95% CI)	36.0 (2.8, -)	15.7 (8.4, -)
	Log-Rank P-value [2]	0.57600	
	Hazard Ratio (95% CI) [3]	0.67 (0.17, 2.71)	
	P-value [3]	0.57817	
Interaction Test	P-value [4]	0.50804	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_iss.sas 09OCT2025 10:02

Protocol: 207499 Page 1 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	4 (57%)	2 (33%)
	Censored, follow-up ended	2 (29%)	2 (33%)
	Censored, follow-up ongoing	1 (14%)	2 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Table 4.0000355

Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	7 (54%)	2 (14%)
	Censored, follow-up ended	6 (46%)	10 (71%)
	Censored, follow-up ongoing	0	2 (14%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Table 4.0000355

Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (38%)	2 (15%)
	Censored, follow-up ended	4 (50%)	9 (69%)
	Censored, follow-up ongoing	1 (13%)	2 (15%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Protocol: 207499 Page 4 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	4 (57%)	1 (17%)
	Censored, follow-up ended	2 (29%)	2 (33%)
	Censored, follow-up ongoing	1 (14%)	3 (50%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Protocol: 207499 Page 5 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	1 (7%)
	Censored, follow-up ended	7 (54%)	10 (71%)
	Censored, follow-up ongoing	0	3 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Protocol: 207499 Page 6 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (38%)	1 (8%)
	Censored, follow-up ended	4 (50%)	10 (77%)
	Censored, follow-up ongoing	1 (13%)	2 (15%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	5 (71%)	3 (50%)
	Censored, follow-up ended	2 (29%)	2 (33%)
	Censored, follow-up ongoing	0	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (2.0, 3.7)	6.5 (3.7, 8.4)
	Median (95% CI)	3.7 (2.0, -)	8.4 (3.7, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (6.5, -)
	Log-Rank P-value [2]	0.27265	
	Hazard Ratio (95% CI) [3]	2.20 (0.52, 9.37)	
	P-value [3]	0.28428	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	7 (54%)	4 (29%)
	Censored, follow-up ended	6 (46%)	9 (64%)
	Censored, follow-up ongoing	0	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.4 (1.0, 6.8)	3.8 (1.0, -)
	Median (95% CI)	6.8 (1.0, -)	- (3.8, -)
	3rd Quartile (95% CI)	7.4 (6.8, -)	- (3.8, -)
	Log-Rank P-value [2]	0.25563	
	Hazard Ratio (95% CI) [3]	2.00 (0.58, 6.96)	
	P-value [3]	0.27337	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Protocol: 207499 Page 9 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (25%)	4 (31%)
	Censored, follow-up ended	4 (50%)	8 (62%)
	Censored, follow-up ongoing	2 (25%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.1, -)	8.3 (1.9, 15.7)
	Median (95% CI)	- (1.1, -)	8.4 (8.3, -)
	3rd Quartile (95% CI)	- (1.1, -)	15.7 (8.3, -)
	Log-Rank P-value [2]	0.76270	
	Hazard Ratio (95% CI) [3]	1.30 (0.24, 7.17)	
	P-value [3]	0.76331	
Interaction Test	P-value [4]	0.84119	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	3 (43%)	2 (33%)
	Censored, follow-up ended	2 (29%)	1 (17%)
	Censored, follow-up ongoing	2 (29%)	3 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.4 (2.0, 7.3)	6.7 (6.7, -)
	Median (95% CI)	5.1 (2.0, -)	8.4 (6.7, -)
	3rd Quartile (95% CI)	- (2.0, -)	- (6.7, -)
	Log-Rank P-value [2]	0.38592	
	Hazard Ratio (95% CI) [3]	2.18 (0.36, 13.18)	
	P-value [3]	0.39733	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Protocol: 207499 Page 11 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	5 (36%)
	Censored, follow-up ended	6 (46%)	7 (50%)
	Censored, follow-up ongoing	2 (15%)	2 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 5.6)	3.3 (0.7, 3.8)
	Median (95% CI)	5.6 (1.0, -)	3.8 (0.7, -)
	3rd Quartile (95% CI)	36.0 (3.0, -)	7.0 (3.8, -)
	Log-Rank P-value [2]	0.78736	
	Hazard Ratio (95% CI) [3]	0.83 (0.21, 3.24)	
	P-value [3]	0.78760	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Protocol: 207499 Page 12 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000355
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (25%)	5 (38%)
	Censored, follow-up ended	5 (63%)	6 (46%)
	Censored, follow-up ongoing	1 (13%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	7.5 (1.1, -)	1.9 (0.7, -)
	Median (95% CI)	14.0 (1.1, -)	15.7 (1.4, -)
	3rd Quartile (95% CI)	14.0 (1.1, -)	15.7 (-, -)
	Log-Rank P-value [2]	0.91360	
	Hazard Ratio (95% CI) [3]	1.10 (0.20, 6.20)	
	P-value [3]	0.91363	
Interaction Test	P-value [4]	0.45100	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line.sas 09OCT2025 10:03

Protocol: 207499 Page 1 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000375
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	11 (55%)	4 (20%)
	Censored, follow-up ended	8 (40%)	12 (60%)
	Censored, follow-up ongoing	1 (5%)	4 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 3.8)	8.4 (2.8, -)
	Median (95% CI)	4.4 (2.0, -)	- (6.5, -)
	3rd Quartile (95% CI)	- (4.4, -)	- (8.4, -)
	Log-Rank P-value [2]	0.04697	
	Hazard Ratio (95% CI) [3]	3.03 (0.96, 9.58)	
	P-value [3]	0.05870	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line2.sas 09OCT2025 10:03

Table 4.0000375
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (38%)	2 (15%)
	Censored, follow-up ended	4 (50%)	9 (69%)
	Censored, follow-up ongoing	1 (13%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	12.0 (8.4, -)
	Median (95% CI)	3.8 (1.0, -)	15.7 (8.4, -)
	3rd Quartile (95% CI)	- (1.1, -)	- (8.4, -)
	Log-Rank P-value [2]	0.00804	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99756	
Interaction Test	P-value [4]	0.41241	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line2.sas 09OCT2025 10:03

Protocol: 207499 Page 3 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000375
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	10 (50%)	2 (10%)
	Censored, follow-up ended	9 (45%)	12 (60%)
	Censored, follow-up ongoing	1 (5%)	6 (30%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (1.0, 6.5)	- (1.9, -)
	Median (95% CI)	7.4 (2.8, -)	- (8.4, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (8.4, -)
	Log-Rank P-value [2]	0.02304	
	Hazard Ratio (95% CI) [3]	4.91 (1.07, 22.47)	
	P-value [3]	0.04006	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line2.sas 09OCT2025 10:03

Protocol: 207499 Page 4 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000375
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (38%)	1 (8%)
	Censored, follow-up ended	4 (50%)	10 (77%)
	Censored, follow-up ongoing	1 (13%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	15.7 (15.7, -)
	Median (95% CI)	1.9 (1.0, -)	- (15.7, -)
	3rd Quartile (95% CI)	- (1.1, -)	- (15.7, -)
	Log-Rank P-value [2]	0.00431	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99774	
Interaction Test	P-value [4]	0.58515	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line2.sas 09OCT2025 10:03

Protocol: 207499 Page 5 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000375
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	12 (60%)	7 (35%)
	Censored, follow-up ended	8 (40%)	11 (55%)
	Censored, follow-up ongoing	0	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 3.7)	3.8 (1.0, 8.4)
	Median (95% CI)	3.7 (2.0, 7.4)	8.4 (3.8, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (8.4, -)
	Log-Rank P-value [2]	0.10734	
	Hazard Ratio (95% CI) [3]	2.12 (0.83, 5.43)	
	P-value [3]	0.11629	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line2.sas 09OCT2025 10:03

Protocol: 207499 Page 6 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000375
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (25%)	4 (31%)
	Censored, follow-up ended	4 (50%)	8 (62%)
	Censored, follow-up ongoing	2 (25%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.1, -)	8.3 (1.9, 15.7)
	Median (95% CI)	- (1.1, -)	8.4 (8.3, -)
	3rd Quartile (95% CI)	- (1.1, -)	15.7 (8.3, -)
	Log-Rank P-value [2]	0.76270	
	Hazard Ratio (95% CI) [3]	1.30 (0.24, 7.17)	
	P-value [3]	0.76331	
Interaction Test	P-value [4]	0.57254	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line2.sas 09OCT2025 10:03

Protocol: 207499 Page 7 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000375
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	8 (40%)	7 (35%)
	Censored, follow-up ended	8 (40%)	8 (40%)
	Censored, follow-up ongoing	4 (20%)	5 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 5.6)	3.8 (0.7, 7.0)
	Median (95% CI)	5.6 (1.0, -)	7.0 (3.8, -)
	3rd Quartile (95% CI)	36.0 (3.0, -)	8.4 (6.7, -)
	Log-Rank P-value [2]	0.76065	
	Hazard Ratio (95% CI) [3]	1.18 (0.41, 3.44)	
	P-value [3]	0.76089	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line2.sas 09OCT2025 10:03

Protocol: 207499 Page 8 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000375
Summary of OSDI Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (25%)	5 (38%)
	Censored, follow-up ended	5 (63%)	6 (46%)
	Censored, follow-up ongoing	1 (13%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	7.5 (1.1, -)	1.9 (0.7, -)
	Median (95% CI)	14.0 (1.1, -)	15.7 (1.4, -)
	3rd Quartile (95% CI)	14.0 (1.1, -)	15.7 (-, -)
	Log-Rank P-value [2]	0.91360	
	Hazard Ratio (95% CI) [3]	1.10 (0.20, 6.20)	
	P-value [3]	0.91363	
Interaction Test	P-value [4]	0.96843	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_ttd_fu_2ref_line2.sas 09OCT2025 10:03

Protocol: 207499 Page 1 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000505
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	5 (18%)	3 (9%)
Censored, follow-up ended	17 (61%)	21 (64%)
Censored, follow-up ongoing	6 (21%)	9 (27%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	- (2.8, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.35566	
Inverse Hazard Ratio (95% CI) [3]	0.52 (0.12, 2.16)	
P-value [3]	0.36530	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_osdi_tti_fu_2ref.sas 09OCT2025 10:03

Table 4.0000505
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	2 (7%)	3 (9%)
Censored, follow-up ended	18 (64%)	21 (64%)
Censored, follow-up ongoing	8 (29%)	9 (27%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	- (1.2, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.78378	
Inverse Hazard Ratio (95% CI) [3]	1.28 (0.21, 7.67)	
P-value [3]	0.78574	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_osdi_tti_fu_2ref.sas 09OCT2025 10:03

Protocol: 207499 Page 3 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000505
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	8 (29%)	5 (15%)
Censored, follow-up ended	15 (54%)	20 (61%)
Censored, follow-up ongoing	5 (18%)	8 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.9 (1.0, -)	- (0.7, -)
Median (95% CI)	- (2.9, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.28517	
Inverse Hazard Ratio (95% CI) [3]	0.55 (0.18, 1.68)	
P-value [3]	0.29524	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_osdi_tti_fu_2ref.sas 09OCT2025 10:03

Protocol: 207499 Page 4 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000505
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	2 (7%)	4 (12%)
Censored, follow-up ended	18 (64%)	21 (64%)
Censored, follow-up ongoing	8 (29%)	8 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	- (1.0, -)
Median (95% CI)	- (-, -)	- (8.3, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.69484	
Inverse Hazard Ratio (95% CI) [3]	1.40 (0.26, 7.71)	
P-value [3]	0.69622	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_osdi_tti_fu_2ref.sas 09OCT2025 10:03

Protocol: 207499 Page 1 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Improved (event)	0	0
	Censored, follow-up ended	9 (82%)	5 (71%)
	Censored, follow-up ongoing	2 (18%)	2 (29%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	5 (36%)	2 (13%)
	Censored, follow-up ended	7 (50%)	9 (60%)
	Censored, follow-up ongoing	2 (14%)	4 (27%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Improved (event)	0	1 (9%)
	Censored, follow-up ended	1 (33%)	7 (64%)
	Censored, follow-up ongoing	2 (67%)	3 (27%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Improved (event)	0	1 (14%)
	Censored, follow-up ended	9 (82%)	4 (57%)
	Censored, follow-up ongoing	2 (18%)	2 (29%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	2 (14%)	1 (7%)
	Censored, follow-up ended	8 (57%)	10 (67%)
	Censored, follow-up ongoing	4 (29%)	4 (27%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Improved (event)	0	1 (9%)
	Censored, follow-up ended	1 (33%)	7 (64%)
	Censored, follow-up ongoing	2 (67%)	3 (27%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Protocol: 207499 Page 7 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Improved (event)	1 (9%)	0
	Censored, follow-up ended	8 (73%)	5 (71%)
	Censored, follow-up ongoing	2 (18%)	2 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.2, -)	- (-, -)
	Median (95% CI)	- (1.2, -)	- (-, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.41422	
	Inverse Hazard Ratio (95% CI) [3]#	0.47 (0.00, 9.38)	
	P-value [3]#	0.74982	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	6 (43%)	4 (27%)
	Censored, follow-up ended	6 (43%)	8 (53%)
	Censored, follow-up ongoing	2 (14%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (1.0, 2.9)	1.0 (0.7, -)
	Median (95% CI)	- (1.1, -)	- (0.7, -)
	3rd Quartile (95% CI)	- (2.9, -)	- (-, -)
	Log-Rank P-value [2]	0.49682	
	Inverse Hazard Ratio (95% CI) [3]	0.65 (0.18, 2.32)	
	P-value [3]	0.50928	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Improved (event)	1 (33%)	1 (9%)
	Censored, follow-up ended	1 (33%)	7 (64%)
	Censored, follow-up ongoing	1 (33%)	3 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (3.8, -)	- (3.7, -)
	Median (95% CI)	- (3.8, -)	- (3.7, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (-, -)
	Log-Rank P-value [2]	0.50373	
	Inverse Hazard Ratio (95% CI) [3]	0.40 (0.03, 6.42)	
	P-value [3]	0.51829	
Interaction Test	P-value [4]	0.90157	

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Improved (event)	1 (9%)	1 (14%)
	Censored, follow-up ended	8 (73%)	4 (57%)
	Censored, follow-up ongoing	2 (18%)	2 (29%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	1 (7%)	1 (7%)
	Censored, follow-up ended	9 (64%)	10 (67%)
	Censored, follow-up ongoing	4 (29%)	4 (27%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Protocol: 207499 Page 12 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000515
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Improved (event)	0	2 (18%)
	Censored, follow-up ended	1 (33%)	7 (64%)
	Censored, follow-up ongoing	2 (67%)	2 (18%)

Note: For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. # Model failed to converge, interpret results with caution. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_age.sas 09OCT2025 12:53

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000525
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	2 (17%)	1 (6%)
	Censored, follow-up ended	8 (67%)	11 (69%)
	Censored, follow-up ongoing	2 (17%)	4 (25%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_gen.sas 09OCT2025 10:03

Table 4.0000525
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	3 (19%)	2 (12%)
	Censored, follow-up ended	9 (56%)	10 (59%)
	Censored, follow-up ongoing	4 (25%)	5 (29%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_gen.sas 09OCT2025 10:03

Table 4.0000525
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	1 (8%)	1 (6%)
	Censored, follow-up ended	9 (75%)	11 (69%)
	Censored, follow-up ongoing	2 (17%)	4 (25%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_gen.sas 09OCT2025 10:03

Table 4.0000525
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	1 (6%)	2 (12%)
	Censored, follow-up ended	9 (56%)	10 (59%)
	Censored, follow-up ongoing	6 (38%)	5 (29%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 5 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000525
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	3 (25%)	2 (13%)
	Censored, follow-up ended	8 (67%)	11 (69%)
	Censored, follow-up ongoing	1 (8%)	3 (19%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 6 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000525
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	5 (31%)	3 (18%)
	Censored, follow-up ended	7 (44%)	9 (53%)
	Censored, follow-up ongoing	4 (25%)	5 (29%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_gen.sas 09OCT2025 10:03

Table 4.0000525
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	1 (8%)	3 (19%)
	Censored, follow-up ended	9 (75%)	10 (63%)
	Censored, follow-up ongoing	2 (17%)	3 (19%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 8 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000525
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	1 (6%)	1 (6%)
	Censored, follow-up ended	9 (56%)	11 (65%)
	Censored, follow-up ongoing	6 (38%)	5 (29%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_gen.sas 09OCT2025 10:03

Protocol: 207499 Page 1 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000535
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Improved (event)	4 (22%)	3 (13%)
	Censored, follow-up ended	11 (61%)	15 (63%)
	Censored, follow-up ongoing	3 (17%)	6 (25%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_reg.sas 09OCT2025 10:03

Table 4.0000535
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Improved (event)	1 (10%)	0
	Censored, follow-up ended	6 (60%)	6 (67%)
	Censored, follow-up ongoing	3 (30%)	3 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_reg.sas 09OCT2025 10:03

Protocol: 207499 Page 3 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000535
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Improved (event)	2 (11%)	3 (13%)
	Censored, follow-up ended	12 (67%)	15 (63%)
	Censored, follow-up ongoing	4 (22%)	6 (25%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_reg.sas 09OCT2025 10:03

Table 4.0000535
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Improved (event)	0	0
	Censored, follow-up ended	6 (60%)	6 (67%)
	Censored, follow-up ongoing	4 (40%)	3 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_reg.sas 09OCT2025 10:03

Protocol: 207499 Page 5 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000535
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Improved (event)	6 (33%)	3 (13%)
	Censored, follow-up ended	9 (50%)	16 (67%)
	Censored, follow-up ongoing	3 (17%)	5 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_reg.sas 09OCT2025 10:03

Protocol: 207499 Page 6 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000535
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Improved (event)	2 (20%)	2 (22%)
	Censored, follow-up ended	6 (60%)	4 (44%)
	Censored, follow-up ongoing	2 (20%)	3 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_reg.sas 09OCT2025 10:03

Table 4.0000535
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Improved (event)	1 (6%)	3 (13%)
	Censored, follow-up ended	13 (72%)	15 (63%)
	Censored, follow-up ongoing	4 (22%)	6 (25%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_reg.sas 09OCT2025 10:03

Protocol: 207499 Page 8 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000535
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Improved (event)	1 (10%)	1 (11%)
	Censored, follow-up ended	5 (50%)	6 (67%)
	Censored, follow-up ongoing	4 (40%)	2 (22%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_reg.sas 09OCT2025 10:03

Protocol: 207499 Page 1 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000545
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Improved (event)	1 (6%)	1 (7%)
	Censored, follow-up ended	12 (67%)	9 (60%)
	Censored, follow-up ongoing	5 (28%)	5 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_iss.sas 09OCT2025 10:04

Table 4.0000545
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Improved (event)	4 (40%)	2 (11%)
	Censored, follow-up ended	5 (50%)	12 (67%)
	Censored, follow-up ongoing	1 (10%)	4 (22%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_iss.sas 09OCT2025 10:04

Protocol: 207499 Page 3 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000545
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Improved (event)	1 (6%)	2 (13%)
	Censored, follow-up ended	11 (61%)	8 (53%)
	Censored, follow-up ongoing	6 (33%)	5 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_iss.sas 09OCT2025 10:04

Protocol: 207499 Page 4 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000545
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Improved (event)	1 (10%)	1 (6%)
	Censored, follow-up ended	7 (70%)	13 (72%)
	Censored, follow-up ongoing	2 (20%)	4 (22%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_iss.sas 09OCT2025 10:04

Protocol: 207499 Page 5 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000545
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Improved (event)	3 (17%)	1 (7%)
	Censored, follow-up ended	11 (61%)	9 (60%)
	Censored, follow-up ongoing	4 (22%)	5 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_iss.sas 09OCT2025 10:04

Table 4.0000545
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Improved (event)	5 (50%)	4 (22%)
	Censored, follow-up ended	4 (40%)	11 (61%)
	Censored, follow-up ongoing	1 (10%)	3 (17%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_iss.sas 09OCT2025 10:04

Protocol: 207499 Page 7 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000545
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Improved (event)	1 (6%)	2 (13%)
	Censored, follow-up ended	11 (61%)	8 (53%)
	Censored, follow-up ongoing	6 (33%)	5 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_iss.sas 09OCT2025 10:04

Protocol: 207499 Page 8 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000545
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Improved (event)	1 (10%)	2 (11%)
	Censored, follow-up ended	7 (70%)	13 (72%)
	Censored, follow-up ongoing	2 (20%)	3 (17%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_iss.sas 09OCT2025 10:04

Protocol: 207499 Page 1 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Improved (event)	2 (29%)	2 (33%)
	Censored, follow-up ended	4 (57%)	1 (17%)
	Censored, follow-up ongoing	1 (14%)	3 (50%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Improved (event)	1 (8%)	1 (7%)
	Censored, follow-up ended	9 (69%)	10 (71%)
	Censored, follow-up ongoing	3 (23%)	3 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Protocol: 207499 Page 3 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (25%)	0
	Censored, follow-up ended	4 (50%)	10 (77%)
	Censored, follow-up ongoing	2 (25%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Improved (event)	1 (14%)	2 (33%)
	Censored, follow-up ended	4 (57%)	1 (17%)
	Censored, follow-up ongoing	2 (29%)	3 (50%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Protocol: 207499 Page 5 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Improved (event)	0	0
	Censored, follow-up ended	10 (77%)	11 (79%)
	Censored, follow-up ongoing	3 (23%)	3 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Improved (event)	1 (13%)	1 (8%)
	Censored, follow-up ended	4 (50%)	9 (69%)
	Censored, follow-up ongoing	3 (38%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Protocol: 207499 Page 7 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Improved (event)	3 (43%)	1 (17%)
	Censored, follow-up ended	4 (57%)	2 (33%)
	Censored, follow-up ongoing	0	3 (50%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Improved (event)	3 (23%)	2 (14%)
	Censored, follow-up ended	7 (54%)	9 (64%)
	Censored, follow-up ongoing	3 (23%)	3 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (25%)	2 (15%)
	Censored, follow-up ended	4 (50%)	9 (69%)
	Censored, follow-up ongoing	2 (25%)	2 (15%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Improved (event)	1 (14%)	2 (33%)
	Censored, follow-up ended	4 (57%)	2 (33%)
	Censored, follow-up ongoing	2 (29%)	2 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Protocol: 207499 Page 11 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Improved (event)	1 (8%)	1 (7%)
	Censored, follow-up ended	9 (69%)	10 (71%)
	Censored, follow-up ongoing	3 (23%)	3 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Protocol: 207499 Page 12 of 12
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000555
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Improved (event)	0	1 (8%)
	Censored, follow-up ended	5 (63%)	9 (69%)
	Censored, follow-up ongoing	3 (38%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line.sas 09OCT2025 10:04

Protocol: 207499 Page 1 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000575
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Improved (event)	3 (15%)	3 (15%)
	Censored, follow-up ended	13 (65%)	11 (55%)
	Censored, follow-up ongoing	4 (20%)	6 (30%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line2.sas 09OCT2025 10:04

Table 4.0000575
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (25%)	0
	Censored, follow-up ended	4 (50%)	10 (77%)
	Censored, follow-up ongoing	2 (25%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line2.sas 09OCT2025 10:04

Protocol: 207499 Page 3 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000575
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Improved (event)	1 (5%)	2 (10%)
	Censored, follow-up ended	14 (70%)	12 (60%)
	Censored, follow-up ongoing	5 (25%)	6 (30%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line2.sas 09OCT2025 10:04

Protocol: 207499 Page 4 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000575
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Improved (event)	1 (13%)	1 (8%)
	Censored, follow-up ended	4 (50%)	9 (69%)
	Censored, follow-up ongoing	3 (38%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line2.sas 09OCT2025 10:04

Protocol: 207499 Page 5 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000575
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Improved (event)	6 (30%)	3 (15%)
	Censored, follow-up ended	11 (55%)	11 (55%)
	Censored, follow-up ongoing	3 (15%)	6 (30%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line2.sas 09OCT2025 10:04

Protocol: 207499 Page 6 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000575
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (25%)	2 (15%)
	Censored, follow-up ended	4 (50%)	9 (69%)
	Censored, follow-up ongoing	2 (25%)	2 (15%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line2.sas 09OCT2025 10:04

Protocol: 207499 Page 7 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000575
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Improved (event)	2 (10%)	3 (15%)
	Censored, follow-up ended	13 (65%)	12 (60%)
	Censored, follow-up ongoing	5 (25%)	5 (25%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line2.sas 09OCT2025 10:04

Protocol: 207499 Page 8 of 8
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000575
Summary of OSDI Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Improved (event)	0	1 (8%)
	Censored, follow-up ended	5 (63%)	9 (69%)
	Censored, follow-up ongoing	3 (38%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_tti_fu_2ref_line2.sas 09OCT2025 10:04

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	11.0 (3.80)	4.0 (3.48)
95% C.I.	(3.6, 18.5)	(-2.8, 10.9)
LS Mean Change from Baseline (SE)	0.5 (3.80)	-6.4 (3.48)
95% C.I.	(-6.9, 8.0)	(-13.3, 0.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.0 (5.16)	
95% C.I.	(-3.2, 17.1)	
p-value	0.17673	
Corrected Hedges' g	0.37	
95% C.I.	(-0.18, 0.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	25
LS Mean (SE)	23.7 (3.84)	8.8 (3.59)
95% C.I.	(16.1, 31.2)	(1.7, 15.9)
LS Mean Change from Baseline (SE)	13.2 (3.84)	-1.7 (3.59)
95% C.I.	(5.6, 20.8)	(-8.8, 5.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.9 (5.26)	
95% C.I.	(4.5, 25.2)	
p-value	0.00500	
Corrected Hedges' g	0.81	
95% C.I.	(0.22, 1.39)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	27
LS Mean (SE)	18.4 (3.91)	4.3 (3.54)
95% C.I.	(10.7, 26.1)	(-2.7, 11.2)
LS Mean Change from Baseline (SE)	7.9 (3.91)	-6.2 (3.54)
95% C.I.	(0.3, 15.6)	(-13.2, 0.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.2 (5.28)	
95% C.I.	(3.8, 24.6)	
p-value	0.00779	
Corrected Hedges' g	0.76	
95% C.I.	(0.18, 1.34)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	24
LS Mean (SE)	18.1 (3.99)	5.5 (3.69)
95% C.I.	(10.3, 26.0)	(-1.7, 12.8)
LS Mean Change from Baseline (SE)	7.6 (3.99)	-4.9 (3.69)
95% C.I.	(-0.2, 15.5)	(-12.2, 2.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.6 (5.44)	
95% C.I.	(1.9, 23.3)	
p-value	0.02162	
Corrected Hedges' g	0.68	
95% C.I.	(0.08, 1.28)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	15	18
LS Mean (SE)	23.1 (4.47)	8.4 (4.15)
95% C.I.	(14.3, 31.9)	(0.3, 16.6)
LS Mean Change from Baseline (SE)	12.6 (4.47)	-2.1 (4.15)
95% C.I.	(3.8, 21.4)	(-10.2, 6.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.7 (6.13)	
95% C.I.	(2.6, 26.7)	
p-value	0.01730	
Corrected Hedges' g	0.82	
95% C.I.	(0.11, 1.53)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	16	15
LS Mean (SE)	30.9 (4.45)	5.7 (4.56)
95% C.I.	(22.1, 39.6)	(-3.3, 14.6)
LS Mean Change from Baseline (SE)	20.4 (4.45)	-4.8 (4.56)
95% C.I.	(11.6, 29.1)	(-13.8, 4.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	25.2 (6.38)	
95% C.I.	(12.7, 37.8)	
p-value	0.00010	
Corrected Hedges' g	1.39	
95% C.I.	(0.60, 2.17)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	15	10
LS Mean (SE)	18.4 (4.58)	8.3 (5.50)
95% C.I.	(9.4, 27.4)	(-2.5, 19.2)
LS Mean Change from Baseline (SE)	7.9 (4.58)	-2.2 (5.50)
95% C.I.	(-1.1, 16.9)	(-13.0, 8.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.1 (7.17)	
95% C.I.	(-4.0, 24.2)	
p-value	0.16108	
Corrected Hedges' g	0.55	
95% C.I.	(-0.26, 1.37)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	20.5 (4.91)	9.6 (6.03)
95% C.I.	(10.8, 30.1)	(-2.2, 21.5)
LS Mean Change from Baseline (SE)	10.0 (4.91)	-0.8 (6.03)
95% C.I.	(0.3, 19.6)	(-12.7, 11.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.8 (7.77)	
95% C.I.	(-4.5, 26.1)	
p-value	0.16475	
Corrected Hedges' g	0.58	
95% C.I.	(-0.28, 1.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	10	8
LS Mean (SE)	20.8 (5.47)	7.2 (6.41)
95% C.I.	(10.0, 31.6)	(-5.4, 19.8)
LS Mean Change from Baseline (SE)	10.3 (5.47)	-3.3 (6.41)
95% C.I.	(-0.5, 21.1)	(-15.9, 9.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.6 (8.41)	
95% C.I.	(-3.0, 30.1)	
p-value	0.10756	
Corrected Hedges' g	0.73	
95% C.I.	(-0.23, 1.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	24.1 (5.61)	9.4 (7.29)
95% C.I.	(13.0, 35.1)	(-4.9, 23.7)
LS Mean Change from Baseline (SE)	13.6 (5.61)	-1.1 (7.29)
95% C.I.	(2.5, 24.6)	(-15.4, 13.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.7 (9.23)	
95% C.I.	(-3.5, 32.8)	
p-value	0.11284	
Corrected Hedges' g	0.78	
95% C.I.	(-0.27, 1.83)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	21.6 (5.56)	20.8 (7.60)
95% C.I.	(10.6, 32.5)	(5.8, 35.7)
LS Mean Change from Baseline (SE)	11.1 (5.56)	10.3 (7.60)
95% C.I.	(0.1, 22.0)	(-4.7, 25.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.8 (9.45)	
95% C.I.	(-17.8, 19.4)	
p-value	0.93273	
Corrected Hedges' g	0.04	
95% C.I.	(-0.95, 1.04)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	21.2 (6.23)	3.4 (8.17)
95% C.I.	(9.0, 33.5)	(-12.7, 19.4)
LS Mean Change from Baseline (SE)	10.7 (6.23)	-7.1 (8.17)
95% C.I.	(-1.5, 23.0)	(-23.2, 9.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	17.9 (10.34)	
95% C.I.	(-2.5, 38.2)	
p-value	0.08523	
Corrected Hedges' g	0.93	
95% C.I.	(-0.24, 2.10)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	7	4
LS Mean (SE)	27.1 (6.71)	4.2 (8.84)
95% C.I.	(13.8, 40.3)	(-13.2, 21.6)
LS Mean Change from Baseline (SE)	16.6 (6.71)	-6.3 (8.84)
95% C.I.	(3.4, 29.8)	(-23.7, 11.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	22.9 (11.18)	
95% C.I.	(0.9, 44.9)	
p-value	0.04156	
Corrected Hedges' g	1.18	
95% C.I.	(-0.14, 2.50)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	23.9 (6.56)	10.4 (8.40)
95% C.I.	(11.0, 36.9)	(-6.1, 27.0)
LS Mean Change from Baseline (SE)	13.4 (6.56)	0.0 (8.40)
95% C.I.	(0.5, 26.4)	(-16.6, 16.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.5 (10.74)	
95% C.I.	(-7.7, 34.6)	
p-value	0.21007	
Corrected Hedges' g	0.67	
95% C.I.	(-0.47, 1.82)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	26.5 (7.32)	8.8 (8.42)
95% C.I.	(12.1, 40.9)	(-7.8, 25.4)
LS Mean Change from Baseline (SE)	16.0 (7.32)	-1.7 (8.42)
95% C.I.	(1.6, 30.4)	(-18.2, 14.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	17.7 (11.32)	
95% C.I.	(-4.6, 40.0)	
p-value	0.11924	
Corrected Hedges' g	0.88	
95% C.I.	(-0.36, 2.12)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	23.4 (7.08)	10.4 (8.42)
95% C.I.	(9.4, 37.3)	(-6.2, 27.0)
LS Mean Change from Baseline (SE)	12.9 (7.08)	-0.1 (8.42)
95% C.I.	(-1.1, 26.8)	(-16.7, 16.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.9 (11.13)	
95% C.I.	(-9.0, 34.9)	
p-value	0.24603	
Corrected Hedges' g	0.64	
95% C.I.	(-0.54, 1.81)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	38.8 (7.48)	12.6 (8.92)
95% C.I.	(24.1, 53.5)	(-4.9, 30.2)
LS Mean Change from Baseline (SE)	28.3 (7.48)	2.1 (8.92)
95% C.I.	(13.6, 43.0)	(-15.4, 19.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	26.2 (11.78)	
95% C.I.	(3.0, 49.4)	
p-value	0.02707	
Corrected Hedges' g	1.30	
95% C.I.	(-0.08, 2.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	26.7 (8.26)	12.9 (8.91)
95% C.I.	(10.4, 42.9)	(-4.7, 30.4)
LS Mean Change from Baseline (SE)	16.2 (8.26)	2.4 (8.91)
95% C.I.	(-0.1, 32.4)	(-15.1, 19.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.8 (11.24)	
95% C.I.	(-8.4, 35.9)	
p-value	0.22214	
Corrected Hedges' g	0.63	
95% C.I.	(-0.59, 1.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	7	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	4	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Ocular Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	20.7 (4.56)	9.3 (4.20)
95% C.I.	(11.7, 29.7)	(1.0, 17.6)
LS Mean Change from Baseline (SE)	5.6 (4.56)	-5.8 (4.20)
95% C.I.	(-3.3, 14.6)	(-14.0, 2.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.4 (6.23)	
95% C.I.	(-0.9, 23.7)	
p-value	0.06805	
Corrected Hedges' g	0.50	
95% C.I.	(-0.05, 1.06)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	25
LS Mean (SE)	29.3 (4.61)	14.7 (4.37)
95% C.I.	(20.2, 38.4)	(6.1, 23.3)
LS Mean Change from Baseline (SE)	14.2 (4.61)	-0.3 (4.37)
95% C.I.	(5.1, 23.3)	(-8.9, 8.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.5 (6.37)	
95% C.I.	(2.0, 27.1)	
p-value	0.02308	
Corrected Hedges' g	0.65	
95% C.I.	(0.07, 1.23)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	27
LS Mean (SE)	20.7 (4.74)	8.3 (4.27)
95% C.I.	(11.4, 30.0)	(-0.1, 16.7)
LS Mean Change from Baseline (SE)	5.6 (4.74)	-6.8 (4.27)
95% C.I.	(-3.7, 14.9)	(-15.2, 1.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.4 (6.41)	
95% C.I.	(-0.3, 25.0)	
p-value	0.05471	
Corrected Hedges' g	0.55	
95% C.I.	(-0.03, 1.12)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	24
LS Mean (SE)	26.4 (4.84)	12.3 (4.47)
95% C.I.	(16.9, 36.0)	(3.5, 21.1)
LS Mean Change from Baseline (SE)	11.4 (4.84)	-2.8 (4.47)
95% C.I.	(1.8, 20.9)	(-11.6, 6.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.2 (6.60)	
95% C.I.	(1.2, 27.2)	
p-value	0.03280	
Corrected Hedges' g	0.63	
95% C.I.	(0.03, 1.23)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	15	18
LS Mean (SE)	32.0 (5.51)	7.6 (5.09)
95% C.I.	(21.2, 42.9)	(-2.5, 17.6)
LS Mean Change from Baseline (SE)	17.0 (5.51)	-7.5 (5.09)
95% C.I.	(6.1, 27.8)	(-17.5, 2.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	24.5 (7.51)	
95% C.I.	(9.7, 39.2)	
p-value	0.00124	
Corrected Hedges' g	1.11	
95% C.I.	(0.38, 1.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	16	15
LS Mean (SE)	37.6 (5.43)	9.2 (5.60)
95% C.I.	(26.9, 48.3)	(-1.8, 20.2)
LS Mean Change from Baseline (SE)	22.6 (5.43)	-5.9 (5.60)
95% C.I.	(11.9, 33.3)	(-16.9, 5.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	28.4 (7.79)	
95% C.I.	(13.1, 43.8)	
p-value	0.00030	
Corrected Hedges' g	1.28	
95% C.I.	(0.50, 2.05)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	15	10
LS Mean (SE)	24.0 (5.60)	21.1 (6.79)
95% C.I.	(13.0, 35.0)	(7.8, 34.5)
LS Mean Change from Baseline (SE)	8.9 (5.60)	6.0 (6.79)
95% C.I.	(-2.1, 20.0)	(-7.3, 19.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.9 (8.80)	
95% C.I.	(-14.4, 20.2)	
p-value	0.74063	
Corrected Hedges' g	0.13	
95% C.I.	(-0.67, 0.93)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	31.4 (6.03)	11.8 (7.32)
95% C.I.	(19.5, 43.2)	(-2.6, 26.2)
LS Mean Change from Baseline (SE)	16.3 (6.03)	-3.3 (7.32)
95% C.I.	(4.4, 28.2)	(-17.7, 11.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	19.6 (9.48)	
95% C.I.	(0.9, 38.2)	
p-value	0.03990	
Corrected Hedges' g	0.86	
95% C.I.	(-0.03, 1.75)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	10	8
LS Mean (SE)	28.9 (6.77)	10.2 (7.73)
95% C.I.	(15.6, 42.2)	(-5.0, 25.4)
LS Mean Change from Baseline (SE)	13.8 (6.77)	-4.8 (7.73)
95% C.I.	(0.5, 27.1)	(-20.0, 10.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	18.6 (10.27)	
95% C.I.	(-1.6, 38.8)	
p-value	0.07044	
Corrected Hedges' g	0.82	
95% C.I.	(-0.15, 1.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	46.4 (7.02)	9.4 (9.17)
95% C.I.	(32.6, 60.2)	(-8.6, 27.5)
LS Mean Change from Baseline (SE)	31.3 (7.02)	-5.6 (9.17)
95% C.I.	(17.5, 45.1)	(-23.7, 12.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	36.9 (11.85)	
95% C.I.	(13.6, 60.3)	
p-value	0.00197	
Corrected Hedges' g	1.57	
95% C.I.	(0.42, 2.72)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	34.3 (6.81)	20.8 (9.43)
95% C.I.	(20.9, 47.7)	(2.3, 39.4)
LS Mean Change from Baseline (SE)	19.2 (6.81)	5.8 (9.43)
95% C.I.	(5.8, 32.6)	(-12.8, 24.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.5 (11.89)	
95% C.I.	(-9.9, 36.9)	
p-value	0.25777	
Corrected Hedges' g	0.56	
95% C.I.	(-0.45, 1.57)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	17.9 (8.09)	8.4 (10.18)
95% C.I.	(2.0, 33.8)	(-11.6, 28.5)
LS Mean Change from Baseline (SE)	2.8 (8.09)	-6.6 (10.18)
95% C.I.	(-13.1, 18.7)	(-26.7, 13.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.5 (13.54)	
95% C.I.	(-17.2, 36.1)	
p-value	0.48542	
Corrected Hedges' g	0.39	
95% C.I.	(-0.74, 1.51)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	7	4
LS Mean (SE)	30.4 (8.33)	5.0 (11.19)
95% C.I.	(14.1, 46.8)	(-17.0, 27.0)
LS Mean Change from Baseline (SE)	15.4 (8.33)	-10.0 (11.19)
95% C.I.	(-1.0, 31.7)	(-32.1, 12.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	25.4 (14.31)	
95% C.I.	(-2.7, 53.5)	
p-value	0.07676	
Corrected Hedges' g	1.05	
95% C.I.	(-0.26, 2.35)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	24.0 (7.93)	8.3 (10.50)
95% C.I.	(8.4, 39.6)	(-12.4, 28.9)
LS Mean Change from Baseline (SE)	8.9 (7.93)	-6.8 (10.50)
95% C.I.	(-6.7, 24.5)	(-27.5, 13.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.7 (13.38)	
95% C.I.	(-10.6, 42.1)	
p-value	0.24123	
Corrected Hedges' g	0.64	
95% C.I.	(-0.50, 1.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	31.1 (9.12)	3.2 (10.57)
95% C.I.	(13.1, 49.0)	(-17.6, 24.0)
LS Mean Change from Baseline (SE)	16.0 (9.12)	-11.9 (10.57)
95% C.I.	(-1.9, 33.9)	(-32.7, 8.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	27.9 (14.53)	
95% C.I.	(-0.7, 56.5)	
p-value	0.05578	
Corrected Hedges' g	1.11	
95% C.I.	(-0.16, 2.39)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	30.0 (8.57)	4.2 (10.54)
95% C.I.	(13.2, 46.9)	(-16.6, 24.9)
LS Mean Change from Baseline (SE)	15.0 (8.57)	-10.9 (10.54)
95% C.I.	(-1.9, 31.8)	(-31.7, 9.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	25.9 (13.99)	
95% C.I.	(-1.7, 53.4)	
p-value	0.06555	
Corrected Hedges' g	1.04	
95% C.I.	(-0.18, 2.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	61.9 (9.25)	-0.7 (11.64)
95% C.I.	(43.7, 80.1)	(-23.6, 22.2)
LS Mean Change from Baseline (SE)	46.9 (9.25)	-15.8 (11.64)
95% C.I.	(28.7, 65.1)	(-38.7, 7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	62.6 (15.60)	
95% C.I.	(32.0, 93.3)	
p-value	0.00007	
Corrected Hedges' g	2.47	
95% C.I.	(0.81, 4.14)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	44.8 (9.39)	14.4 (12.02)
95% C.I.	(26.3, 63.2)	(-9.3, 38.1)
LS Mean Change from Baseline (SE)	29.7 (9.39)	-0.7 (12.02)
95% C.I.	(11.2, 48.2)	(-24.3, 23.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	30.4 (14.16)	
95% C.I.	(2.5, 58.2)	
p-value	0.03283	
Corrected Hedges' g	1.12	
95% C.I.	(-0.16, 2.39)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	7	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	4	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Vision-Related Function

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 5		
n [1]	17	25
n [2]	13	22
LS Mean (SE)	10.6 (4.77)	7.1 (3.84)
95% C.I.	(1.1, 20.0)	(-0.5, 14.7)
LS Mean Change from Baseline (SE)	0.8 (4.77)	-2.7 (3.84)
95% C.I.	(-8.7, 10.2)	(-10.3, 4.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.5 (6.11)	
95% C.I.	(-8.6, 15.5)	
p-value	0.57290	
Corrected Hedges' g	0.19	
95% C.I.	(-0.50, 0.88)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9		
n [1]	17	25
n [2]	13	17
LS Mean (SE)	17.2 (4.75)	9.9 (4.00)
95% C.I.	(7.8, 26.6)	(1.9, 17.8)
LS Mean Change from Baseline (SE)	7.4 (4.75)	0.1 (4.00)
95% C.I.	(-2.0, 16.8)	(-7.8, 8.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.3 (6.23)	
95% C.I.	(-5.0, 19.7)	
p-value	0.24006	
Corrected Hedges' g	0.43	
95% C.I.	(-0.30, 1.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 13		
n [1]	17	25
n [2]	13	16
LS Mean (SE)	19.1 (4.81)	10.0 (4.19)
95% C.I.	(9.6, 28.6)	(1.8, 18.3)
LS Mean Change from Baseline (SE)	9.3 (4.81)	0.2 (4.19)
95% C.I.	(-0.2, 18.8)	(-8.0, 8.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.0 (6.46)	
95% C.I.	(-3.7, 21.8)	
p-value	0.16389	
Corrected Hedges' g	0.52	
95% C.I.	(-0.23, 1.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17		
n [1]	17	25
n [2]	13	16
LS Mean (SE)	14.6 (4.88)	14.5 (4.26)
95% C.I.	(4.9, 24.2)	(6.1, 22.9)
LS Mean Change from Baseline (SE)	4.8 (4.88)	4.7 (4.26)
95% C.I.	(-4.9, 14.4)	(-3.7, 13.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.1 (6.60)	
95% C.I.	(-12.9, 13.2)	
p-value	0.98672	
Corrected Hedges' g	0.01	
95% C.I.	(-0.73, 0.74)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 21		
n [1]	17	25
n [2]	9	13
LS Mean (SE)	15.9 (5.47)	5.9 (4.75)
95% C.I.	(5.1, 26.7)	(-3.5, 15.3)
LS Mean Change from Baseline (SE)	6.1 (5.47)	-3.9 (4.75)
95% C.I.	(-4.7, 16.9)	(-13.3, 5.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.0 (7.24)	
95% C.I.	(-4.3, 24.3)	
p-value	0.16876	
Corrected Hedges' g	0.57	
95% C.I.	(-0.30, 1.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 29		
n [1]	17	25
n [2]	8	10
LS Mean (SE)	42.8 (5.84)	13.7 (5.32)
95% C.I.	(31.3, 54.3)	(3.2, 24.2)
LS Mean Change from Baseline (SE)	33.0 (5.84)	3.9 (5.32)
95% C.I.	(21.5, 44.5)	(-6.6, 14.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	29.1 (7.74)	
95% C.I.	(13.9, 44.4)	
p-value	0.00023	
Corrected Hedges' g	1.66	
95% C.I.	(0.59, 2.74)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 37		
n [1]	17	25
n [2]	10	8
LS Mean (SE)	8.4 (5.46)	5.0 (5.92)
95% C.I.	(-2.3, 19.2)	(-6.7, 16.6)
LS Mean Change from Baseline (SE)	-1.4 (5.46)	-4.8 (5.92)
95% C.I.	(-12.1, 9.4)	(-16.5, 6.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.5 (8.05)	
95% C.I.	(-12.4, 19.4)	
p-value	0.66627	
Corrected Hedges' g	0.19	
95% C.I.	(-0.74, 1.13)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 45		
n [1]	17	25
n [2]	8	6
LS Mean (SE)	33.5 (6.01)	6.9 (6.87)
95% C.I.	(21.7, 45.4)	(-6.7, 20.4)
LS Mean Change from Baseline (SE)	23.8 (6.01)	-2.9 (6.87)
95% C.I.	(11.9, 35.6)	(-16.5, 10.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	26.7 (9.07)	
95% C.I.	(8.8, 44.6)	
p-value	0.00374	
Corrected Hedges' g	1.48	
95% C.I.	(0.28, 2.67)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 53		
n [1]	17	25
n [2]	6	5
LS Mean (SE)	26.1 (6.75)	12.3 (7.52)
95% C.I.	(12.8, 39.4)	(-2.5, 27.2)
LS Mean Change from Baseline (SE)	16.3 (6.75)	2.5 (7.52)
95% C.I.	(3.0, 29.7)	(-12.3, 17.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.8 (9.96)	
95% C.I.	(-5.9, 33.5)	
p-value	0.16766	
Corrected Hedges' g	0.76	
95% C.I.	(-0.47, 1.99)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61		
n [1]	17	25
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 69		
n [1]	17	25
n [2]	7	4
LS Mean (SE)	7.3 (6.43)	23.9 (8.56)
95% C.I.	(-5.4, 20.0)	(7.0, 40.8)
LS Mean Change from Baseline (SE)	-2.5 (6.43)	14.1 (8.56)
95% C.I.	(-15.2, 10.2)	(-2.8, 31.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-16.6 (10.76)	
95% C.I.	(-37.9, 4.6)	
p-value	0.12451	
Corrected Hedges' g	-0.89	
95% C.I.	(-2.17, 0.39)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 77		
n [1]	17	25
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 85		
n [1]	17	25
n [2]	3	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 93		
n [1]	17	25
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 101		
n [1]	17	25
n [2]	3	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 109		
n [1]	17	25
n [2]	3	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 117		
n [1]	17	25
n [2]	3	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125		
n [1]	17	25
n [2]	2	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133		
n [1]	17	25
n [2]	3	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141		
n [1]	17	25
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149		
n [1]	17	25
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157		
n [1]	17	25
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 165		
n [1]	17	25
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173		
n [1]	17	25
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181		
n [1]	17	25
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189		
n [1]	17	25
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Environmental Triggers

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197		
n [1]	17	25
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	16.4 (3.65)	6.6 (3.37)
95% C.I.	(9.2, 23.6)	(0.0, 13.2)
LS Mean Change from Baseline (SE)	4.2 (3.65)	-5.6 (3.37)
95% C.I.	(-3.0, 11.4)	(-12.2, 1.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.8 (4.98)	
95% C.I.	(0.0, 19.6)	
p-value	0.05014	
Corrected Hedges' g	0.54	
95% C.I.	(-0.02, 1.09)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	25
LS Mean (SE)	24.2 (3.70)	11.7 (3.51)
95% C.I.	(16.9, 31.5)	(4.8, 18.6)
LS Mean Change from Baseline (SE)	12.0 (3.70)	-0.5 (3.51)
95% C.I.	(4.7, 19.3)	(-7.4, 6.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.5 (5.11)	
95% C.I.	(2.5, 22.6)	
p-value	0.01482	
Corrected Hedges' g	0.70	
95% C.I.	(0.11, 1.28)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	27
LS Mean (SE)	18.8 (3.79)	6.4 (3.43)
95% C.I.	(11.4, 26.3)	(-0.4, 13.1)
LS Mean Change from Baseline (SE)	6.6 (3.79)	-5.8 (3.43)
95% C.I.	(-0.8, 14.1)	(-12.6, 0.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.4 (5.12)	
95% C.I.	(2.4, 22.5)	
p-value	0.01571	
Corrected Hedges' g	0.69	
95% C.I.	(0.11, 1.27)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	24
LS Mean (SE)	22.3 (3.88)	9.2 (3.59)
95% C.I.	(14.7, 29.9)	(2.1, 16.3)
LS Mean Change from Baseline (SE)	10.1 (3.88)	-3.0 (3.59)
95% C.I.	(2.5, 17.8)	(-10.1, 4.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.1 (5.29)	
95% C.I.	(2.7, 23.5)	
p-value	0.01364	
Corrected Hedges' g	0.73	
95% C.I.	(0.12, 1.33)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	15	18
LS Mean (SE)	26.0 (4.43)	6.8 (4.07)
95% C.I.	(17.3, 34.7)	(-1.2, 14.8)
LS Mean Change from Baseline (SE)	13.8 (4.43)	-5.4 (4.07)
95% C.I.	(5.1, 22.5)	(-13.4, 2.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	19.2 (6.01)	
95% C.I.	(7.4, 31.1)	
p-value	0.00151	
Corrected Hedges' g	1.09	
95% C.I.	(0.36, 1.82)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	16	15
LS Mean (SE)	33.9 (4.37)	7.7 (4.49)
95% C.I.	(25.3, 42.5)	(-1.1, 16.5)
LS Mean Change from Baseline (SE)	21.7 (4.37)	-4.5 (4.49)
95% C.I.	(13.1, 30.3)	(-13.3, 4.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	26.2 (6.26)	
95% C.I.	(13.9, 38.5)	
p-value	0.00004	
Corrected Hedges' g	1.46	
95% C.I.	(0.67, 2.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	15	10
LS Mean (SE)	20.4 (4.50)	13.8 (5.45)
95% C.I.	(11.5, 29.3)	(3.1, 24.5)
LS Mean Change from Baseline (SE)	8.2 (4.50)	1.6 (5.45)
95% C.I.	(-0.7, 17.1)	(-9.1, 12.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.6 (7.07)	
95% C.I.	(-7.3, 20.5)	
p-value	0.35133	
Corrected Hedges' g	0.37	
95% C.I.	(-0.44, 1.17)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	27.1 (4.84)	9.4 (5.89)
95% C.I.	(17.6, 36.6)	(-2.2, 21.0)
LS Mean Change from Baseline (SE)	14.9 (4.84)	-2.8 (5.89)
95% C.I.	(5.4, 24.4)	(-14.4, 8.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	17.7 (7.61)	
95% C.I.	(2.7, 32.7)	
p-value	0.02071	
Corrected Hedges' g	0.97	
95% C.I.	(0.07, 1.87)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	10	8
LS Mean (SE)	25.6 (5.44)	8.6 (6.24)
95% C.I.	(14.9, 36.4)	(-3.6, 20.9)
LS Mean Change from Baseline (SE)	13.5 (5.44)	-3.6 (6.24)
95% C.I.	(2.7, 24.2)	(-15.8, 8.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	17.0 (8.25)	
95% C.I.	(0.8, 33.3)	
p-value	0.04006	
Corrected Hedges' g	0.93	
95% C.I.	(-0.05, 1.91)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	37.3 (5.57)	9.4 (7.37)
95% C.I.	(26.3, 48.2)	(-5.1, 23.9)
LS Mean Change from Baseline (SE)	25.1 (5.57)	-2.8 (7.37)
95% C.I.	(14.1, 36.0)	(-17.3, 11.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	27.9 (9.40)	
95% C.I.	(9.4, 46.4)	
p-value	0.00324	
Corrected Hedges' g	1.48	
95% C.I.	(0.35, 2.62)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	25.9 (5.42)	20.9 (7.60)
95% C.I.	(15.2, 36.5)	(6.0, 35.9)
LS Mean Change from Baseline (SE)	13.7 (5.42)	8.7 (7.60)
95% C.I.	(3.0, 24.4)	(-6.2, 23.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.0 (9.47)	
95% C.I.	(-13.7, 23.6)	
p-value	0.60020	
Corrected Hedges' g	0.26	
95% C.I.	(-0.74, 1.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	20.6 (6.33)	7.4 (8.19)
95% C.I.	(8.1, 33.0)	(-8.7, 23.6)
LS Mean Change from Baseline (SE)	8.4 (6.33)	-4.7 (8.19)
95% C.I.	(-4.1, 20.8)	(-20.9, 11.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.1 (10.67)	
95% C.I.	(-7.9, 34.1)	
p-value	0.21928	
Corrected Hedges' g	0.68	
95% C.I.	(-0.47, 1.82)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	7	4
LS Mean (SE)	28.0 (6.67)	3.8 (8.90)
95% C.I.	(14.9, 41.2)	(-13.7, 21.3)
LS Mean Change from Baseline (SE)	15.8 (6.67)	-8.4 (8.90)
95% C.I.	(2.7, 29.0)	(-25.9, 9.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	24.3 (11.35)	
95% C.I.	(1.9, 46.6)	
p-value	0.03330	
Corrected Hedges' g	1.25	
95% C.I.	(-0.08, 2.59)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	20.7 (6.37)	8.0 (8.32)
95% C.I.	(8.1, 33.2)	(-8.4, 24.3)
LS Mean Change from Baseline (SE)	8.5 (6.37)	-4.2 (8.32)
95% C.I.	(-4.1, 21.0)	(-20.6, 12.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.7 (10.64)	
95% C.I.	(-8.2, 33.6)	
p-value	0.23386	
Corrected Hedges' g	0.65	
95% C.I.	(-0.50, 1.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705

Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	28.4 (7.30)	3.9 (8.36)
95% C.I.	(14.1, 42.8)	(-12.5, 20.4)
LS Mean Change from Baseline (SE)	16.2 (7.30)	-8.3 (8.36)
95% C.I.	(1.9, 30.6)	(-24.7, 8.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	24.5 (11.46)	
95% C.I.	(1.9, 47.0)	
p-value	0.03333	
Corrected Hedges' g	1.23	
95% C.I.	(-0.07, 2.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	28.6 (6.89)	5.5 (8.34)
95% C.I.	(15.0, 42.1)	(-10.9, 21.9)
LS Mean Change from Baseline (SE)	16.4 (6.89)	-6.7 (8.34)
95% C.I.	(2.8, 29.9)	(-23.1, 9.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	23.0 (11.09)	
95% C.I.	(1.2, 44.9)	
p-value	0.03850	
Corrected Hedges' g	1.16	
95% C.I.	(-0.08, 2.39)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	50.8 (7.41)	3.3 (9.11)
95% C.I.	(36.2, 65.4)	(-14.6, 21.2)
LS Mean Change from Baseline (SE)	38.6 (7.41)	-8.9 (9.11)
95% C.I.	(24.0, 53.2)	(-26.8, 9.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	47.5 (12.19)	
95% C.I.	(23.5, 71.5)	
p-value	0.00012	
Corrected Hedges' g	2.36	
95% C.I.	(0.73, 4.00)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	33.9 (8.73)	6.6 (11.44)
95% C.I.	(16.8, 51.1)	(-15.9, 29.1)
LS Mean Change from Baseline (SE)	21.8 (8.73)	-5.6 (11.44)
95% C.I.	(4.6, 38.9)	(-28.1, 16.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	27.4 (11.37)	
95% C.I.	(5.0, 49.8)	
p-value	0.01675	
Corrected Hedges' g	1.07	
95% C.I.	(-0.20, 2.34)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	7	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	4	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

Table 4.0000705
Analysis of OSDI Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Total Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_osdi_mmrm_2ref.sas 09OCT2025 09:02

1.3.1.2 EORTC QLQ-C30

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	54.01	58.59
		SD	20.591	24.363
		Median	50.00	66.67
		Min.	16.7	0.0
		Max.	83.3	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	55.33	58.62
		SD	20.110	21.302
		Median	50.00	58.33
		Min.	25.0	16.7
		Max.	83.3	100.0
	Change from Baseline	n	24	28
		Mean	3.47	1.49
		SD	12.984	17.866
		Median	0.00	0.00
		Min.	-25.0	-33.3
		Max.	41.7	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (38%)	13 (46%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (21%)	9 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (17%)	9 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (8%)	7 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 3 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	58.68	57.41
		SD	17.631	22.209
		Median	54.17	66.67
		Min.	33.3	8.3
		Max.	83.3	100.0
	Change from Baseline	n	23	26
		Mean	7.61	2.56
		SD	20.706	21.444
		Median	8.33	4.17
		Min.	-16.7	-33.3
		Max.	66.7	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	13 (57%)	13 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (26%)	10 (38%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (26%)	9 (35%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (22%)	9 (35%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 4 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	60.51	63.46
		SD	22.222	18.720
		Median	66.67	66.67
		Min.	16.7	16.7
		Max.	100.0	83.3
	Change from Baseline	n	22	26
		Mean	11.74	6.41
		SD	16.797	19.193
		Median	16.67	0.00
		Min.	-33.3	-25.0
		Max.	41.7	58.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	15 (68%)	11 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	12 (55%)	9 (35%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (9%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (9%)	4 (15%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 5 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	56.06	56.67
		SD	24.422	22.179
		Median	50.00	58.33
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	21	25
		Mean	3.57	1.00
		SD	21.980	24.095
		Median	8.33	0.00
		Min.	-58.3	-58.3
		Max.	33.3	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	11 (52%)	10 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (38%)	6 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (24%)	9 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (19%)	8 (32%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 6 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	65.20	62.72
		SD	18.218	24.433
		Median	66.67	66.67
		Min.	33.3	0.0
		Max.	91.7	83.3
	Change from Baseline	n	16	19
		Mean	10.94	2.19
		SD	20.575	24.508
		Median	8.33	0.00
		Min.	-33.3	-33.3
		Max.	66.7	58.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	11 (69%)	8 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (44%)	6 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	6 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (6%)	5 (26%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 7 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	60.65	67.19
		SD	19.345	21.617
		Median	50.00	66.67
		Min.	33.3	16.7
		Max.	100.0	100.0
	Change from Baseline	n	17	16
		Mean	9.31	6.25
		SD	14.398	22.464
		Median	8.33	4.17
		Min.	-16.7	-33.3
		Max.	33.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	11 (65%)	8 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (41%)	7 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (12%)	4 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (12%)	4 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 8 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	58.89	62.75
		SD	17.947	16.955
		Median	58.33	66.67
		Min.	33.3	33.3
		Max.	100.0	91.7
	Change from Baseline	n	14	17
		Mean	5.95	-5.39
		SD	15.480	19.307
		Median	12.50	0.00
		Min.	-16.7	-33.3
		Max.	25.0	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (57%)	6 (35%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (50%)	4 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (29%)	8 (47%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	7 (41%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 9 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	56.25	68.06
		SD	16.527	19.080
		Median	50.00	66.67
		Min.	33.3	41.7
		Max.	91.7	100.0
	Change from Baseline	n	15	12
		Mean	3.89	3.47
		SD	13.313	18.278
		Median	0.00	4.17
		Min.	-16.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (40%)	6 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	4 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (27%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	54.76	69.44
		SD	21.611	13.176
		Median	50.00	66.67
		Min.	33.3	50.0
		Max.	83.3	83.3
	Change from Baseline	n	13	9
		Mean	0.64	1.85
		SD	20.543	16.551
		Median	8.33	0.00
		Min.	-33.3	-25.0
		Max.	33.3	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (54%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 11 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	54.76	62.50
		SD	17.817	23.969
		Median	50.00	66.67
		Min.	16.7	8.3
		Max.	83.3	91.7
	Change from Baseline	n	13	12
		Mean	2.56	-6.25
		SD	17.141	24.650
		Median	0.00	-16.67
		Min.	-33.3	-58.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (46%)	4 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	7 (58%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	7 (58%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 12 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	52.78	65.83
		SD	17.724	19.818
		Median	50.00	70.83
		Min.	33.3	25.0
		Max.	83.3	83.3
	Change from Baseline	n	14	10
		Mean	-1.19	-1.67
		SD	26.525	20.713
		Median	0.00	0.00
		Min.	-41.7	-41.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (36%)	4 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (29%)	2 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (43%)	4 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (36%)	3 (30%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 13 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	56.06	66.67
		SD	9.924	22.438
		Median	50.00	75.00
		Min.	41.7	16.7
		Max.	75.0	83.3
	Change from Baseline	n	11	9
		Mean	3.03	-0.93
		SD	17.189	10.577
		Median	0.00	0.00
		Min.	-25.0	-16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	57.41	62.12
		SD	16.375	23.969
		Median	66.67	66.67
		Min.	33.3	16.7
		Max.	75.0	83.3
	Change from Baseline	n	9	11
		Mean	4.63	-5.30
		SD	23.241	23.650
		Median	0.00	-8.33
		Min.	-33.3	-41.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (44%)	4 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	3 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	6 (55%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	4 (36%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 15 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	53.03	69.44
		SD	17.588	10.206
		Median	50.00	66.67
		Min.	16.7	50.0
		Max.	83.3	83.3
	Change from Baseline	n	11	9
		Mean	2.27	-1.85
		SD	14.949	16.017
		Median	0.00	0.00
		Min.	-25.0	-33.3
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 16 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	51.52	68.06
		SD	11.677	11.076
		Median	50.00	66.67
		Min.	33.3	50.0
		Max.	66.7	83.3
	Change from Baseline	n	11	6
		Mean	0.00	2.78
		SD	18.257	13.608
		Median	-8.33	4.17
		Min.	-25.0	-16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (55%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	54.17	69.44
		SD	9.001	12.546
		Median	50.00	66.67
		Min.	41.7	50.0
		Max.	75.0	83.3
	Change from Baseline	n	10	6
		Mean	9.17	4.17
		SD	18.194	19.543
		Median	8.33	4.17
		Min.	-16.7	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	56.48	72.62
		SD	16.551	12.467
		Median	58.33	75.00
		Min.	33.3	50.0
		Max.	83.3	83.3
	Change from Baseline	n	9	7
		Mean	9.26	2.38
		SD	25.154	18.456
		Median	16.67	8.33
		Min.	-33.3	-33.3
		Max.	50.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (56%)	4 (57%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	3 (43%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	2 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	60.00	70.83
		SD	20.713	12.638
		Median	62.50	70.83
		Min.	25.0	50.0
		Max.	83.3	83.3
	Change from Baseline	n	10	6
		Mean	8.33	5.56
		SD	23.895	18.002
		Median	8.33	4.17
		Min.	-25.0	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (60%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	53.57	77.78
		SD	17.252	8.607
		Median	58.33	83.33
		Min.	33.3	66.7
		Max.	83.3	83.3
	Change from Baseline	n	7	6
		Mean	9.52	8.33
		SD	19.501	17.480
		Median	16.67	8.33
		Min.	-16.7	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 21 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	58.33	78.33
		SD	12.729	11.180
		Median	50.00	83.33
		Min.	50.0	66.7
		Max.	83.3	91.7
	Change from Baseline	n	7	5
		Mean	14.29	8.33
		SD	19.670	18.634
		Median	25.00	8.33
		Min.	-16.7	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 22 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	55.21	79.17
		SD	16.629	6.972
		Median	50.00	83.33
		Min.	33.3	66.7
		Max.	83.3	83.3
	Change from Baseline	n	8	6
		Mean	7.29	4.17
		SD	22.466	22.205
		Median	8.33	8.33
		Min.	-33.3	-25.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	52.08	76.67
		SD	17.107	9.129
		Median	50.00	83.33
		Min.	33.3	66.7
		Max.	83.3	83.3
	Change from Baseline	n	7	5
		Mean	10.71	6.67
		SD	21.362	19.003
		Median	8.33	0.00
		Min.	-16.7	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 24 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	61.46	76.67
		SD	14.731	9.129
		Median	54.17	83.33
		Min.	50.0	66.7
		Max.	83.3	83.3
	Change from Baseline	n	8	5
		Mean	13.54	6.67
		SD	18.865	19.003
		Median	12.50	0.00
		Min.	-16.7	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (63%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 25 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	53.13	70.00
		SD	23.119	17.280
		Median	54.17	75.00
		Min.	16.7	41.7
		Max.	91.7	83.3
	Change from Baseline	n	7	5
		Mean	8.33	0.00
		SD	26.352	28.260
		Median	8.33	0.00
		Min.	-33.3	-41.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	54.76	79.17
		SD	17.910	10.206
		Median	50.00	83.33
		Min.	33.3	66.7
		Max.	83.3	91.7
	Change from Baseline	n	7	6
		Mean	5.95	9.72
		SD	34.599	18.572
		Median	16.67	8.33
		Min.	-41.7	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 27 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	52.78	78.33
		SD	12.546	7.454
		Median	50.00	83.33
		Min.	33.3	66.7
		Max.	66.7	83.3
	Change from Baseline	n	6	5
		Mean	9.72	8.33
		SD	23.814	16.667
		Median	16.67	0.00
		Min.	-33.3	-8.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 28 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	52.38	75.00
		SD	11.501	9.129
		Median	50.00	75.00
		Min.	33.3	66.7
		Max.	66.7	83.3
	Change from Baseline	n	7	6
		Mean	8.33	0.00
		SD	19.837	23.570
		Median	16.67	0.00
		Min.	-16.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	48.96	73.33
		SD	12.939	9.129
		Median	50.00	66.67
		Min.	33.3	66.7
		Max.	66.7	83.3
	Change from Baseline	n	7	5
		Mean	4.76	3.33
		SD	24.465	13.944
		Median	16.67	0.00
		Min.	-33.3	-16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	54.17	79.17
		SD	19.543	8.333
		Median	54.17	83.33
		Min.	33.3	66.7
		Max.	83.3	83.3
	Change from Baseline	n	6	4
		Mean	8.33	4.17
		SD	29.814	15.957
		Median	12.50	8.33
		Min.	-33.3	-16.7
		Max.	41.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 31 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	60.00	70.00
		SD	14.907	13.944
		Median	50.00	66.67
		Min.	50.0	50.0
		Max.	83.3	83.3
	Change from Baseline	n	5	5
		Mean	8.33	0.00
		SD	20.412	16.667
		Median	0.00	0.00
		Min.	-16.7	-16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (40%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 32 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	59.52	70.00
		SD	13.113	13.944
		Median	50.00	66.67
		Min.	50.0	50.0
		Max.	83.3	83.3
	Change from Baseline	n	6	5
		Mean	12.50	0.00
		SD	18.066	11.785
		Median	16.67	0.00
		Min.	-16.7	-16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 33 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	55.56	72.92
		SD	18.002	18.478
		Median	54.17	75.00
		Min.	33.3	50.0
		Max.	83.3	91.7
	Change from Baseline	n	6	4
		Mean	9.72	6.25
		SD	30.008	7.979
		Median	8.33	4.17
		Min.	-33.3	0.0
		Max.	50.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 34 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	50.00	72.92
		SD	11.785	7.979
		Median	54.17	70.83
		Min.	33.3	66.7
		Max.	58.3	83.3
	Change from Baseline	n	4	4
		Mean	-2.08	6.25
		SD	21.916	12.500
		Median	4.17	8.33
		Min.	-33.3	-8.3
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 35 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	58.33	61.11
		SD	15.590	19.245
		Median	50.00	50.00
		Min.	41.7	50.0
		Max.	75.0	83.3
	Change from Baseline	n	5	3
		Mean	6.67	-5.56
		SD	23.124	9.623
		Median	0.00	0.00
		Min.	-25.0	-16.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 36 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	58.33	58.33
		SD	15.811	11.785
		Median	58.33	58.33
		Min.	41.7	50.0
		Max.	83.3	66.7
	Change from Baseline	n	6	2
		Mean	12.50	0.00
		SD	31.069	23.570
		Median	12.50	0.00
		Min.	-25.0	-16.7
		Max.	66.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 37 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	60.00	83.33
		SD	18.066	16.667
		Median	50.00	83.33
		Min.	41.7	66.7
		Max.	83.3	100.0
	Change from Baseline	n	5	3
		Mean	8.33	16.67
		SD	25.000	0.000
		Median	0.00	16.67
		Min.	-25.0	16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	3 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	3 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 38 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	54.17	66.67
		SD	12.638	35.355
		Median	54.17	66.67
		Min.	33.3	41.7
		Max.	66.7	91.7
	Change from Baseline	n	5	2
		Mean	6.67	0.00
		SD	16.029	11.785
		Median	8.33	0.00
		Min.	-16.7	-8.3
		Max.	25.0	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 39 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	50.00	79.17
		SD	6.804	17.678
		Median	50.00	79.17
		Min.	41.7	66.7
		Max.	58.3	91.7
	Change from Baseline	n	4	2
		Mean	-2.08	12.50
		SD	17.180	5.893
		Median	0.00	12.50
		Min.	-25.0	8.3
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 40 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	45.00	77.78
		SD	26.087	9.623
		Median	33.33	83.33
		Min.	16.7	66.7
		Max.	83.3	83.3
	Change from Baseline	n	5	3
		Mean	-6.67	11.11
		SD	30.277	9.623
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 41 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	51.39	66.67
		SD	14.353	
		Median	50.00	66.67
		Min.	33.3	66.7
		Max.	75.0	66.7
	Change from Baseline	n	6	1
		Mean	2.78	16.67
		SD	21.517	
		Median	8.33	16.67
		Min.	-33.3	16.7
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 42 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	51.67	75.00
		SD	17.078	11.785
		Median	50.00	75.00
		Min.	25.0	66.7
		Max.	66.7	83.3
	Change from Baseline	n	5	2
		Mean	0.00	8.33
		SD	21.246	11.785
		Median	0.00	8.33
		Min.	-25.0	0.0
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 43 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	56.94	50.00
		SD	17.010	
		Median	54.17	50.00
		Min.	33.3	50.0
		Max.	83.3	50.0
	Change from Baseline	n	6	1
		Mean	11.11	0.00
		SD	25.640	
		Median	16.67	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 44 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	51.67	50.00
		SD	23.863	
		Median	50.00	50.00
		Min.	25.0	50.0
		Max.	83.3	50.0
	Change from Baseline	n	5	1
		Mean	0.00	0.00
		SD	29.463	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 45 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	63.89	66.67
		SD	12.729	0.000
		Median	66.67	66.67
		Min.	50.0	66.7
		Max.	75.0	66.7
	Change from Baseline	n	3	2
		Mean	16.67	0.00
		SD	14.434	23.570
		Median	25.00	0.00
		Min.	0.0	-16.7
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	61.11	66.67
		SD	9.623	
		Median	66.67	66.67
		Min.	50.0	66.7
		Max.	66.7	66.7
	Change from Baseline	n	3	1
		Mean	13.89	16.67
		SD	12.729	
		Median	16.67	16.67
		Min.	0.0	16.7
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 47 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	44.44	66.67
		SD	19.245	
		Median	33.33	66.67
		Min.	33.3	66.7
		Max.	66.7	66.7
	Change from Baseline	n	3	1
		Mean	-2.78	16.67
		SD	24.056	
		Median	-16.67	16.67
		Min.	-16.7	16.7
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 48 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	66.67	62.50
		SD		5.893
		Median	66.67	62.50
		Min.	66.7	58.3
		Max.	66.7	66.7
	Change from Baseline	n	1	2
		Mean	25.00	-4.17
		SD		29.463
		Median	25.00	-4.17
		Min.	25.0	-25.0
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 49 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	54.17	66.67
		SD	17.678	
		Median	54.17	66.67
		Min.	41.7	66.7
		Max.	66.7	66.7
	Change from Baseline	n	2	1
		Mean	8.33	16.67
		SD	23.570	
		Median	8.33	16.67
		Min.	-8.3	16.7
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 50 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	66.67	66.67
		SD		
		Median	66.67	66.67
		Min.	66.7	66.7
		Max.	66.7	66.7
	Change from Baseline	n	1	1
		Mean	25.00	16.67
		SD		
		Median	25.00	16.67
		Min.	25.0	16.7
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 51 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	58.33	66.67
		SD	11.785	
		Median	58.33	66.67
		Min.	50.0	66.7
		Max.	66.7	66.7
	Change from Baseline	n	2	1
		Mean	12.50	16.67
		SD	17.678	
		Median	12.50	16.67
		Min.	0.0	16.7
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 52 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 53 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		-16.67
		SD		
		Median		-16.67
		Min.		-16.7
		Max.		-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 54 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	54.17	55.68
		SD	21.815	20.954
		Median	50.00	54.17
		Min.	25.0	16.7
		Max.	100.0	83.3
	Change from Baseline	n	18	22
		Mean	4.17	-5.30
		SD	23.614	25.915
		Median	4.17	0.00
		Min.	-33.3	-58.3
		Max.	41.7	58.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (50%)	7 (32%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (39%)	4 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (33%)	9 (41%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (22%)	9 (41%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 55 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	55.21	70.37
		SD	17.783	19.593
		Median	50.00	66.67
		Min.	33.3	25.0
		Max.	91.7	91.7
	Change from Baseline	n	7	9
		Mean	5.95	1.85
		SD	27.519	29.100
		Median	16.67	0.00
		Min.	-41.7	-41.7
		Max.	33.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 56 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	37.82	42.74
		SD	19.753	21.489
		Median	33.33	41.67
		Min.	0.0	0.0
		Max.	83.3	83.3
	Change from Baseline	n	25	30
		Mean	-14.33	-15.56
		SD	20.344	21.300
		Median	-8.33	-16.67
		Min.	-58.3	-58.3
		Max.	16.7	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (24%)	5 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (4%)	2 (7%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	15 (60%)	18 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	12 (48%)	17 (57%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	69.14	67.50
		SD	23.326	25.889
		Median	66.67	76.67
		Min.	20.0	6.7
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 58 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	71.20	68.74
		SD	22.003	24.759
		Median	73.33	73.33
		Min.	33.3	6.7
		Max.	100.0	100.0
	Change from Baseline	n	24	28
		Mean	3.33	1.67
		SD	11.795	15.779
		Median	3.33	0.00
		Min.	-20.0	-26.7
		Max.	26.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	12 (50%)	12 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (25%)	6 (21%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (17%)	9 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (17%)	6 (21%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 59 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	74.72	66.91
		SD	19.558	28.970
		Median	80.00	73.33
		Min.	33.3	0.0
		Max.	100.0	100.0
	Change from Baseline	n	23	26
		Mean	5.80	2.56
		SD	14.114	18.674
		Median	6.67	6.67
		Min.	-20.0	-46.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	12 (52%)	16 (62%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (30%)	9 (35%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (26%)	8 (31%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (9%)	7 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	72.75	68.72
		SD	18.954	27.310
		Median	73.33	73.33
		Min.	33.3	6.7
		Max.	100.0	100.0
	Change from Baseline	n	22	26
		Mean	6.67	2.05
		SD	17.457	18.259
		Median	6.67	0.00
		Min.	-46.7	-40.0
		Max.	33.3	46.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	15 (68%)	12 (46%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	9 (41%)	7 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (18%)	8 (31%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (14%)	7 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 61 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	73.03	68.00
		SD	18.109	27.217
		Median	66.67	80.00
		Min.	40.0	6.7
		Max.	100.0	100.0
	Change from Baseline	n	21	25
		Mean	2.22	1.60
		SD	20.148	23.196
		Median	0.00	6.67
		Min.	-46.7	-66.7
		Max.	40.0	53.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	10 (48%)	13 (52%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (33%)	9 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	8 (38%)	8 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (24%)	7 (28%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 62 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	80.39	71.93
		SD	14.428	29.945
		Median	80.00	80.00
		Min.	60.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	16	19
		Mean	7.92	1.75
		SD	14.030	23.918
		Median	6.67	6.67
		Min.	-13.3	-80.0
		Max.	40.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	10 (63%)	10 (53%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (38%)	6 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	6 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	3 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 63 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	17	16
		Mean	67.45	72.92
		SD	24.707	29.158
		Median	73.33	83.33
		Min.	0.0	6.7
		Max.	100.0	100.0
	Change from Baseline	n	16	16
		Mean	-3.75	5.83
		SD	22.702	15.753
		Median	0.00	3.33
		Min.	-66.7	-26.7
		Max.	46.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (25%)	8 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	7 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (38%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (25%)	3 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 64 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	72.00	77.65
		SD	16.369	18.700
		Median	73.33	80.00
		Min.	40.0	20.0
		Max.	100.0	100.0
	Change from Baseline	n	14	17
		Mean	0.48	3.53
		SD	15.351	12.719
		Median	0.00	6.67
		Min.	-26.7	-20.0
		Max.	33.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (29%)	9 (53%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (29%)	6 (35%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (43%)	5 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	3 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	15	12
		Mean	72.11	77.78
		SD	17.689	22.263
		Median	73.33	86.67
		Min.	40.0	13.3
		Max.	100.0	100.0
	Change from Baseline	n	14	12
		Mean	1.07	5.56
		SD	11.278	12.975
		Median	0.00	3.33
		Min.	-26.7	-13.3
		Max.	13.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (43%)	6 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (29%)	4 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (36%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	1 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	69.05	74.07
		SD	18.966	26.129
		Median	60.00	86.67
		Min.	46.7	6.7
		Max.	100.0	86.7
	Change from Baseline	n	13	9
		Mean	-1.54	2.22
		SD	14.945	12.019
		Median	0.00	0.00
		Min.	-40.0	-13.3
		Max.	20.0	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	66.67	70.00
		SD	27.049	23.868
		Median	70.00	80.00
		Min.	0.0	6.7
		Max.	100.0	93.3
	Change from Baseline	n	13	12
		Mean	-2.56	-2.22
		SD	21.001	19.557
		Median	0.00	0.00
		Min.	-66.7	-40.0
		Max.	20.0	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	4 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	4 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	3 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 68 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	14	10
		Mean	72.86	73.33
		SD	19.649	26.851
		Median	73.33	76.67
		Min.	33.3	13.3
		Max.	100.0	100.0
	Change from Baseline	n	13	10
		Mean	3.59	0.67
		SD	10.755	18.974
		Median	0.00	3.33
		Min.	-13.3	-40.0
		Max.	26.7	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (46%)	5 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	3 (30%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	4 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	2 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	69.09	71.85
		SD	20.061	22.798
		Median	66.67	73.33
		Min.	26.7	20.0
		Max.	100.0	100.0
	Change from Baseline	n	11	9
		Mean	1.82	0.74
		SD	9.471	18.088
		Median	0.00	0.00
		Min.	-20.0	-33.3
		Max.	13.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 70 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	8	11
		Mean	79.17	70.30
		SD	13.063	26.560
		Median	80.00	80.00
		Min.	60.0	20.0
		Max.	100.0	100.0
	Change from Baseline	n	8	11
		Mean	6.67	-0.61
		SD	9.428	24.304
		Median	6.67	0.00
		Min.	-6.7	-40.0
		Max.	20.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	5 (45%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	4 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	5 (45%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	72.12	89.63
		SD	14.551	10.599
		Median	73.33	93.33
		Min.	46.7	73.3
		Max.	100.0	100.0
	Change from Baseline	n	11	9
		Mean	1.82	10.37
		SD	9.929	11.111
		Median	0.00	6.67
		Min.	-13.3	0.0
		Max.	20.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	6 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 72 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	73.33	80.00
		SD	16.865	11.926
		Median	80.00	76.67
		Min.	33.3	66.7
		Max.	86.7	100.0
	Change from Baseline	n	11	6
		Mean	3.03	6.67
		SD	9.123	8.433
		Median	6.67	3.33
		Min.	-13.3	0.0
		Max.	13.3	20.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (64%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 73 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	65.33	88.89
		SD	28.249	10.037
		Median	76.67	86.67
		Min.	0.0	80.0
		Max.	86.7	100.0
	Change from Baseline	n	10	6
		Mean	-2.67	15.56
		SD	25.181	8.074
		Median	0.00	16.67
		Min.	-66.7	6.7
		Max.	26.7	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	6 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 74 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	74.81	86.67
		SD	10.423	10.184
		Median	80.00	86.67
		Min.	60.0	73.3
		Max.	86.7	100.0
	Change from Baseline	n	9	7
		Mean	6.67	9.52
		SD	12.019	15.803
		Median	0.00	13.33
		Min.	-6.7	-20.0
		Max.	26.7	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (44%)	5 (71%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (44%)	4 (57%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	80.00	88.89
		SD	16.330	10.887
		Median	83.33	90.00
		Min.	46.7	73.3
		Max.	100.0	100.0
	Change from Baseline	n	10	6
		Mean	6.00	15.56
		SD	8.578	8.074
		Median	0.00	16.67
		Min.	0.0	6.7
		Max.	20.0	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	6 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	69.52	91.11
		SD	16.265	11.675
		Median	73.33	96.67
		Min.	46.7	73.3
		Max.	86.7	100.0
	Change from Baseline	n	7	6
		Mean	1.90	18.89
		SD	9.201	10.681
		Median	0.00	20.00
		Min.	-6.7	6.7
		Max.	20.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	6 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	72.38	86.67
		SD	12.430	20.548
		Median	73.33	100.00
		Min.	60.0	53.3
		Max.	86.7	100.0
	Change from Baseline	n	7	5
		Mean	4.76	13.33
		SD	9.201	15.635
		Median	0.00	20.00
		Min.	-6.7	-13.3
		Max.	20.0	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 78 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	72.50	97.78
		SD	19.334	3.443
		Median	76.67	100.00
		Min.	33.3	93.3
		Max.	93.3	100.0
	Change from Baseline	n	8	6
		Mean	0.83	14.44
		SD	10.947	13.608
		Median	0.00	16.67
		Min.	-13.3	-6.7
		Max.	20.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 79 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	73.33	88.00
		SD	20.158	11.926
		Median	73.33	86.67
		Min.	40.0	73.3
		Max.	100.0	100.0
	Change from Baseline	n	7	5
		Mean	7.62	14.67
		SD	12.430	10.954
		Median	0.00	20.00
		Min.	-6.7	0.0
		Max.	26.7	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	74.44	90.67
		SD	13.491	8.944
		Median	72.22	86.67
		Min.	60.0	80.0
		Max.	93.3	100.0
	Change from Baseline	n	8	5
		Mean	2.78	17.33
		SD	13.686	12.111
		Median	-1.11	20.00
		Min.	-13.3	0.0
		Max.	26.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	66.67	80.00
		SD	19.841	16.997
		Median	63.33	80.00
		Min.	40.0	60.0
		Max.	100.0	100.0
	Change from Baseline	n	7	5
		Mean	-3.81	6.67
		SD	18.402	18.257
		Median	0.00	6.67
		Min.	-40.0	-20.0
		Max.	20.0	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 82 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	75.24	88.89
		SD	17.518	10.887
		Median	86.67	90.00
		Min.	46.7	73.3
		Max.	93.3	100.0
	Change from Baseline	n	7	6
		Mean	0.95	16.67
		SD	13.569	8.165
		Median	0.00	20.00
		Min.	-13.3	6.7
		Max.	26.7	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	6 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 83 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	74.44	86.67
		SD	16.009	14.142
		Median	70.00	86.67
		Min.	60.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	4.44	13.33
		SD	16.689	12.472
		Median	0.00	20.00
		Min.	-13.3	0.0
		Max.	33.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 84 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	67.62	90.00
		SD	16.069	13.824
		Median	66.67	96.67
		Min.	46.7	66.7
		Max.	93.3	100.0
	Change from Baseline	n	7	6
		Mean	0.00	12.22
		SD	13.333	11.483
		Median	-6.67	13.33
		Min.	-13.3	0.0
		Max.	26.7	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 85 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	71.67	88.00
		SD	13.686	12.824
		Median	73.33	93.33
		Min.	53.3	66.7
		Max.	93.3	100.0
	Change from Baseline	n	7	5
		Mean	3.81	14.67
		SD	11.455	12.824
		Median	0.00	13.33
		Min.	-6.7	0.0
		Max.	26.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	74.44	83.33
		SD	16.555	22.111
		Median	76.67	90.00
		Min.	53.3	53.3
		Max.	93.3	100.0
	Change from Baseline	n	6	4
		Mean	8.89	11.67
		SD	17.722	17.533
		Median	3.33	16.67
		Min.	-13.3	-13.3
		Max.	33.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 87 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	77.78	86.67
		SD	16.405	16.997
		Median	73.33	93.33
		Min.	60.0	60.0
		Max.	100.0	100.0
	Change from Baseline	n	5	5
		Mean	8.44	13.33
		SD	14.940	13.333
		Median	6.67	20.00
		Min.	-6.7	-6.7
		Max.	33.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	75.87	82.67
		SD	8.357	13.824
		Median	73.33	80.00
		Min.	66.7	66.7
		Max.	93.3	100.0
	Change from Baseline	n	6	5
		Mean	5.19	9.33
		SD	15.246	13.824
		Median	0.00	6.67
		Min.	-8.9	-6.7
		Max.	26.7	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 89 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	72.22	81.67
		SD	16.555	17.533
		Median	70.00	80.00
		Min.	46.7	66.7
		Max.	93.3	100.0
	Change from Baseline	n	6	4
		Mean	6.67	11.67
		SD	11.926	23.333
		Median	3.33	10.00
		Min.	-6.7	-13.3
		Max.	26.7	40.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 90 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	71.67	85.00
		SD	10.000	10.000
		Median	73.33	80.00
		Min.	60.0	80.0
		Max.	80.0	100.0
	Change from Baseline	n	4	4
		Mean	1.67	15.00
		SD	8.389	11.386
		Median	0.00	16.67
		Min.	-6.7	0.0
		Max.	13.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 91 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	78.67	77.78
		SD	14.453	10.184
		Median	73.33	80.00
		Min.	66.7	66.7
		Max.	100.0	86.7
	Change from Baseline	n	5	3
		Mean	9.33	2.22
		SD	18.012	3.849
		Median	6.67	0.00
		Min.	-13.3	0.0
		Max.	33.3	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 92 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	74.44	73.33
		SD	16.009	18.856
		Median	73.33	73.33
		Min.	60.0	60.0
		Max.	93.3	86.7
	Change from Baseline	n	6	2
		Mean	8.89	0.00
		SD	21.361	9.428
		Median	3.33	0.00
		Min.	-20.0	-6.7
		Max.	40.0	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 93 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	80.00	86.67
		SD	16.330	11.547
		Median	73.33	80.00
		Min.	60.0	80.0
		Max.	100.0	100.0
	Change from Baseline	n	5	3
		Mean	10.67	15.56
		SD	16.055	13.878
		Median	6.67	20.00
		Min.	-6.7	0.0
		Max.	33.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 94 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	71.11	83.33
		SD	17.722	14.142
		Median	73.33	83.33
		Min.	46.7	73.3
		Max.	100.0	93.3
	Change from Baseline	n	5	2
		Mean	6.67	3.33
		SD	19.437	14.142
		Median	0.00	3.33
		Min.	-13.3	-6.7
		Max.	33.3	13.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 95 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	61.11	86.67
		SD	12.373	0.000
		Median	63.33	86.67
		Min.	44.4	86.7
		Max.	73.3	86.7
	Change from Baseline	n	4	2
		Mean	-8.89	6.67
		SD	26.105	0.000
		Median	-6.67	6.67
		Min.	-42.2	6.7
		Max.	20.0	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 96 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	70.67	82.22
		SD	17.385	3.849
		Median	66.67	80.00
		Min.	53.3	80.0
		Max.	100.0	86.7
	Change from Baseline	n	5	3
		Mean	1.33	11.11
		SD	25.560	13.878
		Median	6.67	6.67
		Min.	-33.3	0.0
		Max.	33.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 97 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	74.44	80.00
		SD	16.009	
		Median	73.33	80.00
		Min.	53.3	80.0
		Max.	100.0	80.0
	Change from Baseline	n	6	1
		Mean	3.33	0.00
		SD	17.256	
		Median	-3.33	0.00
		Min.	-13.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 98 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	76.00	93.33
		SD	15.348	9.428
		Median	73.33	93.33
		Min.	60.0	86.7
		Max.	100.0	100.0
	Change from Baseline	n	5	2
		Mean	6.67	13.33
		SD	19.437	9.428
		Median	0.00	13.33
		Min.	-13.3	6.7
		Max.	33.3	20.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 99 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	73.33	86.67
		SD	16.330	
		Median	66.67	86.67
		Min.	60.0	86.7
		Max.	100.0	86.7
	Change from Baseline	n	6	1
		Mean	7.78	6.67
		SD	18.579	
		Median	6.67	6.67
		Min.	-20.0	6.7
		Max.	33.3	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	76.00	86.67
		SD	11.155	
		Median	73.33	86.67
		Min.	66.7	86.7
		Max.	93.3	86.7
	Change from Baseline	n	5	1
		Mean	6.67	6.67
		SD	16.997	
		Median	6.67	6.67
		Min.	-13.3	6.7
		Max.	26.7	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 101 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	80.00	83.33
		SD	20.000	4.714
		Median	80.00	83.33
		Min.	60.0	80.0
		Max.	100.0	86.7
	Change from Baseline	n	3	2
		Mean	20.00	3.33
		SD	17.638	4.714
		Median	26.67	3.33
		Min.	0.0	0.0
		Max.	33.3	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 102 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	82.22	80.00
		SD	13.878	
		Median	86.67	80.00
		Min.	66.7	80.0
		Max.	93.3	80.0
	Change from Baseline	n	3	1
		Mean	22.22	0.00
		SD	13.878	
		Median	26.67	0.00
		Min.	6.7	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 103 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	75.56	80.00
		SD	7.698	
		Median	80.00	80.00
		Min.	66.7	80.0
		Max.	80.0	80.0
	Change from Baseline	n	3	1
		Mean	11.11	0.00
		SD	13.878	
		Median	6.67	0.00
		Min.	0.0	0.0
		Max.	26.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 104 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	60.00	76.67
		SD		14.142
		Median	60.00	76.67
		Min.	60.0	66.7
		Max.	60.0	86.7
	Change from Baseline	n	1	2
		Mean	0.00	-3.33
		SD		14.142
		Median	0.00	-3.33
		Min.	0.0	-13.3
		Max.	0.0	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 105 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	63.33	73.33
		SD	4.714	
		Median	63.33	73.33
		Min.	60.0	73.3
		Max.	66.7	73.3
	Change from Baseline	n	2	1
		Mean	6.67	-6.67
		SD	9.428	
		Median	6.67	-6.67
		Min.	0.0	-6.7
		Max.	13.3	-6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 106 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	60.00	80.00
		SD		
		Median	60.00	80.00
		Min.	60.0	80.0
		Max.	60.0	80.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 107 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	73.33	80.00
		SD	9.428	
		Median	73.33	80.00
		Min.	66.7	80.0
		Max.	80.0	80.0
	Change from Baseline	n	2	1
		Mean	3.33	0.00
		SD	4.714	
		Median	3.33	0.00
		Min.	0.0	0.0
		Max.	6.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 108 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		73.33
		SD		
		Median		73.33
		Min.		73.3
		Max.		73.3
	Change from Baseline	n	0	1
		Mean		6.67
		SD		
		Median		6.67
		Min.		6.7
		Max.		6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 109 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		-13.33
		SD		
		Median		-13.33
		Min.		-13.3
		Max.		-13.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 110 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	63.70	63.64
		SD	22.430	28.189
		Median	66.67	70.00
		Min.	20.0	13.3
		Max.	100.0	100.0
	Change from Baseline	n	18	22
		Mean	-4.81	-8.18
		SD	23.521	28.945
		Median	0.00	-3.33
		Min.	-46.7	-80.0
		Max.	26.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (39%)	8 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (28%)	6 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	8 (44%)	11 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (33%)	7 (32%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 111 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	70.00	74.81
		SD	33.238	22.798
		Median	80.00	80.00
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	9
		Mean	-8.57	3.70
		SD	27.410	20.578
		Median	0.00	6.67
		Min.	-66.7	-40.0
		Max.	20.0	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	5 (56%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 112 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	54.27	51.18
		SD	23.334	25.785
		Median	50.00	53.33
		Min.	0.0	0.0
		Max.	100.0	93.3
	Change from Baseline	n	25	30
		Mean	-13.96	-16.44
		SD	21.882	23.471
		Median	-13.33	-13.33
		Min.	-66.7	-80.0
		Max.	26.7	20.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (20%)	5 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (16%)	3 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	19 (76%)	22 (73%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	13 (52%)	17 (57%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	31
		Mean	64.20	62.90
		SD	27.621	28.451
		Median	66.67	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 114 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	72.67	65.52
		SD	25.404	26.701
		Median	66.67	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	24	27
		Mean	7.64	7.41
		SD	19.021	25.459
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (38%)	10 (37%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	9 (38%)	10 (37%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (8%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (8%)	5 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 115 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	69.44	62.96
		SD	26.314	32.795
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	23	25
		Mean	3.62	4.67
		SD	26.570	23.824
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (30%)	8 (32%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (30%)	8 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (26%)	5 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (26%)	5 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 116 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	22	26
		Mean	67.42	58.33
		SD	26.466	31.358
		Median	66.67	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	21	25
		Mean	5.56	-2.00
		SD	23.766	26.492
		Median	0.00	0.00
		Min.	-50.0	-66.7
		Max.	50.0	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (33%)	6 (24%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (33%)	6 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (24%)	8 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (24%)	8 (32%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 117 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	73.48	60.00
		SD	28.940	31.180
		Median	75.00	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	21	24
		Mean	7.14	0.69
		SD	26.125	30.880
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (38%)	8 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (38%)	8 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (19%)	7 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (19%)	7 (29%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	76.47	64.91
		SD	21.294	32.344
		Median	66.67	66.67
		Min.	33.3	0.0
		Max.	100.0	100.0
	Change from Baseline	n	16	18
		Mean	5.21	9.26
		SD	22.541	37.146
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	50.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (31%)	8 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	8 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (25%)	2 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (25%)	2 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	61.11	63.54
		SD	30.250	26.680
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	17	15
		Mean	-3.92	8.89
		SD	21.674	25.092
		Median	0.00	0.00
		Min.	-33.3	-50.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (24%)	6 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (24%)	6 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (35%)	1 (7%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (35%)	1 (7%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 120 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	62.22	60.78
		SD	23.117	24.254
		Median	66.67	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	14	17
		Mean	-9.52	-0.98
		SD	29.026	19.957
		Median	-16.67	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	4 (24%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	4 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	8 (57%)	4 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	8 (57%)	4 (24%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 121 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	14	12
		Mean	67.86	59.72
		SD	23.987	25.084
		Median	66.67	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	13	12
		Mean	3.85	-4.17
		SD	22.724	21.468
		Median	0.00	0.00
		Min.	-33.3	-50.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (38%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (38%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	3 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 122 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	71.43	62.96
		SD	28.063	24.689
		Median	66.67	66.67
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	13	9
		Mean	6.41	5.56
		SD	25.036	14.434
		Median	0.00	0.00
		Min.	-33.3	-16.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (38%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (38%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 123 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	65.48	61.11
		SD	31.666	24.958
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	13	12
		Mean	5.13	1.39
		SD	26.688	34.420
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	5 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	5 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	3 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 124 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	61.11	58.33
		SD	24.934	14.164
		Median	66.67	66.67
		Min.	16.7	33.3
		Max.	100.0	66.7
	Change from Baseline	n	14	10
		Mean	-7.14	0.00
		SD	20.375	30.429
		Median	-8.33	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	4 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	4 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (50%)	2 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (50%)	2 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 125 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	63.64	51.85
		SD	27.707	24.216
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	11	9
		Mean	3.03	-5.56
		SD	20.841	28.868
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	62.96	62.12
		SD	13.889	23.677
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	83.3	100.0
	Change from Baseline	n	9	11
		Mean	0.00	6.06
		SD	18.634	38.205
		Median	0.00	16.67
		Min.	-33.3	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	6 (55%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	6 (55%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	3 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	3 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 127 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	65.15	68.52
		SD	18.936	13.029
		Median	66.67	66.67
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	11	9
		Mean	-1.52	3.70
		SD	17.408	24.689
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	60.61	66.67
		SD	21.438	21.082
		Median	66.67	66.67
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	11	6
		Mean	-7.58	13.89
		SD	25.126	16.387
		Median	0.00	8.33
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 129 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	65.00	72.22
		SD	25.398	13.608
		Median	66.67	66.67
		Min.	16.7	66.7
		Max.	100.0	100.0
	Change from Baseline	n	10	6
		Mean	0.00	19.44
		SD	24.845	16.387
		Median	0.00	25.00
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 130 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	70.37	66.67
		SD	13.889	19.245
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	9	7
		Mean	1.85	7.14
		SD	24.216	23.288
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	3 (43%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 131 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	71.67	72.22
		SD	19.325	13.608
		Median	66.67	66.67
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	10	6
		Mean	1.67	19.44
		SD	21.445	16.387
		Median	0.00	25.00
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	66.67	77.78
		SD	9.623	17.213
		Median	66.67	66.67
		Min.	50.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	7	6
		Mean	2.38	30.56
		SD	20.250	22.153
		Median	0.00	33.33
		Min.	-33.3	0.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 133 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	69.05	70.00
		SD	14.996	18.257
		Median	66.67	66.67
		Min.	50.0	50.0
		Max.	100.0	100.0
	Change from Baseline	n	7	5
		Mean	4.76	20.00
		SD	20.893	13.944
		Median	0.00	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 134 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	72.92	77.78
		SD	12.400	17.213
		Median	66.67	66.67
		Min.	66.7	66.7
		Max.	100.0	100.0
	Change from Baseline	n	8	6
		Mean	6.25	13.89
		SD	17.678	34.021
		Median	8.33	8.33
		Min.	-16.7	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 135 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	68.75	80.00
		SD	25.877	21.731
		Median	66.67	83.33
		Min.	16.7	50.0
		Max.	100.0	100.0
	Change from Baseline	n	7	5
		Mean	4.76	30.00
		SD	20.893	7.454
		Median	0.00	33.33
		Min.	-33.3	16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	5 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	5 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 136 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	66.67	70.00
		SD	15.430	18.257
		Median	66.67	66.67
		Min.	33.3	50.0
		Max.	83.3	100.0
	Change from Baseline	n	8	5
		Mean	0.00	20.00
		SD	19.920	13.944
		Median	0.00	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 137 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	66.67	70.00
		SD	17.817	18.257
		Median	66.67	66.67
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	7	5
		Mean	4.76	20.00
		SD	23.002	13.944
		Median	16.67	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 138 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	76.19	72.22
		SD	18.898	25.092
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	4.76	25.00
		SD	15.853	25.276
		Median	0.00	25.00
		Min.	-16.7	0.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 139 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	61.11	70.00
		SD	13.608	18.257
		Median	66.67	66.67
		Min.	33.3	50.0
		Max.	66.7	100.0
	Change from Baseline	n	6	5
		Mean	-5.56	20.00
		SD	22.771	13.944
		Median	-8.33	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	66.67	69.44
		SD	19.245	16.387
		Median	66.67	66.67
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	2.38	11.11
		SD	22.420	25.092
		Median	0.00	16.67
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	68.75	70.00
		SD	18.767	24.721
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	5
		Mean	2.38	20.00
		SD	22.420	27.386
		Median	0.00	16.67
		Min.	-33.3	0.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 142 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	75.00	66.67
		SD	20.412	27.217
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	6	4
		Mean	16.67	20.83
		SD	21.082	31.549
		Median	8.33	8.33
		Min.	0.0	0.0
		Max.	50.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	80.00	66.67
		SD	18.257	23.570
		Median	66.67	66.67
		Min.	66.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	5	5
		Mean	20.00	16.67
		SD	21.731	16.667
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 144 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	76.19	70.00
		SD	16.265	24.721
		Median	66.67	66.67
		Min.	66.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	5.56	20.00
		SD	22.771	13.944
		Median	8.33	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	69.44	75.00
		SD	16.387	31.914
		Median	66.67	83.33
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	6	4
		Mean	11.11	25.00
		SD	13.608	31.914
		Median	8.33	16.67
		Min.	0.0	0.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 146 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	62.50	75.00
		SD	8.333	21.517
		Median	66.67	75.00
		Min.	50.0	50.0
		Max.	66.7	100.0
	Change from Baseline	n	4	4
		Mean	8.33	25.00
		SD	21.517	9.623
		Median	8.33	25.00
		Min.	-16.7	16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	4 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	4 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 147 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	63.33	77.78
		SD	7.454	25.459
		Median	66.67	83.33
		Min.	50.0	50.0
		Max.	66.7	100.0
	Change from Baseline	n	5	3
		Mean	3.33	22.22
		SD	24.721	9.623
		Median	0.00	16.67
		Min.	-33.3	16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	3 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	3 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 148 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	61.11	66.67
		SD	17.213	47.140
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	83.3	100.0
	Change from Baseline	n	6	2
		Mean	2.78	16.67
		SD	19.484	23.570
		Median	0.00	16.67
		Min.	-16.7	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	4	3
		Mean	75.00	83.33
		SD	16.667	16.667
		Median	66.67	83.33
		Min.	66.7	66.7
		Max.	100.0	100.0
	Change from Baseline	n	4	3
		Mean	16.67	27.78
		SD	13.608	9.623
		Median	16.67	33.33
		Min.	0.0	16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (75%)	3 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (75%)	3 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 150 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	66.67	83.33
		SD	10.541	23.570
		Median	66.67	83.33
		Min.	50.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	5	2
		Mean	6.67	16.67
		SD	19.003	23.570
		Median	0.00	16.67
		Min.	-16.7	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 151 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	62.50	100.00
		SD	8.333	0.000
		Median	66.67	100.00
		Min.	50.0	100.0
		Max.	66.7	100.0
	Change from Baseline	n	4	2
		Mean	8.33	33.33
		SD	21.517	0.000
		Median	8.33	33.33
		Min.	-16.7	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 152 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	70.00	88.89
		SD	18.257	19.245
		Median	66.67	100.00
		Min.	50.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	5	3
		Mean	10.00	33.33
		SD	19.003	33.333
		Median	16.67	33.33
		Min.	-16.7	0.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 153 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	69.44	66.67
		SD	16.387	
		Median	66.67	66.67
		Min.	50.0	66.7
		Max.	100.0	66.7
	Change from Baseline	n	6	1
		Mean	2.78	0.00
		SD	24.533	
		Median	8.33	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	70.00	100.00
		SD	7.454	0.000
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	2
		Mean	10.00	33.33
		SD	14.907	0.000
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	69.44	100.00
		SD	6.804	
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	6	1
		Mean	11.11	33.33
		SD	13.608	
		Median	8.33	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	73.33	100.00
		SD	14.907	
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	100.0	100.0
	Change from Baseline	n	5	1
		Mean	13.33	33.33
		SD	13.944	
		Median	16.67	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 157 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	77.78	91.67
		SD	19.245	11.785
		Median	66.67	91.67
		Min.	66.7	83.3
		Max.	100.0	100.0
	Change from Baseline	n	3	2
		Mean	22.22	25.00
		SD	9.623	11.785
		Median	16.67	25.00
		Min.	16.7	16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (100%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (100%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 158 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	72.22	66.67
		SD	25.459	
		Median	66.67	66.67
		Min.	50.0	66.7
		Max.	100.0	66.7
	Change from Baseline	n	3	1
		Mean	16.67	0.00
		SD	0.000	
		Median	16.67	0.00
		Min.	16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	66.67	66.67
		SD	0.000	
		Median	66.67	66.67
		Min.	66.7	66.7
		Max.	66.7	66.7
	Change from Baseline	n	3	1
		Mean	16.67	0.00
		SD	16.667	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 160 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	66.67	83.33
		SD		23.570
		Median	66.67	83.33
		Min.	66.7	66.7
		Max.	66.7	100.0
	Change from Baseline	n	1	2
		Mean	33.33	16.67
		SD		23.570
		Median	33.33	16.67
		Min.	33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 161 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	66.67	83.33
		SD	0.000	
		Median	66.67	83.33
		Min.	66.7	83.3
		Max.	66.7	83.3
	Change from Baseline	n	2	1
		Mean	25.00	16.67
		SD	11.785	
		Median	25.00	16.67
		Min.	16.7	16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 162 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	66.67	83.33
		SD		
		Median	66.67	83.33
		Min.	66.7	83.3
		Max.	66.7	83.3
	Change from Baseline	n	1	1
		Mean	33.33	16.67
		SD		
		Median	33.33	16.67
		Min.	33.3	16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 163 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	66.67	83.33
		SD	0.000	
		Median	66.67	83.33
		Min.	66.7	83.3
		Max.	66.7	83.3
	Change from Baseline	n	2	1
		Mean	16.67	16.67
		SD	23.570	
		Median	16.67	16.67
		Min.	0.0	16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 164 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 165 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 166 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	60.19	49.24
		SD	32.408	29.760
		Median	66.67	58.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	18	22
		Mean	-4.63	-15.15
		SD	20.457	37.057
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (17%)	3 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (17%)	3 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (33%)	10 (45%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (33%)	10 (45%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 167 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	68.75	64.81
		SD	25.877	24.216
		Median	66.67	66.67
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	9
		Mean	-7.14	5.56
		SD	21.207	39.087
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	16.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 168 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	48.72	39.25
		SD	27.049	27.062
		Median	50.00	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	29
		Mean	-16.67	-22.41
		SD	22.567	25.695
		Median	-16.67	-16.67
		Min.	-66.7	-100.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (12%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (12%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	16 (64%)	17 (59%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	16 (64%)	17 (59%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	26	32
		Mean	72.12	73.18
		SD	22.229	25.727
		Median	70.83	75.00
		Min.	25.0	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 170 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	80.00	83.05
		SD	17.678	16.886
		Median	75.00	83.33
		Min.	50.0	41.7
		Max.	100.0	100.0
	Change from Baseline	n	23	28
		Mean	6.88	10.42
		SD	20.666	18.651
		Median	0.00	8.33
		Min.	-33.3	-25.0
		Max.	58.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (39%)	17 (61%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (35%)	11 (39%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (22%)	6 (21%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (9%)	2 (7%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 171 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	76.39	80.25
		SD	23.269	20.820
		Median	83.33	75.00
		Min.	33.3	16.7
		Max.	100.0	100.0
	Change from Baseline	n	22	26
		Mean	7.58	7.69
		SD	17.234	17.468
		Median	0.00	0.00
		Min.	-16.7	-25.0
		Max.	41.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	10 (45%)	11 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (32%)	9 (35%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (23%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (9%)	2 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 172 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	77.90	85.58
		SD	18.224	15.011
		Median	66.67	83.33
		Min.	41.7	50.0
		Max.	100.0	100.0
	Change from Baseline	n	21	26
		Mean	9.13	11.22
		SD	20.225	18.848
		Median	8.33	8.33
		Min.	-33.3	-16.7
		Max.	58.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	11 (52%)	14 (54%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (33%)	11 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (14%)	4 (15%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (10%)	1 (4%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 173 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	77.27	84.00
		SD	21.544	19.082
		Median	83.33	91.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	20	25
		Mean	2.08	8.00
		SD	23.551	22.883
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	41.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (45%)	11 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (30%)	10 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (30%)	6 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (20%)	4 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 174 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	79.90	89.47
		SD	16.940	11.056
		Median	83.33	91.67
		Min.	50.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	15	19
		Mean	5.00	15.79
		SD	16.607	25.291
		Median	0.00	8.33
		Min.	-33.3	-8.3
		Max.	41.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (40%)	10 (53%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (27%)	7 (37%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	1 (5%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 175 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	69.91	84.90
		SD	24.108	14.975
		Median	70.83	83.33
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	16	16
		Mean	-1.56	7.81
		SD	22.406	17.070
		Median	-4.17	0.00
		Min.	-33.3	-8.3
		Max.	41.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (38%)	6 (38%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (38%)	5 (31%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	8 (50%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	75.00	81.37
		SD	19.159	14.592
		Median	75.00	83.33
		Min.	33.3	41.7
		Max.	100.0	100.0
	Change from Baseline	n	13	17
		Mean	3.85	-0.98
		SD	22.468	15.557
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	41.7	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (46%)	6 (35%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	2 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	5 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	4 (24%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 177 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	67.71	84.03
		SD	16.351	13.971
		Median	66.67	83.33
		Min.	33.3	58.3
		Max.	100.0	100.0
	Change from Baseline	n	14	12
		Mean	-4.17	3.47
		SD	17.828	17.573
		Median	0.00	4.17
		Min.	-50.0	-25.0
		Max.	25.0	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (29%)	6 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (36%)	4 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 178 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	73.81	87.04
		SD	17.860	14.500
		Median	66.67	91.67
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	12	9
		Mean	2.78	5.56
		SD	17.528	18.634
		Median	0.00	0.00
		Min.	-33.3	-25.0
		Max.	33.3	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 179 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	73.81	90.28
		SD	19.844	12.223
		Median	83.33	95.83
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	12	12
		Mean	6.25	5.56
		SD	13.355	17.164
		Median	0.00	0.00
		Min.	-8.3	-16.7
		Max.	33.3	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	5 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	4 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 180 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	72.41	82.50
		SD	17.770	14.933
		Median	75.00	83.33
		Min.	33.3	58.3
		Max.	100.0	100.0
	Change from Baseline	n	13	10
		Mean	-0.43	0.00
		SD	16.853	11.785
		Median	-8.33	0.00
		Min.	-25.0	-16.7
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (30%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	2 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (54%)	3 (30%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	2 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 181 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	71.97	87.04
		SD	17.979	10.300
		Median	66.67	83.33
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	10	9
		Mean	2.50	3.70
		SD	13.637	13.889
		Median	0.00	0.00
		Min.	-16.7	-16.7
		Max.	33.3	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	69.44	84.09
		SD	21.246	19.880
		Median	75.00	91.67
		Min.	41.7	41.7
		Max.	100.0	100.0
	Change from Baseline	n	8	11
		Mean	10.42	0.76
		SD	15.269	22.191
		Median	4.17	0.00
		Min.	-8.3	-50.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	5 (45%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	3 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	2 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 183 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	72.73	80.56
		SD	13.484	21.651
		Median	66.67	83.33
		Min.	58.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	10	9
		Mean	6.67	-4.63
		SD	19.954	27.673
		Median	8.33	0.00
		Min.	-33.3	-66.7
		Max.	41.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 184 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	73.48	91.67
		SD	15.731	12.910
		Median	66.67	100.00
		Min.	41.7	75.0
		Max.	100.0	100.0
	Change from Baseline	n	10	6
		Mean	1.67	9.72
		SD	15.615	13.351
		Median	0.00	4.17
		Min.	-33.3	0.0
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 185 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	69.17	94.44
		SD	18.860	10.092
		Median	66.67	100.00
		Min.	33.3	75.0
		Max.	91.7	100.0
	Change from Baseline	n	9	6
		Mean	2.78	12.50
		SD	20.412	12.638
		Median	0.00	12.50
		Min.	-33.3	0.0
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (44%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 186 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	69.44	85.71
		SD	9.317	17.817
		Median	66.67	100.00
		Min.	50.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	8	7
		Mean	0.00	1.19
		SD	16.667	20.654
		Median	4.17	0.00
		Min.	-33.3	-33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	2 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	2 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 187 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	75.83	97.22
		SD	18.194	6.804
		Median	70.83	100.00
		Min.	41.7	83.3
		Max.	100.0	100.0
	Change from Baseline	n	9	6
		Mean	4.63	15.28
		SD	22.481	13.351
		Median	0.00	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	69.05	90.28
		SD	18.456	15.290
		Median	66.67	100.00
		Min.	33.3	66.7
		Max.	91.7	100.0
	Change from Baseline	n	6	6
		Mean	0.00	9.72
		SD	20.412	16.173
		Median	0.00	4.17
		Min.	-33.3	-8.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	65.48	86.67
		SD	16.962	21.731
		Median	66.67	100.00
		Min.	33.3	50.0
		Max.	83.3	100.0
	Change from Baseline	n	6	5
		Mean	-2.78	5.00
		SD	18.758	21.731
		Median	-4.17	0.00
		Min.	-33.3	-25.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	73.96	90.28
		SD	21.099	11.076
		Median	70.83	91.67
		Min.	33.3	75.0
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	4.76	9.72
		SD	22.493	20.694
		Median	0.00	12.50
		Min.	-33.3	-25.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	72.92	90.00
		SD	20.291	13.693
		Median	75.00	100.00
		Min.	33.3	75.0
		Max.	91.7	100.0
	Change from Baseline	n	6	5
		Mean	2.78	8.33
		SD	12.546	14.434
		Median	0.00	0.00
		Min.	-8.3	0.0
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	69.79	98.33
		SD	16.629	3.727
		Median	70.83	100.00
		Min.	33.3	91.7
		Max.	83.3	100.0
	Change from Baseline	n	7	5
		Mean	3.57	16.67
		SD	13.486	16.667
		Median	0.00	16.67
		Min.	-16.7	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	71.88	93.33
		SD	18.865	14.907
		Median	75.00	100.00
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	9.72	11.67
		SD	21.995	20.069
		Median	4.17	0.00
		Min.	-8.3	-8.3
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	80.95	94.44
		SD	17.156	8.607
		Median	83.33	100.00
		Min.	50.0	83.3
		Max.	100.0	100.0
	Change from Baseline	n	6	6
		Mean	5.56	13.89
		SD	13.608	13.608
		Median	4.17	12.50
		Min.	-8.3	0.0
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	72.22	91.67
		SD	22.153	14.434
		Median	75.00	100.00
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	5	5
		Mean	1.67	10.00
		SD	25.276	18.066
		Median	0.00	0.00
		Min.	-33.3	-8.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 196 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	71.43	90.28
		SD	19.159	11.076
		Median	75.00	91.67
		Min.	33.3	75.0
		Max.	91.7	100.0
	Change from Baseline	n	6	6
		Mean	0.00	5.56
		SD	20.412	17.213
		Median	0.00	0.00
		Min.	-33.3	-16.7
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 197 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	72.92	91.67
		SD	20.291	18.634
		Median	70.83	100.00
		Min.	33.3	58.3
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	-1.39	10.00
		SD	20.694	22.361
		Median	-4.17	0.00
		Min.	-33.3	-16.7
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 198 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	70.83	81.25
		SD	20.917	27.534
		Median	75.00	91.67
		Min.	33.3	41.7
		Max.	91.7	100.0
	Change from Baseline	n	5	4
		Mean	8.33	-4.17
		SD	13.176	20.972
		Median	8.33	0.00
		Min.	-8.3	-33.3
		Max.	25.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 199 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	70.00	91.67
		SD	17.280	11.785
		Median	75.00	100.00
		Min.	41.7	75.0
		Max.	83.3	100.0
	Change from Baseline	n	5	5
		Mean	6.67	10.00
		SD	9.129	13.693
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	72.62	86.67
		SD	21.897	21.731
		Median	66.67	100.00
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	-1.39	5.00
		SD	20.694	21.731
		Median	-4.17	0.00
		Min.	-33.3	-25.0
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	72.22	89.58
		SD	16.387	20.833
		Median	66.67	100.00
		Min.	50.0	58.3
		Max.	91.7	100.0
	Change from Baseline	n	5	4
		Mean	10.00	12.50
		SD	14.907	25.000
		Median	8.33	16.67
		Min.	-8.3	-16.7
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 202 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	64.58	91.67
		SD	23.936	16.667
		Median	66.67	100.00
		Min.	33.3	66.7
		Max.	91.7	100.0
	Change from Baseline	n	4	4
		Mean	2.08	14.58
		SD	15.775	21.916
		Median	-4.17	16.67
		Min.	-8.3	-8.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 203 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	75.00	80.56
		SD	17.678	33.679
		Median	75.00	100.00
		Min.	50.0	41.7
		Max.	91.7	100.0
	Change from Baseline	n	5	3
		Mean	11.67	11.11
		SD	12.638	38.490
		Median	8.33	33.33
		Min.	0.0	-33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	76.39	87.50
		SD	26.043	17.678
		Median	79.17	87.50
		Min.	33.3	75.0
		Max.	100.0	100.0
	Change from Baseline	n	5	2
		Mean	8.33	16.67
		SD	19.543	23.570
		Median	0.00	16.67
		Min.	-8.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 205 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	70.00	100.00
		SD	21.731	0.000
		Median	66.67	100.00
		Min.	41.7	100.0
		Max.	91.7	100.0
	Change from Baseline	n	5	3
		Mean	6.67	22.22
		SD	18.066	19.245
		Median	0.00	33.33
		Min.	-16.7	0.0
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 206 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	69.44	100.00
		SD	19.484	0.000
		Median	70.83	100.00
		Min.	41.7	100.0
		Max.	100.0	100.0
	Change from Baseline	n	5	2
		Mean	5.00	33.33
		SD	18.257	0.000
		Median	0.00	33.33
		Min.	-16.7	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 207 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	64.58	100.00
		SD	23.936	0.000
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	91.7	100.0
	Change from Baseline	n	4	2
		Mean	2.08	33.33
		SD	15.775	0.000
		Median	-4.17	33.33
		Min.	-8.3	33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 208 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	61.67	91.67
		SD	26.087	8.333
		Median	66.67	91.67
		Min.	33.3	83.3
		Max.	100.0	100.0
	Change from Baseline	n	5	3
		Mean	-1.67	13.89
		SD	23.863	12.729
		Median	0.00	16.67
		Min.	-33.3	0.0
		Max.	33.3	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 209 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	69.44	100.00
		SD	17.213	
		Median	66.67	100.00
		Min.	41.7	100.0
		Max.	91.7	100.0
	Change from Baseline	n	6	1
		Mean	0.00	33.33
		SD	20.412	
		Median	0.00	33.33
		Min.	-33.3	33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 210 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	73.33	100.00
		SD	24.580	0.000
		Median	83.33	100.00
		Min.	33.3	100.0
		Max.	91.7	100.0
	Change from Baseline	n	5	2
		Mean	10.00	33.33
		SD	17.078	0.000
		Median	16.67	33.33
		Min.	-8.3	33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 211 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	73.61	100.00
		SD	19.305	
		Median	75.00	100.00
		Min.	41.7	100.0
		Max.	91.7	100.0
	Change from Baseline	n	5	1
		Mean	8.33	33.33
		SD	15.590	
		Median	0.00	33.33
		Min.	-8.3	33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 212 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	63.33	100.00
		SD	21.731	
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	1
		Mean	0.00	33.33
		SD	17.678	
		Median	0.00	33.33
		Min.	-25.0	33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 213 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	83.33	91.67
		SD	14.434	11.785
		Median	91.67	91.67
		Min.	66.7	83.3
		Max.	91.7	100.0
	Change from Baseline	n	3	2
		Mean	16.67	25.00
		SD	14.434	11.785
		Median	25.00	25.00
		Min.	0.0	16.7
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 214 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	86.11	100.00
		SD	17.347	
		Median	91.67	100.00
		Min.	66.7	100.0
		Max.	100.0	100.0
	Change from Baseline	n	3	1
		Mean	19.44	33.33
		SD	17.347	
		Median	25.00	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 215 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	63.89	100.00
		SD	29.266	
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	91.7	100.0
	Change from Baseline	n	3	1
		Mean	5.56	33.33
		SD	17.347	
		Median	0.00	33.33
		Min.	-8.3	33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 216 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	91.67	83.33
		SD		23.570
		Median	91.67	83.33
		Min.	91.7	66.7
		Max.	91.7	100.0
	Change from Baseline	n	1	2
		Mean	25.00	16.67
		SD		23.570
		Median	25.00	16.67
		Min.	25.0	0.0
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 217 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	79.17	100.00
		SD	17.678	
		Median	79.17	100.00
		Min.	66.7	100.0
		Max.	91.7	100.0
	Change from Baseline	n	2	1
		Mean	12.50	33.33
		SD	17.678	
		Median	12.50	33.33
		Min.	0.0	33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 218 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	91.67	100.00
		SD		
		Median	91.67	100.00
		Min.	91.7	100.0
		Max.	91.7	100.0
	Change from Baseline	n	1	1
		Mean	25.00	33.33
		SD		
		Median	25.00	33.33
		Min.	25.0	33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	62.50	100.00
		SD	41.248	
		Median	62.50	100.00
		Min.	33.3	100.0
		Max.	91.7	100.0
	Change from Baseline	n	2	1
		Mean	8.33	33.33
		SD	23.570	
		Median	8.33	33.33
		Min.	-8.3	33.3
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 220 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		25.00
		SD		
		Median		25.00
		Min.		25.0
		Max.		25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 221 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 222 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	63.43	80.30
		SD	21.031	20.501
		Median	66.67	87.50
		Min.	25.0	41.7
		Max.	100.0	100.0
	Change from Baseline	n	17	22
		Mean	-6.86	4.17
		SD	26.391	19.712
		Median	-8.33	0.00
		Min.	-66.7	-33.3
		Max.	41.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (29%)	8 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (29%)	8 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	9 (53%)	6 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (41%)	4 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 223 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	72.92	75.00
		SD	20.774	25.000
		Median	75.00	83.33
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	6	9
		Mean	-4.17	-9.26
		SD	29.226	31.304
		Median	-8.33	0.00
		Min.	-33.3	-66.7
		Max.	50.0	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 224 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	58.97	63.98
		SD	22.475	20.793
		Median	62.50	66.67
		Min.	25.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	24	30
		Mean	-11.46	-10.83
		SD	24.303	19.714
		Median	-8.33	-8.33
		Min.	-66.7	-66.7
		Max.	41.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (21%)	6 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (17%)	4 (13%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	16 (67%)	18 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	10 (42%)	13 (43%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	26	32
		Mean	80.77	77.60
		SD	23.894	25.262
		Median	83.33	83.33
		Min.	16.7	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	80.00	85.06
		SD	22.567	15.650
		Median	83.33	83.33
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	23	28
		Mean	0.00	7.74
		SD	24.100	26.248
		Median	0.00	8.33
		Min.	-50.0	-33.3
		Max.	50.0	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (35%)	14 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (35%)	14 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (30%)	7 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (30%)	7 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 227 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	76.39	83.33
		SD	24.533	22.646
		Median	83.33	100.00
		Min.	16.7	16.7
		Max.	100.0	100.0
	Change from Baseline	n	22	26
		Mean	-2.27	8.33
		SD	19.447	25.495
		Median	0.00	0.00
		Min.	-50.0	-50.0
		Max.	33.3	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (23%)	11 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (23%)	11 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (32%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (32%)	5 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 228 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	78.26	86.54
		SD	23.265	17.009
		Median	83.33	91.67
		Min.	16.7	50.0
		Max.	100.0	100.0
	Change from Baseline	n	21	26
		Mean	1.59	10.90
		SD	24.097	21.573
		Median	0.00	0.00
		Min.	-33.3	-16.7
		Max.	50.0	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (33%)	10 (38%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (33%)	10 (38%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (29%)	2 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (29%)	2 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 229 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	80.30	84.67
		SD	26.042	18.584
		Median	91.67	83.33
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	20	25
		Mean	0.00	8.67
		SD	20.943	21.581
		Median	0.00	0.00
		Min.	-50.0	-16.7
		Max.	50.0	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (30%)	10 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (30%)	10 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (25%)	4 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (25%)	4 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 230 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	78.43	88.60
		SD	20.211	13.668
		Median	83.33	100.00
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	15	19
		Mean	-6.67	12.28
		SD	24.234	27.127
		Median	0.00	0.00
		Min.	-50.0	-16.7
		Max.	50.0	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (20%)	9 (47%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	9 (47%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (47%)	3 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (47%)	3 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 231 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	73.15	88.54
		SD	26.898	16.908
		Median	83.33	91.67
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	16	16
		Mean	-6.25	14.58
		SD	19.124	25.000
		Median	0.00	0.00
		Min.	-33.3	-16.7
		Max.	33.3	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (19%)	7 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (19%)	7 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (44%)	1 (6%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (44%)	1 (6%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	72.22	83.33
		SD	24.934	16.667
		Median	66.67	83.33
		Min.	0.0	50.0
		Max.	100.0	100.0
	Change from Baseline	n	13	17
		Mean	-7.69	1.96
		SD	16.124	15.459
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	7 (41%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	7 (41%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (46%)	4 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (46%)	4 (24%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 233 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	72.92	84.72
		SD	15.957	16.603
		Median	66.67	83.33
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	14	12
		Mean	-10.71	6.94
		SD	19.179	20.669
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (14%)	5 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (14%)	5 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	9 (64%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	9 (64%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 234 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	75.00	79.63
		SD	23.342	18.215
		Median	75.00	83.33
		Min.	16.7	50.0
		Max.	100.0	100.0
	Change from Baseline	n	12	9
		Mean	-6.94	0.00
		SD	16.603	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 235 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	73.81	87.50
		SD	21.398	12.563
		Median	83.33	83.33
		Min.	16.7	66.7
		Max.	100.0	100.0
	Change from Baseline	n	12	12
		Mean	-2.78	6.94
		SD	24.447	16.603
		Median	-8.33	8.33
		Min.	-50.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	6 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	6 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (50%)	1 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (50%)	1 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 236 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	73.33	86.67
		SD	13.801	13.147
		Median	66.67	83.33
		Min.	50.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	13	10
		Mean	-10.26	6.67
		SD	22.088	11.653
		Median	-16.67	8.33
		Min.	-33.3	-16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	5 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	5 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	8 (62%)	1 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	8 (62%)	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 237 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	71.21	74.07
		SD	18.395	20.601
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	10	9
		Mean	-8.33	-3.70
		SD	23.895	16.197
		Median	-8.33	0.00
		Min.	-50.0	-33.3
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 238 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	75.93	81.82
		SD	12.108	27.340
		Median	66.67	100.00
		Min.	66.7	16.7
		Max.	100.0	100.0
	Change from Baseline	n	8	11
		Mean	-2.08	3.03
		SD	16.517	25.624
		Median	-8.33	0.00
		Min.	-16.7	-66.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	5 (45%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	5 (45%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	1 (9%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	1 (9%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 239 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	66.67	85.19
		SD	23.570	15.466
		Median	66.67	83.33
		Min.	0.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	10	9
		Mean	-8.33	1.85
		SD	19.642	21.155
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (70%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (70%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 240 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	69.70	91.67
		SD	17.979	13.944
		Median	66.67	100.00
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	10	6
		Mean	-8.33	16.67
		SD	19.642	14.907
		Median	-8.33	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 241 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	68.33	91.67
		SD	14.593	13.944
		Median	66.67	100.00
		Min.	33.3	66.7
		Max.	83.3	100.0
	Change from Baseline	n	9	6
		Mean	-3.70	16.67
		SD	21.695	14.907
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (56%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	68.52	85.71
		SD	17.568	14.996
		Median	66.67	83.33
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	8	7
		Mean	-6.25	7.14
		SD	28.084	16.265
		Median	-16.67	0.00
		Min.	-33.3	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	3 (43%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (63%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (63%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 243 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	66.67	86.11
		SD	28.328	16.387
		Median	66.67	91.67
		Min.	0.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	9	6
		Mean	-9.26	11.11
		SD	20.601	13.608
		Median	-16.67	8.33
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (56%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	69.05	94.44
		SD	17.817	13.608
		Median	66.67	100.00
		Min.	33.3	66.7
		Max.	83.3	100.0
	Change from Baseline	n	6	6
		Mean	-8.33	16.67
		SD	22.973	14.907
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	71.43	93.33
		SD	12.599	9.129
		Median	66.67	100.00
		Min.	50.0	83.3
		Max.	83.3	100.0
	Change from Baseline	n	6	5
		Mean	-2.78	16.67
		SD	24.533	11.785
		Median	-8.33	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	66.67	88.89
		SD	23.570	13.608
		Median	66.67	91.67
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	-9.52	2.78
		SD	18.898	19.484
		Median	-16.67	0.00
		Min.	-33.3	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (71%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 247 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	68.75	90.00
		SD	24.296	9.129
		Median	75.00	83.33
		Min.	33.3	83.3
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	-5.56	13.33
		SD	13.608	18.257
		Median	-8.33	16.67
		Min.	-16.7	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 248 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	62.50	96.67
		SD	21.362	7.454
		Median	66.67	100.00
		Min.	33.3	83.3
		Max.	83.3	100.0
	Change from Baseline	n	7	5
		Mean	-14.29	20.00
		SD	11.501	13.944
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (71%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 249 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	68.75	96.67
		SD	25.877	7.454
		Median	66.67	100.00
		Min.	33.3	83.3
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	-8.33	20.00
		SD	13.944	13.944
		Median	-16.67	16.67
		Min.	-16.7	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 250 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	64.29	100.00
		SD	24.398	0.000
		Median	50.00	100.00
		Min.	33.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	6	6
		Mean	-13.89	22.22
		SD	12.546	13.608
		Median	-16.67	25.00
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 251 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	63.89	96.67
		SD	19.484	7.454
		Median	66.67	100.00
		Min.	33.3	83.3
		Max.	83.3	100.0
	Change from Baseline	n	5	5
		Mean	-16.67	20.00
		SD	16.667	13.944
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 252 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	57.14	100.00
		SD	16.265	0.000
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	66.7	100.0
	Change from Baseline	n	6	6
		Mean	-16.67	19.44
		SD	18.257	16.387
		Median	-16.67	25.00
		Min.	-33.3	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (83%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (83%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 253 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	66.67	93.33
		SD	21.822	9.129
		Median	66.67	100.00
		Min.	33.3	83.3
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	-13.89	16.67
		SD	12.546	20.412
		Median	-16.67	16.67
		Min.	-33.3	-16.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 254 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	58.33	95.83
		SD	20.412	8.333
		Median	66.67	100.00
		Min.	33.3	83.3
		Max.	83.3	100.0
	Change from Baseline	n	5	4
		Mean	-10.00	16.67
		SD	14.907	13.608
		Median	-16.67	16.67
		Min.	-16.7	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (80%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (80%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 255 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	70.00	96.67
		SD	13.944	7.454
		Median	66.67	100.00
		Min.	50.0	83.3
		Max.	83.3	100.0
	Change from Baseline	n	5	5
		Mean	-3.33	20.00
		SD	13.944	13.944
		Median	0.00	16.67
		Min.	-16.7	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 256 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	64.29	93.33
		SD	17.817	9.129
		Median	66.67	100.00
		Min.	50.0	83.3
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	-19.44	16.67
		SD	16.387	20.412
		Median	-25.00	16.67
		Min.	-33.3	-16.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 257 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	61.11	83.33
		SD	17.213	13.608
		Median	66.67	83.33
		Min.	33.3	66.7
		Max.	83.3	100.0
	Change from Baseline	n	5	4
		Mean	-6.67	8.33
		SD	25.276	28.868
		Median	-16.67	16.67
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 258 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	62.50	95.83
		SD	20.972	8.333
		Median	66.67	100.00
		Min.	33.3	83.3
		Max.	83.3	100.0
	Change from Baseline	n	4	4
		Mean	-16.67	20.83
		SD	13.608	15.957
		Median	-16.67	25.00
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (75%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (75%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 259 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	70.00	100.00
		SD	13.944	0.000
		Median	66.67	100.00
		Min.	50.0	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	3
		Mean	-3.33	22.22
		SD	13.944	19.245
		Median	0.00	33.33
		Min.	-16.7	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 260 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	61.11	100.00
		SD	17.213	0.000
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	2
		Mean	-13.33	16.67
		SD	21.731	23.570
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 261 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	66.67	94.44
		SD	16.667	9.623
		Median	66.67	100.00
		Min.	50.0	83.3
		Max.	83.3	100.0
	Change from Baseline	n	5	3
		Mean	-6.67	27.78
		SD	27.889	9.623
		Median	0.00	33.33
		Min.	-33.3	16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	3 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	3 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 262 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	69.44	100.00
		SD	19.484	0.000
		Median	66.67	100.00
		Min.	50.0	100.0
		Max.	100.0	100.0
	Change from Baseline	n	5	2
		Mean	-10.00	33.33
		SD	30.277	0.000
		Median	-16.67	33.33
		Min.	-50.0	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 263 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	54.17	100.00
		SD	15.957	0.000
		Median	58.33	100.00
		Min.	33.3	100.0
		Max.	66.7	100.0
	Change from Baseline	n	4	2
		Mean	-25.00	33.33
		SD	21.517	0.000
		Median	-25.00	33.33
		Min.	-50.0	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (75%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (75%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 264 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	50.00	100.00
		SD	16.667	0.000
		Median	50.00	100.00
		Min.	33.3	100.0
		Max.	66.7	100.0
	Change from Baseline	n	5	3
		Mean	-23.33	33.33
		SD	19.003	0.000
		Median	-16.67	33.33
		Min.	-50.0	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (80%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (80%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	58.33	100.00
		SD	20.412	
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	6	1
		Mean	-19.44	33.33
		SD	6.804	
		Median	-16.67	33.33
		Min.	-33.3	33.3
		Max.	-16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 266 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	60.00	100.00
		SD	9.129	0.000
		Median	66.67	100.00
		Min.	50.0	100.0
		Max.	66.7	100.0
	Change from Baseline	n	5	2
		Mean	-13.33	33.33
		SD	13.944	0.000
		Median	-16.67	33.33
		Min.	-33.3	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 267 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	61.11	100.00
		SD	13.608	
		Median	58.33	100.00
		Min.	50.0	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	1
		Mean	-10.00	33.33
		SD	14.907	
		Median	0.00	33.33
		Min.	-33.3	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 268 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	50.00	100.00
		SD	20.412	
		Median	50.00	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	1
		Mean	-23.33	33.33
		SD	27.889	
		Median	-16.67	33.33
		Min.	-66.7	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 269 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	61.11	100.00
		SD	9.623	0.000
		Median	66.67	100.00
		Min.	50.0	100.0
		Max.	66.7	100.0
	Change from Baseline	n	3	2
		Mean	-16.67	33.33
		SD	16.667	0.000
		Median	-16.67	33.33
		Min.	-33.3	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	77.78	100.00
		SD	9.623	
		Median	83.33	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	3	1
		Mean	0.00	33.33
		SD	16.667	
		Median	0.00	33.33
		Min.	-16.7	33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 271 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	55.56	100.00
		SD	9.623	
		Median	50.00	100.00
		Min.	50.0	100.0
		Max.	66.7	100.0
	Change from Baseline	n	3	1
		Mean	-22.22	33.33
		SD	25.459	
		Median	-16.67	33.33
		Min.	-50.0	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 272 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	66.67	83.33
		SD		23.570
		Median	66.67	83.33
		Min.	66.7	66.7
		Max.	66.7	100.0
	Change from Baseline	n	1	2
		Mean	-33.33	16.67
		SD		23.570
		Median	-33.33	16.67
		Min.	-33.3	0.0
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 273 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	66.67	100.00
		SD	0.000	
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	66.7	100.0
	Change from Baseline	n	2	1
		Mean	-25.00	33.33
		SD	11.785	
		Median	-25.00	33.33
		Min.	-33.3	33.3
		Max.	-16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	50.00	100.00
		SD		
		Median	50.00	100.00
		Min.	50.0	100.0
		Max.	50.0	100.0
	Change from Baseline	n	1	1
		Mean	-50.00	33.33
		SD		
		Median	-50.00	33.33
		Min.	-50.0	33.3
		Max.	-50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 275 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	66.67	100.00
		SD	0.000	
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	66.7	100.0
	Change from Baseline	n	2	1
		Mean	-8.33	33.33
		SD	35.355	
		Median	-8.33	33.33
		Min.	-33.3	33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 276 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 277 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 278 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	63.89	84.85
		SD	23.743	14.465
		Median	66.67	83.33
		Min.	16.7	50.0
		Max.	100.0	100.0
	Change from Baseline	n	17	22
		Mean	-13.73	0.76
		SD	21.437	18.882
		Median	-16.67	0.00
		Min.	-50.0	-33.3
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (18%)	6 (27%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (18%)	6 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	10 (59%)	7 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	10 (59%)	7 (32%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	75.00	79.63
		SD	17.817	27.358
		Median	66.67	83.33
		Min.	50.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	6	9
		Mean	-8.33	-7.41
		SD	22.973	29.001
		Median	-8.33	0.00
		Min.	-33.3	-66.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 280 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	55.13	65.05
		SD	25.285	20.797
		Median	58.33	66.67
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	24	30
		Mean	-23.61	-12.22
		SD	23.008	22.715
		Median	-33.33	-16.67
		Min.	-66.7	-66.7
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (13%)	2 (7%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (13%)	2 (7%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	18 (75%)	16 (53%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	18 (75%)	16 (53%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	69.14	70.83
		SD	27.621	32.791
		Median	66.67	83.33
		Min.	16.7	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 282 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	76.00	72.99
		SD	28.087	26.879
		Median	83.33	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	24	28
		Mean	4.86	4.76
		SD	26.684	26.001
		Median	0.00	0.00
		Min.	-33.3	-50.0
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (33%)	9 (32%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (33%)	9 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (21%)	6 (21%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (21%)	6 (21%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 283 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	72.22	69.14
		SD	32.477	26.836
		Median	83.33	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	23	26
		Mean	0.00	2.56
		SD	21.320	32.212
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (26%)	8 (31%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (26%)	8 (31%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (26%)	9 (35%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (26%)	9 (35%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 284 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	70.29	71.15
		SD	32.936	27.308
		Median	83.33	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	22	26
		Mean	3.03	4.49
		SD	28.469	35.137
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (32%)	10 (38%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (32%)	10 (38%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (32%)	6 (23%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (32%)	6 (23%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 285 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	71.97	68.67
		SD	24.336	29.392
		Median	83.33	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	21	25
		Mean	-0.79	1.33
		SD	22.655	34.668
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	50.0	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (24%)	7 (28%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (24%)	7 (28%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (29%)	8 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (29%)	8 (32%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 286 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	74.51	76.32
		SD	20.512	24.417
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	16	19
		Mean	0.00	12.28
		SD	21.943	37.202
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (19%)	8 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (19%)	8 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (31%)	3 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	3 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	66.67	80.21
		SD	26.813	16.351
		Median	66.67	83.33
		Min.	16.7	50.0
		Max.	100.0	100.0
	Change from Baseline	n	17	16
		Mean	-1.96	19.79
		SD	19.439	23.741
		Median	0.00	16.67
		Min.	-33.3	0.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (24%)	9 (56%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (24%)	9 (56%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (35%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (35%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	66.67	75.49
		SD	24.398	22.140
		Median	66.67	66.67
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	14	17
		Mean	-7.14	4.90
		SD	16.939	26.197
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (7%)	7 (41%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	7 (41%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (43%)	4 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (43%)	4 (24%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 289 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	70.83	73.61
		SD	20.638	21.856
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	15	12
		Mean	4.44	6.94
		SD	25.562	24.056
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (27%)	3 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (27%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (27%)	1 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (27%)	1 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 290 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	70.24	74.07
		SD	27.095	20.601
		Median	66.67	66.67
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	13	9
		Mean	6.41	7.41
		SD	32.302	30.174
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (38%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (38%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	66.67	79.17
		SD	27.735	20.257
		Median	66.67	83.33
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	13	12
		Mean	7.69	9.72
		SD	21.099	26.071
		Median	0.00	0.00
		Min.	-16.7	-33.3
		Max.	50.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (38%)	5 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (38%)	5 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 292 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	58.89	70.00
		SD	25.871	20.488
		Median	66.67	66.67
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	14	10
		Mean	-7.14	6.67
		SD	19.298	23.831
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (14%)	4 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (14%)	4 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (43%)	2 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (43%)	2 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 293 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	8
		Mean	60.61	60.42
		SD	28.159	30.780
		Median	50.00	66.67
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	8
		Mean	0.00	-4.17
		SD	27.889	23.146
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	2 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	3 (38%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	3 (38%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	53.70	66.67
		SD	23.241	25.820
		Median	50.00	66.67
		Min.	16.7	33.3
		Max.	83.3	100.0
	Change from Baseline	n	9	11
		Mean	-11.11	0.00
		SD	16.667	30.732
		Median	-16.67	0.00
		Min.	-33.3	-66.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	4 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	4 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (56%)	3 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	3 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	8
		Mean	62.12	66.67
		SD	21.201	17.817
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	11	8
		Mean	-3.03	4.17
		SD	28.692	23.146
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (38%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (38%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 296 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	59.09	69.44
		SD	17.262	22.153
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	83.3	100.0
	Change from Baseline	n	11	6
		Mean	-9.09	13.89
		SD	22.808	19.484
		Median	0.00	16.67
		Min.	-33.3	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	68.33	69.44
		SD	21.445	22.153
		Median	66.67	66.67
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	10	6
		Mean	5.00	13.89
		SD	28.382	19.484
		Median	0.00	16.67
		Min.	-33.3	-16.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	68.52	69.05
		SD	24.216	20.250
		Median	66.67	66.67
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	9	7
		Mean	3.70	7.14
		SD	28.599	25.198
		Median	0.00	16.67
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	4 (57%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	4 (57%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	2 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	2 (29%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	70.00	75.00
		SD	20.488	13.944
		Median	66.67	66.67
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	10	6
		Mean	1.67	19.44
		SD	28.814	28.707
		Median	0.00	16.67
		Min.	-33.3	-16.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 300 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	66.67	77.78
		SD	9.623	17.213
		Median	66.67	66.67
		Min.	50.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	7	6
		Mean	-2.38	22.22
		SD	33.923	29.187
		Median	0.00	25.00
		Min.	-33.3	-16.7
		Max.	50.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 301 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	66.67	73.33
		SD	13.608	25.276
		Median	66.67	83.33
		Min.	50.0	33.3
		Max.	83.3	100.0
	Change from Baseline	n	7	5
		Mean	-2.38	20.00
		SD	32.530	13.944
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	60.42	77.78
		SD	19.796	17.213
		Median	66.67	66.67
		Min.	16.7	66.7
		Max.	83.3	100.0
	Change from Baseline	n	8	6
		Mean	-8.33	13.89
		SD	17.817	47.629
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	16.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	70.83	66.67
		SD	19.416	23.570
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	5
		Mean	2.38	13.33
		SD	26.227	21.731
		Median	0.00	16.67
		Min.	-33.3	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	70.83	73.33
		SD	14.773	27.889
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	8	5
		Mean	2.08	20.00
		SD	22.603	21.731
		Median	0.00	33.33
		Min.	-33.3	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	68.75	66.67
		SD	20.774	23.570
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	5
		Mean	2.38	13.33
		SD	37.796	21.731
		Median	0.00	16.67
		Min.	-66.7	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	78.57	72.22
		SD	18.545	25.092
		Median	83.33	66.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	4.76	16.67
		SD	35.635	21.082
		Median	0.00	25.00
		Min.	-50.0	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 307 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	66.67	73.33
		SD	10.541	19.003
		Median	66.67	66.67
		Min.	50.0	50.0
		Max.	83.3	100.0
	Change from Baseline	n	6	5
		Mean	-2.78	20.00
		SD	30.581	27.386
		Median	-8.33	33.33
		Min.	-33.3	-16.7
		Max.	33.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 308 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	64.29	66.67
		SD	24.398	21.082
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	-4.76	5.56
		SD	36.911	27.217
		Median	-16.67	8.33
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 309 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	68.75	80.00
		SD	13.909	29.814
		Median	66.67	100.00
		Min.	50.0	33.3
		Max.	83.3	100.0
	Change from Baseline	n	7	5
		Mean	0.00	26.67
		SD	30.429	25.276
		Median	-16.67	33.33
		Min.	-33.3	-16.7
		Max.	50.0	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 310 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	69.44	62.50
		SD	12.546	20.972
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	83.3	83.3
	Change from Baseline	n	6	4
		Mean	5.56	12.50
		SD	31.032	20.972
		Median	0.00	16.67
		Min.	-33.3	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	4	5
		Mean	70.83	66.67
		SD	8.333	23.570
		Median	66.67	66.67
		Min.	66.7	33.3
		Max.	83.3	100.0
	Change from Baseline	n	4	5
		Mean	-4.17	13.33
		SD	28.464	21.731
		Median	-8.33	16.67
		Min.	-33.3	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	71.43	70.00
		SD	15.853	24.721
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	6	5
		Mean	-11.11	16.67
		SD	20.184	20.412
		Median	-8.33	16.67
		Min.	-33.3	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 313 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	72.22	79.17
		SD	13.608	31.549
		Median	75.00	91.67
		Min.	50.0	33.3
		Max.	83.3	100.0
	Change from Baseline	n	6	4
		Mean	8.33	33.33
		SD	27.386	0.000
		Median	0.00	33.33
		Min.	-16.7	33.3
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	4 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	4 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	70.83	75.00
		SD	8.333	31.914
		Median	66.67	83.33
		Min.	66.7	33.3
		Max.	83.3	100.0
	Change from Baseline	n	4	4
		Mean	-12.50	29.17
		SD	15.957	8.333
		Median	-8.33	33.33
		Min.	-33.3	16.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	66.67	77.78
		SD	11.785	38.490
		Median	66.67	100.00
		Min.	50.0	33.3
		Max.	83.3	100.0
	Change from Baseline	n	5	3
		Mean	-6.67	33.33
		SD	19.003	0.000
		Median	0.00	33.33
		Min.	-33.3	33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	3 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	3 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 316 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	58.33	66.67
		SD	17.480	47.140
		Median	58.33	66.67
		Min.	33.3	33.3
		Max.	83.3	100.0
	Change from Baseline	n	6	2
		Mean	-5.56	33.33
		SD	27.217	0.000
		Median	-8.33	33.33
		Min.	-33.3	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	76.67	100.00
		SD	9.129	0.000
		Median	83.33	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	3
		Mean	3.33	38.89
		SD	27.386	9.623
		Median	0.00	33.33
		Min.	-16.7	33.3
		Max.	50.0	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	3 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	3 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	69.44	83.33
		SD	22.153	23.570
		Median	66.67	83.33
		Min.	33.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	5	2
		Mean	-10.00	16.67
		SD	43.461	23.570
		Median	0.00	16.67
		Min.	-66.7	0.0
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 319 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	66.67	100.00
		SD	27.217	0.000
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	4	2
		Mean	-16.67	33.33
		SD	19.245	0.000
		Median	-16.67	33.33
		Min.	-33.3	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 320 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	60.00	94.44
		SD	14.907	9.623
		Median	66.67	100.00
		Min.	33.3	83.3
		Max.	66.7	100.0
	Change from Baseline	n	5	3
		Mean	-13.33	33.33
		SD	38.006	0.000
		Median	0.00	33.33
		Min.	-66.7	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	3 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	3 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 321 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	58.33	100.00
		SD	9.129	
		Median	58.33	100.00
		Min.	50.0	100.0
		Max.	66.7	100.0
	Change from Baseline	n	6	1
		Mean	-19.44	33.33
		SD	24.533	
		Median	-25.00	33.33
		Min.	-50.0	33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	73.33	100.00
		SD	9.129	0.000
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	2
		Mean	0.00	33.33
		SD	35.355	0.000
		Median	0.00	33.33
		Min.	-33.3	33.3
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 323 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	66.67	100.00
		SD	10.541	
		Median	66.67	100.00
		Min.	50.0	100.0
		Max.	83.3	100.0
	Change from Baseline	n	6	1
		Mean	2.78	33.33
		SD	34.021	
		Median	0.00	33.33
		Min.	-33.3	33.3
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 324 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	73.33	100.00
		SD	9.129	
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	5	1
		Mean	0.00	33.33
		SD	31.180	
		Median	0.00	33.33
		Min.	-33.3	33.3
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	83.33	91.67
		SD	16.667	11.785
		Median	83.33	91.67
		Min.	66.7	83.3
		Max.	100.0	100.0
	Change from Baseline	n	3	2
		Mean	16.67	25.00
		SD	44.096	11.785
		Median	0.00	25.00
		Min.	-16.7	16.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 326 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	83.33	100.00
		SD	0.000	
		Median	83.33	100.00
		Min.	83.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	3	1
		Mean	16.67	33.33
		SD	33.333	
		Median	16.67	33.33
		Min.	-16.7	33.3
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 327 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	61.11	100.00
		SD	25.459	
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	3	1
		Mean	-16.67	33.33
		SD	16.667	
		Median	-16.67	33.33
		Min.	-33.3	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 328 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	83.33	83.33
		SD		23.570
		Median	83.33	83.33
		Min.	83.3	66.7
		Max.	83.3	100.0
	Change from Baseline	n	1	2
		Mean	-16.67	16.67
		SD		23.570
		Median	-16.67	16.67
		Min.	-16.7	0.0
		Max.	-16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 329 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	75.00	100.00
		SD	11.785	
		Median	75.00	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	1
		Mean	-8.33	33.33
		SD	11.785	
		Median	-8.33	33.33
		Min.	-16.7	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 330 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	83.33	100.00
		SD		
		Median	83.33	100.00
		Min.	83.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	1	1
		Mean	-16.67	33.33
		SD		
		Median	-16.67	33.33
		Min.	-16.7	33.3
		Max.	-16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 331 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	75.00	100.00
		SD	11.785	
		Median	75.00	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	1
		Mean	-8.33	33.33
		SD	11.785	
		Median	-8.33	33.33
		Min.	-16.7	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 332 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 333 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 334 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	66.67	70.45
		SD	22.866	31.258
		Median	66.67	75.00
		Min.	16.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	18	22
		Mean	0.00	-1.52
		SD	31.311	35.601
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	66.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (33%)	7 (32%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (33%)	7 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (33%)	6 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (33%)	6 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 335 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	77.08	66.67
		SD	19.796	22.048
		Median	66.67	66.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	9
		Mean	2.38	1.85
		SD	27.936	35.789
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 336 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	51.92	51.61
		SD	28.412	27.674
		Median	58.33	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	30
		Mean	-18.00	-17.78
		SD	25.422	27.659
		Median	-16.67	-8.33
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (16%)	4 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (16%)	4 (13%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	18 (72%)	15 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	18 (72%)	15 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	41.98	36.46
		SD	28.634	29.765
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	38.22	39.85
		SD	27.653	26.145
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	24	28
		Mean	-5.09	-0.40
		SD	21.292	19.710
		Median	0.00	0.00
		Min.	-55.6	-44.4
		Max.	22.2	44.4
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (38%)	10 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (33%)	10 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	9 (38%)	11 (39%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	8 (33%)	11 (39%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	31.48	37.04
		SD	22.142	30.351
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	23	26
		Mean	-10.63	-1.28
		SD	23.084	28.859
		Median	-11.11	0.00
		Min.	-77.8	-66.7
		Max.	33.3	88.9
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	13 (57%)	11 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	13 (57%)	11 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (26%)	7 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (26%)	7 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 340 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	31.88	35.47
		SD	19.334	24.347
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	22	26
		Mean	-13.64	-2.99
		SD	22.728	25.251
		Median	-11.11	0.00
		Min.	-55.6	-66.7
		Max.	22.2	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	12 (55%)	8 (31%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	12 (55%)	8 (31%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (14%)	9 (35%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (14%)	9 (35%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 341 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	32.83	39.11
		SD	27.103	29.418
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	88.9	100.0
	Change from Baseline	n	21	25
		Mean	-7.94	1.78
		SD	28.576	25.995
		Median	0.00	0.00
		Min.	-88.9	-55.6
		Max.	33.3	55.6
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	10 (48%)	9 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	10 (48%)	9 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (33%)	8 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (33%)	8 (32%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	28.76	36.26
		SD	21.893	29.593
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	77.8	100.0
	Change from Baseline	n	16	19
		Mean	-10.42	-1.75
		SD	25.810	25.730
		Median	-5.56	0.00
		Min.	-77.8	-44.4
		Max.	22.2	55.6
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (50%)	8 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (50%)	8 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (25%)	7 (37%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (25%)	7 (37%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	17	16
		Mean	39.22	34.03
		SD	26.387	28.823
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	88.9	100.0
	Change from Baseline	n	16	16
		Mean	-4.17	-6.94
		SD	23.263	24.637
		Median	0.00	-5.56
		Min.	-33.3	-55.6
		Max.	33.3	55.6
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (44%)	8 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (44%)	8 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (38%)	2 (13%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (38%)	2 (13%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	35.56	35.95
		SD	23.079	21.706
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	88.9	88.9
	Change from Baseline	n	14	17
		Mean	0.00	5.88
		SD	23.061	22.607
		Median	0.00	11.11
		Min.	-33.3	-33.3
		Max.	33.3	55.6
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (43%)	5 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (43%)	5 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (43%)	9 (53%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (43%)	9 (53%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 345 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	38.89	33.33
		SD	25.010	24.158
		Median	33.33	27.78
		Min.	0.0	0.0
		Max.	100.0	88.9
	Change from Baseline	n	15	12
		Mean	0.74	4.63
		SD	16.516	18.015
		Median	0.00	5.56
		Min.	-33.3	-33.3
		Max.	22.2	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (20%)	3 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (33%)	6 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (33%)	6 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	39.68	37.04
		SD	26.045	21.517
		Median	33.33	33.33
		Min.	0.0	11.1
		Max.	88.9	88.9
	Change from Baseline	n	13	9
		Mean	-3.42	1.23
		SD	30.559	14.103
		Median	0.00	0.00
		Min.	-77.8	-22.2
		Max.	55.6	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (38%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (38%)	4 (44%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	47.62	35.19
		SD	28.051	23.130
		Median	55.56	33.33
		Min.	0.0	0.0
		Max.	88.9	88.9
	Change from Baseline	n	13	12
		Mean	0.00	3.70
		SD	15.713	26.520
		Median	11.11	-5.56
		Min.	-33.3	-33.3
		Max.	11.1	55.6
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	6 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	6 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (54%)	5 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (54%)	5 (42%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	38.52	37.78
		SD	23.332	16.728
		Median	33.33	33.33
		Min.	0.0	22.2
		Max.	88.9	66.7
	Change from Baseline	n	14	10
		Mean	-2.38	3.33
		SD	18.063	22.253
		Median	0.00	0.00
		Min.	-33.3	-22.2
		Max.	22.2	55.6
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (36%)	4 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (36%)	4 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (36%)	3 (30%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (36%)	3 (30%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	41.41	35.80
		SD	16.548	21.357
		Median	33.33	33.33
		Min.	22.2	22.2
		Max.	66.7	88.9
	Change from Baseline	n	11	9
		Mean	-5.05	0.00
		SD	13.484	19.245
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	11.1	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	4 (44%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 350 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	40.74	37.37
		SD	23.570	28.229
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	77.8	88.9
	Change from Baseline	n	9	11
		Mean	-4.94	3.03
		SD	18.519	32.995
		Median	0.00	0.00
		Min.	-33.3	-44.4
		Max.	22.2	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	5 (45%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	5 (45%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	5 (45%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	5 (45%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	38.38	24.69
		SD	21.866	7.407
		Median	33.33	22.22
		Min.	0.0	11.1
		Max.	88.9	33.3
	Change from Baseline	n	11	9
		Mean	-5.05	-3.70
		SD	22.967	20.787
		Median	0.00	0.00
		Min.	-55.6	-22.2
		Max.	22.2	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	35.86	25.93
		SD	20.988	9.072
		Median	33.33	27.78
		Min.	11.1	11.1
		Max.	88.9	33.3
	Change from Baseline	n	11	6
		Mean	-7.58	-12.96
		SD	18.966	12.989
		Median	-11.11	-16.67
		Min.	-44.4	-22.2
		Max.	22.2	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (55%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (55%)	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	40.00	22.22
		SD	15.887	15.713
		Median	33.33	22.22
		Min.	11.1	0.0
		Max.	66.7	44.4
	Change from Baseline	n	10	6
		Mean	-2.22	-16.67
		SD	16.397	15.316
		Median	-5.56	-16.67
		Min.	-22.2	-33.3
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	34.57	19.05
		SD	23.204	12.363
		Median	33.33	22.22
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	9	7
		Mean	-4.94	-14.29
		SD	27.279	21.956
		Median	0.00	-11.11
		Min.	-55.6	-44.4
		Max.	33.3	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (44%)	5 (71%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (44%)	5 (71%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	31.11	16.67
		SD	24.456	11.653
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	77.8	33.3
	Change from Baseline	n	10	6
		Mean	-6.67	-22.22
		SD	14.999	14.055
		Median	-5.56	-22.22
		Min.	-33.3	-44.4
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	41.27	16.67
		SD	23.757	15.316
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	6
		Mean	1.59	-20.37
		SD	19.698	16.355
		Median	0.00	-16.67
		Min.	-33.3	-44.4
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	36.51	17.78
		SD	20.998	20.184
		Median	33.33	11.11
		Min.	0.0	0.0
		Max.	66.7	44.4
	Change from Baseline	n	7	5
		Mean	-3.17	-17.78
		SD	17.817	20.184
		Median	0.00	-11.11
		Min.	-33.3	-44.4
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	36.11	14.81
		SD	20.358	13.456
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	8	6
		Mean	-1.39	-11.11
		SD	16.197	24.343
		Median	0.00	-5.56
		Min.	-33.3	-44.4
		Max.	22.2	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 359 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	36.11	24.44
		SD	28.328	18.257
		Median	38.89	33.33
		Min.	0.0	0.0
		Max.	77.8	44.4
	Change from Baseline	n	7	5
		Mean	-4.76	-11.11
		SD	14.138	13.608
		Median	0.00	-11.11
		Min.	-33.3	-33.3
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 360 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	31.94	15.56
		SD	23.335	12.669
		Median	33.33	11.11
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	8	5
		Mean	-5.56	-20.00
		SD	14.548	14.487
		Median	-5.56	-22.22
		Min.	-33.3	-33.3
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	7	5
		Mean	41.27	24.44
		SD	27.751	16.480
		Median	44.44	22.22
		Min.	0.0	0.0
		Max.	66.7	44.4
	Change from Baseline	n	7	5
		Mean	0.00	-11.11
		SD	19.245	26.058
		Median	0.00	-22.22
		Min.	-22.2	-33.3
		Max.	22.2	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	42.86	22.22
		SD	28.995	15.713
		Median	44.44	22.22
		Min.	0.0	0.0
		Max.	77.8	44.4
	Change from Baseline	n	7	6
		Mean	4.76	-14.81
		SD	27.108	13.456
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	55.6	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	4 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	38.89	22.22
		SD	21.943	20.787
		Median	44.44	22.22
		Min.	0.0	0.0
		Max.	55.6	55.6
	Change from Baseline	n	6	5
		Mean	-1.85	-13.33
		SD	21.564	22.771
		Median	5.56	-22.22
		Min.	-33.3	-33.3
		Max.	22.2	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	2 (40%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	36.51	12.96
		SD	21.956	17.801
		Median	33.33	5.56
		Min.	0.0	0.0
		Max.	66.7	44.4
	Change from Baseline	n	7	6
		Mean	-3.17	-16.67
		SD	17.817	19.563
		Median	0.00	-11.11
		Min.	-33.3	-44.4
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	36.11	31.11
		SD	19.473	9.296
		Median	33.33	33.33
		Min.	0.0	22.2
		Max.	66.7	44.4
	Change from Baseline	n	7	5
		Mean	-3.17	-4.44
		SD	17.817	12.669
		Median	0.00	0.00
		Min.	-33.3	-22.2
		Max.	22.2	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 366 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	35.19	22.22
		SD	20.387	15.713
		Median	33.33	16.67
		Min.	0.0	11.1
		Max.	55.6	44.4
	Change from Baseline	n	6	4
		Mean	-9.26	-13.89
		SD	16.355	16.667
		Median	-5.56	-11.11
		Min.	-33.3	-33.3
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 367 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	35.56	26.67
		SD	12.172	9.938
		Median	33.33	33.33
		Min.	22.2	11.1
		Max.	55.6	33.3
	Change from Baseline	n	5	5
		Mean	-2.22	-8.89
		SD	9.296	9.296
		Median	0.00	-11.11
		Min.	-11.1	-22.2
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	39.68	28.89
		SD	23.002	16.851
		Median	33.33	22.22
		Min.	0.0	11.1
		Max.	66.7	55.6
	Change from Baseline	n	6	5
		Mean	7.41	-6.67
		SD	22.951	12.669
		Median	11.11	-11.11
		Min.	-33.3	-22.2
		Max.	33.3	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 369 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	42.59	30.56
		SD	30.965	18.976
		Median	33.33	27.78
		Min.	0.0	11.1
		Max.	88.9	55.6
	Change from Baseline	n	6	4
		Mean	-1.85	-2.78
		SD	17.801	13.981
		Median	5.56	0.00
		Min.	-33.3	-22.2
		Max.	11.1	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 370 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	38.89	22.22
		SD	11.111	15.713
		Median	33.33	27.78
		Min.	33.3	0.0
		Max.	55.6	33.3
	Change from Baseline	n	4	4
		Mean	0.00	-11.11
		SD	9.072	9.072
		Median	0.00	-11.11
		Min.	-11.1	-22.2
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 371 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	28.89	25.93
		SD	25.580	23.130
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	44.4
	Change from Baseline	n	5	3
		Mean	-8.89	-3.70
		SD	16.480	6.415
		Median	-11.11	0.00
		Min.	-33.3	-11.1
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	38.89	27.78
		SD	20.787	7.857
		Median	44.44	27.78
		Min.	0.0	22.2
		Max.	55.6	33.3
	Change from Baseline	n	6	2
		Mean	-5.56	-11.11
		SD	23.040	0.000
		Median	0.00	-11.11
		Min.	-33.3	-11.1
		Max.	22.2	-11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	33.33	18.52
		SD	20.787	16.973
		Median	33.33	22.22
		Min.	0.0	0.0
		Max.	55.6	33.3
	Change from Baseline	n	5	3
		Mean	-4.44	-11.11
		SD	16.851	11.111
		Median	0.00	-11.11
		Min.	-33.3	-22.2
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 374 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	35.19	16.67
		SD	19.138	23.570
		Median	38.89	16.67
		Min.	0.0	0.0
		Max.	55.6	33.3
	Change from Baseline	n	5	2
		Mean	-2.22	-5.56
		SD	19.876	7.857
		Median	0.00	-5.56
		Min.	-33.3	-11.1
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 375 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	3	2
		Mean	40.74	11.11
		SD	16.973	15.713
		Median	44.44	11.11
		Min.	22.2	0.0
		Max.	55.6	22.2
	Change from Baseline	n	3	2
		Mean	-3.70	-11.11
		SD	6.415	0.000
		Median	0.00	-11.11
		Min.	-11.1	-11.1
		Max.	0.0	-11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	37.78	18.52
		SD	23.040	16.973
		Median	44.44	22.22
		Min.	0.0	0.0
		Max.	55.6	33.3
	Change from Baseline	n	5	3
		Mean	0.00	-11.11
		SD	23.570	11.111
		Median	0.00	-11.11
		Min.	-33.3	-22.2
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 377 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	35.19	33.33
		SD	20.387	
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	55.6	33.3
	Change from Baseline	n	6	1
		Mean	1.85	0.00
		SD	19.138	
		Median	5.56	0.00
		Min.	-33.3	0.0
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	33.33	11.11
		SD	20.787	15.713
		Median	33.33	11.11
		Min.	0.0	0.0
		Max.	55.6	22.2
	Change from Baseline	n	5	2
		Mean	-4.44	-11.11
		SD	18.592	0.000
		Median	0.00	-11.11
		Min.	-33.3	-11.1
		Max.	11.1	-11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 379 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	5	1
		Mean	33.33	11.11
		SD	20.787	
		Median	33.33	11.11
		Min.	0.0	11.1
		Max.	55.6	11.1
	Change from Baseline	n	5	1
		Mean	-4.44	-22.22
		SD	16.851	
		Median	0.00	-22.22
		Min.	-33.3	-22.2
		Max.	11.1	-22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 380 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	31.11	11.11
		SD	19.876	
		Median	33.33	11.11
		Min.	0.0	11.1
		Max.	55.6	11.1
	Change from Baseline	n	5	1
		Mean	-6.67	-22.22
		SD	16.851	
		Median	0.00	-22.22
		Min.	-33.3	-22.2
		Max.	11.1	-22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 381 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	25.93	33.33
		SD	23.130	0.000
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	44.4	33.3
	Change from Baseline	n	3	2
		Mean	-11.11	11.11
		SD	19.245	15.713
		Median	0.00	11.11
		Min.	-33.3	0.0
		Max.	0.0	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 382 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	22.22	33.33
		SD	19.245	
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Change from Baseline	n	3	1
		Mean	-14.81	0.00
		SD	16.973	
		Median	-11.11	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 383 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	44.44	33.33
		SD	19.245	
		Median	33.33	33.33
		Min.	33.3	33.3
		Max.	66.7	33.3
	Change from Baseline	n	3	1
		Mean	0.00	0.00
		SD	11.111	
		Median	0.00	0.00
		Min.	-11.1	0.0
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 384 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	33.33	33.33
		SD		0.000
		Median	33.33	33.33
		Min.	33.3	33.3
		Max.	33.3	33.3
	Change from Baseline	n	1	2
		Mean	-11.11	11.11
		SD		15.713
		Median	-11.11	11.11
		Min.	-11.1	0.0
		Max.	-11.1	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 385 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	33.33	33.33
		SD	0.000	
		Median	33.33	33.33
		Min.	33.3	33.3
		Max.	33.3	33.3
	Change from Baseline	n	2	1
		Mean	-5.56	0.00
		SD	7.857	
		Median	-5.56	0.00
		Min.	-11.1	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 386 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	33.33	33.33
		SD		
		Median	33.33	33.33
		Min.	33.3	33.3
		Max.	33.3	33.3
	Change from Baseline	n	1	1
		Mean	-11.11	0.00
		SD		
		Median	-11.11	0.00
		Min.	-11.1	0.0
		Max.	-11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 387 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	44.44	22.22
		SD	15.713	
		Median	44.44	22.22
		Min.	33.3	22.2
		Max.	55.6	22.2
	Change from Baseline	n	2	1
		Mean	-5.56	-11.11
		SD	7.857	
		Median	-5.56	-11.11
		Min.	-11.1	-11.1
		Max.	0.0	-11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		-11.11
		SD		
		Median		-11.11
		Min.		-11.1
		Max.		-11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 389 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		22.22
		SD		
		Median		22.22
		Min.		22.2
		Max.		22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	45.68	40.91
		SD	24.370	24.340
		Median	50.00	38.89
		Min.	0.0	0.0
		Max.	100.0	88.9
	Change from Baseline	n	18	22
		Mean	-0.62	7.07
		SD	27.607	25.785
		Median	0.00	5.56
		Min.	-44.4	-44.4
		Max.	55.6	55.6
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (44%)	6 (27%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (44%)	6 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (39%)	11 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (39%)	11 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	9	9
		Mean	39.51	32.10
		SD	22.299	20.370
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	77.8	77.8
	Change from Baseline	n	8	9
		Mean	4.17	2.47
		SD	28.444	35.039
		Median	0.00	0.00
		Min.	-33.3	-55.6
		Max.	55.6	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 392 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	58.97	56.99
		SD	23.469	23.786
		Median	66.67	55.56
		Min.	22.2	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	30
		Mean	16.00	19.63
		SD	22.471	25.552
		Median	22.22	16.67
		Min.	-33.3	-33.3
		Max.	55.6	88.9
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (16%)	3 (10%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (16%)	3 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	16 (64%)	20 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	16 (64%)	20 (67%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	26	31
		Mean	5.13	8.60
		SD	9.152	17.144
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	4.67	5.75
		SD	9.027	14.279
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	23	27
		Mean	-1.45	-3.09
		SD	8.577	16.690
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (17%)	4 (15%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (17%)	4 (15%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (9%)	3 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (9%)	3 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	22	27
		Mean	5.30	6.79
		SD	9.465	21.313
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	21	25
		Mean	0.00	-3.33
		SD	7.454	28.868
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	16.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (10%)	7 (28%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (10%)	7 (28%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (10%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (10%)	3 (12%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	4.35	3.21
		SD	9.014	6.699
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	21	25
		Mean	-0.79	-6.67
		SD	9.827	17.347
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (19%)	6 (24%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (19%)	6 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (14%)	2 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (14%)	2 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	3.79	10.00
		SD	8.807	18.002
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	20	25
		Mean	-0.83	-0.67
		SD	11.439	25.676
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	16.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (15%)	6 (24%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (15%)	6 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (15%)	4 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (15%)	4 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	7.84	4.39
		SD	11.957	9.366
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	15	19
		Mean	4.44	-3.51
		SD	13.313	17.194
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	4 (21%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	4 (21%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (33%)	2 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (33%)	2 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	17	16
		Mean	6.86	9.38
		SD	11.871	18.226
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	50.0
	Change from Baseline	n	15	16
		Mean	2.22	0.00
		SD	12.387	21.943
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	33.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	4 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	4 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (20%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	3 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 400 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	8.89	5.88
		SD	12.387	10.106
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	13	17
		Mean	5.13	-1.96
		SD	14.248	16.544
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	3 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	3 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (38%)	2 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (38%)	2 (12%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	7.29	2.78
		SD	10.486	6.487
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	14	12
		Mean	2.38	-4.17
		SD	8.909	10.360
		Median	0.00	0.00
		Min.	-16.7	-33.3
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (7%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 402 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	8.33	3.70
		SD	12.659	7.349
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	12	9
		Mean	5.56	-3.70
		SD	8.206	13.889
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	13	12
		Mean	6.41	9.72
		SD	10.841	15.006
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	50.0
	Change from Baseline	n	11	12
		Mean	1.52	1.39
		SD	11.677	20.669
		Median	0.00	0.00
		Min.	-16.7	-33.3
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	3 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 404 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	8.89	3.33
		SD	18.758	7.027
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	16.7
	Change from Baseline	n	13	10
		Mean	6.41	-1.67
		SD	21.014	12.298
		Median	0.00	0.00
		Min.	-16.7	-33.3
		Max.	66.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	1 (10%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	1 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	1 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	10.61	1.85
		SD	13.484	5.556
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	10	9
		Mean	6.67	-3.70
		SD	14.055	18.215
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 406 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	11.11	12.12
		SD	16.667	29.899
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	50.0	100.0
	Change from Baseline	n	8	11
		Mean	6.25	3.03
		SD	15.269	24.516
		Median	0.00	0.00
		Min.	-16.7	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	2 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	2 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	2 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 407 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	10.61	3.70
		SD	11.237	7.349
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	10	9
		Mean	6.67	-1.85
		SD	11.653	19.444
		Median	8.33	0.00
		Min.	-16.7	-50.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 408 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	9.09	2.78
		SD	13.670	6.804
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	10	6
		Mean	5.00	-5.56
		SD	8.051	22.771
		Median	0.00	0.00
		Min.	0.0	-50.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	11.67	2.78
		SD	13.721	6.804
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	9	6
		Mean	5.56	-5.56
		SD	14.434	22.771
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 410 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	7.41	2.38
		SD	8.784	6.299
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	16.7
	Change from Baseline	n	8	7
		Mean	2.08	-4.76
		SD	10.681	20.893
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	6.67	2.78
		SD	8.607	6.804
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	16.7
	Change from Baseline	n	9	6
		Mean	1.85	-5.56
		SD	10.015	22.771
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	11.90	2.78
		SD	15.853	6.804
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	6	6
		Mean	5.56	0.00
		SD	17.213	10.541
		Median	0.00	0.00
		Min.	-16.7	-16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 413 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	14.29	10.00
		SD	17.817	14.907
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	5
		Mean	8.33	10.00
		SD	13.944	14.907
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (40%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	4.17	2.78
		SD	7.715	6.804
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	16.7
	Change from Baseline	n	7	6
		Mean	-2.38	2.78
		SD	6.299	6.804
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 415 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	6.25	3.33
		SD	12.400	7.454
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	6	5
		Mean	0.00	3.33
		SD	10.541	7.454
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	4.17	3.33
		SD	7.715	7.454
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	16.7
	Change from Baseline	n	7	5
		Mean	-2.38	3.33
		SD	6.299	7.454
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 417 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	10.42	3.33
		SD	15.269	7.454
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	6	5
		Mean	0.00	3.33
		SD	10.541	7.454
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 418 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	4.76	8.33
		SD	8.133	13.944
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	33.3
	Change from Baseline	n	6	6
		Mean	2.78	5.56
		SD	6.804	17.213
		Median	0.00	0.00
		Min.	0.0	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 419 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	11.11	3.33
		SD	17.213	7.454
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	5	5
		Mean	10.00	3.33
		SD	14.907	7.454
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 420 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	9.52	2.78
		SD	13.113	6.804
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	6	6
		Mean	2.78	2.78
		SD	12.546	6.804
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 421 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	8.33	0.00
		SD	12.599	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	5
		Mean	2.78	0.00
		SD	12.546	0.000
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 422 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	5	4
		Mean	10.00	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	4
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	6.67	6.67
		SD	9.129	9.129
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	16.7
	Change from Baseline	n	4	5
		Mean	-4.17	6.67
		SD	8.333	9.129
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 424 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	9.52	3.33
		SD	18.898	7.454
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	50.0	16.7
	Change from Baseline	n	5	5
		Mean	3.33	3.33
		SD	7.454	7.454
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 425 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	5.56	4.17
		SD	8.607	8.333
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	16.7
	Change from Baseline	n	5	4
		Mean	-3.33	4.17
		SD	7.454	8.333
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 426 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	12.50	0.00
		SD	15.957	0.000
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	4
		Mean	0.00	0.00
		SD	16.667	0.000
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 427 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	10.00	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	3
		Mean	0.00	0.00
		SD	13.608	0.000
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	5.56	0.00
		SD	8.607	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	5	2
		Mean	-3.33	0.00
		SD	7.454	0.000
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	6.67	0.00
		SD	9.129	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	4	3
		Mean	-4.17	0.00
		SD	8.333	0.000
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 430 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	5.56	0.00
		SD	8.607	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	4	2
		Mean	-8.33	0.00
		SD	16.667	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	4.17	0.00
		SD	8.333	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	3	2
		Mean	-11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 432 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	10.00	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	3
		Mean	0.00	0.00
		SD	13.608	0.000
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 433 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	11.11	0.00
		SD	13.608	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	1
		Mean	3.33	0.00
		SD	13.944	
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	10.00	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	2
		Mean	0.00	0.00
		SD	13.608	0.000
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 435 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	8.33	0.00
		SD	13.944	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	1
		Mean	0.00	0.00
		SD	11.785	
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 436 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	10.00	0.00
		SD	14.907	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	1
		Mean	0.00	0.00
		SD	13.608	
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 437 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	5.56	0.00
		SD	9.623	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	2
		Mean	-8.33	0.00
		SD	11.785	0.000
		Median	-8.33	0.00
		Min.	-16.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 438 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	5.56	0.00
		SD	9.623	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	11.785	
		Median	-8.33	0.00
		Min.	-16.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 439 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	16.67	0.00
		SD	16.667	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	23.570	
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	0.00	16.67
		SD		23.570
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	0	2
		Mean		16.67
		SD		23.570
		Median		16.67
		Min.		0.0
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	1	1
		Mean	-16.67	0.00
		SD		
		Median	-16.67	0.00
		Min.	-16.7	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 443 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	16.67	0.00
		SD		
		Median	16.67	0.00
		Min.	16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 445 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		16.67
		SD		
		Median		16.67
		Min.		16.7
		Max.		16.7
	Change from Baseline	n	0	1
		Mean		16.67
		SD		
		Median		16.67
		Min.		16.7
		Max.		16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 446 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	9.26	9.09
		SD	11.747	18.349
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	50.0
	Change from Baseline	n	18	21
		Mean	4.63	1.59
		SD	11.152	22.916
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (11%)	3 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (11%)	3 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (39%)	4 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (39%)	4 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 447 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	10.42	20.37
		SD	12.400	34.134
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	7	9
		Mean	4.76	14.81
		SD	8.133	26.932
		Median	0.00	0.00
		Min.	0.0	-16.7
		Max.	16.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	4 (44%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 448 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and Vomiting

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	18.59	26.34
		SD	19.623	29.115
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	24	29
		Mean	13.19	18.39
		SD	19.646	29.326
		Median	8.33	0.00
		Min.	-16.7	-33.3
		Max.	66.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (8%)	3 (10%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (8%)	3 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	12 (50%)	14 (48%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	12 (50%)	14 (48%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	39.51	38.54
		SD	32.075	33.451
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	25.33	26.44
		SD	26.405	30.380
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	83.3	100.0
	Change from Baseline	n	24	28
		Mean	-13.89	-17.86
		SD	22.877	21.242
		Median	-16.67	-16.67
		Min.	-66.7	-50.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	13 (54%)	15 (54%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	13 (54%)	15 (54%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (17%)	1 (4%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (17%)	1 (4%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	25.00	27.78
		SD	22.522	30.312
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	23	26
		Mean	-15.94	-17.31
		SD	24.349	23.796
		Median	-16.67	-16.67
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	14 (61%)	17 (65%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	14 (61%)	17 (65%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (13%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (13%)	3 (12%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	26.81	29.49
		SD	22.326	32.764
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	22	26
		Mean	-15.15	-12.82
		SD	24.618	28.405
		Median	-16.67	-16.67
		Min.	-66.7	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	13 (59%)	14 (54%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	13 (59%)	14 (54%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (14%)	4 (15%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (14%)	4 (15%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	23.48	34.67
		SD	19.693	34.668
		Median	16.67	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	21	25
		Mean	-11.11	-8.67
		SD	29.502	32.674
		Median	0.00	-16.67
		Min.	-83.3	-66.7
		Max.	33.3	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (43%)	13 (52%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	9 (43%)	13 (52%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (19%)	6 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (19%)	6 (24%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	24.51	28.07
		SD	15.721	30.456
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	50.0	100.0
	Change from Baseline	n	16	19
		Mean	-8.33	-15.79
		SD	28.545	34.460
		Median	-8.33	-16.67
		Min.	-83.3	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (50%)	10 (53%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (50%)	10 (53%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (31%)	3 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	3 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	31.48	25.00
		SD	24.845	28.545
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	83.3	100.0
	Change from Baseline	n	17	16
		Mean	-5.88	-19.79
		SD	26.314	28.687
		Median	-16.67	-25.00
		Min.	-50.0	-66.7
		Max.	66.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (53%)	11 (69%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	9 (53%)	11 (69%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (24%)	2 (13%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (24%)	2 (13%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	26.67	27.45
		SD	20.702	16.605
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	83.3	66.7
	Change from Baseline	n	14	17
		Mean	-3.57	-7.84
		SD	24.615	21.342
		Median	-8.33	0.00
		Min.	-50.0	-50.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (50%)	7 (41%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (50%)	7 (41%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (36%)	3 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (36%)	3 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	32.29	20.83
		SD	19.691	16.088
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	15	12
		Mean	0.00	-15.28
		SD	18.898	27.941
		Median	0.00	0.00
		Min.	-50.0	-66.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (20%)	5 (42%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	5 (42%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (27%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (27%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	33.33	20.37
		SD	31.351	18.215
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	100.0	50.0
	Change from Baseline	n	13	9
		Mean	-2.56	-25.93
		SD	37.172	23.733
		Median	0.00	-33.33
		Min.	-83.3	-66.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	6 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	6 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (38%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (38%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	26.19	18.06
		SD	24.209	18.060
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	13	12
		Mean	-16.67	-22.22
		SD	31.180	28.721
		Median	0.00	-33.33
		Min.	-83.3	-50.0
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (46%)	9 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (46%)	9 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	1 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	1 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	28.89	21.67
		SD	24.774	11.249
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	14	10
		Mean	-5.95	-20.00
		SD	23.211	23.307
		Median	0.00	-25.00
		Min.	-66.7	-50.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (36%)	6 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (36%)	6 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (29%)	1 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (29%)	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	36.36	29.63
		SD	17.979	20.031
		Median	33.33	33.33
		Min.	16.7	0.0
		Max.	66.7	66.7
	Change from Baseline	n	11	9
		Mean	-3.03	-14.81
		SD	23.355	24.216
		Median	0.00	-16.67
		Min.	-50.0	-50.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	5 (56%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	5 (56%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 462 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	33.33	25.76
		SD	18.634	23.995
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	9	11
		Mean	-11.11	-18.18
		SD	18.634	28.338
		Median	-16.67	-16.67
		Min.	-50.0	-50.0
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (56%)	8 (73%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	8 (73%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (9%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (9%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	28.79	20.37
		SD	22.473	16.197
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	11	9
		Mean	-10.61	-12.96
		SD	23.889	24.689
		Median	0.00	-16.67
		Min.	-66.7	-50.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	5 (56%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	5 (56%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	34.85	25.00
		SD	21.672	20.412
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	11	6
		Mean	-1.52	-22.22
		SD	18.936	20.184
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	33.33	25.00
		SD	20.787	20.412
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	10	6
		Mean	-6.67	-22.22
		SD	27.442	13.608
		Median	-8.33	-25.00
		Min.	-66.7	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	24.07	21.43
		SD	18.840	15.853
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	50.0	33.3
	Change from Baseline	n	9	7
		Mean	-11.11	-19.05
		SD	25.000	20.250
		Median	-16.67	-33.33
		Min.	-66.7	-33.3
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (56%)	5 (71%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	5 (71%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	18.33	19.44
		SD	18.342	16.387
		Median	16.67	25.00
		Min.	0.0	0.0
		Max.	50.0	33.3
	Change from Baseline	n	10	6
		Mean	-15.00	-27.78
		SD	25.398	17.213
		Median	-8.33	-33.33
		Min.	-66.7	-50.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	28.57	19.44
		SD	23.002	22.153
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	7	6
		Mean	-11.90	-33.33
		SD	26.726	18.257
		Median	0.00	-33.33
		Min.	-66.7	-66.7
		Max.	16.7	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	6 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	6 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	30.95	23.33
		SD	20.250	22.361
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	7	5
		Mean	-9.52	-26.67
		SD	21.207	9.129
		Median	0.00	-33.33
		Min.	-50.0	-33.3
		Max.	16.7	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	5 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	5 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	27.08	13.89
		SD	17.678	12.546
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	50.0	33.3
	Change from Baseline	n	8	6
		Mean	-12.50	-19.44
		SD	24.801	30.581
		Median	-8.33	-16.67
		Min.	-66.7	-66.7
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	22.92	20.00
		SD	19.796	18.257
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	50.0	33.3
	Change from Baseline	n	7	5
		Mean	-19.05	-30.00
		SD	22.420	7.454
		Median	-16.67	-33.33
		Min.	-66.7	-33.3
		Max.	0.0	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	5 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (71%)	5 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	25.00	13.33
		SD	17.817	18.257
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	50.0	33.3
	Change from Baseline	n	8	5
		Mean	-14.58	-36.67
		SD	22.603	18.257
		Median	-8.33	-33.33
		Min.	-66.7	-66.7
		Max.	0.0	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	5 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	5 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	27.08	26.67
		SD	17.678	14.907
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	50.0	33.3
	Change from Baseline	n	7	5
		Mean	-16.67	-23.33
		SD	30.429	22.361
		Median	-16.67	-33.33
		Min.	-66.7	-33.3
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (71%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	23.81	13.89
		SD	13.113	16.387
		Median	33.33	8.33
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	6
		Mean	-9.52	-38.89
		SD	31.706	17.213
		Median	0.00	-33.33
		Min.	-66.7	-66.7
		Max.	16.7	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	6 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	6 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	25.00	26.67
		SD	20.412	19.003
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	50.0	50.0
	Change from Baseline	n	6	5
		Mean	-13.89	-23.33
		SD	28.707	14.907
		Median	-8.33	-33.33
		Min.	-66.7	-33.3
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	35.71	13.89
		SD	20.250	16.387
		Median	33.33	8.33
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	6
		Mean	-4.76	-27.78
		SD	12.599	17.213
		Median	0.00	-33.33
		Min.	-16.7	-50.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	5 (83%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	5 (83%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	27.08	26.67
		SD	17.678	19.003
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	50.0	50.0
	Change from Baseline	n	7	5
		Mean	-16.67	-23.33
		SD	27.217	19.003
		Median	-16.67	-16.67
		Min.	-66.7	-50.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 478 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	25.00	25.00
		SD	20.412	21.517
		Median	33.33	25.00
		Min.	0.0	0.0
		Max.	50.0	50.0
	Change from Baseline	n	6	4
		Mean	-19.44	-29.17
		SD	24.533	15.957
		Median	-16.67	-25.00
		Min.	-66.7	-50.0
		Max.	0.0	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	4 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	4 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	20.00	26.67
		SD	18.257	19.003
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	33.3	50.0
	Change from Baseline	n	5	5
		Mean	-20.00	-23.33
		SD	27.386	19.003
		Median	-16.67	-16.67
		Min.	-66.7	-50.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	28.57	23.33
		SD	15.853	22.361
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	50.0	50.0
	Change from Baseline	n	6	5
		Mean	-11.11	-26.67
		SD	22.771	25.276
		Median	-8.33	-16.67
		Min.	-50.0	-66.7
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	4 (80%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	27.78	20.83
		SD	25.092	25.000
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	6	4
		Mean	-16.67	-25.00
		SD	25.820	28.868
		Median	-8.33	-16.67
		Min.	-66.7	-66.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	25.00	20.83
		SD	16.667	15.957
		Median	33.33	25.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	4	4
		Mean	-8.33	-25.00
		SD	9.623	21.517
		Median	-8.33	-25.00
		Min.	-16.7	-50.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	3 (75%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	26.67	27.78
		SD	14.907	25.459
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	33.3	50.0
	Change from Baseline	n	5	3
		Mean	-13.33	-11.11
		SD	13.944	9.623
		Median	-16.67	-16.67
		Min.	-33.3	-16.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 484 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	30.56	41.67
		SD	16.387	35.355
		Median	33.33	41.67
		Min.	0.0	16.7
		Max.	50.0	66.7
	Change from Baseline	n	6	2
		Mean	-13.89	-8.33
		SD	12.546	11.785
		Median	-16.67	-8.33
		Min.	-33.3	-16.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	16.67	16.67
		SD	16.667	16.667
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	3
		Mean	-23.33	-22.22
		SD	34.561	25.459
		Median	-16.67	-16.67
		Min.	-66.7	-50.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	41.67	16.67
		SD	13.944	23.570
		Median	33.33	16.67
		Min.	33.3	0.0
		Max.	66.7	33.3
	Change from Baseline	n	5	2
		Mean	-3.33	-8.33
		SD	21.731	11.785
		Median	-16.67	-8.33
		Min.	-16.7	-16.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	3	2
		Mean	27.78	8.33
		SD	9.623	11.785
		Median	33.33	8.33
		Min.	16.7	0.0
		Max.	33.3	16.7
	Change from Baseline	n	3	2
		Mean	-16.67	-16.67
		SD	16.667	0.000
		Median	-16.67	-16.67
		Min.	-33.3	-16.7
		Max.	0.0	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	26.67	16.67
		SD	14.907	16.667
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	3
		Mean	-13.33	-22.22
		SD	36.132	25.459
		Median	-16.67	-16.67
		Min.	-66.7	-50.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 489 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	22.22	33.33
		SD	17.213	
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Change from Baseline	n	6	1
		Mean	-13.89	0.00
		SD	28.707	
		Median	-8.33	0.00
		Min.	-66.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	13.33	16.67
		SD	18.257	23.570
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	2
		Mean	-26.67	-8.33
		SD	30.277	11.785
		Median	-16.67	-8.33
		Min.	-66.7	-16.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	36.11	16.67
		SD	16.387	
		Median	33.33	16.67
		Min.	16.7	16.7
		Max.	66.7	16.7
	Change from Baseline	n	6	1
		Mean	-8.33	-16.67
		SD	17.480	
		Median	-8.33	-16.67
		Min.	-33.3	-16.7
		Max.	16.7	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	23.33	16.67
		SD	22.361	
		Median	33.33	16.67
		Min.	0.0	16.7
		Max.	50.0	16.7
	Change from Baseline	n	5	1
		Mean	-16.67	-16.67
		SD	31.180	
		Median	-16.67	-16.67
		Min.	-66.7	-16.7
		Max.	16.7	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 493 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	22.22	8.33
		SD	19.245	11.785
		Median	33.33	8.33
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	3	2
		Mean	-33.33	-16.67
		SD	28.868	0.000
		Median	-16.67	-16.67
		Min.	-66.7	-16.7
		Max.	-16.7	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (100%)	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (100%)	2 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	27.78	33.33
		SD	9.623	
		Median	33.33	33.33
		Min.	16.7	33.3
		Max.	33.3	33.3
	Change from Baseline	n	3	1
		Mean	-27.78	0.00
		SD	9.623	
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	38.89	33.33
		SD	9.623	
		Median	33.33	33.33
		Min.	33.3	33.3
		Max.	50.0	33.3
	Change from Baseline	n	3	1
		Mean	-5.56	0.00
		SD	19.245	
		Median	-16.67	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 496 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	33.33	25.00
		SD		11.785
		Median	33.33	25.00
		Min.	33.3	16.7
		Max.	33.3	33.3
	Change from Baseline	n	1	2
		Mean	-16.67	0.00
		SD		23.570
		Median	-16.67	0.00
		Min.	-16.7	-16.7
		Max.	-16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 497 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	33.33	33.33
		SD	0.000	
		Median	33.33	33.33
		Min.	33.3	33.3
		Max.	33.3	33.3
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	0.000	
		Median	-16.67	0.00
		Min.	-16.7	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	33.33	16.67
		SD		
		Median	33.33	16.67
		Min.	33.3	16.7
		Max.	33.3	16.7
	Change from Baseline	n	1	1
		Mean	-16.67	-16.67
		SD		
		Median	-16.67	-16.67
		Min.	-16.7	-16.7
		Max.	-16.7	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	33.33	16.67
		SD	0.000	
		Median	33.33	16.67
		Min.	33.3	16.7
		Max.	33.3	16.7
	Change from Baseline	n	2	1
		Mean	-8.33	-16.67
		SD	11.785	
		Median	-8.33	-16.67
		Min.	-16.7	-16.7
		Max.	0.0	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 501 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		16.67
		SD		
		Median		16.67
		Min.		16.7
		Max.		16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 502 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	38.89	39.39
		SD	26.813	35.837
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	18	22
		Mean	-2.78	2.27
		SD	30.917	33.450
		Median	0.00	0.00
		Min.	-83.3	-66.7
		Max.	33.3	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (39%)	5 (23%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (39%)	5 (23%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	8 (44%)	7 (32%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	8 (44%)	7 (32%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 503 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	9	9
		Mean	37.04	31.48
		SD	27.358	22.737
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	8	9
		Mean	0.00	-5.56
		SD	17.817	37.268
		Median	0.00	0.00
		Min.	-33.3	-50.0
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 504 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	48.72	53.76
		SD	27.456	32.691
		Median	50.00	50.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	30
		Mean	8.00	12.22
		SD	27.268	29.339
		Median	16.67	8.33
		Min.	-50.0	-50.0
		Max.	66.7	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (28%)	5 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (28%)	5 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	13 (52%)	15 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	13 (52%)	15 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	31
		Mean	28.40	18.28
		SD	31.628	22.507
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	29.33	18.39
		SD	27.756	27.583
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	24	27
		Mean	-1.39	-3.70
		SD	34.723	23.266
		Median	0.00	0.00
		Min.	-100.0	-66.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (25%)	5 (19%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (25%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (21%)	2 (7%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (21%)	2 (7%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	26.39	17.28
		SD	19.608	28.300
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	23	25
		Mean	-4.35	-2.67
		SD	27.163	19.052
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (22%)	5 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (22%)	5 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (17%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (17%)	3 (12%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	22	26
		Mean	28.79	19.23
		SD	23.672	25.251
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	21	25
		Mean	-3.17	1.33
		SD	34.809	28.021
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (29%)	5 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (29%)	5 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (19%)	6 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (19%)	6 (24%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	28.79	17.33
		SD	21.320	25.676
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	21	24
		Mean	-1.59	1.39
		SD	34.118	20.803
		Median	0.00	0.00
		Min.	-100.0	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (29%)	2 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (29%)	2 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (33%)	4 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (33%)	4 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	21.57	8.77
		SD	16.420	15.080
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	16	18
		Mean	-6.25	-7.41
		SD	34.894	21.559
		Median	0.00	0.00
		Min.	-100.0	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (31%)	4 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	4 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (25%)	1 (6%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (25%)	1 (6%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 511 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	27.78	8.33
		SD	26.197	19.245
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	17	15
		Mean	-1.96	-13.33
		SD	39.914	21.082
		Median	0.00	0.00
		Min.	-100.0	-66.7
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (24%)	5 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (24%)	5 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 512 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	16
		Mean	24.44	14.58
		SD	19.787	17.078
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	14	16
		Mean	2.38	-2.08
		SD	20.524	25.730
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (14%)	3 (19%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (14%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	3 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	14	12
		Mean	23.81	5.56
		SD	24.209	12.975
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	13	12
		Mean	2.56	-5.56
		SD	21.350	23.925
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	1 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	1 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	30.95	11.11
		SD	20.524	23.570
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	13	9
		Mean	5.13	-7.41
		SD	32.903	32.394
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 515 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	28.57	16.67
		SD	22.100	26.591
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	13	12
		Mean	0.00	0.00
		SD	23.570	34.816
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	3 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	3 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	22.22	13.33
		SD	16.265	23.307
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	14	10
		Mean	-2.38	-3.33
		SD	27.625	24.595
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	3 (30%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	3 (30%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	2 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	2 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	30.30	14.81
		SD	10.050	24.216
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	11	9
		Mean	0.00	-3.70
		SD	29.814	20.031
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 518 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	29.63	18.18
		SD	11.111	27.340
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	9	11
		Mean	0.00	0.00
		SD	28.868	33.333
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	4 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	4 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	3 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	3 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	24.24	11.11
		SD	15.570	16.667
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	11	9
		Mean	0.00	3.70
		SD	29.814	20.031
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 520 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	27.27	5.56
		SD	13.484	13.608
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	11	6
		Mean	0.00	-5.56
		SD	29.814	13.608
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 521 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	30.00	0.00
		SD	10.541	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	10	6
		Mean	10.00	-11.11
		SD	16.102	17.213
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	29.63	4.76
		SD	11.111	12.599
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	9	7
		Mean	11.11	-4.76
		SD	16.667	23.002
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 523 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	5
		Mean	33.33	0.00
		SD	31.427	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Change from Baseline	n	10	5
		Mean	16.67	-13.33
		SD	32.394	18.257
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	28.57	0.00
		SD	12.599	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	7	6
		Mean	9.52	-16.67
		SD	16.265	18.257
		Median	0.00	-16.67
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	28.57	0.00
		SD	12.599	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	7	5
		Mean	9.52	-13.33
		SD	16.265	18.257
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 526 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	29.17	5.56
		SD	21.362	13.608
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	8	6
		Mean	12.50	0.00
		SD	17.252	21.082
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 527 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	29.17	6.67
		SD	11.785	14.907
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	5
		Mean	9.52	-6.67
		SD	16.265	27.889
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 528 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	29.17	0.00
		SD	11.785	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	8	5
		Mean	12.50	-13.33
		SD	17.252	18.257
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 529 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	25.00	6.67
		SD	15.430	14.907
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	5
		Mean	4.76	-6.67
		SD	12.599	27.889
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 530 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	28.57	11.11
		SD	23.002	17.213
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	6
		Mean	9.52	-5.56
		SD	16.265	25.092
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 531 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	38.89	6.67
		SD	13.608	14.907
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	66.7	33.3
	Change from Baseline	n	6	5
		Mean	22.22	-6.67
		SD	17.213	27.889
		Median	33.33	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 532 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	33.33	11.11
		SD	19.245	17.213
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	6
		Mean	14.29	0.00
		SD	17.817	21.082
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 533 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	33.33	6.67
		SD	17.817	14.907
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	5
		Mean	14.29	-6.67
		SD	17.817	27.889
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 534 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	27.78	0.00
		SD	25.092	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	6	4
		Mean	5.56	-16.67
		SD	25.092	19.245
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 535 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	20.00	6.67
		SD	18.257	14.907
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	5
		Mean	0.00	-6.67
		SD	23.570	27.889
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 536 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	28.57	6.67
		SD	12.599	14.907
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	5
		Mean	11.11	-6.67
		SD	17.213	27.889
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	16.67	16.67
		SD	18.257	19.245
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	4
		Mean	-5.56	8.33
		SD	25.092	31.914
		Median	0.00	16.67
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	2 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 538 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	33.33	8.33
		SD	0.000	16.667
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	33.3
	Change from Baseline	n	4	4
		Mean	8.33	0.00
		SD	16.667	27.217
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 539 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	20.00	11.11
		SD	18.257	19.245
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	3
		Mean	0.00	11.11
		SD	23.570	19.245
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 540 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	27.78	0.00
		SD	25.092	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	6	2
		Mean	5.56	0.00
		SD	32.773	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 541 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	4	3
		Mean	25.00	0.00
		SD	16.667	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	3
		Mean	8.33	-11.11
		SD	16.667	19.245
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 542 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	27.78	0.00
		SD	13.608	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	2
		Mean	6.67	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 543 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	41.67	0.00
		SD	16.667	0.000
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	2
		Mean	16.67	0.00
		SD	19.245	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 544 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	33.33	0.00
		SD	23.570	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	5	3
		Mean	13.33	-11.11
		SD	18.257	19.245
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 545 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	27.78	0.00
		SD	13.608	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	1
		Mean	11.11	0.00
		SD	17.213	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 546 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	26.67	0.00
		SD	14.907	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	2
		Mean	6.67	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 547 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	22.22	33.33
		SD	17.213	
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Change from Baseline	n	6	1
		Mean	0.00	33.33
		SD	21.082	
		Median	0.00	33.33
		Min.	-33.3	33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 548 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	33.33	0.00
		SD	0.000	
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	1
		Mean	13.33	0.00
		SD	18.257	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 549 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	22.22	0.00
		SD	19.245	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	2
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 550 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	22.22	0.00
		SD	19.245	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	1
		Mean	11.11	0.00
		SD	19.245	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	33.33	0.00
		SD	0.000	
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	1
		Mean	11.11	0.00
		SD	19.245	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 552 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	33.33	16.67
		SD		23.570
		Median	33.33	16.67
		Min.	33.3	0.0
		Max.	33.3	33.3
	Change from Baseline	n	1	2
		Mean	33.33	16.67
		SD		23.570
		Median	33.33	16.67
		Min.	33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 553 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	0.000	
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 554 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 555 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	0.000	
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 556 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 557 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 558 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	35.19	22.73
		SD	24.179	29.790
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	18	22
		Mean	3.70	4.55
		SD	32.113	15.585
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (22%)	1 (5%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (22%)	1 (5%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	6 (33%)	4 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	6 (33%)	4 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 559 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	20.83	25.93
		SD	17.252	27.778
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	9
		Mean	0.00	11.11
		SD	19.245	28.868
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	50.00	37.63
		SD	27.080	26.863
		Median	66.67	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	29
		Mean	20.00	17.24
		SD	33.333	26.157
		Median	33.33	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (16%)	2 (7%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (16%)	2 (7%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	14 (56%)	14 (48%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	14 (56%)	14 (48%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	37.04	25.00
		SD	37.363	28.081
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	24.00	27.59
		SD	26.387	30.949
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	24	28
		Mean	-11.11	1.19
		SD	27.217	33.311
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (38%)	6 (21%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	9 (38%)	6 (21%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (13%)	6 (21%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (13%)	6 (21%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 563 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	26.39	27.16
		SD	27.766	33.381
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	23	26
		Mean	-8.70	1.28
		SD	28.810	29.030
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (35%)	5 (19%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	8 (35%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (17%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (17%)	5 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 564 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	26.09	29.49
		SD	28.349	30.298
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	22	26
		Mean	-12.12	3.85
		SD	30.071	27.206
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (27%)	2 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (27%)	2 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (9%)	6 (23%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (9%)	6 (23%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 565 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	19.70	32.00
		SD	19.678	33.993
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	21	25
		Mean	-12.70	6.67
		SD	37.232	33.333
		Median	0.00	0.00
		Min.	-100.0	-66.7
		Max.	33.3	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (33%)	4 (16%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (33%)	4 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (19%)	7 (28%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (19%)	7 (28%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 566 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	23.53	26.32
		SD	28.296	28.499
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	16	19
		Mean	-16.67	1.75
		SD	40.369	20.709
		Median	0.00	0.00
		Min.	-100.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (38%)	3 (16%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (38%)	3 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (19%)	4 (21%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (19%)	4 (21%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	17	16
		Mean	33.33	22.92
		SD	28.868	31.549
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	16	16
		Mean	-4.17	-2.08
		SD	29.502	22.669
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (31%)	2 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	2 (13%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (25%)	2 (13%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (25%)	2 (13%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 568 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	26.67	15.69
		SD	28.730	17.150
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	14	17
		Mean	-9.52	-3.92
		SD	33.150	26.040
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (36%)	4 (24%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (36%)	4 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	3 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	3 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	27.08	16.67
		SD	27.806	17.408
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	15	12
		Mean	-2.22	5.56
		SD	29.457	23.925
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (27%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (27%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (27%)	4 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (27%)	4 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 570 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	28.57	14.81
		SD	36.648	24.216
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	13	9
		Mean	-7.69	3.70
		SD	33.758	26.058
		Median	0.00	0.00
		Min.	-100.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 571 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	30.95	19.44
		SD	30.562	26.432
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	13	12
		Mean	-7.69	2.78
		SD	27.735	26.432
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 572 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	26.67	16.67
		SD	31.371	17.568
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	14	10
		Mean	-7.14	6.67
		SD	32.499	21.082
		Median	0.00	0.00
		Min.	-100.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	1 (10%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	1 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (14%)	3 (30%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (14%)	3 (30%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 573 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	24.24	11.11
		SD	21.556	16.667
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	11	9
		Mean	-12.12	0.00
		SD	30.814	16.667
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 574 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	18.52	12.12
		SD	24.216	22.473
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	9	11
		Mean	-22.22	-6.06
		SD	28.868	32.722
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (44%)	4 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (44%)	4 (36%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	24.24	14.81
		SD	21.556	24.216
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	11	9
		Mean	-18.18	3.70
		SD	27.340	26.058
		Median	-33.33	0.00
		Min.	-66.7	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (55%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (55%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	27.27	16.67
		SD	20.101	18.257
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	11	6
		Mean	-9.09	0.00
		SD	30.151	29.814
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	30.00	5.56
		SD	29.187	13.608
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	10	6
		Mean	-3.33	-11.11
		SD	18.922	27.217
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 578 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	25.93	4.76
		SD	22.222	12.599
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	9	7
		Mean	-7.41	-9.52
		SD	22.222	16.265
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	2 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 579 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	23.33	11.11
		SD	22.498	17.213
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	10	6
		Mean	-13.33	-5.56
		SD	23.307	13.608
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 580 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	23.81	11.11
		SD	16.265	17.213
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	6
		Mean	-4.76	-16.67
		SD	23.002	34.960
		Median	0.00	-16.67
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 581 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	23.81	13.33
		SD	16.265	18.257
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	5
		Mean	-4.76	-6.67
		SD	23.002	27.889
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 582 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	37.50	0.00
		SD	21.362	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	8	6
		Mean	4.17	-11.11
		SD	21.362	17.213
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 583 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	20.83	6.67
		SD	24.801	14.907
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	5
		Mean	-9.52	-13.33
		SD	31.706	29.814
		Median	0.00	-33.33
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	16.67	0.00
		SD	17.817	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	8	5
		Mean	-16.67	-20.00
		SD	17.817	18.257
		Median	-16.67	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (50%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (50%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	7	5
		Mean	23.81	13.33
		SD	16.265	29.814
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	5
		Mean	-14.29	-6.67
		SD	26.227	43.461
		Median	0.00	-33.33
		Min.	-66.7	-33.3
		Max.	0.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 586 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	9.52	22.22
		SD	16.265	27.217
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	6
		Mean	-14.29	-5.56
		SD	17.817	25.092
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	11.11	13.33
		SD	17.213	18.257
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	5
		Mean	-16.67	-6.67
		SD	34.960	27.889
		Median	-16.67	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	23.81	11.11
		SD	16.265	17.213
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	6
		Mean	-4.76	-5.56
		SD	23.002	25.092
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 589 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	25.00	6.67
		SD	23.570	14.907
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	5
		Mean	-4.76	-13.33
		SD	29.991	29.814
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 590 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	22.22	16.67
		SD	17.213	19.245
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	4
		Mean	-11.11	0.00
		SD	17.213	27.217
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	20.00	6.67
		SD	29.814	14.907
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	5	5
		Mean	-6.67	-13.33
		SD	27.889	29.814
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	23.81	6.67
		SD	16.265	14.907
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	5
		Mean	0.00	-13.33
		SD	21.082	29.814
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	3 (60%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	33.33	8.33
		SD	36.515	16.667
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	6	4
		Mean	0.00	-8.33
		SD	21.082	31.914
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	25.00	8.33
		SD	16.667	16.667
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	4	4
		Mean	-8.33	-8.33
		SD	16.667	31.914
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 595 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	20.00	11.11
		SD	18.257	19.245
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	3
		Mean	-6.67	0.00
		SD	14.907	33.333
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 596 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	27.78	0.00
		SD	25.092	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	6	2
		Mean	-5.56	-16.67
		SD	13.608	23.570
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	20.00	0.00
		SD	18.257	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	3
		Mean	-6.67	-22.22
		SD	14.907	19.245
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 598 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	27.78	0.00
		SD	13.608	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	2
		Mean	0.00	-16.67
		SD	0.000	23.570
		Median	0.00	-16.67
		Min.	0.0	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 599 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	3	2
		Mean	22.22	0.00
		SD	19.245	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	2
		Mean	-11.11	-16.67
		SD	19.245	23.570
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	20.00	0.00
		SD	18.257	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	3
		Mean	-6.67	-22.22
		SD	14.907	19.245
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 601 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	33.33	0.00
		SD	21.082	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	6	1
		Mean	11.11	-33.33
		SD	17.213	
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 602 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	13.33	0.00
		SD	18.257	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	2
		Mean	-13.33	-16.67
		SD	18.257	23.570
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 603 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	27.78	33.33
		SD	25.092	
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	66.7	33.3
	Change from Baseline	n	6	1
		Mean	-5.56	0.00
		SD	13.608	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 604 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	20.00	0.00
		SD	18.257	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	1
		Mean	-6.67	-33.33
		SD	14.907	
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 605 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	33.33	0.00
		SD	33.333	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	3	2
		Mean	11.11	-16.67
		SD	19.245	23.570
		Median	0.00	-16.67
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 606 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	11.11	0.00
		SD	19.245	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	1
		Mean	-11.11	-33.33
		SD	19.245	
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 607 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	22.22	0.00
		SD	19.245	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	1
		Mean	-11.11	-33.33
		SD	19.245	
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 608 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	33.33	16.67
		SD		23.570
		Median	33.33	16.67
		Min.	33.3	0.0
		Max.	33.3	33.3
	Change from Baseline	n	1	2
		Mean	0.00	0.00
		SD		47.140
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 609 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	0.000	
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	0.00	-33.33
		SD	0.000	
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	0.00	-33.33
		SD		
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 611 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	0.000	
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	0.00	-33.33
		SD	0.000	
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 612 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 613 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 614 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	27.78	25.76
		SD	28.583	30.744
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	18	22
		Mean	-14.81	1.52
		SD	36.555	16.191
		Median	-16.67	0.00
		Min.	-66.7	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (50%)	2 (9%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	9 (50%)	2 (9%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (17%)	3 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (17%)	3 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 615 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	25.00	33.33
		SD	23.570	33.333
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	7	9
		Mean	-4.76	14.81
		SD	29.991	29.397
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	4 (44%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	46.15	52.69
		SD	34.094	30.761
		Median	33.33	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	30
		Mean	10.67	27.78
		SD	30.000	26.383
		Median	0.00	33.33
		Min.	-66.7	0.0
		Max.	66.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (16%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (16%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	12 (48%)	19 (63%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	12 (48%)	19 (63%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	26	31
		Mean	20.51	16.13
		SD	28.405	28.377
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 618 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	16.00	12.64
		SD	23.805	18.716
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	23	27
		Mean	-5.80	-6.17
		SD	19.207	26.209
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (26%)	4 (15%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (26%)	4 (15%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (9%)	2 (7%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (9%)	2 (7%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 619 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	22	27
		Mean	7.58	14.81
		SD	14.298	26.688
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	21	25
		Mean	-9.52	-5.33
		SD	26.125	36.868
		Median	0.00	0.00
		Min.	-100.0	-100.0
		Max.	33.3	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (24%)	6 (24%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (24%)	6 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (5%)	2 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (5%)	2 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 620 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	10.14	12.82
		SD	15.682	25.081
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	21	25
		Mean	-11.11	-6.67
		SD	26.527	23.570
		Median	0.00	0.00
		Min.	-100.0	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (29%)	7 (28%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (29%)	7 (28%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (5%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (5%)	3 (12%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 621 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	6.06	17.33
		SD	13.159	29.059
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	20	25
		Mean	-15.00	-1.33
		SD	31.484	26.317
		Median	0.00	0.00
		Min.	-100.0	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (30%)	5 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (30%)	5 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (5%)	4 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (5%)	4 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 622 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	15.69	17.54
		SD	20.809	32.142
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	15	19
		Mean	0.00	-5.26
		SD	25.198	16.715
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	4 (21%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	4 (21%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (20%)	1 (5%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	1 (5%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 623 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	17	16
		Mean	13.73	25.00
		SD	20.612	33.333
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	15	16
		Mean	-4.44	0.00
		SD	24.774	24.343
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (20%)	2 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	2 (13%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	3 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 624 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	13.33	15.69
		SD	16.903	17.150
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	13	17
		Mean	-5.13	-1.96
		SD	22.958	32.212
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	4 (24%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	4 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	5 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	5 (29%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 625 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	14.58	11.11
		SD	17.078	21.711
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	14	12
		Mean	-2.38	-5.56
		SD	15.821	27.828
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (14%)	3 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (14%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (7%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 626 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	11.90	18.52
		SD	16.575	24.216
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	12	9
		Mean	-2.78	-3.70
		SD	17.164	26.058
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 627 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	13	12
		Mean	15.38	16.67
		SD	22.008	26.591
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	11	12
		Mean	-9.09	-2.78
		SD	15.570	26.432
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 628 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	13.33	10.00
		SD	21.082	16.102
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	13	10
		Mean	0.00	-10.00
		SD	30.429	22.498
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	2 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	2 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	12.12	11.11
		SD	16.817	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	10	9
		Mean	-3.33	-11.11
		SD	18.922	23.570
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 630 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	7.41	21.21
		SD	14.699	30.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	8	11
		Mean	-8.33	0.00
		SD	23.570	25.820
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	2 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	1 (9%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	1 (9%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 631 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	15.15	11.11
		SD	17.408	23.570
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	10	9
		Mean	0.00	-3.70
		SD	22.222	20.031
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 632 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	18.18	5.56
		SD	17.408	13.608
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	10	6
		Mean	3.33	-16.67
		SD	24.595	27.889
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 633 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	16.67	5.56
		SD	23.570	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	9	6
		Mean	-3.70	-16.67
		SD	20.031	27.889
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 634 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	11.11	4.76
		SD	16.667	12.599
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	8	7
		Mean	-4.17	-14.29
		SD	21.362	26.227
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	2 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	10.00	0.00
		SD	16.102	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	9	6
		Mean	-3.70	-22.22
		SD	20.031	40.369
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 636 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	19.05	0.00
		SD	17.817	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	6
		Mean	0.00	-11.11
		SD	21.082	17.213
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 637 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	14.29	6.67
		SD	17.817	14.907
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	5
		Mean	0.00	0.00
		SD	21.082	23.570
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 638 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	12.50	0.00
		SD	17.252	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	7	6
		Mean	0.00	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 639 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	8.33	0.00
		SD	15.430	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	5
		Mean	-11.11	-6.67
		SD	17.213	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 640 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	16.67	0.00
		SD	17.817	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	7	5
		Mean	4.76	-6.67
		SD	23.002	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 641 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	16.67	13.33
		SD	17.817	18.257
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	5
		Mean	0.00	6.67
		SD	0.000	27.889
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 642 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	4.76	16.67
		SD	12.599	27.889
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	6	6
		Mean	-5.56	5.56
		SD	25.092	25.092
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 643 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	5.56	0.00
		SD	13.608	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	5
		Mean	-6.67	-6.67
		SD	27.889	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 644 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	14.29	0.00
		SD	17.817	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	6
		Mean	0.00	-5.56
		SD	21.082	13.608
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 645 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	12.50	0.00
		SD	17.252	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	5
		Mean	-5.56	-6.67
		SD	25.092	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 646 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	5	4
		Mean	6.67	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	4
		Mean	-8.33	-8.33
		SD	16.667	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 647 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	13.33	0.00
		SD	18.257	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	5
		Mean	-8.33	-6.67
		SD	16.667	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 648 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	19.05	0.00
		SD	17.817	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	5
		Mean	6.67	-6.67
		SD	14.907	14.907
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	11.11	8.33
		SD	17.213	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	4
		Mean	-6.67	0.00
		SD	14.907	27.217
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 650 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	16.67	0.00
		SD	19.245	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	4
		Mean	-11.11	-8.33
		SD	19.245	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 651 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	13.33	11.11
		SD	18.257	19.245
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	4	3
		Mean	-8.33	11.11
		SD	16.667	19.245
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 652 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	11.11	0.00
		SD	17.213	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	2
		Mean	-6.67	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 653 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	6.67	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	3
		Mean	-16.67	-11.11
		SD	19.245	19.245
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 654 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	16.67	0.00
		SD	18.257	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	2
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	3	2
		Mean	-33.33	0.00
		SD	0.000	0.000
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 656 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	20.00	0.00
		SD	18.257	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	3
		Mean	0.00	-11.11
		SD	0.000	19.245
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 657 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	16.67	0.00
		SD	18.257	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	1
		Mean	0.00	0.00
		SD	23.570	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 658 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	13.33	0.00
		SD	18.257	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	2
		Mean	-8.33	0.00
		SD	16.667	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 659 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	11.11	0.00
		SD	17.213	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	1
		Mean	-6.67	0.00
		SD	14.907	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 660 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	20.00	0.00
		SD	29.814	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	1
		Mean	0.00	0.00
		SD	27.217	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 661 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 662 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	11.11	0.00
		SD	19.245	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 663 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	22.22	0.00
		SD	19.245	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	0.00	16.67
		SD		23.570
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	0	2
		Mean		16.67
		SD		23.570
		Median		16.67
		Min.		0.0
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 665 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 666 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	-33.33	0.00
		SD		
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 668 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 669 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 670 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	16.67	13.64
		SD	26.197	22.204
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	18	21
		Mean	-5.56	-3.17
		SD	32.839	27.698
		Median	0.00	0.00
		Min.	-100.0	-100.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (28%)	3 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (28%)	3 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (22%)	3 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (22%)	3 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 671 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	8.33	29.63
		SD	15.430	30.932
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	9
		Mean	-4.76	18.52
		SD	23.002	29.397
		Median	0.00	33.33
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	5 (56%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	5 (56%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 672 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	30.77	39.78
		SD	28.163	30.331
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	24	29
		Mean	9.72	22.99
		SD	26.882	26.879
		Median	0.00	33.33
		Min.	-33.3	-33.3
		Max.	66.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (17%)	1 (3%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (17%)	1 (3%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	10 (42%)	17 (59%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	10 (42%)	17 (59%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	26	31
		Mean	12.82	12.90
		SD	26.795	25.353
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	14.67	20.69
		SD	25.604	28.749
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	23	27
		Mean	-2.90	8.64
		SD	33.201	30.089
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	100.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (22%)	3 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (22%)	3 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (13%)	8 (30%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (13%)	8 (30%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 675 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	22	27
		Mean	12.12	25.93
		SD	19.370	29.719
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	21	25
		Mean	1.59	13.33
		SD	22.301	30.429
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (10%)	3 (12%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (10%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (19%)	10 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (19%)	10 (40%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	11.59	12.82
		SD	19.092	19.037
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	21	25
		Mean	-6.35	2.67
		SD	27.119	28.739
		Median	0.00	0.00
		Min.	-66.7	-100.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (24%)	3 (12%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (24%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (14%)	7 (28%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (14%)	7 (28%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	10.61	17.33
		SD	18.930	23.805
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	20	25
		Mean	-6.67	2.67
		SD	29.814	31.798
		Median	0.00	0.00
		Min.	-100.0	-100.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (15%)	4 (16%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (15%)	4 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (10%)	7 (28%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (10%)	7 (28%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	13.73	21.05
		SD	23.743	31.838
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	15	19
		Mean	-2.22	3.51
		SD	15.258	15.294
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	1 (5%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	1 (5%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (7%)	3 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	3 (16%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	17	16
		Mean	19.61	18.75
		SD	23.743	27.131
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	15	16
		Mean	4.44	2.08
		SD	21.331	42.979
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	3 (19%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (27%)	4 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (27%)	4 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	20.00	23.53
		SD	21.082	36.827
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	13	17
		Mean	2.56	11.76
		SD	25.318	37.158
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	1 (6%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	1 (6%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	4 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	4 (24%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 681 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	22.92	19.44
		SD	29.107	33.207
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	14	12
		Mean	7.14	8.33
		SD	19.298	35.176
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (7%)	1 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	1 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (29%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (29%)	3 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	19.05	11.11
		SD	25.198	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	12	9
		Mean	-2.78	-3.70
		SD	22.285	30.932
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 683 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	13	12
		Mean	33.33	13.89
		SD	30.429	22.285
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	11	12
		Mean	15.15	0.00
		SD	40.452	24.618
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	1 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	24.44	3.33
		SD	34.427	10.541
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	13	10
		Mean	7.69	-6.67
		SD	33.758	21.082
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	1 (10%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	1 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 685 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	21.21	0.00
		SD	22.473	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	10	9
		Mean	0.00	-11.11
		SD	47.140	23.570
		Median	0.00	0.00
		Min.	-100.0	-66.7
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 686 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	22.22	12.12
		SD	28.868	22.473
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	8	11
		Mean	8.33	-3.03
		SD	29.547	37.873
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	2 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	2 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	2 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	27.27	3.70
		SD	38.925	11.111
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	10	9
		Mean	3.33	0.00
		SD	36.683	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 688 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	27.27	5.56
		SD	35.957	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	10	6
		Mean	6.67	0.00
		SD	37.843	21.082
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	26.67	0.00
		SD	30.631	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Change from Baseline	n	9	6
		Mean	0.00	-5.56
		SD	23.570	13.608
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 690 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	25.93	4.76
		SD	22.222	12.599
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	8	7
		Mean	0.00	0.00
		SD	30.861	19.245
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	23.33	5.56
		SD	31.623	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	9	6
		Mean	-3.70	0.00
		SD	30.932	21.082
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	19.05	5.56
		SD	26.227	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	6	6
		Mean	-5.56	-5.56
		SD	38.968	32.773
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 693 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	28.57	0.00
		SD	12.599	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	5
		Mean	11.11	0.00
		SD	27.217	0.000
		Median	16.67	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	33.33	0.00
		SD	17.817	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	7	6
		Mean	14.29	0.00
		SD	26.227	0.000
		Median	33.33	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 695 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	20.83	0.00
		SD	17.252	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	5
		Mean	0.00	0.00
		SD	29.814	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	25.00	0.00
		SD	23.570	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	7	5
		Mean	4.76	0.00
		SD	29.991	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 697 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	25.00	0.00
		SD	23.570	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	6	5
		Mean	5.56	0.00
		SD	32.773	0.000
		Median	16.67	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 698 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	14.29	11.11
		SD	17.817	27.217
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	6	6
		Mean	5.56	0.00
		SD	25.092	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	27.78	0.00
		SD	25.092	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	5	5
		Mean	13.33	0.00
		SD	29.814	0.000
		Median	33.33	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	28.57	5.56
		SD	29.991	13.608
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	6	6
		Mean	5.56	5.56
		SD	25.092	13.608
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	29.17	0.00
		SD	27.817	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	6	5
		Mean	5.56	0.00
		SD	25.092	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 702 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	5	4
		Mean	46.67	0.00
		SD	18.257	0.000
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	4
		Mean	16.67	0.00
		SD	43.033	0.000
		Median	16.67	0.00
		Min.	-33.3	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 703 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	6.67	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	5
		Mean	-16.67	0.00
		SD	33.333	0.000
		Median	0.00	0.00
		Min.	-66.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	19.05	0.00
		SD	32.530	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	5	5
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 705 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	11.11	0.00
		SD	27.217	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	5	4
		Mean	-20.00	0.00
		SD	29.814	0.000
		Median	0.00	0.00
		Min.	-66.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	25.00	0.00
		SD	31.914	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	3	4
		Mean	-11.11	0.00
		SD	50.918	0.000
		Median	0.00	0.00
		Min.	-66.7	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 707 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	46.67	0.00
		SD	29.814	0.000
		Median	66.67	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	3
		Mean	25.00	0.00
		SD	31.914	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 708 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	27.78	0.00
		SD	32.773	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	5	2
		Mean	0.00	0.00
		SD	52.705	0.000
		Median	0.00	0.00
		Min.	-66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	20.00	0.00
		SD	18.257	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	3
		Mean	0.00	0.00
		SD	27.217	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 710 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	38.89	0.00
		SD	25.092	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	2
		Mean	25.00	0.00
		SD	41.944	0.000
		Median	33.33	0.00
		Min.	-33.3	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (75%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (75%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 711 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	25.00	0.00
		SD	31.914	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	3	2
		Mean	-11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	26.67	0.00
		SD	27.889	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	3
		Mean	0.00	0.00
		SD	27.217	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	33.33	0.00
		SD	21.082	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	5	1
		Mean	13.33	0.00
		SD	29.814	
		Median	33.33	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 714 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	26.67	0.00
		SD	36.515	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	2
		Mean	0.00	0.00
		SD	54.433	0.000
		Median	0.00	0.00
		Min.	-66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 715 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	22.22	0.00
		SD	27.217	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	5	1
		Mean	-6.67	0.00
		SD	27.889	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 716 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	26.67	0.00
		SD	36.515	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 717 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	44.44	0.00
		SD	38.490	0.000
		Median	66.67	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	2
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	44.44	0.00
		SD	19.245	
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	47.140	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 719 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	33.33	0.00
		SD	33.333	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	70.711	
		Median	-16.67	0.00
		Min.	-66.7	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 720 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	66.67	16.67
		SD		23.570
		Median	66.67	16.67
		Min.	66.7	0.0
		Max.	66.7	33.3
	Change from Baseline	n	0	2
		Mean		16.67
		SD		23.570
		Median		16.67
		Min.		0.0
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 721 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	1	1
		Mean	-33.33	0.00
		SD		
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 722 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 723 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 724 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 725 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 726 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	20.37	13.64
		SD	30.548	28.469
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	18	21
		Mean	5.56	6.35
		SD	34.773	17.059
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (17%)	1 (5%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (17%)	1 (5%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (28%)	5 (24%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (28%)	5 (24%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 727 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	4.17	29.63
		SD	11.785	30.932
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	9
		Mean	-4.76	22.22
		SD	12.599	28.868
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (44%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (44%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 728 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	38.46	47.31
		SD	30.829	36.285
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	24	29
		Mean	23.61	37.93
		SD	31.819	30.504
		Median	33.33	33.33
		Min.	-33.3	0.0
		Max.	100.0	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (4%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (4%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	13 (54%)	21 (72%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	13 (54%)	21 (72%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	16.05	12.50
		SD	25.099	20.302
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 730 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	24	29
		Mean	11.11	14.94
		SD	21.234	22.863
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	23	28
		Mean	-8.70	3.57
		SD	28.810	30.550
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (26%)	5 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (26%)	5 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (13%)	7 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (13%)	7 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	4.17	8.64
		SD	11.261	21.863
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	23	26
		Mean	-11.59	-1.28
		SD	23.802	27.456
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (30%)	6 (23%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (30%)	6 (23%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (4%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (4%)	3 (12%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	4.35	11.54
		SD	11.478	24.841
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	22	26
		Mean	-9.09	-1.28
		SD	21.036	30.523
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (27%)	7 (27%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (27%)	7 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (5%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (5%)	5 (19%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 733 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	12.12	16.00
		SD	21.932	29.059
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	21	25
		Mean	-3.17	5.33
		SD	25.614	28.350
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (29%)	4 (16%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (29%)	4 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (14%)	5 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (14%)	5 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	7.84	8.77
		SD	25.082	18.732
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	16	19
		Mean	-8.33	-5.26
		SD	28.545	22.942
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (31%)	5 (26%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	5 (26%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (6%)	1 (5%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (6%)	1 (5%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	17	16
		Mean	19.61	14.58
		SD	26.507	24.248
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	16	16
		Mean	2.08	-2.08
		SD	37.454	22.669
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (31%)	3 (19%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	5 (31%)	1 (6%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	5 (31%)	1 (6%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 736 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	13.33	9.80
		SD	27.603	19.596
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	14	17
		Mean	-2.38	0.00
		SD	30.562	28.868
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	3 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	3 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (14%)	3 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (14%)	3 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 737 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	16.67	8.33
		SD	24.343	20.719
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	15	12
		Mean	-2.22	-2.78
		SD	26.627	26.432
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (27%)	3 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (27%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (13%)	1 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (13%)	1 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 738 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	11.90	11.11
		SD	24.832	23.570
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	13	9
		Mean	-5.13	0.00
		SD	32.903	33.333
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	16.67	13.89
		SD	21.681	22.285
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	13	12
		Mean	0.00	2.78
		SD	36.004	26.432
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	3 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	4 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	4 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	14	10
		Mean	9.52	6.67
		SD	20.375	14.055
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	13	10
		Mean	-7.69	-6.67
		SD	27.735	21.082
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (31%)	3 (30%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (31%)	3 (30%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (15%)	1 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (15%)	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	6.06	18.52
		SD	20.101	24.216
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	11	9
		Mean	-12.12	3.70
		SD	26.968	26.058
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 742 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	7.41	12.12
		SD	14.699	22.473
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	9	11
		Mean	-7.41	0.00
		SD	22.222	29.814
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	3 (27%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	3 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	2 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	2 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 743 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	9.09	14.81
		SD	21.556	24.216
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	11	9
		Mean	-3.03	0.00
		SD	23.355	28.868
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	10	6
		Mean	6.67	22.22
		SD	14.055	27.217
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	10	6
		Mean	-10.00	5.56
		SD	22.498	32.773
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	0.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	3.33	11.11
		SD	10.541	27.217
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	10	6
		Mean	-10.00	-5.56
		SD	22.498	38.968
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	7.41	19.05
		SD	14.699	17.817
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	9	7
		Mean	-7.41	0.00
		SD	22.222	19.245
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	6.67	22.22
		SD	14.055	17.213
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	10	6
		Mean	-10.00	5.56
		SD	22.498	25.092
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	9.52	22.22
		SD	16.265	34.427
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	6
		Mean	-4.76	11.11
		SD	29.991	34.427
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 749 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	0.00	20.00
		SD	0.000	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	66.7
	Change from Baseline	n	7	5
		Mean	-14.29	6.67
		SD	17.817	36.515
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	12.50	5.56
		SD	17.252	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	8	6
		Mean	0.00	-5.56
		SD	30.861	13.608
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	0.00	13.33
		SD	0.000	18.257
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	7	5
		Mean	-14.29	0.00
		SD	17.817	23.570
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	0.00	20.00
		SD	0.000	18.257
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	8	5
		Mean	-12.50	6.67
		SD	17.252	27.889
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	4.17	6.67
		SD	11.785	14.907
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	5
		Mean	-9.52	-6.67
		SD	25.198	27.889
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	23.81	16.67
		SD	37.090	27.889
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	7	6
		Mean	4.76	5.56
		SD	23.002	32.773
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 755 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	5.56	13.33
		SD	13.608	18.257
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	5
		Mean	-5.56	0.00
		SD	25.092	23.570
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	9.52	5.56
		SD	16.265	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	6
		Mean	-4.76	-11.11
		SD	23.002	27.217
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	7	5
		Mean	9.52	13.33
		SD	16.265	18.257
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	5
		Mean	-5.56	0.00
		SD	32.773	23.570
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	0.00	8.33
		SD	0.000	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	6	4
		Mean	-16.67	0.00
		SD	18.257	27.217
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	0.00	6.67
		SD	0.000	14.907
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	5	5
		Mean	-20.00	-6.67
		SD	18.257	14.907
		Median	-33.33	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	6	5
		Mean	5.56	13.33
		SD	13.608	18.257
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	5
		Mean	-6.67	0.00
		SD	14.907	23.570
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 761 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	22.22	16.67
		SD	17.213	19.245
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	6	4
		Mean	5.56	0.00
		SD	25.092	27.217
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	8.33	16.67
		SD	16.667	19.245
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	4	4
		Mean	-8.33	0.00
		SD	31.914	27.217
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 763 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	6.67	33.33
		SD	14.907	33.333
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	5	3
		Mean	-13.33	22.22
		SD	29.814	19.245
		Median	-33.33	33.33
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (67%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	0.00	33.33
		SD	0.000	0.000
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	0.0	33.3
	Change from Baseline	n	6	2
		Mean	-16.67	16.67
		SD	18.257	23.570
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	6.67	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	3
		Mean	-13.33	-22.22
		SD	29.814	19.245
		Median	-33.33	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	2 (67%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	5.56	0.00
		SD	13.608	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	2
		Mean	-13.33	-16.67
		SD	29.814	23.570
		Median	-33.33	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 767 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	3	2
		Mean	0.00	16.67
		SD	0.000	23.570
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	3	2
		Mean	-11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	6.67	22.22
		SD	14.907	38.490
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	5	3
		Mean	-13.33	0.00
		SD	18.257	33.333
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 769 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	0.00	33.33
		SD	0.000	
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	0.0	33.3
	Change from Baseline	n	6	1
		Mean	-16.67	0.00
		SD	18.257	
		Median	-16.67	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 770 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	6.67	16.67
		SD	14.907	23.570
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	2
		Mean	-13.33	0.00
		SD	29.814	0.000
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 771 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	5	1
		Mean	0.00	33.33
		SD	0.000	
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	0.0	33.3
	Change from Baseline	n	5	1
		Mean	-20.00	0.00
		SD	18.257	
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	5	1
		Mean	-20.00	-33.33
		SD	18.257	
		Median	-33.33	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 773 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	2
		Mean	-11.11	-16.67
		SD	19.245	23.570
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	0.00	66.67
		SD	0.000	
		Median	0.00	66.67
		Min.	0.0	66.7
		Max.	0.0	66.7
	Change from Baseline	n	3	1
		Mean	-22.22	33.33
		SD	19.245	
		Median	-33.33	33.33
		Min.	-33.3	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 775 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	11.11	33.33
		SD	19.245	
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Change from Baseline	n	3	1
		Mean	0.00	0.00
		SD	33.333	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 776 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	0.00	16.67
		SD		23.570
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	1	2
		Mean	0.00	0.00
		SD		0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 777 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	0.00	33.33
		SD	0.000	
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	0.0	33.3
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	23.570	
		Median	-16.67	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	0.00	33.33
		SD		
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	0.0	33.3
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 779 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	16.67	33.33
		SD	23.570	
		Median	16.67	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 781 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	9.26	12.12
		SD	22.304	24.224
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	18	22
		Mean	-3.70	1.52
		SD	19.433	28.129
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (11%)	4 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (11%)	4 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (6%)	5 (23%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (6%)	5 (23%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 783 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	16.67	22.22
		SD	35.635	28.868
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	7	9
		Mean	9.52	11.11
		SD	16.265	37.268
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (22%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 784 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	26.92	33.33
		SD	32.686	32.203
		Median	16.67	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	25	30
		Mean	9.33	23.33
		SD	29.690	31.744
		Median	0.00	16.67
		Min.	-66.7	-33.3
		Max.	66.7	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (8%)	1 (3%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (8%)	1 (3%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	7 (28%)	15 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	7 (28%)	15 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	26	32
		Mean	19.23	11.46
		SD	28.555	23.355
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	9.33	13.79
		SD	22.608	24.426
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	23	28
		Mean	-8.70	1.19
		SD	22.957	14.293
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (30%)	2 (7%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (30%)	2 (7%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (9%)	3 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (9%)	3 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 787 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	27
		Mean	11.11	8.64
		SD	25.380	23.738
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	22	26
		Mean	-9.09	-5.13
		SD	18.349	15.470
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (32%)	5 (19%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (32%)	5 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (5%)	1 (4%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (5%)	1 (4%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 788 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	11.59	12.82
		SD	25.837	25.081
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	21	26
		Mean	-11.11	-1.28
		SD	21.943	17.590
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (33%)	4 (15%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (33%)	4 (15%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (5%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (5%)	3 (12%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 789 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	25
		Mean	12.12	16.00
		SD	24.224	25.676
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	20	25
		Mean	-1.67	2.67
		SD	17.014	19.052
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (15%)	3 (12%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (15%)	3 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (10%)	5 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (10%)	5 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 790 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	7.84	14.04
		SD	18.743	23.083
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	16	19
		Mean	-6.25	-3.51
		SD	13.437	21.928
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (19%)	3 (16%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (19%)	3 (16%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 791 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	12.96	14.58
		SD	25.918	24.248
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	17	16
		Mean	-1.96	-4.17
		SD	24.918	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (24%)	3 (19%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (24%)	3 (19%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (12%)	1 (6%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (12%)	1 (6%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	15.56	13.73
		SD	27.794	23.743
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	14	17
		Mean	2.38	1.96
		SD	15.821	18.524
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (7%)	2 (12%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (7%)	2 (12%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (14%)	3 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (14%)	3 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 793 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	16.67	11.11
		SD	29.814	21.711
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	15	12
		Mean	2.22	-5.56
		SD	26.627	12.975
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (20%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 794 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	7.14	14.81
		SD	26.726	24.216
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	13	9
		Mean	-7.69	0.00
		SD	14.618	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	14	12
		Mean	11.90	11.11
		SD	30.959	21.711
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	13	12
		Mean	-5.13	-2.78
		SD	18.490	17.164
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (23%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (23%)	2 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	1 (8%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	1 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 796 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	17.78	16.67
		SD	35.337	23.570
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	14	10
		Mean	4.76	-3.33
		SD	25.678	18.922
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (14%)	2 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (14%)	2 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	3 (21%)	1 (10%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	3 (21%)	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 797 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	8
		Mean	15.15	16.67
		SD	27.340	25.198
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	11	8
		Mean	-3.03	0.00
		SD	23.355	25.198
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	2 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	18.52	21.21
		SD	37.680	26.968
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	9	11
		Mean	0.00	6.06
		SD	28.868	29.129
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	2 (18%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	3 (27%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	3 (27%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	18.18	22.22
		SD	34.524	23.570
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	11	9
		Mean	0.00	0.00
		SD	21.082	28.868
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 800 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	15.15	16.67
		SD	27.340	27.889
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	11	6
		Mean	-3.03	-11.11
		SD	23.355	17.213
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 801 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	10	6
		Mean	6.67	27.78
		SD	21.082	25.092
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	10	6
		Mean	-13.33	0.00
		SD	17.213	29.814
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 802 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	14.81	19.05
		SD	33.793	26.227
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	9	7
		Mean	-3.70	-4.76
		SD	20.031	23.002
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	2 (29%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	13.33	27.78
		SD	32.203	25.092
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	10	6
		Mean	-3.33	0.00
		SD	18.922	29.814
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	9.52	16.67
		SD	16.265	27.889
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	6
		Mean	-9.52	-5.56
		SD	31.706	13.608
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	14.29	20.00
		SD	26.227	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	7	5
		Mean	-4.76	-6.67
		SD	23.002	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 806 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	12.50	0.00
		SD	24.801	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	8	6
		Mean	-4.17	-22.22
		SD	21.362	27.217
		Median	0.00	-16.67
		Min.	-33.3	-66.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	3 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	12.50	20.00
		SD	35.355	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	7	5
		Mean	-4.76	-6.67
		SD	12.599	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 808 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	12.50	20.00
		SD	24.801	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	8	5
		Mean	-4.17	-6.67
		SD	21.362	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 809 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	12.50	20.00
		SD	24.801	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	7	5
		Mean	-4.76	-6.67
		SD	23.002	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 810 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	4.76	22.22
		SD	12.599	27.217
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	6
		Mean	-9.52	0.00
		SD	25.198	21.082
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	22.22	20.00
		SD	27.217	29.814
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	6	5
		Mean	5.56	-6.67
		SD	25.092	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	14.29	27.78
		SD	26.227	25.092
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	7	6
		Mean	-4.76	5.56
		SD	23.002	25.092
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	2 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	2 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 813 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	12.50	20.00
		SD	24.801	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	7	5
		Mean	-4.76	-6.67
		SD	23.002	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 814 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	11.11	33.33
		SD	27.217	27.217
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	6	4
		Mean	-11.11	8.33
		SD	17.213	16.667
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 815 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	4	5
		Mean	0.00	26.67
		SD	0.000	27.889
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	0.0	66.7
	Change from Baseline	n	4	5
		Mean	0.00	0.00
		SD	0.000	23.570
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	9.52	20.00
		SD	16.265	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	6	5
		Mean	5.56	-6.67
		SD	25.092	14.907
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (20%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 817 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	16.67	25.00
		SD	27.889	31.914
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	6	4
		Mean	-5.56	-8.33
		SD	25.092	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	0.00	25.00
		SD	0.000	31.914
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	66.7
	Change from Baseline	n	4	4
		Mean	-8.33	-8.33
		SD	16.667	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	6.67	22.22
		SD	14.907	38.490
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	5	3
		Mean	0.00	-11.11
		SD	23.570	19.245
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	11.11	33.33
		SD	17.213	47.140
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	6	2
		Mean	-11.11	-16.67
		SD	34.427	23.570
		Median	0.00	-16.67
		Min.	-66.7	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 821 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	6.67	11.11
		SD	14.907	19.245
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	3
		Mean	0.00	-11.11
		SD	23.570	19.245
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 822 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	5.56	0.00
		SD	13.608	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	2
		Mean	0.00	-16.67
		SD	23.570	23.570
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 823 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	3	2
		Mean	22.22	0.00
		SD	19.245	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	2
		Mean	11.11	-16.67
		SD	38.490	23.570
		Median	33.33	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 824 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	13.33	11.11
		SD	18.257	19.245
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	3
		Mean	6.67	-11.11
		SD	27.889	19.245
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (33%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 825 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	22.22	0.00
		SD	17.213	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	6	1
		Mean	16.67	-33.33
		SD	27.889	
		Median	33.33	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 826 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	13.33	0.00
		SD	18.257	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	2
		Mean	6.67	-16.67
		SD	27.889	23.570
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 827 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	16.67	0.00
		SD	27.889	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	6	1
		Mean	-5.56	-33.33
		SD	25.092	
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 828 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	6.67	0.00
		SD	14.907	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	1
		Mean	0.00	-33.33
		SD	23.570	
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	3	2
		Mean	-11.11	-16.67
		SD	19.245	23.570
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 830 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	3	1
		Mean	-11.11	-33.33
		SD	19.245	
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 831 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	11.11	0.00
		SD	19.245	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	1
		Mean	0.00	-33.33
		SD	33.333	
		Median	0.00	-33.33
		Min.	-33.3	-33.3
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 832 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	0.00	16.67
		SD		23.570
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	1	2
		Mean	0.00	0.00
		SD		47.140
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 833 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	-16.67	-33.33
		SD	23.570	
		Median	-16.67	-33.33
		Min.	-33.3	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 834 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	-33.33
		SD		
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 835 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	16.67	-33.33
		SD	23.570	
		Median	16.67	-33.33
		Min.	0.0	-33.3
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 837 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 838 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	22
		Mean	20.37	12.12
		SD	23.260	21.932
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	17	22
		Mean	-1.96	1.52
		SD	24.918	16.191
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (29%)	2 (9%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (29%)	2 (9%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	4 (24%)	3 (14%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	4 (24%)	3 (14%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Table 4.0000905

Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	8	9
		Mean	16.67	33.33
		SD	25.198	23.570
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	7	9
		Mean	0.00	18.52
		SD	27.217	29.397
		Median	0.00	33.33
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (11%)
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	5 (56%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	5 (56%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 840 of 840
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0000905
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	29.49	25.81
		SD	30.298	25.400
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	24	30
		Mean	11.11	14.44
		SD	28.937	18.944
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (13%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (13%)	0
	Deterioration in EORTC QLQ-C30 domain score >=5	n (%)	8 (33%)	12 (40%)
	Deterioration in EORTC QLQ-C30 domain score >=10	n (%)	8 (33%)	12 (40%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_t1_c30_dom_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 1 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	12 (40%)	17 (52%)
Censored, follow-up ended	13 (43%)	14 (42%)
Censored, follow-up ongoing	5 (17%)	2 (6%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.7 (1.0, 10.2)	1.7 (1.0, 2.8)
Median (95% CI)	10.2 (3.7, -)	3.8 (1.8, 9.3)
3rd Quartile (95% CI)	- (10.2, -)	- (6.6, -)
Log-Rank P-value [2]	0.17652	
Hazard Ratio (95% CI) [3]	0.60 (0.29, 1.26)	
P-value [3]	0.17991	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 2 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	13 (43%)	17 (52%)
Censored, follow-up ended	13 (43%)	15 (45%)
Censored, follow-up ongoing	4 (13%)	1 (3%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.7 (1.0, 5.6)	2.1 (1.1, 3.8)
Median (95% CI)	8.8 (3.7, -)	6.9 (2.8, 22.3)
3rd Quartile (95% CI)	- (13.0, -)	18.4 (6.9, -)
Log-Rank P-value [2]	0.36154	
Hazard Ratio (95% CI) [3]	0.72 (0.35, 1.48)	
P-value [3]	0.36844	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 3 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	16 (53%)	17 (52%)
Censored, follow-up ended	11 (37%)	13 (39%)
Censored, follow-up ongoing	3 (10%)	3 (9%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.0 (1.0, 3.8)	1.9 (1.1, 2.9)
Median (95% CI)	4.2 (2.6, 10.2)	3.8 (2.1, -)
3rd Quartile (95% CI)	10.2 (4.2, -)	- (6.9, -)
Log-Rank P-value [2]	0.76715	
Hazard Ratio (95% CI) [3]	1.11 (0.56, 2.22)	
P-value [3]	0.75795	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 4 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	10 (33%)	13 (39%)
Censored, follow-up ended	15 (50%)	14 (42%)
Censored, follow-up ongoing	5 (17%)	6 (18%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.6 (1.0, 8.4)	6.3 (1.7, 7.9)
Median (95% CI)	33.2 (5.6, -)	10.2 (6.7, -)
3rd Quartile (95% CI)	- (33.2, -)	- (11.2, -)
Log-Rank P-value [2]	0.79835	
Hazard Ratio (95% CI) [3]	0.90 (0.39, 2.06)	
P-value [3]	0.80252	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 5 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	18 (60%)	16 (48%)
Censored, follow-up ended	10 (33%)	13 (39%)
Censored, follow-up ongoing	2 (7%)	4 (12%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.8, 3.7)	1.7 (1.0, 6.7)
Median (95% CI)	4.7 (1.1, 7.5)	11.1 (2.1, -)
3rd Quartile (95% CI)	7.5 (4.7, -)	- (11.1, -)
Log-Rank P-value [2]	0.06210	
Hazard Ratio (95% CI) [3]	1.90 (0.96, 3.76)	
P-value [3]	0.06616	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 6 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	18 (60%)	15 (45%)
Censored, follow-up ended	10 (33%)	12 (36%)
Censored, follow-up ongoing	2 (7%)	6 (18%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.9 (1.0, 3.6)	1.8 (1.0, 2.9)
Median (95% CI)	3.7 (1.9, 5.6)	6.5 (1.8, -)
3rd Quartile (95% CI)	11.3 (3.8, -)	- (11.2, -)
Log-Rank P-value [2]	0.23945	
Hazard Ratio (95% CI) [3]	1.50 (0.75, 2.99)	
P-value [3]	0.24727	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 7 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	16 (53%)	20 (61%)
Censored, follow-up ended	12 (40%)	11 (33%)
Censored, follow-up ongoing	2 (7%)	2 (6%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.8, 3.8)	1.1 (1.0, 1.7)
Median (95% CI)	3.8 (1.1, 9.3)	2.8 (1.1, 7.4)
3rd Quartile (95% CI)	9.3 (5.6, -)	7.4 (4.9, -)
Log-Rank P-value [2]	0.67532	
Hazard Ratio (95% CI) [3]	0.88 (0.45, 1.69)	
P-value [3]	0.69318	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 8 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	12 (40%)	14 (42%)
Censored, follow-up ended	14 (47%)	15 (45%)
Censored, follow-up ongoing	4 (13%)	4 (12%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.9 (1.0, 11.0)	3.7 (1.0, 9.3)
Median (95% CI)	11.0 (3.8, -)	12.5 (4.5, -)
3rd Quartile (95% CI)	- (11.0, -)	43.7 (12.5, -)
Log-Rank P-value [2]	0.89394	
Hazard Ratio (95% CI) [3]	1.06 (0.48, 2.33)	
P-value [3]	0.88938	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 9 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	13 (43%)	15 (45%)
Censored, follow-up ended	13 (43%)	15 (45%)
Censored, follow-up ongoing	4 (13%)	3 (9%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.7 (1.0, 4.7)	3.8 (1.7, 6.9)
Median (95% CI)	4.8 (3.7, -)	7.9 (4.7, -)
3rd Quartile (95% CI)	- (5.7, -)	- (11.1, -)
Log-Rank P-value [2]	0.55012	
Hazard Ratio (95% CI) [3]	1.26 (0.60, 2.64)	
P-value [3]	0.54848	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 10 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	14 (47%)	14 (42%)
Censored, follow-up ended	14 (47%)	16 (48%)
Censored, follow-up ongoing	2 (7%)	3 (9%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.0 (1.0, 3.8)	3.3 (1.1, 6.9)
Median (95% CI)	9.4 (2.8, -)	8.3 (3.7, -)
3rd Quartile (95% CI)	35.1 (9.4, -)	- (8.3, -)
Log-Rank P-value [2]	0.70562	
Hazard Ratio (95% CI) [3]	1.15 (0.55, 2.43)	
P-value [3]	0.70938	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 11 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	12 (40%)	19 (58%)
Censored, follow-up ended	13 (43%)	12 (36%)
Censored, follow-up ongoing	5 (17%)	2 (6%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.7 (0.9, 8.3)	1.8 (1.1, 3.8)
Median (95% CI)	8.3 (4.2, -)	4.7 (2.8, 12.5)
3rd Quartile (95% CI)	- (29.9, -)	43.7 (4.9, -)
Log-Rank P-value [2]	0.16677	
Hazard Ratio (95% CI) [3]	0.60 (0.29, 1.24)	
P-value [3]	0.16482	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 12 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	10 (33%)	17 (52%)
Censored, follow-up ended	14 (47%)	14 (42%)
Censored, follow-up ongoing	6 (20%)	2 (6%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.7 (1.0, 14.3)	3.7 (1.1, 5.7)
Median (95% CI)	14.3 (4.7, -)	6.6 (3.8, -)
3rd Quartile (95% CI)	- (14.3, -)	22.3 (6.7, -)
Log-Rank P-value [2]	0.06234	
Hazard Ratio (95% CI) [3]	0.47 (0.20, 1.06)	
P-value [3]	0.06858	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	13 (43%)	21 (64%)
Censored, follow-up ended	12 (40%)	11 (33%)
Censored, follow-up ongoing	5 (17%)	1 (3%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.9 (1.0, 7.4)	1.1 (1.0, 1.9)
Median (95% CI)	8.8 (2.9, -)	3.0 (1.1, 6.9)
3rd Quartile (95% CI)	- (8.8, -)	12.5 (3.8, -)
Log-Rank P-value [2]	0.09027	
Hazard Ratio (95% CI) [3]	0.55 (0.28, 1.11)	
P-value [3]	0.09478	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 14 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	7 (23%)	15 (45%)
Censored, follow-up ended	17 (57%)	13 (39%)
Censored, follow-up ongoing	6 (20%)	5 (15%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.6 (1.0, -)	1.9 (1.0, 6.9)
Median (95% CI)	- (5.6, -)	8.7 (1.9, -)
3rd Quartile (95% CI)	- (-, -)	- (9.2, -)
Log-Rank P-value [2]	0.08828	
Hazard Ratio (95% CI) [3]	0.47 (0.19, 1.14)	
P-value [3]	0.09531	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 15 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001005

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	8 (27%)	12 (36%)
Censored, follow-up ended	17 (57%)	14 (42%)
Censored, follow-up ongoing	5 (17%)	7 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	21.3 (1.0, 24.3)	4.9 (1.0, 11.1)
Median (95% CI)	24.3 (21.3, -)	11.2 (4.9, -)
3rd Quartile (95% CI)	- (22.2, -)	- (11.2, -)
Log-Rank P-value [2]	0.32819	
Hazard Ratio (95% CI) [3]	0.64 (0.26, 1.58)	
P-value [3]	0.33608	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_ttd_2ref.sas 09OCT2025 10:04

Protocol: 207499 Page 1 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	6 (55%)	4 (57%)
	Censored, follow-up ended	4 (36%)	3 (43%)
	Censored, follow-up ongoing	1 (9%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.7)	2.0 (1.0, 3.8)
	Median (95% CI)	3.7 (1.0, -)	3.3 (1.0, -)
	3rd Quartile (95% CI)	10.2 (3.7, -)	- (2.0, -)
	Log-Rank P-value [2]	0.99130	
	Hazard Ratio (95% CI) [3]	0.99 (0.28, 3.54)	
	P-value [3]	0.99129	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	4 (27%)	6 (40%)
	Censored, follow-up ended	7 (47%)	7 (47%)
	Censored, follow-up ongoing	4 (27%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.6 (1.9, -)	1.8 (1.0, -)
	Median (95% CI)	- (3.8, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (10.2, -)	- (3.8, -)
	Log-Rank P-value [2]	0.24614	
	Hazard Ratio (95% CI) [3]	0.47 (0.13, 1.71)	
	P-value [3]	0.25251	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (50%)	7 (64%)
	Censored, follow-up ended	2 (50%)	4 (36%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (2.0, -)	1.1 (0.8, 6.6)
	Median (95% CI)	11.8 (2.0, -)	6.6 (0.8, 9.3)
	3rd Quartile (95% CI)	11.8 (2.0, -)	9.3 (1.7, -)
	Log-Rank P-value [2]	0.55171	
	Hazard Ratio (95% CI) [3]	0.62 (0.13, 3.05)	
	P-value [3]	0.55522	
Interaction Test	P-value [4]	0.73557	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 4 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	5 (45%)	5 (71%)
	Censored, follow-up ended	5 (45%)	2 (29%)
	Censored, follow-up ongoing	1 (9%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 8.8)	2.1 (1.1, 12.5)
	Median (95% CI)	8.8 (1.0, -)	7.6 (1.1, -)
	3rd Quartile (95% CI)	- (5.6, -)	15.4 (2.1, -)
	Log-Rank P-value [2]	0.45806	
	Hazard Ratio (95% CI) [3]	0.63 (0.18, 2.18)	
	P-value [3]	0.46202	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 5 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	7 (47%)	7 (47%)
	Censored, follow-up ended	6 (40%)	7 (47%)
	Censored, follow-up ongoing	2 (13%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.3 (1.0, 5.6)	1.1 (0.7, 3.8)
	Median (95% CI)	5.6 (1.0, -)	3.8 (1.1, -)
	3rd Quartile (95% CI)	- (5.6, -)	- (3.7, -)
	Log-Rank P-value [2]	0.80196	
	Hazard Ratio (95% CI) [3]	0.87 (0.30, 2.51)	
	P-value [3]	0.79424	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	1 (25%)	5 (45%)
	Censored, follow-up ended	2 (50%)	6 (55%)
	Censored, follow-up ongoing	1 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	13.0 (13.0, -)	4.7 (1.1, 22.3)
	Median (95% CI)	- (13.0, -)	6.9 (1.1, -)
	3rd Quartile (95% CI)	- (13.0, -)	22.3 (4.7, -)
	Log-Rank P-value [2]	0.35325	
	Hazard Ratio (95% CI) [3]	0.37 (0.04, 3.25)	
	P-value [3]	0.37147	
Interaction Test	P-value [4]	0.86641	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 7 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	6 (55%)	4 (57%)
	Censored, follow-up ended	4 (36%)	3 (43%)
	Censored, follow-up ongoing	1 (9%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 6.5)	2.8 (2.1, 12.5)
	Median (95% CI)	6.5 (1.0, -)	6.6 (2.1, -)
	3rd Quartile (95% CI)	10.2 (5.6, -)	12.5 (2.8, -)
	Log-Rank P-value [2]	0.68983	
	Hazard Ratio (95% CI) [3]	1.30 (0.36, 4.67)	
	P-value [3]	0.69060	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 8 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (53%)	8 (53%)
	Censored, follow-up ended	5 (33%)	5 (33%)
	Censored, follow-up ongoing	2 (13%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 3.8)	1.1 (0.9, 3.7)
	Median (95% CI)	3.8 (1.9, -)	3.7 (1.1, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (2.8, -)
	Log-Rank P-value [2]	0.84904	
	Hazard Ratio (95% CI) [3]	0.92 (0.34, 2.45)	
	P-value [3]	0.86308	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -

Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (50%)	5 (45%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	0	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.6 (2.6, -)	1.9 (1.1, 6.9)
	Median (95% CI)	2.9 (2.6, -)	6.9 (1.1, -)
	3rd Quartile (95% CI)	- (2.6, -)	- (2.9, -)
	Log-Rank P-value [2]	0.74730	
	Hazard Ratio (95% CI) [3]	1.35 (0.25, 7.45)	
	P-value [3]	0.72697	
Interaction Test	P-value [4]	0.87932	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 10 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	3 (27%)	5 (71%)
	Censored, follow-up ended	6 (55%)	1 (14%)
	Censored, follow-up ongoing	2 (18%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, -)	6.3 (0.9, 10.2)
	Median (95% CI)	- (1.0, -)	6.7 (0.9, -)
	3rd Quartile (95% CI)	- (5.6, -)	10.2 (6.3, -)
	Log-Rank P-value [2]	0.17132	
	Hazard Ratio (95% CI) [3]	0.38 (0.09, 1.61)	
	P-value [3]	0.18731	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	5 (33%)	5 (33%)
	Censored, follow-up ended	7 (47%)	7 (47%)
	Censored, follow-up ongoing	3 (20%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 8.4)	3.8 (1.0, 7.9)
	Median (95% CI)	8.4 (3.7, -)	7.9 (3.7, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (6.9, -)
	Log-Rank P-value [2]	0.93184	
	Hazard Ratio (95% CI) [3]	1.06 (0.30, 3.67)	
	P-value [3]	0.93182	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (50%)	3 (27%)
	Censored, follow-up ended	2 (50%)	6 (55%)
	Censored, follow-up ongoing	0	2 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.9, -)	11.2 (1.7, -)
	Median (95% CI)	33.2 (1.9, -)	- (1.7, -)
	3rd Quartile (95% CI)	33.2 (1.9, -)	- (11.2, -)
	Log-Rank P-value [2]	0.48566	
	Hazard Ratio (95% CI) [3]	1.90 (0.31, 11.49)	
	P-value [3]	0.48504	
Interaction Test	P-value [4]	0.27114	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	7 (64%)	3 (43%)
	Censored, follow-up ended	4 (36%)	3 (43%)
	Censored, follow-up ongoing	0	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 3.7)	6.7 (0.9, 20.3)
	Median (95% CI)	3.7 (1.0, -)	20.3 (0.9, -)
	3rd Quartile (95% CI)	7.4 (2.8, -)	- (6.7, -)
	Log-Rank P-value [2]	0.11011	
	Hazard Ratio (95% CI) [3]	3.45 (0.69, 17.16)	
	P-value [3]	0.13033	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 14 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	9 (60%)	8 (53%)
	Censored, follow-up ended	4 (27%)	5 (33%)
	Censored, follow-up ongoing	2 (13%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 7.4)	1.1 (0.9, 8.7)
	Median (95% CI)	7.4 (1.0, 23.3)	8.7 (1.1, -)
	3rd Quartile (95% CI)	23.3 (4.7, -)	- (6.5, -)
	Log-Rank P-value [2]	0.37591	
	Hazard Ratio (95% CI) [3]	1.53 (0.59, 4.00)	
	P-value [3]	0.38595	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (50%)	5 (45%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	0	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.1, -)	1.7 (1.0, 11.2)
	Median (95% CI)	1.1 (1.1, -)	11.2 (1.0, -)
	3rd Quartile (95% CI)	- (1.1, -)	- (2.1, -)
	Log-Rank P-value [2]	0.51575	
	Hazard Ratio (95% CI) [3]	1.82 (0.32, 10.21)	
	P-value [3]	0.49806	
Interaction Test	P-value [4]	0.73579	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	7 (64%)	2 (29%)
	Censored, follow-up ended	4 (36%)	3 (43%)
	Censored, follow-up ongoing	0	2 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 5.6)	3.7 (1.0, -)
	Median (95% CI)	5.6 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	11.8 (2.8, -)	- (3.7, -)
	Log-Rank P-value [2]	0.15370	
	Hazard Ratio (95% CI) [3]	3.04 (0.61, 15.03)	
	P-value [3]	0.17288	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	9 (60%)	8 (53%)
	Censored, follow-up ended	4 (27%)	5 (33%)
	Censored, follow-up ongoing	2 (13%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 3.7)	1.8 (1.0, 2.0)
	Median (95% CI)	3.8 (1.0, 11.3)	2.0 (1.1, -)
	3rd Quartile (95% CI)	11.3 (3.7, -)	- (1.9, -)
	Log-Rank P-value [2]	0.95262	
	Hazard Ratio (95% CI) [3]	1.02 (0.39, 2.66)	
	P-value [3]	0.96513	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (50%)	5 (45%)
	Censored, follow-up ended	2 (50%)	4 (36%)
	Censored, follow-up ongoing	0	2 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.1, -)	1.7 (1.0, 11.2)
	Median (95% CI)	1.9 (1.1, -)	11.2 (1.0, -)
	3rd Quartile (95% CI)	- (1.1, -)	- (2.9, -)
	Log-Rank P-value [2]	0.51381	
	Hazard Ratio (95% CI) [3]	1.75 (0.32, 9.70)	
	P-value [3]	0.51918	
Interaction Test	P-value [4]	0.52259	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 19 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	6 (55%)	5 (71%)
	Censored, follow-up ended	5 (45%)	2 (29%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 5.6)	1.1 (1.0, 4.9)
	Median (95% CI)	5.6 (1.0, -)	3.4 (1.0, -)
	3rd Quartile (95% CI)	9.3 (5.6, -)	7.4 (1.1, -)
	Log-Rank P-value [2]	0.55665	
	Hazard Ratio (95% CI) [3]	0.70 (0.21, 2.30)	
	P-value [3]	0.55745	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 20 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (53%)	8 (53%)
	Censored, follow-up ended	5 (33%)	5 (33%)
	Censored, follow-up ongoing	2 (13%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 3.8)	1.1 (0.9, 2.8)
	Median (95% CI)	3.8 (1.0, -)	3.8 (1.0, -)
	3rd Quartile (95% CI)	9.3 (3.8, -)	- (3.8, -)
	Log-Rank P-value [2]	0.68471	
	Hazard Ratio (95% CI) [3]	1.21 (0.45, 3.23)	
	P-value [3]	0.70078	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (50%)	7 (64%)
	Censored, follow-up ended	2 (50%)	4 (36%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.1, -)	1.1 (1.0, 1.7)
	Median (95% CI)	3.8 (1.1, -)	1.7 (1.0, 6.9)
	3rd Quartile (95% CI)	- (1.1, -)	6.9 (1.1, -)
	Log-Rank P-value [2]	0.75772	
	Hazard Ratio (95% CI) [3]	0.79 (0.16, 3.95)	
	P-value [3]	0.77412	
Interaction Test	P-value [4]	0.78974	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 22 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	5 (45%)	3 (43%)
	Censored, follow-up ended	5 (45%)	3 (43%)
	Censored, follow-up ongoing	1 (9%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.6 (2.0, 11.5)	12.5 (0.7, 18.4)
	Median (95% CI)	6.5 (2.0, -)	18.4 (0.7, -)
	3rd Quartile (95% CI)	11.5 (4.4, -)	- (12.5, -)
	Log-Rank P-value [2]	0.16462	
	Hazard Ratio (95% CI) [3]	4.13 (0.47, 35.94)	
	P-value [3]	0.19873	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 23 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (40%)	6 (40%)
	Censored, follow-up ended	7 (47%)	7 (47%)
	Censored, follow-up ongoing	2 (13%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.4 (1.0, 11.0)	2.8 (1.0, 8.7)
	Median (95% CI)	11.0 (1.0, -)	8.7 (1.1, -)
	3rd Quartile (95% CI)	- (11.0, -)	- (8.7, -)
	Log-Rank P-value [2]	0.90415	
	Hazard Ratio (95% CI) [3]	1.07 (0.35, 3.33)	
	P-value [3]	0.90360	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	1 (25%)	5 (45%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	1 (25%)	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	28.4 (28.4, -)	5.7 (1.9, 9.3)
	Median (95% CI)	- (28.4, -)	9.3 (1.9, -)
	3rd Quartile (95% CI)	- (28.4, -)	43.7 (5.7, -)
	Log-Rank P-value [2]	0.35396	
	Hazard Ratio (95% CI) [3]	0.35 (0.04, 3.45)	
	P-value [3]	0.37030	
Interaction Test	P-value [4]	0.44956	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 25 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	4 (36%)	3 (43%)
	Censored, follow-up ended	6 (55%)	3 (43%)
	Censored, follow-up ongoing	1 (9%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, -)	4.9 (2.1, -)
	Median (95% CI)	4.7 (1.0, -)	- (2.1, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (4.9, -)
	Log-Rank P-value [2]	0.73508	
	Hazard Ratio (95% CI) [3]	1.30 (0.28, 5.95)	
	P-value [3]	0.73574	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 26 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (53%)	6 (40%)
	Censored, follow-up ended	5 (33%)	7 (47%)
	Censored, follow-up ongoing	2 (13%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, 4.8)	3.8 (1.1, 11.1)
	Median (95% CI)	4.8 (1.0, 10.2)	11.1 (3.7, -)
	3rd Quartile (95% CI)	10.2 (4.2, -)	- (7.9, -)
	Log-Rank P-value [2]	0.23654	
	Hazard Ratio (95% CI) [3]	1.88 (0.65, 5.48)	
	P-value [3]	0.24520	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	1 (25%)	6 (55%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	1 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.1, -)	4.7 (1.7, 6.9)
	Median (95% CI)	- (1.1, -)	5.1 (1.7, 22.3)
	3rd Quartile (95% CI)	- (1.1, -)	22.3 (4.7, -)
	Log-Rank P-value [2]	0.46985	
	Hazard Ratio (95% CI) [3]	0.46 (0.06, 3.90)	
	P-value [3]	0.48035	
Interaction Test	P-value [4]	0.51383	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 28 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	7 (64%)	3 (43%)
	Censored, follow-up ended	4 (36%)	3 (43%)
	Censored, follow-up ongoing	0	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 3.7)	2.1 (1.9, -)
	Median (95% CI)	2.9 (1.0, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (2.0, -)	- (2.1, -)
	Log-Rank P-value [2]	0.38250	
	Hazard Ratio (95% CI) [3]	1.80 (0.46, 6.99)	
	P-value [3]	0.39458	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 29 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (40%)	7 (47%)
	Censored, follow-up ended	8 (53%)	7 (47%)
	Censored, follow-up ongoing	1 (7%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.2 (1.0, 9.4)	3.5 (1.1, 8.3)
	Median (95% CI)	9.4 (1.0, -)	8.3 (2.8, -)
	3rd Quartile (95% CI)	- (9.4, -)	8.4 (6.9, -)
	Log-Rank P-value [2]	0.63806	
	Hazard Ratio (95% CI) [3]	0.77 (0.25, 2.34)	
	P-value [3]	0.64112	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	1 (25%)	4 (36%)
	Censored, follow-up ended	2 (50%)	6 (55%)
	Censored, follow-up ongoing	1 (25%)	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	35.1 (35.1, -)	6.9 (1.0, 22.3)
	Median (95% CI)	- (35.1, -)	22.3 (1.0, -)
	3rd Quartile (95% CI)	- (35.1, -)	- (22.3, -)
	Log-Rank P-value [2]	0.35826	
	Hazard Ratio (95% CI) [3]	0.35 (0.04, 3.51)	
	P-value [3]	0.37359	
Interaction Test	P-value [4]	0.40047	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	6 (55%)	6 (86%)
	Censored, follow-up ended	5 (45%)	1 (14%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.9, 8.3)	1.1 (0.7, 4.9)
	Median (95% CI)	7.0 (1.9, -)	4.4 (0.7, -)
	3rd Quartile (95% CI)	40.6 (3.7, -)	7.4 (1.1, -)
	Log-Rank P-value [2]	0.22171	
	Hazard Ratio (95% CI) [3]	0.48 (0.15, 1.60)	
	P-value [3]	0.23148	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (40%)	8 (53%)
	Censored, follow-up ended	6 (40%)	6 (40%)
	Censored, follow-up ongoing	3 (20%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.6 (0.9, 29.9)	1.8 (1.0, 4.7)
	Median (95% CI)	29.9 (1.0, -)	4.7 (1.1, -)
	3rd Quartile (95% CI)	- (6.9, -)	- (3.8, -)
	Log-Rank P-value [2]	0.44477	
	Hazard Ratio (95% CI) [3]	0.64 (0.22, 1.91)	
	P-value [3]	0.42801	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	0	5 (45%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	2 (50%)	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (-, -)	2.9 (1.1, -)
	Median (95% CI)	- (-, -)	43.7 (1.1, -)
	3rd Quartile (95% CI)	- (-, -)	43.7 (3.7, -)
	Log-Rank P-value [2]	0.10906	
	Hazard Ratio (95% CI) [3]	0.17 (0.00, 1.58)	
	P-value [3]	0.28356	
Interaction Test	P-value [4]	0.67284	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	4 (36%)	4 (57%)
	Censored, follow-up ended	5 (45%)	3 (43%)
	Censored, follow-up ongoing	2 (18%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.6 (1.0, 10.2)	6.6 (3.8, 8.3)
	Median (95% CI)	10.2 (1.0, -)	6.7 (3.8, -)
	3rd Quartile (95% CI)	- (4.6, -)	8.3 (6.6, -)
	Log-Rank P-value [2]	0.70964	
	Hazard Ratio (95% CI) [3]	0.77 (0.19, 3.13)	
	P-value [3]	0.71039	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 35 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	5 (33%)	6 (40%)
	Censored, follow-up ended	7 (47%)	7 (47%)
	Censored, follow-up ongoing	3 (20%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (1.0, 14.3)	3.0 (1.0, 6.0)
	Median (95% CI)	14.3 (4.2, -)	6.0 (1.1, -)
	3rd Quartile (95% CI)	- (10.3, -)	- (4.5, -)
	Log-Rank P-value [2]	0.44193	
	Hazard Ratio (95% CI) [3]	0.63 (0.19, 2.09)	
	P-value [3]	0.44578	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	1 (25%)	7 (64%)
	Censored, follow-up ended	2 (50%)	4 (36%)
	Censored, follow-up ongoing	1 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	39.7 (39.7, -)	2.9 (1.9, 5.7)
	Median (95% CI)	- (39.7, -)	5.7 (1.9, -)
	3rd Quartile (95% CI)	- (39.7, -)	22.3 (5.6, -)
	Log-Rank P-value [2]	0.02986	
	Hazard Ratio (95% CI) [3]	0.00 (0.00, -)	
	P-value [3]	0.99600	
Interaction Test	P-value [4]	0.50200	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 37 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	6 (55%)	4 (57%)
	Censored, follow-up ended	4 (36%)	3 (43%)
	Censored, follow-up ongoing	1 (9%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 8.8)	1.1 (0.7, 12.5)
	Median (95% CI)	7.4 (1.0, -)	7.7 (0.7, -)
	3rd Quartile (95% CI)	8.8 (1.9, -)	- (1.1, -)
	Log-Rank P-value [2]	0.54524	
	Hazard Ratio (95% CI) [3]	1.54 (0.38, 6.33)	
	P-value [3]	0.54807	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (40%)	8 (53%)
	Censored, follow-up ended	6 (40%)	6 (40%)
	Censored, follow-up ongoing	3 (20%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.0 (1.1, 11.1)	1.9 (1.0, 2.3)
	Median (95% CI)	11.1 (1.9, -)	3.7 (1.1, -)
	3rd Quartile (95% CI)	- (5.8, -)	- (2.3, -)
	Log-Rank P-value [2]	0.27140	
	Hazard Ratio (95% CI) [3]	0.55 (0.19, 1.60)	
	P-value [3]	0.27191	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	1 (25%)	9 (82%)
	Censored, follow-up ended	2 (50%)	2 (18%)
	Censored, follow-up ongoing	1 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (2.9, -)	1.1 (1.0, 1.9)
	Median (95% CI)	- (2.9, -)	1.9 (1.0, 6.9)
	3rd Quartile (95% CI)	- (2.9, -)	5.7 (1.7, -)
	Log-Rank P-value [2]	0.09083	
	Hazard Ratio (95% CI) [3]	0.20 (0.02, 1.58)	
	P-value [3]	0.12710	
Interaction Test	P-value [4]	0.26831	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 40 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	2 (18%)	3 (43%)
	Censored, follow-up ended	8 (73%)	3 (43%)
	Censored, follow-up ongoing	1 (9%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.1, -)	1.1 (1.0, -)
	Median (95% CI)	- (1.1, -)	16.6 (1.0, -)
	3rd Quartile (95% CI)	- (-, -)	- (1.1, -)
	Log-Rank P-value [2]	0.29320	
	Hazard Ratio (95% CI) [3]	0.39 (0.06, 2.39)	
	P-value [3]	0.30984	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	5 (33%)	8 (53%)
	Censored, follow-up ended	7 (47%)	5 (33%)
	Censored, follow-up ongoing	3 (20%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.0 (1.0, 23.3)	1.9 (0.9, 8.7)
	Median (95% CI)	23.3 (1.1, -)	8.7 (1.4, -)
	3rd Quartile (95% CI)	- (23.3, -)	- (6.9, -)
	Log-Rank P-value [2]	0.43079	
	Hazard Ratio (95% CI) [3]	0.64 (0.21, 1.97)	
	P-value [3]	0.43450	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	0	4 (36%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	2 (50%)	2 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (-, -)	1.9 (1.0, -)
	Median (95% CI)	- (-, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (-, -)	- (3.7, -)
	Log-Rank P-value [2]	0.20119	
	Hazard Ratio (95% CI) [3]	0.27 (0.00, 2.56)	
	P-value [3]	0.43472	
Interaction Test	P-value [4]	0.70607	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 43 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	5 (45%)	3 (43%)
	Censored, follow-up ended	6 (55%)	2 (29%)
	Censored, follow-up ongoing	0	2 (29%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 44 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	2 (13%)	6 (40%)
	Censored, follow-up ended	9 (60%)	6 (40%)
	Censored, follow-up ongoing	4 (27%)	3 (20%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 45 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001015
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	1 (25%)	3 (27%)
	Censored, follow-up ended	2 (50%)	6 (55%)
	Censored, follow-up ongoing	1 (25%)	2 (18%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_age.sas 09OCT2025 10:05

Protocol: 207499 Page 1 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	7 (44%)
	Censored, follow-up ended	7 (54%)	8 (50%)
	Censored, follow-up ongoing	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.6 (1.9, 11.8)	1.1 (0.8, 6.6)
	Median (95% CI)	10.2 (2.0, -)	6.6 (1.1, -)
	3rd Quartile (95% CI)	11.8 (10.2, -)	- (6.6, -)
	Log-Rank P-value [2]	0.40977	
	Hazard Ratio (95% CI) [3]	0.61 (0.19, 1.95)	
	P-value [3]	0.40814	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	7 (41%)	10 (59%)
	Censored, follow-up ended	6 (35%)	6 (35%)
	Censored, follow-up ongoing	4 (24%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 10.2)	1.7 (1.0, 2.1)
	Median (95% CI)	10.2 (1.9, -)	2.8 (1.1, -)
	3rd Quartile (95% CI)	- (10.2, -)	- (2.8, -)
	Log-Rank P-value [2]	0.27478	
	Hazard Ratio (95% CI) [3]	0.59 (0.22, 1.55)	
	P-value [3]	0.28142	
Interaction Test	P-value [4]	0.84519	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 3 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	4 (31%)	8 (50%)
	Censored, follow-up ended	8 (62%)	8 (50%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.6 (1.0, -)	3.3 (1.1, 4.7)
	Median (95% CI)	- (2.9, -)	4.7 (2.1, -)
	3rd Quartile (95% CI)	- (13.0, -)	6.9 (4.7, -)
	Log-Rank P-value [2]	0.16917	
	Hazard Ratio (95% CI) [3]	0.43 (0.12, 1.48)	
	P-value [3]	0.17820	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 4 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	9 (53%)	9 (53%)
	Censored, follow-up ended	5 (29%)	7 (41%)
	Censored, follow-up ongoing	3 (18%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 5.6)	1.1 (0.7, 3.7)
	Median (95% CI)	5.6 (1.0, 14.3)	12.5 (1.1, -)
	3rd Quartile (95% CI)	14.3 (5.6, -)	18.4 (12.5, -)
	Log-Rank P-value [2]	0.97311	
	Hazard Ratio (95% CI) [3]	1.02 (0.40, 2.58)	
	P-value [3]	0.96347	
Interaction Test	P-value [4]	0.29336	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 5 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	7 (44%)
	Censored, follow-up ended	7 (54%)	7 (44%)
	Censored, follow-up ongoing	0	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (2.0, 6.5)	2.8 (1.1, 6.9)
	Median (95% CI)	6.5 (2.6, -)	6.9 (1.9, -)
	3rd Quartile (95% CI)	- (5.6, -)	- (3.8, -)
	Log-Rank P-value [2]	0.99255	
	Hazard Ratio (95% CI) [3]	1.00 (0.33, 3.00)	
	P-value [3]	0.99848	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	10 (59%)	10 (59%)
	Censored, follow-up ended	4 (24%)	6 (35%)
	Censored, follow-up ongoing	3 (18%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.8)	1.7 (0.9, 2.8)
	Median (95% CI)	3.8 (1.9, 10.2)	3.7 (1.1, -)
	3rd Quartile (95% CI)	10.2 (3.8, -)	12.5 (3.7, -)
	Log-Rank P-value [2]	0.88765	
	Hazard Ratio (95% CI) [3]	1.08 (0.45, 2.60)	
	P-value [3]	0.86457	
Interaction Test	P-value [4]	0.98507	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 7 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	4 (31%)	6 (38%)
	Censored, follow-up ended	8 (62%)	7 (44%)
	Censored, follow-up ongoing	1 (8%)	3 (19%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	7.4 (1.9, -)	3.8 (0.9, 6.9)
	Median (95% CI)	33.2 (1.9, -)	6.9 (1.9, -)
	3rd Quartile (95% CI)	33.2 (7.4, -)	- (6.3, -)
	Log-Rank P-value [2]	0.63473	
	Hazard Ratio (95% CI) [3]	0.74 (0.20, 2.64)	
	P-value [3]	0.63825	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	6 (35%)	7 (41%)
	Censored, follow-up ended	7 (41%)	7 (41%)
	Censored, follow-up ongoing	4 (24%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 8.4)	7.9 (1.7, 11.2)
	Median (95% CI)	8.4 (3.7, -)	11.2 (6.7, -)
	3rd Quartile (95% CI)	- (5.6, -)	18.4 (10.2, -)
	Log-Rank P-value [2]	0.95594	
	Hazard Ratio (95% CI) [3]	1.04 (0.35, 3.12)	
	P-value [3]	0.94770	
Interaction Test	P-value [4]	0.71873	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 9 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	8 (62%)	8 (50%)
	Censored, follow-up ended	4 (31%)	6 (38%)
	Censored, follow-up ongoing	1 (8%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.8, 7.4)	1.0 (0.9, 1.8)
	Median (95% CI)	7.4 (0.8, 7.5)	5.3 (1.0, -)
	3rd Quartile (95% CI)	7.5 (7.4, -)	- (1.8, -)
	Log-Rank P-value [2]	0.48821	
	Hazard Ratio (95% CI) [3]	1.44 (0.52, 4.01)	
	P-value [3]	0.48727	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Table 4.0001025

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	10 (59%)	8 (47%)
	Censored, follow-up ended	6 (35%)	7 (41%)
	Censored, follow-up ongoing	1 (6%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 3.8)	6.5 (0.9, 11.2)
	Median (95% CI)	3.8 (1.0, 23.3)	11.2 (6.5, -)
	3rd Quartile (95% CI)	23.3 (3.7, -)	- (11.1, -)
	Log-Rank P-value [2]	0.16109	
	Hazard Ratio (95% CI) [3]	2.00 (0.75, 5.30)	
	P-value [3]	0.16421	
Interaction Test	P-value [4]	0.67522	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 11 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	9 (69%)	6 (38%)
	Censored, follow-up ended	4 (31%)	7 (44%)
	Censored, follow-up ongoing	0	3 (19%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.7)	1.1 (1.0, -)
	Median (95% CI)	3.7 (1.1, -)	- (1.1, -)
	3rd Quartile (95% CI)	11.3 (3.6, -)	- (-, -)
	Log-Rank P-value [2]	0.23492	
	Hazard Ratio (95% CI) [3]	1.85 (0.65, 5.27)	
	P-value [3]	0.25272	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 12 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	9 (53%)	9 (53%)
	Censored, follow-up ended	6 (35%)	5 (29%)
	Censored, follow-up ongoing	2 (12%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.8)	1.8 (1.0, 3.7)
	Median (95% CI)	3.8 (1.0, -)	6.5 (1.7, -)
	3rd Quartile (95% CI)	5.6 (3.8, -)	- (6.5, -)
	Log-Rank P-value [2]	0.59358	
	Hazard Ratio (95% CI) [3]	1.29 (0.51, 3.27)	
	P-value [3]	0.59080	
Interaction Test	P-value [4]	0.62614	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 13 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	7 (54%)	9 (56%)
	Censored, follow-up ended	6 (46%)	6 (38%)
	Censored, follow-up ongoing	0	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.8, 3.8)	1.1 (1.0, 4.9)
	Median (95% CI)	3.8 (1.0, -)	4.9 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	7.4 (4.9, -)
	Log-Rank P-value [2]	0.83107	
	Hazard Ratio (95% CI) [3]	1.10 (0.41, 2.96)	
	P-value [3]	0.85306	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 14 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	9 (53%)	11 (65%)
	Censored, follow-up ended	6 (35%)	5 (29%)
	Censored, follow-up ongoing	2 (12%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 5.6)	1.1 (0.9, 1.8)
	Median (95% CI)	5.6 (1.0, -)	1.9 (1.0, -)
	3rd Quartile (95% CI)	9.3 (5.6, -)	- (1.8, -)
	Log-Rank P-value [2]	0.43052	
	Hazard Ratio (95% CI) [3]	0.71 (0.29, 1.75)	
	P-value [3]	0.46181	
Interaction Test	P-value [4]	0.49212	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 15 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	4 (31%)	9 (56%)
	Censored, follow-up ended	7 (54%)	7 (44%)
	Censored, follow-up ongoing	2 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.5 (3.8, -)	2.3 (1.0, 4.5)
	Median (95% CI)	28.4 (3.8, -)	5.7 (1.9, -)
	3rd Quartile (95% CI)	- (28.4, -)	43.7 (4.5, -)
	Log-Rank P-value [2]	0.10896	
	Hazard Ratio (95% CI) [3]	0.38 (0.11, 1.29)	
	P-value [3]	0.12165	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 16 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	8 (47%)	5 (29%)
	Censored, follow-up ended	7 (41%)	8 (47%)
	Censored, follow-up ongoing	2 (12%)	4 (24%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 2.9)	9.3 (0.7, -)
	Median (95% CI)	11.0 (1.9, -)	12.5 (9.3, -)
	3rd Quartile (95% CI)	11.5 (2.9, -)	18.4 (12.5, -)
	Log-Rank P-value [2]	0.03155	
	Hazard Ratio (95% CI) [3]	3.93 (1.03, 14.92)	
	P-value [3]	0.04462	
Interaction Test	P-value [4]	0.01931	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 17 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	7 (44%)
	Censored, follow-up ended	6 (46%)	8 (50%)
	Censored, follow-up ongoing	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (1.0, 5.7)	4.7 (1.1, 6.9)
	Median (95% CI)	4.8 (1.1, -)	6.9 (3.8, -)
	3rd Quartile (95% CI)	- (4.8, -)	22.3 (4.9, -)
	Log-Rank P-value [2]	0.68145	
	Hazard Ratio (95% CI) [3]	1.26 (0.42, 3.76)	
	P-value [3]	0.68192	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 18 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	7 (41%)	8 (47%)
	Censored, follow-up ended	7 (41%)	7 (41%)
	Censored, follow-up ongoing	3 (18%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 4.7)	3.7 (1.7, 11.1)
	Median (95% CI)	10.2 (1.9, -)	11.1 (2.9, -)
	3rd Quartile (95% CI)	- (4.7, -)	- (11.1, -)
	Log-Rank P-value [2]	0.69229	
	Hazard Ratio (95% CI) [3]	1.23 (0.45, 3.42)	
	P-value [3]	0.68634	
Interaction Test	P-value [4]	0.96918	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 19 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	9 (56%)
	Censored, follow-up ended	6 (46%)	7 (44%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (2.0, 9.4)	3.3 (1.0, 6.9)
	Median (95% CI)	9.4 (3.6, -)	6.9 (2.1, -)
	3rd Quartile (95% CI)	35.1 (9.4, -)	8.4 (6.9, -)
	Log-Rank P-value [2]	0.21583	
	Hazard Ratio (95% CI) [3]	0.50 (0.16, 1.51)	
	P-value [3]	0.21678	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 20 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	8 (47%)	5 (29%)
	Censored, follow-up ended	8 (47%)	9 (53%)
	Censored, follow-up ongoing	1 (6%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 2.8)	3.7 (1.9, -)
	Median (95% CI)	4.2 (1.0, -)	- (2.9, -)
	3rd Quartile (95% CI)	- (2.8, -)	- (8.3, -)
	Log-Rank P-value [2]	0.15162	
	Hazard Ratio (95% CI) [3]	2.23 (0.73, 6.83)	
	P-value [3]	0.16142	
Interaction Test	P-value [4]	0.07728	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 21 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	9 (56%)
	Censored, follow-up ended	6 (46%)	5 (31%)
	Censored, follow-up ongoing	2 (15%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.1, 29.9)	1.1 (1.0, 4.9)
	Median (95% CI)	29.9 (1.9, -)	4.9 (1.1, 43.7)
	3rd Quartile (95% CI)	- (29.9, -)	43.7 (4.9, -)
	Log-Rank P-value [2]	0.39680	
	Hazard Ratio (95% CI) [3]	0.61 (0.20, 1.85)	
	P-value [3]	0.38596	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 22 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	7 (41%)	10 (59%)
	Censored, follow-up ended	7 (41%)	7 (41%)
	Censored, follow-up ongoing	3 (18%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.9 (0.9, 8.3)	1.8 (0.7, 3.8)
	Median (95% CI)	8.3 (4.2, -)	4.7 (1.8, -)
	3rd Quartile (95% CI)	40.6 (7.0, -)	12.5 (3.8, -)
	Log-Rank P-value [2]	0.12625	
	Hazard Ratio (95% CI) [3]	0.45 (0.16, 1.27)	
	P-value [3]	0.13169	
Interaction Test	P-value [4]	0.81625	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 23 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	4 (31%)	10 (63%)
	Censored, follow-up ended	7 (54%)	6 (38%)
	Censored, follow-up ongoing	2 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	10.2 (4.6, 39.7)	2.3 (1.0, 5.7)
	Median (95% CI)	39.7 (4.6, -)	5.7 (1.9, -)
	3rd Quartile (95% CI)	- (10.2, -)	9.7 (4.5, -)
	Log-Rank P-value [2]	0.00833	
	Hazard Ratio (95% CI) [3]	0.20 (0.05, 0.75)	
	P-value [3]	0.01649	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 24 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	6 (35%)	7 (41%)
	Censored, follow-up ended	7 (41%)	8 (47%)
	Censored, follow-up ongoing	4 (24%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.0, 14.3)	5.6 (2.8, 6.7)
	Median (95% CI)	14.3 (2.9, -)	6.7 (3.8, -)
	3rd Quartile (95% CI)	- (14.3, -)	- (6.7, -)
	Log-Rank P-value [2]	0.98537	
	Hazard Ratio (95% CI) [3]	0.99 (0.33, 3.00)	
	P-value [3]	0.98537	
Interaction Test	P-value [4]	0.14176	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 25 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	11 (69%)
	Censored, follow-up ended	6 (46%)	5 (31%)
	Censored, follow-up ongoing	2 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.1, 9.3)	1.1 (1.0, 3.8)
	Median (95% CI)	9.3 (1.9, -)	3.8 (1.1, 6.9)
	3rd Quartile (95% CI)	- (7.4, -)	6.9 (3.8, -)
	Log-Rank P-value [2]	0.07162	
	Hazard Ratio (95% CI) [3]	0.39 (0.13, 1.13)	
	P-value [3]	0.08187	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 26 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	8 (47%)	10 (59%)
	Censored, follow-up ended	6 (35%)	6 (35%)
	Censored, follow-up ongoing	3 (18%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 5.8)	1.1 (0.7, 1.9)
	Median (95% CI)	5.8 (1.1, -)	3.0 (1.1, 12.5)
	3rd Quartile (95% CI)	11.1 (5.8, -)	12.5 (1.9, -)
	Log-Rank P-value [2]	0.53666	
	Hazard Ratio (95% CI) [3]	0.75 (0.29, 1.91)	
	P-value [3]	0.54190	
Interaction Test	P-value [4]	0.42800	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 27 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	2 (15%)	8 (50%)
	Censored, follow-up ended	9 (69%)	7 (44%)
	Censored, follow-up ongoing	2 (15%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.1, -)	2.8 (1.1, 6.9)
	Median (95% CI)	- (3.8, -)	8.7 (1.9, -)
	3rd Quartile (95% CI)	- (-, -)	- (6.9, -)
	Log-Rank P-value [2]	0.07555	
	Hazard Ratio (95% CI) [3]	0.27 (0.06, 1.27)	
	P-value [3]	0.09688	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 28 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	5 (29%)	7 (41%)
	Censored, follow-up ended	8 (47%)	6 (35%)
	Censored, follow-up ongoing	4 (24%)	4 (24%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, -)	1.2 (0.9, 16.6)
	Median (95% CI)	23.3 (2.1, -)	16.6 (1.1, -)
	3rd Quartile (95% CI)	- (23.3, -)	- (16.6, -)
	Log-Rank P-value [2]	0.54283	
	Hazard Ratio (95% CI) [3]	0.70 (0.22, 2.21)	
	P-value [3]	0.54492	
Interaction Test	P-value [4]	0.32759	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Table 4.0001025

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	2 (15%)	7 (44%)
	Censored, follow-up ended	9 (69%)	7 (44%)
	Censored, follow-up ongoing	2 (15%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	22.2 (7.4, -)	3.8 (1.0, 6.9)
	Median (95% CI)	- (7.4, -)	9.3 (3.3, -)
	3rd Quartile (95% CI)	- (22.2, -)	- (6.9, -)
	Log-Rank P-value [2]	0.06017	
	Hazard Ratio (95% CI) [3]	0.24 (0.05, 1.19)	
	P-value [3]	0.08171	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 30 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001025
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	6 (35%)	5 (29%)
	Censored, follow-up ended	8 (47%)	7 (41%)
	Censored, follow-up ongoing	3 (18%)	5 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, 24.3)	11.1 (0.7, -)
	Median (95% CI)	21.3 (3.8, -)	- (3.7, -)
	3rd Quartile (95% CI)	24.3 (21.3, -)	- (11.2, -)
	Log-Rank P-value [2]	0.75104	
	Hazard Ratio (95% CI) [3]	1.22 (0.37, 4.03)	
	P-value [3]	0.74386	
Interaction Test	P-value [4]	0.10589	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_gen.sas 09OCT2025 10:05

Protocol: 207499 Page 1 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	5 (25%)	13 (54%)
	Censored, follow-up ended	10 (50%)	10 (42%)
	Censored, follow-up ongoing	5 (25%)	1 (4%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, -)	1.1 (0.8, 2.0)
	Median (95% CI)	- (1.9, -)	3.8 (1.1, -)
	3rd Quartile (95% CI)	- (10.2, -)	- (3.8, -)
	Log-Rank P-value [2]	0.05065	
	Hazard Ratio (95% CI) [3]	0.37 (0.13, 1.04)	
	P-value [3]	0.05932	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	4 (44%)
	Censored, follow-up ended	3 (30%)	4 (44%)
	Censored, follow-up ongoing	0	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.1, 6.6)	4.9 (1.7, 9.3)
	Median (95% CI)	6.6 (1.1, 11.8)	9.3 (1.7, -)
	3rd Quartile (95% CI)	11.8 (6.6, -)	- (6.9, -)
	Log-Rank P-value [2]	0.49560	
	Hazard Ratio (95% CI) [3]	1.53 (0.45, 5.24)	
	P-value [3]	0.49881	
Interaction Test	P-value [4]	0.06438	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 3 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	7 (35%)	13 (54%)
	Censored, follow-up ended	10 (50%)	11 (46%)
	Censored, follow-up ongoing	3 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, 8.8)	2.1 (1.0, 3.8)
	Median (95% CI)	8.8 (1.0, -)	4.7 (2.1, 18.4)
	3rd Quartile (95% CI)	- (8.8, -)	18.4 (4.7, -)
	Log-Rank P-value [2]	0.36368	
	Hazard Ratio (95% CI) [3]	0.65 (0.26, 1.65)	
	P-value [3]	0.36381	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	6 (60%)	4 (44%)
	Censored, follow-up ended	3 (30%)	4 (44%)
	Censored, follow-up ongoing	1 (10%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, 13.0)	2.2 (0.7, -)
	Median (95% CI)	13.0 (1.0, -)	6.9 (0.7, -)
	3rd Quartile (95% CI)	- (13.0, -)	- (2.8, -)
	Log-Rank P-value [2]	0.94517	
	Hazard Ratio (95% CI) [3]	0.97 (0.27, 3.45)	
	P-value [3]	0.96131	
Interaction Test	P-value [4]	0.57992	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	9 (45%)	13 (54%)
	Censored, follow-up ended	9 (45%)	9 (38%)
	Censored, follow-up ongoing	2 (10%)	2 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 4.2)	1.8 (0.9, 2.8)
	Median (95% CI)	4.2 (1.9, -)	3.8 (1.8, -)
	3rd Quartile (95% CI)	6.5 (4.2, -)	- (3.8, -)
	Log-Rank P-value [2]	0.94727	
	Hazard Ratio (95% CI) [3]	1.03 (0.44, 2.43)	
	P-value [3]	0.94400	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 6 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	4 (44%)
	Censored, follow-up ended	2 (20%)	4 (44%)
	Censored, follow-up ongoing	1 (10%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.9, 4.2)	2.8 (1.7, 6.9)
	Median (95% CI)	3.5 (1.9, -)	6.9 (1.7, -)
	3rd Quartile (95% CI)	10.2 (2.9, -)	- (2.9, -)
	Log-Rank P-value [2]	0.50557	
	Hazard Ratio (95% CI) [3]	1.52 (0.44, 5.26)	
	P-value [3]	0.50625	
Interaction Test	P-value [4]	0.61715	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 7 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	4 (20%)	10 (42%)
	Censored, follow-up ended	12 (60%)	10 (42%)
	Censored, follow-up ongoing	4 (20%)	4 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (1.0, -)	3.8 (0.9, 6.9)
	Median (95% CI)	- (3.8, -)	6.9 (3.8, -)
	3rd Quartile (95% CI)	- (5.6, -)	- (6.9, -)
	Log-Rank P-value [2]	0.48787	
	Hazard Ratio (95% CI) [3]	0.67 (0.21, 2.14)	
	P-value [3]	0.49781	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	6 (60%)	3 (33%)
	Censored, follow-up ended	3 (30%)	4 (44%)
	Censored, follow-up ongoing	1 (10%)	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.9, 8.4)	10.2 (1.7, -)
	Median (95% CI)	8.4 (1.9, -)	- (1.7, -)
	3rd Quartile (95% CI)	33.2 (7.4, -)	- (10.2, -)
	Log-Rank P-value [2]	0.48982	
	Hazard Ratio (95% CI) [3]	1.63 (0.40, 6.57)	
	P-value [3]	0.49396	
Interaction Test	P-value [4]	0.30994	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 9 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	9 (45%)	13 (54%)
	Censored, follow-up ended	9 (45%)	8 (33%)
	Censored, follow-up ongoing	2 (10%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 7.4)	1.1 (0.9, 6.7)
	Median (95% CI)	7.4 (1.0, -)	6.7 (1.1, 20.3)
	3rd Quartile (95% CI)	7.6 (3.8, -)	20.3 (8.7, -)
	Log-Rank P-value [2]	0.39563	
	Hazard Ratio (95% CI) [3]	1.45 (0.61, 3.41)	
	P-value [3]	0.40091	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Table 4.0001035

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	9 (90%)	3 (33%)
	Censored, follow-up ended	1 (10%)	5 (56%)
	Censored, follow-up ongoing	0	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 4.7)	6.4 (1.0, -)
	Median (95% CI)	4.2 (1.0, 7.5)	- (1.0, -)
	3rd Quartile (95% CI)	7.5 (3.7, -)	- (11.2, -)
	Log-Rank P-value [2]	0.04218	
	Hazard Ratio (95% CI) [3]	3.72 (0.97, 14.28)	
	P-value [3]	0.05514	
Interaction Test	P-value [4]	0.23189	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	11 (55%)	11 (46%)
	Censored, follow-up ended	8 (40%)	9 (38%)
	Censored, follow-up ongoing	1 (5%)	4 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 3.6)	1.1 (1.0, 1.9)
	Median (95% CI)	3.8 (1.0, 5.6)	6.5 (1.1, -)
	3rd Quartile (95% CI)	5.6 (3.6, -)	- (6.5, -)
	Log-Rank P-value [2]	0.29889	
	Hazard Ratio (95% CI) [3]	1.54 (0.66, 3.60)	
	P-value [3]	0.31313	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 12 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	4 (44%)
	Censored, follow-up ended	2 (20%)	3 (33%)
	Censored, follow-up ongoing	1 (10%)	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.1, 5.6)	3.3 (1.7, -)
	Median (95% CI)	4.7 (1.1, -)	11.2 (1.7, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (3.7, -)
	Log-Rank P-value [2]	0.40198	
	Hazard Ratio (95% CI) [3]	1.68 (0.49, 5.75)	
	P-value [3]	0.41105	
Interaction Test	P-value [4]	0.95041	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 13 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	9 (45%)	16 (67%)
	Censored, follow-up ended	9 (45%)	7 (29%)
	Censored, follow-up ongoing	2 (10%)	1 (4%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 3.8)	1.1 (0.9, 1.1)
	Median (95% CI)	3.8 (1.0, -)	1.9 (1.1, 4.9)
	3rd Quartile (95% CI)	9.3 (3.8, -)	7.4 (2.0, -)
	Log-Rank P-value [2]	0.43927	
	Hazard Ratio (95% CI) [3]	0.72 (0.32, 1.65)	
	P-value [3]	0.43771	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 14 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	4 (44%)
	Censored, follow-up ended	3 (30%)	4 (44%)
	Censored, follow-up ongoing	0	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 5.6)	2.3 (1.0, 6.9)
	Median (95% CI)	4.7 (1.0, -)	6.9 (1.0, -)
	3rd Quartile (95% CI)	9.3 (3.8, -)	- (2.8, -)
	Log-Rank P-value [2]	0.50096	
	Hazard Ratio (95% CI) [3]	1.52 (0.44, 5.21)	
	P-value [3]	0.50407	
Interaction Test	P-value [4]	0.31888	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 15 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	5 (25%)	11 (46%)
	Censored, follow-up ended	12 (60%)	11 (46%)
	Censored, follow-up ongoing	3 (15%)	2 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.4 (1.0, 11.0)	3.7 (1.0, 8.7)
	Median (95% CI)	11.0 (4.4, -)	8.7 (3.7, -)
	3rd Quartile (95% CI)	- (11.0, -)	18.4 (8.7, -)
	Log-Rank P-value [2]	0.69194	
	Hazard Ratio (95% CI) [3]	0.80 (0.27, 2.37)	
	P-value [3]	0.69251	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 16 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	3 (33%)
	Censored, follow-up ended	2 (20%)	4 (44%)
	Censored, follow-up ongoing	1 (10%)	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 11.5)	5.6 (0.7, -)
	Median (95% CI)	7.7 (1.0, -)	- (0.7, -)
	3rd Quartile (95% CI)	28.4 (3.8, -)	- (9.3, -)
	Log-Rank P-value [2]	0.52758	
	Hazard Ratio (95% CI) [3]	1.56 (0.39, 6.25)	
	P-value [3]	0.53097	
Interaction Test	P-value [4]	0.40819	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 17 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	6 (30%)	11 (46%)
	Censored, follow-up ended	11 (55%)	10 (42%)
	Censored, follow-up ongoing	3 (15%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 5.7)	3.8 (1.1, 5.1)
	Median (95% CI)	5.7 (2.8, -)	7.9 (3.8, -)
	3rd Quartile (95% CI)	- (5.7, -)	22.3 (7.9, -)
	Log-Rank P-value [2]	0.96033	
	Hazard Ratio (95% CI) [3]	0.98 (0.36, 2.66)	
	P-value [3]	0.96723	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Table 4.0001035

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	4 (44%)
	Censored, follow-up ended	2 (20%)	5 (56%)
	Censored, follow-up ongoing	1 (10%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 4.8)	4.9 (1.7, 11.1)
	Median (95% CI)	4.7 (1.0, -)	11.1 (1.7, -)
	3rd Quartile (95% CI)	- (4.7, -)	- (6.9, -)
	Log-Rank P-value [2]	0.38786	
	Hazard Ratio (95% CI) [3]	1.71 (0.50, 5.88)	
	P-value [3]	0.39340	
Interaction Test	P-value [4]	0.48737	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 19 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	10 (50%)	12 (50%)
	Censored, follow-up ended	9 (45%)	11 (46%)
	Censored, follow-up ongoing	1 (5%)	1 (4%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 2.8)	2.9 (1.0, 6.9)
	Median (95% CI)	3.6 (1.0, -)	8.3 (2.9, 8.4)
	3rd Quartile (95% CI)	- (3.6, -)	8.4 (6.9, -)
	Log-Rank P-value [2]	0.23830	
	Hazard Ratio (95% CI) [3]	1.67 (0.71, 3.95)	
	P-value [3]	0.24330	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 20 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	4 (40%)	2 (22%)
	Censored, follow-up ended	5 (50%)	5 (56%)
	Censored, follow-up ongoing	1 (10%)	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	9.4 (1.0, 35.1)	6.9 (3.8, -)
	Median (95% CI)	35.1 (1.0, -)	- (3.8, -)
	3rd Quartile (95% CI)	- (35.1, -)	- (-, -)
	Log-Rank P-value [2]	0.71121	
	Hazard Ratio (95% CI) [3]	1.38 (0.25, 7.56)	
	P-value [3]	0.71238	
Interaction Test	P-value [4]	0.86761	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 21 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	8 (40%)	14 (58%)
	Censored, follow-up ended	10 (50%)	9 (38%)
	Censored, follow-up ongoing	2 (10%)	1 (4%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 7.0)	2.8 (1.0, 3.8)
	Median (95% CI)	7.0 (2.0, 40.6)	4.7 (2.8, 12.5)
	3rd Quartile (95% CI)	40.6 (6.9, -)	12.5 (4.7, -)
	Log-Rank P-value [2]	0.58053	
	Hazard Ratio (95% CI) [3]	0.77 (0.32, 1.88)	
	P-value [3]	0.57140	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 22 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	4 (40%)	5 (56%)
	Censored, follow-up ended	3 (30%)	3 (33%)
	Censored, follow-up ongoing	3 (30%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (0.9, -)	1.4 (0.7, 4.7)
	Median (95% CI)	- (0.9, -)	3.8 (0.7, -)
	3rd Quartile (95% CI)	- (8.3, -)	- (1.7, -)
	Log-Rank P-value [2]	0.29894	
	Hazard Ratio (95% CI) [3]	0.50 (0.13, 1.89)	
	P-value [3]	0.30816	
Interaction Test	P-value [4]	0.42310	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 23 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	4 (20%)	12 (50%)
	Censored, follow-up ended	12 (60%)	11 (46%)
	Censored, follow-up ongoing	4 (20%)	1 (4%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.6 (1.0, -)	3.7 (1.0, 5.7)
	Median (95% CI)	- (4.6, -)	6.0 (3.7, -)
	3rd Quartile (95% CI)	- (10.2, -)	22.3 (6.0, -)
	Log-Rank P-value [2]	0.09979	
	Hazard Ratio (95% CI) [3]	0.39 (0.13, 1.24)	
	P-value [3]	0.11140	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 24 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	6 (60%)	5 (56%)
	Censored, follow-up ended	2 (20%)	3 (33%)
	Censored, follow-up ongoing	2 (20%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (1.0, 14.3)	4.2 (2.8, 9.7)
	Median (95% CI)	14.3 (1.0, -)	8.3 (2.8, -)
	3rd Quartile (95% CI)	- (10.3, -)	- (5.6, -)
	Log-Rank P-value [2]	0.47093	
	Hazard Ratio (95% CI) [3]	0.63 (0.18, 2.23)	
	P-value [3]	0.47453	
Interaction Test	P-value [4]	0.54524	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 25 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	6 (30%)	15 (63%)
	Censored, follow-up ended	11 (55%)	9 (38%)
	Censored, follow-up ongoing	3 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.8 (1.9, 8.8)	1.1 (1.0, 2.3)
	Median (95% CI)	8.8 (5.8, -)	3.0 (1.1, 12.5)
	3rd Quartile (95% CI)	- (7.4, -)	12.5 (3.0, -)
	Log-Rank P-value [2]	0.09989	
	Hazard Ratio (95% CI) [3]	0.45 (0.17, 1.19)	
	P-value [3]	0.10760	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 26 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	6 (67%)
	Censored, follow-up ended	1 (10%)	2 (22%)
	Censored, follow-up ongoing	2 (20%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 4.2)	1.3 (0.7, 3.8)
	Median (95% CI)	3.5 (1.0, -)	2.9 (0.7, -)
	3rd Quartile (95% CI)	- (2.9, -)	6.9 (1.7, -)
	Log-Rank P-value [2]	0.65684	
	Hazard Ratio (95% CI) [3]	0.79 (0.26, 2.36)	
	P-value [3]	0.66979	
Interaction Test	P-value [4]	0.55546	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 27 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	3 (15%)	11 (46%)
	Censored, follow-up ended	14 (70%)	10 (42%)
	Censored, follow-up ongoing	3 (15%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (2.1, -)	1.9 (0.9, 6.9)
	Median (95% CI)	- (3.8, -)	8.7 (1.9, -)
	3rd Quartile (95% CI)	- (-, -)	- (8.7, -)
	Log-Rank P-value [2]	0.08418	
	Hazard Ratio (95% CI) [3]	0.34 (0.10, 1.22)	
	P-value [3]	0.09902	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 28 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	4 (40%)	4 (44%)
	Censored, follow-up ended	3 (30%)	3 (33%)
	Censored, follow-up ongoing	3 (30%)	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	1.5 (1.0, 16.6)
	Median (95% CI)	23.3 (1.0, -)	16.6 (1.0, -)
	3rd Quartile (95% CI)	- (23.3, -)	- (1.9, -)
	Log-Rank P-value [2]	0.60485	
	Hazard Ratio (95% CI) [3]	0.71 (0.17, 2.86)	
	P-value [3]	0.62481	
Interaction Test	P-value [4]	0.45239	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 29 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	5 (25%)	10 (42%)
	Censored, follow-up ended	12 (60%)	10 (42%)
	Censored, follow-up ongoing	3 (15%)	4 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, -)	3.8 (1.0, 9.3)
	Median (95% CI)	21.3 (3.8, -)	9.3 (3.8, -)
	3rd Quartile (95% CI)	- (21.3, -)	- (9.3, -)
	Log-Rank P-value [2]	0.52663	
	Hazard Ratio (95% CI) [3]	0.71 (0.24, 2.11)	
	P-value [3]	0.53906	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 30 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001035
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	3 (30%)	2 (22%)
	Censored, follow-up ended	5 (50%)	4 (44%)
	Censored, follow-up ongoing	2 (20%)	3 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	22.2 (5.6, -)	11.2 (0.7, -)
	Median (95% CI)	24.3 (5.6, -)	- (0.7, -)
	3rd Quartile (95% CI)	- (22.2, -)	- (11.2, -)
	Log-Rank P-value [2]	0.85766	
	Hazard Ratio (95% CI) [3]	0.85 (0.14, 5.12)	
	P-value [3]	0.85781	
Interaction Test	P-value [4]	0.78631	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_reg.sas 09OCT2025 10:05

Protocol: 207499 Page 1 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	10 (56%)	9 (60%)
	Censored, follow-up ended	5 (28%)	5 (33%)
	Censored, follow-up ongoing	3 (17%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 6.6)	1.8 (0.8, 2.8)
	Median (95% CI)	6.6 (1.9, -)	3.8 (1.7, -)
	3rd Quartile (95% CI)	11.8 (6.6, -)	- (2.8, -)
	Log-Rank P-value [2]	0.56989	
	Hazard Ratio (95% CI) [3]	0.77 (0.31, 1.91)	
	P-value [3]	0.57126	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	2 (17%)	8 (44%)
	Censored, follow-up ended	8 (67%)	9 (50%)
	Censored, follow-up ongoing	2 (17%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	10.2 (1.9, -)	1.1 (1.0, 6.9)
	Median (95% CI)	- (1.9, -)	6.9 (1.1, -)
	3rd Quartile (95% CI)	- (10.2, -)	- (6.9, -)
	Log-Rank P-value [2]	0.07858	
	Hazard Ratio (95% CI) [3]	0.27 (0.06, 1.28)	
	P-value [3]	0.09890	
Interaction Test	P-value [4]	0.25325	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 3 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (44%)	9 (60%)
	Censored, follow-up ended	7 (39%)	5 (33%)
	Censored, follow-up ongoing	3 (17%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (1.0, 13.0)	2.8 (1.1, 12.5)
	Median (95% CI)	13.0 (3.8, -)	12.5 (2.1, -)
	3rd Quartile (95% CI)	- (13.0, -)	18.4 (12.5, -)
	Log-Rank P-value [2]	0.31562	
	Hazard Ratio (95% CI) [3]	0.62 (0.24, 1.60)	
	P-value [3]	0.32022	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 4 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	5 (42%)	8 (44%)
	Censored, follow-up ended	6 (50%)	10 (56%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, 5.6)	1.1 (0.7, 3.8)
	Median (95% CI)	3.6 (1.0, -)	3.8 (1.1, -)
	3rd Quartile (95% CI)	5.6 (3.6, -)	- (3.8, -)
	Log-Rank P-value [2]	0.87845	
	Hazard Ratio (95% CI) [3]	1.10 (0.36, 3.37)	
	P-value [3]	0.87191	
Interaction Test	P-value [4]	0.56114	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 5 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	12 (67%)	9 (60%)
	Censored, follow-up ended	5 (28%)	4 (27%)
	Censored, follow-up ongoing	1 (6%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 2.6)	2.1 (0.9, 3.7)
	Median (95% CI)	2.8 (1.9, -)	6.6 (1.8, -)
	3rd Quartile (95% CI)	10.2 (2.6, -)	- (6.6, -)
	Log-Rank P-value [2]	0.20007	
	Hazard Ratio (95% CI) [3]	1.80 (0.73, 4.47)	
	P-value [3]	0.20222	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 6 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	4 (33%)	8 (44%)
	Censored, follow-up ended	6 (50%)	9 (50%)
	Censored, follow-up ongoing	2 (17%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (2.9, 5.6)	1.1 (1.0, 3.8)
	Median (95% CI)	5.6 (2.9, -)	3.8 (1.1, -)
	3rd Quartile (95% CI)	- (4.2, -)	- (2.8, -)
	Log-Rank P-value [2]	0.35189	
	Hazard Ratio (95% CI) [3]	0.58 (0.17, 1.94)	
	P-value [3]	0.37479	
Interaction Test	P-value [4]	0.14497	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 7 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	7 (39%)	8 (53%)
	Censored, follow-up ended	8 (44%)	4 (27%)
	Censored, follow-up ongoing	3 (17%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 33.2)	6.3 (0.9, 7.9)
	Median (95% CI)	33.2 (3.8, -)	7.9 (3.7, -)
	3rd Quartile (95% CI)	- (33.2, -)	18.4 (7.9, -)
	Log-Rank P-value [2]	0.42690	
	Hazard Ratio (95% CI) [3]	0.66 (0.24, 1.86)	
	P-value [3]	0.43604	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 8 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	3 (25%)	5 (28%)
	Censored, follow-up ended	7 (58%)	10 (56%)
	Censored, follow-up ongoing	2 (17%)	3 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (3.7, 8.4)	6.9 (1.0, -)
	Median (95% CI)	8.4 (3.7, -)	- (3.8, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (11.2, -)
	Log-Rank P-value [2]	0.63042	
	Hazard Ratio (95% CI) [3]	1.42 (0.33, 6.06)	
	P-value [3]	0.63206	
Interaction Test	P-value [4]	0.42854	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 9 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	13 (72%)	6 (40%)
	Censored, follow-up ended	4 (22%)	6 (40%)
	Censored, follow-up ongoing	1 (6%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 3.7)	6.5 (0.9, 20.3)
	Median (95% CI)	3.8 (1.1, 7.6)	20.3 (1.7, -)
	3rd Quartile (95% CI)	7.6 (3.8, -)	- (20.3, -)
	Log-Rank P-value [2]	0.05794	
	Hazard Ratio (95% CI) [3]	2.48 (0.94, 6.55)	
	P-value [3]	0.06700	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	5 (42%)	10 (56%)
	Censored, follow-up ended	6 (50%)	7 (39%)
	Censored, follow-up ongoing	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 4.7)	1.1 (1.0, 2.1)
	Median (95% CI)	4.7 (0.8, -)	8.7 (1.0, 11.2)
	3rd Quartile (95% CI)	7.4 (1.0, -)	11.2 (8.7, -)
	Log-Rank P-value [2]	0.40238	
	Hazard Ratio (95% CI) [3]	1.63 (0.51, 5.17)	
	P-value [3]	0.41101	
Interaction Test	P-value [4]	0.60683	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 11 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	12 (67%)	6 (40%)
	Censored, follow-up ended	5 (28%)	5 (33%)
	Censored, follow-up ongoing	1 (6%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.7)	2.9 (1.0, -)
	Median (95% CI)	3.8 (1.9, 11.3)	- (1.8, -)
	3rd Quartile (95% CI)	11.3 (3.8, -)	- (6.5, -)
	Log-Rank P-value [2]	0.07659	
	Hazard Ratio (95% CI) [3]	2.39 (0.88, 6.47)	
	P-value [3]	0.08696	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 12 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	6 (50%)	9 (50%)
	Censored, follow-up ended	5 (42%)	7 (39%)
	Censored, follow-up ongoing	1 (8%)	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 3.6)	1.1 (1.0, 1.9)
	Median (95% CI)	3.6 (1.0, -)	2.0 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	- (1.9, -)
	Log-Rank P-value [2]	0.91956	
	Hazard Ratio (95% CI) [3]	1.05 (0.37, 2.97)	
	P-value [3]	0.92174	
Interaction Test	P-value [4]	0.31011	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 13 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	10 (56%)	10 (67%)
	Censored, follow-up ended	6 (33%)	4 (27%)
	Censored, follow-up ongoing	2 (11%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 3.8)	1.1 (0.9, 2.0)
	Median (95% CI)	3.8 (1.1, -)	2.8 (1.1, -)
	3rd Quartile (95% CI)	- (3.8, -)	7.4 (2.8, -)
	Log-Rank P-value [2]	0.76127	
	Hazard Ratio (95% CI) [3]	0.88 (0.36, 2.11)	
	P-value [3]	0.76847	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	6 (50%)	10 (56%)
	Censored, follow-up ended	6 (50%)	7 (39%)
	Censored, follow-up ongoing	0	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, -)	1.0 (1.0, 1.1)
	Median (95% CI)	6.6 (0.8, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	9.3 (3.8, -)	6.9 (2.8, -)
	Log-Rank P-value [2]	0.67973	
	Hazard Ratio (95% CI) [3]	0.86 (0.31, 2.40)	
	P-value [3]	0.76906	
Interaction Test	P-value [4]	0.96565	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 15 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (44%)	7 (47%)
	Censored, follow-up ended	8 (44%)	5 (33%)
	Censored, follow-up ongoing	2 (11%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 11.5)	5.7 (0.7, 18.4)
	Median (95% CI)	11.5 (3.8, -)	18.4 (4.5, -)
	3rd Quartile (95% CI)	28.4 (11.0, -)	43.7 (12.5, -)
	Log-Rank P-value [2]	0.55447	
	Hazard Ratio (95% CI) [3]	1.38 (0.47, 4.03)	
	P-value [3]	0.55606	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 16 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	4 (33%)	7 (39%)
	Censored, follow-up ended	6 (50%)	10 (56%)
	Censored, follow-up ongoing	2 (17%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, 6.5)	2.3 (1.0, 8.7)
	Median (95% CI)	6.5 (1.0, -)	8.7 (1.9, -)
	3rd Quartile (95% CI)	- (2.9, -)	- (8.7, -)
	Log-Rank P-value [2]	0.91094	
	Hazard Ratio (95% CI) [3]	1.09 (0.32, 3.78)	
	P-value [3]	0.88948	
Interaction Test	P-value [4]	0.60976	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 17 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	9 (50%)	9 (60%)
	Censored, follow-up ended	6 (33%)	5 (33%)
	Censored, follow-up ongoing	3 (17%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 4.7)	4.7 (1.7, 11.1)
	Median (95% CI)	4.7 (1.1, -)	11.1 (3.7, -)
	3rd Quartile (95% CI)	- (4.7, -)	22.3 (7.9, -)
	Log-Rank P-value [2]	0.68692	
	Hazard Ratio (95% CI) [3]	1.21 (0.48, 3.07)	
	P-value [3]	0.68237	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 18 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	4 (33%)	6 (33%)
	Censored, follow-up ended	7 (58%)	10 (56%)
	Censored, follow-up ongoing	1 (8%)	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (2.8, 10.2)	3.8 (1.1, 6.9)
	Median (95% CI)	5.7 (2.8, -)	6.9 (2.9, -)
	3rd Quartile (95% CI)	10.2 (4.2, -)	- (6.9, -)
	Log-Rank P-value [2]	0.89044	
	Hazard Ratio (95% CI) [3]	1.09 (0.31, 3.89)	
	P-value [3]	0.89047	
Interaction Test	P-value [4]	0.92271	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 19 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (44%)	6 (40%)
	Censored, follow-up ended	8 (44%)	6 (40%)
	Censored, follow-up ongoing	2 (11%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.4 (1.0, 9.4)	3.7 (1.9, 22.3)
	Median (95% CI)	35.1 (2.0, -)	22.3 (2.9, -)
	3rd Quartile (95% CI)	- (9.4, -)	- (22.3, -)
	Log-Rank P-value [2]	0.94974	
	Hazard Ratio (95% CI) [3]	1.04 (0.35, 3.10)	
	P-value [3]	0.94995	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 20 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	6 (50%)	8 (44%)
	Censored, follow-up ended	6 (50%)	10 (56%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 3.7)	3.3 (1.0, 6.9)
	Median (95% CI)	3.7 (1.0, -)	6.9 (2.8, -)
	3rd Quartile (95% CI)	- (3.6, -)	8.4 (6.9, -)
	Log-Rank P-value [2]	0.31080	
	Hazard Ratio (95% CI) [3]	1.73 (0.59, 5.10)	
	P-value [3]	0.32127	
Interaction Test	P-value [4]	0.51678	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 21 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (44%)	12 (80%)
	Censored, follow-up ended	6 (33%)	3 (20%)
	Censored, follow-up ongoing	4 (22%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (0.9, 7.0)	1.7 (0.7, 3.8)
	Median (95% CI)	8.3 (2.0, -)	4.7 (1.1, 7.4)
	3rd Quartile (95% CI)	- (7.0, -)	7.4 (3.8, -)
	Log-Rank P-value [2]	0.09323	
	Hazard Ratio (95% CI) [3]	0.47 (0.19, 1.16)	
	P-value [3]	0.09959	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 22 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	4 (33%)	7 (39%)
	Censored, follow-up ended	7 (58%)	9 (50%)
	Censored, follow-up ongoing	1 (8%)	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.9, -)	2.9 (1.0, 4.7)
	Median (95% CI)	29.9 (1.9, -)	4.7 (1.1, -)
	3rd Quartile (95% CI)	40.6 (4.2, -)	- (4.7, -)
	Log-Rank P-value [2]	0.75038	
	Hazard Ratio (95% CI) [3]	0.81 (0.24, 2.80)	
	P-value [3]	0.74291	
Interaction Test	P-value [4]	0.48100	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 23 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (33%)	10 (67%)
	Censored, follow-up ended	8 (44%)	4 (27%)
	Censored, follow-up ongoing	4 (22%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	10.3 (1.0, 39.7)	4.5 (2.9, 6.6)
	Median (95% CI)	39.7 (10.2, -)	6.6 (3.8, -)
	3rd Quartile (95% CI)	- (14.3, -)	22.3 (6.6, -)
	Log-Rank P-value [2]	0.03122	
	Hazard Ratio (95% CI) [3]	0.32 (0.11, 0.95)	
	P-value [3]	0.04010	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 24 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	4 (33%)	7 (39%)
	Censored, follow-up ended	6 (50%)	10 (56%)
	Censored, follow-up ongoing	2 (17%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (2.9, 4.7)	2.3 (1.0, 6.0)
	Median (95% CI)	4.6 (2.9, -)	6.0 (1.9, -)
	3rd Quartile (95% CI)	4.7 (4.2, -)	- (6.0, -)
	Log-Rank P-value [2]	0.99697	
	Hazard Ratio (95% CI) [3]	1.00 (0.28, 3.50)	
	P-value [3]	0.99697	
Interaction Test	P-value [4]	0.24603	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 25 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	10 (56%)	10 (67%)
	Censored, follow-up ended	6 (33%)	4 (27%)
	Censored, follow-up ongoing	2 (11%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 5.8)	1.9 (0.7, 3.8)
	Median (95% CI)	8.8 (1.9, 11.1)	5.7 (1.7, -)
	3rd Quartile (95% CI)	11.1 (8.8, -)	43.7 (3.8, -)
	Log-Rank P-value [2]	0.95706	
	Hazard Ratio (95% CI) [3]	1.03 (0.42, 2.50)	
	P-value [3]	0.95060	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 26 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	3 (25%)	11 (61%)
	Censored, follow-up ended	6 (50%)	7 (39%)
	Censored, follow-up ongoing	3 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.9, -)	1.1 (1.0, 1.9)
	Median (95% CI)	7.4 (1.9, -)	1.9 (1.0, 4.7)
	3rd Quartile (95% CI)	- (4.2, -)	4.7 (1.9, -)
	Log-Rank P-value [2]	0.01177	
	Hazard Ratio (95% CI) [3]	0.17 (0.04, 0.79)	
	P-value [3]	0.02406	
Interaction Test	P-value [4]	0.04363	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 27 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	5 (28%)	5 (33%)
	Censored, follow-up ended	9 (50%)	5 (33%)
	Censored, follow-up ongoing	4 (22%)	5 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.1, -)	1.1 (0.9, -)
	Median (95% CI)	- (2.1, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (23.3, -)	- (16.6, -)
	Log-Rank P-value [2]	0.73154	
	Hazard Ratio (95% CI) [3]	0.81 (0.23, 2.79)	
	P-value [3]	0.73266	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	2 (17%)	10 (56%)
	Censored, follow-up ended	8 (67%)	8 (44%)
	Censored, follow-up ongoing	2 (17%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, -)	1.9 (1.0, 3.7)
	Median (95% CI)	- (1.0, -)	5.3 (1.4, 9.2)
	3rd Quartile (95% CI)	- (3.8, -)	9.0 (3.7, -)
	Log-Rank P-value [2]	0.08016	
	Hazard Ratio (95% CI) [3]	0.28 (0.06, 1.28)	
	P-value [3]	0.10052	
Interaction Test	P-value [4]	0.27782	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 29 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (33%)	6 (40%)
	Censored, follow-up ended	9 (50%)	5 (33%)
	Censored, follow-up ongoing	3 (17%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, 24.3)	4.9 (0.7, 11.1)
	Median (95% CI)	24.3 (5.6, -)	11.1 (3.7, -)
	3rd Quartile (95% CI)	- (22.2, -)	- (9.3, -)
	Log-Rank P-value [2]	0.44914	
	Hazard Ratio (95% CI) [3]	0.65 (0.20, 2.06)	
	P-value [3]	0.46139	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 30 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001045
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	2 (17%)	6 (33%)
	Censored, follow-up ended	8 (67%)	9 (50%)
	Censored, follow-up ongoing	2 (17%)	3 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	21.3 (7.4, -)	3.8 (1.0, 11.2)
	Median (95% CI)	21.3 (7.4, -)	11.2 (3.3, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (11.2, -)
	Log-Rank P-value [2]	0.39156	
	Hazard Ratio (95% CI) [3]	0.50 (0.10, 2.51)	
	P-value [3]	0.40058	
Interaction Test	P-value [4]	0.86445	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_iss.sas 09OCT2025 10:05

Protocol: 207499 Page 1 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	3 (38%)	5 (83%)
	Censored, follow-up ended	3 (38%)	0
	Censored, follow-up ongoing	2 (25%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.9, -)	1.8 (1.1, 3.8)
	Median (95% CI)	- (1.9, -)	2.9 (1.1, -)
	3rd Quartile (95% CI)	- (10.2, -)	6.9 (1.8, -)
	Log-Rank P-value [2]	0.12684	
	Hazard Ratio (95% CI) [3]	0.34 (0.08, 1.45)	
	P-value [3]	0.14412	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 2 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	5 (36%)
	Censored, follow-up ended	6 (46%)	9 (64%)
	Censored, follow-up ongoing	2 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.9, 11.8)	2.0 (0.8, 6.6)
	Median (95% CI)	11.8 (1.9, -)	6.6 (1.0, -)
	3rd Quartile (95% CI)	- (6.6, -)	- (6.6, -)
	Log-Rank P-value [2]	0.70782	
	Hazard Ratio (95% CI) [3]	0.79 (0.22, 2.76)	
	P-value [3]	0.70844	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 3 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	7 (54%)
	Censored, follow-up ended	4 (44%)	5 (38%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	1.1 (1.0, 2.8)
	Median (95% CI)	7.0 (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	10.2 (1.1, -)	9.3 (1.7, -)
	Log-Rank P-value [2]	0.84405	
	Hazard Ratio (95% CI) [3]	0.87 (0.25, 3.01)	
	P-value [3]	0.83210	
Interaction Test	P-value [4]	0.54115	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 4 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	4 (50%)	4 (67%)
	Censored, follow-up ended	3 (38%)	1 (17%)
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, 14.3)	3.7 (1.1, 6.9)
	Median (95% CI)	14.3 (1.0, -)	5.4 (1.1, -)
	3rd Quartile (95% CI)	- (13.0, -)	- (3.7, -)
	Log-Rank P-value [2]	0.54660	
	Hazard Ratio (95% CI) [3]	0.65 (0.16, 2.69)	
	P-value [3]	0.54934	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 5 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	6 (43%)
	Censored, follow-up ended	6 (46%)	8 (57%)
	Censored, follow-up ongoing	2 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.6 (1.0, 8.8)	2.1 (0.7, 18.4)
	Median (95% CI)	8.8 (1.0, -)	18.4 (1.1, -)
	3rd Quartile (95% CI)	- (5.6, -)	22.3 (18.4, -)
	Log-Rank P-value [2]	0.65924	
	Hazard Ratio (95% CI) [3]	0.77 (0.23, 2.52)	
	P-value [3]	0.66024	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 6 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	7 (54%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 5.6)	1.1 (1.0, 3.3)
	Median (95% CI)	4.7 (1.0, -)	3.3 (1.1, -)
	3rd Quartile (95% CI)	- (3.7, -)	12.5 (2.8, -)
	Log-Rank P-value [2]	0.93126	
	Hazard Ratio (95% CI) [3]	0.94 (0.26, 3.36)	
	P-value [3]	0.91957	
Interaction Test	P-value [4]	0.88896	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 7 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	6 (75%)	5 (83%)
	Censored, follow-up ended	2 (25%)	0
	Censored, follow-up ongoing	0	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.9, 2.9)	1.8 (1.1, 3.8)
	Median (95% CI)	2.9 (1.9, 6.5)	3.7 (1.1, -)
	3rd Quartile (95% CI)	6.5 (2.9, -)	6.9 (1.8, -)
	Log-Rank P-value [2]	0.89072	
	Hazard Ratio (95% CI) [3]	1.09 (0.33, 3.63)	
	P-value [3]	0.89104	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 8 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	5 (36%)
	Censored, follow-up ended	6 (46%)	8 (57%)
	Censored, follow-up ongoing	1 (8%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.3 (1.0, 10.2)	2.8 (1.9, 6.6)
	Median (95% CI)	7.9 (1.9, -)	6.6 (1.9, -)
	3rd Quartile (95% CI)	- (5.6, -)	- (6.6, -)
	Log-Rank P-value [2]	0.70018	
	Hazard Ratio (95% CI) [3]	1.26 (0.38, 4.16)	
	P-value [3]	0.70264	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 9 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	7 (54%)
	Censored, follow-up ended	3 (33%)	5 (38%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 4.2)	1.1 (0.9, 2.8)
	Median (95% CI)	4.0 (1.0, -)	12.5 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	- (2.8, -)
	Log-Rank P-value [2]	0.99572	
	Hazard Ratio (95% CI) [3]	0.99 (0.29, 3.39)	
	P-value [3]	0.98386	
Interaction Test	P-value [4]	0.94649	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 10 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	2 (25%)	3 (50%)
	Censored, follow-up ended	4 (50%)	1 (17%)
	Censored, follow-up ongoing	2 (25%)	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	33.2 (3.7, -)	3.8 (3.7, -)
	Median (95% CI)	33.2 (3.7, -)	7.9 (3.7, -)
	3rd Quartile (95% CI)	- (33.2, -)	- (3.8, -)
	Log-Rank P-value [2]	0.26233	
	Hazard Ratio (95% CI) [3]	0.30 (0.03, 2.85)	
	P-value [3]	0.29145	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 11 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	4 (29%)
	Censored, follow-up ended	6 (46%)	8 (57%)
	Censored, follow-up ongoing	1 (8%)	2 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 5.6)	1.9 (0.9, -)
	Median (95% CI)	5.6 (1.0, -)	18.4 (1.0, -)
	3rd Quartile (95% CI)	- (5.6, -)	- (18.4, -)
	Log-Rank P-value [2]	0.50444	
	Hazard Ratio (95% CI) [3]	1.55 (0.43, 5.61)	
	P-value [3]	0.50399	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Table 4.0001055

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	6 (46%)
	Censored, follow-up ended	5 (56%)	5 (38%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	8.4 (3.8, -)	6.7 (1.7, 10.2)
	Median (95% CI)	8.4 (3.8, -)	10.2 (6.3, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (6.7, -)
	Log-Rank P-value [2]	0.80399	
	Hazard Ratio (95% CI) [3]	0.82 (0.16, 4.08)	
	P-value [3]	0.80433	
Interaction Test	P-value [4]	0.37699	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 13 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	6 (75%)	4 (67%)
	Censored, follow-up ended	1 (13%)	1 (17%)
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 7.6)	2.1 (1.0, 8.7)
	Median (95% CI)	4.8 (1.0, -)	7.6 (1.0, -)
	3rd Quartile (95% CI)	23.3 (1.1, -)	- (2.1, -)
	Log-Rank P-value [2]	0.88314	
	Hazard Ratio (95% CI) [3]	1.11 (0.28, 4.47)	
	P-value [3]	0.88299	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 14 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	9 (69%)	4 (29%)
	Censored, follow-up ended	4 (31%)	8 (57%)
	Censored, follow-up ongoing	0	2 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 2.8)	1.8 (0.9, -)
	Median (95% CI)	5.1 (1.0, 7.4)	20.3 (1.0, -)
	3rd Quartile (95% CI)	7.4 (2.8, -)	- (20.3, -)
	Log-Rank P-value [2]	0.04798	
	Hazard Ratio (95% CI) [3]	3.54 (0.94, 13.31)	
	P-value [3]	0.06094	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 15 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	8 (62%)
	Censored, follow-up ended	5 (56%)	4 (31%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (3.7, 4.7)	1.1 (0.9, 6.7)
	Median (95% CI)	4.7 (3.7, -)	6.7 (1.1, -)
	3rd Quartile (95% CI)	- (3.7, -)	11.2 (6.7, -)
	Log-Rank P-value [2]	0.79699	
	Hazard Ratio (95% CI) [3]	1.19 (0.28, 5.02)	
	P-value [3]	0.81139	
Interaction Test	P-value [4]	0.31204	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	5 (63%)	4 (67%)
	Censored, follow-up ended	3 (38%)	0
	Censored, follow-up ongoing	0	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.1, 5.6)	1.1 (1.0, 6.5)
	Median (95% CI)	5.6 (1.1, -)	4.1 (1.0, -)
	3rd Quartile (95% CI)	11.8 (2.0, -)	- (1.1, -)
	Log-Rank P-value [2]	0.92967	
	Hazard Ratio (95% CI) [3]	0.94 (0.25, 3.53)	
	P-value [3]	0.92941	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 17 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	10 (77%)	4 (29%)
	Censored, follow-up ended	3 (23%)	7 (50%)
	Censored, follow-up ongoing	0	3 (21%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.4 (1.0, 3.6)	2.0 (1.0, -)
	Median (95% CI)	3.6 (1.0, 5.6)	- (1.8, -)
	3rd Quartile (95% CI)	5.6 (3.6, -)	- (-, -)
	Log-Rank P-value [2]	0.03569	
	Hazard Ratio (95% CI) [3]	3.32 (1.02, 10.84)	
	P-value [3]	0.04711	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Table 4.0001055

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	7 (54%)
	Censored, follow-up ended	4 (44%)	5 (38%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, -)	1.1 (1.0, 3.7)
	Median (95% CI)	3.8 (1.0, -)	3.7 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	11.2 (1.9, -)
	Log-Rank P-value [2]	0.74979	
	Hazard Ratio (95% CI) [3]	0.80 (0.21, 3.11)	
	P-value [3]	0.74756	
Interaction Test	P-value [4]	0.18297	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 19 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	5 (63%)	5 (83%)
	Censored, follow-up ended	2 (25%)	0
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.8)	1.8 (1.1, 3.8)
	Median (95% CI)	3.8 (1.0, -)	3.3 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	6.9 (1.8, -)
	Log-Rank P-value [2]	0.75463	
	Hazard Ratio (95% CI) [3]	0.82 (0.24, 2.84)	
	P-value [3]	0.75313	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 20 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	7 (54%)	6 (43%)
	Censored, follow-up ended	6 (46%)	8 (57%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.1)	1.1 (1.0, -)
	Median (95% CI)	5.2 (1.0, -)	7.4 (1.1, -)
	3rd Quartile (95% CI)	- (1.1, -)	7.4 (2.8, -)
	Log-Rank P-value [2]	0.95192	
	Hazard Ratio (95% CI) [3]	1.05 (0.33, 3.30)	
	P-value [3]	0.93805	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 21 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	9 (69%)
	Censored, follow-up ended	4 (44%)	3 (23%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, -)	1.0 (0.9, 1.1)
	Median (95% CI)	5.6 (1.0, -)	1.1 (1.0, -)
	3rd Quartile (95% CI)	9.3 (3.8, -)	- (1.1, -)
	Log-Rank P-value [2]	0.42612	
	Hazard Ratio (95% CI) [3]	0.61 (0.19, 2.03)	
	P-value [3]	0.42350	
Interaction Test	P-value [4]	0.69988	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 22 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	4 (50%)	3 (50%)
	Censored, follow-up ended	2 (25%)	2 (33%)
	Censored, follow-up ongoing	2 (25%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 11.0)	2.8 (1.9, -)
	Median (95% CI)	11.0 (1.0, -)	8.7 (1.9, -)
	3rd Quartile (95% CI)	- (4.4, -)	- (2.8, -)
	Log-Rank P-value [2]	0.99350	
	Hazard Ratio (95% CI) [3]	1.01 (0.22, 4.59)	
	P-value [3]	0.99350	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 23 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	6 (43%)
	Censored, follow-up ended	6 (46%)	7 (50%)
	Censored, follow-up ongoing	1 (8%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 11.5)	5.7 (1.0, 18.4)
	Median (95% CI)	11.5 (2.9, -)	9.3 (3.7, -)
	3rd Quartile (95% CI)	28.4 (6.5, -)	43.7 (5.7, -)
	Log-Rank P-value [2]	0.57705	
	Hazard Ratio (95% CI) [3]	1.41 (0.42, 4.68)	
	P-value [3]	0.57877	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 24 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	5 (38%)
	Censored, follow-up ended	6 (67%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (2.0, -)	2.3 (0.7, -)
	Median (95% CI)	- (2.0, -)	12.5 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	12.5 (4.5, -)
	Log-Rank P-value [2]	0.98474	
	Hazard Ratio (95% CI) [3]	0.98 (0.18, 5.41)	
	P-value [3]	0.98478	
Interaction Test	P-value [4]	0.82618	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 25 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	5 (63%)	6 (100%)
	Censored, follow-up ended	2 (25%)	0
	Censored, follow-up ongoing	1 (13%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.1, 4.2)	3.8 (3.7, 6.9)
	Median (95% CI)	4.2 (1.1, -)	6.0 (3.7, -)
	3rd Quartile (95% CI)	- (3.7, -)	7.9 (3.8, -)
	Log-Rank P-value [2]	0.79232	
	Hazard Ratio (95% CI) [3]	0.85 (0.26, 2.82)	
	P-value [3]	0.79252	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 26 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	3 (21%)
	Censored, follow-up ended	6 (46%)	10 (71%)
	Censored, follow-up ongoing	2 (15%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	22.3 (2.1, -)
	Median (95% CI)	- (1.0, -)	- (4.7, -)
	3rd Quartile (95% CI)	- (4.8, -)	- (22.3, -)
	Log-Rank P-value [2]	0.33080	
	Hazard Ratio (95% CI) [3]	2.03 (0.48, 8.52)	
	P-value [3]	0.33572	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 27 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	6 (46%)
	Censored, follow-up ended	5 (56%)	5 (38%)
	Censored, follow-up ongoing	1 (11%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (3.8, -)	1.9 (1.1, 12.5)
	Median (95% CI)	10.2 (3.8, -)	4.9 (1.7, -)
	3rd Quartile (95% CI)	10.2 (3.8, -)	- (4.9, -)
	Log-Rank P-value [2]	0.84144	
	Hazard Ratio (95% CI) [3]	1.16 (0.27, 4.94)	
	P-value [3]	0.84158	
Interaction Test	P-value [4]	0.53065	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 28 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	4 (50%)	3 (50%)
	Censored, follow-up ended	4 (50%)	2 (33%)
	Censored, follow-up ongoing	0	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (2.0, -)	6.9 (3.7, 8.4)
	Median (95% CI)	35.1 (2.0, -)	8.4 (3.7, -)
	3rd Quartile (95% CI)	35.1 (3.8, -)	- (6.9, -)
	Log-Rank P-value [2]	0.93919	
	Hazard Ratio (95% CI) [3]	0.94 (0.19, 4.68)	
	P-value [3]	0.93916	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 29 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	7 (54%)	5 (36%)
	Censored, follow-up ended	5 (38%)	8 (57%)
	Censored, follow-up ongoing	1 (8%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (1.0, 3.7)	2.9 (1.0, 22.3)
	Median (95% CI)	3.7 (1.0, -)	22.3 (1.0, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (22.3, -)
	Log-Rank P-value [2]	0.53880	
	Hazard Ratio (95% CI) [3]	1.43 (0.45, 4.56)	
	P-value [3]	0.54330	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 30 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	6 (46%)
	Censored, follow-up ended	5 (56%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	2.8 (1.1, 8.3)
	Median (95% CI)	5.6 (1.0, -)	8.3 (1.9, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (6.9, -)
	Log-Rank P-value [2]	0.76080	
	Hazard Ratio (95% CI) [3]	1.24 (0.31, 5.02)	
	P-value [3]	0.76122	
Interaction Test	P-value [4]	0.95420	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 31 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	5 (63%)	4 (67%)
	Censored, follow-up ended	1 (13%)	1 (17%)
	Censored, follow-up ongoing	2 (25%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (0.9, 4.2)	2.8 (1.8, 4.7)
	Median (95% CI)	4.2 (0.9, -)	4.2 (1.8, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (2.8, -)
	Log-Rank P-value [2]	0.88111	
	Hazard Ratio (95% CI) [3]	0.90 (0.22, 3.60)	
	P-value [3]	0.88094	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 32 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	7 (50%)
	Censored, follow-up ended	7 (54%)	7 (50%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.5 (1.0, 40.6)	1.1 (1.0, 7.4)
	Median (95% CI)	40.6 (1.1, -)	7.4 (1.1, -)
	3rd Quartile (95% CI)	- (7.0, -)	43.7 (3.8, -)
	Log-Rank P-value [2]	0.39295	
	Hazard Ratio (95% CI) [3]	0.60 (0.19, 1.92)	
	P-value [3]	0.39118	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 33 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	8 (62%)
	Censored, follow-up ended	5 (56%)	4 (31%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.9 (6.9, -)	1.1 (0.7, 4.7)
	Median (95% CI)	8.3 (6.9, -)	4.7 (1.1, 12.5)
	3rd Quartile (95% CI)	- (6.9, -)	12.5 (2.9, -)
	Log-Rank P-value [2]	0.12672	
	Hazard Ratio (95% CI) [3]	0.31 (0.06, 1.50)	
	P-value [3]	0.14596	
Interaction Test	P-value [4]	0.73923	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 34 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	4 (50%)	3 (50%)
	Censored, follow-up ended	2 (25%)	2 (33%)
	Censored, follow-up ongoing	2 (25%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	10.2 (4.2, 39.7)	3.7 (1.0, -)
	Median (95% CI)	39.7 (4.2, -)	9.7 (1.0, -)
	3rd Quartile (95% CI)	- (10.2, -)	- (3.7, -)
	Log-Rank P-value [2]	0.31794	
	Hazard Ratio (95% CI) [3]	0.44 (0.08, 2.30)	
	P-value [3]	0.32935	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 35 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	8 (57%)
	Censored, follow-up ended	6 (46%)	6 (43%)
	Censored, follow-up ongoing	2 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, 10.3)	2.9 (1.9, 6.0)
	Median (95% CI)	10.3 (1.0, -)	6.0 (2.8, -)
	3rd Quartile (95% CI)	- (10.3, -)	22.3 (5.7, -)
	Log-Rank P-value [2]	0.44309	
	Hazard Ratio (95% CI) [3]	0.65 (0.21, 1.99)	
	P-value [3]	0.44660	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 36 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	1 (11%)	6 (46%)
	Censored, follow-up ended	6 (67%)	6 (46%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (4.7, -)	4.5 (1.1, 6.7)
	Median (95% CI)	- (4.7, -)	6.7 (1.1, -)
	3rd Quartile (95% CI)	- (4.7, -)	- (5.6, -)
	Log-Rank P-value [2]	0.23037	
	Hazard Ratio (95% CI) [3]	0.30 (0.04, 2.46)	
	P-value [3]	0.25914	
Interaction Test	P-value [4]	0.69722	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 37 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	5 (63%)	4 (67%)
	Censored, follow-up ended	2 (25%)	1 (17%)
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.9, 9.3)	3.7 (1.1, 6.9)
	Median (95% CI)	9.3 (1.9, -)	5.8 (1.1, -)
	3rd Quartile (95% CI)	11.1 (4.2, -)	- (3.7, -)
	Log-Rank P-value [2]	0.88540	
	Hazard Ratio (95% CI) [3]	0.91 (0.24, 3.43)	
	P-value [3]	0.88544	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	7 (54%)	8 (57%)
	Censored, follow-up ended	4 (31%)	6 (43%)
	Censored, follow-up ongoing	2 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 7.4)	1.1 (1.0, 3.8)
	Median (95% CI)	5.8 (1.1, 8.8)	3.8 (1.0, -)
	3rd Quartile (95% CI)	8.8 (5.8, -)	43.7 (3.0, -)
	Log-Rank P-value [2]	0.60950	
	Hazard Ratio (95% CI) [3]	0.77 (0.28, 2.13)	
	P-value [3]	0.61212	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 39 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	1 (11%)	9 (69%)
	Censored, follow-up ended	6 (67%)	4 (31%)
	Censored, follow-up ongoing	2 (22%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.1, -)	1.1 (0.7, 1.9)
	Median (95% CI)	- (1.1, -)	1.9 (1.0, 2.3)
	3rd Quartile (95% CI)	- (1.1, -)	2.3 (1.7, -)
	Log-Rank P-value [2]	0.02909	
	Hazard Ratio (95% CI) [3]	0.14 (0.02, 1.09)	
	P-value [3]	0.06077	
Interaction Test	P-value [4]	0.17092	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 40 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	3 (38%)	2 (33%)
	Censored, follow-up ended	3 (38%)	2 (33%)
	Censored, follow-up ongoing	2 (25%)	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, -)	8.7 (1.9, -)
	Median (95% CI)	23.3 (1.0, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (23.3, -)	- (8.7, -)
	Log-Rank P-value [2]	0.93053	
	Hazard Ratio (95% CI) [3]	1.08 (0.18, 6.67)	
	P-value [3]	0.93055	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Table 4.0001055

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	3 (23%)	4 (29%)
	Censored, follow-up ended	8 (62%)	8 (57%)
	Censored, follow-up ongoing	2 (15%)	2 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.1, -)	2.8 (1.1, -)
	Median (95% CI)	- (2.1, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.56186	
	Hazard Ratio (95% CI) [3]	0.64 (0.14, 2.86)	
	P-value [3]	0.55543	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 42 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	1 (11%)	9 (69%)
	Censored, follow-up ended	6 (67%)	3 (23%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.1, -)	1.1 (0.9, 1.9)
	Median (95% CI)	- (1.1, -)	6.9 (1.0, -)
	3rd Quartile (95% CI)	- (1.1, -)	9.2 (1.9, -)
	Log-Rank P-value [2]	0.06608	
	Hazard Ratio (95% CI) [3]	0.18 (0.02, 1.41)	
	P-value [3]	0.10238	
Interaction Test	P-value [4]	0.40324	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 43 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	1 (13%)	3 (50%)
	Censored, follow-up ended	5 (63%)	1 (17%)
	Censored, follow-up ongoing	2 (25%)	2 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 44 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	3 (21%)
	Censored, follow-up ended	7 (54%)	9 (64%)
	Censored, follow-up ongoing	1 (8%)	2 (14%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 45 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001055
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	6 (46%)
	Censored, follow-up ended	5 (56%)	4 (31%)
	Censored, follow-up ongoing	2 (22%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line.sas 09OCT2025 10:06

Protocol: 207499 Page 1 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	8 (38%)	10 (50%)
	Censored, follow-up ended	9 (43%)	9 (45%)
	Censored, follow-up ongoing	4 (19%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.9, 11.8)	2.0 (0.8, 3.8)
	Median (95% CI)	11.8 (3.7, -)	6.6 (1.8, -)
	3rd Quartile (95% CI)	- (11.8, -)	- (6.6, -)
	Log-Rank P-value [2]	0.20488	
	Hazard Ratio (95% CI) [3]	0.55 (0.22, 1.41)	
	P-value [3]	0.21189	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 2 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	7 (54%)
	Censored, follow-up ended	4 (44%)	5 (38%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	1.1 (1.0, 2.8)
	Median (95% CI)	7.0 (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	10.2 (1.1, -)	9.3 (1.7, -)
	Log-Rank P-value [2]	0.84405	
	Hazard Ratio (95% CI) [3]	0.87 (0.25, 3.01)	
	P-value [3]	0.83210	
Interaction Test	P-value [4]	0.52351	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 3 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	9 (43%)	10 (50%)
	Censored, follow-up ended	9 (43%)	9 (45%)
	Censored, follow-up ongoing	3 (14%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.6 (1.0, 13.0)	3.7 (0.7, 6.9)
	Median (95% CI)	13.0 (3.6, -)	6.9 (2.1, 22.3)
	3rd Quartile (95% CI)	- (13.0, -)	22.3 (6.9, -)
	Log-Rank P-value [2]	0.46100	
	Hazard Ratio (95% CI) [3]	0.71 (0.29, 1.76)	
	P-value [3]	0.46407	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Table 4.0001075

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	7 (54%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 5.6)	1.1 (1.0, 3.3)
	Median (95% CI)	4.7 (1.0, -)	3.3 (1.1, -)
	3rd Quartile (95% CI)	- (3.7, -)	12.5 (2.8, -)
	Log-Rank P-value [2]	0.93126	
	Hazard Ratio (95% CI) [3]	0.94 (0.26, 3.36)	
	P-value [3]	0.91957	
Interaction Test	P-value [4]	0.74314	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 5 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	12 (57%)	10 (50%)
	Censored, follow-up ended	8 (38%)	8 (40%)
	Censored, follow-up ongoing	1 (5%)	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 4.2)	2.4 (1.1, 3.8)
	Median (95% CI)	4.2 (2.0, 10.2)	5.2 (2.1, -)
	3rd Quartile (95% CI)	10.2 (5.6, -)	- (3.8, -)
	Log-Rank P-value [2]	0.64235	
	Hazard Ratio (95% CI) [3]	1.22 (0.52, 2.85)	
	P-value [3]	0.64222	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 6 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	7 (54%)
	Censored, follow-up ended	3 (33%)	5 (38%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 4.2)	1.1 (0.9, 2.8)
	Median (95% CI)	4.0 (1.0, -)	12.5 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	- (2.8, -)
	Log-Rank P-value [2]	0.99572	
	Hazard Ratio (95% CI) [3]	0.99 (0.29, 3.39)	
	P-value [3]	0.98386	
Interaction Test	P-value [4]	0.75579	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 7 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	8 (38%)	7 (35%)
	Censored, follow-up ended	10 (48%)	9 (45%)
	Censored, follow-up ongoing	3 (14%)	4 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, 7.4)	3.8 (0.9, 18.4)
	Median (95% CI)	33.2 (3.7, -)	18.4 (3.7, -)
	3rd Quartile (95% CI)	- (33.2, -)	- (18.4, -)
	Log-Rank P-value [2]	0.95136	
	Hazard Ratio (95% CI) [3]	1.04 (0.37, 2.87)	
	P-value [3]	0.94596	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 8 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	6 (46%)
	Censored, follow-up ended	5 (56%)	5 (38%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	8.4 (3.8, -)	6.7 (1.7, 10.2)
	Median (95% CI)	8.4 (3.8, -)	10.2 (6.3, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (6.7, -)
	Log-Rank P-value [2]	0.80399	
	Hazard Ratio (95% CI) [3]	0.82 (0.16, 4.08)	
	P-value [3]	0.80433	
Interaction Test	P-value [4]	0.66431	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 9 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	15 (71%)	8 (40%)
	Censored, follow-up ended	5 (24%)	9 (45%)
	Censored, follow-up ongoing	1 (5%)	3 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 2.0)	2.1 (0.9, 8.7)
	Median (95% CI)	5.1 (1.0, 7.5)	8.7 (1.8, -)
	3rd Quartile (95% CI)	7.6 (7.4, -)	- (8.7, -)
	Log-Rank P-value [2]	0.06624	
	Hazard Ratio (95% CI) [3]	2.21 (0.93, 5.24)	
	P-value [3]	0.07241	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Table 4.0001075

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	8 (62%)
	Censored, follow-up ended	5 (56%)	4 (31%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (3.7, 4.7)	1.1 (0.9, 6.7)
	Median (95% CI)	4.7 (3.7, -)	6.7 (1.1, -)
	3rd Quartile (95% CI)	- (3.7, -)	11.2 (6.7, -)
	Log-Rank P-value [2]	0.79699	
	Hazard Ratio (95% CI) [3]	1.19 (0.28, 5.02)	
	P-value [3]	0.81139	
Interaction Test	P-value [4]	0.43279	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 11 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	15 (71%)	8 (40%)
	Censored, follow-up ended	6 (29%)	7 (35%)
	Censored, follow-up ongoing	0	5 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.6)	1.8 (1.0, 6.5)
	Median (95% CI)	3.7 (1.9, 5.6)	- (1.8, -)
	3rd Quartile (95% CI)	11.3 (3.7, -)	- (-, -)
	Log-Rank P-value [2]	0.08418	
	Hazard Ratio (95% CI) [3]	2.10 (0.88, 5.01)	
	P-value [3]	0.09453	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 12 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	7 (54%)
	Censored, follow-up ended	4 (44%)	5 (38%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, -)	1.1 (1.0, 3.7)
	Median (95% CI)	3.8 (1.0, -)	3.7 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	11.2 (1.9, -)
	Log-Rank P-value [2]	0.74979	
	Hazard Ratio (95% CI) [3]	0.80 (0.21, 3.11)	
	P-value [3]	0.74756	
Interaction Test	P-value [4]	0.21118	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 13 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	12 (57%)	11 (55%)
	Censored, follow-up ended	8 (38%)	8 (40%)
	Censored, follow-up ongoing	1 (5%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 2.0)	1.8 (1.0, 2.8)
	Median (95% CI)	3.8 (1.0, -)	3.8 (1.1, 7.4)
	3rd Quartile (95% CI)	- (3.8, -)	7.4 (3.8, -)
	Log-Rank P-value [2]	0.92920	
	Hazard Ratio (95% CI) [3]	1.04 (0.46, 2.38)	
	P-value [3]	0.92428	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Table 4.0001075

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	9 (69%)
	Censored, follow-up ended	4 (44%)	3 (23%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, -)	1.0 (0.9, 1.1)
	Median (95% CI)	5.6 (1.0, -)	1.1 (1.0, -)
	3rd Quartile (95% CI)	9.3 (3.8, -)	- (1.1, -)
	Log-Rank P-value [2]	0.42612	
	Hazard Ratio (95% CI) [3]	0.61 (0.19, 2.03)	
	P-value [3]	0.42350	
Interaction Test	P-value [4]	0.45733	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 15 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	10 (48%)	9 (45%)
	Censored, follow-up ended	8 (38%)	9 (45%)
	Censored, follow-up ongoing	3 (14%)	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 11.0)	5.7 (1.0, 9.3)
	Median (95% CI)	11.0 (3.8, -)	9.3 (3.7, -)
	3rd Quartile (95% CI)	- (11.0, -)	43.7 (8.7, -)
	Log-Rank P-value [2]	0.83092	
	Hazard Ratio (95% CI) [3]	1.11 (0.43, 2.82)	
	P-value [3]	0.83128	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 16 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	5 (38%)
	Censored, follow-up ended	6 (67%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (2.0, -)	2.3 (0.7, -)
	Median (95% CI)	- (2.0, -)	12.5 (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	12.5 (4.5, -)
	Log-Rank P-value [2]	0.98474	
	Hazard Ratio (95% CI) [3]	0.98 (0.18, 5.41)	
	P-value [3]	0.98478	
Interaction Test	P-value [4]	0.82270	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 17 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	10 (48%)	9 (45%)
	Censored, follow-up ended	8 (38%)	10 (50%)
	Censored, follow-up ongoing	3 (14%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 4.2)	5.1 (2.1, 7.9)
	Median (95% CI)	4.8 (1.9, -)	7.9 (4.7, -)
	3rd Quartile (95% CI)	- (4.8, -)	- (7.9, -)
	Log-Rank P-value [2]	0.49951	
	Hazard Ratio (95% CI) [3]	1.37 (0.55, 3.38)	
	P-value [3]	0.49793	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 18 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	6 (46%)
	Censored, follow-up ended	5 (56%)	5 (38%)
	Censored, follow-up ongoing	1 (11%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (3.8, -)	1.9 (1.1, 12.5)
	Median (95% CI)	10.2 (3.8, -)	4.9 (1.7, -)
	3rd Quartile (95% CI)	10.2 (3.8, -)	- (4.9, -)
	Log-Rank P-value [2]	0.84144	
	Hazard Ratio (95% CI) [3]	1.16 (0.27, 4.94)	
	P-value [3]	0.84158	
Interaction Test	P-value [4]	0.81090	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 19 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	11 (52%)	8 (40%)
	Censored, follow-up ended	9 (43%)	10 (50%)
	Censored, follow-up ongoing	1 (5%)	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 3.8)	3.7 (1.0, 8.4)
	Median (95% CI)	9.4 (2.0, -)	8.4 (3.7, -)
	3rd Quartile (95% CI)	35.1 (9.4, -)	22.3 (8.4, -)
	Log-Rank P-value [2]	0.66168	
	Hazard Ratio (95% CI) [3]	1.23 (0.49, 3.07)	
	P-value [3]	0.66312	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Table 4.0001075

Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	6 (46%)
	Censored, follow-up ended	5 (56%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	2.8 (1.1, 8.3)
	Median (95% CI)	5.6 (1.0, -)	8.3 (1.9, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (6.9, -)
	Log-Rank P-value [2]	0.76080	
	Hazard Ratio (95% CI) [3]	1.24 (0.31, 5.02)	
	P-value [3]	0.76122	
Interaction Test	P-value [4]	0.93770	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 21 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	10 (48%)	11 (55%)
	Censored, follow-up ended	8 (38%)	8 (40%)
	Censored, follow-up ongoing	3 (14%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (0.9, 7.0)	2.8 (1.0, 3.8)
	Median (95% CI)	29.9 (2.0, -)	4.7 (1.8, -)
	3rd Quartile (95% CI)	- (29.9, -)	43.7 (4.7, -)
	Log-Rank P-value [2]	0.50294	
	Hazard Ratio (95% CI) [3]	0.74 (0.31, 1.77)	
	P-value [3]	0.50051	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 22 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	8 (62%)
	Censored, follow-up ended	5 (56%)	4 (31%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.9 (6.9, -)	1.1 (0.7, 4.7)
	Median (95% CI)	8.3 (6.9, -)	4.7 (1.1, 12.5)
	3rd Quartile (95% CI)	- (6.9, -)	12.5 (2.9, -)
	Log-Rank P-value [2]	0.12672	
	Hazard Ratio (95% CI) [3]	0.31 (0.06, 1.50)	
	P-value [3]	0.14596	
Interaction Test	P-value [4]	0.45812	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 23 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	9 (43%)	11 (55%)
	Censored, follow-up ended	8 (38%)	8 (40%)
	Censored, follow-up ongoing	4 (19%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.6 (1.0, 10.3)	3.7 (1.0, 6.0)
	Median (95% CI)	14.3 (4.2, -)	6.0 (2.9, -)
	3rd Quartile (95% CI)	- (10.3, -)	22.3 (6.0, -)
	Log-Rank P-value [2]	0.16304	
	Hazard Ratio (95% CI) [3]	0.52 (0.21, 1.32)	
	P-value [3]	0.17048	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	1 (11%)	6 (46%)
	Censored, follow-up ended	6 (67%)	6 (46%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (4.7, -)	4.5 (1.1, 6.7)
	Median (95% CI)	- (4.7, -)	6.7 (1.1, -)
	3rd Quartile (95% CI)	- (4.7, -)	- (5.6, -)
	Log-Rank P-value [2]	0.23037	
	Hazard Ratio (95% CI) [3]	0.30 (0.04, 2.46)	
	P-value [3]	0.25914	
Interaction Test	P-value [4]	0.44590	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 25 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	12 (57%)	12 (60%)
	Censored, follow-up ended	6 (29%)	7 (35%)
	Censored, follow-up ongoing	3 (14%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 5.8)	1.9 (1.0, 3.8)
	Median (95% CI)	7.4 (1.9, 11.1)	4.7 (1.1, -)
	3rd Quartile (95% CI)	11.1 (7.4, -)	43.7 (4.7, -)
	Log-Rank P-value [2]	0.68479	
	Hazard Ratio (95% CI) [3]	0.85 (0.38, 1.90)	
	P-value [3]	0.69063	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 26 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	1 (11%)	9 (69%)
	Censored, follow-up ended	6 (67%)	4 (31%)
	Censored, follow-up ongoing	2 (22%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.1, -)	1.1 (0.7, 1.9)
	Median (95% CI)	- (1.1, -)	1.9 (1.0, 2.3)
	3rd Quartile (95% CI)	- (1.1, -)	2.3 (1.7, -)
	Log-Rank P-value [2]	0.02909	
	Hazard Ratio (95% CI) [3]	0.14 (0.02, 1.09)	
	P-value [3]	0.06077	
Interaction Test	P-value [4]	0.06236	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 27 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	6 (29%)	6 (30%)
	Censored, follow-up ended	11 (52%)	10 (50%)
	Censored, follow-up ongoing	4 (19%)	4 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, -)	3.7 (1.1, -)
	Median (95% CI)	- (5.6, -)	- (2.8, -)
	3rd Quartile (95% CI)	- (23.3, -)	- (-, -)
	Log-Rank P-value [2]	0.78129	
	Hazard Ratio (95% CI) [3]	0.85 (0.27, 2.63)	
	P-value [3]	0.77530	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 28 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	1 (11%)	9 (69%)
	Censored, follow-up ended	6 (67%)	3 (23%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.1, -)	1.1 (0.9, 1.9)
	Median (95% CI)	- (1.1, -)	6.9 (1.0, -)
	3rd Quartile (95% CI)	- (1.1, -)	9.2 (1.9, -)
	Log-Rank P-value [2]	0.06608	
	Hazard Ratio (95% CI) [3]	0.18 (0.02, 1.41)	
	P-value [3]	0.10238	
Interaction Test	P-value [4]	0.19958	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 29 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	6 (29%)	6 (30%)
	Censored, follow-up ended	12 (57%)	10 (50%)
	Censored, follow-up ongoing	3 (14%)	4 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	21.3 (1.0, -)	9.3 (2.8, -)
	Median (95% CI)	- (7.4, -)	- (3.8, -)
	3rd Quartile (95% CI)	- (22.2, -)	- (11.1, -)
	Log-Rank P-value [2]	0.65429	
	Hazard Ratio (95% CI) [3]	0.77 (0.25, 2.43)	
	P-value [3]	0.66166	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 30 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001075
Summary of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	6 (46%)
	Censored, follow-up ended	5 (56%)	4 (31%)
	Censored, follow-up ongoing	2 (22%)	3 (23%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	14.0 (3.8, -)	4.9 (0.7, 11.2)
	Median (95% CI)	24.3 (3.8, -)	11.2 (1.0, -)
	3rd Quartile (95% CI)	24.3 (3.8, -)	- (6.9, -)
	Log-Rank P-value [2]	0.54622	
	Hazard Ratio (95% CI) [3]	0.61 (0.12, 3.07)	
	P-value [3]	0.55005	
Interaction Test	P-value [4]	0.79798	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_ttd_2ref_line2.sas 09OCT2025 10:05

Protocol: 207499 Page 1 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	20 (67%)	20 (61%)
Censored, follow-up ended	8 (27%)	11 (33%)
Censored, follow-up ongoing	2 (7%)	2 (6%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.9 (0.9, 2.8)	1.2 (1.0, 2.0)
Median (95% CI)	2.9 (1.9, 4.7)	2.9 (1.4, 15.7)
3rd Quartile (95% CI)	12.2 (3.0, -)	33.5 (4.7, -)
Log-Rank P-value [2]	0.58421	
Inverse Hazard Ratio (95% CI) [3]	0.84 (0.45, 1.56)	
P-value [3]	0.57910	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	15 (50%)	16 (48%)
Censored, follow-up ended	11 (37%)	12 (36%)
Censored, follow-up ongoing	4 (13%)	5 (15%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.9 (0.9, 3.8)	1.9 (1.0, 3.8)
Median (95% CI)	3.8 (1.9, -)	6.0 (1.9, -)
3rd Quartile (95% CI)	- (4.8, -)	18.5 (10.6, -)
Log-Rank P-value [2]	0.99070	
Inverse Hazard Ratio (95% CI) [3]	1.00 (0.49, 2.04)	
P-value [3]	0.99089	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	14 (47%)	16 (48%)
Censored, follow-up ended	13 (43%)	12 (36%)
Censored, follow-up ongoing	3 (10%)	5 (15%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.0 (0.9, 1.9)	1.1 (1.0, 2.8)
Median (95% CI)	7.5 (1.1, -)	6.0 (1.2, -)
3rd Quartile (95% CI)	- (11.2, -)	20.4 (9.7, -)
Log-Rank P-value [2]	0.77679	
Inverse Hazard Ratio (95% CI) [3]	1.09 (0.53, 2.26)	
P-value [3]	0.80785	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Protocol: 207499 Page 4 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001105
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	17 (57%)	16 (48%)
Censored, follow-up ended	10 (33%)	15 (45%)
Censored, follow-up ongoing	3 (10%)	2 (6%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (1.0, 1.9)	1.1 (1.0, 2.0)
Median (95% CI)	2.8 (1.1, 7.9)	3.3 (1.1, -)
3rd Quartile (95% CI)	37.6 (5.7, -)	- (3.7, -)
Log-Rank P-value [2]	0.72104	
Inverse Hazard Ratio (95% CI) [3]	0.88 (0.44, 1.75)	
P-value [3]	0.70917	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Protocol: 207499 Page 5 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001105
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	12 (40%)	17 (52%)
Censored, follow-up ended	13 (43%)	13 (39%)
Censored, follow-up ongoing	5 (17%)	3 (9%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.9, 2.0)	1.0 (0.8, 1.1)
Median (95% CI)	19.2 (1.1, -)	2.8 (1.0, -)
3rd Quartile (95% CI)	- (19.2, -)	- (3.7, -)
Log-Rank P-value [2]	0.35176	
Inverse Hazard Ratio (95% CI) [3]	1.42 (0.67, 2.97)	
P-value [3]	0.35753	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Protocol: 207499 Page 6 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001105
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	15 (50%)	14 (42%)
Censored, follow-up ended	10 (33%)	15 (45%)
Censored, follow-up ongoing	5 (17%)	4 (12%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.9, 3.7)	1.2 (1.0, 2.8)
Median (95% CI)	4.8 (1.2, -)	18.5 (1.4, -)
3rd Quartile (95% CI)	- (7.3, -)	- (18.5, -)
Log-Rank P-value [2]	0.81919	
Inverse Hazard Ratio (95% CI) [3]	0.92 (0.44, 1.93)	
P-value [3]	0.81890	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	19 (63%)	20 (61%)
Censored, follow-up ended	10 (33%)	10 (30%)
Censored, follow-up ongoing	1 (3%)	3 (9%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.9, 1.9)	1.0 (1.0, 2.0)
Median (95% CI)	2.0 (1.1, 14.1)	2.8 (1.2, 5.7)
3rd Quartile (95% CI)	14.1 (2.0, -)	9.7 (3.8, -)
Log-Rank P-value [2]	0.97820	
Inverse Hazard Ratio (95% CI) [3]	0.99 (0.52, 1.88)	
P-value [3]	0.97088	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	6 (20%)	8 (24%)
Censored, follow-up ended	16 (53%)	20 (61%)
Censored, follow-up ongoing	8 (27%)	5 (15%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.2 (1.0, -)	2.1 (1.0, -)
Median (95% CI)	- (9.2, -)	- (4.6, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.70499	
Inverse Hazard Ratio (95% CI) [3]	1.22 (0.42, 3.53)	
P-value [3]	0.71179	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Protocol: 207499 Page 9 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001105
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	19 (63%)	23 (70%)
Censored, follow-up ended	8 (27%)	8 (24%)
Censored, follow-up ongoing	3 (10%)	2 (6%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.0 (0.9, 1.1)	1.0 (1.0, 1.1)
Median (95% CI)	1.2 (1.0, 2.8)	1.4 (1.1, 1.9)
3rd Quartile (95% CI)	20.3 (1.9, -)	2.9 (1.8, -)
Log-Rank P-value [2]	0.72643	
Inverse Hazard Ratio (95% CI) [3]	1.11 (0.60, 2.05)	
P-value [3]	0.73842	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Protocol: 207499 Page 10 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001105
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	13 (43%)	10 (30%)
Censored, follow-up ended	11 (37%)	16 (48%)
Censored, follow-up ongoing	6 (20%)	7 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.9 (0.9, 7.0)	2.1 (1.0, -)
Median (95% CI)	10.3 (1.9, -)	- (5.6, -)
3rd Quartile (95% CI)	- (10.3, -)	- (-, -)
Log-Rank P-value [2]	0.35605	
Inverse Hazard Ratio (95% CI) [3]	0.68 (0.30, 1.55)	
P-value [3]	0.36068	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Protocol: 207499 Page 11 of 15
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001105
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	15 (50%)	11 (33%)
Censored, follow-up ended	12 (40%)	16 (48%)
Censored, follow-up ongoing	3 (10%)	6 (18%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (1.0, 3.7)	2.3 (1.0, 8.3)
Median (95% CI)	10.9 (1.1, 13.3)	- (3.8, -)
3rd Quartile (95% CI)	- (12.1, -)	- (-, -)
Log-Rank P-value [2]	0.20904	
Inverse Hazard Ratio (95% CI) [3]	0.61 (0.28, 1.33)	
P-value [3]	0.21237	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	10 (33%)	10 (30%)
Censored, follow-up ended	15 (50%)	16 (48%)
Censored, follow-up ongoing	5 (17%)	7 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.5 (1.0, 34.9)	2.1 (1.0, -)
Median (95% CI)	34.9 (1.9, -)	- (3.7, -)
3rd Quartile (95% CI)	- (34.9, -)	- (-, -)
Log-Rank P-value [2]	0.71823	
Inverse Hazard Ratio (95% CI) [3]	0.85 (0.35, 2.04)	
P-value [3]	0.71519	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	6 (20%)	7 (21%)
Censored, follow-up ended	18 (60%)	19 (58%)
Censored, follow-up ongoing	6 (20%)	7 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.8 (1.0, -)	5.7 (1.0, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.95099	
Inverse Hazard Ratio (95% CI) [3]	0.97 (0.32, 2.88)	
P-value [3]	0.94992	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	9 (30%)	8 (24%)
Censored, follow-up ended	15 (50%)	18 (55%)
Censored, follow-up ongoing	6 (20%)	7 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.9 (0.9, -)	3.3 (0.8, -)
Median (95% CI)	- (1.9, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.60072	
Inverse Hazard Ratio (95% CI) [3]	0.77 (0.30, 2.00)	
P-value [3]	0.59547	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Table 4.0001105

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	9 (30%)	7 (21%)
Censored, follow-up ended	15 (50%)	19 (58%)
Censored, follow-up ongoing	6 (20%)	7 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (1.0, -)	19.4 (1.9, -)
Median (95% CI)	- (1.2, -)	- (19.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.25636	
Inverse Hazard Ratio (95% CI) [3]	0.56 (0.21, 1.52)	
P-value [3]	0.25846	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlq30_tti_2ref.sas 09OCT2025 10:07

Protocol: 207499 Page 1 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	8 (73%)	4 (57%)
	Censored, follow-up ended	3 (27%)	3 (43%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (1.0, 4.7)	1.2 (1.1, 15.7)
	Median (95% CI)	4.7 (1.0, 13.2)	9.3 (1.1, -)
	3rd Quartile (95% CI)	13.2 (2.8, -)	- (1.2, -)
	Log-Rank P-value [2]	0.42507	
	Inverse Hazard Ratio (95% CI) [3]	0.61 (0.18, 2.07)	
	P-value [3]	0.42939	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	10 (67%)	9 (60%)
	Censored, follow-up ended	4 (27%)	4 (27%)
	Censored, follow-up ongoing	1 (7%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.4 (0.9, 1.9)	1.0 (0.7, 1.8)
	Median (95% CI)	2.4 (1.0, 3.7)	2.3 (1.0, -)
	3rd Quartile (95% CI)	3.4 (1.9, -)	- (1.8, -)
	Log-Rank P-value [2]	0.56812	
	Inverse Hazard Ratio (95% CI) [3]	0.76 (0.31, 1.90)	
	P-value [3]	0.56041	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	2 (50%)	7 (64%)
	Censored, follow-up ended	1 (25%)	4 (36%)
	Censored, follow-up ongoing	1 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (2.9, -)	2.0 (1.0, 3.0)
	Median (95% CI)	4.5 (2.9, -)	3.0 (1.0, -)
	3rd Quartile (95% CI)	- (2.9, -)	33.5 (2.8, -)
	Log-Rank P-value [2]	0.48695	
	Inverse Hazard Ratio (95% CI) [3]	1.75 (0.36, 8.56)	
	P-value [3]	0.49218	
Interaction Test	P-value [4]	0.51783	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	5 (45%)	4 (57%)
	Censored, follow-up ended	4 (36%)	2 (29%)
	Censored, follow-up ongoing	2 (18%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 7.0)	1.2 (1.1, -)
	Median (95% CI)	7.0 (1.0, -)	10.6 (1.1, -)
	3rd Quartile (95% CI)	- (1.9, -)	18.5 (1.2, -)
	Log-Rank P-value [2]	0.80113	
	Inverse Hazard Ratio (95% CI) [3]	1.19 (0.31, 4.47)	
	P-value [3]	0.80135	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 5 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	8 (53%)	7 (47%)
	Censored, follow-up ended	6 (40%)	5 (33%)
	Censored, follow-up ongoing	1 (7%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (0.9, 3.8)	1.9 (1.0, 6.0)
	Median (95% CI)	3.8 (1.1, -)	6.0 (1.8, -)
	3rd Quartile (95% CI)	20.3 (3.8, -)	- (6.0, -)
	Log-Rank P-value [2]	0.61145	
	Inverse Hazard Ratio (95% CI) [3]	0.77 (0.28, 2.13)	
	P-value [3]	0.61264	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	2 (50%)	5 (45%)
	Censored, follow-up ended	1 (25%)	5 (45%)
	Censored, follow-up ongoing	1 (25%)	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.6 (2.6, -)	1.9 (1.0, 5.7)
	Median (95% CI)	3.8 (2.6, -)	5.7 (1.0, -)
	3rd Quartile (95% CI)	- (2.6, -)	- (3.8, -)
	Log-Rank P-value [2]	0.93501	
	Inverse Hazard Ratio (95% CI) [3]	0.91 (0.18, 4.72)	
	P-value [3]	0.91155	
Interaction Test	P-value [4]	0.82699	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 7 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	4 (36%)	4 (57%)
	Censored, follow-up ended	6 (55%)	2 (29%)
	Censored, follow-up ongoing	1 (9%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.1 (0.7, 9.7)
	Median (95% CI)	21.9 (1.0, -)	5.5 (0.7, -)
	3rd Quartile (95% CI)	- (21.9, -)	- (1.1, -)
	Log-Rank P-value [2]	0.29875	
	Inverse Hazard Ratio (95% CI) [3]	2.13 (0.47, 9.54)	
	P-value [3]	0.32464	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	8 (53%)	6 (40%)
	Censored, follow-up ended	5 (33%)	6 (40%)
	Censored, follow-up ongoing	2 (13%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.8)	2.6 (1.0, 6.0)
	Median (95% CI)	1.8 (1.0, -)	6.0 (1.4, -)
	3rd Quartile (95% CI)	- (1.8, -)	- (6.0, -)
	Log-Rank P-value [2]	0.25064	
	Inverse Hazard Ratio (95% CI) [3]	0.53 (0.18, 1.54)	
	P-value [3]	0.24597	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	2 (50%)	6 (55%)
	Censored, follow-up ended	2 (50%)	4 (36%)
	Censored, follow-up ongoing	0	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.1, -)	1.0 (0.8, 1.1)
	Median (95% CI)	7.5 (1.1, -)	1.1 (0.8, -)
	3rd Quartile (95% CI)	7.5 (1.1, -)	20.4 (1.0, -)
	Log-Rank P-value [2]	0.84199	
	Inverse Hazard Ratio (95% CI) [3]	1.16 (0.22, 6.04)	
	P-value [3]	0.85680	
Interaction Test	P-value [4]	0.38437	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 10 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	9 (82%)	3 (43%)
	Censored, follow-up ended	2 (18%)	4 (57%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 1.9)	1.1 (1.1, -)
	Median (95% CI)	1.9 (1.0, 7.3)	- (1.1, -)
	3rd Quartile (95% CI)	7.3 (1.9, -)	- (1.1, -)
	Log-Rank P-value [2]	0.17108	
	Inverse Hazard Ratio (95% CI) [3]	0.41 (0.11, 1.52)	
	P-value [3]	0.18196	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 11 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	5 (33%)	7 (47%)
	Censored, follow-up ended	7 (47%)	7 (47%)
	Censored, follow-up ongoing	3 (20%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	1.0 (0.7, 3.3)
	Median (95% CI)	- (1.0, -)	3.3 (1.0, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (3.3, -)
	Log-Rank P-value [2]	0.63296	
	Inverse Hazard Ratio (95% CI) [3]	1.32 (0.42, 4.18)	
	P-value [3]	0.63281	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	3 (75%)	6 (55%)
	Censored, follow-up ended	1 (25%)	4 (36%)
	Censored, follow-up ongoing	0	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.1 (0.8, 2.8)
	Median (95% CI)	5.7 (1.0, -)	2.8 (0.8, -)
	3rd Quartile (95% CI)	37.6 (1.0, -)	- (2.0, -)
	Log-Rank P-value [2]	0.86450	
	Inverse Hazard Ratio (95% CI) [3]	1.15 (0.23, 5.78)	
	P-value [3]	0.86461	
Interaction Test	P-value [4]	0.40295	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 13 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	5 (45%)	4 (57%)
	Censored, follow-up ended	5 (45%)	2 (29%)
	Censored, follow-up ongoing	1 (9%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	1.1 (1.0, 3.7)
	Median (95% CI)	- (1.0, -)	2.5 (1.0, -)
	3rd Quartile (95% CI)	- (2.9, -)	- (1.1, -)
	Log-Rank P-value [2]	0.61289	
	Inverse Hazard Ratio (95% CI) [3]	1.38 (0.37, 5.16)	
	P-value [3]	0.62791	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 14 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	6 (40%)	6 (40%)
	Censored, follow-up ended	6 (40%)	7 (47%)
	Censored, follow-up ongoing	3 (20%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 2.0)	1.0 (0.7, -)
	Median (95% CI)	2.0 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (-, -)
	Log-Rank P-value [2]	0.74370	
	Inverse Hazard Ratio (95% CI) [3]	0.82 (0.26, 2.55)	
	P-value [3]	0.73171	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 15 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	1 (25%)	7 (64%)
	Censored, follow-up ended	2 (50%)	4 (36%)
	Censored, follow-up ongoing	1 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	19.2 (19.2, -)	1.0 (0.8, 1.1)
	Median (95% CI)	- (19.2, -)	1.1 (0.8, -)
	3rd Quartile (95% CI)	- (19.2, -)	9.7 (1.1, -)
	Log-Rank P-value [2]	0.03195	
	Inverse Hazard Ratio (95% CI) [3]	>999.99 (-, -)	
	P-value [3]	0.99603	
Interaction Test	P-value [4]	0.39420	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	7 (64%)	2 (29%)
	Censored, follow-up ended	2 (18%)	4 (57%)
	Censored, follow-up ongoing	2 (18%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 3.7)	1.2 (1.1, -)
	Median (95% CI)	3.4 (1.0, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (3.0, -)	- (1.2, -)
	Log-Rank P-value [2]	0.22153	
	Inverse Hazard Ratio (95% CI) [3]	0.39 (0.08, 1.87)	
	P-value [3]	0.23866	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 17 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	7 (47%)	6 (40%)
	Censored, follow-up ended	6 (40%)	6 (40%)
	Censored, follow-up ongoing	2 (13%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 4.2)	2.3 (1.0, -)
	Median (95% CI)	4.2 (1.0, -)	- (1.4, -)
	3rd Quartile (95% CI)	- (4.2, -)	- (-, -)
	Log-Rank P-value [2]	0.51512	
	Inverse Hazard Ratio (95% CI) [3]	0.69 (0.23, 2.07)	
	P-value [3]	0.51147	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	1 (25%)	6 (55%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	1 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	37.6 (37.6, -)	1.0 (0.8, 2.8)
	Median (95% CI)	- (37.6, -)	2.8 (0.8, -)
	3rd Quartile (95% CI)	- (37.6, -)	18.5 (1.0, -)
	Log-Rank P-value [2]	0.05158	
	Inverse Hazard Ratio (95% CI) [3]	>999.99 (-, -)	
	P-value [3]	0.99636	
Interaction Test	P-value [4]	0.18748	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 19 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	7 (64%)	6 (86%)
	Censored, follow-up ended	4 (36%)	1 (14%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 1.9)	1.2 (0.7, 3.8)
	Median (95% CI)	1.9 (1.0, -)	2.9 (0.7, -)
	3rd Quartile (95% CI)	14.1 (1.9, -)	3.9 (1.2, -)
	Log-Rank P-value [2]	0.39178	
	Inverse Hazard Ratio (95% CI) [3]	1.64 (0.52, 5.18)	
	P-value [3]	0.39630	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 20 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	9 (60%)	7 (47%)
	Censored, follow-up ended	5 (33%)	6 (40%)
	Censored, follow-up ongoing	1 (7%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.9)	1.0 (1.0, 2.3)
	Median (95% CI)	2.0 (0.9, -)	2.3 (1.0, -)
	3rd Quartile (95% CI)	20.3 (1.9, -)	- (2.3, -)
	Log-Rank P-value [2]	0.31358	
	Inverse Hazard Ratio (95% CI) [3]	0.61 (0.23, 1.63)	
	P-value [3]	0.32191	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 21 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	3 (75%)	7 (64%)
	Censored, follow-up ended	1 (25%)	3 (27%)
	Censored, follow-up ongoing	0	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.9, -)	1.0 (0.8, 2.8)
	Median (95% CI)	2.0 (1.9, -)	2.8 (0.8, 5.7)
	3rd Quartile (95% CI)	34.9 (1.9, -)	5.7 (2.0, -)
	Log-Rank P-value [2]	0.78231	
	Inverse Hazard Ratio (95% CI) [3]	1.22 (0.25, 5.94)	
	P-value [3]	0.80596	
Interaction Test	P-value [4]	0.39873	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 22 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	2 (18%)	2 (29%)
	Censored, follow-up ended	7 (64%)	4 (57%)
	Censored, follow-up ongoing	2 (18%)	1 (14%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 23 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	3 (20%)	3 (20%)
	Censored, follow-up ended	7 (47%)	9 (60%)
	Censored, follow-up ongoing	5 (33%)	3 (20%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 24 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	1 (25%)	3 (27%)
	Censored, follow-up ended	2 (50%)	7 (64%)
	Censored, follow-up ongoing	1 (25%)	1 (9%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 25 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	8 (73%)	5 (71%)
	Censored, follow-up ended	2 (18%)	1 (14%)
	Censored, follow-up ongoing	1 (9%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.2)	1.1 (0.7, 1.9)
	Median (95% CI)	1.1 (1.0, 2.8)	1.5 (0.7, -)
	3rd Quartile (95% CI)	2.8 (1.0, -)	2.9 (1.1, -)
	Log-Rank P-value [2]	0.86032	
	Inverse Hazard Ratio (95% CI) [3]	0.87 (0.28, 2.68)	
	P-value [3]	0.80878	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 26 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	9 (60%)	9 (60%)
	Censored, follow-up ended	5 (33%)	5 (33%)
	Censored, follow-up ongoing	1 (7%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.1)	1.0 (1.0, 1.4)
	Median (95% CI)	1.5 (1.0, 20.3)	1.4 (1.0, -)
	3rd Quartile (95% CI)	20.3 (1.1, -)	- (1.4, -)
	Log-Rank P-value [2]	0.85284	
	Inverse Hazard Ratio (95% CI) [3]	0.92 (0.36, 2.33)	
	P-value [3]	0.86238	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 27 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	2 (50%)	9 (82%)
	Censored, follow-up ended	1 (25%)	2 (18%)
	Censored, follow-up ongoing	1 (25%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.1 (1.0, 1.1)
	Median (95% CI)	1.9 (1.0, -)	1.1 (1.0, 2.8)
	3rd Quartile (95% CI)	- (1.0, -)	1.9 (1.1, -)
	Log-Rank P-value [2]	0.40665	
	Inverse Hazard Ratio (95% CI) [3]	1.84 (0.39, 8.68)	
	P-value [3]	0.44179	
Interaction Test	P-value [4]	0.74355	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 28 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	3 (27%)	3 (43%)
	Censored, follow-up ended	6 (55%)	3 (43%)
	Censored, follow-up ongoing	2 (18%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	7.0 (1.0, -)	2.1 (1.2, -)
	Median (95% CI)	- (1.0, -)	- (1.2, -)
	3rd Quartile (95% CI)	- (-, -)	- (2.1, -)
	Log-Rank P-value [2]	0.58831	
	Inverse Hazard Ratio (95% CI) [3]	1.52 (0.30, 7.56)	
	P-value [3]	0.61027	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 29 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	7 (47%)	3 (20%)
	Censored, follow-up ended	4 (27%)	8 (53%)
	Censored, follow-up ongoing	4 (27%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (0.9, 9.2)	- (1.0, -)
	Median (95% CI)	9.2 (1.0, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (9.2, -)	- (-, -)
	Log-Rank P-value [2]	0.14264	
	Inverse Hazard Ratio (95% CI) [3]	0.38 (0.10, 1.47)	
	P-value [3]	0.16011	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 30 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	3 (75%)	4 (36%)
	Censored, follow-up ended	1 (25%)	5 (45%)
	Censored, follow-up ongoing	0	2 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.1, -)	1.0 (0.8, 12.5)
	Median (95% CI)	3.8 (1.1, -)	12.5 (0.8, -)
	3rd Quartile (95% CI)	13.9 (1.1, -)	- (12.5, -)
	Log-Rank P-value [2]	0.55319	
	Inverse Hazard Ratio (95% CI) [3]	0.63 (0.14, 2.89)	
	P-value [3]	0.55628	
Interaction Test	P-value [4]	0.43625	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	6 (55%)	2 (29%)
	Censored, follow-up ended	5 (45%)	3 (43%)
	Censored, follow-up ongoing	0	2 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 13.2)	8.3 (1.2, -)
	Median (95% CI)	12.1 (1.0, -)	- (1.2, -)
	3rd Quartile (95% CI)	13.2 (12.1, -)	- (8.3, -)
	Log-Rank P-value [2]	0.19802	
	Inverse Hazard Ratio (95% CI) [3]	0.36 (0.07, 1.82)	
	P-value [3]	0.21610	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 32 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	6 (40%)	5 (33%)
	Censored, follow-up ended	6 (40%)	7 (47%)
	Censored, follow-up ongoing	3 (20%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 3.7)	1.8 (0.7, -)
	Median (95% CI)	3.7 (1.0, -)	- (1.4, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (-, -)
	Log-Rank P-value [2]	0.51305	
	Inverse Hazard Ratio (95% CI) [3]	0.67 (0.20, 2.20)	
	P-value [3]	0.50953	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 33 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	3 (75%)	4 (36%)
	Censored, follow-up ended	1 (25%)	6 (55%)
	Censored, follow-up ongoing	0	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	3.8 (0.8, -)
	Median (95% CI)	1.1 (1.0, -)	6.7 (0.8, -)
	3rd Quartile (95% CI)	10.9 (1.0, -)	- (6.7, -)
	Log-Rank P-value [2]	0.28129	
	Inverse Hazard Ratio (95% CI) [3]	0.44 (0.10, 2.02)	
	P-value [3]	0.29381	
Interaction Test	P-value [4]	0.64265	

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 34 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	4 (36%)	2 (29%)
	Censored, follow-up ended	6 (55%)	4 (57%)
	Censored, follow-up ongoing	1 (9%)	1 (14%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 35 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	4 (27%)	4 (27%)
	Censored, follow-up ended	7 (47%)	7 (47%)
	Censored, follow-up ongoing	4 (27%)	4 (27%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 36 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	2 (50%)	4 (36%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	0	2 (18%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 37 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	1 (9%)	0
	Censored, follow-up ended	8 (73%)	5 (71%)
	Censored, follow-up ongoing	2 (18%)	2 (29%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 38 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	4 (27%)	3 (20%)
	Censored, follow-up ended	8 (53%)	9 (60%)
	Censored, follow-up ongoing	3 (20%)	3 (20%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 39 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	1 (25%)	4 (36%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	1 (25%)	2 (18%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 40 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	2 (18%)	0
	Censored, follow-up ended	7 (64%)	5 (71%)
	Censored, follow-up ongoing	2 (18%)	2 (29%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 41 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	5 (33%)	4 (27%)
	Censored, follow-up ended	6 (40%)	9 (60%)
	Censored, follow-up ongoing	4 (27%)	2 (13%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 42 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	2 (50%)	4 (36%)
	Censored, follow-up ended	2 (50%)	4 (36%)
	Censored, follow-up ongoing	0	3 (27%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 43 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	4 (36%)	3 (43%)
	Censored, follow-up ended	5 (45%)	3 (43%)
	Censored, follow-up ongoing	2 (18%)	1 (14%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 44 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	4 (27%)	4 (27%)
	Censored, follow-up ended	8 (53%)	8 (53%)
	Censored, follow-up ongoing	3 (20%)	3 (20%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 45 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001115
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	1 (25%)	0
	Censored, follow-up ended	2 (50%)	8 (73%)
	Censored, follow-up ongoing	1 (25%)	3 (27%)

Note: The % for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for % calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met. #Model failed to converge, interpret results with caution.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_age.sas 09OCT2025 10:06

Protocol: 207499 Page 1 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	9 (69%)	10 (63%)
	Censored, follow-up ended	3 (23%)	6 (38%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.8 (1.0, 2.8)	1.0 (1.0, 2.0)
	Median (95% CI)	2.8 (1.1, 21.9)	2.2 (1.0, -)
	3rd Quartile (95% CI)	21.9 (2.8, -)	33.5 (2.0, -)
	Log-Rank P-value [2]	0.75116	
	Inverse Hazard Ratio (95% CI) [3]	1.13 (0.46, 2.80)	
	P-value [3]	0.78697	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	11 (65%)	10 (59%)
	Censored, follow-up ended	5 (29%)	5 (29%)
	Censored, follow-up ongoing	1 (6%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (0.9, 3.0)	1.4 (0.7, 3.0)
	Median (95% CI)	3.0 (1.2, 12.2)	4.7 (1.4, -)
	3rd Quartile (95% CI)	12.2 (3.0, -)	- (4.7, -)
	Log-Rank P-value [2]	0.23542	
	Inverse Hazard Ratio (95% CI) [3]	0.59 (0.24, 1.44)	
	P-value [3]	0.24675	
Interaction Test	P-value [4]	0.35912	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 3 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	7 (54%)	8 (50%)
	Censored, follow-up ended	5 (38%)	7 (44%)
	Censored, follow-up ongoing	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 3.8)	1.9 (1.0, 6.0)
	Median (95% CI)	3.8 (1.0, -)	6.0 (1.2, -)
	3rd Quartile (95% CI)	- (2.6, -)	10.6 (5.7, -)
	Log-Rank P-value [2]	0.80205	
	Inverse Hazard Ratio (95% CI) [3]	0.88 (0.32, 2.44)	
	P-value [3]	0.80962	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	8 (47%)	8 (47%)
	Censored, follow-up ended	6 (35%)	5 (29%)
	Censored, follow-up ongoing	3 (18%)	4 (24%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (0.9, 7.0)	1.8 (1.0, 3.8)
	Median (95% CI)	7.0 (1.2, -)	18.5 (1.4, -)
	3rd Quartile (95% CI)	- (7.0, -)	- (18.5, -)
	Log-Rank P-value [2]	0.97609	
	Inverse Hazard Ratio (95% CI) [3]	1.01 (0.37, 2.74)	
	P-value [3]	0.98681	
Interaction Test	P-value [4]	0.95864	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 5 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	7 (54%)	9 (56%)
	Censored, follow-up ended	6 (46%)	7 (44%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 11.2)	1.1 (0.8, 2.8)
	Median (95% CI)	11.2 (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	21.9 (7.5, -)	20.4 (2.8, -)
	Log-Rank P-value [2]	0.45980	
	Inverse Hazard Ratio (95% CI) [3]	1.46 (0.52, 4.13)	
	P-value [3]	0.47335	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	7 (41%)	7 (41%)
	Censored, follow-up ended	7 (41%)	5 (29%)
	Censored, follow-up ongoing	3 (18%)	5 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.9)	1.1 (0.7, 9.7)
	Median (95% CI)	1.9 (1.0, -)	9.7 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (9.7, -)
	Log-Rank P-value [2]	0.79154	
	Inverse Hazard Ratio (95% CI) [3]	0.85 (0.30, 2.45)	
	P-value [3]	0.76887	
Interaction Test	P-value [4]	0.74535	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 7 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	8 (62%)	9 (56%)
	Censored, follow-up ended	4 (31%)	7 (44%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 5.7)	1.1 (0.8, 3.1)
	Median (95% CI)	3.8 (1.0, -)	3.1 (1.0, -)
	3rd Quartile (95% CI)	22.4 (1.9, -)	- (3.1, -)
	Log-Rank P-value [2]	0.88640	
	Inverse Hazard Ratio (95% CI) [3]	1.06 (0.39, 2.88)	
	P-value [3]	0.90355	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	9 (53%)	7 (41%)
	Censored, follow-up ended	6 (35%)	8 (47%)
	Censored, follow-up ongoing	2 (12%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 1.9)	1.1 (0.7, 1.4)
	Median (95% CI)	2.8 (1.0, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (-, -)
	Log-Rank P-value [2]	0.56410	
	Inverse Hazard Ratio (95% CI) [3]	0.76 (0.28, 2.04)	
	P-value [3]	0.58606	
Interaction Test	P-value [4]	0.60912	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 9 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	4 (31%)	8 (50%)
	Censored, follow-up ended	7 (54%)	8 (50%)
	Censored, follow-up ongoing	2 (15%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, -)	1.0 (0.7, 1.2)
	Median (95% CI)	19.2 (1.0, -)	1.2 (1.0, -)
	3rd Quartile (95% CI)	- (19.2, -)	- (1.2, -)
	Log-Rank P-value [2]	0.18648	
	Inverse Hazard Ratio (95% CI) [3]	2.25 (0.66, 7.61)	
	P-value [3]	0.19388	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 10 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	8 (47%)	9 (53%)
	Censored, follow-up ended	6 (35%)	5 (29%)
	Censored, follow-up ongoing	3 (18%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.2)	1.0 (0.7, 1.4)
	Median (95% CI)	1.5 (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	- (1.2, -)	- (2.8, -)
	Log-Rank P-value [2]	0.97439	
	Inverse Hazard Ratio (95% CI) [3]	1.01 (0.39, 2.63)	
	P-value [3]	0.97802	
Interaction Test	P-value [4]	0.35749	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 11 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	7 (54%)	7 (44%)
	Censored, follow-up ended	5 (38%)	8 (50%)
	Censored, follow-up ongoing	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 7.3)	1.0 (0.8, 18.5)
	Median (95% CI)	7.3 (1.1, -)	18.5 (1.0, -)
	3rd Quartile (95% CI)	37.6 (4.8, -)	- (18.5, -)
	Log-Rank P-value [2]	0.75976	
	Inverse Hazard Ratio (95% CI) [3]	1.19 (0.40, 3.56)	
	P-value [3]	0.75371	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 12 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	8 (47%)	7 (41%)
	Censored, follow-up ended	5 (29%)	7 (41%)
	Censored, follow-up ongoing	4 (24%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 3.7)	1.4 (1.0, 3.4)
	Median (95% CI)	3.9 (1.0, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (-, -)
	Log-Rank P-value [2]	0.47503	
	Inverse Hazard Ratio (95% CI) [3]	0.69 (0.25, 1.92)	
	P-value [3]	0.48164	
Interaction Test	P-value [4]	0.62165	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	8 (62%)	12 (75%)
	Censored, follow-up ended	5 (38%)	4 (25%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 2.0)	1.0 (0.8, 1.9)
	Median (95% CI)	2.0 (1.0, -)	1.9 (1.0, 2.8)
	3rd Quartile (95% CI)	34.9 (2.0, -)	2.8 (1.9, -)
	Log-Rank P-value [2]	0.11543	
	Inverse Hazard Ratio (95% CI) [3]	2.06 (0.80, 5.29)	
	P-value [3]	0.13561	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 14 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	11 (65%)	8 (47%)
	Censored, follow-up ended	5 (29%)	6 (35%)
	Censored, follow-up ongoing	1 (6%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.9)	1.4 (0.7, 3.8)
	Median (95% CI)	1.9 (1.0, 14.1)	9.7 (1.4, -)
	3rd Quartile (95% CI)	14.1 (1.9, -)	- (9.7, -)
	Log-Rank P-value [2]	0.18440	
	Inverse Hazard Ratio (95% CI) [3]	0.54 (0.21, 1.36)	
	P-value [3]	0.18802	
Interaction Test	P-value [4]	0.02879	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 15 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	3 (23%)	3 (19%)
	Censored, follow-up ended	8 (62%)	11 (69%)
	Censored, follow-up ongoing	2 (15%)	2 (13%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 16 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	3 (18%)	5 (29%)
	Censored, follow-up ended	8 (47%)	9 (53%)
	Censored, follow-up ongoing	6 (35%)	3 (18%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 17 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	8 (62%)	12 (75%)
	Censored, follow-up ended	4 (31%)	4 (25%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.9)	1.1 (1.0, 1.2)
	Median (95% CI)	1.9 (1.0, -)	1.2 (1.0, 2.3)
	3rd Quartile (95% CI)	- (1.9, -)	2.3 (1.2, -)
	Log-Rank P-value [2]	0.40039	
	Inverse Hazard Ratio (95% CI) [3]	1.47 (0.60, 3.62)	
	P-value [3]	0.39797	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	11 (65%)	11 (65%)
	Censored, follow-up ended	4 (24%)	4 (24%)
	Censored, follow-up ongoing	2 (12%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.0)	1.0 (0.7, 1.1)
	Median (95% CI)	1.1 (1.0, 20.3)	1.4 (1.0, 2.8)
	3rd Quartile (95% CI)	20.3 (1.0, -)	- (1.4, -)
	Log-Rank P-value [2]	0.73559	
	Inverse Hazard Ratio (95% CI) [3]	0.86 (0.37, 2.00)	
	P-value [3]	0.72482	
Interaction Test	P-value [4]	0.43207	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 19 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	7 (54%)	5 (31%)
	Censored, follow-up ended	6 (46%)	8 (50%)
	Censored, follow-up ongoing	0	3 (19%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 10.3)	1.8 (0.8, -)
	Median (95% CI)	10.3 (1.1, -)	- (1.2, -)
	3rd Quartile (95% CI)	13.9 (3.8, -)	- (12.5, -)
	Log-Rank P-value [2]	0.26921	
	Inverse Hazard Ratio (95% CI) [3]	0.53 (0.17, 1.67)	
	P-value [3]	0.27711	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	6 (35%)	5 (29%)
	Censored, follow-up ended	5 (29%)	8 (47%)
	Censored, follow-up ongoing	6 (35%)	4 (24%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, -)	2.1 (1.0, -)
	Median (95% CI)	- (1.0, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (9.2, -)	- (-, -)
	Log-Rank P-value [2]	0.74206	
	Inverse Hazard Ratio (95% CI) [3]	0.82 (0.25, 2.70)	
	P-value [3]	0.74303	
Interaction Test	P-value [4]	0.63766	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 21 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	7 (54%)	6 (38%)
	Censored, follow-up ended	6 (46%)	9 (56%)
	Censored, follow-up ongoing	0	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 10.9)	1.2 (0.8, -)
	Median (95% CI)	10.9 (1.1, -)	- (1.0, -)
	3rd Quartile (95% CI)	13.3 (3.7, -)	- (-, -)
	Log-Rank P-value [2]	0.67873	
	Inverse Hazard Ratio (95% CI) [3]	0.80 (0.27, 2.38)	
	P-value [3]	0.68864	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 22 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	8 (47%)	5 (29%)
	Censored, follow-up ended	6 (35%)	7 (41%)
	Censored, follow-up ongoing	3 (18%)	5 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 12.1)	6.7 (0.7, -)
	Median (95% CI)	12.1 (1.0, -)	- (6.7, -)
	3rd Quartile (95% CI)	- (12.1, -)	- (-, -)
	Log-Rank P-value [2]	0.21762	
	Inverse Hazard Ratio (95% CI) [3]	0.50 (0.16, 1.53)	
	P-value [3]	0.22364	
Interaction Test	P-value [4]	0.51322	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 23 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	4 (31%)	5 (31%)
	Censored, follow-up ended	8 (62%)	8 (50%)
	Censored, follow-up ongoing	1 (8%)	3 (19%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	2.9 (1.0, -)
	Median (95% CI)	34.9 (1.0, -)	- (2.1, -)
	3rd Quartile (95% CI)	- (34.9, -)	- (-, -)
	Log-Rank P-value [2]	0.93830	
	Inverse Hazard Ratio (95% CI) [3]	1.05 (0.28, 3.92)	
	P-value [3]	0.93971	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	6 (35%)	5 (29%)
	Censored, follow-up ended	7 (41%)	8 (47%)
	Censored, follow-up ongoing	4 (24%)	4 (24%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	2.1 (0.7, -)
	Median (95% CI)	- (1.0, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (2.9, -)	- (-, -)
	Log-Rank P-value [2]	0.54476	
	Inverse Hazard Ratio (95% CI) [3]	0.69 (0.21, 2.28)	
	P-value [3]	0.54815	
Interaction Test	P-value [4]	0.67862	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 25 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	3 (23%)	3 (19%)
	Censored, follow-up ended	9 (69%)	11 (69%)
	Censored, follow-up ongoing	1 (8%)	2 (13%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 26 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	3 (18%)	4 (24%)
	Censored, follow-up ended	9 (53%)	8 (47%)
	Censored, follow-up ongoing	5 (29%)	5 (29%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Table 4.0001125

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	5 (38%)	3 (19%)
	Censored, follow-up ended	7 (54%)	10 (63%)
	Censored, follow-up ongoing	1 (8%)	3 (19%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 28 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	4 (24%)	5 (29%)
	Censored, follow-up ended	8 (47%)	8 (47%)
	Censored, follow-up ongoing	5 (29%)	4 (24%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 29 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	5 (38%)	3 (19%)
	Censored, follow-up ended	7 (54%)	10 (63%)
	Censored, follow-up ongoing	1 (8%)	3 (19%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 30 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001125
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	4 (24%)	4 (24%)
	Censored, follow-up ended	8 (47%)	9 (53%)
	Censored, follow-up ongoing	5 (29%)	4 (24%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_gen.sas 09OCT2025 10:06

Protocol: 207499 Page 1 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	11 (55%)	13 (54%)
	Censored, follow-up ended	8 (40%)	9 (38%)
	Censored, follow-up ongoing	1 (5%)	2 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (0.9, 2.8)	1.2 (1.0, 2.3)
	Median (95% CI)	2.8 (1.1, -)	3.0 (1.2, -)
	3rd Quartile (95% CI)	21.9 (2.8, -)	33.5 (15.7, -)
	Log-Rank P-value [2]	0.35171	
	Inverse Hazard Ratio (95% CI) [3]	0.68 (0.30, 1.55)	
	P-value [3]	0.35785	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	9 (90%)	7 (78%)
	Censored, follow-up ended	0	2 (22%)
	Censored, follow-up ongoing	1 (10%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (1.0, 3.7)	1.4 (0.7, 2.8)
	Median (95% CI)	3.3 (1.0, 12.2)	2.4 (0.7, 5.7)
	3rd Quartile (95% CI)	12.2 (2.9, -)	5.2 (1.9, -)
	Log-Rank P-value [2]	0.60906	
	Inverse Hazard Ratio (95% CI) [3]	1.29 (0.48, 3.49)	
	P-value [3]	0.61491	
Interaction Test	P-value [4]	0.30783	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 3 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	9 (45%)	11 (46%)
	Censored, follow-up ended	9 (45%)	9 (38%)
	Censored, follow-up ongoing	2 (10%)	4 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 4.8)	1.8 (1.0, 5.7)
	Median (95% CI)	4.8 (1.0, -)	6.0 (1.8, -)
	3rd Quartile (95% CI)	- (4.8, -)	- (6.0, -)
	Log-Rank P-value [2]	0.73762	
	Inverse Hazard Ratio (95% CI) [3]	0.86 (0.35, 2.10)	
	P-value [3]	0.74237	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 4 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	6 (60%)	5 (56%)
	Censored, follow-up ended	2 (20%)	3 (33%)
	Censored, follow-up ongoing	2 (20%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.1, 3.8)	1.9 (1.0, -)
	Median (95% CI)	3.8 (1.1, -)	11.1 (1.0, -)
	3rd Quartile (95% CI)	- (3.8, -)	18.5 (1.9, -)
	Log-Rank P-value [2]	0.85639	
	Inverse Hazard Ratio (95% CI) [3]	1.13 (0.34, 3.75)	
	P-value [3]	0.83675	
Interaction Test	P-value [4]	0.60390	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 5 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	8 (40%)	11 (46%)
	Censored, follow-up ended	10 (50%)	10 (42%)
	Censored, follow-up ongoing	2 (10%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 11.2)	2.3 (0.8, 6.0)
	Median (95% CI)	11.2 (1.0, -)	9.7 (2.3, -)
	3rd Quartile (95% CI)	21.9 (11.2, -)	20.4 (9.7, -)
	Log-Rank P-value [2]	0.95838	
	Inverse Hazard Ratio (95% CI) [3]	0.97 (0.39, 2.44)	
	P-value [3]	0.95163	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	6 (60%)	5 (56%)
	Censored, follow-up ended	3 (30%)	2 (22%)
	Censored, follow-up ongoing	1 (10%)	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 7.5)	1.0 (0.7, 1.0)
	Median (95% CI)	4.3 (1.0, -)	1.0 (0.7, -)
	3rd Quartile (95% CI)	- (1.1, -)	- (1.0, -)
	Log-Rank P-value [2]	0.43737	
	Inverse Hazard Ratio (95% CI) [3]	1.55 (0.47, 5.08)	
	P-value [3]	0.47114	
Interaction Test	P-value [4]	0.32761	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 7 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	9 (45%)	12 (50%)
	Censored, follow-up ended	8 (40%)	11 (46%)
	Censored, follow-up ongoing	3 (15%)	1 (4%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 3.7)	1.1 (0.8, 1.4)
	Median (95% CI)	3.7 (1.0, -)	3.1 (1.1, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (3.1, -)
	Log-Rank P-value [2]	0.90092	
	Inverse Hazard Ratio (95% CI) [3]	1.05 (0.44, 2.50)	
	P-value [3]	0.90927	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 8 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	8 (80%)	4 (44%)
	Censored, follow-up ended	2 (20%)	4 (44%)
	Censored, follow-up ongoing	0	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 1.9)	1.5 (0.7, -)
	Median (95% CI)	1.9 (1.0, -)	- (0.7, -)
	3rd Quartile (95% CI)	37.6 (1.9, -)	- (2.0, -)
	Log-Rank P-value [2]	0.43998	
	Inverse Hazard Ratio (95% CI) [3]	0.61 (0.18, 2.11)	
	P-value [3]	0.43852	
Interaction Test	P-value [4]	0.48266	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 9 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	5 (25%)	9 (38%)
	Censored, follow-up ended	11 (55%)	12 (50%)
	Censored, follow-up ongoing	4 (20%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (0.9, -)	1.1 (0.7, 1.4)
	Median (95% CI)	- (1.0, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.59863	
	Inverse Hazard Ratio (95% CI) [3]	1.34 (0.45, 4.00)	
	P-value [3]	0.60174	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	7 (70%)	8 (89%)
	Censored, follow-up ended	2 (20%)	1 (11%)
	Censored, follow-up ongoing	1 (10%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 2.0)	1.0 (0.7, 1.1)
	Median (95% CI)	2.0 (1.0, -)	1.0 (0.7, 3.7)
	3rd Quartile (95% CI)	- (1.9, -)	3.3 (1.0, -)
	Log-Rank P-value [2]	0.11288	
	Inverse Hazard Ratio (95% CI) [3]	2.28 (0.79, 6.61)	
	P-value [3]	0.12952	
Interaction Test	P-value [4]	0.61551	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 11 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	9 (45%)	8 (33%)
	Censored, follow-up ended	8 (40%)	12 (50%)
	Censored, follow-up ongoing	3 (15%)	4 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 4.2)	1.4 (0.8, 18.5)
	Median (95% CI)	4.8 (1.0, -)	18.5 (1.4, -)
	3rd Quartile (95% CI)	- (4.8, -)	- (18.5, -)
	Log-Rank P-value [2]	0.30960	
	Inverse Hazard Ratio (95% CI) [3]	0.61 (0.24, 1.59)	
	P-value [3]	0.31479	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	6 (60%)	6 (67%)
	Censored, follow-up ended	2 (20%)	3 (33%)
	Censored, follow-up ongoing	2 (20%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 37.6)	1.0 (1.0, 2.8)
	Median (95% CI)	20.6 (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (1.0, -)
	Log-Rank P-value [2]	0.30861	
	Inverse Hazard Ratio (95% CI) [3]	1.84 (0.56, 6.09)	
	P-value [3]	0.31702	
Interaction Test	P-value [4]	0.15481	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 13 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	10 (50%)	14 (58%)
	Censored, follow-up ended	9 (45%)	8 (33%)
	Censored, follow-up ongoing	1 (5%)	2 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 1.9)	1.4 (0.8, 2.3)
	Median (95% CI)	2.0 (1.0, -)	3.8 (1.4, 9.7)
	3rd Quartile (95% CI)	20.3 (1.9, -)	- (3.8, -)
	Log-Rank P-value [2]	0.81436	
	Inverse Hazard Ratio (95% CI) [3]	0.91 (0.40, 2.05)	
	P-value [3]	0.81125	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	9 (90%)	6 (67%)
	Censored, follow-up ended	1 (10%)	2 (22%)
	Censored, follow-up ongoing	0	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 2.0)	1.0 (0.7, 2.0)
	Median (95% CI)	2.0 (0.9, 14.1)	1.5 (0.7, -)
	3rd Quartile (95% CI)	14.1 (1.9, -)	- (1.0, -)
	Log-Rank P-value [2]	0.73140	
	Inverse Hazard Ratio (95% CI) [3]	1.23 (0.41, 3.68)	
	P-value [3]	0.70974	
Interaction Test	P-value [4]	0.53821	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 15 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	3 (15%)	3 (13%)
	Censored, follow-up ended	12 (60%)	16 (67%)
	Censored, follow-up ongoing	5 (25%)	5 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	3 (30%)	5 (56%)
	Censored, follow-up ended	4 (40%)	4 (44%)
	Censored, follow-up ongoing	3 (30%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 17 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	12 (60%)	16 (67%)
	Censored, follow-up ended	7 (35%)	6 (25%)
	Censored, follow-up ongoing	1 (5%)	2 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.1)	1.1 (1.0, 1.2)
	Median (95% CI)	1.1 (1.0, 2.8)	1.8 (1.1, 2.9)
	3rd Quartile (95% CI)	20.3 (1.1, -)	2.9 (1.8, -)
	Log-Rank P-value [2]	0.72700	
	Inverse Hazard Ratio (95% CI) [3]	0.89 (0.42, 1.88)	
	P-value [3]	0.75139	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	7 (70%)	7 (78%)
	Censored, follow-up ended	1 (10%)	2 (22%)
	Censored, follow-up ongoing	2 (20%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.9)	1.0 (0.7, 1.1)
	Median (95% CI)	1.9 (1.0, -)	1.0 (0.7, 2.8)
	3rd Quartile (95% CI)	- (1.9, -)	2.4 (1.0, -)
	Log-Rank P-value [2]	0.39747	
	Inverse Hazard Ratio (95% CI) [3]	1.53 (0.54, 4.38)	
	P-value [3]	0.42613	
Interaction Test	P-value [4]	0.28806	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	5 (25%)	6 (25%)
	Censored, follow-up ended	11 (55%)	13 (54%)
	Censored, follow-up ongoing	4 (20%)	5 (21%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, -)	2.1 (0.8, -)
	Median (95% CI)	- (1.1, -)	- (2.1, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.75431	
	Inverse Hazard Ratio (95% CI) [3]	0.83 (0.25, 2.72)	
	P-value [3]	0.75466	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 20 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	8 (80%)	4 (44%)
	Censored, follow-up ended	0	3 (33%)
	Censored, follow-up ongoing	2 (20%)	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 9.2)	1.0 (1.0, 12.5)
	Median (95% CI)	6.5 (0.9, 13.9)	12.5 (1.0, -)
	3rd Quartile (95% CI)	13.9 (3.8, -)	- (5.6, -)
	Log-Rank P-value [2]	0.70976	
	Inverse Hazard Ratio (95% CI) [3]	0.80 (0.24, 2.67)	
	P-value [3]	0.71514	
Interaction Test	P-value [4]	0.89665	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 21 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	7 (35%)	6 (25%)
	Censored, follow-up ended	10 (50%)	13 (54%)
	Censored, follow-up ongoing	3 (15%)	5 (21%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 13.3)	2.3 (0.8, -)
	Median (95% CI)	12.1 (1.1, -)	- (2.3, -)
	3rd Quartile (95% CI)	- (12.1, -)	- (-, -)
	Log-Rank P-value [2]	0.30000	
	Inverse Hazard Ratio (95% CI) [3]	0.57 (0.19, 1.69)	
	P-value [3]	0.30702	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	8 (80%)	5 (56%)
	Censored, follow-up ended	2 (20%)	3 (33%)
	Censored, follow-up ongoing	0	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 3.7)	2.4 (0.7, 8.3)
	Median (95% CI)	2.4 (1.0, 13.2)	6.7 (0.7, -)
	3rd Quartile (95% CI)	13.2 (1.1, -)	- (3.8, -)
	Log-Rank P-value [2]	0.72853	
	Inverse Hazard Ratio (95% CI) [3]	0.80 (0.26, 2.49)	
	P-value [3]	0.70041	
Interaction Test	P-value [4]	0.80629	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 23 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	3 (15%)	5 (21%)
	Censored, follow-up ended	12 (60%)	13 (54%)
	Censored, follow-up ongoing	5 (25%)	6 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.0, -)	2.9 (1.0, -)
	Median (95% CI)	- (1.0, -)	- (2.9, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.82979	
	Inverse Hazard Ratio (95% CI) [3]	1.15 (0.28, 4.83)	
	P-value [3]	0.84363	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	7 (70%)	5 (56%)
	Censored, follow-up ended	3 (30%)	3 (33%)
	Censored, follow-up ongoing	0	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 2.9)	1.4 (0.7, 7.4)
	Median (95% CI)	2.9 (1.0, -)	5.6 (0.7, -)
	3rd Quartile (95% CI)	34.9 (2.8, -)	- (1.9, -)
	Log-Rank P-value [2]	0.96061	
	Inverse Hazard Ratio (95% CI) [3]	0.97 (0.29, 3.18)	
	P-value [3]	0.95393	
Interaction Test	P-value [4]	0.77940	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 25 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	3 (15%)	2 (8%)
	Censored, follow-up ended	13 (65%)	16 (67%)
	Censored, follow-up ongoing	4 (20%)	6 (25%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 26 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	3 (30%)	5 (56%)
	Censored, follow-up ended	5 (50%)	3 (33%)
	Censored, follow-up ongoing	2 (20%)	1 (11%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 27 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	4 (20%)	5 (21%)
	Censored, follow-up ended	12 (60%)	14 (58%)
	Censored, follow-up ongoing	4 (20%)	5 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 28 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	5 (50%)	3 (33%)
	Censored, follow-up ended	3 (30%)	4 (44%)
	Censored, follow-up ongoing	2 (20%)	2 (22%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 29 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	4 (20%)	5 (21%)
	Censored, follow-up ended	12 (60%)	14 (58%)
	Censored, follow-up ongoing	4 (20%)	5 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 30 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001135
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	5 (50%)	2 (22%)
	Censored, follow-up ended	3 (30%)	5 (56%)
	Censored, follow-up ongoing	2 (20%)	2 (22%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_reg.sas 09OCT2025 10:06

Protocol: 207499 Page 1 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	12 (67%)	9 (60%)
	Censored, follow-up ended	4 (22%)	5 (33%)
	Censored, follow-up ongoing	2 (11%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (0.9, 3.0)	2.0 (1.0, 5.7)
	Median (95% CI)	3.7 (2.8, 13.2)	10.7 (1.2, -)
	3rd Quartile (95% CI)	13.2 (3.7, -)	33.5 (5.7, -)
	Log-Rank P-value [2]	0.50561	
	Inverse Hazard Ratio (95% CI) [3]	0.74 (0.31, 1.77)	
	P-value [3]	0.49790	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 2 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	8 (67%)	11 (61%)
	Censored, follow-up ended	4 (33%)	6 (33%)
	Censored, follow-up ongoing	0	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 1.8)	1.0 (0.7, 1.8)
	Median (95% CI)	1.8 (1.0, 4.7)	1.9 (1.0, 4.7)
	3rd Quartile (95% CI)	1.9 (1.2, -)	4.7 (1.9, -)
	Log-Rank P-value [2]	0.52813	
	Inverse Hazard Ratio (95% CI) [3]	0.74 (0.29, 1.85)	
	P-value [3]	0.51820	
Interaction Test	P-value [4]	0.86891	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	10 (56%)	8 (53%)
	Censored, follow-up ended	5 (28%)	4 (27%)
	Censored, follow-up ongoing	3 (17%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 2.6)	1.8 (1.0, 10.6)
	Median (95% CI)	3.8 (1.1, -)	10.6 (1.2, -)
	3rd Quartile (95% CI)	- (3.8, -)	18.5 (10.6, -)
	Log-Rank P-value [2]	0.90340	
	Inverse Hazard Ratio (95% CI) [3]	0.94 (0.37, 2.43)	
	P-value [3]	0.90391	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 4 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	5 (42%)	8 (44%)
	Censored, follow-up ended	6 (50%)	8 (44%)
	Censored, follow-up ongoing	1 (8%)	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 4.8)	1.9 (1.0, 3.8)
	Median (95% CI)	4.8 (1.0, -)	3.8 (1.4, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (3.8, -)
	Log-Rank P-value [2]	0.91916	
	Inverse Hazard Ratio (95% CI) [3]	1.06 (0.35, 3.24)	
	P-value [3]	0.92188	
Interaction Test	P-value [4]	0.77932	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 5 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	8 (44%)	9 (60%)
	Censored, follow-up ended	7 (39%)	2 (13%)
	Censored, follow-up ongoing	3 (17%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 7.5)	1.1 (0.7, 3.1)
	Median (95% CI)	21.9 (1.0, -)	9.7 (1.1, -)
	3rd Quartile (95% CI)	- (21.9, -)	20.4 (3.1, -)
	Log-Rank P-value [2]	0.51943	
	Inverse Hazard Ratio (95% CI) [3]	1.37 (0.52, 3.59)	
	P-value [3]	0.52453	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	6 (50%)	7 (39%)
	Censored, follow-up ended	6 (50%)	10 (56%)
	Censored, follow-up ongoing	0	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.9)	1.0 (1.0, 6.0)
	Median (95% CI)	1.9 (1.0, -)	6.0 (1.0, -)
	3rd Quartile (95% CI)	11.2 (1.8, -)	- (6.0, -)
	Log-Rank P-value [2]	0.56244	
	Inverse Hazard Ratio (95% CI) [3]	0.71 (0.24, 2.12)	
	P-value [3]	0.54254	
Interaction Test	P-value [4]	0.36378	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 7 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	12 (67%)	8 (53%)
	Censored, follow-up ended	4 (22%)	5 (33%)
	Censored, follow-up ongoing	2 (11%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (1.0, 3.7)	1.1 (0.8, 2.0)
	Median (95% CI)	4.7 (1.1, -)	3.1 (1.0, -)
	3rd Quartile (95% CI)	37.6 (3.7, -)	- (2.0, -)
	Log-Rank P-value [2]	0.89595	
	Inverse Hazard Ratio (95% CI) [3]	0.94 (0.38, 2.34)	
	P-value [3]	0.89583	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	5 (42%)	8 (44%)
	Censored, follow-up ended	6 (50%)	10 (56%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.9)	1.1 (0.7, 3.3)
	Median (95% CI)	1.5 (1.0, -)	3.7 (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (3.3, -)
	Log-Rank P-value [2]	0.56782	
	Inverse Hazard Ratio (95% CI) [3]	0.72 (0.23, 2.21)	
	P-value [3]	0.56508	
Interaction Test	P-value [4]	0.72372	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 9 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	7 (39%)	10 (67%)
	Censored, follow-up ended	8 (44%)	3 (20%)
	Censored, follow-up ongoing	3 (17%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 19.2)	1.0 (0.8, 1.1)
	Median (95% CI)	- (1.0, -)	1.2 (1.0, -)
	3rd Quartile (95% CI)	- (19.2, -)	- (1.1, -)
	Log-Rank P-value [2]	0.14583	
	Inverse Hazard Ratio (95% CI) [3]	2.02 (0.77, 5.33)	
	P-value [3]	0.15428	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 10 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	5 (42%)	7 (39%)
	Censored, follow-up ended	5 (42%)	10 (56%)
	Censored, follow-up ongoing	2 (17%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 2.9)	1.0 (0.7, 9.7)
	Median (95% CI)	2.4 (1.0, -)	9.7 (1.0, -)
	3rd Quartile (95% CI)	- (1.2, -)	- (9.7, -)
	Log-Rank P-value [2]	0.63455	
	Inverse Hazard Ratio (95% CI) [3]	0.76 (0.24, 2.41)	
	P-value [3]	0.64518	
Interaction Test	P-value [4]	0.21998	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 11 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	9 (50%)	7 (47%)
	Censored, follow-up ended	5 (28%)	6 (40%)
	Censored, follow-up ongoing	4 (22%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 7.3)	1.2 (0.8, 18.5)
	Median (95% CI)	7.3 (1.0, -)	18.5 (1.1, -)
	3rd Quartile (95% CI)	- (7.3, -)	- (18.5, -)
	Log-Rank P-value [2]	0.94790	
	Inverse Hazard Ratio (95% CI) [3]	0.97 (0.35, 2.69)	
	P-value [3]	0.95963	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	6 (50%)	7 (39%)
	Censored, follow-up ended	5 (42%)	9 (50%)
	Censored, follow-up ongoing	1 (8%)	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 4.2)	1.0 (1.0, 3.4)
	Median (95% CI)	4.2 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (3.0, -)	- (3.4, -)
	Log-Rank P-value [2]	0.62150	
	Inverse Hazard Ratio (95% CI) [3]	0.76 (0.25, 2.25)	
	P-value [3]	0.61693	
Interaction Test	P-value [4]	0.82988	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	12 (67%)	11 (73%)
	Censored, follow-up ended	5 (28%)	2 (13%)
	Censored, follow-up ongoing	1 (6%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 2.0)	1.0 (0.7, 2.1)
	Median (95% CI)	2.0 (1.0, 20.3)	3.8 (1.0, 9.7)
	3rd Quartile (95% CI)	20.3 (2.0, -)	9.7 (2.1, -)
	Log-Rank P-value [2]	0.57506	
	Inverse Hazard Ratio (95% CI) [3]	1.26 (0.54, 2.95)	
	P-value [3]	0.58942	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	7 (58%)	9 (50%)
	Censored, follow-up ended	5 (42%)	8 (44%)
	Censored, follow-up ongoing	0	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 1.9)	1.0 (1.0, 2.3)
	Median (95% CI)	1.9 (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	2.9 (1.9, -)	- (2.3, -)
	Log-Rank P-value [2]	0.53549	
	Inverse Hazard Ratio (95% CI) [3]	0.73 (0.27, 1.97)	
	P-value [3]	0.53042	
Interaction Test	P-value [4]	0.40981	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 15 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	3 (17%)	5 (33%)
	Censored, follow-up ended	10 (56%)	7 (47%)
	Censored, follow-up ongoing	5 (28%)	3 (20%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 16 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	3 (25%)	3 (17%)
	Censored, follow-up ended	6 (50%)	13 (72%)
	Censored, follow-up ongoing	3 (25%)	2 (11%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 17 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	12 (67%)	12 (80%)
	Censored, follow-up ended	3 (17%)	1 (7%)
	Censored, follow-up ongoing	3 (17%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.9)	1.1 (0.7, 1.2)
	Median (95% CI)	2.0 (1.0, 20.3)	1.8 (1.0, 2.9)
	3rd Quartile (95% CI)	20.3 (1.9, -)	2.9 (1.2, -)
	Log-Rank P-value [2]	0.48521	
	Inverse Hazard Ratio (95% CI) [3]	1.34 (0.60, 3.01)	
	P-value [3]	0.47479	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	7 (58%)	11 (61%)
	Censored, follow-up ended	5 (42%)	7 (39%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.0)	1.0 (1.0, 1.1)
	Median (95% CI)	1.0 (1.0, -)	1.4 (1.0, 2.3)
	3rd Quartile (95% CI)	1.2 (1.0, -)	2.3 (1.1, -)
	Log-Rank P-value [2]	0.50666	
	Inverse Hazard Ratio (95% CI) [3]	0.71 (0.28, 1.85)	
	P-value [3]	0.48594	
Interaction Test	P-value [4]	0.35914	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 19 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	9 (50%)	4 (27%)
	Censored, follow-up ended	5 (28%)	6 (40%)
	Censored, follow-up ongoing	4 (22%)	5 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 7.0)	5.6 (0.8, -)
	Median (95% CI)	10.3 (1.1, -)	- (2.1, -)
	3rd Quartile (95% CI)	- (10.3, -)	- (-, -)
	Log-Rank P-value [2]	0.15861	
	Inverse Hazard Ratio (95% CI) [3]	0.44 (0.13, 1.43)	
	P-value [3]	0.17055	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	4 (33%)	6 (33%)
	Censored, follow-up ended	6 (50%)	10 (56%)
	Censored, follow-up ongoing	2 (17%)	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, -)	1.8 (1.0, 12.5)
	Median (95% CI)	9.2 (1.0, -)	12.5 (1.0, -)
	3rd Quartile (95% CI)	- (9.2, -)	- (12.5, -)
	Log-Rank P-value [2]	0.97512	
	Inverse Hazard Ratio (95% CI) [3]	1.03 (0.29, 3.65)	
	P-value [3]	0.96925	
Interaction Test	P-value [4]	0.32757	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 21 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	8 (44%)	5 (33%)
	Censored, follow-up ended	7 (39%)	5 (33%)
	Censored, follow-up ongoing	3 (17%)	5 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 13.2)	6.7 (0.8, -)
	Median (95% CI)	13.2 (1.1, -)	- (1.2, -)
	3rd Quartile (95% CI)	- (13.2, -)	- (-, -)
	Log-Rank P-value [2]	0.53982	
	Inverse Hazard Ratio (95% CI) [3]	0.71 (0.23, 2.16)	
	P-value [3]	0.54185	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 22 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	7 (58%)	6 (33%)
	Censored, follow-up ended	5 (42%)	11 (61%)
	Censored, follow-up ongoing	0	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.2)	1.8 (0.7, -)
	Median (95% CI)	1.2 (1.0, -)	- (1.4, -)
	3rd Quartile (95% CI)	12.1 (1.1, -)	- (-, -)
	Log-Rank P-value [2]	0.08281	
	Inverse Hazard Ratio (95% CI) [3]	0.39 (0.13, 1.17)	
	P-value [3]	0.09206	
Interaction Test	P-value [4]	0.50797	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 23 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	6 (33%)	5 (33%)
	Censored, follow-up ended	9 (50%)	6 (40%)
	Censored, follow-up ongoing	3 (17%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.4 (1.0, -)	2.1 (1.0, -)
	Median (95% CI)	34.9 (1.9, -)	- (2.1, -)
	3rd Quartile (95% CI)	- (34.9, -)	- (-, -)
	Log-Rank P-value [2]	0.99487	
	Inverse Hazard Ratio (95% CI) [3]	1.00 (0.30, 3.27)	
	P-value [3]	0.99578	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	4 (33%)	5 (28%)
	Censored, follow-up ended	6 (50%)	10 (56%)
	Censored, follow-up ongoing	2 (17%)	3 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	3.7 (0.7, -)
	Median (95% CI)	- (1.0, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (7.4, -)
	Log-Rank P-value [2]	0.43146	
	Inverse Hazard Ratio (95% CI) [3]	0.59 (0.16, 2.22)	
	P-value [3]	0.43576	
Interaction Test	P-value [4]	0.58861	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 25 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	1 (6%)	2 (13%)
	Censored, follow-up ended	12 (67%)	8 (53%)
	Censored, follow-up ongoing	5 (28%)	5 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.1, -)	- (2.0, -)
	Median (95% CI)	- (-, -)	- (-, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.53598	
	Inverse Hazard Ratio (95% CI) [3]	2.10 (0.19, 23.14)	
	P-value [3]	0.54524	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	5 (42%)	5 (28%)
	Censored, follow-up ended	6 (50%)	11 (61%)
	Censored, follow-up ongoing	1 (8%)	2 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 2.8)	3.0 (0.7, -)
	Median (95% CI)	2.0 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (-, -)
	Log-Rank P-value [2]	0.18877	
	Inverse Hazard Ratio (95% CI) [3]	0.44 (0.12, 1.56)	
	P-value [3]	0.20194	
Interaction Test	P-value [4]	0.24001	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 27 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	7 (39%)	3 (20%)
	Censored, follow-up ended	8 (44%)	8 (53%)
	Censored, follow-up ongoing	3 (17%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (0.9, -)	- (0.7, -)
	Median (95% CI)	- (1.1, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.26322	
	Inverse Hazard Ratio (95% CI) [3]	0.47 (0.12, 1.82)	
	P-value [3]	0.27388	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	2 (17%)	5 (28%)
	Censored, follow-up ended	7 (58%)	10 (56%)
	Censored, follow-up ongoing	3 (25%)	3 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.0, -)	1.9 (0.7, -)
	Median (95% CI)	- (1.0, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.59312	
	Inverse Hazard Ratio (95% CI) [3]	1.56 (0.30, 8.03)	
	P-value [3]	0.59625	
Interaction Test	P-value [4]	0.24418	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 29 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	4 (22%)	4 (27%)
	Censored, follow-up ended	9 (50%)	7 (47%)
	Censored, follow-up ongoing	5 (28%)	4 (27%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 30 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001145
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	5 (42%)	3 (17%)
	Censored, follow-up ended	6 (50%)	12 (67%)
	Censored, follow-up ongoing	1 (8%)	3 (17%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_iss.sas 09OCT2025 10:07

Protocol: 207499 Page 1 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	6 (75%)	4 (67%)
	Censored, follow-up ended	1 (13%)	1 (17%)
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 2.8)	1.0 (1.0, 5.7)
	Median (95% CI)	2.8 (0.9, 21.9)	4.4 (1.0, -)
	3rd Quartile (95% CI)	21.9 (1.9, -)	- (1.0, -)
	Log-Rank P-value [2]	0.62422	
	Inverse Hazard Ratio (95% CI) [3]	0.73 (0.20, 2.61)	
	P-value [3]	0.62559	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	10 (77%)	9 (64%)
	Censored, follow-up ended	3 (23%)	5 (36%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.3 (1.0, 2.8)	1.1 (0.7, 2.9)
	Median (95% CI)	2.9 (1.2, -)	2.9 (1.1, 15.7)
	3rd Quartile (95% CI)	8.4 (2.8, -)	15.7 (2.0, -)
	Log-Rank P-value [2]	0.63344	
	Inverse Hazard Ratio (95% CI) [3]	0.79 (0.30, 2.10)	
	P-value [3]	0.63970	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 3 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	7 (54%)
	Censored, follow-up ended	4 (44%)	5 (38%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	1.3 (1.0, 2.3)
	Median (95% CI)	2.9 (1.0, -)	2.6 (1.0, -)
	3rd Quartile (95% CI)	13.2 (1.9, -)	- (2.3, -)
	Log-Rank P-value [2]	0.87041	
	Inverse Hazard Ratio (95% CI) [3]	0.90 (0.26, 3.10)	
	P-value [3]	0.86651	
Interaction Test	P-value [4]	0.98968	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 4 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	3 (38%)	3 (50%)
	Censored, follow-up ended	4 (50%)	1 (17%)
	Censored, follow-up ongoing	1 (13%)	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, -)	1.9 (1.8, -)
	Median (95% CI)	- (0.9, -)	- (1.8, -)
	3rd Quartile (95% CI)	- (4.8, -)	- (1.9, -)
	Log-Rank P-value [2]	0.92126	
	Inverse Hazard Ratio (95% CI) [3]	1.12 (0.22, 5.62)	
	P-value [3]	0.88628	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 5 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	9 (69%)	7 (50%)
	Censored, follow-up ended	3 (23%)	6 (43%)
	Censored, follow-up ongoing	1 (8%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 1.9)	2.0 (1.0, 6.0)
	Median (95% CI)	2.3 (1.1, 20.3)	5.7 (1.1, -)
	3rd Quartile (95% CI)	20.3 (1.9, -)	10.6 (5.7, -)
	Log-Rank P-value [2]	0.90542	
	Inverse Hazard Ratio (95% CI) [3]	0.94 (0.33, 2.65)	
	P-value [3]	0.90553	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	3 (33%)	6 (46%)
	Censored, follow-up ended	4 (44%)	5 (38%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.9, -)	1.2 (1.0, -)
	Median (95% CI)	3.8 (1.9, -)	18.5 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	18.5 (2.3, -)
	Log-Rank P-value [2]	0.70627	
	Inverse Hazard Ratio (95% CI) [3]	1.31 (0.32, 5.26)	
	P-value [3]	0.70709	
Interaction Test	P-value [4]	0.81530	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 7 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	6 (75%)	3 (50%)
	Censored, follow-up ended	2 (25%)	1 (17%)
	Censored, follow-up ongoing	0	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 7.5)	1.0 (1.0, -)
	Median (95% CI)	7.5 (0.9, 21.9)	- (1.0, -)
	3rd Quartile (95% CI)	21.9 (1.0, -)	- (1.0, -)
	Log-Rank P-value [2]	0.49593	
	Inverse Hazard Ratio (95% CI) [3]	0.61 (0.15, 2.46)	
	P-value [3]	0.48600	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 8 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	6 (46%)	6 (43%)
	Censored, follow-up ended	6 (46%)	7 (50%)
	Censored, follow-up ongoing	1 (8%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.8)	1.1 (0.8, 6.0)
	Median (95% CI)	- (1.0, -)	6.0 (0.8, -)
	3rd Quartile (95% CI)	- (1.8, -)	20.4 (6.0, -)
	Log-Rank P-value [2]	0.72663	
	Inverse Hazard Ratio (95% CI) [3]	1.23 (0.40, 3.81)	
	P-value [3]	0.72423	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 9 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	7 (54%)
	Censored, follow-up ended	5 (56%)	4 (31%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	1.2 (0.7, 2.8)
	Median (95% CI)	- (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (2.3, -)
	Log-Rank P-value [2]	0.46269	
	Inverse Hazard Ratio (95% CI) [3]	1.79 (0.37, 8.63)	
	P-value [3]	0.46891	
Interaction Test	P-value [4]	0.51596	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 10 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	4 (50%)	4 (67%)
	Censored, follow-up ended	3 (38%)	1 (17%)
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.9, 7.3)	1.0 (1.0, 3.7)
	Median (95% CI)	6.5 (1.9, -)	2.4 (1.0, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (1.0, -)
	Log-Rank P-value [2]	0.50094	
	Inverse Hazard Ratio (95% CI) [3]	1.61 (0.40, 6.52)	
	P-value [3]	0.50475	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 11 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	8 (62%)	7 (50%)
	Censored, follow-up ended	4 (31%)	7 (50%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (1.0, 1.9)	1.1 (0.7, 2.0)
	Median (95% CI)	4.9 (1.1, -)	2.0 (0.8, -)
	3rd Quartile (95% CI)	37.6 (1.9, -)	- (1.1, -)
	Log-Rank P-value [2]	0.56699	
	Inverse Hazard Ratio (95% CI) [3]	1.35 (0.47, 3.88)	
	P-value [3]	0.57268	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	5 (56%)	5 (38%)
	Censored, follow-up ended	3 (33%)	7 (54%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.0)	1.4 (1.0, -)
	Median (95% CI)	1.0 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	1.1 (1.0, -)	- (3.3, -)
	Log-Rank P-value [2]	0.03843	
	Inverse Hazard Ratio (95% CI) [3]	0.27 (0.08, 1.00)	
	P-value [3]	0.04915	
Interaction Test	P-value [4]	0.06187	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 13 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	2 (25%)	3 (50%)
	Censored, follow-up ended	4 (50%)	2 (33%)
	Censored, follow-up ongoing	2 (25%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (0.9, -)	1.0 (1.0, -)
	Median (95% CI)	- (0.9, -)	9.7 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (1.0, -)
	Log-Rank P-value [2]	0.58299	
	Inverse Hazard Ratio (95% CI) [3]	1.65 (0.27, 9.94)	
	P-value [3]	0.58675	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 14 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	6 (46%)	6 (43%)
	Censored, follow-up ended	5 (38%)	7 (50%)
	Censored, follow-up ongoing	2 (15%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.6 (1.0, 19.2)	1.0 (0.7, 1.1)
	Median (95% CI)	19.2 (1.0, -)	1.1 (0.8, -)
	3rd Quartile (95% CI)	- (19.2, -)	- (1.1, -)
	Log-Rank P-value [2]	0.53282	
	Inverse Hazard Ratio (95% CI) [3]	1.45 (0.46, 4.50)	
	P-value [3]	0.52460	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 15 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	8 (62%)
	Censored, follow-up ended	4 (44%)	4 (31%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.1)	1.0 (0.7, 1.4)
	Median (95% CI)	1.1 (1.0, -)	1.4 (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (1.2, -)
	Log-Rank P-value [2]	0.92708	
	Inverse Hazard Ratio (95% CI) [3]	0.94 (0.28, 3.15)	
	P-value [3]	0.92324	
Interaction Test	P-value [4]	0.79567	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 16 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	5 (63%)	2 (33%)
	Censored, follow-up ended	2 (25%)	2 (33%)
	Censored, follow-up ongoing	1 (13%)	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 4.8)	2.8 (1.0, -)
	Median (95% CI)	4.8 (0.9, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (2.8, -)
	Log-Rank P-value [2]	0.27286	
	Inverse Hazard Ratio (95% CI) [3]	0.41 (0.08, 2.09)	
	P-value [3]	0.28107	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 17 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	7 (54%)	6 (43%)
	Censored, follow-up ended	4 (31%)	7 (50%)
	Censored, follow-up ongoing	2 (15%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (1.0, 3.7)	1.0 (0.8, 18.5)
	Median (95% CI)	3.7 (1.1, -)	18.5 (1.0, -)
	3rd Quartile (95% CI)	37.6 (3.7, -)	- (3.4, -)
	Log-Rank P-value [2]	0.73080	
	Inverse Hazard Ratio (95% CI) [3]	1.23 (0.40, 3.82)	
	P-value [3]	0.72084	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	3 (33%)	6 (46%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.2 (1.0, 2.8)
	Median (95% CI)	- (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (2.3, -)
	Log-Rank P-value [2]	0.85617	
	Inverse Hazard Ratio (95% CI) [3]	1.13 (0.28, 4.56)	
	P-value [3]	0.86375	
Interaction Test	P-value [4]	0.54046	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 19 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	7 (88%)	3 (50%)
	Censored, follow-up ended	1 (13%)	2 (33%)
	Censored, follow-up ongoing	0	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.9, 1.9)	1.0 (1.0, -)
	Median (95% CI)	1.9 (0.9, 2.0)	- (1.0, -)
	3rd Quartile (95% CI)	2.0 (1.0, -)	- (1.0, -)
	Log-Rank P-value [2]	0.15855	
	Inverse Hazard Ratio (95% CI) [3]	0.39 (0.10, 1.52)	
	P-value [3]	0.17462	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 20 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	8 (62%)	9 (64%)
	Censored, follow-up ended	5 (38%)	5 (36%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 1.9)	1.0 (0.8, 2.8)
	Median (95% CI)	11.1 (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	27.6 (1.9, -)	5.7 (2.1, -)
	Log-Rank P-value [2]	0.27181	
	Inverse Hazard Ratio (95% CI) [3]	1.80 (0.63, 5.16)	
	P-value [3]	0.27543	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 21 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	8 (62%)
	Censored, follow-up ended	4 (44%)	3 (23%)
	Censored, follow-up ongoing	1 (11%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	1.2 (0.7, 2.3)
	Median (95% CI)	2.9 (1.0, -)	2.3 (1.0, -)
	3rd Quartile (95% CI)	14.1 (1.9, -)	9.7 (1.9, -)
	Log-Rank P-value [2]	0.61256	
	Inverse Hazard Ratio (95% CI) [3]	1.39 (0.37, 5.24)	
	P-value [3]	0.62938	
Interaction Test	P-value [4]	0.10459	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	1 (13%)	3 (50%)
	Censored, follow-up ended	4 (50%)	2 (33%)
	Censored, follow-up ongoing	3 (38%)	1 (17%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 23 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	3 (23%)	3 (21%)
	Censored, follow-up ended	8 (62%)	9 (64%)
	Censored, follow-up ongoing	2 (15%)	2 (14%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 24 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	2 (15%)
	Censored, follow-up ended	4 (44%)	9 (69%)
	Censored, follow-up ongoing	3 (33%)	2 (15%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 25 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	5 (63%)	5 (83%)
	Censored, follow-up ended	2 (25%)	0
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.1)	1.0 (1.0, 1.8)
	Median (95% CI)	1.1 (0.9, -)	1.4 (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	1.9 (1.0, -)
	Log-Rank P-value [2]	0.82301	
	Inverse Hazard Ratio (95% CI) [3]	1.12 (0.32, 3.96)	
	P-value [3]	0.85483	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	10 (77%)	8 (57%)
	Censored, follow-up ended	3 (23%)	5 (36%)
	Censored, follow-up ongoing	0	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 1.9)	1.1 (1.0, 1.9)
	Median (95% CI)	1.9 (1.0, -)	1.9 (1.0, -)
	3rd Quartile (95% CI)	11.5 (1.9, -)	- (1.1, -)
	Log-Rank P-value [2]	0.86068	
	Inverse Hazard Ratio (95% CI) [3]	0.95 (0.37, 2.49)	
	P-value [3]	0.92423	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 27 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	10 (77%)
	Censored, follow-up ended	3 (33%)	3 (23%)
	Censored, follow-up ongoing	2 (22%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.0)	1.0 (0.7, 1.2)
	Median (95% CI)	1.0 (1.0, -)	1.2 (1.0, 2.3)
	3rd Quartile (95% CI)	- (1.0, -)	2.3 (1.1, -)
	Log-Rank P-value [2]	0.74079	
	Inverse Hazard Ratio (95% CI) [3]	1.17 (0.36, 3.77)	
	P-value [3]	0.79361	
Interaction Test	P-value [4]	0.86805	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 28 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	4 (50%)	1 (17%)
	Censored, follow-up ended	3 (38%)	2 (33%)
	Censored, follow-up ongoing	1 (13%)	3 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (0.9, 13.9)	12.5 (12.5, -)
	Median (95% CI)	13.9 (0.9, -)	- (12.5, -)
	3rd Quartile (95% CI)	- (9.2, -)	- (12.5, -)
	Log-Rank P-value [2]	0.24538	
	Inverse Hazard Ratio (95% CI) [3]	0.29 (0.03, 2.64)	
	P-value [3]	0.27439	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 29 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	7 (54%)	4 (29%)
	Censored, follow-up ended	4 (31%)	8 (57%)
	Censored, follow-up ongoing	2 (15%)	2 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 7.0)	1.8 (0.8, -)
	Median (95% CI)	7.0 (1.0, -)	- (0.8, -)
	3rd Quartile (95% CI)	- (7.0, -)	- (-, -)
	Log-Rank P-value [2]	0.56568	
	Inverse Hazard Ratio (95% CI) [3]	0.69 (0.20, 2.38)	
	P-value [3]	0.56129	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	5 (38%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	3 (33%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, -)	1.6 (1.0, -)
	Median (95% CI)	- (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (5.6, -)
	Log-Rank P-value [2]	0.80352	
	Inverse Hazard Ratio (95% CI) [3]	1.23 (0.24, 6.38)	
	P-value [3]	0.80387	
Interaction Test	P-value [4]	0.48469	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 31 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	4 (50%)	2 (33%)
	Censored, follow-up ended	3 (38%)	2 (33%)
	Censored, follow-up ongoing	1 (13%)	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 13.3)	1.8 (1.0, -)
	Median (95% CI)	13.3 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (1.1, -)	- (1.8, -)
	Log-Rank P-value [2]	0.51649	
	Inverse Hazard Ratio (95% CI) [3]	0.57 (0.10, 3.15)	
	P-value [3]	0.52179	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 32 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	7 (54%)	3 (21%)
	Censored, follow-up ended	5 (38%)	8 (57%)
	Censored, follow-up ongoing	1 (8%)	3 (21%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.6 (1.0, 10.9)	3.8 (0.7, -)
	Median (95% CI)	10.9 (1.1, -)	- (0.8, -)
	3rd Quartile (95% CI)	- (10.9, -)	- (-, -)
	Log-Rank P-value [2]	0.26121	
	Inverse Hazard Ratio (95% CI) [3]	0.47 (0.12, 1.82)	
	P-value [3]	0.27237	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 33 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	6 (46%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.4 (1.0, 8.3)
	Median (95% CI)	7.1 (1.0, -)	8.3 (1.2, -)
	3rd Quartile (95% CI)	13.2 (1.0, -)	- (6.7, -)
	Log-Rank P-value [2]	0.62794	
	Inverse Hazard Ratio (95% CI) [3]	0.69 (0.17, 2.80)	
	P-value [3]	0.60296	
Interaction Test	P-value [4]	0.98369	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	2 (25%)	2 (33%)
	Censored, follow-up ended	4 (50%)	2 (33%)
	Censored, follow-up ongoing	2 (25%)	2 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	4 (31%)	5 (36%)
	Censored, follow-up ended	7 (54%)	7 (50%)
	Censored, follow-up ongoing	2 (15%)	2 (14%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 36 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	3 (23%)
	Censored, follow-up ended	4 (44%)	7 (54%)
	Censored, follow-up ongoing	1 (11%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	2 (25%)	4 (67%)
	Censored, follow-up ended	4 (50%)	1 (17%)
	Censored, follow-up ongoing	2 (25%)	1 (17%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	2 (15%)	2 (14%)
	Censored, follow-up ended	9 (69%)	9 (64%)
	Censored, follow-up ongoing	2 (15%)	3 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 39 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	1 (8%)
	Censored, follow-up ended	5 (56%)	9 (69%)
	Censored, follow-up ongoing	2 (22%)	3 (23%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 40 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	3 (38%)	3 (50%)
	Censored, follow-up ended	4 (50%)	1 (17%)
	Censored, follow-up ongoing	1 (13%)	2 (33%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 41 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	4 (31%)	4 (29%)
	Censored, follow-up ended	7 (54%)	7 (50%)
	Censored, follow-up ongoing	2 (15%)	3 (21%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Table 4.0001155

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	1 (8%)
	Censored, follow-up ended	4 (44%)	10 (77%)
	Censored, follow-up ongoing	3 (33%)	2 (15%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 43 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	3 (38%)	1 (17%)
	Censored, follow-up ended	3 (38%)	2 (33%)
	Censored, follow-up ongoing	2 (25%)	3 (50%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 44 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	5 (38%)	3 (21%)
	Censored, follow-up ended	6 (46%)	9 (64%)
	Censored, follow-up ongoing	2 (15%)	2 (14%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 45 of 45
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001155
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	1 (11%)	3 (23%)
	Censored, follow-up ended	6 (67%)	8 (62%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model. Subgroup analysis was not performed when the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line.sas 09OCT2025 10:08

Protocol: 207499 Page 1 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	16 (76%)	13 (65%)
	Censored, follow-up ended	4 (19%)	6 (30%)
	Censored, follow-up ongoing	1 (5%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.8 (0.9, 2.8)	1.1 (0.7, 2.9)
	Median (95% CI)	2.8 (1.8, 4.7)	3.0 (1.1, 15.7)
	3rd Quartile (95% CI)	12.2 (2.8, -)	15.7 (3.0, -)
	Log-Rank P-value [2]	0.70989	
	Inverse Hazard Ratio (95% CI) [3]	0.87 (0.42, 1.81)	
	P-value [3]	0.70211	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	7 (54%)
	Censored, follow-up ended	4 (44%)	5 (38%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	1.3 (1.0, 2.3)
	Median (95% CI)	2.9 (1.0, -)	2.6 (1.0, -)
	3rd Quartile (95% CI)	13.2 (1.9, -)	- (2.3, -)
	Log-Rank P-value [2]	0.87041	
	Inverse Hazard Ratio (95% CI) [3]	0.90 (0.26, 3.10)	
	P-value [3]	0.86651	
Interaction Test	P-value [4]	0.89460	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	12 (57%)	10 (50%)
	Censored, follow-up ended	7 (33%)	7 (35%)
	Censored, follow-up ongoing	2 (10%)	3 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 2.6)	1.9 (1.0, 5.7)
	Median (95% CI)	4.8 (1.1, -)	5.7 (1.9, -)
	3rd Quartile (95% CI)	- (4.8, -)	10.6 (5.7, -)
	Log-Rank P-value [2]	0.95481	
	Inverse Hazard Ratio (95% CI) [3]	0.98 (0.42, 2.30)	
	P-value [3]	0.96061	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	3 (33%)	6 (46%)
	Censored, follow-up ended	4 (44%)	5 (38%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.9, -)	1.2 (1.0, -)
	Median (95% CI)	3.8 (1.9, -)	18.5 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	18.5 (2.3, -)
	Log-Rank P-value [2]	0.70627	
	Inverse Hazard Ratio (95% CI) [3]	1.31 (0.32, 5.26)	
	P-value [3]	0.70709	
Interaction Test	P-value [4]	0.82924	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 5 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	12 (57%)	9 (45%)
	Censored, follow-up ended	8 (38%)	8 (40%)
	Censored, follow-up ongoing	1 (5%)	3 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.8)	1.0 (0.8, 6.0)
	Median (95% CI)	7.5 (1.0, -)	6.0 (1.0, -)
	3rd Quartile (95% CI)	- (7.5, -)	20.4 (6.0, -)
	Log-Rank P-value [2]	0.92853	
	Inverse Hazard Ratio (95% CI) [3]	0.95 (0.40, 2.27)	
	P-value [3]	0.91042	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 6 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	7 (54%)
	Censored, follow-up ended	5 (56%)	4 (31%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	1.2 (0.7, 2.8)
	Median (95% CI)	- (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (2.3, -)
	Log-Rank P-value [2]	0.46269	
	Inverse Hazard Ratio (95% CI) [3]	1.79 (0.37, 8.63)	
	P-value [3]	0.46891	
Interaction Test	P-value [4]	0.40139	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 7 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	12 (57%)	11 (55%)
	Censored, follow-up ended	7 (33%)	8 (40%)
	Censored, follow-up ongoing	2 (10%)	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 3.7)	1.1 (0.7, 1.1)
	Median (95% CI)	5.7 (1.9, -)	2.0 (1.0, -)
	3rd Quartile (95% CI)	37.6 (5.7, -)	- (2.0, -)
	Log-Rank P-value [2]	0.38925	
	Inverse Hazard Ratio (95% CI) [3]	1.43 (0.62, 3.31)	
	P-value [3]	0.39913	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 8 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	5 (56%)	5 (38%)
	Censored, follow-up ended	3 (33%)	7 (54%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.0)	1.4 (1.0, -)
	Median (95% CI)	1.0 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	1.1 (1.0, -)	- (3.3, -)
	Log-Rank P-value [2]	0.03843	
	Inverse Hazard Ratio (95% CI) [3]	0.27 (0.08, 1.00)	
	P-value [3]	0.04915	
Interaction Test	P-value [4]	0.01838	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 9 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	8 (38%)	9 (45%)
	Censored, follow-up ended	9 (43%)	9 (45%)
	Censored, follow-up ongoing	4 (19%)	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (0.9, 19.2)	1.0 (0.7, 1.1)
	Median (95% CI)	- (1.9, -)	9.7 (1.0, -)
	3rd Quartile (95% CI)	- (19.2, -)	- (9.7, -)
	Log-Rank P-value [2]	0.39924	
	Inverse Hazard Ratio (95% CI) [3]	1.51 (0.58, 3.94)	
	P-value [3]	0.39543	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	8 (62%)
	Censored, follow-up ended	4 (44%)	4 (31%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.1)	1.0 (0.7, 1.4)
	Median (95% CI)	1.1 (1.0, -)	1.4 (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (1.2, -)
	Log-Rank P-value [2]	0.92708	
	Inverse Hazard Ratio (95% CI) [3]	0.94 (0.28, 3.15)	
	P-value [3]	0.92324	
Interaction Test	P-value [4]	0.52594	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	12 (57%)	8 (40%)
	Censored, follow-up ended	6 (29%)	9 (45%)
	Censored, follow-up ongoing	3 (14%)	3 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 3.7)	1.1 (0.8, 18.5)
	Median (95% CI)	4.8 (1.1, -)	18.5 (1.0, -)
	3rd Quartile (95% CI)	- (4.8, -)	- (18.5, -)
	Log-Rank P-value [2]	0.70794	
	Inverse Hazard Ratio (95% CI) [3]	0.84 (0.34, 2.10)	
	P-value [3]	0.71405	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	3 (33%)	6 (46%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.2 (1.0, 2.8)
	Median (95% CI)	- (1.0, -)	2.8 (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (2.3, -)
	Log-Rank P-value [2]	0.85617	
	Inverse Hazard Ratio (95% CI) [3]	1.13 (0.28, 4.56)	
	P-value [3]	0.86375	
Interaction Test	P-value [4]	0.63900	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	15 (71%)	12 (60%)
	Censored, follow-up ended	6 (29%)	7 (35%)
	Censored, follow-up ongoing	0	1 (5%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.9)	1.0 (0.8, 2.1)
	Median (95% CI)	1.9 (1.0, 20.3)	2.8 (1.0, 5.7)
	3rd Quartile (95% CI)	20.3 (1.9, -)	5.7 (2.8, -)
	Log-Rank P-value [2]	0.89827	
	Inverse Hazard Ratio (95% CI) [3]	0.95 (0.44, 2.08)	
	P-value [3]	0.90338	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 14 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	8 (62%)
	Censored, follow-up ended	4 (44%)	3 (23%)
	Censored, follow-up ongoing	1 (11%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	1.2 (0.7, 2.3)
	Median (95% CI)	2.9 (1.0, -)	2.3 (1.0, -)
	3rd Quartile (95% CI)	14.1 (1.9, -)	9.7 (1.9, -)
	Log-Rank P-value [2]	0.61256	
	Inverse Hazard Ratio (95% CI) [3]	1.39 (0.37, 5.24)	
	P-value [3]	0.62938	
Interaction Test	P-value [4]	0.87995	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 15 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	4 (19%)	6 (30%)
	Censored, follow-up ended	12 (57%)	11 (55%)
	Censored, follow-up ongoing	5 (24%)	3 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.0, -)	2.1 (1.0, -)
	Median (95% CI)	- (9.2, -)	- (1.8, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.35204	
	Inverse Hazard Ratio (95% CI) [3]	1.81 (0.51, 6.45)	
	P-value [3]	0.36027	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 16 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	2 (15%)
	Censored, follow-up ended	4 (44%)	9 (69%)
	Censored, follow-up ongoing	3 (33%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	- (1.0, -)
	Median (95% CI)	- (1.0, -)	- (1.7, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (-, -)
	Log-Rank P-value [2]	0.50009	
	Inverse Hazard Ratio (95% CI) [3]	0.52 (0.07, 3.67)	
	P-value [3]	0.50787	
Interaction Test	P-value [4]	0.30152	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	15 (71%)	13 (65%)
	Censored, follow-up ended	5 (24%)	5 (25%)
	Censored, follow-up ongoing	1 (5%)	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.2)	1.1 (1.0, 1.1)
	Median (95% CI)	1.9 (1.0, 2.8)	1.8 (1.0, 2.9)
	3rd Quartile (95% CI)	20.3 (1.9, -)	2.9 (1.8, -)
	Log-Rank P-value [2]	0.99414	
	Inverse Hazard Ratio (95% CI) [3]	1.01 (0.48, 2.13)	
	P-value [3]	0.98284	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	10 (77%)
	Censored, follow-up ended	3 (33%)	3 (23%)
	Censored, follow-up ongoing	2 (22%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.0)	1.0 (0.7, 1.2)
	Median (95% CI)	1.0 (1.0, -)	1.2 (1.0, 2.3)
	3rd Quartile (95% CI)	- (1.0, -)	2.3 (1.1, -)
	Log-Rank P-value [2]	0.74079	
	Inverse Hazard Ratio (95% CI) [3]	1.17 (0.36, 3.77)	
	P-value [3]	0.79361	
Interaction Test	P-value [4]	0.70584	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 19 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	11 (52%)	5 (25%)
	Censored, follow-up ended	7 (33%)	10 (50%)
	Censored, follow-up ongoing	3 (14%)	5 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 9.2)	7.3 (0.8, -)
	Median (95% CI)	9.2 (1.1, -)	- (2.1, -)
	3rd Quartile (95% CI)	- (9.2, -)	- (-, -)
	Log-Rank P-value [2]	0.18966	
	Inverse Hazard Ratio (95% CI) [3]	0.50 (0.17, 1.44)	
	P-value [3]	0.19726	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 20 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	5 (38%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	3 (33%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, -)	1.6 (1.0, -)
	Median (95% CI)	- (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (5.6, -)
	Log-Rank P-value [2]	0.80352	
	Inverse Hazard Ratio (95% CI) [3]	1.23 (0.24, 6.38)	
	P-value [3]	0.80387	
Interaction Test	P-value [4]	0.31202	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 21 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	11 (52%)	5 (25%)
	Censored, follow-up ended	8 (38%)	10 (50%)
	Censored, follow-up ongoing	2 (10%)	5 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 10.9)	3.8 (0.7, -)
	Median (95% CI)	12.1 (1.1, -)	- (1.8, -)
	3rd Quartile (95% CI)	- (12.1, -)	- (-, -)
	Log-Rank P-value [2]	0.19873	
	Inverse Hazard Ratio (95% CI) [3]	0.51 (0.18, 1.46)	
	P-value [3]	0.20744	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 22 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	6 (46%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.4 (1.0, 8.3)
	Median (95% CI)	7.1 (1.0, -)	8.3 (1.2, -)
	3rd Quartile (95% CI)	13.2 (1.0, -)	- (6.7, -)
	Log-Rank P-value [2]	0.62794	
	Inverse Hazard Ratio (95% CI) [3]	0.69 (0.17, 2.80)	
	P-value [3]	0.60296	
Interaction Test	P-value [4]	0.98316	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 23 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	6 (29%)	7 (35%)
	Censored, follow-up ended	11 (52%)	9 (45%)
	Censored, follow-up ongoing	4 (19%)	4 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (1.0, -)	2.9 (0.7, -)
	Median (95% CI)	- (2.8, -)	- (2.1, -)
	3rd Quartile (95% CI)	- (34.9, -)	- (-, -)
	Log-Rank P-value [2]	0.59970	
	Inverse Hazard Ratio (95% CI) [3]	1.34 (0.45, 4.02)	
	P-value [3]	0.59646	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 24 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	3 (23%)
	Censored, follow-up ended	4 (44%)	7 (54%)
	Censored, follow-up ongoing	1 (11%)	3 (23%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 2.9)	2.1 (1.0, -)
	Median (95% CI)	2.0 (1.0, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (-, -)
	Log-Rank P-value [2]	0.12972	
	Inverse Hazard Ratio (95% CI) [3]	0.33 (0.07, 1.49)	
	P-value [3]	0.15066	
Interaction Test	P-value [4]	0.10959	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 25 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	4 (19%)	6 (30%)
	Censored, follow-up ended	13 (62%)	10 (50%)
	Censored, follow-up ongoing	4 (19%)	4 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.0, -)	2.8 (0.7, -)
	Median (95% CI)	- (-, -)	- (2.0, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.39767	
	Inverse Hazard Ratio (95% CI) [3]	1.71 (0.48, 6.07)	
	P-value [3]	0.40554	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 26 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	1 (8%)
	Censored, follow-up ended	5 (56%)	9 (69%)
	Censored, follow-up ongoing	2 (22%)	3 (23%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	- (5.7, -)
	Median (95% CI)	- (1.0, -)	- (5.7, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (-, -)
	Log-Rank P-value [2]	0.18495	
	Inverse Hazard Ratio (95% CI) [3]	0.23 (0.02, 2.50)	
	P-value [3]	0.22533	
Interaction Test	P-value [4]	0.10856	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 27 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	7 (33%)	7 (35%)
	Censored, follow-up ended	11 (52%)	8 (40%)
	Censored, follow-up ongoing	3 (14%)	5 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (0.9, -)	1.1 (0.7, -)
	Median (95% CI)	- (1.9, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.63149	
	Inverse Hazard Ratio (95% CI) [3]	1.29 (0.45, 3.67)	
	P-value [3]	0.63848	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Table 4.0001175

Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	1 (8%)
	Censored, follow-up ended	4 (44%)	10 (77%)
	Censored, follow-up ongoing	3 (33%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	- (3.3, -)
	Median (95% CI)	- (1.0, -)	- (3.3, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (-, -)
	Log-Rank P-value [2]	0.18208	
	Inverse Hazard Ratio (95% CI) [3]	0.22 (0.02, 2.48)	
	P-value [3]	0.22301	
Interaction Test	P-value [4]	0.18078	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 29 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	8 (38%)	4 (20%)
	Censored, follow-up ended	9 (43%)	11 (55%)
	Censored, follow-up ongoing	4 (19%)	5 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	19.4 (1.9, -)
	Median (95% CI)	- (1.1, -)	- (4.9, -)
	3rd Quartile (95% CI)	- (-, -)	- (19.4, -)
	Log-Rank P-value [2]	0.19299	
	Inverse Hazard Ratio (95% CI) [3]	0.46 (0.14, 1.52)	
	P-value [3]	0.20162	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 30 of 30
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001175
Summary of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	1 (11%)	3 (23%)
	Censored, follow-up ended	6 (67%)	8 (62%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.0, -)	2.1 (0.7, -)
	Median (95% CI)	- (1.0, -)	- (1.2, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (-, -)
	Log-Rank P-value [2]	0.93590	
	Inverse Hazard Ratio (95% CI) [3]	1.10 (0.11, 10.61)	
	P-value [3]	0.93593	
Interaction Test	P-value [4]	0.47199	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlq30_tti_2ref_line2.sas 09OCT2025 10:07

Protocol: 207499 Page 1 of 780
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001205
Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	59.1 (3.32)	57.8 (3.03)
95% C.I.	(52.6, 65.7)	(51.9, 63.8)
LS Mean Change from Baseline (SE)	2.0 (3.32)	0.7 (3.03)
95% C.I.	(-4.5, 8.6)	(-5.2, 6.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.3 (4.49)	
95% C.I.	(-7.5, 10.2)	
p-value	0.77023	
Corrected Hedges' g	0.08	
95% C.I.	(-0.47, 0.63)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	26
LS Mean (SE)	61.5 (3.35)	58.9 (3.09)
95% C.I.	(54.9, 68.1)	(52.8, 65.0)
LS Mean Change from Baseline (SE)	4.4 (3.35)	1.8 (3.09)
95% C.I.	(-2.2, 11.0)	(-4.3, 7.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.6 (4.55)	
95% C.I.	(-6.4, 11.6)	
p-value	0.56838	
Corrected Hedges' g	0.16	
95% C.I.	(-0.40, 0.72)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	26
LS Mean (SE)	66.2 (3.45)	65.0 (3.11)
95% C.I.	(59.5, 73.0)	(58.8, 71.1)
LS Mean Change from Baseline (SE)	9.1 (3.45)	7.9 (3.11)
95% C.I.	(2.4, 15.9)	(1.7, 14.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.3 (4.64)	
95% C.I.	(-7.9, 10.4)	
p-value	0.78344	
Corrected Hedges' g	0.08	
95% C.I.	(-0.49, 0.65)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	25
LS Mean (SE)	59.3 (3.48)	56.8 (3.16)
95% C.I.	(52.5, 66.2)	(50.6, 63.0)
LS Mean Change from Baseline (SE)	2.3 (3.48)	-0.3 (3.16)
95% C.I.	(-4.6, 9.1)	(-6.5, 5.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.5 (4.70)	
95% C.I.	(-6.7, 11.8)	
p-value	0.58824	
Corrected Hedges' g	0.16	
95% C.I.	(-0.42, 0.74)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	16	19
LS Mean (SE)	66.8 (3.82)	58.9 (3.51)
95% C.I.	(59.3, 74.3)	(52.0, 65.8)
LS Mean Change from Baseline (SE)	9.7 (3.82)	1.8 (3.51)
95% C.I.	(2.2, 17.2)	(-5.1, 8.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.9 (5.20)	
95% C.I.	(-2.3, 18.1)	
p-value	0.12952	
Corrected Hedges' g	0.50	
95% C.I.	(-0.17, 1.18)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	30
n [2]	17	16
LS Mean (SE)	64.5 (3.84)	63.8 (3.80)
95% C.I.	(57.0, 72.1)	(56.3, 71.3)
LS Mean Change from Baseline (SE)	7.4 (3.84)	6.7 (3.80)
95% C.I.	(-0.1, 15.0)	(-0.8, 14.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.7 (5.44)	
95% C.I.	(-10.0, 11.4)	
p-value	0.89479	
Corrected Hedges' g	0.05	
95% C.I.	(-0.64, 0.73)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	14	17
LS Mean (SE)	61.5 (4.09)	58.3 (4.06)
95% C.I.	(53.5, 69.6)	(50.3, 66.2)
LS Mean Change from Baseline (SE)	4.5 (4.09)	1.2 (4.06)
95% C.I.	(-3.6, 12.5)	(-6.8, 9.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.3 (5.83)	
95% C.I.	(-8.2, 14.7)	
p-value	0.57379	
Corrected Hedges' g	0.20	
95% C.I.	(-0.51, 0.91)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	30
n [2]	15	12
LS Mean (SE)	60.2 (4.07)	62.9 (4.54)
95% C.I.	(52.2, 68.2)	(54.0, 71.9)
LS Mean Change from Baseline (SE)	3.1 (4.07)	5.8 (4.54)
95% C.I.	(-4.9, 11.1)	(-3.1, 14.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.7 (6.18)	
95% C.I.	(-14.9, 9.4)	
p-value	0.66116	
Corrected Hedges' g	-0.17	
95% C.I.	(-0.93, 0.59)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Protocol: 207499 Page 9 of 780
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001205
Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	56.3 (4.29)	68.0 (5.18)
95% C.I.	(47.9, 64.8)	(57.8, 78.2)
LS Mean Change from Baseline (SE)	-0.8 (4.29)	10.9 (5.18)
95% C.I.	(-9.2, 7.7)	(0.7, 21.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.7 (6.81)	
95% C.I.	(-25.0, 1.7)	
p-value	0.08767	
Corrected Hedges' g	-0.72	
95% C.I.	(-1.60, 0.15)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	30
n [2]	13	12
LS Mean (SE)	56.7 (4.37)	57.0 (4.88)
95% C.I.	(48.1, 65.3)	(47.4, 66.6)
LS Mean Change from Baseline (SE)	-0.4 (4.37)	-0.1 (4.88)
95% C.I.	(-9.0, 8.2)	(-9.7, 9.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.3 (6.73)	
95% C.I.	(-13.5, 13.0)	
p-value	0.96674	
Corrected Hedges' g	-0.02	
95% C.I.	(-0.80, 0.77)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	14	10
LS Mean (SE)	53.1 (4.28)	63.8 (5.19)
95% C.I.	(44.7, 61.5)	(53.6, 74.0)
LS Mean Change from Baseline (SE)	-4.0 (4.28)	6.7 (5.19)
95% C.I.	(-12.4, 4.4)	(-3.5, 16.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.7 (6.82)	
95% C.I.	(-24.1, 2.7)	
p-value	0.11783	
Corrected Hedges' g	-0.64	
95% C.I.	(-1.47, 0.19)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	57.4 (4.70)	60.8 (5.43)
95% C.I.	(48.2, 66.7)	(50.1, 71.5)
LS Mean Change from Baseline (SE)	0.3 (4.70)	3.7 (5.43)
95% C.I.	(-8.9, 9.6)	(-7.0, 14.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.4 (7.34)	
95% C.I.	(-17.8, 11.1)	
p-value	0.64773	
Corrected Hedges' g	-0.20	
95% C.I.	(-1.09, 0.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	9	11
LS Mean (SE)	59.7 (5.10)	59.0 (5.14)
95% C.I.	(49.7, 69.8)	(48.9, 69.1)
LS Mean Change from Baseline (SE)	2.7 (5.10)	1.9 (5.14)
95% C.I.	(-7.4, 12.7)	(-8.2, 12.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.7 (7.44)	
95% C.I.	(-13.9, 15.4)	
p-value	0.92071	
Corrected Hedges' g	0.04	
95% C.I.	(-0.84, 0.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	57.0 (4.92)	56.7 (5.85)
95% C.I.	(47.3, 66.6)	(45.2, 68.2)
LS Mean Change from Baseline (SE)	-0.1 (4.92)	-0.4 (5.85)
95% C.I.	(-9.8, 9.5)	(-11.9, 11.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.3 (8.06)	
95% C.I.	(-15.6, 16.1)	
p-value	0.97436	
Corrected Hedges' g	0.01	
95% C.I.	(-0.87, 0.90)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	54.2 (4.93)	61.9 (6.55)
95% C.I.	(44.5, 63.9)	(49.1, 74.8)
LS Mean Change from Baseline (SE)	-2.9 (4.93)	4.8 (6.55)
95% C.I.	(-12.5, 6.8)	(-8.0, 17.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.7 (8.50)	
95% C.I.	(-24.4, 9.0)	
p-value	0.36582	
Corrected Hedges' g	-0.45	
95% C.I.	(-1.46, 0.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	55.9 (5.60)	66.0 (6.77)
95% C.I.	(44.9, 66.9)	(52.7, 79.3)
LS Mean Change from Baseline (SE)	-1.2 (5.60)	8.9 (6.77)
95% C.I.	(-12.2, 9.8)	(-4.4, 22.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.1 (9.42)	
95% C.I.	(-28.6, 8.4)	
p-value	0.28469	
Corrected Hedges' g	-0.55	
95% C.I.	(-1.58, 0.48)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	9	7
LS Mean (SE)	60.3 (5.58)	70.0 (6.76)
95% C.I.	(49.3, 71.2)	(56.7, 83.3)
LS Mean Change from Baseline (SE)	3.2 (5.58)	12.9 (6.76)
95% C.I.	(-7.8, 14.2)	(-0.4, 26.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.7 (9.45)	
95% C.I.	(-28.3, 8.9)	
p-value	0.30489	
Corrected Hedges' g	-0.53	
95% C.I.	(-1.54, 0.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	61.4 (5.17)	68.2 (6.67)
95% C.I.	(51.2, 71.5)	(55.1, 81.3)
LS Mean Change from Baseline (SE)	4.3 (5.17)	11.1 (6.67)
95% C.I.	(-5.9, 14.4)	(-2.0, 24.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.8 (8.72)	
95% C.I.	(-24.0, 10.3)	
p-value	0.43284	
Corrected Hedges' g	-0.40	
95% C.I.	(-1.42, 0.63)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	64.0 (6.84)	69.1 (7.36)
95% C.I.	(50.6, 77.5)	(54.6, 83.5)
LS Mean Change from Baseline (SE)	7.0 (6.84)	12.0 (7.36)
95% C.I.	(-6.5, 20.4)	(-2.5, 26.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.0 (11.29)	
95% C.I.	(-27.2, 17.1)	
p-value	0.65618	
Corrected Hedges' g	-0.26	
95% C.I.	(-1.35, 0.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	64.7 (7.02)	74.3 (7.91)
95% C.I.	(50.9, 78.5)	(58.8, 89.9)
LS Mean Change from Baseline (SE)	7.6 (7.02)	17.3 (7.91)
95% C.I.	(-6.1, 21.4)	(1.7, 32.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.6 (11.93)	
95% C.I.	(-33.1, 13.8)	
p-value	0.42110	
Corrected Hedges' g	-0.49	
95% C.I.	(-1.65, 0.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	55.9 (6.17)	79.8 (7.76)
95% C.I.	(43.8, 68.0)	(64.5, 95.0)
LS Mean Change from Baseline (SE)	-1.2 (6.17)	22.7 (7.76)
95% C.I.	(-13.3, 10.9)	(7.4, 37.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-23.9 (10.92)	
95% C.I.	(-45.3, -2.4)	
p-value	0.02924	
Corrected Hedges' g	-1.23	
95% C.I.	(-2.39, -0.08)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	59.8 (6.94)	74.1 (8.09)
95% C.I.	(46.2, 73.4)	(58.2, 90.0)
LS Mean Change from Baseline (SE)	2.7 (6.94)	17.0 (8.09)
95% C.I.	(-10.9, 16.4)	(1.1, 32.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-14.3 (11.97)	
95% C.I.	(-37.8, 9.3)	
p-value	0.23381	
Corrected Hedges' g	-0.72	
95% C.I.	(-1.91, 0.46)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	62.5 (6.24)	75.4 (8.02)
95% C.I.	(50.3, 74.8)	(59.7, 91.2)
LS Mean Change from Baseline (SE)	5.5 (6.24)	18.4 (8.02)
95% C.I.	(-6.8, 17.7)	(2.6, 34.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.9 (11.06)	
95% C.I.	(-34.6, 8.8)	
p-value	0.24374	
Corrected Hedges' g	-0.68	
95% C.I.	(-1.82, 0.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	55.9 (6.21)	74.2 (7.93)
95% C.I.	(43.7, 68.2)	(58.6, 89.8)
LS Mean Change from Baseline (SE)	-1.1 (6.21)	17.1 (7.93)
95% C.I.	(-13.4, 11.1)	(1.5, 32.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-18.2 (10.80)	
95% C.I.	(-39.5, 3.0)	
p-value	0.09192	
Corrected Hedges' g	-0.99	
95% C.I.	(-2.21, 0.22)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	54.7 (6.24)	81.9 (7.36)
95% C.I.	(42.5, 67.0)	(67.4, 96.3)
LS Mean Change from Baseline (SE)	-2.4 (6.24)	24.8 (7.36)
95% C.I.	(-14.6, 9.9)	(10.3, 39.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-27.1 (10.31)	
95% C.I.	(-47.4, -6.9)	
p-value	0.00882	
Corrected Hedges' g	-1.47	
95% C.I.	(-2.69, -0.24)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	50.4 (7.43)	80.8 (8.15)
95% C.I.	(35.8, 65.0)	(64.8, 96.8)
LS Mean Change from Baseline (SE)	-6.7 (7.43)	23.7 (8.15)
95% C.I.	(-21.3, 7.9)	(7.7, 39.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-30.4 (12.45)	
95% C.I.	(-54.8, -5.9)	
p-value	0.01494	
Corrected Hedges' g	-1.53	
95% C.I.	(-2.87, -0.18)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	51.6 (7.12)	77.7 (8.36)
95% C.I.	(37.6, 65.6)	(61.3, 94.1)
LS Mean Change from Baseline (SE)	-5.5 (7.12)	20.6 (8.36)
95% C.I.	(-19.5, 8.5)	(4.2, 37.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-26.1 (12.61)	
95% C.I.	(-50.9, -1.3)	
p-value	0.03891	
Corrected Hedges' g	-1.24	
95% C.I.	(-2.43, -0.05)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	47.3 (7.43)	75.0 (8.43)
95% C.I.	(32.7, 61.9)	(58.4, 91.5)
LS Mean Change from Baseline (SE)	-9.8 (7.43)	17.9 (8.43)
95% C.I.	(-24.4, 4.8)	(1.3, 34.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-27.7 (12.85)	
95% C.I.	(-52.9, -2.4)	
p-value	0.03194	
Corrected Hedges' g	-1.32	
95% C.I.	(-2.58, -0.06)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	49.9 (7.78)	84.5 (9.85)
95% C.I.	(34.6, 65.2)	(65.1, 103.8)
LS Mean Change from Baseline (SE)	-7.2 (7.78)	27.4 (9.85)
95% C.I.	(-22.5, 8.1)	(8.0, 46.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-34.6 (14.51)	
95% C.I.	(-63.1, -6.1)	
p-value	0.01760	
Corrected Hedges' g	-1.62	
95% C.I.	(-3.07, -0.17)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	59.6 (7.64)	68.7 (9.19)
95% C.I.	(44.5, 74.6)	(50.7, 86.8)
LS Mean Change from Baseline (SE)	2.5 (7.64)	11.6 (9.19)
95% C.I.	(-12.5, 17.5)	(-6.4, 29.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.2 (13.36)	
95% C.I.	(-35.4, 17.1)	
p-value	0.49295	
Corrected Hedges' g	-0.44	
95% C.I.	(-1.69, 0.82)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Protocol: 207499 Page 31 of 780
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001205
Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	63.8 (7.56)	67.0 (8.96)
95% C.I.	(48.9, 78.7)	(49.4, 84.7)
LS Mean Change from Baseline (SE)	6.7 (7.56)	10.0 (8.96)
95% C.I.	(-8.2, 21.6)	(-7.7, 27.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.3 (13.34)	
95% C.I.	(-29.5, 23.0)	
p-value	0.80755	
Corrected Hedges' g	-0.15	
95% C.I.	(-1.34, 1.03)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	54.4 (7.73)	72.4 (8.72)
95% C.I.	(39.2, 69.6)	(55.2, 89.5)
LS Mean Change from Baseline (SE)	-2.7 (7.73)	15.3 (8.72)
95% C.I.	(-17.9, 12.5)	(-1.9, 32.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-18.0 (12.97)	
95% C.I.	(-43.5, 7.5)	
p-value	0.16648	
Corrected Hedges' g	-0.88	
95% C.I.	(-2.21, 0.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	30
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Global Health Status

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	73.2 (3.33)	71.0 (3.06)
95% C.I.	(66.6, 79.8)	(65.0, 77.0)
LS Mean Change from Baseline (SE)	2.8 (3.33)	0.5 (3.06)
95% C.I.	(-3.8, 9.3)	(-5.5, 6.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.2 (4.51)	
95% C.I.	(-6.7, 11.1)	
p-value	0.62413	
Corrected Hedges' g	0.13	
95% C.I.	(-0.41, 0.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	26
LS Mean (SE)	75.4 (3.35)	72.0 (3.11)
95% C.I.	(68.8, 82.0)	(65.9, 78.1)
LS Mean Change from Baseline (SE)	5.0 (3.35)	1.6 (3.11)
95% C.I.	(-1.6, 11.6)	(-4.5, 7.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.4 (4.56)	
95% C.I.	(-5.6, 12.4)	
p-value	0.45432	
Corrected Hedges' g	0.21	
95% C.I.	(-0.35, 0.77)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	26
LS Mean (SE)	75.8 (3.40)	71.7 (3.13)
95% C.I.	(69.1, 82.5)	(65.5, 77.8)
LS Mean Change from Baseline (SE)	5.4 (3.40)	1.2 (3.13)
95% C.I.	(-1.3, 12.1)	(-5.0, 7.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.2 (4.61)	
95% C.I.	(-4.9, 13.3)	
p-value	0.36505	
Corrected Hedges' g	0.26	
95% C.I.	(-0.31, 0.83)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	25
LS Mean (SE)	73.6 (3.45)	70.2 (3.17)
95% C.I.	(66.8, 80.4)	(63.9, 76.4)
LS Mean Change from Baseline (SE)	3.2 (3.45)	-0.3 (3.17)
95% C.I.	(-3.6, 10.0)	(-6.5, 6.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.5 (4.69)	
95% C.I.	(-5.8, 12.7)	
p-value	0.45965	
Corrected Hedges' g	0.22	
95% C.I.	(-0.37, 0.80)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	16	19
LS Mean (SE)	74.6 (3.71)	68.4 (3.40)
95% C.I.	(67.3, 81.9)	(61.7, 75.1)
LS Mean Change from Baseline (SE)	4.1 (3.71)	-2.0 (3.40)
95% C.I.	(-3.2, 11.4)	(-8.7, 4.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.2 (5.04)	
95% C.I.	(-3.7, 16.1)	
p-value	0.22117	
Corrected Hedges' g	0.41	
95% C.I.	(-0.27, 1.08)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	30
n [2]	16	16
LS Mean (SE)	66.0 (3.80)	71.4 (3.63)
95% C.I.	(58.5, 73.5)	(64.2, 78.5)
LS Mean Change from Baseline (SE)	-4.5 (3.80)	0.9 (3.63)
95% C.I.	(-12.0, 3.0)	(-6.2, 8.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.4 (5.26)	
95% C.I.	(-15.8, 4.9)	
p-value	0.30374	
Corrected Hedges' g	-0.36	
95% C.I.	(-1.05, 0.34)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	14	17
LS Mean (SE)	69.2 (3.96)	70.7 (3.72)
95% C.I.	(61.4, 77.0)	(63.4, 78.0)
LS Mean Change from Baseline (SE)	-1.2 (3.96)	0.2 (3.72)
95% C.I.	(-9.0, 6.6)	(-7.1, 7.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.5 (5.42)	
95% C.I.	(-12.1, 9.2)	
p-value	0.78656	
Corrected Hedges' g	-0.09	
95% C.I.	(-0.80, 0.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	30
n [2]	14	12
LS Mean (SE)	68.8 (4.03)	72.2 (4.15)
95% C.I.	(60.9, 76.7)	(64.1, 80.4)
LS Mean Change from Baseline (SE)	-1.7 (4.03)	1.8 (4.15)
95% C.I.	(-9.6, 6.3)	(-6.4, 10.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.4 (5.77)	
95% C.I.	(-14.8, 7.9)	
p-value	0.55084	
Corrected Hedges' g	-0.23	
95% C.I.	(-1.00, 0.55)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	65.0 (4.16)	69.8 (4.57)
95% C.I.	(56.9, 73.2)	(60.8, 78.8)
LS Mean Change from Baseline (SE)	-5.4 (4.16)	-0.7 (4.57)
95% C.I.	(-13.6, 2.8)	(-9.7, 8.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.7 (6.16)	
95% C.I.	(-16.9, 7.4)	
p-value	0.44329	
Corrected Hedges' g	-0.31	
95% C.I.	(-1.17, 0.54)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	30
n [2]	13	12
LS Mean (SE)	66.2 (4.23)	67.0 (4.43)
95% C.I.	(57.8, 74.5)	(58.3, 75.7)
LS Mean Change from Baseline (SE)	-4.3 (4.23)	-3.4 (4.43)
95% C.I.	(-12.6, 4.0)	(-12.2, 5.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.9 (6.11)	
95% C.I.	(-12.9, 11.2)	
p-value	0.88746	
Corrected Hedges' g	-0.05	
95% C.I.	(-0.84, 0.73)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	13	10
LS Mean (SE)	70.0 (4.32)	69.5 (4.74)
95% C.I.	(61.5, 78.5)	(60.2, 78.8)
LS Mean Change from Baseline (SE)	-0.4 (4.32)	-0.9 (4.74)
95% C.I.	(-8.9, 8.1)	(-10.3, 8.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.5 (6.39)	
95% C.I.	(-12.1, 13.1)	
p-value	0.93439	
Corrected Hedges' g	0.03	
95% C.I.	(-0.79, 0.86)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	67.1 (4.56)	70.5 (4.92)
95% C.I.	(58.1, 76.0)	(60.8, 80.2)
LS Mean Change from Baseline (SE)	-3.4 (4.56)	0.1 (4.92)
95% C.I.	(-12.3, 5.6)	(-9.6, 9.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.4 (6.70)	
95% C.I.	(-16.6, 9.7)	
p-value	0.60875	
Corrected Hedges' g	-0.22	
95% C.I.	(-1.10, 0.66)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	8	11
LS Mean (SE)	70.1 (4.95)	69.2 (4.72)
95% C.I.	(60.4, 79.9)	(59.9, 78.5)
LS Mean Change from Baseline (SE)	-0.3 (4.95)	-1.2 (4.72)
95% C.I.	(-10.0, 9.4)	(-10.5, 8.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.9 (6.83)	
95% C.I.	(-12.5, 14.3)	
p-value	0.89437	
Corrected Hedges' g	0.06	
95% C.I.	(-0.85, 0.97)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	66.4 (4.71)	79.5 (5.25)
95% C.I.	(57.1, 75.7)	(69.2, 89.8)
LS Mean Change from Baseline (SE)	-4.1 (4.71)	9.0 (5.25)
95% C.I.	(-13.3, 5.2)	(-1.3, 19.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-13.1 (7.02)	
95% C.I.	(-26.9, 0.7)	
p-value	0.06296	
Corrected Hedges' g	-0.80	
95% C.I.	(-1.72, 0.11)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	68.7 (4.71)	72.8 (5.95)
95% C.I.	(59.4, 77.9)	(61.1, 84.5)
LS Mean Change from Baseline (SE)	-1.8 (4.71)	2.4 (5.95)
95% C.I.	(-11.1, 7.5)	(-9.3, 14.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.2 (7.54)	
95% C.I.	(-19.0, 10.7)	
p-value	0.58193	
Corrected Hedges' g	-0.26	
95% C.I.	(-1.26, 0.74)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	67.3 (4.89)	82.9 (6.22)
95% C.I.	(57.7, 77.0)	(70.6, 95.1)
LS Mean Change from Baseline (SE)	-3.1 (4.89)	12.4 (6.22)
95% C.I.	(-12.7, 6.5)	(0.2, 24.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.5 (7.94)	
95% C.I.	(-31.2, 0.1)	
p-value	0.05118	
Corrected Hedges' g	-0.95	
95% C.I.	(-2.02, 0.11)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	9	7
LS Mean (SE)	70.9 (5.05)	83.1 (6.20)
95% C.I.	(61.0, 80.9)	(70.9, 95.3)
LS Mean Change from Baseline (SE)	0.5 (5.05)	12.7 (6.20)
95% C.I.	(-9.5, 10.4)	(0.5, 24.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.2 (8.01)	
95% C.I.	(-28.0, 3.6)	
p-value	0.12897	
Corrected Hedges' g	-0.73	
95% C.I.	(-1.75, 0.29)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	73.5 (5.05)	84.4 (6.23)
95% C.I.	(63.5, 83.4)	(72.1, 96.6)
LS Mean Change from Baseline (SE)	3.0 (5.05)	13.9 (6.23)
95% C.I.	(-6.9, 13.0)	(1.7, 26.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.9 (7.91)	
95% C.I.	(-26.5, 4.7)	
p-value	0.16870	
Corrected Hedges' g	-0.66	
95% C.I.	(-1.69, 0.38)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	70.3 (5.63)	85.4 (6.26)
95% C.I.	(59.2, 81.4)	(73.1, 97.8)
LS Mean Change from Baseline (SE)	-0.2 (5.63)	15.0 (6.26)
95% C.I.	(-11.2, 10.9)	(2.7, 27.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.2 (8.39)	
95% C.I.	(-31.7, 1.3)	
p-value	0.07156	
Corrected Hedges' g	-0.93	
95% C.I.	(-2.08, 0.21)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	73.4 (5.81)	82.5 (6.56)
95% C.I.	(62.0, 84.8)	(69.6, 95.4)
LS Mean Change from Baseline (SE)	2.9 (5.81)	12.0 (6.56)
95% C.I.	(-8.5, 14.4)	(-0.9, 25.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.1 (8.75)	
95% C.I.	(-26.3, 8.1)	
p-value	0.29959	
Corrected Hedges' g	-0.56	
95% C.I.	(-1.72, 0.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	70.6 (5.71)	92.8 (6.81)
95% C.I.	(59.3, 81.8)	(79.4, 106.2)
LS Mean Change from Baseline (SE)	0.1 (5.71)	22.3 (6.81)
95% C.I.	(-11.1, 11.3)	(8.9, 35.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-22.2 (8.76)	
95% C.I.	(-39.5, -5.0)	
p-value	0.01169	
Corrected Hedges' g	-1.27	
95% C.I.	(-2.43, -0.11)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	77.5 (5.89)	83.3 (6.84)
95% C.I.	(65.9, 89.1)	(69.9, 96.8)
LS Mean Change from Baseline (SE)	7.0 (5.89)	12.9 (6.84)
95% C.I.	(-4.6, 18.6)	(-0.6, 26.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.8 (9.00)	
95% C.I.	(-23.5, 11.9)	
p-value	0.51750	
Corrected Hedges' g	-0.35	
95% C.I.	(-1.50, 0.81)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	72.8 (5.74)	88.1 (6.97)
95% C.I.	(61.5, 84.1)	(74.3, 101.8)
LS Mean Change from Baseline (SE)	2.4 (5.74)	17.6 (6.97)
95% C.I.	(-9.0, 13.7)	(3.9, 31.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.3 (8.97)	
95% C.I.	(-32.9, 2.4)	
p-value	0.08977	
Corrected Hedges' g	-0.89	
95% C.I.	(-2.06, 0.28)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	65.6 (5.84)	77.4 (6.91)
95% C.I.	(54.0, 77.1)	(63.8, 91.0)
LS Mean Change from Baseline (SE)	-4.9 (5.84)	7.0 (6.91)
95% C.I.	(-16.4, 6.6)	(-6.6, 20.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.8 (8.99)	
95% C.I.	(-29.5, 5.8)	
p-value	0.18854	
Corrected Hedges' g	-0.71	
95% C.I.	(-1.89, 0.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	73.7 (5.92)	86.0 (6.61)
95% C.I.	(62.0, 85.4)	(73.0, 99.1)
LS Mean Change from Baseline (SE)	3.3 (5.92)	15.6 (6.61)
95% C.I.	(-8.4, 14.9)	(2.6, 28.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.3 (8.78)	
95% C.I.	(-29.6, 5.0)	
p-value	0.16130	
Corrected Hedges' g	-0.72	
95% C.I.	(-1.85, 0.40)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	73.9 (6.17)	84.2 (6.88)
95% C.I.	(61.7, 86.0)	(70.6, 97.7)
LS Mean Change from Baseline (SE)	3.4 (6.17)	13.7 (6.88)
95% C.I.	(-8.7, 15.6)	(0.2, 27.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.3 (9.25)	
95% C.I.	(-28.5, 7.9)	
p-value	0.26663	
Corrected Hedges' g	-0.62	
95% C.I.	(-1.83, 0.60)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	69.7 (6.14)	85.2 (6.91)
95% C.I.	(57.6, 81.8)	(71.5, 98.8)
LS Mean Change from Baseline (SE)	-0.8 (6.14)	14.7 (6.91)
95% C.I.	(-12.9, 11.3)	(1.1, 28.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.5 (9.37)	
95% C.I.	(-33.9, 3.0)	
p-value	0.09973	
Corrected Hedges' g	-0.87	
95% C.I.	(-2.01, 0.27)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	73.3 (6.22)	85.6 (7.16)
95% C.I.	(61.0, 85.5)	(71.5, 99.7)
LS Mean Change from Baseline (SE)	2.8 (6.22)	15.1 (7.16)
95% C.I.	(-9.4, 15.1)	(1.0, 29.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.3 (9.60)	
95% C.I.	(-31.2, 6.6)	
p-value	0.19992	
Corrected Hedges' g	-0.70	
95% C.I.	(-1.88, 0.48)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Protocol: 207499 Page 81 of 780
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001205
Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	76.4 (6.52)	83.2 (7.54)
95% C.I.	(63.6, 89.3)	(68.4, 98.1)
LS Mean Change from Baseline (SE)	6.0 (6.52)	12.8 (7.54)
95% C.I.	(-6.9, 18.8)	(-2.0, 27.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.8 (10.09)	
95% C.I.	(-26.7, 13.1)	
p-value	0.50026	
Corrected Hedges' g	-0.39	
95% C.I.	(-1.67, 0.88)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	75.7 (6.71)	83.9 (7.37)
95% C.I.	(62.5, 88.9)	(69.4, 98.4)
LS Mean Change from Baseline (SE)	5.2 (6.71)	13.5 (7.37)
95% C.I.	(-8.0, 18.5)	(-1.1, 28.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.2 (10.06)	
95% C.I.	(-28.0, 11.6)	
p-value	0.41419	
Corrected Hedges' g	-0.47	
95% C.I.	(-1.73, 0.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	73.9 (6.46)	81.1 (7.40)
95% C.I.	(61.2, 86.7)	(66.5, 95.7)
LS Mean Change from Baseline (SE)	3.5 (6.46)	10.7 (7.40)
95% C.I.	(-9.3, 16.2)	(-3.9, 25.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.2 (9.88)	
95% C.I.	(-26.7, 12.3)	
p-value	0.46815	
Corrected Hedges' g	-0.41	
95% C.I.	(-1.61, 0.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	74.0 (6.63)	82.5 (7.80)
95% C.I.	(61.0, 87.1)	(67.2, 97.9)
LS Mean Change from Baseline (SE)	3.6 (6.63)	12.1 (7.80)
95% C.I.	(-9.5, 16.6)	(-3.3, 27.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.5 (10.27)	
95% C.I.	(-28.8, 11.7)	
p-value	0.40688	
Corrected Hedges' g	-0.48	
95% C.I.	(-1.76, 0.80)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	30
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Physical Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	29
n [2]	24	27
LS Mean (SE)	71.3 (4.43)	68.2 (4.13)
95% C.I.	(62.6, 80.0)	(60.1, 76.4)
LS Mean Change from Baseline (SE)	9.2 (4.43)	6.1 (4.13)
95% C.I.	(0.5, 17.9)	(-2.0, 14.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.0 (6.05)	
95% C.I.	(-8.9, 15.0)	
p-value	0.61496	
Corrected Hedges' g	0.14	
95% C.I.	(-0.41, 0.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	29
n [2]	23	25
LS Mean (SE)	67.2 (4.46)	66.6 (4.19)
95% C.I.	(58.4, 75.9)	(58.4, 74.9)
LS Mean Change from Baseline (SE)	5.0 (4.46)	4.5 (4.19)
95% C.I.	(-3.8, 13.8)	(-3.8, 12.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.5 (6.12)	
95% C.I.	(-11.5, 12.6)	
p-value	0.92947	
Corrected Hedges' g	0.03	
95% C.I.	(-0.54, 0.59)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	29
n [2]	21	25
LS Mean (SE)	66.9 (4.56)	61.5 (4.22)
95% C.I.	(57.9, 75.9)	(53.2, 69.8)
LS Mean Change from Baseline (SE)	4.8 (4.56)	-0.6 (4.22)
95% C.I.	(-4.2, 13.8)	(-9.0, 7.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.4 (6.22)	
95% C.I.	(-6.8, 17.7)	
p-value	0.38429	
Corrected Hedges' g	0.25	
95% C.I.	(-0.33, 0.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	29
n [2]	21	24
LS Mean (SE)	70.2 (4.62)	62.5 (4.29)
95% C.I.	(61.1, 79.3)	(54.1, 71.0)
LS Mean Change from Baseline (SE)	8.1 (4.62)	0.4 (4.29)
95% C.I.	(-1.0, 17.2)	(-8.0, 8.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.7 (6.31)	
95% C.I.	(-4.8, 20.1)	
p-value	0.22618	
Corrected Hedges' g	0.36	
95% C.I.	(-0.23, 0.95)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	29
n [2]	16	18
LS Mean (SE)	67.2 (5.05)	62.5 (4.67)
95% C.I.	(57.2, 77.1)	(53.3, 71.7)
LS Mean Change from Baseline (SE)	5.1 (5.05)	0.4 (4.67)
95% C.I.	(-4.9, 15.0)	(-8.8, 9.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.7 (6.91)	
95% C.I.	(-8.9, 18.3)	
p-value	0.49837	
Corrected Hedges' g	0.23	
95% C.I.	(-0.45, 0.90)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	29
n [2]	17	15
LS Mean (SE)	58.4 (5.06)	66.4 (5.02)
95% C.I.	(48.4, 68.3)	(56.5, 76.2)
LS Mean Change from Baseline (SE)	-3.7 (5.06)	4.3 (5.02)
95% C.I.	(-13.7, 6.2)	(-5.6, 14.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.0 (7.14)	
95% C.I.	(-22.0, 6.1)	
p-value	0.26492	
Corrected Hedges' g	-0.38	
95% C.I.	(-1.09, 0.32)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	29
n [2]	14	17
LS Mean (SE)	55.4 (5.44)	58.5 (5.02)
95% C.I.	(44.7, 66.1)	(48.6, 68.3)
LS Mean Change from Baseline (SE)	-6.7 (5.44)	-3.6 (5.02)
95% C.I.	(-17.4, 4.0)	(-13.5, 6.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.1 (7.41)	
95% C.I.	(-17.7, 11.5)	
p-value	0.67778	
Corrected Hedges' g	-0.15	
95% C.I.	(-0.85, 0.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	29
n [2]	13	12
LS Mean (SE)	64.6 (5.53)	59.4 (5.62)
95% C.I.	(53.7, 75.5)	(48.3, 70.4)
LS Mean Change from Baseline (SE)	2.5 (5.53)	-2.8 (5.62)
95% C.I.	(-8.4, 13.4)	(-13.8, 8.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.2 (7.87)	
95% C.I.	(-10.2, 20.7)	
p-value	0.50563	
Corrected Hedges' g	0.26	
95% C.I.	(-0.53, 1.05)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	29
n [2]	13	9
LS Mean (SE)	66.2 (5.60)	67.4 (6.21)
95% C.I.	(55.2, 77.2)	(55.1, 79.6)
LS Mean Change from Baseline (SE)	4.1 (5.60)	5.2 (6.21)
95% C.I.	(-7.0, 15.1)	(-7.0, 17.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.2 (8.38)	
95% C.I.	(-17.7, 15.3)	
p-value	0.88825	
Corrected Hedges' g	-0.06	
95% C.I.	(-0.91, 0.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	29
n [2]	13	12
LS Mean (SE)	65.5 (5.68)	59.9 (5.94)
95% C.I.	(54.3, 76.7)	(48.2, 71.6)
LS Mean Change from Baseline (SE)	3.4 (5.68)	-2.2 (5.94)
95% C.I.	(-7.8, 14.6)	(-13.9, 9.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.6 (8.22)	
95% C.I.	(-10.6, 21.8)	
p-value	0.49524	
Corrected Hedges' g	0.26	
95% C.I.	(-0.52, 1.05)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	29
n [2]	14	10
LS Mean (SE)	55.6 (5.71)	61.8 (6.37)
95% C.I.	(44.4, 66.8)	(49.3, 74.3)
LS Mean Change from Baseline (SE)	-6.5 (5.71)	-0.3 (6.37)
95% C.I.	(-17.8, 4.7)	(-12.9, 12.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.2 (8.60)	
95% C.I.	(-23.1, 10.7)	
p-value	0.47151	
Corrected Hedges' g	-0.29	
95% C.I.	(-1.10, 0.53)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	29
n [2]	11	9
LS Mean (SE)	62.7 (6.11)	55.3 (6.64)
95% C.I.	(50.7, 74.7)	(42.2, 68.4)
LS Mean Change from Baseline (SE)	0.6 (6.11)	-6.8 (6.64)
95% C.I.	(-11.4, 12.6)	(-19.9, 6.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.4 (9.03)	
95% C.I.	(-10.4, 25.2)	
p-value	0.41295	
Corrected Hedges' g	0.35	
95% C.I.	(-0.54, 1.24)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	29
n [2]	9	11
LS Mean (SE)	59.5 (6.52)	62.0 (6.34)
95% C.I.	(46.7, 72.3)	(49.5, 74.4)
LS Mean Change from Baseline (SE)	-2.6 (6.52)	-0.2 (6.34)
95% C.I.	(-15.4, 10.2)	(-12.6, 12.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.4 (9.11)	
95% C.I.	(-20.4, 15.5)	
p-value	0.78867	
Corrected Hedges' g	-0.11	
95% C.I.	(-1.00, 0.77)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	29
n [2]	11	9
LS Mean (SE)	59.3 (6.36)	64.2 (6.73)
95% C.I.	(46.8, 71.8)	(50.9, 77.4)
LS Mean Change from Baseline (SE)	-2.8 (6.36)	2.0 (6.73)
95% C.I.	(-15.3, 9.7)	(-11.2, 15.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.8 (9.24)	
95% C.I.	(-23.0, 13.3)	
p-value	0.60061	
Corrected Hedges' g	-0.22	
95% C.I.	(-1.11, 0.66)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	29
n [2]	11	6
LS Mean (SE)	55.3 (6.39)	64.0 (8.03)
95% C.I.	(42.8, 67.9)	(48.2, 79.8)
LS Mean Change from Baseline (SE)	-6.8 (6.39)	1.9 (8.03)
95% C.I.	(-19.3, 5.8)	(-13.9, 17.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.7 (10.39)	
95% C.I.	(-29.1, 11.7)	
p-value	0.40355	
Corrected Hedges' g	-0.40	
95% C.I.	(-1.40, 0.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	29
n [2]	10	6
LS Mean (SE)	63.8 (6.55)	71.1 (8.38)
95% C.I.	(50.9, 76.7)	(54.6, 87.6)
LS Mean Change from Baseline (SE)	1.6 (6.55)	9.0 (8.38)
95% C.I.	(-11.2, 14.5)	(-7.5, 25.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.3 (10.74)	
95% C.I.	(-28.5, 13.8)	
p-value	0.49429	
Corrected Hedges' g	-0.34	
95% C.I.	(-1.36, 0.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	29
n [2]	9	7
LS Mean (SE)	66.6 (6.91)	66.7 (8.01)
95% C.I.	(53.0, 80.2)	(50.9, 82.5)
LS Mean Change from Baseline (SE)	4.5 (6.91)	4.6 (8.01)
95% C.I.	(-9.1, 18.1)	(-11.2, 20.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.1 (10.69)	
95% C.I.	(-21.1, 20.9)	
p-value	0.99261	
Corrected Hedges' g	0.00	
95% C.I.	(-0.99, 0.98)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	29
n [2]	10	6
LS Mean (SE)	66.0 (6.99)	73.3 (8.52)
95% C.I.	(52.3, 79.8)	(56.5, 90.1)
LS Mean Change from Baseline (SE)	3.9 (6.99)	11.2 (8.52)
95% C.I.	(-9.9, 17.7)	(-5.6, 27.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.3 (11.39)	
95% C.I.	(-29.7, 15.1)	
p-value	0.52293	
Corrected Hedges' g	-0.32	
95% C.I.	(-1.34, 0.70)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	29
n [2]	7	6
LS Mean (SE)	69.2 (7.64)	74.5 (9.04)
95% C.I.	(54.1, 84.2)	(56.8, 92.3)
LS Mean Change from Baseline (SE)	7.0 (7.64)	12.4 (9.04)
95% C.I.	(-8.0, 22.1)	(-5.4, 30.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.4 (12.15)	
95% C.I.	(-29.3, 18.5)	
p-value	0.65861	
Corrected Hedges' g	-0.24	
95% C.I.	(-1.33, 0.86)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	29
n [2]	7	5
LS Mean (SE)	69.9 (7.84)	71.3 (9.14)
95% C.I.	(54.5, 85.3)	(53.3, 89.3)
LS Mean Change from Baseline (SE)	7.8 (7.84)	9.2 (9.14)
95% C.I.	(-7.6, 23.2)	(-8.8, 27.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.4 (12.25)	
95% C.I.	(-25.5, 22.7)	
p-value	0.91035	
Corrected Hedges' g	-0.06	
95% C.I.	(-1.21, 1.09)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	29
n [2]	8	6
LS Mean (SE)	74.0 (7.71)	80.1 (8.36)
95% C.I.	(58.8, 89.2)	(63.6, 96.5)
LS Mean Change from Baseline (SE)	11.9 (7.71)	18.0 (8.36)
95% C.I.	(-3.3, 27.1)	(1.5, 34.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.1 (11.43)	
95% C.I.	(-28.6, 16.4)	
p-value	0.59461	
Corrected Hedges' g	-0.27	
95% C.I.	(-1.33, 0.80)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	29
n [2]	7	5
LS Mean (SE)	68.6 (7.92)	88.4 (9.42)
95% C.I.	(53.0, 84.2)	(69.9, 106.9)
LS Mean Change from Baseline (SE)	6.5 (7.92)	26.3 (9.42)
95% C.I.	(-9.1, 22.1)	(7.7, 44.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-19.8 (12.54)	
95% C.I.	(-44.5, 4.9)	
p-value	0.11527	
Corrected Hedges' g	-0.87	
95% C.I.	(-2.07, 0.33)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	29
n [2]	8	5
LS Mean (SE)	66.1 (7.78)	73.9 (9.87)
95% C.I.	(50.8, 81.5)	(54.5, 93.3)
LS Mean Change from Baseline (SE)	4.0 (7.78)	11.8 (9.87)
95% C.I.	(-11.3, 19.3)	(-7.6, 31.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.8 (12.99)	
95% C.I.	(-33.3, 17.8)	
p-value	0.55112	
Corrected Hedges' g	-0.33	
95% C.I.	(-1.45, 0.80)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	29
n [2]	7	5
LS Mean (SE)	66.2 (7.89)	73.3 (10.03)
95% C.I.	(50.6, 81.7)	(53.6, 93.1)
LS Mean Change from Baseline (SE)	4.0 (7.89)	11.2 (10.03)
95% C.I.	(-11.5, 19.6)	(-8.5, 30.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.2 (13.10)	
95% C.I.	(-32.9, 18.6)	
p-value	0.58407	
Corrected Hedges' g	-0.31	
95% C.I.	(-1.46, 0.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	29
n [2]	7	6
LS Mean (SE)	75.0 (8.16)	76.9 (9.58)
95% C.I.	(59.0, 91.1)	(58.1, 95.8)
LS Mean Change from Baseline (SE)	12.9 (8.16)	14.8 (9.58)
95% C.I.	(-3.1, 29.0)	(-4.1, 33.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.9 (13.33)	
95% C.I.	(-28.1, 24.4)	
p-value	0.88824	
Corrected Hedges' g	-0.08	
95% C.I.	(-1.17, 1.01)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	29
n [2]	6	5
LS Mean (SE)	63.9 (8.40)	74.1 (9.57)
95% C.I.	(47.4, 80.4)	(55.2, 92.9)
LS Mean Change from Baseline (SE)	1.8 (8.40)	11.9 (9.57)
95% C.I.	(-14.7, 18.3)	(-6.9, 30.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.2 (13.18)	
95% C.I.	(-36.1, 15.8)	
p-value	0.44152	
Corrected Hedges' g	-0.44	
95% C.I.	(-1.64, 0.76)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	29
n [2]	7	6
LS Mean (SE)	68.1 (8.15)	73.0 (8.84)
95% C.I.	(52.0, 84.1)	(55.6, 90.5)
LS Mean Change from Baseline (SE)	6.0 (8.15)	10.9 (8.84)
95% C.I.	(-10.1, 22.0)	(-6.5, 28.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.0 (12.13)	
95% C.I.	(-28.9, 18.9)	
p-value	0.68244	
Corrected Hedges' g	-0.21	
95% C.I.	(-1.31, 0.88)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	29
n [2]	7	5
LS Mean (SE)	67.6 (8.22)	72.2 (9.79)
95% C.I.	(51.4, 83.8)	(53.0, 91.5)
LS Mean Change from Baseline (SE)	5.5 (8.22)	10.1 (9.79)
95% C.I.	(-10.7, 21.7)	(-9.2, 29.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.6 (12.95)	
95% C.I.	(-30.1, 20.9)	
p-value	0.72362	
Corrected Hedges' g	-0.19	
95% C.I.	(-1.34, 0.96)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	29
n [2]	6	4
LS Mean (SE)	74.7 (8.61)	72.7 (11.26)
95% C.I.	(57.8, 91.7)	(50.6, 94.8)
LS Mean Change from Baseline (SE)	12.6 (8.61)	10.6 (11.26)
95% C.I.	(-4.3, 29.6)	(-11.5, 32.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.0 (13.89)	
95% C.I.	(-25.3, 29.3)	
p-value	0.88479	
Corrected Hedges' g	0.08	
95% C.I.	(-1.18, 1.35)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	29
n [2]	5	5
LS Mean (SE)	75.1 (8.97)	70.8 (10.64)
95% C.I.	(57.4, 92.7)	(49.9, 91.7)
LS Mean Change from Baseline (SE)	12.9 (8.97)	8.7 (10.64)
95% C.I.	(-4.7, 30.6)	(-12.3, 29.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.3 (13.87)	
95% C.I.	(-23.0, 31.6)	
p-value	0.75798	
Corrected Hedges' g	0.18	
95% C.I.	(-1.07, 1.42)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	29
n [2]	6	5
LS Mean (SE)	67.8 (8.62)	76.2 (10.53)
95% C.I.	(50.9, 84.8)	(55.4, 96.9)
LS Mean Change from Baseline (SE)	5.7 (8.62)	14.1 (10.53)
95% C.I.	(-11.3, 22.7)	(-6.7, 34.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.3 (13.94)	
95% C.I.	(-35.8, 19.1)	
p-value	0.55047	
Corrected Hedges' g	-0.34	
95% C.I.	(-1.54, 0.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	29
n [2]	6	4
LS Mean (SE)	68.6 (8.68)	78.1 (11.34)
95% C.I.	(51.5, 85.7)	(55.8, 100.4)
LS Mean Change from Baseline (SE)	6.5 (8.68)	16.0 (11.34)
95% C.I.	(-10.6, 23.6)	(-6.4, 38.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.5 (14.08)	
95% C.I.	(-37.2, 18.2)	
p-value	0.50096	
Corrected Hedges' g	-0.39	
95% C.I.	(-1.67, 0.88)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	29
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	29
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	29
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	29
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	29
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	29
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	29
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	29
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	29
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	29
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	29
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	29
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	29
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	29
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	29
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Role Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	24	30
n [2]	23	28
LS Mean (SE)	79.5 (3.34)	83.5 (3.00)
95% C.I.	(72.9, 86.0)	(77.6, 89.4)
LS Mean Change from Baseline (SE)	4.7 (3.34)	8.8 (3.00)
95% C.I.	(-1.9, 11.3)	(2.9, 14.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.1 (4.48)	
95% C.I.	(-12.9, 4.7)	
p-value	0.36218	
Corrected Hedges' g	-0.25	
95% C.I.	(-0.81, 0.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	24	30
n [2]	22	26
LS Mean (SE)	81.9 (3.38)	82.0 (3.05)
95% C.I.	(75.2, 88.5)	(76.0, 88.0)
LS Mean Change from Baseline (SE)	7.1 (3.38)	7.3 (3.05)
95% C.I.	(0.5, 13.8)	(1.3, 13.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.1 (4.54)	
95% C.I.	(-9.1, 8.8)	
p-value	0.97581	
Corrected Hedges' g	-0.01	
95% C.I.	(-0.58, 0.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	24	30
n [2]	21	26
LS Mean (SE)	81.1 (3.44)	85.5 (3.07)
95% C.I.	(74.3, 87.8)	(79.4, 91.5)
LS Mean Change from Baseline (SE)	6.3 (3.44)	10.7 (3.07)
95% C.I.	(-0.4, 13.1)	(4.7, 16.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.4 (4.61)	
95% C.I.	(-13.5, 4.7)	
p-value	0.34090	
Corrected Hedges' g	-0.28	
95% C.I.	(-0.85, 0.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	24	30
n [2]	20	25
LS Mean (SE)	77.6 (3.50)	83.6 (3.12)
95% C.I.	(70.8, 84.5)	(77.5, 89.7)
LS Mean Change from Baseline (SE)	2.9 (3.50)	8.9 (3.12)
95% C.I.	(-4.0, 9.8)	(2.7, 15.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.0 (4.68)	
95% C.I.	(-15.2, 3.2)	
p-value	0.20330	
Corrected Hedges' g	-0.38	
95% C.I.	(-0.97, 0.22)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	24	30
n [2]	15	19
LS Mean (SE)	76.4 (3.83)	86.7 (3.41)
95% C.I.	(68.8, 83.9)	(80.0, 93.4)
LS Mean Change from Baseline (SE)	1.6 (3.83)	12.0 (3.41)
95% C.I.	(-5.9, 9.2)	(5.3, 18.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.3 (5.13)	
95% C.I.	(-20.4, -0.2)	
p-value	0.04490	
Corrected Hedges' g	-0.68	
95% C.I.	(-1.37, 0.02)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	24	30
n [2]	16	16
LS Mean (SE)	71.9 (3.86)	81.7 (3.68)
95% C.I.	(64.3, 79.5)	(74.5, 88.9)
LS Mean Change from Baseline (SE)	-2.8 (3.86)	7.0 (3.68)
95% C.I.	(-10.4, 4.8)	(-0.3, 14.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.8 (5.35)	
95% C.I.	(-20.3, 0.7)	
p-value	0.06821	
Corrected Hedges' g	-0.63	
95% C.I.	(-1.34, 0.08)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	24	30
n [2]	13	17
LS Mean (SE)	77.4 (4.11)	77.8 (3.85)
95% C.I.	(69.3, 85.5)	(70.2, 85.4)
LS Mean Change from Baseline (SE)	2.7 (4.11)	3.1 (3.85)
95% C.I.	(-5.4, 10.8)	(-4.5, 10.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.4 (5.67)	
95% C.I.	(-11.5, 10.8)	
p-value	0.94586	
Corrected Hedges' g	-0.02	
95% C.I.	(-0.75, 0.70)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	24	30
n [2]	14	12
LS Mean (SE)	68.9 (4.10)	78.7 (4.35)
95% C.I.	(60.9, 77.0)	(70.1, 87.2)
LS Mean Change from Baseline (SE)	-5.8 (4.10)	3.9 (4.35)
95% C.I.	(-13.9, 2.3)	(-4.6, 12.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.7 (6.02)	
95% C.I.	(-21.6, 2.1)	
p-value	0.10710	
Corrected Hedges' g	-0.62	
95% C.I.	(-1.41, 0.17)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	24	30
n [2]	12	9
LS Mean (SE)	73.8 (4.36)	79.6 (4.87)
95% C.I.	(65.2, 82.3)	(70.1, 89.2)
LS Mean Change from Baseline (SE)	-1.0 (4.36)	4.9 (4.87)
95% C.I.	(-9.5, 7.6)	(-4.7, 14.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.9 (6.64)	
95% C.I.	(-18.9, 7.2)	
p-value	0.37698	
Corrected Hedges' g	-0.38	
95% C.I.	(-1.25, 0.49)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	24	30
n [2]	12	12
LS Mean (SE)	75.5 (4.49)	83.3 (4.78)
95% C.I.	(66.6, 84.3)	(73.9, 92.7)
LS Mean Change from Baseline (SE)	0.7 (4.49)	8.6 (4.78)
95% C.I.	(-8.1, 9.6)	(-0.8, 18.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.8 (6.80)	
95% C.I.	(-21.2, 5.5)	
p-value	0.24975	
Corrected Hedges' g	-0.47	
95% C.I.	(-1.28, 0.34)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	24	30
n [2]	13	10
LS Mean (SE)	72.9 (4.36)	75.5 (5.01)
95% C.I.	(64.3, 81.5)	(65.6, 85.3)
LS Mean Change from Baseline (SE)	-1.8 (4.36)	0.7 (5.01)
95% C.I.	(-10.4, 6.7)	(-9.1, 10.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.6 (6.70)	
95% C.I.	(-15.7, 10.6)	
p-value	0.70287	
Corrected Hedges' g	-0.16	
95% C.I.	(-0.98, 0.67)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	24	30
n [2]	10	9
LS Mean (SE)	70.7 (4.81)	78.2 (5.29)
95% C.I.	(61.2, 80.1)	(67.8, 88.7)
LS Mean Change from Baseline (SE)	-4.1 (4.81)	3.5 (5.29)
95% C.I.	(-13.5, 5.4)	(-6.9, 13.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.6 (7.34)	
95% C.I.	(-22.0, 6.9)	
p-value	0.30313	
Corrected Hedges' g	-0.47	
95% C.I.	(-1.38, 0.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	24	30
n [2]	8	11
LS Mean (SE)	78.0 (5.76)	76.6 (5.13)
95% C.I.	(66.7, 89.3)	(66.5, 86.7)
LS Mean Change from Baseline (SE)	3.2 (5.76)	1.9 (5.13)
95% C.I.	(-8.1, 14.6)	(-8.2, 12.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.4 (8.33)	
95% C.I.	(-15.0, 17.7)	
p-value	0.86942	
Corrected Hedges' g	0.08	
95% C.I.	(-0.83, 0.99)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	24	30
n [2]	10	9
LS Mean (SE)	74.7 (5.11)	77.8 (5.53)
95% C.I.	(64.7, 84.8)	(66.9, 88.7)
LS Mean Change from Baseline (SE)	0.0 (5.11)	3.0 (5.53)
95% C.I.	(-10.0, 10.0)	(-7.8, 13.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.0 (7.94)	
95% C.I.	(-18.7, 12.6)	
p-value	0.70137	
Corrected Hedges' g	-0.18	
95% C.I.	(-1.08, 0.72)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	24	30
n [2]	10	6
LS Mean (SE)	73.5 (4.95)	80.7 (6.28)
95% C.I.	(63.8, 83.2)	(68.3, 93.0)
LS Mean Change from Baseline (SE)	-1.2 (4.95)	5.9 (6.28)
95% C.I.	(-11.0, 8.5)	(-6.4, 18.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.2 (8.19)	
95% C.I.	(-23.3, 8.9)	
p-value	0.38144	
Corrected Hedges' g	-0.44	
95% C.I.	(-1.46, 0.59)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	24	30
n [2]	9	6
LS Mean (SE)	74.3 (5.28)	85.8 (6.53)
95% C.I.	(64.0, 84.7)	(73.0, 98.7)
LS Mean Change from Baseline (SE)	-0.4 (5.28)	11.1 (6.53)
95% C.I.	(-10.8, 10.0)	(-1.7, 23.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.5 (8.74)	
95% C.I.	(-28.7, 5.7)	
p-value	0.18893	
Corrected Hedges' g	-0.68	
95% C.I.	(-1.74, 0.38)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	24	30
n [2]	8	7
LS Mean (SE)	72.4 (5.43)	81.1 (6.43)
95% C.I.	(61.7, 83.1)	(68.5, 93.8)
LS Mean Change from Baseline (SE)	-2.3 (5.43)	6.4 (6.43)
95% C.I.	(-13.0, 8.3)	(-6.2, 19.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.7 (8.77)	
95% C.I.	(-26.0, 8.5)	
p-value	0.31926	
Corrected Hedges' g	-0.51	
95% C.I.	(-1.54, 0.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	24	30
n [2]	9	6
LS Mean (SE)	77.0 (5.27)	92.5 (6.44)
95% C.I.	(66.7, 87.4)	(79.9, 105.2)
LS Mean Change from Baseline (SE)	2.3 (5.27)	17.8 (6.44)
95% C.I.	(-8.1, 12.7)	(5.2, 30.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.5 (8.49)	
95% C.I.	(-32.2, 1.2)	
p-value	0.06866	
Corrected Hedges' g	-0.92	
95% C.I.	(-2.01, 0.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	24	30
n [2]	6	6
LS Mean (SE)	72.9 (6.17)	84.3 (6.45)
95% C.I.	(60.8, 85.1)	(71.6, 97.0)
LS Mean Change from Baseline (SE)	-1.8 (6.17)	9.5 (6.45)
95% C.I.	(-13.9, 10.3)	(-3.2, 22.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.3 (9.18)	
95% C.I.	(-29.4, 6.7)	
p-value	0.21786	
Corrected Hedges' g	-0.68	
95% C.I.	(-1.84, 0.49)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	69.4 (6.44)	81.3 (6.80)
95% C.I.	(56.7, 82.0)	(67.9, 94.6)
LS Mean Change from Baseline (SE)	-5.4 (6.44)	6.5 (6.80)
95% C.I.	(-18.0, 7.3)	(-6.9, 19.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.9 (9.71)	
95% C.I.	(-31.0, 7.2)	
p-value	0.22161	
Corrected Hedges' g	-0.70	
95% C.I.	(-1.92, 0.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	24	30
n [2]	7	6
LS Mean (SE)	73.6 (6.39)	90.5 (6.52)
95% C.I.	(61.1, 86.2)	(77.7, 103.3)
LS Mean Change from Baseline (SE)	-1.1 (6.39)	15.8 (6.52)
95% C.I.	(-13.7, 11.5)	(2.9, 28.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-16.9 (9.56)	
95% C.I.	(-35.7, 1.9)	
p-value	0.07872	
Corrected Hedges' g	-0.95	
95% C.I.	(-2.10, 0.20)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	75.9 (6.52)	82.6 (7.04)
95% C.I.	(63.1, 88.8)	(68.8, 96.4)
LS Mean Change from Baseline (SE)	1.2 (6.52)	7.9 (7.04)
95% C.I.	(-11.6, 14.0)	(-6.0, 21.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.7 (9.99)	
95% C.I.	(-26.3, 13.0)	
p-value	0.50564	
Corrected Hedges' g	-0.38	
95% C.I.	(-1.58, 0.81)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	24	30
n [2]	7	5
LS Mean (SE)	73.5 (6.37)	93.9 (7.19)
95% C.I.	(61.0, 86.0)	(79.7, 108.0)
LS Mean Change from Baseline (SE)	-1.3 (6.37)	19.2 (7.19)
95% C.I.	(-13.8, 11.3)	(5.0, 33.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-20.4 (10.01)	
95% C.I.	(-40.1, -0.7)	
p-value	0.04229	
Corrected Hedges' g	-1.14	
95% C.I.	(-2.37, 0.10)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	75.2 (7.04)	90.6 (7.18)
95% C.I.	(61.4, 89.1)	(76.4, 104.7)
LS Mean Change from Baseline (SE)	0.5 (7.04)	15.8 (7.18)
95% C.I.	(-13.3, 14.4)	(1.7, 29.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.3 (10.71)	
95% C.I.	(-36.4, 5.7)	
p-value	0.15327	
Corrected Hedges' g	-0.84	
95% C.I.	(-2.07, 0.40)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	24	30
n [2]	6	6
LS Mean (SE)	83.0 (6.23)	90.8 (6.67)
95% C.I.	(70.8, 95.3)	(77.6, 103.9)
LS Mean Change from Baseline (SE)	8.3 (6.23)	16.0 (6.67)
95% C.I.	(-4.0, 20.5)	(2.9, 29.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.7 (9.19)	
95% C.I.	(-25.8, 10.3)	
p-value	0.40031	
Corrected Hedges' g	-0.45	
95% C.I.	(-1.60, 0.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	24	30
n [2]	5	5
LS Mean (SE)	74.5 (6.75)	89.2 (7.06)
95% C.I.	(61.3, 87.8)	(75.3, 103.1)
LS Mean Change from Baseline (SE)	-0.2 (6.75)	14.5 (7.06)
95% C.I.	(-13.5, 13.1)	(0.6, 28.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-14.6 (10.00)	
95% C.I.	(-34.3, 5.0)	
p-value	0.14392	
Corrected Hedges' g	-0.86	
95% C.I.	(-2.15, 0.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	24	30
n [2]	6	6
LS Mean (SE)	72.3 (6.62)	87.9 (7.04)
95% C.I.	(59.3, 85.3)	(74.0, 101.7)
LS Mean Change from Baseline (SE)	-2.4 (6.62)	13.1 (7.04)
95% C.I.	(-15.5, 10.6)	(-0.7, 27.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.6 (10.04)	
95% C.I.	(-35.3, 4.2)	
p-value	0.12182	
Corrected Hedges' g	-0.86	
95% C.I.	(-2.04, 0.32)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	70.4 (6.70)	88.6 (7.31)
95% C.I.	(57.2, 83.6)	(74.2, 103.0)
LS Mean Change from Baseline (SE)	-4.4 (6.70)	13.9 (7.31)
95% C.I.	(-17.5, 8.8)	(-0.5, 28.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-18.2 (10.25)	
95% C.I.	(-38.4, 2.0)	
p-value	0.07659	
Corrected Hedges' g	-1.02	
95% C.I.	(-2.28, 0.24)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	24	30
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	24	30
n [2]	5	5
LS Mean (SE)	72.4 (7.47)	88.4 (7.49)
95% C.I.	(57.7, 87.1)	(73.7, 103.2)
LS Mean Change from Baseline (SE)	-2.3 (7.47)	13.7 (7.49)
95% C.I.	(-17.0, 12.4)	(-1.0, 28.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-16.0 (11.20)	
95% C.I.	(-38.0, 6.0)	
p-value	0.15327	
Corrected Hedges' g	-0.87	
95% C.I.	(-2.16, 0.43)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	70.7 (6.74)	83.2 (7.45)
95% C.I.	(57.4, 84.0)	(68.5, 97.8)
LS Mean Change from Baseline (SE)	-4.0 (6.74)	8.4 (7.45)
95% C.I.	(-17.3, 9.3)	(-6.2, 23.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.4 (10.37)	
95% C.I.	(-32.9, 8.0)	
p-value	0.23108	
Corrected Hedges' g	-0.69	
95% C.I.	(-1.91, 0.53)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	24	30
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	24	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	24	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	24	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	24	30
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	24	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	24	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	24	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	24	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	24	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	24	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	24	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	24	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	24	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	24	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	24	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	24	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Emotional Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	24	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	24	30
n [2]	23	28
LS Mean (SE)	79.5 (3.27)	85.4 (2.95)
95% C.I.	(73.1, 85.9)	(79.6, 91.2)
LS Mean Change from Baseline (SE)	0.1 (3.27)	6.0 (2.95)
95% C.I.	(-6.4, 6.5)	(0.2, 11.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.9 (4.40)	
95% C.I.	(-14.6, 2.8)	
p-value	0.18036	
Corrected Hedges' g	-0.37	
95% C.I.	(-0.93, 0.18)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	24	30
n [2]	22	26
LS Mean (SE)	78.8 (3.31)	85.1 (3.03)
95% C.I.	(72.2, 85.3)	(79.2, 91.1)
LS Mean Change from Baseline (SE)	-0.7 (3.31)	5.7 (3.03)
95% C.I.	(-7.2, 5.8)	(-0.3, 11.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.4 (4.49)	
95% C.I.	(-15.2, 2.5)	
p-value	0.15633	
Corrected Hedges' g	-0.41	
95% C.I.	(-0.98, 0.17)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	24	30
n [2]	21	26
LS Mean (SE)	81.0 (3.38)	87.2 (3.05)
95% C.I.	(74.4, 87.6)	(81.2, 93.2)
LS Mean Change from Baseline (SE)	1.5 (3.38)	7.8 (3.05)
95% C.I.	(-5.1, 8.2)	(1.8, 13.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.2 (4.55)	
95% C.I.	(-15.2, 2.7)	
p-value	0.17176	
Corrected Hedges' g	-0.39	
95% C.I.	(-0.98, 0.19)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	24	30
n [2]	20	25
LS Mean (SE)	82.5 (3.47)	85.9 (3.10)
95% C.I.	(75.6, 89.3)	(79.8, 92.0)
LS Mean Change from Baseline (SE)	3.0 (3.47)	6.4 (3.10)
95% C.I.	(-3.8, 9.8)	(0.3, 12.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.4 (4.67)	
95% C.I.	(-12.6, 5.7)	
p-value	0.46198	
Corrected Hedges' g	-0.22	
95% C.I.	(-0.81, 0.37)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	24	30
n [2]	15	19
LS Mean (SE)	76.5 (3.93)	85.6 (3.46)
95% C.I.	(68.8, 84.2)	(78.8, 92.4)
LS Mean Change from Baseline (SE)	-2.9 (3.93)	6.2 (3.46)
95% C.I.	(-10.7, 4.8)	(-0.6, 13.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.1 (5.28)	
95% C.I.	(-19.5, 1.3)	
p-value	0.08539	
Corrected Hedges' g	-0.59	
95% C.I.	(-1.28, 0.10)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	24	30
n [2]	16	16
LS Mean (SE)	75.8 (3.90)	89.8 (3.76)
95% C.I.	(68.1, 83.5)	(82.4, 97.2)
LS Mean Change from Baseline (SE)	-3.6 (3.90)	10.3 (3.76)
95% C.I.	(-11.3, 4.0)	(2.9, 17.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-14.0 (5.48)	
95% C.I.	(-24.7, -3.2)	
p-value	0.01122	
Corrected Hedges' g	-0.89	
95% C.I.	(-1.61, -0.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	24	30
n [2]	13	17
LS Mean (SE)	75.2 (4.27)	82.7 (3.72)
95% C.I.	(66.9, 83.6)	(75.4, 90.0)
LS Mean Change from Baseline (SE)	-4.2 (4.27)	3.3 (3.72)
95% C.I.	(-12.6, 4.2)	(-4.1, 10.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.5 (5.64)	
95% C.I.	(-18.5, 3.6)	
p-value	0.18598	
Corrected Hedges' g	-0.47	
95% C.I.	(-1.20, 0.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	24	30
n [2]	14	12
LS Mean (SE)	75.1 (4.26)	83.6 (4.30)
95% C.I.	(66.7, 83.5)	(75.1, 92.0)
LS Mean Change from Baseline (SE)	-4.3 (4.26)	4.1 (4.30)
95% C.I.	(-12.7, 4.0)	(-4.3, 12.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.5 (6.08)	
95% C.I.	(-20.4, 3.5)	
p-value	0.16534	
Corrected Hedges' g	-0.53	
95% C.I.	(-1.31, 0.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	24	30
n [2]	12	9
LS Mean (SE)	74.5 (4.47)	75.9 (4.84)
95% C.I.	(65.7, 83.2)	(66.3, 85.4)
LS Mean Change from Baseline (SE)	-5.0 (4.47)	-3.6 (4.84)
95% C.I.	(-13.8, 3.8)	(-13.1, 5.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.4 (6.59)	
95% C.I.	(-14.3, 11.5)	
p-value	0.83133	
Corrected Hedges' g	-0.09	
95% C.I.	(-0.95, 0.78)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	24	30
n [2]	12	12
LS Mean (SE)	76.3 (4.42)	86.9 (4.44)
95% C.I.	(67.6, 85.0)	(78.2, 95.6)
LS Mean Change from Baseline (SE)	-3.2 (4.42)	7.5 (4.44)
95% C.I.	(-11.9, 5.5)	(-1.3, 16.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.6 (6.25)	
95% C.I.	(-22.9, 1.6)	
p-value	0.08951	
Corrected Hedges' g	-0.67	
95% C.I.	(-1.49, 0.15)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	24	30
n [2]	13	10
LS Mean (SE)	74.6 (4.45)	84.7 (4.81)
95% C.I.	(65.9, 83.4)	(75.3, 94.2)
LS Mean Change from Baseline (SE)	-4.8 (4.45)	5.3 (4.81)
95% C.I.	(-13.6, 3.9)	(-4.2, 14.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.1 (6.53)	
95% C.I.	(-22.9, 2.7)	
p-value	0.12272	
Corrected Hedges' g	-0.62	
95% C.I.	(-1.46, 0.22)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	24	30
n [2]	10	9
LS Mean (SE)	70.9 (4.83)	71.0 (5.03)
95% C.I.	(61.4, 80.4)	(61.1, 80.9)
LS Mean Change from Baseline (SE)	-8.6 (4.83)	-8.4 (5.03)
95% C.I.	(-18.1, 0.9)	(-18.3, 1.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.1 (6.98)	
95% C.I.	(-13.9, 13.6)	
p-value	0.98325	
Corrected Hedges' g	-0.01	
95% C.I.	(-0.91, 0.89)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	24	30
n [2]	8	11
LS Mean (SE)	76.4 (5.26)	81.7 (4.66)
95% C.I.	(66.0, 86.7)	(72.5, 90.8)
LS Mean Change from Baseline (SE)	-3.1 (5.26)	2.2 (4.66)
95% C.I.	(-13.4, 7.3)	(-6.9, 11.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.3 (7.01)	
95% C.I.	(-19.1, 8.5)	
p-value	0.44994	
Corrected Hedges' g	-0.33	
95% C.I.	(-1.25, 0.58)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	24	30
n [2]	10	9
LS Mean (SE)	73.6 (4.92)	81.2 (5.10)
95% C.I.	(63.9, 83.3)	(71.1, 91.2)
LS Mean Change from Baseline (SE)	-5.9 (4.92)	1.7 (5.10)
95% C.I.	(-15.5, 3.8)	(-8.3, 11.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.6 (7.03)	
95% C.I.	(-21.4, 6.3)	
p-value	0.28229	
Corrected Hedges' g	-0.47	
95% C.I.	(-1.38, 0.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	24	30
n [2]	10	6
LS Mean (SE)	72.7 (4.89)	89.9 (6.17)
95% C.I.	(63.1, 82.3)	(77.8, 102.0)
LS Mean Change from Baseline (SE)	-6.8 (4.89)	10.5 (6.17)
95% C.I.	(-16.4, 2.9)	(-1.7, 22.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-17.2 (7.90)	
95% C.I.	(-32.7, -1.7)	
p-value	0.02988	
Corrected Hedges' g	-1.06	
95% C.I.	(-2.14, 0.02)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	24	30
n [2]	9	6
LS Mean (SE)	74.6 (5.14)	90.9 (6.31)
95% C.I.	(64.5, 84.7)	(78.5, 103.3)
LS Mean Change from Baseline (SE)	-4.9 (5.14)	11.4 (6.31)
95% C.I.	(-15.0, 5.2)	(-1.0, 23.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-16.3 (8.07)	
95% C.I.	(-32.1, -0.4)	
p-value	0.04430	
Corrected Hedges' g	-0.99	
95% C.I.	(-2.08, 0.10)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	24	30
n [2]	8	7
LS Mean (SE)	75.5 (5.35)	85.2 (5.92)
95% C.I.	(65.0, 86.0)	(73.5, 96.8)
LS Mean Change from Baseline (SE)	-3.9 (5.35)	5.7 (5.92)
95% C.I.	(-14.5, 6.6)	(-5.9, 17.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.7 (7.98)	
95% C.I.	(-25.3, 6.0)	
p-value	0.22680	
Corrected Hedges' g	-0.59	
95% C.I.	(-1.63, 0.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	24	30
n [2]	9	6
LS Mean (SE)	71.8 (5.24)	87.1 (6.25)
95% C.I.	(61.5, 82.1)	(74.9, 99.4)
LS Mean Change from Baseline (SE)	-7.7 (5.24)	7.7 (6.25)
95% C.I.	(-18.0, 2.6)	(-4.6, 20.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.4 (8.24)	
95% C.I.	(-31.6, 0.8)	
p-value	0.06289	
Corrected Hedges' g	-0.93	
95% C.I.	(-2.01, 0.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	24	30
n [2]	6	6
LS Mean (SE)	72.5 (6.14)	93.9 (6.27)
95% C.I.	(60.4, 84.5)	(81.6, 106.3)
LS Mean Change from Baseline (SE)	-7.0 (6.14)	14.5 (6.27)
95% C.I.	(-19.0, 5.1)	(2.2, 26.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-21.5 (8.77)	
95% C.I.	(-38.7, -4.2)	
p-value	0.01478	
Corrected Hedges' g	-1.30	
95% C.I.	(-2.55, -0.06)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	76.3 (6.26)	91.4 (6.66)
95% C.I.	(64.0, 88.6)	(78.4, 104.5)
LS Mean Change from Baseline (SE)	-3.1 (6.26)	12.0 (6.66)
95% C.I.	(-15.4, 9.2)	(-1.1, 25.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.1 (9.12)	
95% C.I.	(-33.0, 2.8)	
p-value	0.09784	
Corrected Hedges' g	-0.91	
95% C.I.	(-2.16, 0.33)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	24	30
n [2]	7	6
LS Mean (SE)	70.9 (5.95)	85.5 (6.36)
95% C.I.	(59.2, 82.6)	(73.0, 98.0)
LS Mean Change from Baseline (SE)	-8.6 (5.95)	6.0 (6.36)
95% C.I.	(-20.3, 3.1)	(-6.5, 18.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-14.6 (8.65)	
95% C.I.	(-31.6, 2.4)	
p-value	0.09206	
Corrected Hedges' g	-0.87	
95% C.I.	(-2.01, 0.27)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	73.8 (6.24)	89.1 (6.81)
95% C.I.	(61.5, 86.1)	(75.7, 102.5)
LS Mean Change from Baseline (SE)	-5.6 (6.24)	9.6 (6.81)
95% C.I.	(-17.9, 6.6)	(-3.8, 23.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.3 (9.22)	
95% C.I.	(-33.4, 2.9)	
p-value	0.09853	
Corrected Hedges' g	-0.91	
95% C.I.	(-2.16, 0.33)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	24	30
n [2]	7	5
LS Mean (SE)	65.9 (5.94)	96.8 (6.97)
95% C.I.	(54.2, 77.6)	(83.1, 110.6)
LS Mean Change from Baseline (SE)	-13.5 (5.94)	17.4 (6.97)
95% C.I.	(-25.2, -1.9)	(3.7, 31.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-30.9 (9.19)	
95% C.I.	(-49.0, -12.9)	
p-value	0.00084	
Corrected Hedges' g	-1.82	
95% C.I.	(-3.18, -0.46)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	72.4 (6.20)	97.5 (6.90)
95% C.I.	(60.2, 84.6)	(83.9, 111.0)
LS Mean Change from Baseline (SE)	-7.1 (6.20)	18.0 (6.90)
95% C.I.	(-19.3, 5.1)	(4.4, 31.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-25.1 (9.26)	
95% C.I.	(-43.3, -6.9)	
p-value	0.00711	
Corrected Hedges' g	-1.50	
95% C.I.	(-2.84, -0.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	24	30
n [2]	6	6
LS Mean (SE)	66.5 (6.25)	100.7 (6.41)
95% C.I.	(54.2, 78.8)	(88.1, 113.4)
LS Mean Change from Baseline (SE)	-13.0 (6.25)	21.3 (6.41)
95% C.I.	(-25.3, -0.7)	(8.7, 33.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-34.3 (8.97)	
95% C.I.	(-51.9, -16.6)	
p-value	0.00016	
Corrected Hedges' g	-2.04	
95% C.I.	(-3.44, -0.64)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	24	30
n [2]	5	5
LS Mean (SE)	62.3 (6.75)	97.0 (6.77)
95% C.I.	(49.0, 75.5)	(83.7, 110.3)
LS Mean Change from Baseline (SE)	-17.2 (6.75)	17.6 (6.77)
95% C.I.	(-30.4, -3.9)	(4.2, 30.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-34.7 (9.53)	
95% C.I.	(-53.5, -16.0)	
p-value	0.00030	
Corrected Hedges' g	-2.08	
95% C.I.	(-3.61, -0.54)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	24	30
n [2]	6	6
LS Mean (SE)	61.9 (6.41)	99.5 (6.41)
95% C.I.	(49.3, 74.5)	(86.9, 112.1)
LS Mean Change from Baseline (SE)	-17.5 (6.41)	20.1 (6.41)
95% C.I.	(-30.1, -4.9)	(7.5, 32.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-37.6 (9.07)	
95% C.I.	(-55.5, -19.8)	
p-value	0.00004	
Corrected Hedges' g	-2.21	
95% C.I.	(-3.65, -0.78)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	64.9 (6.43)	94.0 (6.91)
95% C.I.	(52.2, 77.5)	(80.4, 107.6)
LS Mean Change from Baseline (SE)	-14.6 (6.43)	14.6 (6.91)
95% C.I.	(-27.3, -1.9)	(1.0, 28.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-29.2 (9.42)	
95% C.I.	(-47.7, -10.6)	
p-value	0.00211	
Corrected Hedges' g	-1.71	
95% C.I.	(-3.09, -0.32)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	24	30
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	24	30
n [2]	5	5
LS Mean (SE)	72.2 (6.94)	97.4 (7.04)
95% C.I.	(58.6, 85.9)	(83.6, 111.3)
LS Mean Change from Baseline (SE)	-7.2 (6.94)	18.0 (7.04)
95% C.I.	(-20.9, 6.4)	(4.1, 31.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-25.2 (9.79)	
95% C.I.	(-44.5, -6.0)	
p-value	0.01038	
Corrected Hedges' g	-1.46	
95% C.I.	(-2.85, -0.06)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	58.7 (6.44)	93.7 (7.07)
95% C.I.	(46.0, 71.3)	(79.8, 107.6)
LS Mean Change from Baseline (SE)	-20.8 (6.44)	14.2 (7.07)
95% C.I.	(-33.4, -8.1)	(0.3, 28.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-35.0 (9.53)	
95% C.I.	(-53.7, -16.2)	
p-value	0.00028	
Corrected Hedges' g	-2.03	
95% C.I.	(-3.48, -0.57)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	24	30
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	24	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	24	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	24	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	24	30
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	24	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	24	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	24	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	24	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	24	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	24	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	24	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	24	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	24	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	24	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	24	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	24	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Cognitive Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	24	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	72.6 (4.25)	70.9 (3.91)
95% C.I.	(64.3, 81.0)	(63.2, 78.6)
LS Mean Change from Baseline (SE)	6.7 (4.25)	5.0 (3.91)
95% C.I.	(-1.6, 15.1)	(-2.7, 12.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.7 (5.76)	
95% C.I.	(-9.6, 13.1)	
p-value	0.76483	
Corrected Hedges' g	0.08	
95% C.I.	(-0.46, 0.63)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	26
LS Mean (SE)	70.2 (4.31)	69.7 (3.99)
95% C.I.	(61.7, 78.7)	(61.9, 77.6)
LS Mean Change from Baseline (SE)	4.3 (4.31)	3.8 (3.99)
95% C.I.	(-4.2, 12.8)	(-4.0, 11.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.5 (5.86)	
95% C.I.	(-11.0, 12.0)	
p-value	0.93173	
Corrected Hedges' g	0.02	
95% C.I.	(-0.54, 0.59)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	26
LS Mean (SE)	70.2 (4.38)	71.2 (4.02)
95% C.I.	(61.6, 78.8)	(63.3, 79.1)
LS Mean Change from Baseline (SE)	4.3 (4.38)	5.3 (4.02)
95% C.I.	(-4.3, 12.9)	(-2.6, 13.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.0 (5.94)	
95% C.I.	(-12.7, 10.6)	
p-value	0.86166	
Corrected Hedges' g	-0.05	
95% C.I.	(-0.62, 0.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	25
LS Mean (SE)	69.4 (4.50)	68.7 (4.09)
95% C.I.	(60.5, 78.2)	(60.7, 76.7)
LS Mean Change from Baseline (SE)	3.5 (4.50)	2.8 (4.09)
95% C.I.	(-5.4, 12.3)	(-5.2, 10.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.7 (6.06)	
95% C.I.	(-11.2, 12.6)	
p-value	0.91150	
Corrected Hedges' g	0.03	
95% C.I.	(-0.55, 0.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	16	19
LS Mean (SE)	70.7 (5.02)	74.8 (4.55)
95% C.I.	(60.9, 80.6)	(65.9, 83.8)
LS Mean Change from Baseline (SE)	4.8 (5.02)	8.9 (4.55)
95% C.I.	(-5.0, 14.7)	(0.0, 17.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.1 (6.79)	
95% C.I.	(-17.5, 9.2)	
p-value	0.54581	
Corrected Hedges' g	-0.20	
95% C.I.	(-0.87, 0.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	30
n [2]	17	16
LS Mean (SE)	65.5 (4.96)	80.6 (4.93)
95% C.I.	(55.7, 75.2)	(70.9, 90.3)
LS Mean Change from Baseline (SE)	-0.4 (4.96)	14.7 (4.93)
95% C.I.	(-10.2, 9.3)	(5.0, 24.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.1 (7.02)	
95% C.I.	(-28.9, -1.3)	
p-value	0.03173	
Corrected Hedges' g	-0.73	
95% C.I.	(-1.44, -0.03)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	14	17
LS Mean (SE)	64.4 (5.36)	73.1 (4.93)
95% C.I.	(53.9, 75.0)	(63.4, 82.8)
LS Mean Change from Baseline (SE)	-1.5 (5.36)	7.2 (4.93)
95% C.I.	(-12.0, 9.1)	(-2.5, 16.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.6 (7.23)	
95% C.I.	(-22.8, 5.6)	
p-value	0.23295	
Corrected Hedges' g	-0.42	
95% C.I.	(-1.13, 0.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	30
n [2]	15	12
LS Mean (SE)	73.4 (5.24)	73.0 (5.67)
95% C.I.	(63.1, 83.7)	(61.9, 84.2)
LS Mean Change from Baseline (SE)	7.5 (5.24)	7.1 (5.67)
95% C.I.	(-2.8, 17.8)	(-4.0, 18.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.4 (7.71)	
95% C.I.	(-14.8, 15.5)	
p-value	0.96037	
Corrected Hedges' g	0.02	
95% C.I.	(-0.74, 0.78)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	71.1 (5.55)	73.5 (6.39)
95% C.I.	(60.2, 82.0)	(61.0, 86.1)
LS Mean Change from Baseline (SE)	5.2 (5.55)	7.6 (6.39)
95% C.I.	(-5.7, 16.1)	(-4.9, 20.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.4 (8.47)	
95% C.I.	(-19.1, 14.2)	
p-value	0.77367	
Corrected Hedges' g	-0.12	
95% C.I.	(-0.97, 0.73)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	30
n [2]	13	12
LS Mean (SE)	68.7 (5.63)	76.9 (5.89)
95% C.I.	(57.6, 79.8)	(65.3, 88.5)
LS Mean Change from Baseline (SE)	2.8 (5.63)	11.0 (5.89)
95% C.I.	(-8.3, 13.9)	(-0.6, 22.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.2 (8.17)	
95% C.I.	(-24.2, 7.9)	
p-value	0.31736	
Corrected Hedges' g	-0.39	
95% C.I.	(-1.18, 0.40)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	14	10
LS Mean (SE)	60.3 (5.51)	71.9 (6.36)
95% C.I.	(49.4, 71.1)	(59.4, 84.4)
LS Mean Change from Baseline (SE)	-5.6 (5.51)	6.0 (6.36)
95% C.I.	(-16.5, 5.2)	(-6.5, 18.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.6 (8.41)	
95% C.I.	(-28.2, 4.9)	
p-value	0.16781	
Corrected Hedges' g	-0.55	
95% C.I.	(-1.38, 0.28)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	30
n [2]	11	8
LS Mean (SE)	62.1 (6.07)	60.7 (6.89)
95% C.I.	(50.1, 74.0)	(47.2, 74.3)
LS Mean Change from Baseline (SE)	-3.8 (6.07)	-5.2 (6.89)
95% C.I.	(-15.8, 8.1)	(-18.7, 8.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.3 (9.18)	
95% C.I.	(-16.7, 19.4)	
p-value	0.88460	
Corrected Hedges' g	0.06	
95% C.I.	(-0.85, 0.98)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	9	11
LS Mean (SE)	58.2 (6.55)	66.1 (6.20)
95% C.I.	(45.4, 71.1)	(53.9, 78.2)
LS Mean Change from Baseline (SE)	-7.7 (6.55)	0.2 (6.20)
95% C.I.	(-20.5, 5.2)	(-12.0, 12.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.8 (9.02)	
95% C.I.	(-25.6, 9.9)	
p-value	0.38570	
Corrected Hedges' g	-0.37	
95% C.I.	(-1.26, 0.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	30
n [2]	11	8
LS Mean (SE)	62.1 (6.17)	66.9 (7.06)
95% C.I.	(50.0, 74.3)	(53.0, 80.7)
LS Mean Change from Baseline (SE)	-3.8 (6.17)	1.0 (7.06)
95% C.I.	(-15.9, 8.4)	(-12.9, 14.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.7 (9.37)	
95% C.I.	(-23.2, 13.7)	
p-value	0.61376	
Corrected Hedges' g	-0.22	
95% C.I.	(-1.14, 0.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	58.3 (6.15)	71.6 (8.26)
95% C.I.	(46.2, 70.3)	(55.4, 87.8)
LS Mean Change from Baseline (SE)	-7.6 (6.15)	5.7 (8.26)
95% C.I.	(-19.7, 4.4)	(-10.5, 21.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-13.3 (10.34)	
95% C.I.	(-33.7, 7.0)	
p-value	0.19794	
Corrected Hedges' g	-0.62	
95% C.I.	(-1.64, 0.39)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	67.9 (6.41)	71.4 (8.41)
95% C.I.	(55.3, 80.5)	(54.8, 87.9)
LS Mean Change from Baseline (SE)	2.0 (6.41)	5.5 (8.41)
95% C.I.	(-10.6, 14.6)	(-11.1, 22.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.4 (10.53)	
95% C.I.	(-24.1, 17.3)	
p-value	0.74473	
Corrected Hedges' g	-0.16	
95% C.I.	(-1.17, 0.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	9	7
LS Mean (SE)	69.3 (6.66)	71.3 (7.86)
95% C.I.	(56.2, 82.4)	(55.8, 86.7)
LS Mean Change from Baseline (SE)	3.4 (6.66)	5.4 (7.86)
95% C.I.	(-9.7, 16.5)	(-10.1, 20.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.0 (10.30)	
95% C.I.	(-22.2, 18.3)	
p-value	0.84758	
Corrected Hedges' g	-0.09	
95% C.I.	(-1.08, 0.90)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	69.9 (6.50)	76.9 (8.32)
95% C.I.	(57.1, 82.7)	(60.5, 93.2)
LS Mean Change from Baseline (SE)	4.0 (6.50)	11.0 (8.32)
95% C.I.	(-8.8, 16.8)	(-5.4, 27.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.0 (10.62)	
95% C.I.	(-27.9, 13.9)	
p-value	0.51065	
Corrected Hedges' g	-0.32	
95% C.I.	(-1.34, 0.70)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	71.4 (7.53)	76.3 (8.45)
95% C.I.	(56.6, 86.2)	(59.6, 92.9)
LS Mean Change from Baseline (SE)	5.5 (7.53)	10.4 (8.45)
95% C.I.	(-9.3, 20.3)	(-6.3, 27.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.9 (11.41)	
95% C.I.	(-27.3, 17.5)	
p-value	0.66822	
Corrected Hedges' g	-0.22	
95% C.I.	(-1.32, 0.87)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	68.6 (7.69)	76.3 (8.97)
95% C.I.	(53.5, 83.7)	(58.7, 94.0)
LS Mean Change from Baseline (SE)	2.7 (7.69)	10.4 (8.97)
95% C.I.	(-12.4, 17.9)	(-7.2, 28.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.7 (11.91)	
95% C.I.	(-31.1, 15.7)	
p-value	0.51830	
Corrected Hedges' g	-0.35	
95% C.I.	(-1.51, 0.80)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	61.3 (7.37)	79.4 (8.23)
95% C.I.	(46.8, 75.8)	(63.2, 95.6)
LS Mean Change from Baseline (SE)	-4.6 (7.37)	13.5 (8.23)
95% C.I.	(-19.1, 9.9)	(-2.7, 29.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-18.1 (11.08)	
95% C.I.	(-39.9, 3.7)	
p-value	0.10342	
Corrected Hedges' g	-0.82	
95% C.I.	(-1.92, 0.28)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	71.2 (7.68)	70.0 (9.20)
95% C.I.	(56.1, 86.3)	(52.0, 88.1)
LS Mean Change from Baseline (SE)	5.3 (7.68)	4.1 (9.20)
95% C.I.	(-9.8, 20.4)	(-13.9, 22.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.1 (12.08)	
95% C.I.	(-22.6, 24.9)	
p-value	0.92539	
Corrected Hedges' g	0.05	
95% C.I.	(-1.10, 1.20)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	70.3 (7.37)	79.0 (9.47)
95% C.I.	(55.8, 84.8)	(60.4, 97.6)
LS Mean Change from Baseline (SE)	4.4 (7.37)	13.1 (9.47)
95% C.I.	(-10.1, 18.9)	(-5.5, 31.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.7 (12.12)	
95% C.I.	(-32.5, 15.1)	
p-value	0.47325	
Corrected Hedges' g	-0.39	
95% C.I.	(-1.51, 0.74)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	67.7 (7.60)	71.2 (9.39)
95% C.I.	(52.7, 82.6)	(52.8, 89.7)
LS Mean Change from Baseline (SE)	1.8 (7.60)	5.3 (9.39)
95% C.I.	(-13.2, 16.7)	(-13.1, 23.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.6 (12.10)	
95% C.I.	(-27.3, 20.2)	
p-value	0.76919	
Corrected Hedges' g	-0.16	
95% C.I.	(-1.31, 0.99)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	78.8 (7.76)	74.2 (8.68)
95% C.I.	(63.6, 94.1)	(57.1, 91.2)
LS Mean Change from Baseline (SE)	12.9 (7.76)	8.3 (8.68)
95% C.I.	(-2.3, 28.2)	(-8.8, 25.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.7 (11.87)	
95% C.I.	(-18.7, 28.0)	
p-value	0.69480	
Corrected Hedges' g	0.21	
95% C.I.	(-0.89, 1.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	68.5 (8.19)	77.7 (9.14)
95% C.I.	(52.4, 84.6)	(59.7, 95.6)
LS Mean Change from Baseline (SE)	2.6 (8.19)	11.8 (9.14)
95% C.I.	(-13.5, 18.7)	(-6.2, 29.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.2 (12.41)	
95% C.I.	(-33.6, 15.2)	
p-value	0.46026	
Corrected Hedges' g	-0.41	
95% C.I.	(-1.61, 0.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	64.6 (7.86)	69.1 (8.51)
95% C.I.	(49.1, 80.1)	(52.4, 85.9)
LS Mean Change from Baseline (SE)	-1.3 (7.86)	3.2 (8.51)
95% C.I.	(-16.8, 14.2)	(-13.5, 20.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.5 (11.64)	
95% C.I.	(-27.4, 18.4)	
p-value	0.69738	
Corrected Hedges' g	-0.20	
95% C.I.	(-1.30, 0.89)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	68.6 (7.89)	83.7 (9.35)
95% C.I.	(53.1, 84.1)	(65.3, 102.1)
LS Mean Change from Baseline (SE)	2.7 (7.89)	17.8 (9.35)
95% C.I.	(-12.8, 18.2)	(-0.6, 36.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.1 (12.34)	
95% C.I.	(-39.4, 9.2)	
p-value	0.22152	
Corrected Hedges' g	-0.67	
95% C.I.	(-1.85, 0.51)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	68.8 (8.26)	70.6 (10.34)
95% C.I.	(52.5, 85.0)	(50.3, 91.0)
LS Mean Change from Baseline (SE)	2.9 (8.26)	4.7 (10.34)
95% C.I.	(-13.4, 19.1)	(-15.6, 25.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.9 (13.22)	
95% C.I.	(-27.9, 24.1)	
p-value	0.88622	
Corrected Hedges' g	-0.08	
95% C.I.	(-1.35, 1.18)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	30
n [2]	4	5

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	61.0 (8.53)	75.7 (9.71)
95% C.I.	(44.2, 77.7)	(56.6, 94.8)
LS Mean Change from Baseline (SE)	-4.9 (8.53)	9.8 (9.71)
95% C.I.	(-21.7, 11.8)	(-9.3, 28.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-14.7 (13.33)	
95% C.I.	(-41.0, 11.5)	
p-value	0.26937	
Corrected Hedges' g	-0.63	
95% C.I.	(-1.85, 0.58)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	72.3 (8.36)	85.7 (10.91)
95% C.I.	(55.9, 88.8)	(64.3, 107.2)
LS Mean Change from Baseline (SE)	6.4 (8.36)	19.8 (10.91)
95% C.I.	(-10.0, 22.9)	(-1.6, 41.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-13.4 (13.67)	
95% C.I.	(-40.3, 13.5)	
p-value	0.32707	
Corrected Hedges' g	-0.58	
95% C.I.	(-1.87, 0.71)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	30
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Social Functioning

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	35.5 (3.96)	40.6 (3.63)
95% C.I.	(27.7, 43.3)	(33.4, 47.7)
LS Mean Change from Baseline (SE)	-2.9 (3.96)	2.2 (3.63)
95% C.I.	(-10.7, 4.9)	(-5.0, 9.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.0 (5.37)	
95% C.I.	(-15.6, 5.5)	
p-value	0.34818	
Corrected Hedges' g	-0.26	
95% C.I.	(-0.81, 0.29)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	26
LS Mean (SE)	30.2 (3.99)	35.3 (3.68)
95% C.I.	(22.3, 38.0)	(28.0, 42.5)
LS Mean Change from Baseline (SE)	-8.2 (3.99)	-3.1 (3.68)
95% C.I.	(-16.1, -0.4)	(-10.4, 4.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.1 (5.44)	
95% C.I.	(-15.8, 5.6)	
p-value	0.34913	
Corrected Hedges' g	-0.26	
95% C.I.	(-0.83, 0.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	26
LS Mean (SE)	28.7 (4.07)	34.6 (3.71)
95% C.I.	(20.7, 36.7)	(27.3, 41.9)
LS Mean Change from Baseline (SE)	-9.8 (4.07)	-3.8 (3.71)
95% C.I.	(-17.8, -1.8)	(-11.1, 3.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.9 (5.51)	
95% C.I.	(-16.8, 4.9)	
p-value	0.28344	
Corrected Hedges' g	-0.31	
95% C.I.	(-0.88, 0.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	25
LS Mean (SE)	30.9 (4.13)	39.4 (3.77)
95% C.I.	(22.8, 39.0)	(31.9, 46.8)
LS Mean Change from Baseline (SE)	-7.5 (4.13)	1.0 (3.77)
95% C.I.	(-15.6, 0.6)	(-6.5, 8.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.5 (5.59)	
95% C.I.	(-19.5, 2.5)	
p-value	0.13120	
Corrected Hedges' g	-0.44	
95% C.I.	(-1.03, 0.15)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	16	19
LS Mean (SE)	32.7 (4.49)	41.0 (4.11)
95% C.I.	(23.9, 41.5)	(33.0, 49.1)
LS Mean Change from Baseline (SE)	-5.7 (4.49)	2.6 (4.11)
95% C.I.	(-14.5, 3.1)	(-5.5, 10.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.3 (6.09)	
95% C.I.	(-20.3, 3.6)	
p-value	0.17208	
Corrected Hedges' g	-0.45	
95% C.I.	(-1.13, 0.22)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	30
n [2]	16	16
LS Mean (SE)	37.0 (4.60)	33.9 (4.42)
95% C.I.	(28.0, 46.1)	(25.2, 42.5)
LS Mean Change from Baseline (SE)	-1.4 (4.60)	-4.6 (4.42)
95% C.I.	(-10.4, 7.7)	(-13.3, 4.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.2 (6.37)	
95% C.I.	(-9.4, 15.7)	
p-value	0.61837	
Corrected Hedges' g	0.17	
95% C.I.	(-0.52, 0.87)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	14	17
LS Mean (SE)	34.2 (4.82)	39.7 (4.58)
95% C.I.	(24.8, 43.7)	(30.7, 48.7)
LS Mean Change from Baseline (SE)	-4.2 (4.82)	1.2 (4.58)
95% C.I.	(-13.7, 5.3)	(-7.8, 10.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.4 (6.57)	
95% C.I.	(-18.4, 7.5)	
p-value	0.40952	
Corrected Hedges' g	-0.29	
95% C.I.	(-1.00, 0.43)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	30
n [2]	15	12
LS Mean (SE)	36.2 (4.80)	38.0 (5.25)
95% C.I.	(26.8, 45.6)	(27.7, 48.4)
LS Mean Change from Baseline (SE)	-2.2 (4.80)	-0.4 (5.25)
95% C.I.	(-11.6, 7.2)	(-10.7, 10.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.8 (7.07)	
95% C.I.	(-15.7, 12.1)	
p-value	0.79476	
Corrected Hedges' g	-0.10	
95% C.I.	(-0.86, 0.66)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	37.9 (5.04)	38.1 (5.72)
95% C.I.	(28.0, 47.9)	(26.8, 49.3)
LS Mean Change from Baseline (SE)	-0.5 (5.04)	-0.3 (5.72)
95% C.I.	(-10.4, 9.4)	(-11.6, 10.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.1 (7.66)	
95% C.I.	(-15.2, 14.9)	
p-value	0.98548	
Corrected Hedges' g	-0.01	
95% C.I.	(-0.86, 0.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	30
n [2]	13	12
LS Mean (SE)	43.4 (5.17)	39.2 (5.47)
95% C.I.	(33.2, 53.6)	(28.5, 50.0)
LS Mean Change from Baseline (SE)	5.0 (5.17)	0.8 (5.47)
95% C.I.	(-5.2, 15.1)	(-9.9, 11.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.2 (7.63)	
95% C.I.	(-10.8, 19.2)	
p-value	0.58565	
Corrected Hedges' g	0.21	
95% C.I.	(-0.57, 1.00)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	14	10
LS Mean (SE)	38.1 (5.08)	40.1 (5.82)
95% C.I.	(28.1, 48.1)	(28.6, 51.5)
LS Mean Change from Baseline (SE)	-0.3 (5.08)	1.7 (5.82)
95% C.I.	(-10.3, 9.6)	(-9.8, 13.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.0 (7.74)	
95% C.I.	(-17.2, 13.2)	
p-value	0.79642	
Corrected Hedges' g	-0.10	
95% C.I.	(-0.91, 0.71)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	40.2 (5.58)	37.4 (6.03)
95% C.I.	(29.2, 51.2)	(25.5, 49.3)
LS Mean Change from Baseline (SE)	1.8 (5.58)	-1.0 (6.03)
95% C.I.	(-9.2, 12.7)	(-12.9, 10.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.8 (8.28)	
95% C.I.	(-13.5, 19.1)	
p-value	0.73583	
Corrected Hedges' g	0.15	
95% C.I.	(-0.74, 1.03)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	9	11
LS Mean (SE)	38.3 (5.97)	39.7 (5.73)
95% C.I.	(26.5, 50.0)	(28.5, 51.0)
LS Mean Change from Baseline (SE)	-0.2 (5.97)	1.3 (5.73)
95% C.I.	(-11.9, 11.6)	(-10.0, 12.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.5 (8.37)	
95% C.I.	(-17.9, 15.0)	
p-value	0.85951	
Corrected Hedges' g	-0.08	
95% C.I.	(-0.96, 0.80)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	37.6 (5.71)	32.7 (6.27)
95% C.I.	(26.4, 48.9)	(20.4, 45.0)
LS Mean Change from Baseline (SE)	-0.8 (5.71)	-5.7 (6.27)
95% C.I.	(-12.0, 10.4)	(-18.0, 6.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.9 (8.63)	
95% C.I.	(-12.1, 21.9)	
p-value	0.56976	
Corrected Hedges' g	0.25	
95% C.I.	(-0.64, 1.13)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	34.8 (5.73)	31.5 (7.24)
95% C.I.	(23.5, 46.0)	(17.3, 45.8)
LS Mean Change from Baseline (SE)	-3.7 (5.73)	-6.9 (7.24)
95% C.I.	(-14.9, 7.6)	(-21.1, 7.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.2 (9.29)	
95% C.I.	(-15.0, 21.5)	
p-value	0.72870	
Corrected Hedges' g	0.16	
95% C.I.	(-0.83, 1.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	37.3 (5.94)	25.9 (7.49)
95% C.I.	(25.7, 49.0)	(11.2, 40.7)
LS Mean Change from Baseline (SE)	-1.1 (5.94)	-12.5 (7.49)
95% C.I.	(-12.8, 10.6)	(-27.2, 2.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.4 (9.60)	
95% C.I.	(-7.5, 30.3)	
p-value	0.23558	
Corrected Hedges' g	0.58	
95% C.I.	(-0.45, 1.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	9	7
LS Mean (SE)	32.5 (6.09)	21.1 (7.29)
95% C.I.	(20.5, 44.4)	(6.8, 35.4)
LS Mean Change from Baseline (SE)	-6.0 (6.09)	-17.3 (7.29)
95% C.I.	(-17.9, 6.0)	(-31.7, -3.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.4 (9.54)	
95% C.I.	(-7.4, 30.1)	
p-value	0.23363	
Corrected Hedges' g	0.58	
95% C.I.	(-0.43, 1.58)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	33.6 (5.99)	17.4 (7.46)
95% C.I.	(21.8, 45.4)	(2.7, 32.1)
LS Mean Change from Baseline (SE)	-4.8 (5.99)	-21.0 (7.46)
95% C.I.	(-16.6, 7.0)	(-35.7, -6.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	16.2 (9.56)	
95% C.I.	(-2.6, 35.0)	
p-value	0.09135	
Corrected Hedges' g	0.82	
95% C.I.	(-0.23, 1.87)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	39.7 (6.78)	21.8 (7.53)
95% C.I.	(26.4, 53.1)	(7.0, 36.6)
LS Mean Change from Baseline (SE)	1.3 (6.78)	-16.6 (7.53)
95% C.I.	(-12.0, 14.6)	(-31.4, -1.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	17.9 (10.14)	
95% C.I.	(-2.0, 37.9)	
p-value	0.07763	
Corrected Hedges' g	0.92	
95% C.I.	(-0.23, 2.06)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	36.2 (6.99)	21.1 (7.97)
95% C.I.	(22.5, 50.0)	(5.4, 36.8)
LS Mean Change from Baseline (SE)	-2.2 (6.99)	-17.3 (7.97)
95% C.I.	(-15.9, 11.5)	(-33.0, -1.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.1 (10.59)	
95% C.I.	(-5.7, 35.9)	
p-value	0.15465	
Corrected Hedges' g	0.77	
95% C.I.	(-0.42, 1.95)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	37.4 (6.82)	19.2 (8.04)
95% C.I.	(24.0, 50.8)	(3.4, 35.0)
LS Mean Change from Baseline (SE)	-1.0 (6.82)	-19.2 (8.04)
95% C.I.	(-14.4, 12.4)	(-35.0, -3.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	18.2 (10.47)	
95% C.I.	(-2.4, 38.8)	
p-value	0.08314	
Corrected Hedges' g	0.88	
95% C.I.	(-0.23, 1.98)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	36.3 (7.04)	30.2 (8.27)
95% C.I.	(22.4, 50.1)	(14.0, 46.5)
LS Mean Change from Baseline (SE)	-2.1 (7.04)	-8.2 (8.27)
95% C.I.	(-16.0, 11.7)	(-24.5, 8.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.0 (10.84)	
95% C.I.	(-15.3, 27.4)	
p-value	0.57795	
Corrected Hedges' g	0.30	
95% C.I.	(-0.85, 1.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	35.1 (6.82)	19.7 (8.44)
95% C.I.	(21.7, 48.5)	(3.1, 36.3)
LS Mean Change from Baseline (SE)	-3.3 (6.82)	-18.7 (8.44)
95% C.I.	(-16.7, 10.1)	(-35.3, -2.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.4 (10.81)	
95% C.I.	(-5.8, 36.7)	
p-value	0.15430	
Corrected Hedges' g	0.75	
95% C.I.	(-0.40, 1.90)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	43.5 (6.99)	27.8 (8.34)
95% C.I.	(29.8, 57.3)	(11.4, 44.3)
LS Mean Change from Baseline (SE)	5.1 (6.99)	-10.6 (8.34)
95% C.I.	(-8.6, 18.9)	(-27.0, 5.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.7 (10.90)	
95% C.I.	(-5.8, 37.1)	
p-value	0.15119	
Corrected Hedges' g	0.78	
95% C.I.	(-0.41, 1.97)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	39.5 (7.02)	24.2 (7.87)
95% C.I.	(25.7, 53.3)	(8.7, 39.7)
LS Mean Change from Baseline (SE)	1.1 (7.02)	-14.2 (7.87)
95% C.I.	(-12.7, 14.9)	(-29.7, 1.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.4 (10.52)	
95% C.I.	(-5.3, 36.0)	
p-value	0.14535	
Corrected Hedges' g	0.76	
95% C.I.	(-0.37, 1.88)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	41.5 (7.42)	24.8 (8.24)
95% C.I.	(27.0, 56.1)	(8.6, 41.0)
LS Mean Change from Baseline (SE)	3.1 (7.42)	-13.6 (8.24)
95% C.I.	(-11.5, 17.7)	(-29.9, 2.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	16.8 (11.11)	
95% C.I.	(-5.1, 38.6)	
p-value	0.13240	
Corrected Hedges' g	0.84	
95% C.I.	(-0.40, 2.08)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	37.5 (7.26)	18.2 (8.19)
95% C.I.	(23.2, 51.7)	(2.1, 34.3)
LS Mean Change from Baseline (SE)	-1.0 (7.26)	-20.2 (8.19)
95% C.I.	(-15.3, 13.3)	(-36.3, -4.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	19.2 (11.00)	
95% C.I.	(-2.4, 40.9)	
p-value	0.08116	
Corrected Hedges' g	0.91	
95% C.I.	(-0.23, 2.06)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	36.9 (7.32)	33.3 (8.52)
95% C.I.	(22.5, 51.3)	(16.6, 50.1)
LS Mean Change from Baseline (SE)	-1.5 (7.32)	-5.1 (8.52)
95% C.I.	(-15.9, 12.9)	(-21.9, 11.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.6 (11.27)	
95% C.I.	(-18.6, 25.8)	
p-value	0.74949	
Corrected Hedges' g	0.17	
95% C.I.	(-0.98, 1.32)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	34.7 (7.81)	25.0 (9.08)
95% C.I.	(19.3, 50.1)	(7.2, 42.9)
LS Mean Change from Baseline (SE)	-3.7 (7.81)	-13.4 (9.08)
95% C.I.	(-19.1, 11.6)	(-31.2, 4.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.7 (12.08)	
95% C.I.	(-14.1, 33.4)	
p-value	0.42487	
Corrected Hedges' g	0.46	
95% C.I.	(-0.82, 1.75)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	39.1 (8.13)	28.4 (8.75)
95% C.I.	(23.1, 55.0)	(11.2, 45.6)
LS Mean Change from Baseline (SE)	0.6 (8.13)	-10.0 (8.75)
95% C.I.	(-15.3, 16.6)	(-27.2, 7.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.6 (11.93)	
95% C.I.	(-12.9, 34.1)	
p-value	0.37405	
Corrected Hedges' g	0.51	
95% C.I.	(-0.75, 1.77)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	46.4 (7.84)	31.5 (8.76)
95% C.I.	(31.0, 61.8)	(14.3, 48.8)
LS Mean Change from Baseline (SE)	8.0 (7.84)	-6.9 (8.76)
95% C.I.	(-7.4, 23.4)	(-24.1, 10.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.9 (11.65)	
95% C.I.	(-8.0, 37.8)	
p-value	0.20237	
Corrected Hedges' g	0.70	
95% C.I.	(-0.52, 1.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	37.4 (7.91)	35.7 (9.44)
95% C.I.	(21.9, 53.0)	(17.1, 54.2)
LS Mean Change from Baseline (SE)	-1.0 (7.91)	-2.8 (9.44)
95% C.I.	(-16.5, 14.6)	(-21.3, 15.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.8 (12.54)	
95% C.I.	(-22.9, 26.4)	
p-value	0.88809	
Corrected Hedges' g	0.08	
95% C.I.	(-1.18, 1.35)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	24	29
n [2]	23	27
LS Mean (SE)	4.5 (2.63)	4.6 (2.44)
95% C.I.	(-0.7, 9.7)	(-0.2, 9.4)
LS Mean Change from Baseline (SE)	-1.9 (2.63)	-1.7 (2.44)
95% C.I.	(-7.0, 3.3)	(-6.5, 3.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.2 (3.59)	
95% C.I.	(-7.2, 6.9)	
p-value	0.96528	
Corrected Hedges' g	-0.01	
95% C.I.	(-0.57, 0.54)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	24	29
n [2]	21	25
LS Mean (SE)	5.6 (2.71)	7.2 (2.52)
95% C.I.	(0.3, 10.9)	(2.2, 12.1)
LS Mean Change from Baseline (SE)	-0.8 (2.71)	0.8 (2.52)
95% C.I.	(-6.1, 4.6)	(-4.1, 5.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.6 (3.72)	
95% C.I.	(-8.9, 5.7)	
p-value	0.67239	
Corrected Hedges' g	-0.12	
95% C.I.	(-0.70, 0.46)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	24	29
n [2]	21	25
LS Mean (SE)	4.9 (2.72)	2.8 (2.52)
95% C.I.	(-0.4, 10.3)	(-2.2, 7.8)
LS Mean Change from Baseline (SE)	-1.4 (2.72)	-3.6 (2.52)
95% C.I.	(-6.8, 3.9)	(-8.5, 1.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.1 (3.72)	
95% C.I.	(-5.2, 9.5)	
p-value	0.56546	
Corrected Hedges' g	0.17	
95% C.I.	(-0.41, 0.75)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	24	29
n [2]	20	25
LS Mean (SE)	4.1 (2.78)	9.5 (2.54)
95% C.I.	(-1.4, 9.6)	(4.5, 14.5)
LS Mean Change from Baseline (SE)	-2.3 (2.78)	3.2 (2.54)
95% C.I.	(-7.8, 3.2)	(-1.8, 8.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.4 (3.79)	
95% C.I.	(-12.9, 2.0)	
p-value	0.15210	
Corrected Hedges' g	-0.42	
95% C.I.	(-1.02, 0.17)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	24	29
n [2]	15	19
LS Mean (SE)	8.6 (3.12)	6.3 (2.79)
95% C.I.	(2.5, 14.7)	(0.8, 11.8)
LS Mean Change from Baseline (SE)	2.2 (3.12)	0.0 (2.79)
95% C.I.	(-3.9, 8.4)	(-5.5, 5.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.3 (4.20)	
95% C.I.	(-6.0, 10.5)	
p-value	0.58989	
Corrected Hedges' g	0.18	
95% C.I.	(-0.50, 0.86)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	24	29
n [2]	15	16
LS Mean (SE)	6.7 (3.17)	9.9 (3.03)
95% C.I.	(0.5, 12.9)	(4.0, 15.9)
LS Mean Change from Baseline (SE)	0.3 (3.17)	3.6 (3.03)
95% C.I.	(-5.9, 6.6)	(-2.4, 9.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.2 (4.40)	
95% C.I.	(-11.9, 5.4)	
p-value	0.46298	
Corrected Hedges' g	-0.26	
95% C.I.	(-0.97, 0.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	24	29
n [2]	13	17
LS Mean (SE)	9.5 (3.35)	7.7 (3.01)
95% C.I.	(2.9, 16.1)	(1.8, 13.6)
LS Mean Change from Baseline (SE)	3.1 (3.35)	1.3 (3.01)
95% C.I.	(-3.4, 9.7)	(-4.6, 7.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.8 (4.52)	
95% C.I.	(-7.0, 10.7)	
p-value	0.68400	
Corrected Hedges' g	0.15	
95% C.I.	(-0.58, 0.87)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	24	29
n [2]	14	12
LS Mean (SE)	6.8 (3.31)	5.9 (3.47)
95% C.I.	(0.3, 13.3)	(-1.0, 12.7)
LS Mean Change from Baseline (SE)	0.5 (3.31)	-0.5 (3.47)
95% C.I.	(-6.0, 7.0)	(-7.3, 6.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.0 (4.80)	
95% C.I.	(-8.5, 10.4)	
p-value	0.84111	
Corrected Hedges' g	0.08	
95% C.I.	(-0.69, 0.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	24	29
n [2]	12	9
LS Mean (SE)	9.6 (3.54)	4.7 (3.92)
95% C.I.	(2.7, 16.6)	(-3.0, 12.4)
LS Mean Change from Baseline (SE)	3.3 (3.54)	-1.6 (3.92)
95% C.I.	(-3.7, 10.2)	(-9.3, 6.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.9 (5.29)	
95% C.I.	(-5.5, 15.3)	
p-value	0.35346	
Corrected Hedges' g	0.39	
95% C.I.	(-0.48, 1.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	24	29
n [2]	11	12
LS Mean (SE)	6.5 (3.65)	8.6 (3.59)
95% C.I.	(-0.6, 13.7)	(1.6, 15.7)
LS Mean Change from Baseline (SE)	0.2 (3.65)	2.2 (3.59)
95% C.I.	(-7.0, 7.3)	(-4.8, 9.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.1 (5.13)	
95% C.I.	(-12.2, 8.0)	
p-value	0.68514	
Corrected Hedges' g	-0.16	
95% C.I.	(-0.98, 0.66)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	24	29
n [2]	13	10
LS Mean (SE)	10.8 (3.51)	6.2 (3.88)
95% C.I.	(3.9, 17.7)	(-1.5, 13.8)
LS Mean Change from Baseline (SE)	4.5 (3.51)	-0.2 (3.88)
95% C.I.	(-2.4, 11.4)	(-7.8, 7.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.7 (5.21)	
95% C.I.	(-5.6, 14.9)	
p-value	0.36945	
Corrected Hedges' g	0.36	
95% C.I.	(-0.47, 1.19)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	24	29
n [2]	10	9
LS Mean (SE)	14.0 (3.86)	5.3 (4.05)
95% C.I.	(6.4, 21.6)	(-2.7, 13.3)
LS Mean Change from Baseline (SE)	7.7 (3.86)	-1.1 (4.05)
95% C.I.	(0.1, 15.2)	(-9.0, 6.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	8.7 (5.60)	
95% C.I.	(-2.3, 19.7)	
p-value	0.12033	
Corrected Hedges' g	0.68	
95% C.I.	(-0.24, 1.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	24	29
n [2]	8	11
LS Mean (SE)	10.6 (4.22)	10.3 (3.77)
95% C.I.	(2.3, 18.9)	(2.9, 17.7)
LS Mean Change from Baseline (SE)	4.3 (4.22)	3.9 (3.77)
95% C.I.	(-4.0, 12.6)	(-3.5, 11.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.4 (5.67)	
95% C.I.	(-10.8, 11.5)	
p-value	0.95045	
Corrected Hedges' g	0.03	
95% C.I.	(-0.88, 0.94)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	24	29
n [2]	10	9
LS Mean (SE)	11.2 (3.94)	6.0 (4.07)
95% C.I.	(3.4, 18.9)	(-2.0, 14.0)
LS Mean Change from Baseline (SE)	4.8 (3.94)	-0.4 (4.07)
95% C.I.	(-3.0, 12.5)	(-8.4, 7.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.2 (5.66)	
95% C.I.	(-6.0, 16.3)	
p-value	0.36124	
Corrected Hedges' g	0.40	
95% C.I.	(-0.51, 1.31)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	24	29
n [2]	10	6
LS Mean (SE)	11.0 (3.92)	3.8 (4.92)
95% C.I.	(3.3, 18.7)	(-5.9, 13.5)
LS Mean Change from Baseline (SE)	4.6 (3.92)	-2.6 (4.92)
95% C.I.	(-3.1, 12.3)	(-12.2, 7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.2 (6.30)	
95% C.I.	(-5.2, 19.6)	
p-value	0.25620	
Corrected Hedges' g	0.55	
95% C.I.	(-0.48, 1.58)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	24	29
n [2]	9	6
LS Mean (SE)	12.1 (4.10)	3.2 (5.04)
95% C.I.	(4.0, 20.1)	(-6.7, 13.1)
LS Mean Change from Baseline (SE)	5.7 (4.10)	-3.2 (5.04)
95% C.I.	(-2.4, 13.8)	(-13.1, 6.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	8.9 (6.49)	
95% C.I.	(-3.9, 21.6)	
p-value	0.17273	
Corrected Hedges' g	0.68	
95% C.I.	(-0.38, 1.74)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	24	29
n [2]	8	7
LS Mean (SE)	8.2 (4.29)	2.6 (4.76)
95% C.I.	(-0.2, 16.7)	(-6.8, 12.0)
LS Mean Change from Baseline (SE)	1.9 (4.29)	-3.7 (4.76)
95% C.I.	(-6.6, 10.3)	(-13.1, 5.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.6 (6.42)	
95% C.I.	(-7.0, 18.2)	
p-value	0.38125	
Corrected Hedges' g	0.43	
95% C.I.	(-0.60, 1.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	24	29
n [2]	9	6
LS Mean (SE)	7.9 (4.16)	2.3 (5.02)
95% C.I.	(-0.2, 16.1)	(-7.6, 12.2)
LS Mean Change from Baseline (SE)	1.6 (4.16)	-4.1 (5.02)
95% C.I.	(-6.6, 9.8)	(-13.9, 5.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.6 (6.53)	
95% C.I.	(-7.2, 18.5)	
p-value	0.38876	
Corrected Hedges' g	0.43	
95% C.I.	(-0.62, 1.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	14.8 (4.97)	2.7 (5.19)
95% C.I.	(5.1, 24.6)	(-7.5, 12.9)
LS Mean Change from Baseline (SE)	8.4 (4.97)	-3.7 (5.19)
95% C.I.	(-1.3, 18.2)	(-13.8, 6.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.1 (7.29)	
95% C.I.	(-2.2, 26.4)	
p-value	0.09768	
Corrected Hedges' g	0.90	
95% C.I.	(-0.29, 2.09)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	15.7 (5.08)	13.6 (5.82)
95% C.I.	(5.7, 25.7)	(2.1, 25.0)
LS Mean Change from Baseline (SE)	9.3 (5.08)	7.2 (5.82)
95% C.I.	(-0.7, 19.3)	(-4.2, 18.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.1 (7.92)	
95% C.I.	(-13.4, 17.7)	
p-value	0.78794	
Corrected Hedges' g	0.15	
95% C.I.	(-1.04, 1.34)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	24	29
n [2]	7	6
LS Mean (SE)	4.4 (4.78)	5.0 (5.58)
95% C.I.	(-5.0, 13.8)	(-6.0, 15.9)
LS Mean Change from Baseline (SE)	-1.9 (4.78)	-1.4 (5.58)
95% C.I.	(-11.4, 7.5)	(-12.4, 9.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.6 (7.45)	
95% C.I.	(-15.2, 14.1)	
p-value	0.94077	
Corrected Hedges' g	-0.04	
95% C.I.	(-1.13, 1.05)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	6.8 (5.05)	7.1 (6.02)
95% C.I.	(-3.1, 16.8)	(-4.8, 18.9)
LS Mean Change from Baseline (SE)	0.5 (5.05)	0.7 (6.02)
95% C.I.	(-9.5, 10.4)	(-11.1, 12.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.2 (8.05)	
95% C.I.	(-16.1, 15.6)	
p-value	0.97572	
Corrected Hedges' g	-0.02	
95% C.I.	(-1.20, 1.17)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	24	29
n [2]	7	5
LS Mean (SE)	4.2 (4.78)	6.3 (6.12)
95% C.I.	(-5.2, 13.6)	(-5.7, 18.4)
LS Mean Change from Baseline (SE)	-2.2 (4.78)	0.0 (6.12)
95% C.I.	(-11.6, 7.2)	(-12.0, 12.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.2 (7.85)	
95% C.I.	(-17.6, 13.3)	
p-value	0.78313	
Corrected Hedges' g	-0.15	
95% C.I.	(-1.30, 1.00)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	7.4 (5.00)	6.8 (6.07)
95% C.I.	(-2.5, 17.2)	(-5.1, 18.8)
LS Mean Change from Baseline (SE)	1.0 (5.00)	0.5 (6.07)
95% C.I.	(-8.8, 10.8)	(-11.5, 12.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.5 (8.05)	
95% C.I.	(-15.3, 16.4)	
p-value	0.94633	
Corrected Hedges' g	0.04	
95% C.I.	(-1.15, 1.23)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	3.5 (5.36)	7.3 (5.52)
95% C.I.	(-7.1, 14.0)	(-3.6, 18.1)
LS Mean Change from Baseline (SE)	-2.9 (5.36)	0.9 (5.52)
95% C.I.	(-13.4, 7.6)	(-9.9, 11.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.8 (7.21)	
95% C.I.	(-18.0, 10.4)	
p-value	0.59786	
Corrected Hedges' g	-0.26	
95% C.I.	(-1.40, 0.87)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	24	29
n [2]	5	5
LS Mean (SE)	13.4 (5.83)	6.5 (6.98)
95% C.I.	(2.0, 24.9)	(-7.2, 20.3)
LS Mean Change from Baseline (SE)	7.1 (5.83)	0.2 (6.98)
95% C.I.	(-4.4, 18.5)	(-13.5, 13.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.9 (8.11)	
95% C.I.	(-9.0, 22.8)	
p-value	0.39541	
Corrected Hedges' g	0.43	
95% C.I.	(-0.82, 1.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	9.7 (5.20)	6.2 (5.75)
95% C.I.	(-0.5, 19.9)	(-5.1, 17.5)
LS Mean Change from Baseline (SE)	3.4 (5.20)	-0.2 (5.75)
95% C.I.	(-6.9, 13.6)	(-11.5, 11.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.5 (8.00)	
95% C.I.	(-12.2, 19.3)	
p-value	0.65789	
Corrected Hedges' g	0.24	
95% C.I.	(-0.89, 1.38)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	9.9 (5.22)	3.2 (6.11)
95% C.I.	(-0.4, 20.1)	(-8.8, 15.3)
LS Mean Change from Baseline (SE)	3.5 (5.22)	-3.1 (6.11)
95% C.I.	(-6.8, 13.8)	(-15.1, 8.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.6 (8.29)	
95% C.I.	(-9.7, 22.9)	
p-value	0.42525	
Corrected Hedges' g	0.46	
95% C.I.	(-0.74, 1.66)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	24	29
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	24	29
n [2]	4	5

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	24	29
n [2]	5	5
LS Mean (SE)	7.3 (5.71)	12.5 (6.23)
95% C.I.	(-4.0, 18.5)	(0.3, 24.8)
LS Mean Change from Baseline (SE)	0.9 (5.71)	6.1 (6.23)
95% C.I.	(-10.3, 12.1)	(-6.1, 18.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.2 (8.88)	
95% C.I.	(-22.7, 12.2)	
p-value	0.55563	
Corrected Hedges' g	-0.35	
95% C.I.	(-1.60, 0.90)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	24	29
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	24	29
n [2]	3	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	24	29
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	24	29
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	24	29
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	24	29
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	24	29
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	24	29
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	24	29
n [2]	4	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	24	29
n [2]	2	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	24	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	24	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	24	29
n [2]	0	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	24	29
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	24	29
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Nausea and vomiting

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	26.6 (4.12)	23.9 (3.80)
95% C.I.	(18.5, 34.7)	(16.4, 31.4)
LS Mean Change from Baseline (SE)	-14.1 (4.12)	-16.8 (3.80)
95% C.I.	(-22.2, -6.0)	(-24.3, -9.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.7 (5.61)	
95% C.I.	(-8.3, 13.8)	
p-value	0.62756	
Corrected Hedges' g	0.13	
95% C.I.	(-0.41, 0.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	26
LS Mean (SE)	23.4 (4.17)	24.3 (3.87)
95% C.I.	(15.2, 31.6)	(16.7, 31.9)
LS Mean Change from Baseline (SE)	-17.4 (4.17)	-16.5 (3.87)
95% C.I.	(-25.6, -9.2)	(-24.1, -8.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.9 (5.69)	
95% C.I.	(-12.1, 10.3)	
p-value	0.87404	
Corrected Hedges' g	-0.04	
95% C.I.	(-0.61, 0.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	26
LS Mean (SE)	25.8 (4.24)	27.7 (3.90)
95% C.I.	(17.4, 34.1)	(20.0, 35.4)
LS Mean Change from Baseline (SE)	-14.9 (4.24)	-13.0 (3.90)
95% C.I.	(-23.3, -6.6)	(-20.7, -5.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.9 (5.76)	
95% C.I.	(-13.2, 9.4)	
p-value	0.74206	
Corrected Hedges' g	-0.09	
95% C.I.	(-0.66, 0.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	25
LS Mean (SE)	25.7 (4.34)	33.3 (3.96)
95% C.I.	(17.2, 34.3)	(25.5, 41.1)
LS Mean Change from Baseline (SE)	-15.0 (4.34)	-7.4 (3.96)
95% C.I.	(-23.5, -6.5)	(-15.2, 0.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.6 (5.89)	
95% C.I.	(-19.1, 4.0)	
p-value	0.20065	
Corrected Hedges' g	-0.37	
95% C.I.	(-0.96, 0.21)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	16	19
LS Mean (SE)	27.9 (4.80)	30.8 (4.36)
95% C.I.	(18.4, 37.3)	(22.2, 39.4)
LS Mean Change from Baseline (SE)	-12.8 (4.80)	-9.9 (4.36)
95% C.I.	(-22.3, -3.4)	(-18.5, -1.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.9 (6.52)	
95% C.I.	(-15.7, 9.9)	
p-value	0.65490	
Corrected Hedges' g	-0.15	
95% C.I.	(-0.82, 0.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	30
n [2]	17	16
LS Mean (SE)	33.3 (4.79)	26.4 (4.69)
95% C.I.	(23.8, 42.7)	(17.2, 35.6)
LS Mean Change from Baseline (SE)	-7.5 (4.79)	-14.3 (4.69)
95% C.I.	(-16.9, 2.0)	(-23.5, -5.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.9 (6.73)	
95% C.I.	(-6.4, 20.1)	
p-value	0.30924	
Corrected Hedges' g	0.35	
95% C.I.	(-0.34, 1.03)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	14	17
LS Mean (SE)	30.0 (5.24)	33.2 (4.77)
95% C.I.	(19.7, 40.3)	(23.8, 42.5)
LS Mean Change from Baseline (SE)	-10.7 (5.24)	-7.6 (4.77)
95% C.I.	(-21.0, -0.4)	(-16.9, 1.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.1 (6.96)	
95% C.I.	(-16.8, 10.6)	
p-value	0.65258	
Corrected Hedges' g	-0.16	
95% C.I.	(-0.86, 0.55)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	30
n [2]	15	12
LS Mean (SE)	30.3 (5.19)	25.0 (5.43)
95% C.I.	(20.1, 40.5)	(14.3, 35.7)
LS Mean Change from Baseline (SE)	-10.4 (5.19)	-15.7 (5.43)
95% C.I.	(-20.7, -0.2)	(-26.4, -5.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.3 (7.40)	
95% C.I.	(-9.3, 19.8)	
p-value	0.47646	
Corrected Hedges' g	0.26	
95% C.I.	(-0.50, 1.02)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	34.1 (5.36)	22.0 (6.05)
95% C.I.	(23.5, 44.6)	(10.1, 33.8)
LS Mean Change from Baseline (SE)	-6.6 (5.36)	-18.8 (6.05)
95% C.I.	(-17.2, 3.9)	(-30.7, -6.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.1 (8.11)	
95% C.I.	(-3.8, 28.1)	
p-value	0.13539	
Corrected Hedges' g	0.62	
95% C.I.	(-0.25, 1.49)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	30
n [2]	13	12
LS Mean (SE)	26.3 (5.39)	18.9 (5.65)
95% C.I.	(15.7, 36.9)	(7.8, 30.0)
LS Mean Change from Baseline (SE)	-14.5 (5.39)	-21.9 (5.65)
95% C.I.	(-25.1, -3.9)	(-33.0, -10.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.4 (7.80)	
95% C.I.	(-7.9, 22.7)	
p-value	0.34425	
Corrected Hedges' g	0.37	
95% C.I.	(-0.42, 1.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	14	10
LS Mean (SE)	29.5 (5.40)	24.4 (6.08)
95% C.I.	(18.8, 40.1)	(12.5, 36.4)
LS Mean Change from Baseline (SE)	-11.3 (5.40)	-16.3 (6.08)
95% C.I.	(-21.9, -0.6)	(-28.2, -4.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.0 (8.14)	
95% C.I.	(-11.0, 21.0)	
p-value	0.53754	
Corrected Hedges' g	0.24	
95% C.I.	(-0.57, 1.06)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	34.9 (5.82)	32.5 (6.35)
95% C.I.	(23.5, 46.4)	(20.0, 45.0)
LS Mean Change from Baseline (SE)	-5.8 (5.82)	-8.2 (6.35)
95% C.I.	(-17.2, 5.7)	(-20.7, 4.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.4 (8.62)	
95% C.I.	(-14.5, 19.4)	
p-value	0.77841	
Corrected Hedges' g	0.12	
95% C.I.	(-0.76, 1.00)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	9	11
LS Mean (SE)	33.3 (6.27)	25.8 (5.96)
95% C.I.	(21.0, 45.6)	(14.1, 37.5)
LS Mean Change from Baseline (SE)	-7.4 (6.27)	-14.9 (5.96)
95% C.I.	(-19.7, 4.9)	(-26.7, -3.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.5 (8.62)	
95% C.I.	(-9.4, 24.5)	
p-value	0.38421	
Corrected Hedges' g	0.37	
95% C.I.	(-0.52, 1.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	29.6 (5.97)	24.1 (6.48)
95% C.I.	(17.9, 41.4)	(11.3, 36.8)
LS Mean Change from Baseline (SE)	-11.1 (5.97)	-16.7 (6.48)
95% C.I.	(-22.9, 0.6)	(-29.4, -3.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.5 (8.77)	
95% C.I.	(-11.7, 22.8)	
p-value	0.52825	
Corrected Hedges' g	0.27	
95% C.I.	(-0.61, 1.15)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	37.8 (5.97)	22.6 (7.70)
95% C.I.	(26.1, 49.6)	(7.5, 37.7)
LS Mean Change from Baseline (SE)	-2.9 (5.97)	-18.1 (7.70)
95% C.I.	(-14.6, 8.9)	(-33.2, -3.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.2 (9.77)	
95% C.I.	(-4.0, 34.4)	
p-value	0.12023	
Corrected Hedges' g	0.74	
95% C.I.	(-0.28, 1.77)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	32.7 (6.17)	23.4 (7.95)
95% C.I.	(20.6, 44.8)	(7.7, 39.0)
LS Mean Change from Baseline (SE)	-8.0 (6.17)	-17.4 (7.95)
95% C.I.	(-20.2, 4.1)	(-33.0, -1.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.3 (10.08)	
95% C.I.	(-10.5, 29.1)	
p-value	0.35538	
Corrected Hedges' g	0.45	
95% C.I.	(-0.57, 1.48)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	9	7
LS Mean (SE)	26.2 (6.49)	20.8 (7.57)
95% C.I.	(13.5, 39.0)	(5.9, 35.7)
LS Mean Change from Baseline (SE)	-14.5 (6.49)	-19.9 (7.57)
95% C.I.	(-27.2, -1.7)	(-34.8, -5.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.5 (9.98)	
95% C.I.	(-14.2, 25.1)	
p-value	0.58484	
Corrected Hedges' g	0.26	
95% C.I.	(-0.73, 1.25)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	22.0 (6.48)	17.0 (7.96)
95% C.I.	(9.3, 34.8)	(1.4, 32.7)
LS Mean Change from Baseline (SE)	-18.7 (6.48)	-23.7 (7.96)
95% C.I.	(-31.5, -6.0)	(-39.3, -8.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.0 (10.43)	
95% C.I.	(-15.5, 25.5)	
p-value	0.63316	
Corrected Hedges' g	0.23	
95% C.I.	(-0.78, 1.25)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	29.3 (7.23)	18.0 (8.29)
95% C.I.	(15.0, 43.5)	(1.7, 34.3)
LS Mean Change from Baseline (SE)	-11.5 (7.23)	-22.7 (8.29)
95% C.I.	(-25.7, 2.8)	(-39.0, -6.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.3 (11.08)	
95% C.I.	(-10.5, 33.0)	
p-value	0.31003	
Corrected Hedges' g	0.53	
95% C.I.	(-0.58, 1.64)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	31.9 (7.39)	18.5 (8.52)
95% C.I.	(17.3, 46.4)	(1.7, 35.2)
LS Mean Change from Baseline (SE)	-8.9 (7.39)	-22.2 (8.52)
95% C.I.	(-23.4, 5.7)	(-39.0, -5.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.4 (11.30)	
95% C.I.	(-8.8, 35.6)	
p-value	0.23675	
Corrected Hedges' g	0.64	
95% C.I.	(-0.54, 1.81)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	27.4 (7.16)	14.2 (7.99)
95% C.I.	(13.3, 41.5)	(-1.5, 29.9)
LS Mean Change from Baseline (SE)	-13.3 (7.16)	-26.5 (7.99)
95% C.I.	(-27.4, 0.8)	(-42.2, -10.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.2 (10.70)	
95% C.I.	(-7.8, 34.3)	
p-value	0.21794	
Corrected Hedges' g	0.62	
95% C.I.	(-0.46, 1.70)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	22.8 (7.40)	16.4 (8.76)
95% C.I.	(8.2, 37.3)	(-0.8, 33.7)
LS Mean Change from Baseline (SE)	-18.0 (7.40)	-24.3 (8.76)
95% C.I.	(-32.5, -3.4)	(-41.5, -7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.3 (11.49)	
95% C.I.	(-16.3, 28.9)	
p-value	0.58156	
Corrected Hedges' g	0.30	
95% C.I.	(-0.86, 1.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	25.4 (7.16)	11.0 (9.10)
95% C.I.	(11.4, 39.5)	(-6.9, 28.9)
LS Mean Change from Baseline (SE)	-15.3 (7.16)	-29.7 (9.10)
95% C.I.	(-29.4, -1.2)	(-47.6, -11.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.5 (11.66)	
95% C.I.	(-8.5, 37.4)	
p-value	0.21585	
Corrected Hedges' g	0.66	
95% C.I.	(-0.48, 1.81)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	27.0 (7.34)	27.4 (9.08)
95% C.I.	(12.5, 41.4)	(9.6, 45.3)
LS Mean Change from Baseline (SE)	-13.7 (7.34)	-13.3 (9.08)
95% C.I.	(-28.2, 0.7)	(-31.1, 4.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.5 (11.72)	
95% C.I.	(-23.5, 22.6)	
p-value	0.96852	
Corrected Hedges' g	-0.02	
95% C.I.	(-1.17, 1.13)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	22.7 (7.51)	13.5 (8.63)
95% C.I.	(7.9, 37.4)	(-3.5, 30.5)
LS Mean Change from Baseline (SE)	-18.1 (7.51)	-27.2 (8.63)
95% C.I.	(-32.8, -3.3)	(-44.2, -10.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.2 (11.78)	
95% C.I.	(-14.0, 32.3)	
p-value	0.43642	
Corrected Hedges' g	0.42	
95% C.I.	(-0.68, 1.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	23.4 (7.86)	25.2 (8.80)
95% C.I.	(8.0, 38.9)	(8.0, 42.5)
LS Mean Change from Baseline (SE)	-17.3 (7.86)	-15.5 (8.80)
95% C.I.	(-32.7, -1.8)	(-32.8, 1.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.8 (11.93)	
95% C.I.	(-25.3, 21.7)	
p-value	0.87947	
Corrected Hedges' g	-0.09	
95% C.I.	(-1.27, 1.10)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	34.9 (7.62)	13.4 (8.24)
95% C.I.	(19.9, 49.9)	(-2.8, 29.6)
LS Mean Change from Baseline (SE)	-5.8 (7.62)	-27.3 (8.24)
95% C.I.	(-20.8, 9.2)	(-43.5, -11.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	21.5 (11.24)	
95% C.I.	(-0.6, 43.6)	
p-value	0.05657	
Corrected Hedges' g	0.99	
95% C.I.	(-0.16, 2.15)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	23.3 (7.67)	26.1 (9.00)
95% C.I.	(8.2, 38.4)	(8.4, 43.8)
LS Mean Change from Baseline (SE)	-17.4 (7.67)	-14.7 (9.00)
95% C.I.	(-32.5, -2.3)	(-32.3, 3.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.8 (11.83)	
95% C.I.	(-26.1, 20.5)	
p-value	0.81399	
Corrected Hedges' g	-0.13	
95% C.I.	(-1.28, 1.02)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	25.3 (8.08)	24.0 (9.97)
95% C.I.	(9.4, 41.2)	(4.4, 43.6)
LS Mean Change from Baseline (SE)	-15.4 (8.08)	-16.8 (9.97)
95% C.I.	(-31.3, 0.5)	(-36.4, 2.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.4 (12.67)	
95% C.I.	(-23.6, 26.3)	
p-value	0.91515	
Corrected Hedges' g	0.06	
95% C.I.	(-1.20, 1.33)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	25.4 (8.51)	24.1 (9.42)
95% C.I.	(8.7, 42.1)	(5.5, 42.6)
LS Mean Change from Baseline (SE)	-15.3 (8.51)	-16.7 (9.42)
95% C.I.	(-32.1, 1.4)	(-35.2, 1.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.4 (12.72)	
95% C.I.	(-23.7, 26.4)	
p-value	0.91537	
Corrected Hedges' g	0.06	
95% C.I.	(-1.18, 1.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	30.1 (8.11)	20.0 (9.43)
95% C.I.	(14.1, 46.0)	(1.4, 38.5)
LS Mean Change from Baseline (SE)	-10.6 (8.11)	-20.7 (9.43)
95% C.I.	(-26.6, 5.3)	(-39.3, -2.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.1 (12.60)	
95% C.I.	(-14.7, 34.9)	
p-value	0.42325	
Corrected Hedges' g	0.45	
95% C.I.	(-0.75, 1.65)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	27.6 (8.13)	19.6 (9.96)
95% C.I.	(11.6, 43.6)	(0.0, 39.2)
LS Mean Change from Baseline (SE)	-13.1 (8.13)	-21.1 (9.96)
95% C.I.	(-29.1, 2.9)	(-40.7, -1.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	8.0 (12.79)	
95% C.I.	(-17.2, 33.1)	
p-value	0.53389	
Corrected Hedges' g	0.36	
95% C.I.	(-0.91, 1.64)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	29
n [2]	24	27
LS Mean (SE)	25.1 (4.17)	16.0 (3.80)
95% C.I.	(16.9, 33.3)	(8.5, 23.5)
LS Mean Change from Baseline (SE)	5.0 (4.17)	-4.1 (3.80)
95% C.I.	(-3.2, 13.2)	(-11.6, 3.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.1 (5.66)	
95% C.I.	(-2.0, 20.2)	
p-value	0.10828	
Corrected Hedges' g	0.45	
95% C.I.	(-0.11, 1.00)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	29
n [2]	23	25
LS Mean (SE)	23.4 (4.21)	14.7 (3.89)
95% C.I.	(15.1, 31.7)	(7.0, 22.3)
LS Mean Change from Baseline (SE)	3.3 (4.21)	-5.4 (3.89)
95% C.I.	(-5.0, 11.6)	(-13.1, 2.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	8.7 (5.79)	
95% C.I.	(-2.7, 20.1)	
p-value	0.13334	
Corrected Hedges' g	0.43	
95% C.I.	(-0.14, 1.01)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	29
n [2]	21	25
LS Mean (SE)	24.5 (4.34)	19.4 (3.92)
95% C.I.	(16.0, 33.0)	(11.7, 27.1)
LS Mean Change from Baseline (SE)	4.4 (4.34)	-0.7 (3.92)
95% C.I.	(-4.1, 12.9)	(-8.4, 7.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.1 (5.89)	
95% C.I.	(-6.5, 16.7)	
p-value	0.38741	
Corrected Hedges' g	0.25	
95% C.I.	(-0.33, 0.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	29
n [2]	21	24
LS Mean (SE)	25.3 (4.36)	18.7 (3.99)
95% C.I.	(16.7, 33.9)	(10.9, 26.6)
LS Mean Change from Baseline (SE)	5.2 (4.36)	-1.3 (3.99)
95% C.I.	(-3.4, 13.8)	(-9.2, 6.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.6 (5.96)	
95% C.I.	(-5.2, 18.3)	
p-value	0.27167	
Corrected Hedges' g	0.33	
95% C.I.	(-0.26, 0.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	29
n [2]	16	18
LS Mean (SE)	20.1 (4.81)	15.4 (4.44)
95% C.I.	(10.7, 29.6)	(6.6, 24.1)
LS Mean Change from Baseline (SE)	0.0 (4.81)	-4.7 (4.44)
95% C.I.	(-9.4, 9.5)	(-13.5, 4.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.7 (6.60)	
95% C.I.	(-8.2, 17.7)	
p-value	0.47269	
Corrected Hedges' g	0.24	
95% C.I.	(-0.43, 0.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	29
n [2]	17	15
LS Mean (SE)	23.4 (4.81)	10.3 (4.81)
95% C.I.	(13.9, 32.8)	(0.8, 19.7)
LS Mean Change from Baseline (SE)	3.3 (4.81)	-9.8 (4.81)
95% C.I.	(-6.2, 12.7)	(-19.3, -0.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.1 (6.82)	
95% C.I.	(-0.3, 26.5)	
p-value	0.05528	
Corrected Hedges' g	0.66	
95% C.I.	(-0.05, 1.38)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	29
n [2]	14	16
LS Mean (SE)	17.8 (5.05)	17.6 (4.82)
95% C.I.	(7.8, 27.7)	(8.1, 27.0)
LS Mean Change from Baseline (SE)	-2.3 (5.05)	-2.5 (4.82)
95% C.I.	(-12.3, 7.6)	(-12.0, 7.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.2 (6.99)	
95% C.I.	(-13.5, 13.9)	
p-value	0.97608	
Corrected Hedges' g	0.01	
95% C.I.	(-0.71, 0.73)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	29
n [2]	13	12
LS Mean (SE)	19.1 (5.23)	13.6 (5.56)
95% C.I.	(8.8, 29.4)	(2.6, 24.5)
LS Mean Change from Baseline (SE)	-1.0 (5.23)	-6.5 (5.56)
95% C.I.	(-11.3, 9.3)	(-17.4, 4.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.5 (7.61)	
95% C.I.	(-9.4, 20.5)	
p-value	0.46710	
Corrected Hedges' g	0.28	
95% C.I.	(-0.51, 1.07)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	29
n [2]	13	9
LS Mean (SE)	28.9 (5.35)	15.7 (6.08)
95% C.I.	(18.4, 39.4)	(3.8, 27.6)
LS Mean Change from Baseline (SE)	8.8 (5.35)	-4.4 (6.08)
95% C.I.	(-1.7, 19.3)	(-16.3, 7.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.2 (8.15)	
95% C.I.	(-2.8, 29.2)	
p-value	0.10562	
Corrected Hedges' g	0.67	
95% C.I.	(-0.20, 1.55)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	29
n [2]	13	12
LS Mean (SE)	24.8 (5.44)	18.9 (5.63)
95% C.I.	(14.1, 35.5)	(7.8, 29.9)
LS Mean Change from Baseline (SE)	4.7 (5.44)	-1.2 (5.63)
95% C.I.	(-6.0, 15.4)	(-12.3, 9.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.9 (7.92)	
95% C.I.	(-9.6, 21.5)	
p-value	0.45370	
Corrected Hedges' g	0.29	
95% C.I.	(-0.50, 1.08)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	29
n [2]	14	10
LS Mean (SE)	19.7 (5.29)	18.6 (6.07)
95% C.I.	(9.2, 30.1)	(6.7, 30.6)
LS Mean Change from Baseline (SE)	-0.4 (5.29)	-1.5 (6.07)
95% C.I.	(-10.8, 10.0)	(-13.4, 10.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.0 (8.10)	
95% C.I.	(-14.9, 16.9)	
p-value	0.89979	
Corrected Hedges' g	0.05	
95% C.I.	(-0.76, 0.86)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	29
n [2]	11	9
LS Mean (SE)	25.8 (5.93)	18.4 (6.31)
95% C.I.	(14.1, 37.4)	(6.0, 30.8)
LS Mean Change from Baseline (SE)	5.7 (5.93)	-1.7 (6.31)
95% C.I.	(-5.9, 17.4)	(-14.1, 10.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.4 (8.71)	
95% C.I.	(-9.7, 24.5)	
p-value	0.39705	
Corrected Hedges' g	0.37	
95% C.I.	(-0.52, 1.25)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	29
n [2]	9	11
LS Mean (SE)	30.0 (6.37)	19.2 (5.88)
95% C.I.	(17.5, 42.6)	(7.6, 30.7)
LS Mean Change from Baseline (SE)	10.0 (6.37)	-0.9 (5.88)
95% C.I.	(-2.6, 22.5)	(-12.5, 10.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.9 (8.73)	
95% C.I.	(-6.3, 28.1)	
p-value	0.21361	
Corrected Hedges' g	0.54	
95% C.I.	(-0.36, 1.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	29
n [2]	11	9
LS Mean (SE)	23.6 (5.94)	19.2 (6.68)
95% C.I.	(11.9, 35.2)	(6.1, 32.3)
LS Mean Change from Baseline (SE)	3.5 (5.94)	-0.9 (6.68)
95% C.I.	(-8.2, 15.1)	(-14.0, 12.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.4 (9.12)	
95% C.I.	(-13.5, 22.3)	
p-value	0.63161	
Corrected Hedges' g	0.21	
95% C.I.	(-0.67, 1.09)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	29
n [2]	11	6
LS Mean (SE)	24.5 (6.00)	10.9 (7.85)
95% C.I.	(12.7, 36.3)	(-4.6, 26.3)
LS Mean Change from Baseline (SE)	4.4 (6.00)	-9.2 (7.85)
95% C.I.	(-7.4, 16.2)	(-24.7, 6.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.7 (10.12)	
95% C.I.	(-6.2, 33.5)	
p-value	0.17789	
Corrected Hedges' g	0.66	
95% C.I.	(-0.36, 1.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	29
n [2]	10	6
LS Mean (SE)	27.6 (6.14)	3.3 (8.27)
95% C.I.	(15.6, 39.7)	(-13.0, 19.5)
LS Mean Change from Baseline (SE)	7.6 (6.14)	-16.8 (8.27)
95% C.I.	(-4.5, 19.6)	(-33.1, -0.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	24.4 (10.36)	
95% C.I.	(4.0, 44.8)	
p-value	0.01905	
Corrected Hedges' g	1.17	
95% C.I.	(0.08, 2.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	29
n [2]	9	7
LS Mean (SE)	25.6 (6.36)	7.0 (8.08)
95% C.I.	(13.1, 38.1)	(-8.9, 22.9)
LS Mean Change from Baseline (SE)	5.5 (6.36)	-13.1 (8.08)
95% C.I.	(-7.0, 18.0)	(-29.0, 2.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	18.6 (10.19)	
95% C.I.	(-1.4, 38.6)	
p-value	0.06858	
Corrected Hedges' g	0.88	
95% C.I.	(-0.16, 1.91)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	29
n [2]	10	5
LS Mean (SE)	34.4 (6.26)	4.9 (8.53)
95% C.I.	(22.1, 46.8)	(-11.9, 21.6)
LS Mean Change from Baseline (SE)	14.4 (6.26)	-15.2 (8.53)
95% C.I.	(2.0, 26.7)	(-32.0, 1.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	29.6 (10.42)	
95% C.I.	(9.1, 50.0)	
p-value	0.00475	
Corrected Hedges' g	1.42	
95% C.I.	(0.23, 2.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	29
n [2]	7	6
LS Mean (SE)	26.9 (7.16)	1.7 (7.99)
95% C.I.	(12.8, 41.0)	(-14.0, 17.4)
LS Mean Change from Baseline (SE)	6.8 (7.16)	-18.4 (7.99)
95% C.I.	(-7.2, 20.9)	(-34.1, -2.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	25.2 (10.65)	
95% C.I.	(4.2, 46.1)	
p-value	0.01853	
Corrected Hedges' g	1.22	
95% C.I.	(0.03, 2.40)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	29
n [2]	7	5
LS Mean (SE)	28.5 (7.33)	3.3 (8.64)
95% C.I.	(14.1, 42.9)	(-13.7, 20.2)
LS Mean Change from Baseline (SE)	8.4 (7.33)	-16.8 (8.64)
95% C.I.	(-6.0, 22.9)	(-33.8, 0.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	25.3 (11.20)	
95% C.I.	(3.2, 47.3)	
p-value	0.02460	
Corrected Hedges' g	1.20	
95% C.I.	(-0.04, 2.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	29
n [2]	8	6
LS Mean (SE)	30.5 (7.12)	10.2 (8.97)
95% C.I.	(16.5, 44.5)	(-7.4, 27.8)
LS Mean Change from Baseline (SE)	10.4 (7.12)	-9.9 (8.97)
95% C.I.	(-3.6, 24.4)	(-27.5, 7.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	20.3 (11.01)	
95% C.I.	(-1.4, 41.9)	
p-value	0.06626	
Corrected Hedges' g	0.91	
95% C.I.	(-0.20, 2.02)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	29
n [2]	7	5
LS Mean (SE)	29.5 (7.34)	9.7 (8.91)
95% C.I.	(15.1, 43.9)	(-7.9, 27.2)
LS Mean Change from Baseline (SE)	9.4 (7.34)	-10.4 (8.91)
95% C.I.	(-5.0, 23.9)	(-27.9, 7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	19.9 (11.38)	
95% C.I.	(-2.5, 42.2)	
p-value	0.08170	
Corrected Hedges' g	0.93	
95% C.I.	(-0.27, 2.14)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	29
n [2]	8	5
LS Mean (SE)	29.6 (7.10)	3.3 (9.03)
95% C.I.	(15.6, 43.5)	(-14.5, 21.0)
LS Mean Change from Baseline (SE)	9.5 (7.10)	-16.8 (9.03)
95% C.I.	(-4.5, 23.4)	(-34.6, 0.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	26.3 (11.27)	
95% C.I.	(4.2, 48.5)	
p-value	0.02004	
Corrected Hedges' g	1.22	
95% C.I.	(0.01, 2.43)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	29
n [2]	7	5
LS Mean (SE)	23.4 (7.23)	10.9 (8.90)
95% C.I.	(9.1, 37.6)	(-6.6, 28.3)
LS Mean Change from Baseline (SE)	3.3 (7.23)	-9.2 (8.90)
95% C.I.	(-10.9, 17.5)	(-26.7, 8.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.5 (11.38)	
95% C.I.	(-9.8, 34.9)	
p-value	0.27200	
Corrected Hedges' g	0.59	
95% C.I.	(-0.58, 1.77)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	29
n [2]	7	6
LS Mean (SE)	28.1 (7.28)	13.1 (8.17)
95% C.I.	(13.8, 42.4)	(-3.0, 29.1)
LS Mean Change from Baseline (SE)	8.0 (7.28)	-7.0 (8.17)
95% C.I.	(-6.3, 22.3)	(-23.1, 9.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.0 (10.91)	
95% C.I.	(-6.4, 36.5)	
p-value	0.16924	
Corrected Hedges' g	0.71	
95% C.I.	(-0.41, 1.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	29
n [2]	6	5
LS Mean (SE)	37.9 (7.80)	8.4 (8.80)
95% C.I.	(22.6, 53.3)	(-8.9, 25.7)
LS Mean Change from Baseline (SE)	17.8 (7.80)	-11.7 (8.80)
95% C.I.	(2.5, 33.2)	(-29.0, 5.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	29.5 (11.60)	
95% C.I.	(6.7, 52.3)	
p-value	0.01130	
Corrected Hedges' g	1.39	
95% C.I.	(0.07, 2.72)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	29
n [2]	7	6
LS Mean (SE)	33.3 (7.49)	16.2 (8.62)
95% C.I.	(18.6, 48.1)	(-0.8, 33.1)
LS Mean Change from Baseline (SE)	13.3 (7.49)	-3.9 (8.62)
95% C.I.	(-1.5, 28.0)	(-20.9, 13.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	17.2 (11.34)	
95% C.I.	(-5.1, 39.5)	
p-value	0.13100	
Corrected Hedges' g	0.78	
95% C.I.	(-0.35, 1.91)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	29
n [2]	7	5
LS Mean (SE)	33.3 (7.53)	8.1 (9.05)
95% C.I.	(18.5, 48.1)	(-9.7, 25.9)
LS Mean Change from Baseline (SE)	13.2 (7.53)	-12.0 (9.05)
95% C.I.	(-1.6, 28.0)	(-29.8, 5.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	25.2 (11.70)	
95% C.I.	(2.2, 48.2)	
p-value	0.03172	
Corrected Hedges' g	1.16	
95% C.I.	(-0.08, 2.40)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	29
n [2]	6	4
LS Mean (SE)	27.6 (7.96)	-0.2 (9.64)
95% C.I.	(11.9, 43.3)	(-19.1, 18.8)
LS Mean Change from Baseline (SE)	7.5 (7.96)	-20.3 (9.64)
95% C.I.	(-8.1, 23.2)	(-39.2, -1.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	27.8 (12.54)	
95% C.I.	(3.1, 52.4)	
p-value	0.02738	
Corrected Hedges' g	1.29	
95% C.I.	(-0.09, 2.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	29
n [2]	5	5
LS Mean (SE)	23.8 (8.45)	6.4 (9.25)
95% C.I.	(7.2, 40.4)	(-11.8, 24.6)
LS Mean Change from Baseline (SE)	3.7 (8.45)	-13.7 (9.25)
95% C.I.	(-12.9, 20.3)	(-31.9, 4.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	17.3 (12.50)	
95% C.I.	(-7.2, 41.9)	
p-value	0.16627	
Corrected Hedges' g	0.79	
95% C.I.	(-0.50, 2.08)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	29
n [2]	6	5
LS Mean (SE)	28.0 (8.00)	6.9 (9.24)
95% C.I.	(12.2, 43.7)	(-11.2, 25.1)
LS Mean Change from Baseline (SE)	7.9 (8.00)	-13.1 (9.24)
95% C.I.	(-7.8, 23.6)	(-31.3, 5.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	21.0 (12.03)	
95% C.I.	(-2.6, 44.7)	
p-value	0.08134	
Corrected Hedges' g	0.96	
95% C.I.	(-0.29, 2.21)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	29
n [2]	6	4
LS Mean (SE)	17.9 (8.00)	11.9 (10.57)
95% C.I.	(2.2, 33.6)	(-8.9, 32.7)
LS Mean Change from Baseline (SE)	-2.2 (8.00)	-8.2 (10.57)
95% C.I.	(-17.9, 13.5)	(-29.0, 12.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.0 (13.46)	
95% C.I.	(-20.5, 32.4)	
p-value	0.65685	
Corrected Hedges' g	0.27	
95% C.I.	(-1.00, 1.54)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	29
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	29
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	29
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	29
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	29
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	29
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	29
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	29
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	29
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	29
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	29
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	29
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	29
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	29
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	29
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Dyspnea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	21.5 (4.82)	30.0 (4.39)
95% C.I.	(12.0, 31.0)	(21.3, 38.6)
LS Mean Change from Baseline (SE)	-6.1 (4.82)	2.3 (4.39)
95% C.I.	(-15.6, 3.4)	(-6.3, 11.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.4 (6.53)	
95% C.I.	(-21.3, 4.4)	
p-value	0.19735	
Corrected Hedges' g	-0.36	
95% C.I.	(-0.90, 0.19)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	26
LS Mean (SE)	21.6 (4.88)	26.2 (4.48)
95% C.I.	(12.0, 31.2)	(17.4, 35.0)
LS Mean Change from Baseline (SE)	-6.0 (4.88)	-1.4 (4.48)
95% C.I.	(-15.6, 3.6)	(-10.2, 7.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.6 (6.65)	
95% C.I.	(-17.6, 8.5)	
p-value	0.49392	
Corrected Hedges' g	-0.19	
95% C.I.	(-0.76, 0.37)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	26
LS Mean (SE)	21.2 (5.01)	29.9 (4.51)
95% C.I.	(11.4, 31.1)	(21.0, 38.7)
LS Mean Change from Baseline (SE)	-6.4 (5.01)	2.2 (4.51)
95% C.I.	(-16.2, 3.5)	(-6.6, 11.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.6 (6.76)	
95% C.I.	(-21.9, 4.7)	
p-value	0.20336	
Corrected Hedges' g	-0.36	
95% C.I.	(-0.94, 0.21)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	25
LS Mean (SE)	19.0 (5.05)	31.6 (4.58)
95% C.I.	(9.1, 28.9)	(22.6, 40.6)
LS Mean Change from Baseline (SE)	-8.6 (5.05)	4.0 (4.58)
95% C.I.	(-18.5, 1.3)	(-5.0, 13.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.6 (6.83)	
95% C.I.	(-26.1, 0.8)	
p-value	0.06533	
Corrected Hedges' g	-0.54	
95% C.I.	(-1.13, 0.05)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	16	19
LS Mean (SE)	17.0 (5.66)	31.2 (5.07)
95% C.I.	(5.9, 28.1)	(21.2, 41.2)
LS Mean Change from Baseline (SE)	-10.6 (5.66)	3.6 (5.07)
95% C.I.	(-21.7, 0.5)	(-6.4, 13.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-14.2 (7.65)	
95% C.I.	(-29.2, 0.8)	
p-value	0.06357	
Corrected Hedges' g	-0.62	
95% C.I.	(-1.30, 0.06)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	30
n [2]	16	16
LS Mean (SE)	24.7 (5.73)	27.6 (5.47)
95% C.I.	(13.5, 36.0)	(16.8, 38.3)
LS Mean Change from Baseline (SE)	-2.9 (5.73)	-0.1 (5.47)
95% C.I.	(-14.1, 8.4)	(-10.8, 10.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.8 (7.97)	
95% C.I.	(-18.5, 12.9)	
p-value	0.72475	
Corrected Hedges' g	-0.12	
95% C.I.	(-0.82, 0.57)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	14	17
LS Mean (SE)	21.5 (5.99)	20.5 (5.58)
95% C.I.	(9.7, 33.3)	(9.6, 31.5)
LS Mean Change from Baseline (SE)	-6.1 (5.99)	-7.1 (5.58)
95% C.I.	(-17.9, 5.6)	(-18.0, 3.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.9 (8.31)	
95% C.I.	(-15.4, 17.3)	
p-value	0.91046	
Corrected Hedges' g	0.04	
95% C.I.	(-0.67, 0.75)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	30
n [2]	15	12
LS Mean (SE)	23.8 (5.87)	23.4 (6.72)
95% C.I.	(12.2, 35.3)	(10.2, 36.6)
LS Mean Change from Baseline (SE)	-3.8 (5.87)	-4.3 (6.72)
95% C.I.	(-15.4, 7.7)	(-17.5, 8.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.4 (9.01)	
95% C.I.	(-17.3, 18.1)	
p-value	0.96400	
Corrected Hedges' g	0.02	
95% C.I.	(-0.74, 0.78)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	23.0 (6.30)	26.8 (7.45)
95% C.I.	(10.6, 35.4)	(12.1, 41.4)
LS Mean Change from Baseline (SE)	-4.6 (6.30)	-0.8 (7.45)
95% C.I.	(-17.0, 7.8)	(-15.5, 13.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.8 (10.04)	
95% C.I.	(-23.5, 16.0)	
p-value	0.70749	
Corrected Hedges' g	-0.16	
95% C.I.	(-1.01, 0.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	30
n [2]	13	12
LS Mean (SE)	22.4 (6.41)	26.6 (6.78)
95% C.I.	(9.8, 35.0)	(13.2, 39.9)
LS Mean Change from Baseline (SE)	-5.3 (6.41)	-1.1 (6.78)
95% C.I.	(-17.8, 7.3)	(-14.4, 12.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.2 (9.57)	
95% C.I.	(-23.0, 14.6)	
p-value	0.66113	
Corrected Hedges' g	-0.17	
95% C.I.	(-0.96, 0.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	14	10
LS Mean (SE)	22.9 (6.24)	31.3 (7.53)
95% C.I.	(10.7, 35.2)	(16.5, 46.1)
LS Mean Change from Baseline (SE)	-4.7 (6.24)	3.7 (7.53)
95% C.I.	(-17.0, 7.6)	(-11.1, 18.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.4 (10.01)	
95% C.I.	(-28.0, 11.3)	
p-value	0.40420	
Corrected Hedges' g	-0.34	
95% C.I.	(-1.16, 0.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	23.5 (6.88)	22.9 (7.84)
95% C.I.	(10.0, 37.0)	(7.5, 38.3)
LS Mean Change from Baseline (SE)	-4.1 (6.88)	-4.8 (7.84)
95% C.I.	(-17.6, 9.4)	(-20.2, 10.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.6 (10.77)	
95% C.I.	(-20.5, 21.8)	
p-value	0.95212	
Corrected Hedges' g	0.03	
95% C.I.	(-0.85, 0.91)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	9	11
LS Mean (SE)	18.2 (7.62)	16.8 (7.13)
95% C.I.	(3.2, 33.2)	(2.7, 30.8)
LS Mean Change from Baseline (SE)	-9.4 (7.62)	-10.9 (7.13)
95% C.I.	(-24.4, 5.6)	(-24.9, 3.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.4 (10.83)	
95% C.I.	(-19.8, 22.7)	
p-value	0.89444	
Corrected Hedges' g	0.06	
95% C.I.	(-0.82, 0.94)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	17.8 (7.32)	23.6 (7.94)
95% C.I.	(3.4, 32.1)	(8.0, 39.2)
LS Mean Change from Baseline (SE)	-9.9 (7.32)	-4.1 (7.94)
95% C.I.	(-24.2, 4.5)	(-19.7, 11.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.8 (11.39)	
95% C.I.	(-28.2, 16.6)	
p-value	0.61086	
Corrected Hedges' g	-0.23	
95% C.I.	(-1.11, 0.65)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	25.8 (7.08)	23.6 (9.20)
95% C.I.	(11.9, 39.7)	(5.5, 41.7)
LS Mean Change from Baseline (SE)	-1.8 (7.08)	-4.0 (9.20)
95% C.I.	(-15.7, 12.1)	(-22.1, 14.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.3 (11.94)	
95% C.I.	(-21.2, 25.7)	
p-value	0.85034	
Corrected Hedges' g	0.09	
95% C.I.	(-0.90, 1.09)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	25.3 (7.29)	13.9 (9.52)
95% C.I.	(11.0, 39.6)	(-4.8, 32.6)
LS Mean Change from Baseline (SE)	-2.3 (7.29)	-13.7 (9.52)
95% C.I.	(-16.7, 12.0)	(-32.4, 5.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.4 (12.29)	
95% C.I.	(-12.8, 35.5)	
p-value	0.35498	
Corrected Hedges' g	0.46	
95% C.I.	(-0.56, 1.49)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	9	7
LS Mean (SE)	22.5 (7.55)	11.5 (9.21)
95% C.I.	(7.7, 37.4)	(-6.7, 29.6)
LS Mean Change from Baseline (SE)	-5.1 (7.55)	-16.2 (9.21)
95% C.I.	(-19.9, 9.7)	(-34.3, 2.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.1 (12.21)	
95% C.I.	(-12.9, 35.1)	
p-value	0.36535	
Corrected Hedges' g	0.45	
95% C.I.	(-0.55, 1.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	18.5 (7.48)	16.1 (9.40)
95% C.I.	(3.8, 33.2)	(-2.4, 34.6)
LS Mean Change from Baseline (SE)	-9.1 (7.48)	-11.5 (9.40)
95% C.I.	(-23.8, 5.6)	(-30.0, 7.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.4 (12.31)	
95% C.I.	(-21.8, 26.6)	
p-value	0.84374	
Corrected Hedges' g	0.10	
95% C.I.	(-0.91, 1.11)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	24.2 (8.43)	12.0 (9.23)
95% C.I.	(7.6, 40.8)	(-6.2, 30.1)
LS Mean Change from Baseline (SE)	-3.4 (8.43)	-15.6 (9.23)
95% C.I.	(-20.0, 13.1)	(-33.8, 2.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.2 (12.55)	
95% C.I.	(-12.5, 36.9)	
p-value	0.33119	
Corrected Hedges' g	0.51	
95% C.I.	(-0.60, 1.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	24.9 (8.63)	14.2 (10.05)
95% C.I.	(7.9, 41.8)	(-5.5, 34.0)
LS Mean Change from Baseline (SE)	-2.7 (8.63)	-13.4 (10.05)
95% C.I.	(-19.7, 14.2)	(-33.1, 6.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.6 (13.40)	
95% C.I.	(-15.7, 37.0)	
p-value	0.42840	
Corrected Hedges' g	0.43	
95% C.I.	(-0.73, 1.59)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	35.3 (8.43)	7.0 (10.18)
95% C.I.	(18.7, 51.9)	(-13.0, 27.0)
LS Mean Change from Baseline (SE)	7.7 (8.43)	-20.6 (10.18)
95% C.I.	(-8.9, 24.3)	(-40.6, -0.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	28.3 (13.76)	
95% C.I.	(1.3, 55.4)	
p-value	0.04019	
Corrected Hedges' g	1.09	
95% C.I.	(-0.04, 2.22)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	20.1 (8.65)	8.6 (10.40)
95% C.I.	(3.1, 37.2)	(-11.8, 29.1)
LS Mean Change from Baseline (SE)	-7.5 (8.65)	-19.0 (10.40)
95% C.I.	(-24.5, 9.5)	(-39.4, 1.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.5 (13.75)	
95% C.I.	(-15.5, 38.5)	
p-value	0.40265	
Corrected Hedges' g	0.46	
95% C.I.	(-0.70, 1.62)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	14.3 (8.41)	5.2 (10.53)
95% C.I.	(-2.3, 30.8)	(-15.5, 25.9)
LS Mean Change from Baseline (SE)	-13.4 (8.41)	-22.4 (10.53)
95% C.I.	(-29.9, 3.2)	(-43.1, -1.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.0 (13.77)	
95% C.I.	(-18.0, 36.1)	
p-value	0.51135	
Corrected Hedges' g	0.36	
95% C.I.	(-0.77, 1.48)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	24.8 (8.89)	15.7 (10.40)
95% C.I.	(7.4, 42.3)	(-4.8, 36.1)
LS Mean Change from Baseline (SE)	-2.8 (8.89)	-12.0 (10.40)
95% C.I.	(-20.2, 14.7)	(-32.4, 8.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.2 (14.11)	
95% C.I.	(-18.5, 36.9)	
p-value	0.51544	
Corrected Hedges' g	0.36	
95% C.I.	(-0.79, 1.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	10.5 (8.57)	21.8 (9.50)
95% C.I.	(-6.4, 27.4)	(3.1, 40.5)
LS Mean Change from Baseline (SE)	-17.1 (8.57)	-5.8 (9.50)
95% C.I.	(-34.0, -0.3)	(-24.5, 12.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.3 (12.80)	
95% C.I.	(-36.5, 13.8)	
p-value	0.37655	
Corrected Hedges' g	-0.46	
95% C.I.	(-1.56, 0.65)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	11.3 (9.10)	14.7 (10.26)
95% C.I.	(-6.6, 29.2)	(-5.4, 34.9)
LS Mean Change from Baseline (SE)	-16.3 (9.10)	-12.9 (10.26)
95% C.I.	(-34.2, 1.6)	(-33.0, 7.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.4 (13.73)	
95% C.I.	(-30.4, 23.6)	
p-value	0.80241	
Corrected Hedges' g	-0.14	
95% C.I.	(-1.33, 1.05)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	23.1 (8.80)	15.0 (10.13)
95% C.I.	(5.8, 40.5)	(-5.0, 34.9)
LS Mean Change from Baseline (SE)	-4.5 (8.80)	-12.6 (10.13)
95% C.I.	(-21.8, 12.8)	(-32.6, 7.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	8.2 (13.50)	
95% C.I.	(-18.4, 34.7)	
p-value	0.54495	
Corrected Hedges' g	0.32	
95% C.I.	(-0.78, 1.41)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	23.5 (8.85)	7.3 (10.61)
95% C.I.	(6.1, 40.9)	(-13.6, 28.1)
LS Mean Change from Baseline (SE)	-4.1 (8.85)	-20.4 (10.61)
95% C.I.	(-21.5, 13.3)	(-41.2, 0.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	16.2 (13.88)	
95% C.I.	(-11.1, 43.5)	
p-value	0.24345	
Corrected Hedges' g	0.64	
95% C.I.	(-0.54, 1.81)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	22.2 (9.50)	17.7 (11.70)
95% C.I.	(3.5, 40.9)	(-5.3, 40.7)
LS Mean Change from Baseline (SE)	-5.4 (9.50)	-9.9 (11.70)
95% C.I.	(-24.1, 13.2)	(-32.9, 13.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.5 (15.49)	
95% C.I.	(-25.9, 34.9)	
p-value	0.77159	
Corrected Hedges' g	0.17	
95% C.I.	(-1.09, 1.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	23.9 (9.97)	7.4 (11.00)
95% C.I.	(4.3, 43.5)	(-14.2, 29.0)
LS Mean Change from Baseline (SE)	-3.7 (9.97)	-20.2 (11.00)
95% C.I.	(-23.3, 15.9)	(-41.9, 1.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	16.5 (14.79)	
95% C.I.	(-12.6, 45.6)	
p-value	0.26528	
Corrected Hedges' g	0.63	
95% C.I.	(-0.64, 1.91)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	27.2 (9.52)	8.6 (10.94)
95% C.I.	(8.4, 45.9)	(-12.9, 30.1)
LS Mean Change from Baseline (SE)	-0.4 (9.52)	-19.0 (10.94)
95% C.I.	(-19.2, 18.3)	(-40.5, 2.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	18.6 (14.16)	
95% C.I.	(-9.3, 46.4)	
p-value	0.19051	
Corrected Hedges' g	0.71	
95% C.I.	(-0.51, 1.94)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	30.3 (9.56)	15.0 (12.04)
95% C.I.	(11.5, 49.1)	(-8.7, 38.6)
LS Mean Change from Baseline (SE)	2.7 (9.56)	-12.6 (12.04)
95% C.I.	(-16.1, 21.5)	(-36.3, 11.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.3 (15.85)	
95% C.I.	(-15.8, 46.5)	
p-value	0.33380	
Corrected Hedges' g	0.59	
95% C.I.	(-0.71, 1.88)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Insomnia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	24	29
n [2]	23	27
LS Mean (SE)	13.9 (3.74)	11.5 (3.42)
95% C.I.	(6.5, 21.2)	(4.8, 18.2)
LS Mean Change from Baseline (SE)	-3.5 (3.74)	-5.9 (3.42)
95% C.I.	(-10.9, 3.8)	(-12.6, 0.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.3 (5.06)	
95% C.I.	(-7.6, 12.3)	
p-value	0.64317	
Corrected Hedges' g	0.13	
95% C.I.	(-0.43, 0.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	24	29
n [2]	21	25
LS Mean (SE)	7.4 (3.84)	12.8 (3.52)
95% C.I.	(-0.1, 15.0)	(5.9, 19.7)
LS Mean Change from Baseline (SE)	-9.9 (3.84)	-4.6 (3.52)
95% C.I.	(-17.5, -2.4)	(-11.5, 2.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.4 (5.20)	
95% C.I.	(-15.6, 4.9)	
p-value	0.30268	
Corrected Hedges' g	-0.30	
95% C.I.	(-0.88, 0.28)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	24	29
n [2]	21	25
LS Mean (SE)	8.7 (3.88)	11.0 (3.53)
95% C.I.	(1.1, 16.3)	(4.1, 18.0)
LS Mean Change from Baseline (SE)	-8.6 (3.88)	-6.3 (3.53)
95% C.I.	(-16.3, -1.0)	(-13.3, 0.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.3 (5.24)	
95% C.I.	(-12.6, 8.0)	
p-value	0.65755	
Corrected Hedges' g	-0.13	
95% C.I.	(-0.71, 0.45)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	24	29
n [2]	20	25
LS Mean (SE)	3.9 (3.95)	16.0 (3.54)
95% C.I.	(-3.8, 11.7)	(9.1, 23.0)
LS Mean Change from Baseline (SE)	-13.4 (3.95)	-1.3 (3.54)
95% C.I.	(-21.2, -5.7)	(-8.3, 5.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.1 (5.30)	
95% C.I.	(-22.5, -1.7)	
p-value	0.02315	
Corrected Hedges' g	-0.67	
95% C.I.	(-1.28, -0.07)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	24	29
n [2]	15	19
LS Mean (SE)	15.1 (4.45)	17.8 (3.99)
95% C.I.	(6.3, 23.8)	(9.9, 25.6)
LS Mean Change from Baseline (SE)	-2.3 (4.45)	0.4 (3.99)
95% C.I.	(-11.1, 6.4)	(-7.4, 8.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.7 (5.99)	
95% C.I.	(-14.5, 9.1)	
p-value	0.65071	
Corrected Hedges' g	-0.15	
95% C.I.	(-0.83, 0.53)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	24	29
n [2]	15	16
LS Mean (SE)	13.0 (4.51)	23.5 (4.35)
95% C.I.	(4.2, 21.9)	(15.0, 32.1)
LS Mean Change from Baseline (SE)	-4.3 (4.51)	6.1 (4.35)
95% C.I.	(-13.2, 4.5)	(-2.4, 14.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.5 (6.24)	
95% C.I.	(-22.7, 1.8)	
p-value	0.09402	
Corrected Hedges' g	-0.59	
95% C.I.	(-1.30, 0.13)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	24	29
n [2]	13	17
LS Mean (SE)	9.7 (4.78)	17.8 (4.26)
95% C.I.	(0.3, 19.1)	(9.4, 26.1)
LS Mean Change from Baseline (SE)	-7.7 (4.78)	0.4 (4.26)
95% C.I.	(-17.1, 1.7)	(-8.0, 8.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.1 (6.40)	
95% C.I.	(-20.6, 4.5)	
p-value	0.20899	
Corrected Hedges' g	-0.45	
95% C.I.	(-1.18, 0.28)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	24	29
n [2]	14	12
LS Mean (SE)	12.4 (4.70)	14.5 (4.96)
95% C.I.	(3.1, 21.6)	(4.8, 24.3)
LS Mean Change from Baseline (SE)	-5.0 (4.70)	-2.9 (4.96)
95% C.I.	(-14.3, 4.2)	(-12.6, 6.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.2 (6.83)	
95% C.I.	(-15.6, 11.3)	
p-value	0.75264	
Corrected Hedges' g	-0.12	
95% C.I.	(-0.89, 0.65)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	24	29
n [2]	12	9
LS Mean (SE)	13.5 (5.03)	18.3 (5.65)
95% C.I.	(3.6, 23.3)	(7.2, 29.4)
LS Mean Change from Baseline (SE)	-3.9 (5.03)	0.9 (5.65)
95% C.I.	(-13.8, 6.0)	(-10.2, 12.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.8 (7.60)	
95% C.I.	(-19.8, 10.1)	
p-value	0.52532	
Corrected Hedges' g	-0.27	
95% C.I.	(-1.14, 0.60)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	24	29
n [2]	11	12
LS Mean (SE)	10.8 (5.22)	16.0 (5.08)
95% C.I.	(0.5, 21.0)	(6.0, 26.0)
LS Mean Change from Baseline (SE)	-6.6 (5.22)	-1.3 (5.08)
95% C.I.	(-16.8, 3.7)	(-11.3, 8.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.2 (7.27)	
95% C.I.	(-19.5, 9.1)	
p-value	0.47155	
Corrected Hedges' g	-0.29	
95% C.I.	(-1.11, 0.53)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	24	29
n [2]	13	10
LS Mean (SE)	15.4 (4.96)	13.2 (5.52)
95% C.I.	(5.6, 25.1)	(2.3, 24.1)
LS Mean Change from Baseline (SE)	-2.0 (4.96)	-4.2 (5.52)
95% C.I.	(-11.7, 7.8)	(-15.0, 6.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.2 (7.45)	
95% C.I.	(-12.5, 16.8)	
p-value	0.77063	
Corrected Hedges' g	0.12	
95% C.I.	(-0.71, 0.94)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	24	29
n [2]	10	9
LS Mean (SE)	18.5 (5.49)	12.4 (5.81)
95% C.I.	(7.7, 29.3)	(1.0, 23.8)
LS Mean Change from Baseline (SE)	1.1 (5.49)	-4.9 (5.81)
95% C.I.	(-9.7, 11.9)	(-16.4, 6.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.1 (8.01)	
95% C.I.	(-9.7, 21.8)	
p-value	0.44926	
Corrected Hedges' g	0.33	
95% C.I.	(-0.57, 1.24)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	24	29
n [2]	8	11
LS Mean (SE)	10.4 (6.04)	20.3 (5.34)
95% C.I.	(-1.5, 22.2)	(9.8, 30.7)
LS Mean Change from Baseline (SE)	-7.0 (6.04)	2.9 (5.34)
95% C.I.	(-18.9, 4.9)	(-7.6, 13.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.9 (8.07)	
95% C.I.	(-25.8, 6.0)	
p-value	0.22116	
Corrected Hedges' g	-0.54	
95% C.I.	(-1.47, 0.39)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	24	29
n [2]	10	9
LS Mean (SE)	17.2 (5.59)	14.2 (5.81)
95% C.I.	(6.3, 28.2)	(2.8, 25.6)
LS Mean Change from Baseline (SE)	-0.1 (5.59)	-3.2 (5.81)
95% C.I.	(-11.1, 10.9)	(-14.6, 8.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.1 (8.05)	
95% C.I.	(-12.8, 18.9)	
p-value	0.70493	
Corrected Hedges' g	0.17	
95% C.I.	(-0.74, 1.07)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	24	29
n [2]	10	6
LS Mean (SE)	19.3 (5.57)	6.9 (7.06)
95% C.I.	(8.4, 30.3)	(-6.9, 20.8)
LS Mean Change from Baseline (SE)	2.0 (5.57)	-10.4 (7.06)
95% C.I.	(-9.0, 12.9)	(-24.3, 3.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.4 (8.99)	
95% C.I.	(-5.3, 30.1)	
p-value	0.16837	
Corrected Hedges' g	0.67	
95% C.I.	(-0.37, 1.71)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	24	29
n [2]	9	6
LS Mean (SE)	17.1 (5.88)	4.6 (7.19)
95% C.I.	(5.6, 28.7)	(-9.6, 18.7)
LS Mean Change from Baseline (SE)	-0.2 (5.88)	-12.8 (7.19)
95% C.I.	(-11.8, 11.3)	(-26.9, 1.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.6 (9.24)	
95% C.I.	(-5.6, 30.7)	
p-value	0.17462	
Corrected Hedges' g	0.67	
95% C.I.	(-0.39, 1.73)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	24	29
n [2]	8	7
LS Mean (SE)	11.9 (6.14)	4.7 (6.75)
95% C.I.	(-0.2, 23.9)	(-8.6, 18.0)
LS Mean Change from Baseline (SE)	-5.5 (6.14)	-12.7 (6.75)
95% C.I.	(-17.6, 6.5)	(-26.0, 0.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.2 (9.13)	
95% C.I.	(-10.8, 25.1)	
p-value	0.43283	
Corrected Hedges' g	0.38	
95% C.I.	(-0.64, 1.41)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	24	29
n [2]	9	6
LS Mean (SE)	10.9 (5.92)	-0.2 (7.16)
95% C.I.	(-0.7, 22.6)	(-14.3, 13.9)
LS Mean Change from Baseline (SE)	-6.4 (5.92)	-17.6 (7.16)
95% C.I.	(-18.1, 5.2)	(-31.6, -3.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.1 (9.33)	
95% C.I.	(-7.2, 29.5)	
p-value	0.23396	
Corrected Hedges' g	0.59	
95% C.I.	(-0.46, 1.65)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	13.9 (7.05)	0.7 (7.43)
95% C.I.	(0.1, 27.8)	(-13.9, 15.3)
LS Mean Change from Baseline (SE)	-3.4 (7.05)	-16.7 (7.43)
95% C.I.	(-17.3, 10.4)	(-31.3, -2.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.2 (10.21)	
95% C.I.	(-6.8, 33.3)	
p-value	0.19547	
Corrected Hedges' g	0.69	
95% C.I.	(-0.48, 1.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	14.9 (7.18)	7.9 (8.45)
95% C.I.	(0.8, 29.1)	(-8.7, 24.5)
LS Mean Change from Baseline (SE)	-2.4 (7.18)	-9.5 (8.45)
95% C.I.	(-16.5, 11.7)	(-26.1, 7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.1 (10.97)	
95% C.I.	(-14.5, 28.6)	
p-value	0.51887	
Corrected Hedges' g	0.36	
95% C.I.	(-0.84, 1.55)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	24	29
n [2]	7	6
LS Mean (SE)	14.9 (6.86)	4.3 (9.53)
95% C.I.	(1.4, 28.4)	(-14.4, 23.0)
LS Mean Change from Baseline (SE)	-2.5 (6.86)	-13.1 (9.53)
95% C.I.	(-16.0, 11.0)	(-31.8, 5.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.6 (11.09)	
95% C.I.	(-11.2, 32.4)	
p-value	0.34127	
Corrected Hedges' g	0.48	
95% C.I.	(-0.63, 1.58)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	6.0 (7.16)	3.3 (8.68)
95% C.I.	(-8.1, 20.1)	(-13.7, 20.4)
LS Mean Change from Baseline (SE)	-11.4 (7.16)	-14.1 (8.68)
95% C.I.	(-25.5, 2.7)	(-31.1, 3.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.7 (11.08)	
95% C.I.	(-19.1, 24.4)	
p-value	0.80954	
Corrected Hedges' g	0.13	
95% C.I.	(-1.06, 1.32)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	24	29
n [2]	7	5
LS Mean (SE)	19.5 (6.83)	3.9 (8.72)
95% C.I.	(6.1, 33.0)	(-13.3, 21.0)
LS Mean Change from Baseline (SE)	2.2 (6.83)	-13.5 (8.72)
95% C.I.	(-11.3, 15.6)	(-30.6, 3.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.7 (10.73)	
95% C.I.	(-5.4, 36.8)	
p-value	0.14547	
Corrected Hedges' g	0.77	
95% C.I.	(-0.41, 1.96)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	19.9 (7.11)	23.3 (8.61)
95% C.I.	(5.9, 33.9)	(6.4, 40.3)
LS Mean Change from Baseline (SE)	2.5 (7.11)	6.0 (8.61)
95% C.I.	(-11.5, 16.5)	(-11.0, 22.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.5 (11.02)	
95% C.I.	(-25.1, 18.2)	
p-value	0.75430	
Corrected Hedges' g	-0.17	
95% C.I.	(-1.36, 1.02)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	7.3 (7.38)	18.5 (7.57)
95% C.I.	(-7.2, 21.8)	(3.6, 33.4)
LS Mean Change from Baseline (SE)	-10.1 (7.38)	1.2 (7.57)
95% C.I.	(-24.6, 4.4)	(-13.7, 16.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.3 (10.20)	
95% C.I.	(-31.3, 8.8)	
p-value	0.27019	
Corrected Hedges' g	-0.57	
95% C.I.	(-1.72, 0.59)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	24	29
n [2]	5	5
LS Mean (SE)	7.6 (7.86)	5.0 (8.62)
95% C.I.	(-7.8, 23.1)	(-11.9, 22.0)
LS Mean Change from Baseline (SE)	-9.7 (7.86)	-12.3 (8.62)
95% C.I.	(-25.2, 5.7)	(-29.3, 4.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.6 (11.24)	
95% C.I.	(-19.5, 24.7)	
p-value	0.81757	
Corrected Hedges' g	0.13	
95% C.I.	(-1.11, 1.37)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	16.7 (7.29)	5.2 (8.36)
95% C.I.	(2.3, 31.0)	(-11.2, 21.6)
LS Mean Change from Baseline (SE)	-0.7 (7.29)	-12.2 (8.36)
95% C.I.	(-15.0, 13.6)	(-28.6, 4.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.5 (11.00)	
95% C.I.	(-10.2, 33.1)	
p-value	0.29809	
Corrected Hedges' g	0.55	
95% C.I.	(-0.60, 1.70)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	11.0 (7.31)	1.3 (8.76)
95% C.I.	(-3.3, 25.4)	(-15.9, 18.5)
LS Mean Change from Baseline (SE)	-6.3 (7.31)	-16.1 (8.76)
95% C.I.	(-20.7, 8.0)	(-33.3, 1.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.7 (11.33)	
95% C.I.	(-12.5, 32.0)	
p-value	0.38988	
Corrected Hedges' g	0.48	
95% C.I.	(-0.73, 1.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	24	29
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	24	29
n [2]	4	5

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	24	29
n [2]	5	5
LS Mean (SE)	24.7 (7.92)	4.3 (8.94)
95% C.I.	(9.2, 40.3)	(-13.3, 21.8)
LS Mean Change from Baseline (SE)	7.4 (7.92)	-13.1 (8.94)
95% C.I.	(-8.2, 22.9)	(-30.7, 4.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	20.5 (12.20)	
95% C.I.	(-3.5, 44.4)	
p-value	0.09428	
Corrected Hedges' g	0.98	
95% C.I.	(-0.33, 2.29)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	24	29
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	24	29
n [2]	3	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	24	29
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	24	29
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	24	29
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	24	29
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	24	29
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	24	29
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	24	29
n [2]	4	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	24	29
n [2]	2	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	24	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	24	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	24	29
n [2]	0	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	24	29
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	24	29
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Appetite Loss

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	24	29
n [2]	23	27
LS Mean (SE)	11.0 (4.59)	21.9 (4.22)
95% C.I.	(2.0, 20.0)	(13.6, 30.2)
LS Mean Change from Baseline (SE)	-2.1 (4.59)	8.8 (4.22)
95% C.I.	(-11.1, 6.9)	(0.5, 17.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.9 (6.23)	
95% C.I.	(-23.1, 1.4)	
p-value	0.08137	
Corrected Hedges' g	-0.49	
95% C.I.	(-1.05, 0.08)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	24	29
n [2]	21	25
LS Mean (SE)	12.6 (4.74)	27.3 (4.33)
95% C.I.	(3.3, 21.9)	(18.8, 35.8)
LS Mean Change from Baseline (SE)	-0.5 (4.74)	14.2 (4.33)
95% C.I.	(-9.8, 8.8)	(5.7, 22.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-14.7 (6.43)	
95% C.I.	(-27.3, -2.1)	
p-value	0.02264	
Corrected Hedges' g	-0.67	
95% C.I.	(-1.26, -0.07)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	24	29
n [2]	21	25
LS Mean (SE)	8.5 (4.76)	13.0 (4.36)
95% C.I.	(-0.9, 17.9)	(4.4, 21.5)
LS Mean Change from Baseline (SE)	-4.6 (4.76)	-0.1 (4.36)
95% C.I.	(-14.0, 4.7)	(-8.7, 8.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.5 (6.46)	
95% C.I.	(-17.2, 8.2)	
p-value	0.48847	
Corrected Hedges' g	-0.20	
95% C.I.	(-0.78, 0.38)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	24	29
n [2]	20	25
LS Mean (SE)	7.4 (4.86)	16.2 (4.36)
95% C.I.	(-2.1, 17.0)	(7.6, 24.7)
LS Mean Change from Baseline (SE)	-5.7 (4.86)	3.0 (4.36)
95% C.I.	(-15.2, 3.9)	(-5.5, 11.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.7 (6.53)	
95% C.I.	(-21.6, 4.1)	
p-value	0.18216	
Corrected Hedges' g	-0.39	
95% C.I.	(-0.99, 0.20)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	24	29
n [2]	15	19
LS Mean (SE)	9.0 (5.45)	22.5 (4.88)
95% C.I.	(-1.8, 19.7)	(12.9, 32.1)
LS Mean Change from Baseline (SE)	-4.2 (5.45)	9.4 (4.88)
95% C.I.	(-14.9, 6.6)	(-0.2, 19.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-13.5 (7.31)	
95% C.I.	(-27.9, 0.8)	
p-value	0.06485	
Corrected Hedges' g	-0.62	
95% C.I.	(-1.32, 0.07)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	24	29
n [2]	15	16
LS Mean (SE)	16.4 (5.54)	20.9 (5.27)
95% C.I.	(5.5, 27.2)	(10.5, 31.2)
LS Mean Change from Baseline (SE)	3.3 (5.54)	7.8 (5.27)
95% C.I.	(-7.6, 14.1)	(-2.6, 18.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.5 (7.64)	
95% C.I.	(-19.5, 10.5)	
p-value	0.55319	
Corrected Hedges' g	-0.21	
95% C.I.	(-0.91, 0.50)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	24	29
n [2]	13	17
LS Mean (SE)	13.6 (5.86)	25.5 (5.23)
95% C.I.	(2.1, 25.1)	(15.2, 35.8)
LS Mean Change from Baseline (SE)	0.5 (5.86)	12.4 (5.23)
95% C.I.	(-11.0, 12.0)	(2.1, 22.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.9 (7.86)	
95% C.I.	(-27.3, 3.6)	
p-value	0.13112	
Corrected Hedges' g	-0.54	
95% C.I.	(-1.28, 0.19)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	24	29
n [2]	14	12
LS Mean (SE)	19.1 (5.76)	20.9 (6.07)
95% C.I.	(7.7, 30.4)	(9.0, 32.9)
LS Mean Change from Baseline (SE)	5.9 (5.76)	7.8 (6.07)
95% C.I.	(-5.4, 17.3)	(-4.1, 19.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.9 (8.37)	
95% C.I.	(-18.3, 14.6)	
p-value	0.82392	
Corrected Hedges' g	-0.08	
95% C.I.	(-0.86, 0.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	24	29
n [2]	12	9
LS Mean (SE)	11.6 (6.17)	13.8 (6.86)
95% C.I.	(-0.5, 23.7)	(0.3, 27.2)
LS Mean Change from Baseline (SE)	-1.5 (6.17)	0.6 (6.86)
95% C.I.	(-13.6, 10.6)	(-12.8, 14.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.2 (9.21)	
95% C.I.	(-20.3, 15.9)	
p-value	0.81532	
Corrected Hedges' g	-0.10	
95% C.I.	(-0.96, 0.77)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	24	29
n [2]	11	12
LS Mean (SE)	28.2 (6.42)	14.7 (6.24)
95% C.I.	(15.6, 40.8)	(2.4, 26.9)
LS Mean Change from Baseline (SE)	15.1 (6.42)	1.6 (6.24)
95% C.I.	(2.5, 27.7)	(-10.7, 13.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.5 (8.95)	
95% C.I.	(-4.1, 31.1)	
p-value	0.13163	
Corrected Hedges' g	0.61	
95% C.I.	(-0.23, 1.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	24	29
n [2]	13	10
LS Mean (SE)	21.8 (6.08)	8.8 (6.78)
95% C.I.	(9.8, 33.7)	(-4.5, 22.2)
LS Mean Change from Baseline (SE)	8.7 (6.08)	-4.3 (6.78)
95% C.I.	(-3.3, 20.6)	(-17.6, 9.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	13.0 (9.13)	
95% C.I.	(-5.0, 30.9)	
p-value	0.15632	
Corrected Hedges' g	0.58	
95% C.I.	(-0.27, 1.42)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	24	29
n [2]	10	9
LS Mean (SE)	19.1 (6.81)	3.6 (7.09)
95% C.I.	(5.7, 32.5)	(-10.3, 17.6)
LS Mean Change from Baseline (SE)	6.0 (6.81)	-9.5 (7.09)
95% C.I.	(-7.4, 19.4)	(-23.4, 4.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.4 (9.86)	
95% C.I.	(-3.9, 34.8)	
p-value	0.11789	
Corrected Hedges' g	0.69	
95% C.I.	(-0.24, 1.62)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	24	29
n [2]	8	11
LS Mean (SE)	20.5 (7.41)	13.4 (6.55)
95% C.I.	(5.9, 35.0)	(0.6, 26.3)
LS Mean Change from Baseline (SE)	7.4 (7.41)	0.3 (6.55)
95% C.I.	(-7.2, 21.9)	(-12.5, 13.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.0 (9.89)	
95% C.I.	(-12.4, 26.5)	
p-value	0.47819	
Corrected Hedges' g	0.31	
95% C.I.	(-0.60, 1.23)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	24	29
n [2]	10	9
LS Mean (SE)	20.0 (6.99)	7.9 (7.33)
95% C.I.	(6.3, 33.8)	(-6.5, 22.3)
LS Mean Change from Baseline (SE)	6.9 (6.99)	-5.2 (7.33)
95% C.I.	(-6.8, 20.7)	(-19.6, 9.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.2 (10.32)	
95% C.I.	(-8.1, 32.4)	
p-value	0.23881	
Corrected Hedges' g	0.53	
95% C.I.	(-0.39, 1.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	24	29
n [2]	10	6
LS Mean (SE)	23.2 (6.97)	10.8 (8.74)
95% C.I.	(9.5, 36.9)	(-6.3, 28.0)
LS Mean Change from Baseline (SE)	10.1 (6.97)	-2.3 (8.74)
95% C.I.	(-3.6, 23.8)	(-19.4, 14.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.3 (11.35)	
95% C.I.	(-10.0, 34.6)	
p-value	0.27814	
Corrected Hedges' g	0.53	
95% C.I.	(-0.49, 1.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	24	29
n [2]	9	6
LS Mean (SE)	21.6 (7.56)	5.0 (8.93)
95% C.I.	(6.8, 36.5)	(-12.5, 22.6)
LS Mean Change from Baseline (SE)	8.5 (7.56)	-8.1 (8.93)
95% C.I.	(-6.3, 23.4)	(-25.6, 9.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	16.6 (12.01)	
95% C.I.	(-7.0, 40.2)	
p-value	0.16739	
Corrected Hedges' g	0.70	
95% C.I.	(-0.36, 1.76)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	24	29
n [2]	8	7
LS Mean (SE)	22.2 (7.85)	7.9 (8.49)
95% C.I.	(6.8, 37.6)	(-8.8, 24.6)
LS Mean Change from Baseline (SE)	9.1 (7.85)	-5.2 (8.49)
95% C.I.	(-6.3, 24.5)	(-21.9, 11.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.4 (11.87)	
95% C.I.	(-9.0, 37.7)	
p-value	0.22753	
Corrected Hedges' g	0.61	
95% C.I.	(-0.43, 1.64)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	24	29
n [2]	9	6
LS Mean (SE)	14.8 (7.47)	8.9 (8.88)
95% C.I.	(0.1, 29.5)	(-8.6, 26.3)
LS Mean Change from Baseline (SE)	1.7 (7.47)	-4.2 (8.88)
95% C.I.	(-13.0, 16.4)	(-21.7, 13.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.9 (11.79)	
95% C.I.	(-17.3, 29.1)	
p-value	0.61630	
Corrected Hedges' g	0.25	
95% C.I.	(-0.79, 1.29)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	11.6 (8.69)	4.0 (8.83)
95% C.I.	(-5.5, 28.7)	(-13.4, 21.3)
LS Mean Change from Baseline (SE)	-1.5 (8.69)	-9.2 (8.83)
95% C.I.	(-18.6, 15.6)	(-26.5, 8.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.6 (12.41)	
95% C.I.	(-16.7, 32.0)	
p-value	0.53822	
Corrected Hedges' g	0.33	
95% C.I.	(-0.81, 1.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	27.5 (8.87)	2.3 (10.20)
95% C.I.	(10.1, 45.0)	(-17.7, 22.4)
LS Mean Change from Baseline (SE)	14.4 (8.87)	-10.8 (10.20)
95% C.I.	(-3.0, 31.9)	(-30.8, 9.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	25.2 (13.80)	
95% C.I.	(-1.9, 52.3)	
p-value	0.06864	
Corrected Hedges' g	1.04	
95% C.I.	(-0.23, 2.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	24	29
n [2]	7	6
LS Mean (SE)	28.5 (8.35)	2.0 (9.80)
95% C.I.	(12.0, 44.9)	(-17.2, 21.3)
LS Mean Change from Baseline (SE)	15.3 (8.35)	-11.1 (9.80)
95% C.I.	(-1.1, 31.8)	(-30.3, 8.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	26.4 (13.01)	
95% C.I.	(0.8, 52.0)	
p-value	0.04298	
Corrected Hedges' g	1.07	
95% C.I.	(-0.10, 2.23)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	17.6 (8.83)	2.0 (10.59)
95% C.I.	(0.3, 35.0)	(-18.8, 22.9)
LS Mean Change from Baseline (SE)	4.5 (8.83)	-11.1 (10.59)
95% C.I.	(-12.8, 21.9)	(-31.9, 9.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	15.6 (14.09)	
95% C.I.	(-12.1, 43.3)	
p-value	0.26929	
Corrected Hedges' g	0.63	
95% C.I.	(-0.58, 1.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	24	29
n [2]	7	5
LS Mean (SE)	18.7 (8.33)	2.2 (10.76)
95% C.I.	(2.3, 35.1)	(-19.0, 23.3)
LS Mean Change from Baseline (SE)	5.6 (8.33)	-11.0 (10.76)
95% C.I.	(-10.8, 22.0)	(-32.1, 10.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	16.6 (13.74)	
95% C.I.	(-10.4, 43.6)	
p-value	0.22861	
Corrected Hedges' g	0.67	
95% C.I.	(-0.51, 1.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	19.7 (8.73)	2.9 (10.72)
95% C.I.	(2.5, 36.9)	(-18.2, 23.9)
LS Mean Change from Baseline (SE)	6.6 (8.73)	-10.2 (10.72)
95% C.I.	(-10.6, 23.8)	(-31.3, 10.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	16.8 (14.13)	
95% C.I.	(-10.9, 44.6)	
p-value	0.23430	
Corrected Hedges' g	0.68	
95% C.I.	(-0.54, 1.90)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	16.6 (9.10)	12.5 (9.01)
95% C.I.	(-1.3, 34.5)	(-5.3, 30.2)
LS Mean Change from Baseline (SE)	3.5 (9.10)	-0.6 (9.01)
95% C.I.	(-14.4, 21.4)	(-18.4, 17.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.1 (12.69)	
95% C.I.	(-20.8, 29.1)	
p-value	0.74481	
Corrected Hedges' g	0.17	
95% C.I.	(-0.96, 1.31)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	24	29
n [2]	5	5
LS Mean (SE)	21.4 (10.26)	3.2 (12.34)
95% C.I.	(1.2, 41.5)	(-21.0, 27.5)
LS Mean Change from Baseline (SE)	8.3 (10.26)	-9.9 (12.34)
95% C.I.	(-11.9, 28.4)	(-34.1, 14.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	18.2 (14.22)	
95% C.I.	(-9.8, 46.1)	
p-value	0.20240	
Corrected Hedges' g	0.65	
95% C.I.	(-0.63, 1.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	24	29
n [2]	6	6
LS Mean (SE)	19.4 (9.07)	14.3 (10.11)
95% C.I.	(1.6, 37.2)	(-5.6, 34.2)
LS Mean Change from Baseline (SE)	6.3 (9.07)	1.2 (10.11)
95% C.I.	(-11.5, 24.1)	(-18.7, 21.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.1 (13.99)	
95% C.I.	(-22.4, 32.6)	
p-value	0.71446	
Corrected Hedges' g	0.20	
95% C.I.	(-0.93, 1.34)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	24	29
n [2]	6	5
LS Mean (SE)	19.8 (9.10)	7.5 (10.74)
95% C.I.	(1.9, 37.7)	(-13.6, 28.7)
LS Mean Change from Baseline (SE)	6.7 (9.10)	-5.6 (10.74)
95% C.I.	(-11.2, 24.6)	(-26.7, 15.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.3 (14.48)	
95% C.I.	(-16.2, 40.7)	
p-value	0.39786	
Corrected Hedges' g	0.49	
95% C.I.	(-0.72, 1.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	24	29
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	24	29
n [2]	4	5

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	24	29
n [2]	5	5
LS Mean (SE)	9.9 (9.71)	12.0 (10.95)
95% C.I.	(-9.2, 28.9)	(-9.5, 33.5)
LS Mean Change from Baseline (SE)	-3.2 (9.71)	-1.1 (10.95)
95% C.I.	(-22.3, 15.8)	(-22.6, 20.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.1 (14.74)	
95% C.I.	(-31.1, 26.9)	
p-value	0.88460	
Corrected Hedges' g	-0.08	
95% C.I.	(-1.32, 1.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	24	29
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	24	29
n [2]	3	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	24	29
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	24	29
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	24	29
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	24	29
n [2]	4	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	24	29
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	24	29
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	24	29
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	24	29
n [2]	4	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	24	29
n [2]	2	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	24	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	24	29
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	24	29
n [2]	0	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	24	29
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	24	29
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	24	29
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	23	28
LS Mean (SE)	9.5 (4.36)	15.5 (3.94)
95% C.I.	(0.9, 18.0)	(7.7, 23.2)
LS Mean Change from Baseline (SE)	-4.7 (4.36)	1.3 (3.94)
95% C.I.	(-13.3, 3.8)	(-6.5, 9.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.0 (5.91)	
95% C.I.	(-17.6, 5.6)	
p-value	0.31059	
Corrected Hedges' g	-0.28	
95% C.I.	(-0.84, 0.27)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	26
LS Mean (SE)	3.8 (4.32)	8.2 (4.05)
95% C.I.	(-4.7, 12.3)	(0.2, 16.1)
LS Mean Change from Baseline (SE)	-10.4 (4.32)	-6.0 (4.05)
95% C.I.	(-18.9, -1.9)	(-14.0, 1.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.4 (5.94)	
95% C.I.	(-16.1, 7.3)	
p-value	0.46124	
Corrected Hedges' g	-0.21	
95% C.I.	(-0.77, 0.35)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	26
LS Mean (SE)	4.3 (4.40)	12.7 (4.05)
95% C.I.	(-4.4, 12.9)	(4.7, 20.7)
LS Mean Change from Baseline (SE)	-9.9 (4.40)	-1.5 (4.05)
95% C.I.	(-18.5, -1.2)	(-9.4, 6.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.4 (5.98)	
95% C.I.	(-20.2, 3.3)	
p-value	0.16049	
Corrected Hedges' g	-0.40	
95% C.I.	(-0.97, 0.17)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	25
LS Mean (SE)	10.6 (4.49)	16.6 (4.14)
95% C.I.	(1.8, 19.4)	(8.5, 24.7)
LS Mean Change from Baseline (SE)	-3.6 (4.49)	2.4 (4.14)
95% C.I.	(-12.4, 5.3)	(-5.7, 10.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.0 (6.11)	
95% C.I.	(-18.0, 6.0)	
p-value	0.32648	
Corrected Hedges' g	-0.29	
95% C.I.	(-0.87, 0.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	16	19
LS Mean (SE)	6.6 (5.00)	11.2 (4.58)
95% C.I.	(-3.2, 16.4)	(2.2, 20.2)
LS Mean Change from Baseline (SE)	-7.6 (5.00)	-2.9 (4.58)
95% C.I.	(-17.4, 2.2)	(-11.9, 6.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.6 (6.78)	
95% C.I.	(-18.0, 8.7)	
p-value	0.49355	
Corrected Hedges' g	-0.23	
95% C.I.	(-0.89, 0.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	30
n [2]	16	16
LS Mean (SE)	16.8 (5.08)	14.1 (4.96)
95% C.I.	(6.8, 26.8)	(4.4, 23.9)
LS Mean Change from Baseline (SE)	2.6 (5.08)	0.0 (4.96)
95% C.I.	(-7.4, 12.6)	(-9.8, 9.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.6 (7.09)	
95% C.I.	(-11.3, 16.6)	
p-value	0.71119	
Corrected Hedges' g	0.13	
95% C.I.	(-0.57, 0.82)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	14	17
LS Mean (SE)	12.8 (5.33)	11.2 (4.99)
95% C.I.	(2.3, 23.2)	(1.4, 21.0)
LS Mean Change from Baseline (SE)	-1.4 (5.33)	-3.0 (4.99)
95% C.I.	(-11.9, 9.1)	(-12.8, 6.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.6 (7.31)	
95% C.I.	(-12.8, 15.9)	
p-value	0.83150	
Corrected Hedges' g	0.07	
95% C.I.	(-0.63, 0.78)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	30
n [2]	15	12
LS Mean (SE)	13.1 (5.30)	9.8 (5.75)
95% C.I.	(2.7, 23.6)	(-1.5, 21.1)
LS Mean Change from Baseline (SE)	-1.0 (5.30)	-4.4 (5.75)
95% C.I.	(-11.4, 9.4)	(-15.7, 6.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.3 (7.86)	
95% C.I.	(-12.1, 18.8)	
p-value	0.67203	
Corrected Hedges' g	0.16	
95% C.I.	(-0.60, 0.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	10.8 (5.60)	15.4 (6.49)
95% C.I.	(-0.2, 21.8)	(2.6, 28.1)
LS Mean Change from Baseline (SE)	-3.3 (5.60)	1.2 (6.49)
95% C.I.	(-14.3, 7.7)	(-11.5, 14.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.5 (8.59)	
95% C.I.	(-21.4, 12.3)	
p-value	0.59660	
Corrected Hedges' g	-0.22	
95% C.I.	(-1.07, 0.63)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	30
n [2]	13	12
LS Mean (SE)	14.8 (5.64)	12.2 (5.95)
95% C.I.	(3.8, 25.9)	(0.5, 23.9)
LS Mean Change from Baseline (SE)	0.7 (5.64)	-1.9 (5.95)
95% C.I.	(-10.4, 11.8)	(-13.6, 9.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.6 (8.21)	
95% C.I.	(-13.5, 18.7)	
p-value	0.75064	
Corrected Hedges' g	0.12	
95% C.I.	(-0.66, 0.91)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	13	10
LS Mean (SE)	7.7 (5.67)	8.4 (6.41)
95% C.I.	(-3.4, 18.9)	(-4.2, 21.0)
LS Mean Change from Baseline (SE)	-6.5 (5.67)	-5.8 (6.41)
95% C.I.	(-17.6, 4.7)	(-18.4, 6.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.7 (8.56)	
95% C.I.	(-17.5, 16.1)	
p-value	0.93696	
Corrected Hedges' g	-0.03	
95% C.I.	(-0.86, 0.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	4.3 (6.13)	20.6 (6.70)
95% C.I.	(-7.8, 16.3)	(7.5, 33.8)
LS Mean Change from Baseline (SE)	-9.9 (6.13)	6.5 (6.70)
95% C.I.	(-21.9, 2.2)	(-6.7, 19.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-16.3 (9.07)	
95% C.I.	(-34.2, 1.5)	
p-value	0.07214	
Corrected Hedges' g	-0.77	
95% C.I.	(-1.69, 0.14)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	9	11
LS Mean (SE)	5.4 (6.61)	12.1 (6.23)
95% C.I.	(-7.6, 18.4)	(-0.2, 24.3)
LS Mean Change from Baseline (SE)	-8.8 (6.61)	-2.1 (6.23)
95% C.I.	(-21.7, 4.2)	(-14.4, 10.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.6 (9.08)	
95% C.I.	(-24.5, 11.2)	
p-value	0.46487	
Corrected Hedges' g	-0.31	
95% C.I.	(-1.20, 0.57)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	8.3 (6.24)	15.1 (6.75)
95% C.I.	(-3.9, 20.6)	(1.9, 28.4)
LS Mean Change from Baseline (SE)	-5.8 (6.24)	1.0 (6.75)
95% C.I.	(-18.1, 6.4)	(-12.3, 14.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.8 (9.20)	
95% C.I.	(-24.9, 11.3)	
p-value	0.45945	
Corrected Hedges' g	-0.32	
95% C.I.	(-1.20, 0.57)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	5.3 (6.40)	20.4 (8.13)
95% C.I.	(-7.2, 17.9)	(4.4, 36.4)
LS Mean Change from Baseline (SE)	-8.9 (6.40)	6.2 (8.13)
95% C.I.	(-21.4, 3.7)	(-9.7, 22.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.1 (10.32)	
95% C.I.	(-35.4, 5.2)	
p-value	0.14444	
Corrected Hedges' g	-0.71	
95% C.I.	(-1.75, 0.33)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	2.3 (6.46)	9.7 (8.35)
95% C.I.	(-10.4, 15.0)	(-6.7, 26.2)
LS Mean Change from Baseline (SE)	-11.9 (6.46)	-4.4 (8.35)
95% C.I.	(-24.6, 0.8)	(-20.9, 12.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.4 (10.57)	
95% C.I.	(-28.2, 13.3)	
p-value	0.48316	
Corrected Hedges' g	-0.34	
95% C.I.	(-1.36, 0.68)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	9	7
LS Mean (SE)	7.2 (6.73)	16.8 (8.00)
95% C.I.	(-6.1, 20.4)	(1.1, 32.5)
LS Mean Change from Baseline (SE)	-7.0 (6.73)	2.6 (8.00)
95% C.I.	(-20.2, 6.2)	(-13.1, 18.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-9.7 (10.42)	
95% C.I.	(-30.1, 10.8)	
p-value	0.35493	
Corrected Hedges' g	-0.44	
95% C.I.	(-1.44, 0.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	5.3 (6.57)	18.2 (8.27)
95% C.I.	(-7.6, 18.2)	(1.9, 34.4)
LS Mean Change from Baseline (SE)	-8.9 (6.57)	4.0 (8.27)
95% C.I.	(-21.8, 4.1)	(-12.2, 20.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.9 (10.52)	
95% C.I.	(-33.5, 7.8)	
p-value	0.22190	
Corrected Hedges' g	-0.59	
95% C.I.	(-1.62, 0.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	9.5 (7.58)	22.6 (8.37)
95% C.I.	(-5.4, 24.4)	(6.2, 39.1)
LS Mean Change from Baseline (SE)	-4.7 (7.58)	8.5 (8.37)
95% C.I.	(-19.6, 10.2)	(-8.0, 24.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-13.2 (11.29)	
95% C.I.	(-35.4, 9.0)	
p-value	0.24387	
Corrected Hedges' g	-0.60	
95% C.I.	(-1.72, 0.51)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	-0.7 (7.73)	17.9 (8.84)
95% C.I.	(-15.9, 14.5)	(0.5, 35.2)
LS Mean Change from Baseline (SE)	-14.9 (7.73)	3.7 (8.84)
95% C.I.	(-30.0, 0.3)	(-13.7, 21.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-18.5 (11.74)	
95% C.I.	(-41.6, 4.6)	
p-value	0.11537	
Corrected Hedges' g	-0.85	
95% C.I.	(-2.04, 0.35)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	12.7 (7.42)	2.0 (8.33)
95% C.I.	(-1.9, 27.3)	(-14.4, 18.4)
LS Mean Change from Baseline (SE)	-1.5 (7.42)	-12.2 (8.33)
95% C.I.	(-16.1, 13.1)	(-28.6, 4.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.7 (11.12)	
95% C.I.	(-11.1, 32.6)	
p-value	0.33565	
Corrected Hedges' g	0.48	
95% C.I.	(-0.59, 1.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	-0.1 (7.72)	12.6 (9.03)
95% C.I.	(-15.3, 15.1)	(-5.1, 30.4)
LS Mean Change from Baseline (SE)	-14.3 (7.72)	-1.6 (9.03)
95% C.I.	(-29.4, 0.9)	(-19.3, 16.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-12.7 (11.88)	
95% C.I.	(-36.1, 10.6)	
p-value	0.28522	
Corrected Hedges' g	-0.58	
95% C.I.	(-1.75, 0.59)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	1.4 (7.41)	19.3 (9.24)
95% C.I.	(-13.1, 16.0)	(1.1, 37.5)
LS Mean Change from Baseline (SE)	-12.8 (7.41)	5.1 (9.24)
95% C.I.	(-27.3, 1.8)	(-13.0, 23.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-17.9 (11.84)	
95% C.I.	(-41.2, 5.4)	
p-value	0.13145	
Corrected Hedges' g	-0.80	
95% C.I.	(-1.96, 0.36)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	7.0 (7.65)	5.7 (9.15)
95% C.I.	(-8.0, 22.1)	(-12.3, 23.7)
LS Mean Change from Baseline (SE)	-7.1 (7.65)	-8.5 (9.15)
95% C.I.	(-22.2, 7.9)	(-26.5, 9.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.4 (11.95)	
95% C.I.	(-22.1, 24.8)	
p-value	0.90974	
Corrected Hedges' g	0.06	
95% C.I.	(-1.09, 1.21)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	19.4 (7.80)	18.9 (8.55)
95% C.I.	(4.0, 34.7)	(2.1, 35.7)
LS Mean Change from Baseline (SE)	5.2 (7.80)	4.8 (8.55)
95% C.I.	(-10.1, 20.5)	(-12.1, 21.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.4 (11.66)	
95% C.I.	(-22.5, 23.3)	
p-value	0.97094	
Corrected Hedges' g	0.02	
95% C.I.	(-1.07, 1.11)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	11.1 (8.29)	12.3 (9.00)
95% C.I.	(-5.2, 27.4)	(-5.4, 30.0)
LS Mean Change from Baseline (SE)	-3.0 (8.29)	-1.9 (9.00)
95% C.I.	(-19.3, 13.2)	(-19.5, 15.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.2 (12.23)	
95% C.I.	(-25.2, 22.9)	
p-value	0.92286	
Corrected Hedges' g	-0.05	
95% C.I.	(-1.24, 1.13)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	10.8 (7.89)	5.1 (8.56)
95% C.I.	(-4.7, 26.3)	(-11.7, 22.0)
LS Mean Change from Baseline (SE)	-3.4 (7.89)	-9.0 (8.56)
95% C.I.	(-18.9, 12.1)	(-25.9, 7.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.6 (11.64)	
95% C.I.	(-17.2, 28.5)	
p-value	0.62806	
Corrected Hedges' g	0.25	
95% C.I.	(-0.84, 1.35)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	11.6 (8.33)	12.4 (9.17)
95% C.I.	(-4.8, 28.0)	(-5.7, 30.4)
LS Mean Change from Baseline (SE)	-2.6 (8.33)	-1.8 (9.17)
95% C.I.	(-18.9, 13.8)	(-19.8, 16.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.7 (12.41)	
95% C.I.	(-25.1, 23.6)	
p-value	0.95249	
Corrected Hedges' g	-0.03	
95% C.I.	(-1.22, 1.15)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	1.7 (8.42)	12.9 (10.18)
95% C.I.	(-14.9, 18.2)	(-7.1, 32.9)
LS Mean Change from Baseline (SE)	-12.5 (8.42)	-1.3 (10.18)
95% C.I.	(-29.1, 4.0)	(-21.3, 18.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.3 (13.34)	
95% C.I.	(-37.5, 14.9)	
p-value	0.39889	
Corrected Hedges' g	-0.50	
95% C.I.	(-1.78, 0.79)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	-0.3 (9.14)	6.7 (9.36)
95% C.I.	(-18.2, 17.7)	(-11.7, 25.1)
LS Mean Change from Baseline (SE)	-14.4 (9.14)	-7.5 (9.36)
95% C.I.	(-32.4, 3.5)	(-25.9, 10.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.9 (13.12)	
95% C.I.	(-32.7, 18.9)	
p-value	0.59802	
Corrected Hedges' g	-0.30	
95% C.I.	(-1.55, 0.94)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	5.9 (8.90)	13.4 (9.37)
95% C.I.	(-11.6, 23.4)	(-5.0, 31.9)
LS Mean Change from Baseline (SE)	-8.3 (8.90)	-0.8 (9.37)
95% C.I.	(-25.7, 9.2)	(-19.2, 17.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.5 (12.92)	
95% C.I.	(-32.9, 17.9)	
p-value	0.56201	
Corrected Hedges' g	-0.33	
95% C.I.	(-1.58, 0.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	21.9 (8.45)	15.2 (10.24)
95% C.I.	(5.3, 38.5)	(-4.9, 35.3)
LS Mean Change from Baseline (SE)	7.8 (8.45)	1.0 (10.24)
95% C.I.	(-8.8, 24.4)	(-19.1, 21.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.7 (13.22)	
95% C.I.	(-19.2, 32.7)	
p-value	0.61052	
Corrected Hedges' g	0.30	
95% C.I.	(-0.98, 1.57)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Diarrhea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	24	30
n [2]	23	28
LS Mean (SE)	9.5 (3.80)	17.3 (3.46)
95% C.I.	(2.0, 17.0)	(10.5, 24.1)
LS Mean Change from Baseline (SE)	-8.2 (3.80)	-0.4 (3.46)
95% C.I.	(-15.7, -0.7)	(-7.2, 6.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.8 (5.14)	
95% C.I.	(-17.9, 2.3)	
p-value	0.12920	
Corrected Hedges' g	-0.42	
95% C.I.	(-0.98, 0.14)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	24	30
n [2]	22	26
LS Mean (SE)	8.0 (3.83)	12.8 (3.50)
95% C.I.	(0.5, 15.6)	(5.9, 19.7)
LS Mean Change from Baseline (SE)	-9.7 (3.83)	-4.9 (3.50)
95% C.I.	(-17.2, -2.1)	(-11.8, 2.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.8 (5.19)	
95% C.I.	(-15.0, 5.4)	
p-value	0.35766	
Corrected Hedges' g	-0.26	
95% C.I.	(-0.83, 0.31)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	24	30
n [2]	21	26
LS Mean (SE)	7.9 (3.90)	15.9 (3.53)
95% C.I.	(0.2, 15.5)	(8.9, 22.8)
LS Mean Change from Baseline (SE)	-9.9 (3.90)	-1.9 (3.53)
95% C.I.	(-17.5, -2.2)	(-8.8, 5.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.0 (5.27)	
95% C.I.	(-18.4, 2.4)	
p-value	0.13004	
Corrected Hedges' g	-0.44	
95% C.I.	(-1.02, 0.14)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	24	30
n [2]	20	25
LS Mean (SE)	13.7 (3.97)	19.1 (3.58)
95% C.I.	(5.9, 21.6)	(12.0, 26.1)
LS Mean Change from Baseline (SE)	-4.0 (3.97)	1.4 (3.58)
95% C.I.	(-11.8, 3.8)	(-5.7, 8.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.4 (5.34)	
95% C.I.	(-15.9, 5.2)	
p-value	0.31685	
Corrected Hedges' g	-0.29	
95% C.I.	(-0.89, 0.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	24	30
n [2]	16	19
LS Mean (SE)	9.6 (4.25)	16.1 (3.87)
95% C.I.	(1.3, 18.0)	(8.5, 23.7)
LS Mean Change from Baseline (SE)	-8.1 (4.25)	-1.6 (3.87)
95% C.I.	(-16.5, 0.3)	(-9.2, 6.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.5 (5.74)	
95% C.I.	(-17.8, 4.8)	
p-value	0.25720	
Corrected Hedges' g	-0.38	
95% C.I.	(-1.05, 0.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	24	30
n [2]	17	16
LS Mean (SE)	15.1 (4.27)	17.3 (4.14)
95% C.I.	(6.7, 23.5)	(9.1, 25.4)
LS Mean Change from Baseline (SE)	-2.6 (4.27)	-0.4 (4.14)
95% C.I.	(-11.0, 5.8)	(-8.6, 7.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.2 (5.94)	
95% C.I.	(-13.8, 9.5)	
p-value	0.71539	
Corrected Hedges' g	-0.12	
95% C.I.	(-0.81, 0.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	24	30
n [2]	14	17
LS Mean (SE)	17.6 (4.51)	19.5 (4.24)
95% C.I.	(8.8, 26.5)	(11.2, 27.9)
LS Mean Change from Baseline (SE)	-0.1 (4.51)	1.8 (4.24)
95% C.I.	(-8.9, 8.8)	(-6.5, 10.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.9 (6.15)	
95% C.I.	(-14.0, 10.2)	
p-value	0.75748	
Corrected Hedges' g	-0.11	
95% C.I.	(-0.82, 0.60)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	24	30
n [2]	15	12
LS Mean (SE)	18.4 (4.49)	17.6 (4.75)
95% C.I.	(9.5, 27.2)	(8.3, 26.9)
LS Mean Change from Baseline (SE)	0.7 (4.49)	-0.1 (4.75)
95% C.I.	(-8.2, 9.5)	(-9.4, 9.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.8 (6.52)	
95% C.I.	(-12.1, 13.6)	
p-value	0.90582	
Corrected Hedges' g	0.04	
95% C.I.	(-0.72, 0.80)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	24	30
n [2]	13	9
LS Mean (SE)	8.4 (4.72)	16.9 (5.27)
95% C.I.	(-0.8, 17.7)	(6.5, 27.2)
LS Mean Change from Baseline (SE)	-9.3 (4.72)	-0.8 (5.27)
95% C.I.	(-18.6, 0.0)	(-11.2, 9.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-8.5 (7.05)	
95% C.I.	(-22.3, 5.4)	
p-value	0.23095	
Corrected Hedges' g	-0.49	
95% C.I.	(-1.35, 0.37)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	24	30
n [2]	13	12
LS Mean (SE)	13.6 (4.78)	14.1 (5.04)
95% C.I.	(4.2, 23.0)	(4.2, 24.0)
LS Mean Change from Baseline (SE)	-4.1 (4.78)	-3.6 (5.04)
95% C.I.	(-13.5, 5.3)	(-13.5, 6.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.5 (6.94)	
95% C.I.	(-14.2, 13.1)	
p-value	0.93867	
Corrected Hedges' g	-0.03	
95% C.I.	(-0.81, 0.75)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	24	30
n [2]	14	10
LS Mean (SE)	19.8 (4.79)	16.7 (5.39)
95% C.I.	(10.3, 29.2)	(6.1, 27.3)
LS Mean Change from Baseline (SE)	2.1 (4.79)	-1.0 (5.39)
95% C.I.	(-7.4, 11.5)	(-11.6, 9.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.1 (7.21)	
95% C.I.	(-11.1, 17.3)	
p-value	0.66672	
Corrected Hedges' g	0.17	
95% C.I.	(-0.64, 0.98)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	24	30
n [2]	11	8
LS Mean (SE)	14.2 (5.15)	21.1 (5.74)
95% C.I.	(4.1, 24.4)	(9.8, 32.4)
LS Mean Change from Baseline (SE)	-3.5 (5.15)	3.4 (5.74)
95% C.I.	(-13.6, 6.6)	(-7.9, 14.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.9 (7.71)	
95% C.I.	(-22.0, 8.3)	
p-value	0.37434	
Corrected Hedges' g	-0.39	
95% C.I.	(-1.31, 0.53)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	24	30
n [2]	9	11
LS Mean (SE)	17.8 (5.50)	22.2 (5.32)
95% C.I.	(6.9, 28.6)	(11.7, 32.7)
LS Mean Change from Baseline (SE)	0.0 (5.50)	4.5 (5.32)
95% C.I.	(-10.8, 10.8)	(-6.0, 15.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-4.5 (7.65)	
95% C.I.	(-19.5, 10.6)	
p-value	0.55952	
Corrected Hedges' g	-0.25	
95% C.I.	(-1.13, 0.63)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	24	30
n [2]	11	9
LS Mean (SE)	17.3 (5.31)	23.1 (5.71)
95% C.I.	(6.8, 27.7)	(11.9, 34.3)
LS Mean Change from Baseline (SE)	-0.4 (5.31)	5.4 (5.71)
95% C.I.	(-10.9, 10.0)	(-5.8, 16.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.8 (7.79)	
95% C.I.	(-21.2, 9.5)	
p-value	0.45379	
Corrected Hedges' g	-0.32	
95% C.I.	(-1.21, 0.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	24	30
n [2]	11	6
LS Mean (SE)	13.8 (5.30)	11.8 (6.77)
95% C.I.	(3.4, 24.2)	(-1.5, 25.1)
LS Mean Change from Baseline (SE)	-3.9 (5.30)	-5.9 (6.77)
95% C.I.	(-14.3, 6.5)	(-19.2, 7.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.0 (8.58)	
95% C.I.	(-14.9, 18.8)	
p-value	0.81821	
Corrected Hedges' g	0.11	
95% C.I.	(-0.89, 1.10)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	24	30
n [2]	10	6
LS Mean (SE)	8.3 (5.49)	23.6 (7.04)
95% C.I.	(-2.5, 19.1)	(9.7, 37.4)
LS Mean Change from Baseline (SE)	-9.4 (5.49)	5.9 (7.04)
95% C.I.	(-20.2, 1.4)	(-8.0, 19.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-15.3 (8.89)	
95% C.I.	(-32.8, 2.2)	
p-value	0.08692	
Corrected Hedges' g	-0.83	
95% C.I.	(-1.89, 0.22)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	24	30
n [2]	9	7
LS Mean (SE)	15.0 (5.67)	15.2 (6.79)
95% C.I.	(3.8, 26.1)	(1.8, 28.6)
LS Mean Change from Baseline (SE)	-2.7 (5.67)	-2.5 (6.79)
95% C.I.	(-13.9, 8.4)	(-15.9, 10.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.2 (8.85)	
95% C.I.	(-17.6, 17.2)	
p-value	0.97985	
Corrected Hedges' g	-0.01	
95% C.I.	(-1.00, 0.98)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	24	30
n [2]	10	6
LS Mean (SE)	14.8 (5.63)	21.3 (7.04)
95% C.I.	(3.7, 25.8)	(7.5, 35.1)
LS Mean Change from Baseline (SE)	-2.9 (5.63)	3.6 (7.04)
95% C.I.	(-14.0, 8.1)	(-10.3, 17.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-6.5 (9.03)	
95% C.I.	(-24.3, 11.3)	
p-value	0.47130	
Corrected Hedges' g	-0.35	
95% C.I.	(-1.37, 0.67)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	24	30
n [2]	7	6
LS Mean (SE)	6.6 (6.33)	12.4 (7.05)
95% C.I.	(-5.9, 19.0)	(-1.5, 26.2)
LS Mean Change from Baseline (SE)	-11.2 (6.33)	-5.3 (7.05)
95% C.I.	(-23.6, 1.3)	(-19.2, 8.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.8 (9.47)	
95% C.I.	(-24.5, 12.8)	
p-value	0.53790	
Corrected Hedges' g	-0.32	
95% C.I.	(-1.42, 0.78)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	24	30
n [2]	7	5
LS Mean (SE)	11.6 (6.54)	11.9 (7.37)
95% C.I.	(-1.3, 24.4)	(-2.6, 26.4)
LS Mean Change from Baseline (SE)	-6.2 (6.54)	-5.8 (7.37)
95% C.I.	(-19.0, 6.7)	(-20.3, 8.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.3 (9.84)	
95% C.I.	(-19.7, 19.0)	
p-value	0.97219	
Corrected Hedges' g	-0.02	
95% C.I.	(-1.17, 1.13)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	24	30
n [2]	8	6
LS Mean (SE)	12.2 (6.41)	-2.0 (7.08)
95% C.I.	(-0.4, 24.8)	(-16.0, 11.9)
LS Mean Change from Baseline (SE)	-5.5 (6.41)	-19.7 (7.08)
95% C.I.	(-18.2, 7.1)	(-33.7, -5.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.2 (9.57)	
95% C.I.	(-4.6, 33.0)	
p-value	0.13899	
Corrected Hedges' g	0.75	
95% C.I.	(-0.35, 1.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	24	30
n [2]	7	5
LS Mean (SE)	12.1 (6.60)	10.7 (7.66)
95% C.I.	(-0.9, 25.1)	(-4.4, 25.8)
LS Mean Change from Baseline (SE)	-5.6 (6.60)	-7.0 (7.66)
95% C.I.	(-18.6, 7.4)	(-22.1, 8.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.4 (10.11)	
95% C.I.	(-18.5, 21.3)	
p-value	0.88916	
Corrected Hedges' g	0.08	
95% C.I.	(-1.07, 1.22)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	24	30
n [2]	8	5
LS Mean (SE)	13.0 (6.41)	13.2 (7.91)
95% C.I.	(0.4, 25.6)	(-2.3, 28.8)
LS Mean Change from Baseline (SE)	-4.7 (6.41)	-4.5 (7.91)
95% C.I.	(-17.3, 7.9)	(-20.0, 11.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.2 (10.20)	
95% C.I.	(-20.3, 19.9)	
p-value	0.98303	
Corrected Hedges' g	-0.01	
95% C.I.	(-1.13, 1.11)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	24	30
n [2]	7	5
LS Mean (SE)	13.7 (6.51)	13.1 (7.83)
95% C.I.	(0.9, 26.5)	(-2.3, 28.5)
LS Mean Change from Baseline (SE)	-4.0 (6.51)	-4.6 (7.83)
95% C.I.	(-16.8, 8.8)	(-20.0, 10.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.6 (10.19)	
95% C.I.	(-19.5, 20.6)	
p-value	0.95416	
Corrected Hedges' g	0.03	
95% C.I.	(-1.12, 1.18)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	24	30
n [2]	7	6
LS Mean (SE)	2.8 (6.58)	21.8 (7.39)
95% C.I.	(-10.2, 15.7)	(7.3, 36.3)
LS Mean Change from Baseline (SE)	-14.9 (6.58)	4.1 (7.39)
95% C.I.	(-27.9, -2.0)	(-10.4, 18.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-19.0 (9.92)	
95% C.I.	(-38.6, 0.5)	
p-value	0.05601	
Corrected Hedges' g	-1.00	
95% C.I.	(-2.16, 0.16)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	19.7 (6.93)	15.0 (7.66)
95% C.I.	(6.0, 33.3)	(0.0, 30.1)
LS Mean Change from Baseline (SE)	2.0 (6.93)	-2.7 (7.66)
95% C.I.	(-11.7, 15.6)	(-17.7, 12.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.6 (10.34)	
95% C.I.	(-15.7, 25.0)	
p-value	0.65379	
Corrected Hedges' g	0.25	
95% C.I.	(-0.94, 1.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	24	30
n [2]	7	6
LS Mean (SE)	13.6 (6.83)	24.0 (7.42)
95% C.I.	(0.2, 27.1)	(9.4, 38.6)
LS Mean Change from Baseline (SE)	-4.1 (6.83)	6.2 (7.42)
95% C.I.	(-17.5, 9.4)	(-8.4, 20.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-10.3 (10.07)	
95% C.I.	(-30.1, 9.5)	
p-value	0.30608	
Corrected Hedges' g	-0.53	
95% C.I.	(-1.64, 0.58)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	24	30
n [2]	7	5
LS Mean (SE)	13.5 (6.89)	15.8 (7.93)
95% C.I.	(-0.1, 27.1)	(0.2, 31.5)
LS Mean Change from Baseline (SE)	-4.2 (6.89)	-1.9 (7.93)
95% C.I.	(-17.8, 9.4)	(-17.5, 13.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.3 (10.49)	
95% C.I.	(-23.0, 18.3)	
p-value	0.82343	
Corrected Hedges' g	-0.12	
95% C.I.	(-1.27, 1.03)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	24	30
n [2]	6	4
LS Mean (SE)	13.0 (7.15)	24.5 (8.52)
95% C.I.	(-1.1, 27.0)	(7.7, 41.2)
LS Mean Change from Baseline (SE)	-4.8 (7.15)	6.8 (8.52)
95% C.I.	(-18.8, 9.3)	(-10.0, 23.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.5 (11.07)	
95% C.I.	(-33.3, 10.2)	
p-value	0.29790	
Corrected Hedges' g	-0.60	
95% C.I.	(-1.89, 0.69)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	24	30
n [2]	4	5

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	24	30
n [2]	6	5
LS Mean (SE)	19.7 (7.48)	14.8 (8.37)
95% C.I.	(5.0, 34.5)	(-1.7, 31.2)
LS Mean Change from Baseline (SE)	2.0 (7.48)	-3.0 (8.37)
95% C.I.	(-12.7, 16.7)	(-19.4, 13.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.0 (11.51)	
95% C.I.	(-17.7, 27.6)	
p-value	0.66493	
Corrected Hedges' g	0.25	
95% C.I.	(-0.94, 1.44)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	24	30
n [2]	6	4
LS Mean (SE)	16.9 (7.27)	15.7 (9.05)
95% C.I.	(2.6, 31.2)	(-2.1, 33.5)
LS Mean Change from Baseline (SE)	-0.8 (7.27)	-2.0 (9.05)
95% C.I.	(-15.1, 13.5)	(-19.8, 15.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.2 (11.49)	
95% C.I.	(-21.4, 23.8)	
p-value	0.91781	
Corrected Hedges' g	0.06	
95% C.I.	(-1.21, 1.33)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	24	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	24	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	24	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	24	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	24	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	24	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	24	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	24	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	24	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	24	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	24	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	24	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	24	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	24	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	24	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	24	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	24	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

Table 4.0001205

Analysis of EORTC QLQ-C30 Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Financial Difficulties

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	24	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An Autoregressive (AR(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_c30_mmrm_2ref.sas 09OCT2025 09:08

1.3.1.3 EORTC-IL52

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	26	32
		Mean	29.15	27.53
		SD	22.082	22.198
		Median	27.78	27.78
		Min.	0.0	0.0
		Max.	88.9	88.9

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	19.33	21.26
		SD	19.186	24.128
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	66.7	94.4
	Change from Baseline	n	24	28
		Mean	-10.28	-8.85
		SD	16.899	19.421
		Median	-9.44	-8.33
		Min.	-44.4	-50.0
		Max.	33.3	47.8
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	18 (75%)	16 (57%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	12 (50%)	14 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	3 (13%)	4 (14%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	3 (13%)	3 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 3 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	Actual Score	n	24	25
		Mean	16.44	15.33
		SD	16.091	21.293
		Median	11.11	5.56
		Min.	0.0	0.0
		Max.	61.1	77.8
	Change from Baseline	n	23	25
		Mean	-12.90	-12.98
		SD	15.533	17.704
		Median	-11.11	-11.11
		Min.	-50.0	-50.0
		Max.	22.2	25.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	17 (74%)	17 (68%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	14 (61%)	14 (56%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (9%)	2 (8%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (4%)	2 (8%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 4 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	26
		Mean	17.63	16.45
		SD	17.136	20.993
		Median	16.67	8.33
		Min.	0.0	0.0
		Max.	66.7	88.9
	Change from Baseline	n	22	26
		Mean	-12.98	-12.48
		SD	18.220	16.307
		Median	-11.11	-11.11
		Min.	-50.0	-44.4
		Max.	33.3	27.8
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	16 (73%)	16 (62%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	14 (64%)	15 (58%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	4 (18%)	2 (8%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	2 (9%)	1 (4%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 5 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	Actual Score	n	22	24
		Mean	24.49	21.06
		SD	14.715	19.104
		Median	30.56	16.67
		Min.	0.0	0.0
		Max.	50.0	66.7
	Change from Baseline	n	21	24
		Mean	-1.69	-7.27
		SD	21.495	17.663
		Median	-5.56	-11.11
		Min.	-44.4	-33.3
		Max.	33.3	44.4
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	11 (52%)	15 (63%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	7 (33%)	13 (54%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	8 (38%)	5 (21%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	5 (24%)	4 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	17	19
		Mean	18.63	13.74
		SD	17.888	21.940
		Median	11.11	5.56
		Min.	0.0	0.0
		Max.	77.8	83.3
	Change from Baseline	n	16	19
		Mean	-4.17	-14.74
		SD	17.743	22.638
		Median	-5.56	-11.11
		Min.	-33.3	-66.7
		Max.	33.3	36.7
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	10 (63%)	13 (68%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	7 (44%)	13 (68%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	5 (31%)	2 (11%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	4 (25%)	2 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 7 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	Actual Score	n	18	16
		Mean	22.53	18.40
		SD	19.570	22.746
		Median	19.44	16.67
		Min.	0.0	0.0
		Max.	77.8	83.3
	Change from Baseline	n	17	16
		Mean	-4.90	-12.29
		SD	21.950	22.827
		Median	-11.11	-11.11
		Min.	-55.6	-66.7
		Max.	33.3	36.7
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	9 (53%)	9 (56%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	9 (53%)	9 (56%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	7 (41%)	2 (13%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	5 (29%)	1 (6%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	15	17
		Mean	18.89	18.95
		SD	13.576	15.348
		Median	22.22	22.22
		Min.	0.0	0.0
		Max.	55.6	50.0
	Change from Baseline	n	14	17
		Mean	-2.38	-7.84
		SD	16.265	18.432
		Median	-2.78	0.00
		Min.	-27.8	-44.4
		Max.	22.2	22.2
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	7 (50%)	8 (47%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	6 (43%)	7 (41%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	5 (36%)	4 (24%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	4 (29%)	3 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 9 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	Actual Score	n	16	12
		Mean	20.83	12.96
		SD	15.248	13.260
		Median	19.44	11.11
		Min.	0.0	0.0
		Max.	50.0	38.9
	Change from Baseline	n	15	12
		Mean	-4.44	-11.57
		SD	21.124	20.983
		Median	-5.56	0.00
		Min.	-38.9	-55.6
		Max.	33.3	11.1
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	8 (53%)	5 (42%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	6 (40%)	5 (42%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	4 (27%)	3 (25%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	3 (20%)	2 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 10 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	14	9
		Mean	19.05	12.35
		SD	16.410	11.034
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	61.1	27.8
	Change from Baseline	n	13	9
		Mean	-8.97	-15.43
		SD	17.204	20.746
		Median	0.00	-5.56
		Min.	-50.0	-61.1
		Max.	11.1	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	6 (46%)	5 (56%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	5 (38%)	4 (44%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	3 (23%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (8%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 11 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	Actual Score	n	13	12
		Mean	18.38	14.26
		SD	14.939	14.212
		Median	16.67	11.11
		Min.	0.0	0.0
		Max.	50.0	50.0
	Change from Baseline	n	12	12
		Mean	-12.04	-14.91
		SD	19.074	18.168
		Median	-13.89	-11.11
		Min.	-50.0	-55.6
		Max.	16.7	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	9 (75%)	7 (58%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	8 (67%)	7 (58%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	3 (25%)	1 (8%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	2 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	15	10
		Mean	18.15	11.67
		SD	14.917	11.843
		Median	16.67	11.11
		Min.	0.0	0.0
		Max.	55.6	33.3
	Change from Baseline	n	14	10
		Mean	-7.54	-13.89
		SD	16.824	19.816
		Median	-5.56	-16.67
		Min.	-33.3	-55.6
		Max.	16.7	16.7
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	9 (64%)	6 (60%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	6 (43%)	6 (60%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	4 (29%)	1 (10%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	3 (21%)	1 (10%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 13 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	Actual Score	n	11	9
		Mean	21.21	12.35
		SD	18.562	12.037
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	66.7	27.8
	Change from Baseline	n	11	9
		Mean	-10.10	-16.05
		SD	16.633	18.519
		Median	-11.11	-16.67
		Min.	-33.3	-44.4
		Max.	16.7	11.1
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	6 (55%)	6 (67%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	6 (55%)	5 (56%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	3 (27%)	1 (11%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (9%)	1 (11%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	9	11
		Mean	23.46	16.87
		SD	16.846	12.831
		Median	22.22	16.67
		Min.	0.0	0.0
		Max.	55.6	38.9
	Change from Baseline	n	9	11
		Mean	-6.79	-13.94
		SD	13.545	21.496
		Median	-5.56	-16.67
		Min.	-27.8	-47.8
		Max.	11.1	16.7
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (56%)	6 (55%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (44%)	6 (55%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	3 (33%)	2 (18%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (11%)	2 (18%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 15 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	Actual Score	n	11	9
		Mean	27.78	14.20
		SD	23.174	15.243
		Median	22.22	11.11
		Min.	0.0	0.0
		Max.	77.8	38.9
	Change from Baseline	n	11	9
		Mean	1.01	-4.94
		SD	17.359	20.307
		Median	0.00	0.00
		Min.	-27.8	-44.4
		Max.	33.3	27.8
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (45%)	4 (44%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (27%)	3 (33%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	5 (45%)	2 (22%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	3 (27%)	2 (22%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	6
		Mean	20.20	10.19
		SD	19.448	10.194
		Median	22.22	8.33
		Min.	0.0	0.0
		Max.	55.6	22.2
	Change from Baseline	n	11	6
		Mean	-6.06	-16.67
		SD	11.237	16.480
		Median	-5.56	-19.44
		Min.	-27.8	-33.3
		Max.	11.1	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	6 (55%)	4 (67%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (36%)	4 (67%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (18%)	1 (17%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (9%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	Actual Score	n	11	6
		Mean	20.20	12.96
		SD	11.725	11.476
		Median	22.22	13.89
		Min.	0.0	0.0
		Max.	33.3	27.8
	Change from Baseline	n	10	6
		Mean	-8.33	-13.89
		SD	19.988	13.494
		Median	-11.11	-8.33
		Min.	-27.8	-33.3
		Max.	22.2	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (50%)	5 (83%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	5 (50%)	3 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (20%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	2 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 18 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	9	7
		Mean	17.90	8.73
		SD	12.662	8.399
		Median	16.67	11.11
		Min.	0.0	0.0
		Max.	33.3	16.7
	Change from Baseline	n	9	7
		Mean	-7.41	-14.29
		SD	18.426	15.335
		Median	0.00	-11.11
		Min.	-33.3	-33.3
		Max.	16.7	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (44%)	4 (57%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (44%)	4 (57%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	3 (33%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	2 (22%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	Actual Score	n	10	6
		Mean	15.56	12.96
		SD	11.944	11.476
		Median	13.89	13.89
		Min.	0.0	0.0
		Max.	33.3	27.8
	Change from Baseline	n	10	6
		Mean	-8.89	-13.89
		SD	13.907	16.759
		Median	-5.56	-16.67
		Min.	-27.8	-33.3
		Max.	11.1	11.1
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (50%)	4 (67%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	5 (50%)	4 (67%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (20%)	1 (17%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (10%)	1 (17%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	7	6
		Mean	20.63	8.33
		SD	15.946	9.782
		Median	22.22	5.56
		Min.	0.0	0.0
		Max.	38.9	22.2
	Change from Baseline	n	7	6
		Mean	-7.14	-25.93
		SD	20.213	20.688
		Median	-11.11	-22.22
		Min.	-27.8	-61.1
		Max.	33.3	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (71%)	5 (83%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (57%)	5 (83%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 21 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	Actual Score	n	7	5
		Mean	20.00	11.11
		SD	16.777	11.111
		Median	16.67	11.11
		Min.	0.0	0.0
		Max.	50.0	22.2
	Change from Baseline	n	7	5
		Mean	-7.78	-17.78
		SD	20.628	15.416
		Median	-11.11	-16.67
		Min.	-27.8	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (71%)	4 (80%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (57%)	3 (60%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (14%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 22 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	17.36	3.70
		SD	12.751	9.072
		Median	19.44	0.00
		Min.	0.0	0.0
		Max.	33.3	22.2
	Change from Baseline	n	8	6
		Mean	-9.03	-12.96
		SD	22.603	15.181
		Median	-13.89	-8.33
		Min.	-27.8	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (50%)	3 (50%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (50%)	3 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (25%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	Actual Score	n	8	5
		Mean	15.28	12.22
		SD	14.164	14.907
		Median	19.44	5.56
		Min.	0.0	0.0
		Max.	38.9	33.3
	Change from Baseline	n	7	5
		Mean	-13.49	-16.67
		SD	11.501	19.642
		Median	-16.67	-16.67
		Min.	-27.8	-38.9
		Max.	0.0	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (71%)	3 (60%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (57%)	3 (60%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	1 (20%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	8	5
		Mean	15.28	7.78
		SD	10.179	10.830
		Median	13.89	0.00
		Min.	0.0	0.0
		Max.	27.8	22.2
	Change from Baseline	n	8	5
		Mean	-11.11	-21.11
		SD	18.545	17.743
		Median	-11.11	-16.67
		Min.	-33.3	-44.4
		Max.	16.7	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	6 (75%)	4 (80%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (50%)	4 (80%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (25%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	2 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 25 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	Actual Score	n	8	5
		Mean	16.67	10.00
		SD	12.244	9.129
		Median	19.44	5.56
		Min.	0.0	0.0
		Max.	33.3	22.2
	Change from Baseline	n	7	5
		Mean	-14.29	-18.89
		SD	21.956	17.830
		Median	-16.67	-16.67
		Min.	-33.3	-38.9
		Max.	33.3	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	6 (86%)	4 (80%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	6 (86%)	4 (80%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (14%)	1 (20%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	8	6
		Mean	14.58	17.59
		SD	11.855	21.204
		Median	16.67	11.11
		Min.	0.0	0.0
		Max.	33.3	50.0
	Change from Baseline	n	8	6
		Mean	-11.11	-16.67
		SD	21.207	19.245
		Median	-16.67	-13.89
		Min.	-33.3	-44.4
		Max.	33.3	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	6 (75%)	4 (67%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	5 (63%)	4 (67%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (13%)	1 (17%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (13%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	Actual Score	n	6	5
		Mean	17.59	10.00
		SD	12.870	11.386
		Median	19.44	5.56
		Min.	0.0	0.0
		Max.	33.3	22.2
	Change from Baseline	n	6	5
		Mean	-7.41	-18.89
		SD	23.483	16.942
		Median	-13.89	-16.67
		Min.	-27.8	-38.9
		Max.	33.3	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (67%)	4 (80%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (67%)	3 (60%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	7	6
		Mean	19.84	9.26
		SD	12.773	12.505
		Median	22.22	2.78
		Min.	0.0	0.0
		Max.	33.3	27.8
	Change from Baseline	n	7	6
		Mean	-7.94	-14.81
		SD	21.482	17.801
		Median	-16.67	-8.33
		Min.	-27.8	-38.9
		Max.	33.3	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (71%)	3 (50%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (57%)	3 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (29%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	Actual Score	n	8	5
		Mean	23.61	14.44
		SD	21.771	13.380
		Median	22.22	11.11
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	5
		Mean	-2.38	-14.44
		SD	33.465	17.830
		Median	-11.11	-16.67
		Min.	-33.3	-38.9
		Max.	66.7	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (57%)	3 (60%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (57%)	3 (60%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (29%)	1 (20%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (14%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 30 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	14.81	12.50
		SD	13.907	14.611
		Median	13.89	11.11
		Min.	0.0	0.0
		Max.	33.3	27.8
	Change from Baseline	n	6	4
		Mean	-17.59	-15.28
		SD	13.796	20.972
		Median	-19.44	-8.33
		Min.	-33.3	-44.4
		Max.	0.0	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	5 (83%)	2 (50%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (67%)	2 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 31 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	Actual Score	n	5	5
		Mean	13.33	11.78
		SD	12.790	10.932
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	27.8	22.2
	Change from Baseline	n	5	5
		Mean	-14.44	-17.11
		SD	10.092	16.788
		Median	-16.67	-16.67
		Min.	-27.8	-44.4
		Max.	0.0	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (80%)	4 (80%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	4 (80%)	3 (60%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	7	5
		Mean	22.22	15.56
		SD	14.344	14.380
		Median	27.78	11.11
		Min.	0.0	0.0
		Max.	38.9	33.3
	Change from Baseline	n	6	5
		Mean	-1.85	-13.33
		SD	20.387	17.830
		Median	-5.56	-11.11
		Min.	-27.8	-38.9
		Max.	33.3	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (67%)	3 (60%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	2 (33%)	3 (60%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (33%)	1 (20%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 33 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	Actual Score	n	6	4
		Mean	22.22	16.67
		SD	20.787	19.245
		Median	19.44	16.67
		Min.	0.0	0.0
		Max.	55.6	33.3
	Change from Baseline	n	6	4
		Mean	-10.19	-9.72
		SD	14.664	23.296
		Median	-5.56	0.00
		Min.	-27.8	-44.4
		Max.	5.6	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	3 (50%)	1 (25%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (50%)	1 (25%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (17%)	1 (25%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 34 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	4	4
		Mean	20.83	8.33
		SD	10.516	9.623
		Median	25.00	8.33
		Min.	5.6	0.0
		Max.	27.8	16.7
	Change from Baseline	n	4	4
		Mean	-6.94	-18.06
		SD	11.453	18.908
		Median	-8.33	-13.89
		Min.	-16.7	-44.4
		Max.	5.6	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	2 (50%)	3 (75%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	2 (50%)	3 (75%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 35 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	Actual Score	n	5	3
		Mean	16.67	16.67
		SD	13.608	16.667
		Median	22.22	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	3
		Mean	-11.11	-3.70
		SD	12.423	11.565
		Median	-11.11	0.00
		Min.	-27.8	-16.7
		Max.	5.6	5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (80%)	1 (33%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (60%)	1 (33%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (20%)	1 (33%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	2
		Mean	26.85	27.78
		SD	16.260	23.570
		Median	27.78	27.78
		Min.	0.0	11.1
		Max.	50.0	44.4
	Change from Baseline	n	6	2
		Mean	-5.56	-2.78
		SD	20.184	27.499
		Median	-8.33	-2.78
		Min.	-27.8	-22.2
		Max.	27.8	16.7
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (67%)	1 (50%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (50%)	1 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (33%)	1 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (17%)	1 (50%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 37 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	Actual Score	n	5	3
		Mean	13.33	12.96
		SD	12.172	13.981
		Median	22.22	11.11
		Min.	0.0	0.0
		Max.	22.2	27.8
	Change from Baseline	n	5	3
		Mean	-14.44	-12.96
		SD	11.520	17.859
		Median	-16.67	-5.56
		Min.	-27.8	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (80%)	2 (67%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (60%)	1 (33%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	24.07	8.33
		SD	20.082	11.785
		Median	25.00	8.33
		Min.	0.0	0.0
		Max.	55.6	16.7
	Change from Baseline	n	5	2
		Mean	-10.00	-8.33
		SD	14.907	11.785
		Median	-16.67	-8.33
		Min.	-27.8	-16.7
		Max.	5.6	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	3 (60%)	1 (50%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (60%)	1 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (40%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	Actual Score	n	4	2
		Mean	27.78	2.78
		SD	6.415	3.928
		Median	27.78	2.78
		Min.	22.2	0.0
		Max.	33.3	5.6
	Change from Baseline	n	4	2
		Mean	0.00	-13.89
		SD	22.680	19.642
		Median	-8.33	-13.89
		Min.	-16.7	-27.8
		Max.	33.3	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	3 (75%)	1 (50%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	2 (50%)	1 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (25%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (25%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 40 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	22.22	11.11
		SD	10.393	19.245
		Median	22.22	0.00
		Min.	5.6	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	3
		Mean	-5.56	-14.81
		SD	22.567	25.660
		Median	-16.67	0.00
		Min.	-22.2	-44.4
		Max.	33.3	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (80%)	1 (33%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (60%)	1 (33%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (20%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (20%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 41 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	Actual Score	n	6	1
		Mean	22.22	16.67
		SD	16.102	
		Median	27.78	16.67
		Min.	0.0	16.7
		Max.	38.9	16.7
	Change from Baseline	n	6	1
		Mean	-0.93	-16.67
		SD	19.694	
		Median	-2.78	-16.67
		Min.	-22.2	-16.7
		Max.	33.3	-16.7
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	3 (50%)	1 (100%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	2 (33%)	1 (100%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	2 (33%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (17%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 42 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	5	2
		Mean	13.33	2.78
		SD	9.296	3.928
		Median	11.11	2.78
		Min.	0.0	0.0
		Max.	22.2	5.6
	Change from Baseline	n	5	2
		Mean	-14.44	-13.89
		SD	11.520	19.642
		Median	-16.67	-13.89
		Min.	-27.8	-27.8
		Max.	0.0	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (80%)	1 (50%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (60%)	1 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 43 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	Actual Score	n	6	1
		Mean	21.30	22.22
		SD	22.338	
		Median	22.22	22.22
		Min.	0.0	22.2
		Max.	61.1	22.2
	Change from Baseline	n	6	1
		Mean	-11.11	-11.11
		SD	13.147	
		Median	-11.11	-11.11
		Min.	-27.8	-11.1
		Max.	5.6	-11.1
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (67%)	1 (100%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (50%)	1 (100%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (17%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	5	1
		Mean	20.00	22.22
		SD	18.675	
		Median	27.78	22.22
		Min.	0.0	22.2
		Max.	38.9	22.2
	Change from Baseline	n	5	1
		Mean	-7.78	-11.11
		SD	12.172	
		Median	0.00	-11.11
		Min.	-27.8	-11.1
		Max.	0.0	-11.1
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	2 (40%)	1 (100%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	2 (40%)	1 (100%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 45 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	Actual Score	n	3	2
		Mean	16.67	16.67
		SD	16.667	23.570
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	3	2
		Mean	-16.67	0.00
		SD	9.623	0.000
		Median	-11.11	0.00
		Min.	-27.8	0.0
		Max.	-11.1	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	3 (100%)	0
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (100%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	1
		Mean	14.81	33.33
		SD	13.981	
		Median	16.67	33.33
		Min.	0.0	33.3
		Max.	27.8	33.3
	Change from Baseline	n	3	1
		Mean	-18.52	0.00
		SD	8.486	
		Median	-16.67	0.00
		Min.	-27.8	0.0
		Max.	-11.1	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	3 (100%)	0
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (100%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	Actual Score	n	3	1
		Mean	29.63	33.33
		SD	3.208	
		Median	27.78	33.33
		Min.	27.8	33.3
		Max.	33.3	33.3
	Change from Baseline	n	3	1
		Mean	-7.41	0.00
		SD	6.415	
		Median	-11.11	0.00
		Min.	-11.1	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	2 (67%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	1	2
		Mean	22.22	13.89
		SD		19.642
		Median	22.22	13.89
		Min.	22.2	0.0
		Max.	22.2	27.8
	Change from Baseline	n	1	2
		Mean	-5.56	-2.78
		SD		3.928
		Median	-5.56	-2.78
		Min.	-5.6	-5.6
		Max.	-5.6	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	1 (100%)	1 (50%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	Actual Score	n	2	1
		Mean	36.11	33.33
		SD	19.642	
		Median	36.11	33.33
		Min.	22.2	33.3
		Max.	50.0	33.3
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	7.857	
		Median	0.00	0.00
		Min.	-5.6	0.0
		Max.	5.6	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 50 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	1	1
		Mean	38.89	33.33
		SD		
		Median	38.89	33.33
		Min.	38.9	33.3
		Max.	38.9	33.3
	Change from Baseline	n	1	1
		Mean	11.11	0.00
		SD		
		Median	11.11	0.00
		Min.	11.1	0.0
		Max.	11.1	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	1 (100%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	1 (100%)	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 51 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	Actual Score	n	2	1
		Mean	25.00	33.33
		SD	3.928	
		Median	25.00	33.33
		Min.	22.2	33.3
		Max.	27.8	33.3
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	3.928	
		Median	-8.33	0.00
		Min.	-11.1	0.0
		Max.	-5.6	0.0
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	1 (50%)	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 52 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		5.56
		SD		
		Median		5.56
		Min.		5.6
		Max.		5.6
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	0

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 53 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		16.67
		SD		
		Median		16.67
		Min.		16.7
		Max.		16.7
	Change from Baseline	n	0	1
		Mean		16.67
		SD		
		Median		16.67
		Min.		16.7
		Max.		16.7
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	0	0
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	0	1 (100%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	0	1 (100%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 54 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	21
		Mean	34.57	23.28
		SD	17.830	21.845
		Median	33.33	27.78
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	18	21
		Mean	2.04	-0.85
		SD	23.258	20.509
		Median	-1.11	0.00
		Min.	-27.8	-44.4
		Max.	66.7	44.4
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	9 (50%)	7 (33%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	5 (28%)	7 (33%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	8 (44%)	7 (33%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	5 (28%)	7 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 55 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	9	9
		Mean	29.63	25.31
		SD	20.601	21.357
		Median	27.78	33.33
		Min.	0.0	0.0
		Max.	61.1	50.0
	Change from Baseline	n	8	9
		Mean	-0.69	1.85
		SD	19.345	20.787
		Median	-2.78	5.56
		Min.	-27.8	-44.4
		Max.	33.3	27.8
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	4 (50%)	2 (22%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	3 (38%)	2 (22%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	3 (38%)	5 (56%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	2 (25%)	3 (33%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 56 of 56
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003805
Summary of Change in EORTC QLQ-IL52 Score from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	38.46	34.95
		SD	20.057	22.825
		Median	36.11	33.33
		Min.	0.0	0.0
		Max.	77.8	94.4
	Change from Baseline	n	25	30
		Mean	8.80	5.63
		SD	20.745	19.333
		Median	5.56	2.78
		Min.	-22.2	-33.3
		Max.	66.7	47.8
	Improvement in EORTC QLQ-IL52 domain score >=5	n (%)	6 (24%)	8 (27%)
	Improvement in EORTC QLQ-IL52 domain score >=10	n (%)	5 (20%)	8 (27%)
	Deterioration in EORTC QLQ-IL52 domain score >=5	n (%)	15 (60%)	15 (50%)
	Deterioration in EORTC QLQ-IL52 domain score >=10	n (%)	11 (44%)	13 (43%)

Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_t1_il52_dom_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003905
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	11 (37%)	13 (39%)
Censored, follow-up ended	15 (50%)	15 (45%)
Censored, follow-up ongoing	4 (13%)	5 (15%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.8 (1.0, 11.5)	4.7 (1.1, 10.2)
Median (95% CI)	15.8 (4.8, -)	32.3 (6.3, -)
3rd Quartile (95% CI)	- (15.8, -)	49.0 (32.3, -)
Log-Rank P-value [2]	0.75543	
Hazard Ratio (95% CI) [3]	1.14 (0.50, 2.58)	
P-value [3]	0.75543	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlqil52_ttd_2ref.sas 09OCT2025 10:21

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003915
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	3 (27%)	4 (57%)
	Censored, follow-up ended	7 (64%)	3 (43%)
	Censored, follow-up ongoing	1 (9%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	11.5 (1.0, -)	3.7 (2.1, -)
	Median (95% CI)	- (1.0, -)	19.3 (2.1, -)
	3rd Quartile (95% CI)	- (11.5, -)	32.3 (3.7, -)
	Log-Rank P-value [2]	0.47252	
	Hazard Ratio (95% CI) [3]	0.58 (0.13, 2.61)	
	P-value [3]	0.47782	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_age.sas 09OCT2025 10:21

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003915
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	7 (47%)	6 (40%)
	Censored, follow-up ended	6 (40%)	6 (40%)
	Censored, follow-up ongoing	2 (13%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.3 (1.0, 6.6)	6.9 (0.7, 10.2)
	Median (95% CI)	6.6 (3.6, -)	10.2 (3.8, -)
	3rd Quartile (95% CI)	- (5.6, -)	- (7.9, -)
	Log-Rank P-value [2]	0.67208	
	Hazard Ratio (95% CI) [3]	1.27 (0.42, 3.78)	
	P-value [3]	0.67272	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_age.sas 09OCT2025 10:21

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003915
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	1 (25%)	3 (27%)
	Censored, follow-up ended	2 (50%)	6 (55%)
	Censored, follow-up ongoing	1 (25%)	2 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.1, -)	49.0 (1.1, -)
	Median (95% CI)	- (1.1, -)	49.0 (1.1, -)
	3rd Quartile (95% CI)	- (1.1, -)	49.0 (-, -)
	Log-Rank P-value [2]	0.69835	
	Hazard Ratio (95% CI) [3]	1.65 (0.15, 18.17)	
	P-value [3]	0.68454	
Interaction Test	P-value [4]	0.65843	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_age.sas 09OCT2025 10:21

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003925
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	7 (44%)
	Censored, follow-up ended	6 (46%)	7 (44%)
	Censored, follow-up ongoing	1 (8%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.6 (1.1, 6.6)	4.7 (1.0, 6.9)
	Median (95% CI)	6.6 (2.8, -)	6.9 (3.8, -)
	3rd Quartile (95% CI)	- (5.6, -)	49.0 (6.3, -)
	Log-Rank P-value [2]	0.70260	
	Hazard Ratio (95% CI) [3]	1.25 (0.40, 3.87)	
	P-value [3]	0.70341	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_gen.sas 09OCT2025 10:21

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003925
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	5 (29%)	6 (35%)
	Censored, follow-up ended	9 (53%)	8 (47%)
	Censored, follow-up ongoing	3 (18%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	11.5 (1.0, -)	7.9 (0.7, 32.3)
	Median (95% CI)	15.8 (3.8, -)	32.3 (3.7, -)
	3rd Quartile (95% CI)	- (15.8, -)	- (32.3, -)
	Log-Rank P-value [2]	0.84480	
	Hazard Ratio (95% CI) [3]	0.89 (0.27, 2.91)	
	P-value [3]	0.84489	
Interaction Test	P-value [4]	0.66941	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_gen.sas 09OCT2025 10:21

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003935
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	6 (30%)	10 (42%)
	Censored, follow-up ended	12 (60%)	11 (46%)
	Censored, follow-up ongoing	2 (10%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.6 (1.0, -)	4.7 (1.0, 7.9)
	Median (95% CI)	- (2.8, -)	7.9 (4.7, -)
	3rd Quartile (95% CI)	- (4.8, -)	49.0 (7.9, -)
	Log-Rank P-value [2]	0.64745	
	Hazard Ratio (95% CI) [3]	1.27 (0.45, 3.60)	
	P-value [3]	0.64773	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_reg.sas 09OCT2025 10:22

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003935
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	5 (50%)	3 (33%)
	Censored, follow-up ended	3 (30%)	4 (44%)
	Censored, follow-up ongoing	2 (20%)	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.6 (1.1, 15.8)	5.6 (0.7, -)
	Median (95% CI)	15.8 (1.1, -)	- (0.7, -)
	3rd Quartile (95% CI)	- (11.5, -)	- (10.2, -)
	Log-Rank P-value [2]	0.76601	
	Hazard Ratio (95% CI) [3]	1.24 (0.30, 5.18)	
	P-value [3]	0.77115	
Interaction Test	P-value [4]	0.95671	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_reg.sas 09OCT2025 10:22

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003945
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	6 (33%)	9 (60%)
	Censored, follow-up ended	8 (44%)	4 (27%)
	Censored, follow-up ongoing	4 (22%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.6 (1.0, -)	4.7 (1.1, 10.2)
	Median (95% CI)	- (5.6, -)	10.2 (3.7, -)
	3rd Quartile (95% CI)	- (-, -)	32.3 (7.9, -)
	Log-Rank P-value [2]	0.42958	
	Hazard Ratio (95% CI) [3]	0.66 (0.23, 1.89)	
	P-value [3]	0.43452	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_iss.sas 09OCT2025 10:22

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003945
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	5 (42%)	4 (22%)
	Censored, follow-up ended	7 (58%)	11 (61%)
	Censored, follow-up ongoing	0	3 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.6 (1.0, 4.8)	6.9 (0.7, -)
	Median (95% CI)	4.8 (1.0, -)	- (3.8, -)
	3rd Quartile (95% CI)	15.8 (3.6, -)	- (-, -)
	Log-Rank P-value [2]	0.12975	
	Hazard Ratio (95% CI) [3]	2.68 (0.71, 10.11)	
	P-value [3]	0.14583	
Interaction Test	P-value [4]	0.09141	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_iss.sas 09OCT2025 10:22

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003955
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	2 (25%)	3 (50%)
	Censored, follow-up ended	5 (63%)	1 (17%)
	Censored, follow-up ongoing	1 (13%)	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.8 (1.1, -)	7.9 (3.8, -)
	Median (95% CI)	- (1.1, -)	10.2 (3.8, -)
	3rd Quartile (95% CI)	- (-, -)	- (7.9, -)
	Log-Rank P-value [2]	0.55640	
	Hazard Ratio (95% CI) [3]	0.59 (0.10, 3.53)	
	P-value [3]	0.56098	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_line.sas 09OCT2025 10:23

Table 4.0003955
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	7 (54%)	6 (43%)
	Censored, follow-up ended	5 (38%)	8 (57%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.2 (1.0, 6.6)	2.1 (0.7, 32.3)
	Median (95% CI)	6.6 (1.0, -)	32.3 (1.1, -)
	3rd Quartile (95% CI)	- (5.6, -)	49.0 (32.3, -)
	Log-Rank P-value [2]	0.47535	
	Hazard Ratio (95% CI) [3]	1.52 (0.48, 4.88)	
	P-value [3]	0.47838	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_line.sas 09OCT2025 10:23

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003955
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	4 (31%)
	Censored, follow-up ended	5 (56%)	6 (46%)
	Censored, follow-up ongoing	2 (22%)	3 (23%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	15.8 (3.8, -)	6.3 (1.0, -)
	Median (95% CI)	15.8 (3.8, -)	- (3.7, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (6.9, -)
	Log-Rank P-value [2]	0.91382	
	Hazard Ratio (95% CI) [3]	0.91 (0.16, 5.08)	
	P-value [3]	0.91385	
Interaction Test	P-value [4]	0.58552	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_line.sas 09OCT2025 10:23

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003975
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	9 (43%)	9 (45%)
	Censored, follow-up ended	10 (48%)	9 (45%)
	Censored, follow-up ongoing	2 (10%)	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.6 (1.0, 6.6)	4.7 (0.7, 10.2)
	Median (95% CI)	11.5 (3.6, -)	32.3 (3.8, -)
	3rd Quartile (95% CI)	- (11.5, -)	49.0 (10.2, -)
	Log-Rank P-value [2]	0.85462	
	Hazard Ratio (95% CI) [3]	1.09 (0.42, 2.84)	
	P-value [3]	0.85530	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_line2.sas 09OCT2025 10:22

Table 4.0003975
Summary of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	2 (22%)	4 (31%)
	Censored, follow-up ended	5 (56%)	6 (46%)
	Censored, follow-up ongoing	2 (22%)	3 (23%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	15.8 (3.8, -)	6.3 (1.0, -)
	Median (95% CI)	15.8 (3.8, -)	- (3.7, -)
	3rd Quartile (95% CI)	- (3.8, -)	- (6.9, -)
	Log-Rank P-value [2]	0.91382	
	Hazard Ratio (95% CI) [3]	0.91 (0.16, 5.08)	
	P-value [3]	0.91385	
Interaction Test	P-value [4]	0.90255	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_ttd_2ref_line2.sas 09OCT2025 10:22

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004005

Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	18 (60%)	20 (61%)
Censored, follow-up ended	9 (30%)	10 (30%)
Censored, follow-up ongoing	3 (10%)	3 (9%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.0 (0.9, 1.1)	1.0 (0.8, 1.1)
Median (95% CI)	1.8 (1.0, 2.8)	1.7 (1.0, 1.9)
3rd Quartile (95% CI)	- (1.9, -)	- (1.9, -)
Log-Rank P-value [2]	0.86473	
Inverse Hazard Ratio (95% CI) [3]	1.05 (0.56, 1.99)	
P-value [3]	0.87449	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_qlqil52_tti_2ref.sas 09OCT2025 10:22

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004015
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	9 (82%)	4 (57%)
	Censored, follow-up ended	2 (18%)	2 (29%)
	Censored, follow-up ongoing	0	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.2)	1.1 (0.7, 1.9)
	Median (95% CI)	1.1 (1.0, 2.0)	1.5 (0.7, -)
	3rd Quartile (95% CI)	2.0 (1.1, -)	- (1.1, -)
	Log-Rank P-value [2]	0.43454	
	Inverse Hazard Ratio (95% CI) [3]	0.62 (0.19, 2.03)	
	P-value [3]	0.42942	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_age.sas 09OCT2025 10:23

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004015
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	7 (47%)	9 (60%)
	Censored, follow-up ended	6 (40%)	5 (33%)
	Censored, follow-up ongoing	2 (13%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.8)	1.0 (0.7, 1.8)
	Median (95% CI)	1.8 (0.9, -)	1.8 (1.0, -)
	3rd Quartile (95% CI)	- (1.8, -)	- (1.8, -)
	Log-Rank P-value [2]	0.70885	
	Inverse Hazard Ratio (95% CI) [3]	1.19 (0.44, 3.21)	
	P-value [3]	0.72947	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_age.sas 09OCT2025 10:23

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004015
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	2 (50%)	7 (64%)
	Censored, follow-up ended	1 (25%)	3 (27%)
	Censored, follow-up ongoing	1 (25%)	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.0 (0.8, 1.1)
	Median (95% CI)	1.9 (1.0, -)	1.1 (0.8, -)
	3rd Quartile (95% CI)	- (1.0, -)	1.9 (1.0, -)
	Log-Rank P-value [2]	0.54754	
	Inverse Hazard Ratio (95% CI) [3]	1.54 (0.32, 7.49)	
	P-value [3]	0.59041	
Interaction Test	P-value [4]	0.65071	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_age.sas 09OCT2025 10:23

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004025
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	8 (62%)	10 (63%)
	Censored, follow-up ended	4 (31%)	5 (31%)
	Censored, follow-up ongoing	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.9)	1.0 (0.7, 1.2)
	Median (95% CI)	1.9 (1.0, -)	1.2 (1.0, 1.9)
	3rd Quartile (95% CI)	- (1.8, -)	1.9 (1.2, -)
	Log-Rank P-value [2]	0.51119	
	Inverse Hazard Ratio (95% CI) [3]	1.37 (0.54, 3.50)	
	P-value [3]	0.50428	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_gen.sas 09OCT2025 10:22

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004025
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	10 (59%)	10 (59%)
	Censored, follow-up ended	5 (29%)	5 (29%)
	Censored, follow-up ongoing	2 (12%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.1)	1.0 (0.7, 1.1)
	Median (95% CI)	1.1 (1.0, -)	1.7 (1.0, -)
	3rd Quartile (95% CI)	- (1.1, -)	- (1.7, -)
	Log-Rank P-value [2]	0.75029	
	Inverse Hazard Ratio (95% CI) [3]	0.87 (0.36, 2.08)	
	P-value [3]	0.75053	
Interaction Test	P-value [4]	0.51011	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_gen.sas 09OCT2025 10:22

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004035
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	10 (50%)	14 (58%)
	Censored, follow-up ended	8 (40%)	7 (29%)
	Censored, follow-up ongoing	2 (10%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.8)	1.1 (0.7, 1.2)
	Median (95% CI)	1.9 (1.0, -)	1.9 (1.1, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (1.9, -)
	Log-Rank P-value [2]	0.77622	
	Inverse Hazard Ratio (95% CI) [3]	1.13 (0.50, 2.55)	
	P-value [3]	0.76303	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_reg.sas 09OCT2025 10:23

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004035
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	8 (80%)	6 (67%)
	Censored, follow-up ended	1 (10%)	3 (33%)
	Censored, follow-up ongoing	1 (10%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.1)	1.0 (0.7, 1.0)
	Median (95% CI)	1.1 (0.9, 1.9)	1.0 (0.7, -)
	3rd Quartile (95% CI)	1.9 (1.0, -)	- (1.0, -)
	Log-Rank P-value [2]	0.83002	
	Inverse Hazard Ratio (95% CI) [3]	1.12 (0.39, 3.23)	
	P-value [3]	0.83551	
Interaction Test	P-value [4]	0.97973	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_reg.sas 09OCT2025 10:23

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004045
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	11 (61%)	9 (60%)
	Censored, follow-up ended	4 (22%)	3 (20%)
	Censored, follow-up ongoing	3 (17%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.9)	1.0 (0.7, 1.7)
	Median (95% CI)	1.9 (1.0, -)	1.9 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (1.7, -)
	Log-Rank P-value [2]	0.89008	
	Inverse Hazard Ratio (95% CI) [3]	0.93 (0.38, 2.24)	
	P-value [3]	0.86689	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_iss.sas 09OCT2025 10:23

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004045
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	7 (58%)	11 (61%)
	Censored, follow-up ended	5 (42%)	7 (39%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.2)	1.0 (0.7, 1.1)
	Median (95% CI)	1.2 (1.0, -)	1.1 (1.0, 1.9)
	3rd Quartile (95% CI)	2.8 (1.1, -)	1.9 (1.1, -)
	Log-Rank P-value [2]	0.76509	
	Inverse Hazard Ratio (95% CI) [3]	1.16 (0.45, 3.00)	
	P-value [3]	0.76609	
Interaction Test	P-value [4]	0.74878	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_iss.sas 09OCT2025 10:23

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004055
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	6 (75%)	5 (83%)
	Censored, follow-up ended	1 (13%)	0
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.9, 1.0)	1.0 (1.0, 1.1)
	Median (95% CI)	1.0 (0.9, 2.0)	1.1 (1.0, -)
	3rd Quartile (95% CI)	2.0 (1.0, -)	3.1 (1.0, -)
	Log-Rank P-value [2]	0.64857	
	Inverse Hazard Ratio (95% CI) [3]	0.74 (0.23, 2.45)	
	P-value [3]	0.62581	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_line.sas 09OCT2025 10:23

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004055
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	8 (62%)	5 (36%)
	Censored, follow-up ended	4 (31%)	7 (50%)
	Censored, follow-up ongoing	1 (8%)	2 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.5 (1.0, 1.9)	1.1 (0.8, -)
	Median (95% CI)	1.9 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (1.9, -)
	Log-Rank P-value [2]	0.53172	
	Inverse Hazard Ratio (95% CI) [3]	0.70 (0.23, 2.13)	
	P-value [3]	0.52656	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_line.sas 09OCT2025 10:23

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004055
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	10 (77%)
	Censored, follow-up ended	4 (44%)	3 (23%)
	Censored, follow-up ongoing	1 (11%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.1)	1.0 (0.7, 1.1)
	Median (95% CI)	1.1 (1.0, -)	1.1 (1.0, 1.9)
	3rd Quartile (95% CI)	- (1.0, -)	1.9 (1.1, -)
	Log-Rank P-value [2]	0.53451	
	Inverse Hazard Ratio (95% CI) [3]	1.44 (0.45, 4.62)	
	P-value [3]	0.53968	
Interaction Test	P-value [4]	0.52420	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_line.sas 09OCT2025 10:23

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004075
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2- Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	14 (67%)	10 (50%)
	Censored, follow-up ended	5 (24%)	7 (35%)
	Censored, follow-up ongoing	2 (10%)	3 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.8)	1.0 (0.8, 1.8)
	Median (95% CI)	1.9 (1.0, 2.8)	1.9 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (1.9, -)
	Log-Rank P-value [2]	0.50565	
	Inverse Hazard Ratio (95% CI) [3]	0.76 (0.34, 1.71)	
	P-value [3]	0.50640	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_line2.sas 09OCT2025 10:23

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004075
Summary of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2-
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	4 (44%)	10 (77%)
	Censored, follow-up ended	4 (44%)	3 (23%)
	Censored, follow-up ongoing	1 (11%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.1)	1.0 (0.7, 1.1)
	Median (95% CI)	1.1 (1.0, -)	1.1 (1.0, 1.9)
	3rd Quartile (95% CI)	- (1.0, -)	1.9 (1.1, -)
	Log-Rank P-value [2]	0.53451	
	Inverse Hazard Ratio (95% CI) [3]	1.44 (0.45, 4.62)	
	P-value [3]	0.53968	
Interaction Test	P-value [4]	0.28402	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_qlqil52_tti_2ref_line2.sas 09OCT2025 10:23

Protocol: 207499 Page 1 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	18.0 (3.47)	18.7 (3.18)
95% C.I.	(11.0, 24.9)	(12.3, 25.0)
LS Mean Change from Baseline (SE)	-9.7 (3.47)	-9.0 (3.18)
95% C.I.	(-16.6, -2.8)	(-15.3, -2.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.7 (4.70)	
95% C.I.	(-10.1, 8.7)	
p-value	0.87973	
Corrected Hedges' g	-0.04	
95% C.I.	(-0.59, 0.50)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9		
n [1]	25	30
n [2]	23	25
LS Mean (SE)	14.9 (2.87)	15.2 (2.67)
95% C.I.	(9.2, 20.6)	(9.9, 20.6)
LS Mean Change from Baseline (SE)	-12.7 (2.87)	-12.4 (2.67)
95% C.I.	(-18.5, -7.0)	(-17.8, -7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.3 (3.92)	
95% C.I.	(-8.2, 7.5)	
p-value	0.93274	
Corrected Hedges' g	-0.02	
95% C.I.	(-0.59, 0.54)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	26
LS Mean (SE)	15.5 (3.04)	16.2 (2.80)
95% C.I.	(9.4, 21.6)	(10.6, 21.8)
LS Mean Change from Baseline (SE)	-12.2 (3.04)	-11.5 (2.80)
95% C.I.	(-18.2, -6.1)	(-17.1, -5.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.7 (4.13)	
95% C.I.	(-8.9, 7.6)	
p-value	0.87417	
Corrected Hedges' g	-0.05	
95% C.I.	(-0.61, 0.52)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17		
n [1]	25	30
n [2]	21	24
LS Mean (SE)	25.5 (3.46)	20.7 (3.20)
95% C.I.	(18.6, 32.4)	(14.3, 27.1)
LS Mean Change from Baseline (SE)	-2.1 (3.46)	-6.9 (3.20)
95% C.I.	(-9.1, 4.8)	(-13.3, -0.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.8 (4.71)	
95% C.I.	(-4.7, 14.2)	
p-value	0.31573	
Corrected Hedges' g	0.30	
95% C.I.	(-0.29, 0.89)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	16	19
LS Mean (SE)	24.2 (4.74)	18.2 (4.33)
95% C.I.	(14.6, 33.7)	(9.4, 26.9)
LS Mean Change from Baseline (SE)	-3.5 (4.74)	-9.5 (4.33)
95% C.I.	(-13.0, 6.1)	(-18.2, -0.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.0 (6.43)	
95% C.I.	(-6.9, 19.0)	
p-value	0.35437	
Corrected Hedges' g	0.31	
95% C.I.	(-0.36, 0.98)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25		
n [1]	25	30
n [2]	17	16
LS Mean (SE)	26.1 (4.37)	21.7 (4.24)
95% C.I.	(17.2, 34.9)	(13.2, 30.3)
LS Mean Change from Baseline (SE)	-1.6 (4.37)	-5.9 (4.24)
95% C.I.	(-10.4, 7.2)	(-14.5, 2.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.3 (6.09)	
95% C.I.	(-7.9, 16.6)	
p-value	0.48155	
Corrected Hedges' g	0.24	
95% C.I.	(-0.44, 0.93)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	14	17
LS Mean (SE)	20.0 (3.40)	22.7 (3.15)
95% C.I.	(13.2, 26.9)	(16.3, 29.1)
LS Mean Change from Baseline (SE)	-7.6 (3.40)	-4.9 (3.15)
95% C.I.	(-14.5, -0.7)	(-11.3, 1.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-2.7 (4.63)	
95% C.I.	(-12.1, 6.7)	
p-value	0.56492	
Corrected Hedges' g	-0.20	
95% C.I.	(-0.91, 0.51)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33		
n [1]	25	30
n [2]	15	12
LS Mean (SE)	19.1 (3.79)	20.6 (3.97)
95% C.I.	(11.4, 26.9)	(12.5, 28.7)
LS Mean Change from Baseline (SE)	-8.5 (3.79)	-7.0 (3.97)
95% C.I.	(-16.2, -0.8)	(-15.1, 1.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.5 (5.48)	
95% C.I.	(-12.6, 9.7)	
p-value	0.79085	
Corrected Hedges' g	-0.10	
95% C.I.	(-0.86, 0.66)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 9 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	13	9
LS Mean (SE)	21.1 (3.61)	15.8 (3.98)
95% C.I.	(13.7, 28.4)	(7.7, 23.9)
LS Mean Change from Baseline (SE)	-6.6 (3.61)	-11.8 (3.98)
95% C.I.	(-14.0, 0.8)	(-20.0, -3.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.2 (5.37)	
95% C.I.	(-5.7, 16.2)	
p-value	0.33647	
Corrected Hedges' g	0.40	
95% C.I.	(-0.46, 1.26)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41		
n [1]	25	30
n [2]	12	12
LS Mean (SE)	19.3 (3.75)	16.1 (3.87)
95% C.I.	(11.6, 27.0)	(8.2, 24.0)
LS Mean Change from Baseline (SE)	-8.4 (3.75)	-11.6 (3.87)
95% C.I.	(-16.0, -0.7)	(-19.5, -3.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.2 (5.38)	
95% C.I.	(-7.8, 14.2)	
p-value	0.55503	
Corrected Hedges' g	0.24	
95% C.I.	(-0.57, 1.04)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	14	10
LS Mean (SE)	18.9 (4.09)	17.5 (4.56)
95% C.I.	(10.5, 27.3)	(8.2, 26.9)
LS Mean Change from Baseline (SE)	-8.7 (4.09)	-10.1 (4.56)
95% C.I.	(-17.1, -0.3)	(-19.5, -0.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	1.4 (6.12)	
95% C.I.	(-11.2, 13.9)	
p-value	0.82310	
Corrected Hedges' g	0.09	
95% C.I.	(-0.72, 0.90)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 12 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	21.4 (4.56)	16.6 (4.92)
95% C.I.	(12.0, 30.8)	(6.4, 26.7)
LS Mean Change from Baseline (SE)	-6.2 (4.56)	-11.1 (4.92)
95% C.I.	(-15.7, 3.2)	(-21.2, -1.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.9 (6.69)	
95% C.I.	(-9.0, 18.7)	
p-value	0.47560	
Corrected Hedges' g	0.31	
95% C.I.	(-0.58, 1.20)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	9	11
LS Mean (SE)	23.9 (3.94)	18.1 (3.83)
95% C.I.	(15.8, 32.0)	(10.2, 26.0)
LS Mean Change from Baseline (SE)	-3.7 (3.94)	-9.6 (3.83)
95% C.I.	(-11.8, 4.4)	(-17.5, -1.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.9 (5.48)	
95% C.I.	(-5.4, 17.1)	
p-value	0.29467	
Corrected Hedges' g	0.46	
95% C.I.	(-0.44, 1.35)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57		
n [1]	25	30
n [2]	11	9
LS Mean (SE)	28.2 (5.20)	17.2 (5.71)
95% C.I.	(17.5, 38.9)	(5.4, 28.9)
LS Mean Change from Baseline (SE)	0.5 (5.20)	-10.5 (5.71)
95% C.I.	(-10.2, 11.2)	(-22.2, 1.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	11.0 (7.70)	
95% C.I.	(-4.8, 26.8)	
p-value	0.16463	
Corrected Hedges' g	0.61	
95% C.I.	(-0.29, 1.51)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 15 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	11	6
LS Mean (SE)	20.8 (3.60)	11.2 (4.50)
95% C.I.	(13.4, 28.3)	(1.9, 20.5)
LS Mean Change from Baseline (SE)	-6.8 (3.60)	-16.5 (4.50)
95% C.I.	(-14.3, 0.6)	(-25.8, -7.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.6 (5.75)	
95% C.I.	(-2.3, 21.5)	
p-value	0.10794	
Corrected Hedges' g	0.79	
95% C.I.	(-0.24, 1.81)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	20.5 (3.72)	12.9 (4.69)
95% C.I.	(12.7, 28.2)	(3.2, 22.7)
LS Mean Change from Baseline (SE)	-7.2 (3.72)	-14.7 (4.69)
95% C.I.	(-14.9, 0.6)	(-24.5, -5.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.5 (5.98)	
95% C.I.	(-4.9, 20.0)	
p-value	0.22230	
Corrected Hedges' g	0.61	
95% C.I.	(-0.42, 1.64)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	9	7
LS Mean (SE)	18.7 (3.07)	9.5 (3.67)
95% C.I.	(12.3, 25.0)	(2.0, 17.1)
LS Mean Change from Baseline (SE)	-9.0 (3.07)	-18.1 (3.67)
95% C.I.	(-15.3, -2.6)	(-25.7, -10.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.1 (4.76)	
95% C.I.	(-0.7, 19.0)	
p-value	0.06763	
Corrected Hedges' g	0.92	
95% C.I.	(-0.12, 1.95)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73		
n [1]	25	30
n [2]	10	6
LS Mean (SE)	17.6 (2.87)	11.9 (3.51)
95% C.I.	(11.6, 23.6)	(4.7, 19.2)
LS Mean Change from Baseline (SE)	-10.1 (2.87)	-15.7 (3.51)
95% C.I.	(-16.0, -4.1)	(-23.0, -8.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.7 (4.53)	
95% C.I.	(-3.7, 15.1)	
p-value	0.22272	
Corrected Hedges' g	0.60	
95% C.I.	(-0.43, 1.64)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	22.7 (4.29)	10.5 (4.80)
95% C.I.	(13.7, 31.7)	(0.4, 20.6)
LS Mean Change from Baseline (SE)	-5.0 (4.29)	-17.2 (4.80)
95% C.I.	(-14.0, 4.0)	(-27.3, -7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	12.2 (6.44)	
95% C.I.	(-1.3, 25.7)	
p-value	0.07460	
Corrected Hedges' g	0.98	
95% C.I.	(-0.17, 2.14)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	22.1 (4.86)	11.7 (5.45)
95% C.I.	(11.8, 32.4)	(0.1, 23.2)
LS Mean Change from Baseline (SE)	-5.5 (4.86)	-16.0 (5.45)
95% C.I.	(-15.8, 4.7)	(-27.5, -4.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	10.5 (7.29)	
95% C.I.	(-5.0, 25.9)	
p-value	0.17051	
Corrected Hedges' g	0.77	
95% C.I.	(-0.42, 1.95)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	18.9 (4.87)	4.4 (5.54)
95% C.I.	(8.5, 29.3)	(-7.4, 16.1)
LS Mean Change from Baseline (SE)	-8.7 (4.87)	-23.3 (5.54)
95% C.I.	(-19.1, 1.6)	(-35.1, -11.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	14.6 (7.33)	
95% C.I.	(-1.0, 30.1)	
p-value	0.06507	
Corrected Hedges' g	1.00	
95% C.I.	(-0.13, 2.12)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	15.4 (4.76)	13.1 (5.47)
95% C.I.	(5.2, 25.6)	(1.4, 24.9)
LS Mean Change from Baseline (SE)	-12.2 (4.76)	-14.5 (5.47)
95% C.I.	(-22.4, -2.0)	(-26.3, -2.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	2.3 (7.24)	
95% C.I.	(-13.2, 17.8)	
p-value	0.75599	
Corrected Hedges' g	0.17	
95% C.I.	(-0.98, 1.32)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 23 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	16.1 (3.77)	9.3 (4.57)
95% C.I.	(8.1, 24.1)	(-0.4, 19.0)
LS Mean Change from Baseline (SE)	-11.5 (3.77)	-18.3 (4.57)
95% C.I.	(-19.5, -3.5)	(-28.0, -8.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	6.8 (5.94)	
95% C.I.	(-5.8, 19.4)	
p-value	0.26784	
Corrected Hedges' g	0.60	
95% C.I.	(-0.54, 1.74)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	18.8 (4.82)	13.2 (5.72)
95% C.I.	(8.5, 29.2)	(1.0, 25.5)
LS Mean Change from Baseline (SE)	-8.8 (4.82)	-14.4 (5.72)
95% C.I.	(-19.2, 1.5)	(-26.7, -2.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.6 (7.50)	
95% C.I.	(-10.5, 21.7)	
p-value	0.46806	
Corrected Hedges' g	0.40	
95% C.I.	(-0.75, 1.56)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 25 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	8	6
LS Mean (SE)	14.1 (4.67)	15.2 (5.47)
95% C.I.	(4.3, 23.9)	(3.8, 26.7)
LS Mean Change from Baseline (SE)	-13.6 (4.67)	-12.4 (5.47)
95% C.I.	(-23.3, -3.8)	(-23.9, -1.0)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.1 (7.25)	
95% C.I.	(-16.3, 14.0)	
p-value	0.87664	
Corrected Hedges' g	-0.08	
95% C.I.	(-1.14, 0.98)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	17.3 (3.34)	11.7 (3.70)
95% C.I.	(10.3, 24.3)	(4.0, 19.4)
LS Mean Change from Baseline (SE)	-10.4 (3.34)	-16.0 (3.70)
95% C.I.	(-17.3, -3.4)	(-23.7, -8.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.6 (5.01)	
95% C.I.	(-4.8, 16.1)	
p-value	0.27321	
Corrected Hedges' g	0.63	
95% C.I.	(-0.59, 1.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 27 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	19.2 (3.48)	12.0 (3.79)
95% C.I.	(11.9, 26.4)	(4.1, 19.8)
LS Mean Change from Baseline (SE)	-8.5 (3.48)	-15.7 (3.79)
95% C.I.	(-15.7, -1.3)	(-23.5, -7.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	7.2 (5.15)	
95% C.I.	(-3.5, 17.8)	
p-value	0.17761	
Corrected Hedges' g	0.72	
95% C.I.	(-0.40, 1.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113		
n [1]	25	30
n [2]	7	5
LS Mean (SE)	24.6 (6.06)	15.9 (6.89)
95% C.I.	(11.9, 37.2)	(1.5, 30.3)
LS Mean Change from Baseline (SE)	-3.1 (6.06)	-11.8 (6.89)
95% C.I.	(-15.8, 9.6)	(-26.2, 2.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	8.7 (9.18)	
95% C.I.	(-10.5, 27.9)	
p-value	0.35671	
Corrected Hedges' g	0.51	
95% C.I.	(-0.66, 1.67)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	18.1 (5.10)	13.6 (5.90)
95% C.I.	(7.1, 29.2)	(0.8, 26.4)
LS Mean Change from Baseline (SE)	-9.5 (5.10)	-14.1 (5.90)
95% C.I.	(-20.6, 1.5)	(-26.8, -1.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.5 (7.79)	
95% C.I.	(-12.3, 21.4)	
p-value	0.57090	
Corrected Hedges' g	0.33	
95% C.I.	(-0.94, 1.61)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 30 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	17.4 (3.75)	11.8 (4.06)
95% C.I.	(9.3, 25.4)	(3.1, 20.6)
LS Mean Change from Baseline (SE)	-10.3 (3.75)	-15.8 (4.06)
95% C.I.	(-18.3, -2.2)	(-24.5, -7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	5.5 (5.53)	
95% C.I.	(-6.3, 17.4)	
p-value	0.33353	
Corrected Hedges' g	0.57	
95% C.I.	(-0.69, 1.84)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	6	5
LS Mean (SE)	24.7 (4.89)	15.5 (5.52)
95% C.I.	(14.3, 35.1)	(3.8, 27.2)
LS Mean Change from Baseline (SE)	-3.0 (4.89)	-12.2 (5.52)
95% C.I.	(-13.3, 7.4)	(-23.9, -0.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	9.2 (7.39)	
95% C.I.	(-6.5, 24.9)	
p-value	0.23091	
Corrected Hedges' g	0.69	
95% C.I.	(-0.53, 1.92)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 32 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	23.2 (6.61)	19.6 (7.86)
95% C.I.	(8.5, 37.9)	(2.2, 37.1)
LS Mean Change from Baseline (SE)	-4.5 (6.61)	-8.0 (7.86)
95% C.I.	(-19.2, 10.2)	(-25.5, 9.4)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	3.5 (10.30)	
95% C.I.	(-19.3, 26.4)	
p-value	0.73869	
Corrected Hedges' g	0.20	
95% C.I.	(-1.07, 1.47)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	4	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 38 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153		
n [1]	25	30
n [2]	4	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 39 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169		
n [1]	25	30
n [2]	6	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	5	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 44 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185		
n [1]	25	30
n [2]	3	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	1	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105

Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	1	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

Protocol: 207499 Page 52 of 52
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004105
Analysis of EORTC QLQ-IL52 Score based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: Disease Symptoms

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. An autoregressive with heterogeneity (ARH(1)) covariance structure was used to estimate the within subject covariance.
/mnt/code/prod/tfls/t_pro_il52_mmrm_2ref.sas 09OCT2025 09:18

1.3.1.4 EQ-5D VAS

Protocol: 207499 Page 1 of 31
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	Actual Score	n	27	32
		Mean	65.33	63.75
		SD	15.166	20.333
		Median	62.00	70.00
		Min.	30.0	20.0
		Max.	94.0	92.0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5	Actual Score	n	25	29
		Mean	66.16	64.45
		SD	15.721	18.816
		Median	68.00	70.00
		Min.	39.0	20.0
		Max.	93.0	96.0
	Change from Baseline	n	24	28
		Mean	0.71	1.29
		SD	15.933	15.311
		Median	-2.00	1.00
		Min.	-17.0	-30.0
		Max.	60.0	33.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	2 (8%)	5 (18%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	2 (8%)	5 (18%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	Actual Score	n	23	27
		Mean	62.22	66.15
		SD	22.931	18.702
		Median	70.00	70.00
		Min.	0.0	25.0
		Max.	95.0	95.0
	Change from Baseline	n	22	27
		Mean	-1.82	2.22
		SD	24.428	17.212
		Median	-1.50	0.00
		Min.	-53.0	-40.0
		Max.	65.0	41.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	3 (14%)	5 (19%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	4 (18%)	4 (15%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21	Actual Score	n	19	20
		Mean	66.00	65.85
		SD	17.720	24.143
		Median	70.00	72.50
		Min.	40.0	0.0
		Max.	94.0	94.0
	Change from Baseline	n	18	20
		Mean	-0.39	0.90
		SD	16.389	22.907
		Median	-0.50	0.00
		Min.	-32.0	-32.0
		Max.	36.0	44.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	4 (22%)	5 (25%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	4 (22%)	6 (30%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29	Actual Score	n	17	18
		Mean	63.82	71.94
		SD	17.900	16.604
		Median	69.00	73.00
		Min.	31.0	30.0
		Max.	95.0	94.0
	Change from Baseline	n	16	18
		Mean	-1.31	2.00
		SD	14.800	19.814
		Median	-1.50	3.50
		Min.	-24.0	-42.0
		Max.	29.0	44.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	3 (19%)	4 (22%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	2 (13%)	4 (22%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37	Actual Score	n	16	10
		Mean	62.94	69.50
		SD	13.839	15.094
		Median	62.00	71.00
		Min.	41.0	49.0
		Max.	90.0	95.0
	Change from Baseline	n	15	10
		Mean	-2.07	3.00
		SD	12.186	12.111
		Median	-5.00	3.50
		Min.	-17.0	-15.0
		Max.	23.0	22.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	2 (13%)	1 (10%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	2 (13%)	1 (10%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45	Actual Score	n	13	13
		Mean	65.69	72.54
		SD	12.459	17.943
		Median	64.00	75.00
		Min.	42.0	25.0
		Max.	90.0	93.0
	Change from Baseline	n	13	13
		Mean	-1.69	1.23
		SD	16.987	17.603
		Median	0.00	-5.00
		Min.	-29.0	-25.0
		Max.	28.0	42.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	2 (15%)	2 (15%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	4 (31%)	2 (15%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53	Actual Score	n	11	11
		Mean	53.73	70.27
		SD	22.786	22.209
		Median	52.00	79.00
		Min.	0.0	28.0
		Max.	80.0	95.0
	Change from Baseline	n	10	11
		Mean	-5.40	-3.45
		SD	13.049	24.545
		Median	-5.50	-7.00
		Min.	-32.0	-52.0
		Max.	18.0	43.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (10%)	1 (9%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (10%)	4 (36%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	Actual Score	n	11	7
		Mean	60.45	74.00
		SD	15.326	11.874
		Median	62.00	71.00
		Min.	31.0	60.0
		Max.	80.0	95.0
	Change from Baseline	n	11	7
		Mean	-5.64	8.00
		SD	14.672	12.610
		Median	-5.00	9.00
		Min.	-40.0	-9.0
		Max.	18.0	30.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (9%)	1 (14%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (9%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69	Actual Score	n	11	7
		Mean	59.18	74.14
		SD	13.927	14.171
		Median	56.00	78.00
		Min.	42.0	53.0
		Max.	80.0	94.0
	Change from Baseline	n	11	7
		Mean	-4.27	4.43
		SD	12.150	22.560
		Median	-2.00	12.00
		Min.	-21.0	-38.0
		Max.	18.0	28.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (9%)	3 (43%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	2 (18%)	1 (14%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77	Actual Score	n	9	6
		Mean	60.44	80.67
		SD	18.722	9.070
		Median	50.00	80.00
		Min.	40.0	69.0
		Max.	90.0	97.0
	Change from Baseline	n	9	6
		Mean	-2.33	11.50
		SD	10.536	11.309
		Median	-2.00	12.00
		Min.	-10.0	-3.0
		Max.	23.0	30.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (11%)	2 (33%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	0	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Protocol: 207499 Page 12 of 31
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	Actual Score	n	8	6
		Mean	55.50	78.67
		SD	15.033	8.140
		Median	51.00	79.50
		Min.	40.0	66.0
		Max.	85.0	90.0
	Change from Baseline	n	7	6
		Mean	-3.43	8.67
		SD	16.702	19.149
		Median	-4.00	15.50
		Min.	-29.0	-25.0
		Max.	23.0	29.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (14%)	3 (50%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (14%)	1 (17%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93	Actual Score	n	9	5
		Mean	57.67	76.00
		SD	15.676	13.910
		Median	56.00	79.00
		Min.	35.0	60.0
		Max.	85.0	96.0
	Change from Baseline	n	8	5
		Mean	-0.38	6.80
		SD	10.239	17.138
		Median	-1.50	12.00
		Min.	-10.0	-12.0
		Max.	23.0	29.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (13%)	1 (20%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	0	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101	Actual Score	n	7	6
		Mean	56.57	79.00
		SD	11.458	12.394
		Median	51.00	79.00
		Min.	42.0	60.0
		Max.	72.0	95.0
	Change from Baseline	n	7	6
		Mean	-5.43	9.83
		SD	16.061	14.798
		Median	0.00	13.00
		Min.	-40.0	-12.0
		Max.	9.0	28.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	2 (33%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (14%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	Actual Score	n	8	6
		Mean	54.88	77.00
		SD	13.389	12.696
		Median	54.50	76.50
		Min.	38.0	61.0
		Max.	74.0	96.0
	Change from Baseline	n	7	6
		Mean	-3.71	4.17
		SD	8.751	20.913
		Median	-2.00	5.50
		Min.	-12.0	-24.0
		Max.	10.0	35.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	1 (17%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	0	1 (17%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	Actual Score	n	6	4
		Mean	51.67	78.75
		SD	12.044	13.124
		Median	50.00	78.50
		Min.	39.0	63.0
		Max.	70.0	95.0
	Change from Baseline	n	6	4
		Mean	-5.83	4.75
		SD	10.265	10.532
		Median	-6.00	7.50
		Min.	-21.0	-9.0
		Max.	8.0	13.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	0
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (17%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125	Actual Score	n	6	5
		Mean	57.67	75.80
		SD	19.284	12.498
		Median	58.00	72.00
		Min.	33.0	62.0
		Max.	81.0	95.0
	Change from Baseline	n	5	5
		Mean	2.20	6.60
		SD	12.194	12.542
		Median	6.00	13.00
		Min.	-17.0	-10.0
		Max.	13.0	20.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	1 (20%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (20%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	Actual Score	n	5	4
		Mean	54.60	80.25
		SD	10.784	13.841
		Median	53.00	82.00
		Min.	41.0	62.0
		Max.	70.0	95.0
	Change from Baseline	n	5	4
		Mean	-2.00	10.50
		SD	8.916	16.010
		Median	-2.00	11.50
		Min.	-12.0	-10.0
		Max.	10.0	29.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	1 (25%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	0	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141	Actual Score	n	6	3
		Mean	58.33	74.67
		SD	17.682	18.448
		Median	55.50	70.00
		Min.	42.0	59.0
		Max.	89.0	95.0
	Change from Baseline	n	6	3
		Mean	0.83	6.67
		SD	21.812	17.388
		Median	-0.50	13.00
		Min.	-28.0	-13.0
		Max.	39.0	20.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (17%)	1 (33%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (17%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149	Actual Score	n	6	2
		Mean	54.83	74.00
		SD	14.049	7.071
		Median	54.50	74.00
		Min.	39.0	69.0
		Max.	70.0	79.0
	Change from Baseline	n	5	2
		Mean	-1.40	11.50
		SD	14.876	10.607
		Median	8.00	11.50
		Min.	-23.0	4.0
		Max.	10.0	19.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	1 (50%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (20%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	Actual Score	n	5	3
		Mean	52.60	78.00
		SD	23.923	20.075
		Median	40.00	80.00
		Min.	31.0	57.0
		Max.	85.0	97.0
	Change from Baseline	n	5	3
		Mean	-6.40	9.00
		SD	22.601	24.556
		Median	-14.00	15.00
		Min.	-31.0	-18.0
		Max.	23.0	30.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (20%)	2 (67%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	2 (40%)	1 (33%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165	Actual Score	n	7	2
		Mean	53.14	88.00
		SD	19.369	11.314
		Median	50.00	88.00
		Min.	29.0	80.0
		Max.	80.0	96.0
	Change from Baseline	n	7	2
		Mean	-6.14	25.50
		SD	17.468	6.364
		Median	-2.00	25.50
		Min.	-34.0	21.0
		Max.	18.0	30.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (14%)	2 (100%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	2 (29%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	Actual Score	n	4	1
		Mean	52.50	80.00
		SD	21.016	
		Median	55.00	80.00
		Min.	25.0	80.0
		Max.	75.0	80.0
	Change from Baseline	n	4	1
		Mean	-5.75	30.00
		SD	20.189	
		Median	-6.50	30.00
		Min.	-25.0	30.0
		Max.	15.0	30.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (25%)	1 (100%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	2 (50%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	Actual Score	n	3	2
		Mean	60.67	85.50
		SD	12.097	7.778
		Median	65.00	85.50
		Min.	47.0	80.0
		Max.	70.0	91.0
	Change from Baseline	n	3	2
		Mean	-3.67	23.00
		SD	17.954	9.899
		Median	3.00	23.00
		Min.	-24.0	16.0
		Max.	10.0	30.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	2 (100%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (33%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	Actual Score	n	3	2
		Mean	49.00	84.50
		SD	19.079	6.364
		Median	39.00	84.50
		Min.	37.0	80.0
		Max.	71.0	89.0
	Change from Baseline	n	3	2
		Mean	-11.33	22.00
		SD	21.548	11.314
		Median	-13.00	22.00
		Min.	-32.0	14.0
		Max.	11.0	30.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	1 (50%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	1 (33%)	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197	Actual Score	n	2	1
		Mean	57.00	80.00
		SD	14.142	
		Median	57.00	80.00
		Min.	47.0	80.0
		Max.	67.0	80.0
	Change from Baseline	n	2	1
		Mean	2.00	30.00
		SD	7.071	
		Median	2.00	30.00
		Min.	-3.0	30.0
		Max.	7.0	30.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	1 (100%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	0	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205	Actual Score	n	0	1
		Mean		60.00
		SD		
		Median		60.00
		Min.		60.0
		Max.		60.0
	Change from Baseline	n	0	1
		Mean		-12.00
		SD		
		Median		-12.00
		Min.		-12.0
		Max.		-12.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	0
	Worsening in EQ VAS score >=15% from Baseline	n (%)	0	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	Actual Score	n	0	1
		Mean		83.00
		SD		
		Median		83.00
		Min.		83.0
		Max.		83.0
	Change from Baseline	n	0	1
		Mean		8.00
		SD		
		Median		8.00
		Min.		8.0
		Max.		8.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	0
	Worsening in EQ VAS score >=15% from Baseline	n (%)	0	0

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	Actual Score	n	18	20
		Mean	56.39	61.40
		SD	24.641	20.072
		Median	60.00	59.00
		Min.	0.0	25.0
		Max.	96.0	95.0
	Change from Baseline	n	17	20
		Mean	-5.12	-4.35
		SD	21.561	17.661
		Median	-10.00	-6.50
		Min.	-32.0	-40.0
		Max.	66.0	29.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (6%)	3 (15%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	6 (35%)	6 (30%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	Actual Score	n	9	9
		Mean	55.44	73.11
		SD	14.859	20.307
		Median	50.00	79.00
		Min.	39.0	28.0
		Max.	80.0	97.0
	Change from Baseline	n	8	9
		Mean	-12.25	-1.67
		SD	14.636	25.155
		Median	-13.50	8.00
		Min.	-40.0	-52.0
		Max.	8.0	23.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	0	4 (44%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	4 (50%)	2 (22%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Protocol: 207499 Page 31 of 31
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001705

Summary of EQ-5D-3L VAS Value and Change from Baseline by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint			Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	Actual Score	n	26	31
		Mean	50.23	51.35
		SD	23.288	20.519
		Median	55.50	53.00
		Min.	0.0	0.0
		Max.	90.0	90.0
	Change from Baseline	n	25	30
		Mean	-13.88	-12.43
		SD	22.480	18.959
		Median	-17.00	-14.00
		Min.	-53.0	-52.0
		Max.	60.0	18.0
	Improvement in EQ VAS score >=15% from Baseline	n (%)	1 (4%)	2 (7%)
	Worsening in EQ VAS score >=15% from Baseline	n (%)	14 (56%)	15 (50%)

Note: EQ-5D-3L assessments are done once in every 8 weeks.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_eqchg_2ref.sas 09OCT2025 10:10

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001805

Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	14 (47%)	15 (45%)
Censored, follow-up ended	13 (43%)	13 (39%)
Censored, follow-up ongoing	3 (10%)	5 (15%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.8 (1.0, 7.4)	3.7 (1.0, 4.8)
Median (95% CI)	7.6 (4.2, 28.8)	6.7 (4.6, -)
3rd Quartile (95% CI)	28.8 (7.6, -)	35.9 (10.3, -)
Log-Rank P-value [2]	0.97798	
Hazard Ratio (95% CI) [3]	1.01 (0.49, 2.09)	
P-value [3]	0.98421	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_eq5d3l_ttd_2ref.sas 09OCT2025 10:10

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001815
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	4 (36%)	3 (43%)
	Censored, follow-up ended	7 (64%)	4 (57%)
	Censored, follow-up ongoing	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.7 (1.0, -)	3.7 (1.0, -)
	Median (95% CI)	28.8 (1.0, -)	- (1.0, -)
	3rd Quartile (95% CI)	28.8 (7.6, -)	- (3.7, -)
	Log-Rank P-value [2]	0.63116	
	Hazard Ratio (95% CI) [3]	0.67 (0.13, 3.40)	
	P-value [3]	0.63180	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_age.sas 09OCT2025 10:10

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001815
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (53%)	7 (47%)
	Censored, follow-up ended	4 (27%)	5 (33%)
	Censored, follow-up ongoing	3 (20%)	3 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (2.8, 7.4)	2.7 (1.0, 4.8)
	Median (95% CI)	7.4 (3.8, 23.2)	4.8 (1.1, -)
	3rd Quartile (95% CI)	23.2 (6.5, -)	- (4.8, -)
	Log-Rank P-value [2]	0.70790	
	Hazard Ratio (95% CI) [3]	0.82 (0.29, 2.28)	
	P-value [3]	0.70133	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_age.sas 09OCT2025 10:10

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001815
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (50%)	5 (45%)
	Censored, follow-up ended	2 (50%)	4 (36%)
	Censored, follow-up ongoing	0	2 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	5.0 (1.0, -)
	Median (95% CI)	2.8 (1.0, -)	10.3 (1.0, -)
	3rd Quartile (95% CI)	- (1.0, -)	35.9 (5.0, -)
	Log-Rank P-value [2]	0.25235	
	Hazard Ratio (95% CI) [3]	2.77 (0.45, 17.11)	
	P-value [3]	0.27155	
Interaction Test	P-value [4]	0.45177	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_age.sas 09OCT2025 10:10

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001825
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	5 (31%)
	Censored, follow-up ended	7 (54%)	8 (50%)
	Censored, follow-up ongoing	0	3 (19%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.5 (1.0, 7.6)	4.6 (1.0, 35.9)
	Median (95% CI)	7.6 (2.8, -)	35.9 (1.1, -)
	3rd Quartile (95% CI)	10.2 (7.4, -)	- (35.9, -)
	Log-Rank P-value [2]	0.42730	
	Hazard Ratio (95% CI) [3]	1.67 (0.47, 5.96)	
	P-value [3]	0.43209	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_gen.sas 09OCT2025 10:10

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001825
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	8 (47%)	10 (59%)
	Censored, follow-up ended	6 (35%)	5 (29%)
	Censored, follow-up ongoing	3 (18%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 4.7)	2.8 (1.0, 4.8)
	Median (95% CI)	23.2 (3.7, -)	5.0 (2.7, -)
	3rd Quartile (95% CI)	- (4.7, -)	- (5.0, -)
	Log-Rank P-value [2]	0.67314	
	Hazard Ratio (95% CI) [3]	0.82 (0.32, 2.10)	
	P-value [3]	0.67447	
Interaction Test	P-value [4]	0.34404	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_gen.sas 09OCT2025 10:10

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001835
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	5 (25%)	13 (54%)
	Censored, follow-up ended	12 (60%)	9 (38%)
	Censored, follow-up ongoing	3 (15%)	2 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.5 (1.0, -)	2.7 (1.0, 4.6)
	Median (95% CI)	- (3.8, -)	4.6 (2.7, 35.9)
	3rd Quartile (95% CI)	- (7.6, -)	35.9 (4.6, -)
	Log-Rank P-value [2]	0.09501	
	Hazard Ratio (95% CI) [3]	0.42 (0.15, 1.19)	
	P-value [3]	0.10401	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_reg.sas 09OCT2025 10:11

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001835
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	9 (90%)	2 (22%)
	Censored, follow-up ended	1 (10%)	4 (44%)
	Censored, follow-up ongoing	0	3 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 7.4)	10.3 (4.8, -)
	Median (95% CI)	6.0 (1.0, 23.2)	- (4.8, -)
	3rd Quartile (95% CI)	16.7 (4.7, -)	- (10.3, -)
	Log-Rank P-value [2]	0.01708	
	Hazard Ratio (95% CI) [3]	5.41 (1.15, 25.38)	
	P-value [3]	0.03241	
Interaction Test	P-value [4]	0.00808	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_reg.sas 09OCT2025 10:11

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001845
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	9 (50%)	7 (47%)
	Censored, follow-up ended	6 (33%)	6 (40%)
	Censored, follow-up ongoing	3 (17%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.0, 10.2)	4.6 (1.0, 6.7)
	Median (95% CI)	10.2 (3.7, -)	35.9 (3.7, -)
	3rd Quartile (95% CI)	28.8 (10.2, -)	35.9 (6.7, -)
	Log-Rank P-value [2]	0.79083	
	Hazard Ratio (95% CI) [3]	0.87 (0.32, 2.35)	
	P-value [3]	0.78014	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_iss.sas 09OCT2025 10:11

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001845
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	5 (42%)	8 (44%)
	Censored, follow-up ended	7 (58%)	7 (39%)
	Censored, follow-up ongoing	0	3 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.0, 4.7)	1.1 (1.0, 5.0)
	Median (95% CI)	4.7 (1.0, -)	5.0 (1.0, -)
	3rd Quartile (95% CI)	6.5 (4.2, -)	- (5.0, -)
	Log-Rank P-value [2]	0.63919	
	Hazard Ratio (95% CI) [3]	1.31 (0.41, 4.19)	
	P-value [3]	0.64902	
Interaction Test	P-value [4]	0.50121	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_iss.sas 09OCT2025 10:11

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001855
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	5 (63%)	3 (50%)
	Censored, follow-up ended	2 (25%)	0
	Censored, follow-up ongoing	1 (13%)	3 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (2.8, 7.6)	5.0 (2.8, -)
	Median (95% CI)	7.6 (2.8, -)	- (2.8, -)
	3rd Quartile (95% CI)	23.2 (6.5, -)	- (5.0, -)
	Log-Rank P-value [2]	0.87573	
	Hazard Ratio (95% CI) [3]	1.13 (0.25, 5.05)	
	P-value [3]	0.87580	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_line.sas 09OCT2025 10:11

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001855
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	5 (38%)	7 (50%)
	Censored, follow-up ended	7 (54%)	7 (50%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.7 (1.0, 10.2)	3.7 (1.0, 4.8)
	Median (95% CI)	10.2 (1.0, -)	4.8 (1.0, -)
	3rd Quartile (95% CI)	- (7.4, -)	35.9 (4.6, -)
	Log-Rank P-value [2]	0.51248	
	Hazard Ratio (95% CI) [3]	0.68 (0.21, 2.14)	
	P-value [3]	0.50513	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_line.sas 09OCT2025 10:11

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001855
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	5 (38%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (2.8, -)	1.1 (1.0, 10.3)
	Median (95% CI)	4.7 (2.8, -)	10.3 (1.0, -)
	3rd Quartile (95% CI)	28.8 (2.8, -)	- (10.3, -)
	Log-Rank P-value [2]	0.65113	
	Hazard Ratio (95% CI) [3]	1.36 (0.36, 5.12)	
	P-value [3]	0.65232	
Interaction Test	P-value [4]	0.61404	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_line.sas 09OCT2025 10:11

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001875
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	10 (48%)	10 (50%)
	Censored, follow-up ended	9 (43%)	7 (35%)
	Censored, follow-up ongoing	2 (10%)	3 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.0, 7.6)	4.6 (1.0, 5.0)
	Median (95% CI)	7.6 (4.2, -)	5.0 (3.7, -)
	3rd Quartile (95% CI)	- (7.6, -)	35.9 (5.0, -)
	Log-Rank P-value [2]	0.69624	
	Hazard Ratio (95% CI) [3]	0.84 (0.35, 2.02)	
	P-value [3]	0.69022	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_line2.sas 09OCT2025 10:11

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001875
Summary of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (44%)	5 (38%)
	Censored, follow-up ended	4 (44%)	6 (46%)
	Censored, follow-up ongoing	1 (11%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (2.8, -)	1.1 (1.0, 10.3)
	Median (95% CI)	4.7 (2.8, -)	10.3 (1.0, -)
	3rd Quartile (95% CI)	28.8 (2.8, -)	- (10.3, -)
	Log-Rank P-value [2]	0.65113	
	Hazard Ratio (95% CI) [3]	1.36 (0.36, 5.12)	
	P-value [3]	0.65232	
Interaction Test	P-value [4]	0.44480	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_ttd_2ref_line2.sas 09OCT2025 10:11

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001905
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	7 (23%)	13 (39%)
Censored, follow-up ended	18 (60%)	17 (52%)
Censored, follow-up ongoing	5 (17%)	3 (9%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.7 (1.0, -)	6.0 (1.0, 17.5)
Median (95% CI)	39.6 (39.6, -)	17.5 (6.0, -)
3rd Quartile (95% CI)	- (39.6, -)	19.8 (17.5, -)
Log-Rank P-value [2]	0.06459	
Inverse Hazard Ratio (95% CI) [3]	2.43 (0.91, 6.48)	
P-value [3]	0.07503	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_eq5d3l_tti_2ref.sas 09OCT2025 10:12

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001915
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	3 (27%)	3 (43%)
	Censored, follow-up ended	7 (64%)	3 (43%)
	Censored, follow-up ongoing	1 (9%)	1 (14%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_age.sas 09OCT2025 10:12

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001915
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	3 (20%)	6 (40%)
	Censored, follow-up ended	9 (60%)	7 (47%)
	Censored, follow-up ongoing	3 (20%)	2 (13%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_age.sas 09OCT2025 10:12

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001915
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	1 (25%)	4 (36%)
	Censored, follow-up ended	2 (50%)	7 (64%)
	Censored, follow-up ongoing	1 (25%)	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_age.sas 09OCT2025 10:12

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001925
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	4 (31%)	7 (44%)
	Censored, follow-up ended	8 (62%)	9 (56%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.8 (1.0, -)	2.3 (0.9, 19.8)
	Median (95% CI)	- (2.8, -)	19.8 (1.0, -)
	3rd Quartile (95% CI)	- (-, -)	37.7 (19.8, -)
	Log-Rank P-value [2]	0.41626	
	Inverse Hazard Ratio (95% CI) [3]	1.64 (0.48, 5.60)	
	P-value [3]	0.43239	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_gen.sas 09OCT2025 10:12

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001925
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	3 (18%)	6 (35%)
	Censored, follow-up ended	10 (59%)	8 (47%)
	Censored, follow-up ongoing	4 (24%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	39.6 (1.2, -)	15.7 (1.0, 17.5)
	Median (95% CI)	39.6 (4.6, -)	17.5 (2.8, -)
	3rd Quartile (95% CI)	- (39.6, -)	19.3 (15.7, -)
	Log-Rank P-value [2]	0.11632	
	Inverse Hazard Ratio (95% CI) [3]	3.38 (0.67, 16.97)	
	P-value [3]	0.13843	
Interaction Test	P-value [4]	0.66385	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_gen.sas 09OCT2025 10:12

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001935
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	5 (25%)	8 (33%)
	Censored, follow-up ended	13 (65%)	13 (54%)
	Censored, follow-up ongoing	2 (10%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (1.2, -)	6.0 (1.0, 19.8)
	Median (95% CI)	39.6 (4.6, -)	19.8 (6.0, -)
	3rd Quartile (95% CI)	39.6 (-, -)	37.7 (19.3, -)
	Log-Rank P-value [2]	0.49559	
	Inverse Hazard Ratio (95% CI) [3]	1.52 (0.46, 5.06)	
	P-value [3]	0.49550	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_reg.sas 09OCT2025 10:12

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001935
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	2 (20%)	5 (56%)
	Censored, follow-up ended	5 (50%)	4 (44%)
	Censored, follow-up ongoing	3 (30%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.0, -)	1.9 (0.9, 15.7)
	Median (95% CI)	- (1.0, -)	15.7 (0.9, -)
	3rd Quartile (95% CI)	- (-, -)	17.5 (2.8, -)
	Log-Rank P-value [2]	0.05336	
	Inverse Hazard Ratio (95% CI) [3]	4.39 (0.84, 23.02)	
	P-value [3]	0.08001	
Interaction Test	P-value [4]	0.08451	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_reg.sas 09OCT2025 10:12

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001945
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	3 (17%)	7 (47%)
	Censored, follow-up ended	11 (61%)	6 (40%)
	Censored, follow-up ongoing	4 (22%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.0, -)	15.7 (1.0, 19.8)
	Median (95% CI)	- (-, -)	19.3 (2.8, -)
	3rd Quartile (95% CI)	- (-, -)	37.7 (15.7, -)
	Log-Rank P-value [2]	0.08366	
	Inverse Hazard Ratio (95% CI) [3]	3.10 (0.80, 12.04)	
	P-value [3]	0.10249	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_iss.sas 09OCT2025 10:12

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001945
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	4 (33%)	6 (33%)
	Censored, follow-up ended	7 (58%)	11 (61%)
	Censored, follow-up ongoing	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.7 (1.2, -)	2.3 (0.9, -)
	Median (95% CI)	39.6 (1.2, -)	17.5 (1.3, -)
	3rd Quartile (95% CI)	39.6 (4.7, -)	17.5 (6.0, -)
	Log-Rank P-value [2]	0.63466	
	Inverse Hazard Ratio (95% CI) [3]	1.40 (0.35, 5.62)	
	P-value [3]	0.63623	
Interaction Test	P-value [4]	0.40522	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_iss.sas 09OCT2025 10:12

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001955
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	3 (38%)	3 (50%)
	Censored, follow-up ended	5 (63%)	2 (33%)
	Censored, follow-up ongoing	0	1 (17%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_line.sas 09OCT2025 10:12

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001955
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	4 (31%)	5 (36%)
	Censored, follow-up ended	7 (54%)	8 (57%)
	Censored, follow-up ongoing	2 (15%)	1 (7%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_line.sas 09OCT2025 10:12

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001955
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	0	5 (38%)
	Censored, follow-up ended	6 (67%)	7 (54%)
	Censored, follow-up ongoing	3 (33%)	1 (8%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_line.sas 09OCT2025 10:12

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001975
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	7 (33%)	8 (40%)
	Censored, follow-up ended	12 (57%)	10 (50%)
	Censored, follow-up ongoing	2 (10%)	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.6 (1.0, 39.6)	6.0 (0.9, 19.3)
	Median (95% CI)	39.6 (4.6, -)	19.3 (6.0, -)
	3rd Quartile (95% CI)	- (39.6, -)	37.7 (17.5, -)
	Log-Rank P-value [2]	0.32545	
	Inverse Hazard Ratio (95% CI) [3]	1.69 (0.58, 4.88)	
	P-value [3]	0.33408	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_line2.sas 09OCT2025 10:13

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0001975
Summary of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	0	5 (38%)
	Censored, follow-up ended	6 (67%)	7 (54%)
	Censored, follow-up ongoing	3 (33%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (-, -)	2.3 (1.0, -)
	Median (95% CI)	- (-, -)	15.7 (1.3, -)
	3rd Quartile (95% CI)	- (-, -)	15.7 (-, -)
	Log-Rank P-value [2]	0.05123	
	Inverse Hazard Ratio (95% CI) [3]	9.38 (0.96, >999.99)	
	P-value [3]	0.18394	
Interaction Test	P-value [4]	0.23896	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eq5d3l_tti_2ref_line2.sas 09OCT2025 10:13

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 5		
n [1]	25	30
n [2]	24	28
LS Mean (SE)	66.7 (3.19)	66.7 (2.95)
95% C.I.	(60.3, 73.2)	(60.8, 72.7)
LS Mean Change from Baseline (SE)	0.7 (3.19)	0.7 (2.95)
95% C.I.	(-5.7, 7.1)	(-5.2, 6.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.0 (4.35)	
95% C.I.	(-8.8, 8.7)	
p-value	0.99409	
Corrected Hedges' g	0.00	
95% C.I.	(-0.55, 0.54)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13		
n [1]	25	30
n [2]	22	27
LS Mean (SE)	64.1 (4.17)	67.6 (3.80)
95% C.I.	(55.7, 72.5)	(59.9, 75.2)
LS Mean Change from Baseline (SE)	-1.9 (4.17)	1.6 (3.80)
95% C.I.	(-10.3, 6.5)	(-6.1, 9.2)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.4 (5.64)	
95% C.I.	(-14.8, 7.9)	
p-value	0.54444	
Corrected Hedges' g	-0.17	
95% C.I.	(-0.74, 0.39)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 21		
n [1]	25	30
n [2]	18	20
LS Mean (SE)	67.4 (4.53)	63.3 (4.27)
95% C.I.	(58.2, 76.5)	(54.6, 71.9)
LS Mean Change from Baseline (SE)	1.4 (4.53)	-2.7 (4.27)
95% C.I.	(-7.8, 10.5)	(-11.4, 5.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	4.1 (6.23)	
95% C.I.	(-8.5, 16.7)	
p-value	0.51655	
Corrected Hedges' g	0.21	
95% C.I.	(-0.43, 0.85)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 29		
n [1]	25	30
n [2]	16	18
LS Mean (SE)	67.1 (3.70)	67.7 (3.53)
95% C.I.	(59.6, 74.6)	(60.5, 74.8)
LS Mean Change from Baseline (SE)	1.1 (3.70)	1.7 (3.53)
95% C.I.	(-6.4, 8.6)	(-5.5, 8.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-0.6 (5.10)	
95% C.I.	(-10.9, 9.7)	
p-value	0.90816	
Corrected Hedges' g	-0.04	
95% C.I.	(-0.71, 0.63)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 37		
n [1]	25	30
n [2]	15	10
LS Mean (SE)	65.7 (2.72)	65.6 (3.07)
95% C.I.	(60.2, 71.3)	(59.4, 71.9)
LS Mean Change from Baseline (SE)	-0.3 (2.72)	-0.4 (3.07)
95% C.I.	(-5.8, 5.3)	(-6.6, 5.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	0.1 (4.10)	
95% C.I.	(-8.3, 8.5)	
p-value	0.97980	
Corrected Hedges' g	0.01	
95% C.I.	(-0.79, 0.81)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 45		
n [1]	25	30
n [2]	13	13
LS Mean (SE)	67.0 (3.60)	68.4 (3.68)
95% C.I.	(59.7, 74.3)	(60.9, 75.8)
LS Mean Change from Baseline (SE)	1.0 (3.60)	2.3 (3.68)
95% C.I.	(-6.3, 8.3)	(-5.1, 9.8)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.4 (5.11)	
95% C.I.	(-11.8, 9.0)	
p-value	0.79025	
Corrected Hedges' g	-0.10	
95% C.I.	(-0.87, 0.67)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 53		
n [1]	25	30
n [2]	10	11
LS Mean (SE)	62.1 (4.64)	63.4 (4.78)
95% C.I.	(52.7, 71.6)	(53.6, 73.1)
LS Mean Change from Baseline (SE)	-3.9 (4.64)	-2.6 (4.78)
95% C.I.	(-13.3, 5.6)	(-12.4, 7.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.2 (6.73)	
95% C.I.	(-15.0, 12.5)	
p-value	0.85734	
Corrected Hedges' g	-0.08	
95% C.I.	(-0.93, 0.78)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61		
n [1]	25	30
n [2]	11	7
LS Mean (SE)	61.4 (3.39)	66.4 (4.02)
95% C.I.	(54.3, 68.4)	(58.1, 74.7)
LS Mean Change from Baseline (SE)	-4.7 (3.39)	0.4 (4.02)
95% C.I.	(-11.7, 2.4)	(-7.9, 8.7)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-5.0 (5.25)	
95% C.I.	(-15.9, 5.9)	
p-value	0.35047	
Corrected Hedges' g	-0.43	
95% C.I.	(-1.39, 0.53)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 69		
n [1]	25	30
n [2]	11	7
LS Mean (SE)	62.5 (3.75)	66.2 (4.49)
95% C.I.	(54.7, 70.3)	(57.0, 75.5)
LS Mean Change from Baseline (SE)	-3.5 (3.75)	0.2 (4.49)
95% C.I.	(-11.3, 4.3)	(-9.0, 9.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.7 (5.92)	
95% C.I.	(-16.0, 8.5)	
p-value	0.53402	
Corrected Hedges' g	-0.29	
95% C.I.	(-1.24, 0.66)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 77		
n [1]	25	30
n [2]	9	6
LS Mean (SE)	65.0 (2.92)	72.0 (3.47)
95% C.I.	(58.9, 71.0)	(64.8, 79.3)
LS Mean Change from Baseline (SE)	-1.1 (2.92)	6.0 (3.47)
95% C.I.	(-7.1, 5.0)	(-1.2, 13.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-7.1 (4.60)	
95% C.I.	(-16.7, 2.5)	
p-value	0.13909	
Corrected Hedges' g	-0.77	
95% C.I.	(-1.84, 0.30)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	59.4 (4.92)	76.4 (5.09)
95% C.I.	(48.9, 69.9)	(65.6, 87.3)
LS Mean Change from Baseline (SE)	-6.6 (4.92)	10.4 (5.09)
95% C.I.	(-17.1, 3.9)	(-0.4, 21.3)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-17.0 (7.36)	
95% C.I.	(-32.7, -1.3)	
p-value	0.03534	
Corrected Hedges' g	-1.24	
95% C.I.	(-2.43, -0.05)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 93		
n [1]	25	30
n [2]	8	5
LS Mean (SE)	64.3 (4.06)	67.4 (4.78)
95% C.I.	(55.7, 72.9)	(57.3, 77.5)
LS Mean Change from Baseline (SE)	-1.7 (4.06)	1.4 (4.78)
95% C.I.	(-10.3, 6.9)	(-8.7, 11.5)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-3.1 (6.49)	
95% C.I.	(-16.8, 10.6)	
p-value	0.63749	
Corrected Hedges' g	-0.26	
95% C.I.	(-1.38, 0.86)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 101		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	56.9 (4.00)	71.5 (4.27)
95% C.I.	(48.3, 65.5)	(62.4, 80.6)
LS Mean Change from Baseline (SE)	-9.1 (4.00)	5.5 (4.27)
95% C.I.	(-17.7, -0.5)	(-3.6, 14.6)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-14.6 (5.96)	
95% C.I.	(-27.3, -1.9)	
p-value	0.02744	
Corrected Hedges' g	-1.29	
95% C.I.	(-2.49, -0.09)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Protocol: 207499 Page 14 of 27
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002005
Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109		
n [1]	25	30
n [2]	7	6
LS Mean (SE)	59.5 (4.07)	70.7 (4.39)
95% C.I.	(50.9, 68.0)	(61.6, 79.9)
LS Mean Change from Baseline (SE)	-6.5 (4.07)	4.7 (4.39)
95% C.I.	(-15.1, 2.0)	(-4.4, 13.9)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-11.3 (6.42)	
95% C.I.	(-24.7, 2.2)	
p-value	0.09502	
Corrected Hedges' g	-0.97	
95% C.I.	(-2.13, 0.18)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117		
n [1]	25	30
n [2]	6	4
LS Mean (SE)	55.6 (4.52)	72.4 (4.94)
95% C.I.	(45.8, 65.4)	(61.7, 83.1)
LS Mean Change from Baseline (SE)	-10.4 (4.52)	6.4 (4.94)
95% C.I.	(-20.2, -0.6)	(-4.3, 17.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-16.8 (7.92)	
95% C.I.	(-34.0, 0.3)	
p-value	0.05399	
Corrected Hedges' g	-1.43	
95% C.I.	(-2.84, -0.02)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 125		
n [1]	25	30
n [2]	5	5
LS Mean (SE)	65.4 (4.10)	66.8 (3.81)
95% C.I.	(56.3, 74.4)	(58.5, 75.1)
LS Mean Change from Baseline (SE)	-0.7 (4.10)	0.8 (3.81)
95% C.I.	(-9.7, 8.4)	(-7.5, 9.1)
Belmaf 2.5/1.9 mg/kg + POM/DEX vs. POM + BOR/DEX		
Difference (SE)	-1.4 (5.89)	
95% C.I.	(-14.4, 11.5)	
p-value	0.81112	
Corrected Hedges' g	-0.15	
95% C.I.	(-1.39, 1.09)	

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133		
n [1]	25	30
n [2]	5	4

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 141		
n [1]	25	30
n [2]	6	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 149		
n [1]	25	30
n [2]	5	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157		
n [1]	25	30
n [2]	5	3

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 165		
n [1]	25	30
n [2]	7	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173		
n [1]	25	30
n [2]	4	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189		
n [1]	25	30
n [2]	3	2

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 197		
n [1]	25	30
n [2]	2	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Table 4.0002005

Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 205		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

Protocol: 207499 Page 27 of 27
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002005
Analysis of EQ-5D-3L VAS Domain Scores based on Mixed Model for Repeated Measures (MMRM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain: EQ VAS Score

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213		
n [1]	25	30
n [2]	0	1

[1] Number of subjects with analyzable data for one or more time points.
[2] Number of subjects with analyzable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects and subject as a random effect.
Note: Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. A Toeplitz with heterogeneity (TOEPH) covariance structure was used to estimate the within subject covariance.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_eqchg_mmrm_2ref.sas 09OCT2025 09:12

1.3.1.5 FACT-GP5

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Baseline	n	27		32	
	0	13	(48%)	22	(69%)
	1	7	(26%)	4	(13%)
	2	7	(26%)	4	(13%)
	3	0		1	(3%)
	4	0		1	(3%)
	3+4	0		2	(6%)
	Any Scale >0	14	(52%)	10	(31%)
Week 5	n	25		29	
	0	9	(36%)	15	(52%)
	1	10	(40%)	5	(17%)
	2	3	(12%)	6	(21%)
	3	3	(12%)	3	(10%)
	4	0		0	
	3+4	3	(12%)	3	(10%)
	Any Scale >0	16	(64%)	14	(48%)
	Worsening in FACT-GP5 score >=1 from Baseline	9/24	(38%)	9/28	(32%)
	Improvement in FACT-GP5 score >=1 from Baseline	5/24	(21%)	5/28	(18%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 9	n	24		27	
	0	8	(33%)	13	(48%)
	1	8	(33%)	8	(30%)
	2	5	(21%)	4	(15%)
	3	3	(13%)	2	(7%)
	4	0		0	
	3+4	3	(13%)	2	(7%)
	Any Scale >0	16	(67%)	14	(52%)
	Worsening in FACT-GP5 score >=1 from Baseline	10/23	(43%)	9/26	(35%)
	Improvement in FACT-GP5 score >=1 from Baseline	4/23	(17%)	4/26	(15%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 13	n	23		27	
	0	6	(26%)	15	(56%)
	1	8	(35%)	8	(30%)
	2	7	(30%)	0	
	3	2	(9%)	3	(11%)
	4	0		1	(4%)
	3+4	2	(9%)	4	(15%)
	Any Scale >0	17	(74%)	12	(44%)
	Worsening in FACT-GP5 score >=1 from Baseline	10/22	(45%)	9/27	(33%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/22	(9%)	5/27	(19%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 4 of 52
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 17	n	22		24	
	0	8	(36%)	11	(46%)
	1	7	(32%)	8	(33%)
	2	5	(23%)	4	(17%)
	3	1	(5%)	1	(4%)
	4	1	(5%)	0	
	3+4	2	(9%)	1	(4%)
	Any Scale >0	14	(64%)	13	(54%)
	Worsening in FACT-GP5 score >=1 from Baseline	6/21	(29%)	9/24	(38%)
	Improvement in FACT-GP5 score >=1 from Baseline	5/21	(24%)	4/24	(17%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 21	n	17		19	
	0	4	(24%)	9	(47%)
	1	9	(53%)	7	(37%)
	2	2	(12%)	2	(11%)
	3	2	(12%)	1	(5%)
	4	0		0	
	3+4	2	(12%)	1	(5%)
	Any Scale >0	13	(76%)	10	(53%)
	Worsening in FACT-GP5 score >=1 from Baseline	5/16	(31%)	7/19	(37%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/16	(13%)	2/19	(11%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 25	n	17		15	
	0	2	(12%)	7	(47%)
	1	8	(47%)	6	(40%)
	2	3	(18%)	2	(13%)
	3	3	(18%)	0	
	4	1	(6%)	0	
	3+4	4	(24%)	0	
	Any Scale >0	15	(88%)	8	(53%)
	Worsening in FACT-GP5 score >=1 from Baseline	8/16	(50%)	6/15	(40%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/16	(13%)	3/15	(20%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 29	n	14		15	
	0	3	(21%)	9	(60%)
	1	4	(29%)	4	(27%)
	2	5	(36%)	1	(7%)
	3	2	(14%)	1	(7%)
	4	0		0	
	3+4	2	(14%)	1	(7%)
	Any Scale >0	11	(79%)	6	(40%)
	Worsening in FACT-GP5 score >=1 from Baseline	5/13	(38%)	4/15	(27%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/13	(8%)	2/15	(13%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 33	n	16		11	
	0	2	(13%)	8	(73%)
	1	5	(31%)	1	(9%)
	2	7	(44%)	2	(18%)
	3	2	(13%)	0	
	4	0		0	
	3+4	2	(13%)	0	
	Any Scale >0	14	(88%)	3	(27%)
	Worsening in FACT-GP5 score >=1 from Baseline	6/15	(40%)	3/11	(27%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/15	(7%)	0/11	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 37	n	14		9	
	0	1	(7%)	6	(67%)
	1	9	(64%)	2	(22%)
	2	2	(14%)	1	(11%)
	3	2	(14%)	0	
	4	0		0	
	3+4	2	(14%)	0	
	Any Scale >0	13	(93%)	3	(33%)
	Worsening in FACT-GP5 score >=1 from Baseline	5/13	(38%)	3/ 9	(33%)
	Improvement in FACT-GP5 score >=1 from Baseline	3/13	(23%)	1/ 9	(11%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 41	n	12	9
	0	0	2 (22%)
	1	7 (58%)	4 (44%)
	2	4 (33%)	3 (33%)
	3	1 (8%)	0
	4	0	0
	3+4	1 (8%)	0
	Any Scale >0	12 (100%)	7 (78%)
	Worsening in FACT-GP5 score >=1 from Baseline	4/11 (36%)	6/ 9 (67%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/11 (9%)	0/ 9

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 45	n	14		9	
	0	3	(21%)	4	(44%)
	1	5	(36%)	4	(44%)
	2	5	(36%)	1	(11%)
	3	0		0	
	4	1	(7%)	0	
	3+4	1	(7%)	0	
	Any Scale >0	11	(79%)	5	(56%)
	Worsening in FACT-GP5 score >=1 from Baseline	5/13	(38%)	5/ 9	(56%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/13	(15%)	1/ 9	(11%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 49	n	11		9	
	0	2	(18%)	4	(44%)
	1	3	(27%)	5	(56%)
	2	5	(45%)	0	
	3	1	(9%)	0	
	4	0		0	
	3+4	1	(9%)	0	
	Any Scale >0	9	(82%)	5	(56%)
	Worsening in FACT-GP5 score >=1 from Baseline	5/11	(45%)	4/ 9	(44%)
	Improvement in FACT-GP5 score >=1 from Baseline	3/11	(27%)	0/ 9	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 53	n	10		9	
	0	2	(20%)	4	(44%)
	1	4	(40%)	4	(44%)
	2	3	(30%)	1	(11%)
	3	1	(10%)	0	
	4	0		0	
	3+4	1	(10%)	0	
	Any Scale >0	8	(80%)	5	(56%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/ 9	(33%)	4/ 9	(44%)
	Improvement in FACT-GP5 score >=1 from Baseline	3/ 9	(33%)	0/ 9	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 57	n	11		7	
	0	1	(9%)	1	(14%)
	1	5	(45%)	4	(57%)
	2	5	(45%)	2	(29%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	10	(91%)	6	(86%)
	Worsening in FACT-GP5 score >=1 from Baseline	4/11	(36%)	5/ 7	(71%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/11	(9%)	0/ 7	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 61	n	9	6
	0	0	1 (17%)
	1	2 (22%)	4 (67%)
	2	6 (67%)	1 (17%)
	3	1 (11%)	0
	4	0	0
	3+4	1 (11%)	0
	Any Scale >0	9 (100%)	5 (83%)
	Worsening in FACT-GP5 score >=1 from Baseline	6/ 9 (67%)	5/ 6 (83%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 9 (11%)	1/ 6 (17%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 65	n	9	6
	0	0	2 (33%)
	1	3 (33%)	4 (67%)
	2	6 (67%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	9 (100%)	4 (67%)
	Worsening in FACT-GP5 score >=1 from Baseline	4/ 9 (44%)	3/ 6 (50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 9	0/ 6

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 69	n	9		6	
	0	1	(11%)	3	(50%)
	1	3	(33%)	3	(50%)
	2	4	(44%)	0	
	3	1	(11%)	0	
	4	0		0	
	3+4	1	(11%)	0	
	Any Scale >0	8	(89%)	3	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	4/ 9	(44%)	3/ 6	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 9	(11%)	1/ 6	(17%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 73	n	9		6	
	0	1	(11%)	3	(50%)
	1	3	(33%)	3	(50%)
	2	4	(44%)	0	
	3	1	(11%)	0	
	4	0		0	
	3+4	1	(11%)	0	
	Any Scale >0	8	(89%)	3	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	5/ 9	(56%)	2/ 6	(33%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 9	(22%)	0/ 6	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 77	n	7		5	
	0	3	(43%)	2	(40%)
	1	1	(14%)	3	(60%)
	2	3	(43%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	4	(57%)	3	(60%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	2/ 5	(40%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	0/ 5	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 81	n	7	5
	0	0	4 (80%)
	1	4 (57%)	0
	2	3 (43%)	1 (20%)
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	7 (100%)	1 (20%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/ 7 (43%)	1/ 5 (20%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 7	1/ 5 (20%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 85	n	7		4	
	0	1	(14%)	3	(75%)
	1	3	(43%)	1	(25%)
	2	3	(43%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	6	(86%)	1	(25%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 7	(14%)	1/ 4	(25%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 7		1/ 4	(25%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 89	n	7		5	
	0	1	(14%)	2	(40%)
	1	3	(43%)	2	(40%)
	2	3	(43%)	1	(20%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	6	(86%)	3	(60%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	2/ 5	(40%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 7		0/ 5	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 93	n	7		5	
	0	1	(14%)	2	(40%)
	1	3	(43%)	2	(40%)
	2	2	(29%)	1	(20%)
	3	1	(14%)	0	
	4	0		0	
	3+4	1	(14%)	0	
	Any Scale >0	6	(86%)	3	(60%)
	Worsening in FACT-GP5 score >=1 from Baseline	4/ 7	(57%)	2/ 5	(40%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 7	(14%)	0/ 5	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 24 of 52
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 97	n	6		5	
	0	1	(17%)	3	(60%)
	1	3	(50%)	1	(20%)
	2	2	(33%)	1	(20%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	5	(83%)	2	(40%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 6	(17%)	2/ 5	(40%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 6	(33%)	1/ 5	(20%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 101	n	7		5	
	0	1	(14%)	2	(40%)
	1	2	(29%)	2	(40%)
	2	2	(29%)	1	(20%)
	3	1	(14%)	0	
	4	1	(14%)	0	
	3+4	2	(29%)	0	
	Any Scale >0	6	(86%)	3	(60%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/ 7	(43%)	2/ 5	(40%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 7		0/ 5	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 105	n	6		4	
	0	1	(17%)	0	
	1	2	(33%)	4	(100%)
	2	2	(33%)	0	
	3	1	(17%)	0	
	4	0		0	
	3+4	1	(17%)	0	
	Any Scale >0	5	(83%)	4	(100%)
	Worsening in FACT-GP5 score >=1 from Baseline	4/ 6	(67%)	3/ 4	(75%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 6	(17%)	0/ 4	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 109	n	7		5	
	0	2	(29%)	3	(60%)
	1	1	(14%)	1	(20%)
	2	4	(57%)	1	(20%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	5	(71%)	2	(40%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	1/ 5	(20%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 7	(14%)	0/ 5	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 113	n	7		5	
	0	1	(14%)	2	(40%)
	1	2	(29%)	2	(40%)
	2	2	(29%)	1	(20%)
	3	2	(29%)	0	
	4	0		0	
	3+4	2	(29%)	0	
	Any Scale >0	6	(86%)	3	(60%)
	Worsening in FACT-GP5 score >=1 from Baseline	5/ 7	(71%)	2/ 5	(40%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 7	(14%)	0/ 5	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 117	n	6		4	
	0	1	(17%)	2	(50%)
	1	1	(17%)	1	(25%)
	2	3	(50%)	1	(25%)
	3	1	(17%)	0	
	4	0		0	
	3+4	1	(17%)	0	
	Any Scale >0	5	(83%)	2	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/ 6	(50%)	1/ 4	(25%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 6	(17%)	0/ 4	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 121	n	5	5
	0	0	2 (40%)
	1	3 (60%)	3 (60%)
	2	2 (40%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	5 (100%)	3 (60%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 5 (20%)	2/ 5 (40%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 5	0/ 5

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 125	n	5	5
	0	0	2 (40%)
	1	2 (40%)	2 (40%)
	2	2 (40%)	1 (20%)
	3	1 (20%)	0
	4	0	0
	3+4	1 (20%)	0
	Any Scale >0	5 (100%)	3 (60%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/ 5 (60%)	2/ 5 (40%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 5 (20%)	0/ 5

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 129	n	5	4
	0	0	2 (50%)
	1	1 (20%)	0
	2	2 (40%)	2 (50%)
	3	2 (40%)	0
	4	0	0
	3+4	2 (40%)	0
	Any Scale >0	5 (100%)	2 (50%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/ 5 (60%)	2/ 4 (50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 5	0/ 4

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 133	n	4	4
	0	0	2 (50%)
	1	2 (50%)	2 (50%)
	2	2 (50%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	4 (100%)	2 (50%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 4 (25%)	2/ 4 (50%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 4 (25%)	0/ 4

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 137	n	5	3
	0	0	1 (33%)
	1	1 (20%)	1 (33%)
	2	4 (80%)	1 (33%)
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	5 (100%)	2 (67%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 5 (40%)	2/ 3 (67%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 5	0/ 3

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 35 of 52
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 141	n	5	2
	0	1 (20%)	0
	1	1 (20%)	2 (100%)
	2	3 (60%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	4 (80%)	2 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 5 (40%)	2/ 2 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 5 (40%)	0/ 2

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 36 of 52
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 145	n	5	2
	0	0	1 (50%)
	1	3 (60%)	1 (50%)
	2	2 (40%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	5 (100%)	1 (50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 5 (40%)	1/ 2 (50%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 5 (40%)	0/ 2

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 149	n	5	2
	0	0	1 (50%)
	1	1 (20%)	1 (50%)
	2	4 (80%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	5 (100%)	1 (50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 5 (40%)	1/ 2 (50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 5	0/ 2

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 38 of 52
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 153	n	4	2
	0	0	1 (50%)
	1	0	1 (50%)
	2	4 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	4 (100%)	1 (50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 4 (50%)	1/ 2 (50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 4	0/ 2

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 157	n	5	2
	0	0	1 (50%)
	1	1 (20%)	1 (50%)
	2	3 (60%)	0
	3	1 (20%)	0
	4	0	0
	3+4	1 (20%)	0
	Any Scale >0	5 (100%)	1 (50%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/ 5 (60%)	1/ 2 (50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 5	0/ 2

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 161	n	5	1
	0	0	0
	1	2 (40%)	1 (100%)
	2	3 (60%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	5 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 5 (40%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 5 (20%)	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Week 165	n	5		2	
	0	1	(20%)	1	(50%)
	1	0		1	(50%)
	2	3	(60%)	0	
	3	0		0	
	4	1	(20%)	0	
	3+4	1	(20%)	0	
	Any Scale >0	4	(80%)	1	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 5	(40%)	1/ 2	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 5	(20%)	0/ 2	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 169	n	5	1
	0	0	0
	1	2 (40%)	0
	2	3 (60%)	1 (100%)
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	5 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 5 (40%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 5 (20%)	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 43 of 52
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 173	n	5	1
	0	0	0
	1	3 (60%)	1 (100%)
	2	2 (40%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	5 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 5 (20%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 5	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 177	n	3	1
	0	0	0
	1	2 (67%)	1 (100%)
	2	1 (33%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	3 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 3 (67%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 3	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 181	n	3	1
	0	0	0
	1	1 (33%)	1 (100%)
	2	1 (33%)	0
	3	1 (33%)	0
	4	0	0
	3+4	1 (33%)	0
	Any Scale >0	3 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 3 (67%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 3	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 46 of 52
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 185	n	2	1
	0	1 (50%)	0
	1	0	1 (100%)
	2	1 (50%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	1 (50%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 2 (50%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 2 (50%)	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 189	n	1	1
	0	0	0
	1	0	1 (100%)
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	1 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 1 (100%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 1	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 193	n	2	1
	0	0	0
	1	1 (50%)	1 (100%)
	2	1 (50%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	2 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 2 (50%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 197	n	1	1
	0	0	0
	1	0	1 (100%)
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	1 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 1 (100%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 1	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 201	n	1	1
	0	0	0
	1	0	1 (100%)
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	1 (100%)	1 (100%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 1 (100%)	1/ 1 (100%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 1	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
End of Treatment	n	18		20	
	0	5	(28%)	9	(45%)
	1	5	(28%)	6	(30%)
	2	7	(39%)	4	(20%)
	3	1	(6%)	1	(5%)
	4	0		0	
	3+4	1	(6%)	1	(5%)
	Any Scale >0	13	(72%)	11	(55%)
	Worsening in FACT-GP5 score >=1 from Baseline	10/17	(59%)	7/20	(35%)
	Improvement in FACT-GP5 score >=1 from Baseline	3/17	(18%)	1/20	(5%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 52 of 52
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002105
Summary of FACT-GP5 Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Levels	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Worst Case Post Baseline	n	26		31	
	0	3	(12%)	3	(10%)
	1	3	(12%)	12	(39%)
	2	11	(42%)	10	(32%)
	3	6	(23%)	5	(16%)
	4	3	(12%)	1	(3%)
	3+4	9	(35%)	6	(19%)
	Any Scale >0	23	(88%)	28	(90%)
	Worsening in FACT-GP5 score >=1 from Baseline	20/25	(80%)	21/30	(70%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/25	(4%)	3/30	(10%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_fact_gp5_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002205
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	20 (71%)	21 (64%)
Censored	8 (29%)	12 (36%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.0 (0.8, 2.0)	1.1 (1.0, 1.9)
Median (95% CI)	2.9 (1.0, 3.8)	3.0 (1.4, 4.7)
3rd Quartile (95% CI)	5.6 (2.9, -)	6.5 (4.7, -)
Log-Rank P-value [2]	0.51303	
Hazard Ratio (95% CI) [3]	1.23 (0.66, 2.26)	
P-value [3]	0.51486	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_factgp5_ttd_2ref.sas 09OCT2025 10:13

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002215
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	9 (82%)	3 (43%)
	Censored	2 (18%)	4 (57%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.1)	1.9 (1.1, -)
	Median (95% CI)	1.1 (1.0, 5.6)	- (1.1, -)
	3rd Quartile (95% CI)	5.6 (1.1, -)	- (1.9, -)
	Log-Rank P-value [2]	0.07661	
	Hazard Ratio (95% CI) [3]	3.10 (0.83, 11.62)	
	P-value [3]	0.09321	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_age.sas 09OCT2025 10:13

Protocol: 207499 Page 2 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002215
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	9 (64%)	11 (73%)
	Censored	5 (36%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 2.9)	1.0 (0.7, 1.4)
	Median (95% CI)	2.9 (0.9, -)	1.8 (1.0, -)
	3rd Quartile (95% CI)	- (2.9, -)	6.5 (1.4, -)
	Log-Rank P-value [2]	0.74998	
	Hazard Ratio (95% CI) [3]	0.86 (0.35, 2.09)	
	P-value [3]	0.73598	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_age.sas 09OCT2025 10:13

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002215
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (67%)	7 (64%)
	Censored	1 (33%)	4 (36%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (2.0, -)	1.9 (1.0, 4.7)
	Median (95% CI)	2.6 (2.0, -)	4.7 (1.0, -)
	3rd Quartile (95% CI)	- (2.0, -)	9.3 (3.0, -)
	Log-Rank P-value [2]	0.96516	
	Hazard Ratio (95% CI) [3]	1.00 (0.20, 5.02)	
	P-value [3]	0.99929	
Interaction Test	P-value [4]	0.20700	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_age.sas 09OCT2025 10:13

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002225
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	8 (67%)	9 (56%)
	Censored	4 (33%)	7 (44%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 2.6)	1.0 (0.7, 4.7)
	Median (95% CI)	2.6 (1.0, -)	4.7 (1.0, -)
	3rd Quartile (95% CI)	- (2.0, -)	6.5 (4.7, -)
	Log-Rank P-value [2]	0.96071	
	Hazard Ratio (95% CI) [3]	1.01 (0.39, 2.63)	
	P-value [3]	0.98383	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_gen.sas 09OCT2025 10:14

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002225
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	12 (75%)	12 (71%)
	Censored	4 (25%)	5 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 2.9)	1.7 (1.0, 1.9)
	Median (95% CI)	2.9 (1.0, 3.8)	2.0 (1.4, 4.7)
	3rd Quartile (95% CI)	3.8 (2.9, -)	9.3 (2.0, -)
	Log-Rank P-value [2]	0.39070	
	Hazard Ratio (95% CI) [3]	1.44 (0.63, 3.28)	
	P-value [3]	0.38196	
Interaction Test	P-value [4]	0.56238	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_gen.sas 09OCT2025 10:14

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002235
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	13 (72%)	17 (71%)
	Censored	5 (28%)	7 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.0)	1.0 (0.7, 1.8)
	Median (95% CI)	2.9 (1.0, 3.8)	1.9 (1.0, 4.7)
	3rd Quartile (95% CI)	3.8 (2.9, -)	4.7 (2.0, -)
	Log-Rank P-value [2]	0.46727	
	Hazard Ratio (95% CI) [3]	1.30 (0.63, 2.71)	
	P-value [3]	0.48158	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_reg.sas 09OCT2025 10:14

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002235
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	7 (70%)	4 (44%)
	Censored	3 (30%)	5 (56%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, 2.9)	3.3 (1.7, 9.3)
	Median (95% CI)	2.7 (1.0, -)	9.3 (1.7, -)
	3rd Quartile (95% CI)	- (2.6, -)	- (4.7, -)
	Log-Rank P-value [2]	0.37165	
	Hazard Ratio (95% CI) [3]	1.75 (0.51, 6.04)	
	P-value [3]	0.37753	
Interaction Test	P-value [4]	0.64592	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_reg.sas 09OCT2025 10:14

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002245
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	11 (61%)	10 (67%)
	Censored	7 (39%)	5 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 3.0)	1.8 (1.0, 3.7)
	Median (95% CI)	3.0 (1.1, 6.5)	4.2 (1.7, 4.7)
	3rd Quartile (95% CI)	6.5 (3.0, -)	- (3.7, -)
	Log-Rank P-value [2]	0.99558	
	Hazard Ratio (95% CI) [3]	0.99 (0.42, 2.33)	
	P-value [3]	0.97607	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_iss.sas 09OCT2025 10:13

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002245
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	9 (90%)	11 (61%)
	Censored	1 (10%)	7 (39%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.0)	1.0 (0.7, 1.4)
	Median (95% CI)	1.0 (0.8, 3.8)	1.9 (1.0, -)
	3rd Quartile (95% CI)	2.9 (1.0, -)	6.5 (1.9, -)
	Log-Rank P-value [2]	0.11519	
	Hazard Ratio (95% CI) [3]	2.07 (0.82, 5.24)	
	P-value [3]	0.12454	
Interaction Test	P-value [4]	0.26608	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_iss.sas 09OCT2025 10:13

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002255
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	7 (100%)	5 (83%)
	Censored	0	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.9)	3.0 (1.8, 4.7)
	Median (95% CI)	1.9 (0.9, 3.8)	4.2 (1.8, -)
	3rd Quartile (95% CI)	3.8 (1.0, -)	6.5 (3.0, -)
	Log-Rank P-value [2]	0.09504	
	Hazard Ratio (95% CI) [3]	2.80 (0.80, 9.74)	
	P-value [3]	0.10574	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_line.sas 09OCT2025 10:14

Protocol: 207499 Page 2 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002255
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	9 (69%)	7 (50%)
	Censored	4 (31%)	7 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 2.9)	1.1 (1.0, 4.7)
	Median (95% CI)	2.9 (1.0, 5.6)	4.7 (1.0, -)
	3rd Quartile (95% CI)	5.6 (2.9, -)	- (2.0, -)
	Log-Rank P-value [2]	0.87071	
	Hazard Ratio (95% CI) [3]	1.07 (0.39, 2.92)	
	P-value [3]	0.89515	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_line.sas 09OCT2025 10:14

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002255
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (50%)	9 (69%)
	Censored	4 (50%)	4 (31%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 3.8)	1.0 (0.7, 1.4)
	Median (95% CI)	2.9 (1.0, -)	1.7 (1.0, 9.3)
	3rd Quartile (95% CI)	3.8 (1.1, -)	9.3 (1.4, -)
	Log-Rank P-value [2]	0.89167	
	Hazard Ratio (95% CI) [3]	0.92 (0.27, 3.05)	
	P-value [3]	0.88600	
Interaction Test	P-value [4]	0.56830	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_line.sas 09OCT2025 10:14

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002275
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	16 (80%)	12 (60%)
	Censored	4 (20%)	8 (40%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 2.0)	1.9 (1.0, 3.7)
	Median (95% CI)	2.6 (1.0, 5.6)	4.7 (1.8, 6.5)
	3rd Quartile (95% CI)	5.6 (2.6, -)	6.5 (4.7, -)
	Log-Rank P-value [2]	0.34391	
	Hazard Ratio (95% CI) [3]	1.43 (0.67, 3.03)	
	P-value [3]	0.35016	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_line2.sas 09OCT2025 10:14

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002275
Summary of FACT-GP5 Scores Time to First Deterioration (Up to and Including End of Treatment) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	4 (50%)	9 (69%)
	Censored	4 (50%)	4 (31%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, 3.8)	1.0 (0.7, 1.4)
	Median (95% CI)	2.9 (1.0, -)	1.7 (1.0, 9.3)
	3rd Quartile (95% CI)	3.8 (1.1, -)	9.3 (1.4, -)
	Log-Rank P-value [2]	0.89167	
	Hazard Ratio (95% CI) [3]	0.92 (0.27, 3.05)	
	P-value [3]	0.88600	
Interaction Test	P-value [4]	0.53294	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_ttd_2ref_line2.sas 09OCT2025 10:14

Protocol: 207499 Page 1 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 5

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	24	28
Bothered	15 (63%)	13 (46%)
Not Bothered	9 (38%)	15 (54%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	2.55 (0.34, 19.20)	
P-Value [1]	0.36129	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 2 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 9

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	23	26
Bothered	15 (65%)	13 (50%)
Not Bothered	8 (35%)	13 (50%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	1.41 (0.16, 12.22)	
P-Value [1]	0.75249	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 13

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	22	27
Bothered	16 (73%)	12 (44%)
Not Bothered	6 (27%)	15 (56%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	4.19 (0.51, 34.53)	
P-Value [1]	0.18278	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 4 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 17

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	21	24
Bothered	13 (62%)	13 (54%)
Not Bothered	8 (38%)	11 (46%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.49 (0.05, 4.65)	
P-Value [1]	0.53702	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 5 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 21

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	16	19
Bothered	12 (75%)	10 (53%)
Not Bothered	4 (25%)	9 (47%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.80 (0.06, 11.16)	
P-Value [1]	0.86560	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 25

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	16	15
Bothered	14 (88%)	8 (53%)
Not Bothered	2 (13%)	7 (47%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	6.06 (0.40, 93.07)	
P-Value [1]	0.19526	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 29

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	13	15
Bothered	10 (77%)	6 (40%)
Not Bothered	3 (23%)	9 (60%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	4.94 (0.36, 67.91)	
P-Value [1]	0.23146	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 33

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	15	11
Bothered	13 (87%)	3 (27%)
Not Bothered	2 (13%)	8 (73%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	6.21 (0.33, 115.97)	
P-Value [1]	0.22059	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 37

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	13	9
Bothered	12 (92%)	3 (33%)
Not Bothered	1 (8%)	6 (67%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	11.38 (0.33, 388.52)	
P-Value [1]	0.17646	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 41

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	11	9
Bothered	11 (100%)	7 (78%)
Not Bothered	0	2 (22%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (>999.99, >999.99)	
P-Value [1]	<0.00001	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 11 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 45

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	13	9
Bothered	10 (77%)	5 (56%)
Not Bothered	3 (23%)	4 (44%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	3.85 (0.14, 104.36)	
P-Value [1]	0.42308	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 12 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 49

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	11	9
Bothered	9 (82%)	5 (56%)
Not Bothered	2 (18%)	4 (44%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	1.54 (0.04, 55.81)	
P-Value [1]	0.81179	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 13 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 53

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	9	9
Bothered	8 (89%)	5 (56%)
Not Bothered	1 (11%)	4 (44%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.41 (<0.01, 82.05)	
P-Value [1]	0.73865	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 14 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 57

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	11	7
Bothered	10 (91%)	6 (86%)
Not Bothered	1 (9%)	1 (14%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.16 (<0.01, 11.06)	
P-Value [1]	0.40003	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 15 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 61

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	9	6
Bothered	9 (100%)	5 (83%)
Not Bothered	0	1 (17%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (>999.99, >999.99)	
P-Value [1]	<0.00001	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 16 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	9	6
Bothered	9 (100%)	4 (67%)
Not Bothered	0	2 (33%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (>999.99, >999.99)	
P-Value [1]	<0.00001	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 69

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	9	6
Bothered	8 (89%)	3 (50%)
Not Bothered	1 (11%)	3 (50%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	7.36 (0.23, 236.77)	
P-Value [1]	0.25900	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 73

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	9	6
Bothered	8 (89%)	3 (50%)
Not Bothered	1 (11%)	3 (50%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	9.60 (0.29, 314.49)	
P-Value [1]	0.20334	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 77

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	7	5
Bothered	4 (57%)	3 (60%)
Not Bothered	3 (43%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.13 (<0.01, 6.64)	
P-Value [1]	0.30817	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 81

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	7	5
Bothered	7 (100%)	1 (20%)
Not Bothered	0	4 (80%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (>999.99, >999.99)	
P-Value [1]	<0.00001	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 21 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 85

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	7	4
Bothered	6 (86%)	1 (25%)
Not Bothered	1 (14%)	3 (75%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	19.71 (0.29, >999.99)	
P-Value [1]	0.16539	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 89

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	7	5
Bothered	6 (86%)	3 (60%)
Not Bothered	1 (14%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.56 (<0.01, 87.67)	
P-Value [1]	0.82011	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 23 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 93

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	7	5
Bothered	6 (86%)	3 (60%)
Not Bothered	1 (14%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	2.73 (0.06, 125.64)	
P-Value [1]	0.60709	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 24 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 97

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	6	5
Bothered	5 (83%)	2 (40%)
Not Bothered	1 (17%)	3 (60%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (>999.99, >999.99)	
P-Value [1]	<0.00001	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 25 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 101

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	7	5
Bothered	6 (86%)	3 (60%)
Not Bothered	1 (14%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.56 (<0.01, 87.67)	
P-Value [1]	0.82011	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 105

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	6	4
Bothered	5 (83%)	4 (100%)
Not Bothered	1 (17%)	0
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	<0.01 (<0.01, <0.01)	
P-Value [1]	<0.00001	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 27 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 109

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	7	5
Bothered	5 (71%)	2 (40%)
Not Bothered	2 (29%)	3 (60%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.70 (0.01, 40.13)	
P-Value [1]	0.86445	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 113

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	7	5
Bothered	6 (86%)	3 (60%)
Not Bothered	1 (14%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	2.73 (0.06, 125.64)	
P-Value [1]	0.60709	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 117

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	6	4
Bothered	5 (83%)	2 (50%)
Not Bothered	1 (17%)	2 (50%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.56 (<0.01, 50.86)	
P-Value [1]	0.80263	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 30 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 121

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	5
Bothered	5 (100%)	3 (60%)
Not Bothered	0	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (>999.99, >999.99)	
P-Value [1]	<0.00001	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 31 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 125

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	5
Bothered	5 (100%)	3 (60%)
Not Bothered	0	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (>999.99, >999.99)	
P-Value [1]	<0.00001	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 129

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	4
Bothered	5 (100%)	2 (50%)
Not Bothered	0	2 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 133

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	4	4
Bothered	4 (100%)	2 (50%)
Not Bothered	0	2 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 137

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	3
Bothered	5 (100%)	2 (67%)
Not Bothered	0	1 (33%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 141

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	2
Bothered	4 (80%)	2 (100%)
Not Bothered	1 (20%)	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 145

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	2
Bothered	5 (100%)	1 (50%)
Not Bothered	0	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 149

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	2
Bothered	5 (100%)	1 (50%)
Not Bothered	0	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 153

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	4	2
Bothered	4 (100%)	1 (50%)
Not Bothered	0	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 157

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	2
Bothered	5 (100%)	1 (50%)
Not Bothered	0	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 161

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	1
Bothered	5 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 165

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	2
Bothered	4 (80%)	1 (50%)
Not Bothered	1 (20%)	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 169

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	1
Bothered	5 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 43 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 173

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	5	1
Bothered	5 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 177

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	3	1
Bothered	3 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 181

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	3	1
Bothered	3 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 185

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	2	1
Bothered	1 (50%)	1 (100%)
Not Bothered	1 (50%)	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 189

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	1	1
Bothered	1 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 193

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	2	1
Bothered	2 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 49 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 197

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	1	1
Bothered	1 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

Protocol: 207499 Page 50 of 50
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002305
Analysis of FACT-GP5 Scores based on Generalised Linear Mixed Model (GLMM) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 201

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
n	1	1
Bothered	1 (100%)	1 (100%)
Not Bothered	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions as fixed effects, and subject as a random effect.
Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_factgp5_glmm_2ref.sas 09OCT2025 09:33

1.3.1.6 PGIC

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	n	0	1
	0	0	0
	1	0	0
	2	0	1 (100%)
	3	0	0
	4	0	0
	0+1	0	0
	3+4	0	0
Week 5	n	25	29
	0	3 (12%)	5 (17%)
	1	11 (44%)	15 (52%)
	2	9 (36%)	6 (21%)
	3	2 (8%)	2 (7%)
	4	0	1 (3%)
	0+1	14 (56%)	20 (69%)
	3+4	2 (8%)	3 (10%)
Week 9	n	24	27
	0	6 (25%)	5 (19%)
	1	11 (46%)	14 (52%)
	2	5 (21%)	7 (26%)
	3	2 (8%)	1 (4%)
	4	0	0
	0+1	17 (71%)	19 (70%)
	3+4	2 (8%)	1 (4%)

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 13	n	23	27
	0	4 (17%)	6 (22%)
	1	10 (43%)	14 (52%)
	2	7 (30%)	5 (19%)
	3	2 (9%)	2 (7%)
	4	0	0
	0+1	14 (61%)	20 (74%)
	3+4	2 (9%)	2 (7%)
Week 17	n	22	24
	0	4 (18%)	5 (21%)
	1	9 (41%)	13 (54%)
	2	7 (32%)	4 (17%)
	3	2 (9%)	1 (4%)
	4	0	1 (4%)
	0+1	13 (59%)	18 (75%)
	3+4	2 (9%)	2 (8%)
Week 21	n	17	19
	0	7 (41%)	5 (26%)
	1	6 (35%)	7 (37%)
	2	3 (18%)	4 (21%)
	3	1 (6%)	2 (11%)
	4	0	1 (5%)
	0+1	13 (76%)	12 (63%)
	3+4	1 (6%)	3 (16%)

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 25	n	17		14	
	0	3	(18%)	2	(14%)
	1	6	(35%)	9	(64%)
	2	7	(41%)	2	(14%)
	3	1	(6%)	1	(7%)
	4	0		0	
	0+1	9	(53%)	11	(79%)
	3+4	1	(6%)	1	(7%)
Week 29	n	14		15	
	0	3	(21%)	4	(27%)
	1	4	(29%)	7	(47%)
	2	6	(43%)	3	(20%)
	3	1	(7%)	1	(7%)
	4	0		0	
	0+1	7	(50%)	11	(73%)
	3+4	1	(7%)	1	(7%)
Week 33	n	15		11	
	0	4	(27%)	5	(45%)
	1	3	(20%)	5	(45%)
	2	5	(33%)	1	(9%)
	3	3	(20%)	0	
	4	0		0	
	0+1	7	(47%)	10	(91%)
	3+4	3	(20%)	0	

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 37	n	14		9	
	0	4	(29%)	2	(22%)
	1	4	(29%)	6	(67%)
	2	4	(29%)	0	
	3	1	(7%)	1	(11%)
	4	1	(7%)	0	
	0+1	8	(57%)	8	(89%)
	3+4	2	(14%)	1	(11%)
Week 41	n	12		9	
	0	4	(33%)	1	(11%)
	1	3	(25%)	7	(78%)
	2	5	(42%)	1	(11%)
	3	0		0	
	4	0		0	
	0+1	7	(58%)	8	(89%)
	3+4	0		0	
Week 45	n	14		9	
	0	3	(21%)	2	(22%)
	1	4	(29%)	6	(67%)
	2	6	(43%)	1	(11%)
	3	1	(7%)	0	
	4	0		0	
	0+1	7	(50%)	8	(89%)
	3+4	1	(7%)	0	

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	n	11	9
	0	4 (36%)	3 (33%)
	1	2 (18%)	5 (56%)
	2	4 (36%)	1 (11%)
	3	1 (9%)	0
	4	0	0
	0+1	6 (55%)	8 (89%)
	3+4	1 (9%)	0
Week 53	n	10	9
	0	3 (30%)	2 (22%)
	1	2 (20%)	6 (67%)
	2	5 (50%)	1 (11%)
	3	0	0
	4	0	0
	0+1	5 (50%)	8 (89%)
	3+4	0	0
Week 57	n	10	7
	0	4 (40%)	1 (14%)
	1	2 (20%)	4 (57%)
	2	3 (30%)	2 (29%)
	3	1 (10%)	0
	4	0	0
	0+1	6 (60%)	5 (71%)
	3+4	1 (10%)	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 61	n	9	6
	0	2 (22%)	1 (17%)
	1	3 (33%)	4 (67%)
	2	4 (44%)	1 (17%)
	3	0	0
	4	0	0
	0+1	5 (56%)	5 (83%)
	3+4	0	0
Week 65	n	9	6
	0	2 (22%)	1 (17%)
	1	6 (67%)	3 (50%)
	2	1 (11%)	2 (33%)
	3	0	0
	4	0	0
	0+1	8 (89%)	4 (67%)
	3+4	0	0
Week 69	n	9	6
	0	2 (22%)	1 (17%)
	1	1 (11%)	3 (50%)
	2	6 (67%)	2 (33%)
	3	0	0
	4	0	0
	0+1	3 (33%)	4 (67%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	n	9	6
	0	4 (44%)	2 (33%)
	1	2 (22%)	3 (50%)
	2	2 (22%)	1 (17%)
	3	0	0
	4	1 (11%)	0
	0+1	6 (67%)	5 (83%)
	3+4	1 (11%)	0
Week 77	n	7	5
	0	2 (29%)	2 (40%)
	1	3 (43%)	2 (40%)
	2	2 (29%)	1 (20%)
	3	0	0
	4	0	0
	0+1	5 (71%)	4 (80%)
	3+4	0	0
Week 81	n	7	5
	0	3 (43%)	2 (40%)
	1	3 (43%)	3 (60%)
	2	1 (14%)	0
	3	0	0
	4	0	0
	0+1	6 (86%)	5 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 85	n	7	4
	0	3 (43%)	1 (25%)
	1	3 (43%)	2 (50%)
	2	1 (14%)	1 (25%)
	3	0	0
	4	0	0
	0+1	6 (86%)	3 (75%)
	3+4	0	0
Week 89	n	8	5
	0	3 (38%)	2 (40%)
	1	3 (38%)	3 (60%)
	2	2 (25%)	0
	3	0	0
	4	0	0
	0+1	6 (75%)	5 (100%)
	3+4	0	0
Week 93	n	8	5
	0	4 (50%)	2 (40%)
	1	4 (50%)	2 (40%)
	2	0	1 (20%)
	3	0	0
	4	0	0
	0+1	8 (100%)	4 (80%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	n	7	5
	0	4 (57%)	1 (20%)
	1	1 (14%)	4 (80%)
	2	2 (29%)	0
	3	0	0
	4	0	0
	0+1	5 (71%)	5 (100%)
	3+4	0	0
Week 101	n	6	5
	0	2 (33%)	3 (60%)
	1	3 (50%)	2 (40%)
	2	1 (17%)	0
	3	0	0
	4	0	0
	0+1	5 (83%)	5 (100%)
	3+4	0	0
Week 105	n	6	4
	0	2 (33%)	1 (25%)
	1	3 (50%)	3 (75%)
	2	1 (17%)	0
	3	0	0
	4	0	0
	0+1	5 (83%)	4 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 109	n	7	5
	0	2 (29%)	2 (40%)
	1	3 (43%)	3 (60%)
	2	2 (29%)	0
	3	0	0
	4	0	0
	0+1	5 (71%)	5 (100%)
	3+4	0	0
Week 113	n	7	5
	0	2 (29%)	1 (20%)
	1	4 (57%)	4 (80%)
	2	1 (14%)	0
	3	0	0
	4	0	0
	0+1	6 (86%)	5 (100%)
	3+4	0	0
Week 117	n	6	4
	0	2 (33%)	2 (50%)
	1	3 (50%)	2 (50%)
	2	1 (17%)	0
	3	0	0
	4	0	0
	0+1	5 (83%)	4 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	n	5	5
	0	2 (40%)	1 (20%)
	1	2 (40%)	4 (80%)
	2	1 (20%)	0
	3	0	0
	4	0	0
	0+1	4 (80%)	5 (100%)
	3+4	0	0
Week 125	n	5	5
	0	3 (60%)	1 (20%)
	1	1 (20%)	4 (80%)
	2	1 (20%)	0
	3	0	0
	4	0	0
	0+1	4 (80%)	5 (100%)
	3+4	0	0
Week 129	n	5	4
	0	3 (60%)	2 (50%)
	1	1 (20%)	2 (50%)
	2	1 (20%)	0
	3	0	0
	4	0	0
	0+1	4 (80%)	4 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 133	n	4	4
	0	2 (50%)	2 (50%)
	1	0	2 (50%)
	2	1 (25%)	0
	3	1 (25%)	0
	4	0	0
	0+1	2 (50%)	4 (100%)
	3+4	1 (25%)	0
Week 137	n	5	3
	0	2 (40%)	1 (33%)
	1	1 (20%)	2 (67%)
	2	2 (40%)	0
	3	0	0
	4	0	0
	0+1	3 (60%)	3 (100%)
	3+4	0	0
Week 141	n	5	2
	0	3 (60%)	0
	1	1 (20%)	2 (100%)
	2	1 (20%)	0
	3	0	0
	4	0	0
	0+1	4 (80%)	2 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	n	5	2
	0	3 (60%)	1 (50%)
	1	1 (20%)	1 (50%)
	2	1 (20%)	0
	3	0	0
	4	0	0
	0+1	4 (80%)	2 (100%)
	3+4	0	0
Week 149	n	5	2
	0	3 (60%)	1 (50%)
	1	1 (20%)	1 (50%)
	2	1 (20%)	0
	3	0	0
	4	0	0
	0+1	4 (80%)	2 (100%)
	3+4	0	0
Week 153	n	3	2
	0	2 (67%)	1 (50%)
	1	0	1 (50%)
	2	1 (33%)	0
	3	0	0
	4	0	0
	0+1	2 (67%)	2 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 157	n	5	2
	0	3 (60%)	0
	1	1 (20%)	2 (100%)
	2	1 (20%)	0
	3	0	0
	4	0	0
	0+1	4 (80%)	2 (100%)
	3+4	0	0
Week 161	n	5	1
	0	2 (40%)	0
	1	0	1 (100%)
	2	3 (60%)	0
	3	0	0
	4	0	0
	0+1	2 (40%)	1 (100%)
	3+4	0	0
Week 165	n	5	2
	0	3 (60%)	1 (50%)
	1	1 (20%)	1 (50%)
	2	1 (20%)	0
	3	0	0
	4	0	0
	0+1	4 (80%)	2 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	n	5	1
	0	2 (40%)	0
	1	1 (20%)	1 (100%)
	2	1 (20%)	0
	3	1 (20%)	0
	4	0	0
	0+1	3 (60%)	1 (100%)
	3+4	1 (20%)	0
Week 173	n	5	1
	0	2 (40%)	1 (100%)
	1	1 (20%)	0
	2	0	0
	3	1 (20%)	0
	4	1 (20%)	0
	0+1	3 (60%)	1 (100%)
	3+4	2 (40%)	0
Week 177	n	3	1
	0	2 (67%)	0
	1	1 (33%)	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	0+1	3 (100%)	1 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 181	n	3	1
	0	2 (67%)	0
	1	1 (33%)	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	0+1	3 (100%)	1 (100%)
	3+4	0	0
Week 185	n	2	1
	0	2 (100%)	0
	1	0	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	0+1	2 (100%)	1 (100%)
	3+4	0	0
Week 189	n	1	1
	0	1 (100%)	0
	1	0	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	0+1	1 (100%)	1 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	n	2	1
	0	2 (100%)	1 (100%)
	1	0	0
	2	0	0
	3	0	0
	4	0	0
	0+1	2 (100%)	1 (100%)
	3+4	0	0
Week 197	n	1	1
	0	1 (100%)	0
	1	0	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	0+1	1 (100%)	1 (100%)
	3+4	0	0
Week 201	n	1	1
	0	1 (100%)	1 (100%)
	1	0	0
	2	0	0
	3	0	0
	4	0	0
	0+1	1 (100%)	1 (100%)
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
End of Treatment	n	18	20
	0	2 (11%)	4 (20%)
	1	4 (22%)	4 (20%)
	2	5 (28%)	5 (25%)
	3	4 (22%)	5 (25%)
	4	3 (17%)	2 (10%)
	0+1	6 (33%)	8 (40%)
	3+4	7 (39%)	7 (35%)
Unscheduled	n	0	1
	0	0	0
	1	0	0
	2	0	1 (100%)
	3	0	0
	4	0	0
	0+1	0	0
	3+4	0	0
Last Follow-up	n	2	0
	0	0	0
	1	1 (50%)	0
	2	1 (50%)	0
	3	0	0
	4	0	0
	0+1	1 (50%)	0
	3+4	0	0

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Table 4.0002405
Summary of PGIC Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Change	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Worst Case Post Baseline	n	26	31
	0	1 (4%)	1 (3%)
	1	4 (15%)	6 (19%)
	2	8 (31%)	13 (42%)
	3	9 (35%)	8 (26%)
	4	4 (15%)	3 (10%)
	0+1	5 (19%)	7 (23%)
	3+4	13 (50%)	11 (35%)

Note: 0 = Much Better, 1 = A little better, 2 = No change, 3 = A little worse, 4 = Much worse.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgic_2ref.sas 09OCT2025 10:14

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002705
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	13 (43%)	11 (33%)
Censored	17 (57%)	22 (67%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.2 (1.1, 7.6)	3.8 (1.1, 8.7)
Median (95% CI)	8.6 (4.2, -)	- (4.5, -)
3rd Quartile (95% CI)	- (11.5, -)	- (-, -)
Log-Rank P-value [2]	0.71815	
Hazard Ratio (95% CI) [3]	1.16 (0.52, 2.61)	
P-value [3]	0.71894	

Note: If a subject is not a negative responder, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_pgic_ttfneg_2ref.sas 09OCT2025 10:15

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002715
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Event	7 (64%)	2 (29%)
	Censored	4 (36%)	5 (71%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.5 (1.0, 8.6)	8.4 (3.8, -)
	Median (95% CI)	8.6 (1.0, 39.0)	8.4 (3.8, -)
	3rd Quartile (95% CI)	39.0 (7.6, -)	- (3.8, -)
	Log-Rank P-value [2]	0.61486	
	Hazard Ratio (95% CI) [3]	1.51 (0.30, 7.64)	
	P-value [3]	0.61736	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_age.sas 09OCT2025 10:14

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002715
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Event	5 (33%)	6 (40%)
	Censored	10 (67%)	9 (60%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.1, -)	3.6 (0.7, 8.7)
	Median (95% CI)	- (3.8, -)	8.7 (2.8, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (8.7, -)
	Log-Rank P-value [2]	0.68336	
	Hazard Ratio (95% CI) [3]	0.78 (0.24, 2.57)	
	P-value [3]	0.68444	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_age.sas 09OCT2025 10:14

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002715
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Event	1 (25%)	3 (27%)
	Censored	3 (75%)	8 (73%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (2.0, -)	4.7 (1.1, -)
	Median (95% CI)	- (2.0, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (2.0, -)	- (4.7, -)
	Log-Rank P-value [2]	0.98949	
	Hazard Ratio (95% CI) [3]	0.98 (0.10, 9.51)	
	P-value [3]	0.98953	
Interaction Test	P-value [4]	0.64169	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_age.sas 09OCT2025 10:14

Table 4.0002725
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Event	7 (54%)	5 (31%)
	Censored	6 (46%)	11 (69%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.1, 7.6)	4.5 (1.0, 8.7)
	Median (95% CI)	7.4 (2.0, -)	8.7 (3.6, -)
	3rd Quartile (95% CI)	8.6 (7.4, -)	- (8.7, -)
	Log-Rank P-value [2]	0.51286	
	Hazard Ratio (95% CI) [3]	1.47 (0.46, 4.67)	
	P-value [3]	0.51532	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_gen.sas 09OCT2025 10:15

Table 4.0002725
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Event	6 (35%)	6 (35%)
	Censored	11 (65%)	11 (65%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.0, 39.0)	2.8 (0.7, -)
	Median (95% CI)	39.0 (3.8, -)	- (2.8, -)
	3rd Quartile (95% CI)	- (39.0, -)	- (8.4, -)
	Log-Rank P-value [2]	0.71871	
	Hazard Ratio (95% CI) [3]	0.80 (0.25, 2.64)	
	P-value [3]	0.71924	
Interaction Test	P-value [4]	0.47934	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_gen.sas 09OCT2025 10:15

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002735
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Event	8 (40%)	9 (38%)
	Censored	12 (60%)	15 (63%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (1.0, 7.6)	3.8 (1.0, 8.4)
	Median (95% CI)	7.6 (2.9, -)	8.7 (3.8, -)
	3rd Quartile (95% CI)	- (6.5, -)	- (8.4, -)
	Log-Rank P-value [2]	0.59804	
	Hazard Ratio (95% CI) [3]	1.29 (0.50, 3.35)	
	P-value [3]	0.59875	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_reg.sas 09OCT2025 10:15

Table 4.0002735
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Event	5 (50%)	2 (22%)
	Censored	5 (50%)	7 (78%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	7.4 (2.0, 39.0)	- (0.7, -)
	Median (95% CI)	39.0 (2.0, -)	- (0.7, -)
	3rd Quartile (95% CI)	- (11.5, -)	- (-, -)
	Log-Rank P-value [2]	0.74470	
	Hazard Ratio (95% CI) [3]	1.33 (0.24, 7.27)	
	P-value [3]	0.74551	
Interaction Test	P-value [4]	0.84668	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_reg.sas 09OCT2025 10:15

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002745
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Event	9 (50%)	4 (27%)
	Censored	9 (50%)	11 (73%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	6.5 (1.0, 7.6)	6.6 (3.8, -)
	Median (95% CI)	11.5 (3.8, -)	- (4.5, -)
	3rd Quartile (95% CI)	- (11.5, -)	- (8.4, -)
	Log-Rank P-value [2]	0.40446	
	Hazard Ratio (95% CI) [3]	1.66 (0.50, 5.53)	
	P-value [3]	0.40946	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_iss.sas 09OCT2025 10:15

Table 4.0002745
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Event	4 (33%)	7 (39%)
	Censored	8 (67%)	11 (61%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.1, 8.6)	2.8 (0.7, 8.7)
	Median (95% CI)	8.6 (1.1, -)	8.7 (2.8, -)
	3rd Quartile (95% CI)	- (4.2, -)	- (8.7, -)
	Log-Rank P-value [2]	0.70104	
	Hazard Ratio (95% CI) [3]	0.79 (0.23, 2.71)	
	P-value [3]	0.70486	
Interaction Test	P-value [4]	0.35426	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_iss.sas 09OCT2025 10:15

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002755
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Event	5 (63%)	2 (33%)
	Censored	3 (38%)	4 (67%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.1, 6.5)	8.7 (1.1, -)
	Median (95% CI)	6.5 (1.1, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (4.2, -)	- (8.7, -)
	Log-Rank P-value [2]	0.23832	
	Hazard Ratio (95% CI) [3]	2.57 (0.49, 13.33)	
	P-value [3]	0.26191	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_line.sas 09OCT2025 10:16

Table 4.0002755
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Event	5 (38%)	6 (43%)
	Censored	8 (62%)	8 (57%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	7.4 (1.0, 11.5)	2.8 (0.7, 8.4)
	Median (95% CI)	11.5 (2.9, -)	4.7 (1.0, -)
	3rd Quartile (95% CI)	- (8.6, -)	8.4 (3.8, -)
	Log-Rank P-value [2]	0.16588	
	Hazard Ratio (95% CI) [3]	0.42 (0.12, 1.47)	
	P-value [3]	0.17620	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_line.sas 09OCT2025 10:16

Table 4.0002755
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Event	3 (33%)	3 (23%)
	Censored	6 (67%)	10 (77%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.9, -)	4.5 (2.8, -)
	Median (95% CI)	39.0 (1.9, -)	- (3.6, -)
	3rd Quartile (95% CI)	39.0 (3.8, -)	- (-, -)
	Log-Rank P-value [2]	0.51662	
	Hazard Ratio (95% CI) [3]	1.70 (0.34, 8.55)	
	P-value [3]	0.52120	
Interaction Test	P-value [4]	0.18466	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_line.sas 09OCT2025 10:16

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002775
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Event	10 (48%)	8 (40%)
	Censored	11 (52%)	12 (60%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.0, 7.6)	3.8 (0.7, 8.4)
	Median (95% CI)	8.6 (4.2, -)	8.7 (2.8, -)
	3rd Quartile (95% CI)	- (8.6, -)	- (8.4, -)
	Log-Rank P-value [2]	0.84297	
	Hazard Ratio (95% CI) [3]	0.91 (0.36, 2.32)	
	P-value [3]	0.84296	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_line2.sas 09OCT2025 10:16

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002775
Summary of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Event	3 (33%)	3 (23%)
	Censored	6 (67%)	10 (77%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.9, -)	4.5 (2.8, -)
	Median (95% CI)	39.0 (1.9, -)	- (3.6, -)
	3rd Quartile (95% CI)	39.0 (3.8, -)	- (-, -)
	Log-Rank P-value [2]	0.51662	
	Hazard Ratio (95% CI) [3]	1.70 (0.34, 8.55)	
	P-value [3]	0.52120	
Interaction Test	P-value [4]	0.43079	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfneg_2ref_line2.sas 09OCT2025 10:16

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002805
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	26 (87%)	28 (85%)
Censored	4 (13%)	5 (15%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.0 (0.9, 1.0)	1.0 (0.9, 1.1)
Median (95% CI)	1.2 (1.0, 2.0)	1.1 (1.0, 1.7)
3rd Quartile (95% CI)	2.0 (1.9, 3.8)	1.9 (1.1, 3.0)
Log-Rank P-value [2]	0.52784	
Inverse Hazard Ratio (95% CI) [3]	1.18 (0.68, 2.04)	
P-value [3]	0.55646	

Note: If a subject is not a positive responder, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_pgic_ttfpos_2ref.sas 09OCT2025 10:16

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002815
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Event	10 (91%)	6 (86%)
	Censored	1 (9%)	1 (14%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.2)	1.1 (0.9, 1.2)
	Median (95% CI)	1.1 (1.0, 2.0)	1.1 (0.9, -)
	3rd Quartile (95% CI)	2.0 (1.0, -)	2.8 (1.1, -)
	Log-Rank P-value [2]	0.97517	
	Inverse Hazard Ratio (95% CI) [3]	0.96 (0.34, 2.72)	
	P-value [3]	0.94286	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_age.sas 09OCT2025 10:16

Table 4.0002815
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Event	13 (87%)	13 (87%)
	Censored	2 (13%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.9)	1.0 (0.7, 1.1)
	Median (95% CI)	1.9 (0.9, 2.0)	1.1 (1.0, 1.8)
	3rd Quartile (95% CI)	2.0 (1.1, -)	1.8 (1.1, -)
	Log-Rank P-value [2]	0.45470	
	Inverse Hazard Ratio (95% CI) [3]	1.35 (0.61, 3.01)	
	P-value [3]	0.45630	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_age.sas 09OCT2025 10:16

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002815
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Event	3 (75%)	9 (82%)
	Censored	1 (25%)	2 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, -)	1.0 (1.0, 1.1)
	Median (95% CI)	1.1 (1.0, -)	1.1 (1.0, 2.9)
	3rd Quartile (95% CI)	11.2 (1.0, -)	2.9 (1.1, -)
	Log-Rank P-value [2]	0.46133	
	Inverse Hazard Ratio (95% CI) [3]	1.69 (0.36, 8.00)	
	P-value [3]	0.50778	
Interaction Test	P-value [4]	0.83669	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_age.sas 09OCT2025 10:16

Table 4.0002825
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Event	11 (85%)	14 (88%)
	Censored	2 (15%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.9)	1.0 (0.7, 1.0)
	Median (95% CI)	1.9 (1.0, 2.8)	1.1 (1.0, 1.1)
	3rd Quartile (95% CI)	2.8 (1.1, -)	1.2 (1.1, -)
	Log-Rank P-value [2]	0.28481	
	Inverse Hazard Ratio (95% CI) [3]	1.54 (0.68, 3.50)	
	P-value [3]	0.30404	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_gen.sas 09OCT2025 10:16

Table 4.0002825
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Event	15 (88%)	14 (82%)
	Censored	2 (12%)	3 (18%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.0)	1.0 (0.7, 1.1)
	Median (95% CI)	1.1 (1.0, 1.9)	1.4 (1.0, 1.9)
	3rd Quartile (95% CI)	2.0 (1.1, -)	2.8 (1.4, -)
	Log-Rank P-value [2]	0.81049	
	Inverse Hazard Ratio (95% CI) [3]	0.91 (0.43, 1.92)	
	P-value [3]	0.80473	
Interaction Test	P-value [4]	0.29773	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_gen.sas 09OCT2025 10:16

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002835
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Event	16 (80%)	21 (88%)
	Censored	4 (20%)	3 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.0)	1.0 (0.7, 1.1)
	Median (95% CI)	1.1 (1.0, 2.0)	1.1 (1.0, 1.4)
	3rd Quartile (95% CI)	2.0 (1.0, 3.8)	1.8 (1.1, 3.0)
	Log-Rank P-value [2]	0.59191	
	Inverse Hazard Ratio (95% CI) [3]	1.19 (0.60, 2.36)	
	P-value [3]	0.60841	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_reg.sas 09OCT2025 10:17

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002835
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Event	10 (100%)	7 (78%)
	Censored	0	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.9)	1.0 (1.0, 1.7)
	Median (95% CI)	1.9 (0.9, 2.8)	1.4 (1.0, 2.8)
	3rd Quartile (95% CI)	2.8 (1.9, -)	2.3 (1.0, -)
	Log-Rank P-value [2]	0.66610	
	Inverse Hazard Ratio (95% CI) [3]	1.24 (0.46, 3.35)	
	P-value [3]	0.67211	
Interaction Test	P-value [4]	0.87415	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_reg.sas 09OCT2025 10:17

Table 4.0002845
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Event	17 (94%)	14 (93%)
	Censored	1 (6%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.1)	1.1 (0.7, 1.1)
	Median (95% CI)	1.1 (1.0, 2.8)	1.2 (1.0, 1.9)
	3rd Quartile (95% CI)	2.8 (1.1, 11.2)	1.9 (1.1, -)
	Log-Rank P-value [2]	0.35539	
	Inverse Hazard Ratio (95% CI) [3]	1.40 (0.66, 2.95)	
	P-value [3]	0.38307	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_iss.sas 09OCT2025 10:16

Table 4.0002845
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Event	9 (75%)	14 (78%)
	Censored	3 (25%)	4 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.2)	1.0 (0.7, 1.0)
	Median (95% CI)	1.2 (0.8, 2.0)	1.0 (1.0, 1.4)
	3rd Quartile (95% CI)	1.9 (1.0, -)	2.1 (1.0, -)
	Log-Rank P-value [2]	0.83344	
	Inverse Hazard Ratio (95% CI) [3]	0.92 (0.39, 2.17)	
	P-value [3]	0.85579	
Interaction Test	P-value [4]	0.47075	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_iss.sas 09OCT2025 10:16

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002855
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Event	7 (88%)	6 (100%)
	Censored	1 (13%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.9, 2.0)	1.0 (0.7, 1.8)
	Median (95% CI)	2.0 (0.9, 2.8)	1.4 (0.7, -)
	3rd Quartile (95% CI)	2.8 (1.9, -)	1.9 (1.0, -)
	Log-Rank P-value [2]	0.31486	
	Inverse Hazard Ratio (95% CI) [3]	1.73 (0.54, 5.51)	
	P-value [3]	0.35578	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_line.sas 09OCT2025 10:17

Table 4.0002855
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Event	12 (92%)	10 (71%)
	Censored	1 (8%)	4 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.0)	1.0 (0.9, 1.1)
	Median (95% CI)	1.0 (1.0, 1.9)	1.1 (1.0, 2.8)
	3rd Quartile (95% CI)	1.5 (1.0, -)	2.8 (1.1, -)
	Log-Rank P-value [2]	0.37682	
	Inverse Hazard Ratio (95% CI) [3]	0.70 (0.30, 1.63)	
	P-value [3]	0.41052	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_line.sas 09OCT2025 10:17

Table 4.0002855
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Event	7 (78%)	12 (92%)
	Censored	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.9)	1.0 (0.7, 1.1)
	Median (95% CI)	1.9 (1.0, 2.9)	1.1 (1.0, 1.7)
	3rd Quartile (95% CI)	2.9 (1.0, -)	1.7 (1.1, -)
	Log-Rank P-value [2]	0.24539	
	Inverse Hazard Ratio (95% CI) [3]	1.76 (0.65, 4.78)	
	P-value [3]	0.26821	
Interaction Test	P-value [4]	0.24621	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_line.sas 09OCT2025 10:17

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002875
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Event	19 (90%)	16 (80%)
	Censored	2 (10%)	4 (20%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.1)	1.0 (0.7, 1.1)
	Median (95% CI)	1.1 (1.0, 2.0)	1.1 (1.0, 1.9)
	3rd Quartile (95% CI)	2.0 (1.1, 3.8)	2.8 (1.1, -)
	Log-Rank P-value [2]	0.93278	
	Inverse Hazard Ratio (95% CI) [3]	0.96 (0.49, 1.89)	
	P-value [3]	0.91250	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_line2.sas 09OCT2025 10:17

Table 4.0002875
Summary of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Event	7 (78%)	12 (92%)
	Censored	2 (22%)	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (1.0, 1.9)	1.0 (0.7, 1.1)
	Median (95% CI)	1.9 (1.0, 2.9)	1.1 (1.0, 1.7)
	3rd Quartile (95% CI)	2.9 (1.0, -)	1.7 (1.1, -)
	Log-Rank P-value [2]	0.24539	
	Inverse Hazard Ratio (95% CI) [3]	1.76 (0.65, 4.78)	
	P-value [3]	0.26821	
Interaction Test	P-value [4]	0.24973	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgic_ttfpos_2ref_line2.sas 09OCT2025 10:17

1.3.1.7 PGIS

Protocol: 207499 Page 1 of 53
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Baseline	n	27		32	
	0	6	(22%)	7	(22%)
	1	6	(22%)	9	(28%)
	2	13	(48%)	10	(31%)
	3	2	(7%)	4	(13%)
	4	0		2	(6%)
	3+4	2	(7%)	6	(19%)
	Any Scale > 0	21	(78%)	25	(78%)
Week 5	n	25		29	
	0	8	(32%)	6	(21%)
	1	9	(36%)	14	(48%)
	2	8	(32%)	7	(24%)
	3	0		0	
	4	0		2	(7%)
	3+4	0		2	(7%)
	Any Scale > 0	17	(68%)	23	(79%)
	Worsening in PGIS score >=1 from Baseline	2/24	(8%)	4/28	(14%)
	Improvement in PGIS score >=1 from Baseline	10/24	(42%)	14/28	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 9	n	24		27	
	0	6	(25%)	12	(44%)
	1	9	(38%)	7	(26%)
	2	9	(38%)	7	(26%)
	3	0		0	
	4	0		1	(4%)
	3+4	0		1	(4%)
	Any Scale > 0	18	(75%)	15	(56%)
	Worsening in PGIS score >=1 from Baseline	3/23	(13%)	2/26	(8%)
	Improvement in PGIS score >=1 from Baseline	6/23	(26%)	13/26	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 13	n	23		27	
	0	7	(30%)	11	(41%)
	1	8	(35%)	10	(37%)
	2	8	(35%)	4	(15%)
	3	0		1	(4%)
	4	0		1	(4%)
	3+4	0		2	(7%)
	Any Scale > 0	16	(70%)	16	(59%)
	Worsening in PGIS score >=1 from Baseline	2/22	(9%)	4/27	(15%)
	Improvement in PGIS score >=1 from Baseline	9/22	(41%)	15/27	(56%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 17	n	22		24	
	0	5	(23%)	8	(33%)
	1	10	(45%)	11	(46%)
	2	7	(32%)	2	(8%)
	3	0		1	(4%)
	4	0		2	(8%)
	3+4	0		3	(13%)
	Any Scale > 0	17	(77%)	16	(67%)
	Worsening in PGIS score >=1 from Baseline	3/21	(14%)	3/24	(13%)
	Improvement in PGIS score >=1 from Baseline	8/21	(38%)	13/24	(54%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 21	n	17		19	
	0	5	(29%)	9	(47%)
	1	9	(53%)	4	(21%)
	2	3	(18%)	6	(32%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	12	(71%)	10	(53%)
	Worsening in PGIS score >=1 from Baseline	3/16	(19%)	4/19	(21%)
	Improvement in PGIS score >=1 from Baseline	7/16	(44%)	12/19	(63%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 25	n	17		15	
	0	3	(18%)	6	(40%)
	1	10	(59%)	7	(47%)
	2	4	(24%)	2	(13%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	14	(82%)	9	(60%)
	Worsening in PGIS score >=1 from Baseline	3/16	(19%)	2/15	(13%)
	Improvement in PGIS score >=1 from Baseline	6/16	(38%)	7/15	(47%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 29	n	14		15	
	0	3	(21%)	6	(40%)
	1	9	(64%)	6	(40%)
	2	2	(14%)	3	(20%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	11	(79%)	9	(60%)
	Worsening in PGIS score >=1 from Baseline	3/13	(23%)	2/15	(13%)
	Improvement in PGIS score >=1 from Baseline	5/13	(38%)	7/15	(47%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 33	n	15		11	
	0	2	(13%)	8	(73%)
	1	6	(40%)	2	(18%)
	2	6	(40%)	1	(9%)
	3	1	(7%)	0	
	4	0		0	
	3+4	1	(7%)	0	
	Any Scale > 0	13	(87%)	3	(27%)
	Worsening in PGIS score >=1 from Baseline	7/14	(50%)	3/11	(27%)
	Improvement in PGIS score >=1 from Baseline	6/14	(43%)	8/11	(73%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 37	n	14		9	
	0	4	(29%)	3	(33%)
	1	4	(29%)	4	(44%)
	2	6	(43%)	2	(22%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	10	(71%)	6	(67%)
	Worsening in PGIS score >=1 from Baseline	3/13	(23%)	2/ 9	(22%)
	Improvement in PGIS score >=1 from Baseline	7/13	(54%)	6/ 9	(67%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 41	n	12		9	
	0	2	(17%)	5	(56%)
	1	5	(42%)	1	(11%)
	2	5	(42%)	3	(33%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	10	(83%)	4	(44%)
	Worsening in PGIS score >=1 from Baseline	3/11	(27%)	3/ 9	(33%)
	Improvement in PGIS score >=1 from Baseline	5/11	(45%)	5/ 9	(56%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 45	n	14		9	
	0	2	(14%)	4	(44%)
	1	6	(43%)	5	(56%)
	2	6	(43%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	12	(86%)	5	(56%)
	Worsening in PGIS score >=1 from Baseline	5/13	(38%)	2/ 9	(22%)
	Improvement in PGIS score >=1 from Baseline	5/13	(38%)	6/ 9	(67%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 49	n	11		9	
	0	1	(9%)	5	(56%)
	1	7	(64%)	4	(44%)
	2	3	(27%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	10	(91%)	4	(44%)
	Worsening in PGIS score >=1 from Baseline	1/11	(9%)	2/ 9	(22%)
	Improvement in PGIS score >=1 from Baseline	6/11	(55%)	6/ 9	(67%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 53	n	10		9	
	0	4	(40%)	4	(44%)
	1	1	(10%)	4	(44%)
	2	5	(50%)	1	(11%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	6	(60%)	5	(56%)
	Worsening in PGIS score >=1 from Baseline	3/ 9	(33%)	1/ 9	(11%)
	Improvement in PGIS score >=1 from Baseline	3/ 9	(33%)	4/ 9	(44%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 57	n	10		7	
	0	2	(20%)	3	(43%)
	1	5	(50%)	2	(29%)
	2	3	(30%)	2	(29%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	8	(80%)	4	(57%)
	Worsening in PGIS score >=1 from Baseline	2/10	(20%)	2/ 7	(29%)
	Improvement in PGIS score >=1 from Baseline	3/10	(30%)	4/ 7	(57%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 61	n	9		6	
	0	1	(11%)	1	(17%)
	1	3	(33%)	4	(67%)
	2	5	(56%)	1	(17%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	8	(89%)	5	(83%)
	Worsening in PGIS score >=1 from Baseline	4/ 9	(44%)	2/ 6	(33%)
	Improvement in PGIS score >=1 from Baseline	4/ 9	(44%)	3/ 6	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 65	n	9		6	
	0	1	(11%)	2	(33%)
	1	4	(44%)	3	(50%)
	2	4	(44%)	1	(17%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	8	(89%)	4	(67%)
	Worsening in PGIS score >=1 from Baseline	3/ 9	(33%)	2/ 6	(33%)
	Improvement in PGIS score >=1 from Baseline	4/ 9	(44%)	3/ 6	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 69	n	9		6	
	0	3	(33%)	3	(50%)
	1	3	(33%)	2	(33%)
	2	3	(33%)	1	(17%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	6	(67%)	3	(50%)
	Worsening in PGIS score >=1 from Baseline	3/ 9	(33%)	2/ 6	(33%)
	Improvement in PGIS score >=1 from Baseline	6/ 9	(67%)	3/ 6	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 73	n	9		6	
	0	2	(22%)	2	(33%)
	1	4	(44%)	4	(67%)
	2	3	(33%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	7	(78%)	4	(67%)
	Worsening in PGIS score >=1 from Baseline	3/ 9	(33%)	2/ 6	(33%)
	Improvement in PGIS score >=1 from Baseline	3/ 9	(33%)	3/ 6	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 77	n	7		5	
	0	1	(14%)	3	(60%)
	1	2	(29%)	1	(20%)
	2	4	(57%)	1	(20%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	6	(86%)	2	(40%)
	Worsening in PGIS score >=1 from Baseline	3/ 7	(43%)	1/ 5	(20%)
	Improvement in PGIS score >=1 from Baseline	2/ 7	(29%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 81	n	7		5	
	0	1	(14%)	3	(60%)
	1	4	(57%)	2	(40%)
	2	2	(29%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	6	(86%)	2	(40%)
	Worsening in PGIS score >=1 from Baseline	2/ 7	(29%)	0/ 5	
	Improvement in PGIS score >=1 from Baseline	3/ 7	(43%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 85	n	7		4	
	0	3	(43%)	3	(75%)
	1	2	(29%)	1	(25%)
	2	2	(29%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	4	(57%)	1	(25%)
	Worsening in PGIS score >=1 from Baseline	2/ 7	(29%)	0/ 4	
	Improvement in PGIS score >=1 from Baseline	4/ 7	(57%)	3/ 4	(75%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 89	n	8		5	
	0	1	(13%)	2	(40%)
	1	4	(50%)	2	(40%)
	2	3	(38%)	1	(20%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	7	(88%)	3	(60%)
	Worsening in PGIS score >=1 from Baseline	3/ 7	(43%)	2/ 5	(40%)
	Improvement in PGIS score >=1 from Baseline	3/ 7	(43%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 93	n	8		5	
	0	2	(25%)	3	(60%)
	1	4	(50%)	1	(20%)
	2	2	(25%)	1	(20%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	6	(75%)	2	(40%)
	Worsening in PGIS score >=1 from Baseline	3/ 8	(38%)	1/ 5	(20%)
	Improvement in PGIS score >=1 from Baseline	4/ 8	(50%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 97	n	7		5	
	0	2	(29%)	2	(40%)
	1	2	(29%)	2	(40%)
	2	3	(43%)	1	(20%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	5	(71%)	3	(60%)
	Worsening in PGIS score >=1 from Baseline	2/ 6	(33%)	2/ 5	(40%)
	Improvement in PGIS score >=1 from Baseline	3/ 6	(50%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 101	n	7		5	
	0	4	(57%)	2	(40%)
	1	2	(29%)	3	(60%)
	2	1	(14%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	3	(43%)	3	(60%)
	Worsening in PGIS score >=1 from Baseline	2/ 7	(29%)	0/ 5	
	Improvement in PGIS score >=1 from Baseline	4/ 7	(57%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	n	6	4
	0	0	1 (25%)
	1	4 (67%)	3 (75%)
	2	2 (33%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	6 (100%)	3 (75%)
	Worsening in PGIS score >=1 from Baseline	2/ 6 (33%)	0/ 4
	Improvement in PGIS score >=1 from Baseline	2/ 6 (33%)	2/ 4 (50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 109	n	7		5	
	0	1	(14%)	3	(60%)
	1	3	(43%)	2	(40%)
	2	3	(43%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	6	(86%)	2	(40%)
	Worsening in PGIS score >=1 from Baseline	2/ 7	(29%)	0/ 5	
	Improvement in PGIS score >=1 from Baseline	1/ 7	(14%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 113	n	7		5	
	0	1	(14%)	2	(40%)
	1	5	(71%)	3	(60%)
	2	1	(14%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	6	(86%)	3	(60%)
	Worsening in PGIS score >=1 from Baseline	2/ 7	(29%)	0/ 5	
	Improvement in PGIS score >=1 from Baseline	3/ 7	(43%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 117	n	6	4
	0	0	2 (50%)
	1	2 (33%)	2 (50%)
	2	3 (50%)	0
	3	1 (17%)	0
	4	0	0
	3+4	1 (17%)	0
	Any Scale > 0	6 (100%)	2 (50%)
	Worsening in PGIS score >=1 from Baseline	2/ 6 (33%)	0/ 4
	Improvement in PGIS score >=1 from Baseline	1/ 6 (17%)	2/ 4 (50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 121	n	5		5	
	0	1	(20%)	1	(20%)
	1	2	(40%)	4	(80%)
	2	2	(40%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	4	(80%)	4	(80%)
	Worsening in PGIS score >=1 from Baseline	2/ 5	(40%)	1/ 5	(20%)
	Improvement in PGIS score >=1 from Baseline	2/ 5	(40%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 125	n	5		5	
	0	1	(20%)	1	(20%)
	1	1	(20%)	4	(80%)
	2	3	(60%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	4	(80%)	4	(80%)
	Worsening in PGIS score >=1 from Baseline	2/ 5	(40%)	0/ 5	
	Improvement in PGIS score >=1 from Baseline	1/ 5	(20%)	3/ 5	(60%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	n	5	4
	0	0	2 (50%)
	1	4 (80%)	0
	2	1 (20%)	2 (50%)
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	5 (100%)	2 (50%)
	Worsening in PGIS score >=1 from Baseline	1/ 5 (20%)	1/ 4 (25%)
	Improvement in PGIS score >=1 from Baseline	2/ 5 (40%)	1/ 4 (25%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 133	n	4		4	
	0	1	(25%)	2	(50%)
	1	1	(25%)	2	(50%)
	2	2	(50%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	3	(75%)	2	(50%)
	Worsening in PGIS score >=1 from Baseline	2/ 4	(50%)	0/ 4	
	Improvement in PGIS score >=1 from Baseline	1/ 4	(25%)	2/ 4	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	n	5	3
	0	0	1 (33%)
	1	4 (80%)	1 (33%)
	2	1 (20%)	1 (33%)
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	5 (100%)	2 (67%)
	Worsening in PGIS score >=1 from Baseline	1/ 5 (20%)	0/ 3
	Improvement in PGIS score >=1 from Baseline	2/ 5 (40%)	0/ 3

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 141	n	5		2	
	0	1	(20%)	0	
	1	2	(40%)	1	(50%)
	2	2	(40%)	1	(50%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	4	(80%)	2	(100%)
	Worsening in PGIS score >=1 from Baseline	1/ 5	(20%)	1/ 2	(50%)
	Improvement in PGIS score >=1 from Baseline	1/ 5	(20%)	1/ 2	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 145	n	5		2	
	0	1	(20%)	1	(50%)
	1	3	(60%)	1	(50%)
	2	1	(20%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	4	(80%)	1	(50%)
	Worsening in PGIS score >=1 from Baseline	1/ 5	(20%)	0/ 2	
	Improvement in PGIS score >=1 from Baseline	2/ 5	(40%)	1/ 2	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 149	n	5		2	
	0	1	(20%)	1	(50%)
	1	3	(60%)	1	(50%)
	2	1	(20%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	4	(80%)	1	(50%)
	Worsening in PGIS score >=1 from Baseline	1/ 5	(20%)	0/ 2	
	Improvement in PGIS score >=1 from Baseline	2/ 5	(40%)	1/ 2	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	n	3	2
	0	0	0
	1	2 (67%)	2 (100%)
	2	1 (33%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	3 (100%)	2 (100%)
	Worsening in PGIS score >=1 from Baseline	1/ 3 (33%)	1/ 2 (50%)
	Improvement in PGIS score >=1 from Baseline	0/ 3	1/ 2 (50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 157	n	5		2	
	0	1	(20%)	1	(50%)
	1	3	(60%)	1	(50%)
	2	0		0	
	3	1	(20%)	0	
	4	0		0	
	3+4	1	(20%)	0	
	Any Scale > 0	4	(80%)	1	(50%)
	Worsening in PGIS score >=1 from Baseline	1/ 5	(20%)	0/ 2	
	Improvement in PGIS score >=1 from Baseline	2/ 5	(40%)	1/ 2	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 161	n	5		1	
	0	2	(40%)	0	
	1	1	(20%)	1	(100%)
	2	2	(40%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	3	(60%)	1	(100%)
	Worsening in PGIS score >=1 from Baseline	2/ 5	(40%)	0/ 1	
	Improvement in PGIS score >=1 from Baseline	2/ 5	(40%)	1/ 1	(100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 165	n	5		2	
	0	2	(40%)	1	(50%)
	1	1	(20%)	1	(50%)
	2	2	(40%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	3	(60%)	1	(50%)
	Worsening in PGIS score >=1 from Baseline	2/ 5	(40%)	0/ 2	
	Improvement in PGIS score >=1 from Baseline	2/ 5	(40%)	1/ 2	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 169	n	5		1	
	0	3	(60%)	0	
	1	1	(20%)	1	(100%)
	2	1	(20%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	2	(40%)	1	(100%)
	Worsening in PGIS score >=1 from Baseline	1/ 5	(20%)	0/ 1	
	Improvement in PGIS score >=1 from Baseline	3/ 5	(60%)	1/ 1	(100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 173	n	5	1
	0	0	0
	1	2 (40%)	1 (100%)
	2	3 (60%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	5 (100%)	1 (100%)
	Worsening in PGIS score >=1 from Baseline	3/ 5 (60%)	0/ 1
	Improvement in PGIS score >=1 from Baseline	2/ 5 (40%)	1/ 1 (100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 177	n	3		1	
	0	1	(33%)	0	
	1	0		1	(100%)
	2	2	(67%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	2	(67%)	1	(100%)
	Worsening in PGIS score >=1 from Baseline	1/ 3	(33%)	0/ 1	
	Improvement in PGIS score >=1 from Baseline	1/ 3	(33%)	1/ 1	(100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 181	n	3		1	
	0	1	(33%)	0	
	1	0		1	(100%)
	2	2	(67%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	2	(67%)	1	(100%)
	Worsening in PGIS score >=1 from Baseline	1/ 3	(33%)	0/ 1	
	Improvement in PGIS score >=1 from Baseline	1/ 3	(33%)	1/ 1	(100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 185	n	2		1	
	0	1	(50%)	0	
	1	1	(50%)	1	(100%)
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	1	(50%)	1	(100%)
	Worsening in PGIS score >=1 from Baseline	0/ 2		0/ 1	
	Improvement in PGIS score >=1 from Baseline	1/ 2	(50%)	1/ 1	(100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 189	n	1	1
	0	0	0
	1	0	1 (100%)
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	1 (100%)	1 (100%)
	Worsening in PGIS score >=1 from Baseline	1/ 1 (100%)	0/ 1
	Improvement in PGIS score >=1 from Baseline	0/ 1	1/ 1 (100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	n	2	1
	0	0	0
	1	1 (50%)	1 (100%)
	2	1 (50%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	2 (100%)	1 (100%)
	Worsening in PGIS score >=1 from Baseline	1/ 2 (50%)	0/ 1
	Improvement in PGIS score >=1 from Baseline	1/ 2 (50%)	1/ 1 (100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Week 197	n	1		1	
	0	0		0	
	1	1	(100%)	1	(100%)
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	1	(100%)	1	(100%)
	Worsening in PGIS score >=1 from Baseline	0/ 1		0/ 1	
	Improvement in PGIS score >=1 from Baseline	0/ 1		1/ 1	(100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	n	1	1
	0	0	1 (100%)
	1	1 (100%)	0
	2	0	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	1 (100%)	0
	Worsening in PGIS score >=1 from Baseline	0/ 1	0/ 1
	Improvement in PGIS score >=1 from Baseline	0/ 1	1/ 1 (100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
End of Treatment	n	18		20	
	0	4	(22%)	7	(35%)
	1	2	(11%)	4	(20%)
	2	10	(56%)	7	(35%)
	3	2	(11%)	0	
	4	0		2	(10%)
	3+4	2	(11%)	2	(10%)
	Any Scale > 0	14	(78%)	13	(65%)
	Worsening in PGIS score >=1 from Baseline	7/17	(41%)	4/20	(20%)
	Improvement in PGIS score >=1 from Baseline	3/17	(18%)	9/20	(45%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Last Follow-up	n	2	0
	0	0	0
	1	0	0
	2	2 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	2 (100%)	0
	Worsening in PGIS score >=1 from Baseline	1/ 1 (100%)	0
	Improvement in PGIS score >=1 from Baseline	0/ 1	0

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Table 4.0002905
Summary of PGIS Scores by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint	Severity	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)		POM + BOR/DEX (N=33)	
Worst Case Post Baseline	n	26		31	
	0	0		1	(3%)
	1	4	(15%)	10	(32%)
	2	19	(73%)	15	(48%)
	3	3	(12%)	2	(6%)
	4	0		3	(10%)
	3+4	3	(12%)	5	(16%)
	Any Scale > 0	26	(100%)	30	(97%)
	Worsening in PGIS score >=1 from Baseline	11/25	(44%)	12/30	(40%)
	Improvement in PGIS score >=1 from Baseline	2/25	(8%)	7/30	(23%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/prod/tfls/t_pro_pgis_visit_2ref.sas 09OCT2025 10:17

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003005
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Deteriorated (event)	11 (37%)	12 (36%)
Censored, follow-up ended	14 (47%)	16 (48%)
Censored, follow-up ongoing	5 (17%)	5 (15%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.0 (1.0, 7.4)	3.7 (1.1, 4.7)
Median (95% CI)	7.6 (3.8, -)	- (3.7, -)
3rd Quartile (95% CI)	- (7.6, -)	- (-, -)
Log-Rank P-value [2]	0.94539	
Hazard Ratio (95% CI) [3]	1.03 (0.45, 2.33)	
P-value [3]	0.95273	

Note: If a subject has not deteriorated, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_pgis_ttd_2ref.sas 09OCT2025 10:17

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003015
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Deteriorated (event)	5 (45%)	2 (29%)
	Censored, follow-up ended	6 (55%)	5 (71%)
	Censored, follow-up ongoing	0	0

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_age.sas 09OCT2025 10:17

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003015
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	4 (27%)	4 (27%)
	Censored, follow-up ended	7 (47%)	7 (47%)
	Censored, follow-up ongoing	4 (27%)	4 (27%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_age.sas 09OCT2025 10:17

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003015
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Deteriorated (event)	2 (50%)	6 (55%)
	Censored, follow-up ended	1 (25%)	4 (36%)
	Censored, follow-up ongoing	1 (25%)	1 (9%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_age.sas 09OCT2025 10:17

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003025
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Deteriorated (event)	6 (46%)	6 (38%)
	Censored, follow-up ended	5 (38%)	7 (44%)
	Censored, follow-up ongoing	2 (15%)	3 (19%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (1.0, 7.6)	2.8 (1.0, -)
	Median (95% CI)	7.6 (1.9, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (4.7, -)
	Log-Rank P-value [2]	0.90340	
	Hazard Ratio (95% CI) [3]	1.07 (0.34, 3.40)	
	P-value [3]	0.90282	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_gen.sas 09OCT2025 10:17

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003025
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Deteriorated (event)	5 (29%)	6 (35%)
	Censored, follow-up ended	9 (53%)	9 (53%)
	Censored, follow-up ongoing	3 (18%)	2 (12%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.0, -)	3.7 (1.1, -)
	Median (95% CI)	- (3.8, -)	- (3.7, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.86957	
	Hazard Ratio (95% CI) [3]	0.90 (0.27, 2.95)	
	P-value [3]	0.85934	
Interaction Test	P-value [4]	0.75546	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_gen.sas 09OCT2025 10:17

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003035
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Deteriorated (event)	6 (30%)	9 (38%)
	Censored, follow-up ended	11 (55%)	11 (46%)
	Censored, follow-up ongoing	3 (15%)	4 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.0 (1.0, 7.6)	3.7 (1.0, 4.7)
	Median (95% CI)	7.6 (2.0, -)	4.7 (3.7, -)
	3rd Quartile (95% CI)	- (7.6, -)	- (4.7, -)
	Log-Rank P-value [2]	0.98570	
	Hazard Ratio (95% CI) [3]	1.01 (0.36, 2.84)	
	P-value [3]	0.98840	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_reg.sas 09OCT2025 10:18

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003035
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Deteriorated (event)	5 (50%)	3 (33%)
	Censored, follow-up ended	3 (30%)	5 (56%)
	Censored, follow-up ongoing	2 (20%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.9, -)	2.7 (1.1, -)
	Median (95% CI)	- (1.9, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (3.7, -)
	Log-Rank P-value [2]	0.88815	
	Hazard Ratio (95% CI) [3]	1.11 (0.26, 4.65)	
	P-value [3]	0.88820	
Interaction Test	P-value [4]	0.86690	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_reg.sas 09OCT2025 10:18

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003045
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Deteriorated (event)	8 (44%)	8 (53%)
	Censored, follow-up ended	7 (39%)	6 (40%)
	Censored, follow-up ongoing	3 (17%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.0 (1.9, 7.4)	3.7 (1.1, 4.7)
	Median (95% CI)	7.6 (2.0, -)	4.7 (2.9, -)
	3rd Quartile (95% CI)	- (7.6, -)	- (4.7, -)
	Log-Rank P-value [2]	0.50907	
	Hazard Ratio (95% CI) [3]	0.70 (0.26, 1.91)	
	P-value [3]	0.49114	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_iss.sas 09OCT2025 10:18

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003045
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Deteriorated (event)	3 (25%)	4 (22%)
	Censored, follow-up ended	7 (58%)	10 (56%)
	Censored, follow-up ongoing	2 (17%)	4 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.2 (1.0, -)	2.8 (1.0, -)
	Median (95% CI)	- (1.0, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (4.2, -)	- (-, -)
	Log-Rank P-value [2]	0.76247	
	Hazard Ratio (95% CI) [3]	1.28 (0.29, 5.74)	
	P-value [3]	0.74401	
Interaction Test	P-value [4]	0.44615	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_iss.sas 09OCT2025 10:18

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003055
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Deteriorated (event)	4 (50%)	3 (50%)
	Censored, follow-up ended	2 (25%)	0
	Censored, follow-up ongoing	2 (25%)	3 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.0 (2.0, 7.6)	3.7 (1.1, -)
	Median (95% CI)	7.6 (2.0, -)	- (1.1, -)
	3rd Quartile (95% CI)	- (4.2, -)	- (3.7, -)
	Log-Rank P-value [2]	0.97441	
	Hazard Ratio (95% CI) [3]	0.99 (0.22, 4.47)	
	P-value [3]	0.99112	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_line.sas 09OCT2025 10:18

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003055
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Deteriorated (event)	4 (31%)	7 (50%)
	Censored, follow-up ended	8 (62%)	7 (50%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.0 (1.0, -)	2.8 (1.0, 4.7)
	Median (95% CI)	- (1.0, -)	4.7 (1.1, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (3.8, -)
	Log-Rank P-value [2]	0.21218	
	Hazard Ratio (95% CI) [3]	0.46 (0.13, 1.61)	
	P-value [3]	0.22335	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_line.sas 09OCT2025 10:18

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003055
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	2 (15%)
	Censored, follow-up ended	4 (44%)	9 (69%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.9, 4.7)	- (1.0, -)
	Median (95% CI)	4.7 (1.9, -)	- (1.7, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (-, -)
	Log-Rank P-value [2]	0.20371	
	Hazard Ratio (95% CI) [3]	3.03 (0.50, 18.23)	
	P-value [3]	0.22646	
Interaction Test	P-value [4]	0.22381	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_line.sas 09OCT2025 10:18

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003075
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Deteriorated (event)	8 (38%)	10 (50%)
	Censored, follow-up ended	10 (48%)	7 (35%)
	Censored, follow-up ongoing	3 (14%)	3 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.0 (1.0, 7.6)	2.9 (1.0, 3.8)
	Median (95% CI)	- (3.0, -)	4.7 (2.8, -)
	3rd Quartile (95% CI)	- (-, -)	- (4.7, -)
	Log-Rank P-value [2]	0.37065	
	Hazard Ratio (95% CI) [3]	0.65 (0.25, 1.66)	
	P-value [3]	0.36811	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_line2.sas 09OCT2025 10:18

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003075
Summary of PGIS Time to First Deterioration (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Deteriorated (event)	3 (33%)	2 (15%)
	Censored, follow-up ended	4 (44%)	9 (69%)
	Censored, follow-up ongoing	2 (22%)	2 (15%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.8 (1.9, 4.7)	- (1.0, -)
	Median (95% CI)	4.7 (1.9, -)	- (1.7, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (-, -)
	Log-Rank P-value [2]	0.20371	
	Hazard Ratio (95% CI) [3]	3.03 (0.50, 18.23)	
	P-value [3]	0.22646	
Interaction Test	P-value [4]	0.11260	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_ttd_2ref_line2.sas 09OCT2025 10:18

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003105
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Number of Subjects		
Improved (event)	14 (47%)	21 (64%)
Censored, follow-up ended	12 (40%)	10 (30%)
Censored, follow-up ongoing	4 (13%)	2 (6%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.8, 1.9)	1.0 (0.9, 1.1)
Median (95% CI)	1.9 (1.1, -)	1.9 (1.0, 3.0)
3rd Quartile (95% CI)	- (2.6, -)	19.4 (2.8, -)
Log-Rank P-value [2]	0.31690	
Inverse Hazard Ratio (95% CI) [3]	1.40 (0.71, 2.76)	
P-value [3]	0.33094	

Note: If a subject has not improved, they are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Inverse hazard ratio and associated p-value estimated using unstratified Cox model (Firth correction as applicable) with treatment arm as the only covariate.
/mnt/code/prod/tfls/t_pro_pgis_tti_2ref.sas 09OCT2025 10:18

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003115
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (37%)	7 (21%)
	Number of Subjects		
	Improved (event)	5 (45%)	6 (86%)
	Censored, follow-up ended	5 (45%)	1 (14%)
	Censored, follow-up ongoing	1 (9%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (1.0, 1.9)	1.0 (0.9, 2.8)
	Median (95% CI)	1.9 (1.0, -)	2.0 (0.9, -)
	3rd Quartile (95% CI)	- (1.9, -)	3.0 (1.0, -)
	Log-Rank P-value [2]	0.16863	
	Inverse Hazard Ratio (95% CI) [3]	2.20 (0.67, 7.24)	
	P-value [3]	0.19428	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_age.sas 09OCT2025 10:19

Table 4.0003115
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	15 (50%)	15 (45%)
	Number of Subjects		
	Improved (event)	8 (53%)	10 (67%)
	Censored, follow-up ended	5 (33%)	4 (27%)
	Censored, follow-up ongoing	2 (13%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.8, 1.1)	1.0 (0.7, 1.1)
	Median (95% CI)	1.1 (0.9, -)	1.4 (0.9, -)
	3rd Quartile (95% CI)	- (1.1, -)	- (1.1, -)
	Log-Rank P-value [2]	0.87661	
	Inverse Hazard Ratio (95% CI) [3]	1.06 (0.42, 2.70)	
	P-value [3]	0.89791	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_age.sas 09OCT2025 10:19

Table 4.0003115
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	4 (13%)	11 (33%)
	Number of Subjects		
	Improved (event)	1 (25%)	5 (45%)
	Censored, follow-up ended	2 (50%)	5 (45%)
	Censored, follow-up ongoing	1 (25%)	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.6 (2.6, -)	1.0 (1.0, 2.9)
	Median (95% CI)	- (2.6, -)	2.9 (1.0, -)
	3rd Quartile (95% CI)	- (2.6, -)	- (2.8, -)
	Log-Rank P-value [2]	0.48715	
	Inverse Hazard Ratio (95% CI) [3]	2.11 (0.25, 18.09)	
	P-value [3]	0.49705	
Interaction Test	P-value [4]	0.61327	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_age.sas 09OCT2025 10:19

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003125
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	13 (43%)	16 (48%)
	Number of Subjects		
	Improved (event)	6 (46%)	8 (50%)
	Censored, follow-up ended	6 (46%)	7 (44%)
	Censored, follow-up ongoing	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.8, 2.6)	1.0 (0.7, 1.9)
	Median (95% CI)	2.6 (1.0, -)	1.9 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (1.9, -)
	Log-Rank P-value [2]	0.66323	
	Inverse Hazard Ratio (95% CI) [3]	1.26 (0.44, 3.64)	
	P-value [3]	0.66954	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_gen.sas 09OCT2025 10:19

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003125
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	17 (57%)	17 (52%)
	Number of Subjects		
	Improved (event)	8 (47%)	13 (76%)
	Censored, follow-up ended	6 (35%)	3 (18%)
	Censored, follow-up ongoing	3 (18%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 1.9)	1.0 (0.7, 1.4)
	Median (95% CI)	1.9 (1.0, -)	1.8 (1.0, 3.0)
	3rd Quartile (95% CI)	- (1.9, -)	11.2 (1.4, -)
	Log-Rank P-value [2]	0.35268	
	Inverse Hazard Ratio (95% CI) [3]	1.50 (0.62, 3.63)	
	P-value [3]	0.37316	
Interaction Test	P-value [4]	0.85711	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_gen.sas 09OCT2025 10:19

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003135
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	20 (67%)	24 (73%)
	Number of Subjects		
	Improved (event)	7 (35%)	14 (58%)
	Censored, follow-up ended	10 (50%)	9 (38%)
	Censored, follow-up ongoing	3 (15%)	1 (4%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.8, 1.9)	1.0 (0.7, 1.2)
	Median (95% CI)	- (1.0, -)	1.4 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	19.4 (1.9, -)
	Log-Rank P-value [2]	0.31465	
	Inverse Hazard Ratio (95% CI) [3]	1.59 (0.64, 3.94)	
	P-value [3]	0.32043	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_reg.sas 09OCT2025 10:19

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003135
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (33%)	9 (27%)
	Number of Subjects		
	Improved (event)	7 (70%)	7 (78%)
	Censored, follow-up ended	2 (20%)	1 (11%)
	Censored, follow-up ongoing	1 (10%)	1 (11%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 1.9)	1.0 (1.0, 2.8)
	Median (95% CI)	1.9 (0.9, -)	2.5 (1.0, 2.9)
	3rd Quartile (95% CI)	- (1.9, -)	2.9 (1.0, -)
	Log-Rank P-value [2]	0.77234	
	Inverse Hazard Ratio (95% CI) [3]	1.16 (0.40, 3.32)	
	P-value [3]	0.78658	
Interaction Test	P-value [4]	0.72659	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_reg.sas 09OCT2025 10:19

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003145
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (60%)	15 (45%)
	Number of Subjects		
	Improved (event)	10 (56%)	11 (73%)
	Censored, follow-up ended	5 (28%)	2 (13%)
	Censored, follow-up ongoing	3 (17%)	2 (13%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.9, 1.9)	1.0 (0.7, 2.8)
	Median (95% CI)	1.9 (1.1, -)	2.8 (0.9, 19.4)
	3rd Quartile (95% CI)	- (1.9, -)	19.4 (2.8, -)
	Log-Rank P-value [2]	0.84916	
	Inverse Hazard Ratio (95% CI) [3]	1.08 (0.46, 2.56)	
	P-value [3]	0.85953	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_iss.sas 09OCT2025 10:19

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003145
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	12 (40%)	18 (55%)
	Number of Subjects		
	Improved (event)	4 (33%)	10 (56%)
	Censored, follow-up ended	7 (58%)	8 (44%)
	Censored, follow-up ongoing	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.8, -)	1.0 (0.7, 1.1)
	Median (95% CI)	- (0.8, -)	1.4 (1.0, -)
	3rd Quartile (95% CI)	- (1.2, -)	- (1.1, -)
	Log-Rank P-value [2]	0.30131	
	Inverse Hazard Ratio (95% CI) [3]	1.82 (0.57, 5.84)	
	P-value [3]	0.31088	
Interaction Test	P-value [4]	0.42545	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_iss.sas 09OCT2025 10:19

Protocol: 207499 Page 1 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003155
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	8 (27%)	6 (18%)
	Number of Subjects		
	Improved (event)	4 (50%)	3 (50%)
	Censored, follow-up ended	3 (38%)	2 (33%)
	Censored, follow-up ongoing	1 (13%)	1 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.9, 1.1)	1.0 (0.7, -)
	Median (95% CI)	1.1 (0.9, -)	- (0.7, -)
	3rd Quartile (95% CI)	- (1.0, -)	- (1.0, -)
	Log-Rank P-value [2]	0.89701	
	Inverse Hazard Ratio (95% CI) [3]	0.89 (0.20, 3.98)	
	P-value [3]	0.87580	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_line.sas 09OCT2025 10:19

Protocol: 207499 Page 2 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003155
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (43%)	14 (42%)
	Number of Subjects		
	Improved (event)	8 (62%)	7 (50%)
	Censored, follow-up ended	3 (23%)	6 (43%)
	Censored, follow-up ongoing	2 (15%)	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.2 (0.8, 1.9)	1.1 (0.9, 3.0)
	Median (95% CI)	1.9 (1.1, -)	3.0 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	19.4 (2.9, -)
	Log-Rank P-value [2]	0.71566	
	Inverse Hazard Ratio (95% CI) [3]	0.82 (0.30, 2.28)	
	P-value [3]	0.70641	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_line.sas 09OCT2025 10:19

Protocol: 207499 Page 3 of 3
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003155
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	11 (85%)
	Censored, follow-up ended	6 (67%)	2 (15%)
	Censored, follow-up ongoing	1 (11%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	1.0 (0.7, 1.2)
	Median (95% CI)	- (1.0, -)	1.2 (1.0, 2.8)
	3rd Quartile (95% CI)	- (1.1, -)	2.8 (1.0, -)
	Log-Rank P-value [2]	0.06337	
	Inverse Hazard Ratio (95% CI) [3]	3.79 (0.83, 17.32)	
	P-value [3]	0.08523	
Interaction Test	P-value [4]	0.24912	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_line.sas 09OCT2025 10:19

Protocol: 207499 Page 1 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003175
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	21 (70%)	20 (61%)
	Number of Subjects		
	Improved (event)	12 (57%)	10 (50%)
	Censored, follow-up ended	6 (29%)	8 (40%)
	Censored, follow-up ongoing	3 (14%)	2 (10%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (0.8, 1.9)	1.0 (0.7, 2.9)
	Median (95% CI)	1.9 (1.1, -)	3.0 (1.0, -)
	3rd Quartile (95% CI)	- (1.9, -)	19.4 (3.0, -)
	Log-Rank P-value [2]	0.79214	
	Inverse Hazard Ratio (95% CI) [3]	0.89 (0.38, 2.06)	
	P-value [3]	0.77897	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_line2.sas 09OCT2025 10:20

Protocol: 207499 Page 2 of 2
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003175
Summary of PGIS Time to First Improvement (Up to and Including Last Follow-Up)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	9 (30%)	13 (39%)
	Number of Subjects		
	Improved (event)	2 (22%)	11 (85%)
	Censored, follow-up ended	6 (67%)	2 (15%)
	Censored, follow-up ongoing	1 (11%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.1 (1.0, -)	1.0 (0.7, 1.2)
	Median (95% CI)	- (1.0, -)	1.2 (1.0, 2.8)
	3rd Quartile (95% CI)	- (1.1, -)	2.8 (1.0, -)
	Log-Rank P-value [2]	0.06337	
	Inverse Hazard Ratio (95% CI) [3]	3.79 (0.83, 17.32)	
	P-value [3]	0.08523	
Interaction Test	P-value [4]	0.09514	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the latest post-baseline assessment or at treatment initiation if no post-baseline assessments. Patients without treatment initiation are censored at 0 months. [1] CIs for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] HR and associated p-value are estimated using the unstratified Cox PH model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox PH model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_pgis_tti_2ref_line2.sas 09OCT2025 10:20

Protocol: 207499 Page 1 of 50
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 5

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	24	28
Symptoms	16 (67%)	22 (79%)
No Symptoms	8 (33%)	6 (21%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.23 (0.03, 2.03)	
P-Value [1]	0.18640	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 9

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	23	26
Symptoms	17 (74%)	14 (54%)
No Symptoms	6 (26%)	12 (46%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	2.86 (0.33, 24.69)	
P-Value [1]	0.33859	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 13

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	22	27
Symptoms	15 (68%)	16 (59%)
No Symptoms	7 (32%)	11 (41%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	1.32 (0.16, 11.18)	
P-Value [1]	0.80059	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 17

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	21	24
Symptoms	16 (76%)	16 (67%)
No Symptoms	5 (24%)	8 (33%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	1.50 (0.15, 14.59)	
P-Value [1]	0.72871	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 21

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	16	19
Symptoms	11 (69%)	10 (53%)
No Symptoms	5 (31%)	9 (47%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	2.23 (0.20, 24.56)	
P-Value [1]	0.51054	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 25

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	16	15
Symptoms	13 (81%)	9 (60%)
No Symptoms	3 (19%)	6 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	2.36 (0.17, 32.34)	
P-Value [1]	0.52040	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 29

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	13	15
Symptoms	10 (77%)	9 (60%)
No Symptoms	3 (23%)	6 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	2.83 (0.20, 40.42)	
P-Value [1]	0.44164	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 33

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	14	11
Symptoms	12 (86%)	3 (27%)
No Symptoms	2 (14%)	8 (73%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	21.40 (1.09, 420.60)	
P-Value [1]	0.04383	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 37

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	13	9
Symptoms	9 (69%)	6 (67%)
No Symptoms	4 (31%)	3 (33%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.37 (0.02, 6.38)	
P-Value [1]	0.49613	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 41

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	11	9
Symptoms	9 (82%)	4 (44%)
No Symptoms	2 (18%)	5 (56%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	8.48 (0.35, 204.58)	
P-Value [1]	0.18766	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 45

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	13	9
Symptoms	11 (85%)	5 (56%)
No Symptoms	2 (15%)	4 (44%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	4.18 (0.19, 90.20)	
P-Value [1]	0.36112	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 49

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	11	9
Symptoms	10 (91%)	4 (44%)
No Symptoms	1 (9%)	5 (56%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	22.40 (0.56, 897.66)	
P-Value [1]	0.09859	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 53

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	9	9
Symptoms	6 (67%)	5 (56%)
No Symptoms	3 (33%)	4 (44%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	1.19 (0.06, 24.60)	
P-Value [1]	0.91147	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 57

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	10	7
Symptoms	8 (80%)	4 (57%)
No Symptoms	2 (20%)	3 (43%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	7.45 (0.28, 195.95)	
P-Value [1]	0.22805	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 61

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	9	6
Symptoms	8 (89%)	5 (83%)
No Symptoms	1 (11%)	1 (17%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	5.07 (0.10, 269.10)	
P-Value [1]	0.42276	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 65

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	9	6
Symptoms	8 (89%)	4 (67%)
No Symptoms	1 (11%)	2 (33%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	18.03 (0.40, 807.16)	
P-Value [1]	0.13558	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 69

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	9	6
Symptoms	6 (67%)	3 (50%)
No Symptoms	3 (33%)	3 (50%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	6.58 (0.24, 179.44)	
P-Value [1]	0.26322	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 73

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	9	6
Symptoms	7 (78%)	4 (67%)
No Symptoms	2 (22%)	2 (33%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	3.37 (0.14, 83.69)	
P-Value [1]	0.45731	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 77

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	7	5
Symptoms	6 (86%)	2 (40%)
No Symptoms	1 (14%)	3 (60%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	61.11 (0.79, >999.99)	
P-Value [1]	0.06406	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 81

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	7	5
Symptoms	6 (86%)	2 (40%)
No Symptoms	1 (14%)	3 (60%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	61.11 (0.79, >999.99)	
P-Value [1]	0.06406	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 85

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	7	4
Symptoms	4 (57%)	1 (25%)
No Symptoms	3 (43%)	3 (75%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	117.31 (1.51, >999.99)	
P-Value [1]	0.03202	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 89

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	7	5
Symptoms	6 (86%)	3 (60%)
No Symptoms	1 (14%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	7.57 (0.18, 325.27)	
P-Value [1]	0.29089	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 93

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	8	5
Symptoms	6 (75%)	2 (40%)
No Symptoms	2 (25%)	3 (60%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	37.04 (0.59, >999.99)	
P-Value [1]	0.08654	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 97

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	6	5
Symptoms	4 (67%)	3 (60%)
No Symptoms	2 (33%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	1.62 (0.04, 60.43)	
P-Value [1]	0.79305	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 101

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	7	5
Symptoms	3 (43%)	3 (60%)
No Symptoms	4 (57%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.45 (0.01, 15.77)	
P-Value [1]	0.65771	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 105

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	6	4
Symptoms	6 (100%)	3 (75%)
No Symptoms	0	1 (25%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (<0.01, >999.99)	
P-Value [1]	0.98473	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 109

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	7	5
Symptoms	6 (86%)	2 (40%)
No Symptoms	1 (14%)	3 (60%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	61.11 (0.79, >999.99)	
P-Value [1]	0.06406	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 113

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	7	5
Symptoms	6 (86%)	3 (60%)
No Symptoms	1 (14%)	2 (40%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	7.57 (0.18, 325.27)	
P-Value [1]	0.29089	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 117

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	6	4
Symptoms	6 (100%)	2 (50%)
No Symptoms	0	2 (50%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	>999.99 (<0.01, >999.99)	
P-Value [1]	0.98488	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 121

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	5
Symptoms	4 (80%)	4 (80%)
No Symptoms	1 (20%)	1 (20%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.89 (0.02, 45.87)	
P-Value [1]	0.95197	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 125

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	5
Symptoms	4 (80%)	4 (80%)
No Symptoms	1 (20%)	1 (20%)
Adjusted OR (95% CI) [1] vs. POM + BOR/DEX	0.89 (0.02, 45.87)	
P-Value [1]	0.95161	

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 129

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	4
Symptoms	5 (100%)	2 (50%)
No Symptoms	0	2 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 133

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	4	4
Symptoms	3 (75%)	2 (50%)
No Symptoms	1 (25%)	2 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 137

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	3
Symptoms	5 (100%)	2 (67%)
No Symptoms	0	1 (33%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 141

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	2
Symptoms	4 (80%)	2 (100%)
No Symptoms	1 (20%)	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 145

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	2
Symptoms	4 (80%)	1 (50%)
No Symptoms	1 (20%)	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 149

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	2
Symptoms	4 (80%)	1 (50%)
No Symptoms	1 (20%)	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 153

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	3	2
Symptoms	3 (100%)	2 (100%)
No Symptoms	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 157

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	2
Symptoms	4 (80%)	1 (50%)
No Symptoms	1 (20%)	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 161

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	1
Symptoms	3 (60%)	1 (100%)
No Symptoms	2 (40%)	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 165

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	2
Symptoms	3 (60%)	1 (50%)
No Symptoms	2 (40%)	1 (50%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 169

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	1
Symptoms	2 (40%)	1 (100%)
No Symptoms	3 (60%)	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 173

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	5	1
Symptoms	5 (100%)	1 (100%)
No Symptoms	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 177

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	3	1
Symptoms	2 (67%)	1 (100%)
No Symptoms	1 (33%)	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 181

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	3	1
Symptoms	2 (67%)	1 (100%)
No Symptoms	1 (33%)	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 185

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	2	1
Symptoms	1 (50%)	1 (100%)
No Symptoms	1 (50%)	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 189

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	1	1
Symptoms	1 (100%)	1 (100%)
No Symptoms	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 193

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	2	1
Symptoms	2 (100%)	1 (100%)
No Symptoms	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Protocol: 207499 Page 49 of 50
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 197

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	1	1
Symptoms	1 (100%)	1 (100%)
No Symptoms	0	0

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

Protocol: 207499 Page 50 of 50
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003205
Analysis of PGIS Domain Scores based on Generalised Linear Mixed Model (GLMM)
Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint: Week 201

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
n	1	1
Symptoms	1 (100%)	0
No Symptoms	0	1 (100%)

Note: Percentages are based on n.
[1] Analysis performed using a GLMM with covariates of treatment group, visit, baseline value and treatment by visit interactions as fixed effects, and subject as a random effect. Visits are only included in the model if the number of subjects with analyzable data at the current time point is >= 10 across treatments. Unstructured covariance structure was used to estimate the within subject covariance. Two-sided P-value is presented.
/mnt/code/prod/tfls/t_pro_pgis_glmm_2ref.sas 09OCT2025 09:34

1.3.1.8 PRO-CTCAE

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)			POM + BOR/DEX (N=33)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Blurred Vision						
n	26	20		31	21	
0	6 (23%)	0		10 (32%)	3 (14%)	
1	2 (8%)	3 (15%)		12 (39%)	7 (33%)	
2	6 (23%)	5 (25%)		7 (23%)	7 (33%)	
3	8 (31%)	6 (30%)		2 (6%)	3 (14%)	
4	4 (15%)	6 (30%)		0	1 (5%)	
3+4	12 (46%)	12 (60%)		2 (6%)	4 (19%)	
Any Scale >0	20 (77%)	20 (100%)		21 (68%)	18 (86%)	
Constipation						
n	26			31		
0	8 (31%)			11 (35%)		
1	7 (27%)			5 (16%)		
2	5 (19%)			8 (26%)		
3	5 (19%)			2 (6%)		
4	1 (4%)			5 (16%)		
3+4	6 (23%)			7 (23%)		
Any Scale >0	18 (69%)			20 (65%)		

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)			POM + BOR/DEX (N=33)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Cough						
n	26	19		31	14	
0	7 (27%)	5 (26%)		18 (58%)	7 (50%)	
1	9 (35%)	6 (32%)		8 (26%)	4 (29%)	
2	6 (23%)	3 (16%)		3 (10%)	2 (14%)	
3	2 (8%)	5 (26%)		2 (6%)	1 (7%)	
4	2 (8%)	0		0	0	
3+4	4 (15%)	5 (26%)		2 (6%)	1 (7%)	
Any Scale >0	19 (73%)	14 (74%)		13 (42%)	7 (50%)	
Decreased Appetite						
n	26	18		31	18	
0	8 (31%)	3 (17%)		13 (42%)	6 (33%)	
1	5 (19%)	9 (50%)		11 (35%)	6 (33%)	
2	12 (46%)	6 (33%)		3 (10%)	2 (11%)	
3	1 (4%)	0		3 (10%)	3 (17%)	
4	0	0		1 (3%)	1 (6%)	
3+4	1 (4%)	0		4 (13%)	4 (22%)	
Any Scale >0	18 (69%)	15 (83%)		18 (58%)	12 (67%)	

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)			POM + BOR/DEX (N=33)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Fatigue						
n	26	25		31	27	
0	1 (4%)	1 (4%)		4 (13%)	0	
1	6 (23%)	8 (32%)		10 (32%)	10 (37%)	
2	6 (23%)	5 (20%)		8 (26%)	7 (26%)	
3	12 (46%)	10 (40%)		6 (19%)	5 (19%)	
4	1 (4%)	1 (4%)		3 (10%)	5 (19%)	
3+4	13 (50%)	11 (44%)		9 (29%)	10 (37%)	
Any Scale >0	25 (96%)	24 (96%)		27 (87%)	27 (100%)	
Itchy						
n	26			31		
0	16 (62%)			23 (74%)		
1	6 (23%)			4 (13%)		
2	3 (12%)			3 (10%)		
3	1 (4%)			1 (3%)		
4	0			0		
3+4	1 (4%)			1 (3%)		
Any Scale >0	10 (38%)			8 (26%)		

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)			POM + BOR/DEX (N=33)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Loose/Watery Stools						
n	26			31		
0	10 (38%)			11 (35%)		
1	5 (19%)			9 (29%)		
2	7 (27%)			7 (23%)		
3	3 (12%)			1 (3%)		
4	1 (4%)			3 (10%)		
3+4	4 (15%)			4 (13%)		
Any Scale >0	16 (62%)			20 (65%)		
Mouth/Throat Sores						
n		26	16		31	9
0		10 (38%)	2 (13%)		22 (71%)	5 (56%)
1		7 (27%)	9 (56%)		5 (16%)	1 (11%)
2		4 (15%)	4 (25%)		2 (6%)	1 (11%)
3		4 (15%)	1 (6%)		0	0
4		1 (4%)	0		2 (6%)	2 (22%)
3+4		5 (19%)	1 (6%)		2 (6%)	2 (22%)
Any Scale >0		16 (62%)	14 (88%)		9 (29%)	4 (44%)

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)				POM + BOR/DEX (N=33)			
	Frequency		Severity	Interference	Frequency		Severity	Interference
Nausea								
n	26		18		31		17	
0	8	(31%)	2	(11%)	14	(45%)	2	(12%)
1	9	(35%)	8	(44%)	9	(29%)	9	(53%)
2	4	(15%)	5	(28%)	6	(19%)	3	(18%)
3	4	(15%)	3	(17%)	1	(3%)	2	(12%)
4	1	(4%)	0		1	(3%)	1	(6%)
3+4	5	(19%)	3	(17%)	2	(6%)	3	(18%)
Any Scale >0	18	(69%)	16	(89%)	17	(55%)	15	(88%)
Nosebleeds								
n	26		8		31		7	
0	18	(69%)	3	(38%)	25	(81%)	1	(14%)
1	6	(23%)	5	(63%)	4	(13%)	5	(71%)
2	2	(8%)	0		1	(3%)	1	(14%)
3	0		0		1	(3%)	0	
4	0		0		0		0	
3+4	0		0		1	(3%)	0	
Any Scale >0	8	(31%)	5	(63%)	6	(19%)	6	(86%)

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Protocol: 207499 Page 6 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)			POM + BOR/DEX (N=33)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Numb/Tingling Hands/Feet						
n	26	22		31	21	
0	4 (15%)	4 (18%)		10 (32%)	5 (24%)	
1	5 (19%)	9 (41%)		10 (32%)	8 (38%)	
2	12 (46%)	4 (18%)		9 (29%)	5 (24%)	
3	4 (15%)	4 (18%)		0	1 (5%)	
4	1 (4%)	1 (5%)		2 (6%)	2 (10%)	
3+4	5 (19%)	5 (23%)		2 (6%)	3 (14%)	
Any Scale >0	22 (85%)	18 (82%)		21 (68%)	16 (76%)	
Pain in the Abdomen (Belly Area)						
n	26	20	18	31	20	19
0	6 (23%)	2 (10%)	3 (17%)	11 (35%)	1 (5%)	7 (37%)
1	6 (23%)	7 (35%)	8 (44%)	7 (23%)	8 (40%)	4 (21%)
2	7 (27%)	7 (35%)	5 (28%)	9 (29%)	9 (45%)	5 (26%)
3	6 (23%)	3 (15%)	1 (6%)	3 (10%)	0	1 (5%)
4	1 (4%)	1 (5%)	1 (6%)	1 (3%)	2 (10%)	2 (11%)
3+4	7 (27%)	4 (20%)	2 (11%)	4 (13%)	2 (10%)	3 (16%)
Any Scale >0	20 (77%)	18 (90%)	15 (83%)	20 (65%)	19 (95%)	12 (63%)

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)			POM + BOR/DEX (N=33)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Pain/Burning Urination						
n	26			31		
0	14	(54%)		22	(71%)	
1	7	(27%)		5	(16%)	
2	4	(15%)		4	(13%)	
3	1	(4%)		0		
4	0			0		
3+4	1	(4%)		0		
Any Scale >0	12	(46%)		9	(29%)	
Problems Tasting Food/Drink						
n	26			31		
0	7	(27%)		19	(61%)	
1	6	(23%)		8	(26%)	
2	8	(31%)		0		
3	4	(15%)		3	(10%)	
4	1	(4%)		1	(3%)	
3+4	5	(19%)		4	(13%)	
Any Scale >0	19	(73%)		12	(39%)	

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Protocol: 207499 Page 8 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)			POM + BOR/DEX (N=33)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Shivering/Shaking Chills						
n	26	16		31	12	
0	10 (38%)	3 (19%)		19 (61%)	1 (8%)	
1	8 (31%)	6 (38%)		3 (10%)	7 (58%)	
2	8 (31%)	7 (44%)		8 (26%)	4 (33%)	
3	0	0		1 (3%)	0	
4	0	0		0	0	
3+4	0	0		1 (3%)	0	
Any Scale >0	16 (62%)	13 (81%)		12 (39%)	11 (92%)	
Shortness of Breath						
n		26	23		31	22
0		3 (12%)	1 (4%)		9 (29%)	5 (23%)
1		8 (31%)	7 (30%)		15 (48%)	10 (45%)
2		9 (35%)	11 (48%)		4 (13%)	3 (14%)
3		6 (23%)	4 (17%)		2 (6%)	1 (5%)
4		0	0		1 (3%)	3 (14%)
3+4		6 (23%)	4 (17%)		3 (10%)	4 (18%)
Any Scale >0		23 (88%)	22 (96%)		22 (71%)	17 (77%)

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Protocol: 207499 Page 9 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0003305
Summary of Maximum Post-Baseline PRO-CTCAE Score -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)						POM + BOR/DEX (N=33)					
	Frequency		Severity		Interference		Frequency		Severity		Interference	
Vomiting												
n	26		9				31		8			
0	17	(65%)	3	(33%)			23	(74%)	2	(25%)		
1	7	(27%)	5	(56%)			4	(13%)	2	(25%)		
2	2	(8%)	1	(11%)			4	(13%)	2	(25%)		
3	0		0				0		2	(25%)		
4	0		0				0		0			
3+4	0		0				0		2	(25%)		
Any Scale >0	9	(35%)	6	(67%)			8	(26%)	6	(75%)		
Watery Eyes												
n			26		16				31		15	
0			10	(38%)	2	(13%)			17	(55%)	4	(27%)
1			9	(35%)	7	(44%)			8	(26%)	7	(47%)
2			4	(15%)	4	(25%)			3	(10%)	3	(20%)
3			2	(8%)	2	(13%)			3	(10%)	1	(7%)
4			1	(4%)	1	(6%)			0		0	
3+4			3	(12%)	3	(19%)			3	(10%)	1	(7%)
Any Scale >0			16	(62%)	14	(88%)			14	(45%)	11	(73%)

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/prod/tfls/t_pro_t3_ctcae_max_2ref.sas 09OCT2025 10:20

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004405
Summary of Maximum Post-Baseline PRO-CTCAE Score (Yes/No Responses) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Bruise Easily- Occurrence				
n	26		31	
Yes	13	(50%)	15	(48%)
No	13	(50%)	16	(52%)
Flashing Light Front Eyes- Occurrence				
n	26		31	
Yes	12	(46%)	9	(29%)
No	14	(54%)	22	(71%)
Hives- Occurrence				
n	26		31	
Yes	9	(35%)	9	(29%)
No	17	(65%)	22	(71%)
Spots/Lines Front of Eyes- Occurrence				
n	26		31	
Yes	16	(62%)	9	(29%)
No	10	(38%)	22	(71%)

Note: n is the number of subjects with at least one post-baseline response scale of the attribute for a given item, and is used as the denominator for calculation of percentages.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_ctcae_sum_2ref.sas 09OCT2025 10:25

1.3.1.9 Beobachtungsdauern

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0002905
Summary of Duration of Observation for EORTC QLQ-C30 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Observation for EORTC QLQ-C30 (Months) [1]	n	28	33
	Mean	17.95	12.79
	SD	15.968	13.984
	Median	12.63	6.83
	Min.	0.0	0.0
	Max.	46.0	48.9

[1] Time from the start of the first dose of study medication until the date the patients filled out last EORTC QLQ-C30 questionnaire.
/mnt/code/sSAP/sSAP02/prod/tfls/t_sp_doo_qlqc30_2ref.sas 19AUG2025 08:29

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0003005
Summary of Duration of Observation for EORTC QLQ-MY20 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Observation for EORTC QLQ-MY20 (Months) [1]	n	27	33
	Mean	18.62	12.76
	SD	15.872	14.013
	Median	13.77	6.83
	Min.	0.0	0.0
	Max.	46.0	48.9

[1] Time from the start of the first dose of study medication until the date the patients filled out last EORTC QLQ-MY20 questionnaire.
/mnt/code/sSAP/sSAP02/prod/tfls/t_sp_doo_qlqmy20_2ref.sas 19AUG2025 08:29

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0003105
Summary of Duration of Observation for OSDI -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Duration of Observation for OSDI (Months) [1]	n	28	33
	Mean	16.65	9.84
	SD	15.618	11.561
	Median	11.27	4.96
	Min.	0.0	0.0
	Max.	45.6	45.1

[1] Time from the start of the first dose of study medication until the date the patients filled out last OSDI questionnaire.
/mnt/code/sSAP/sSAP02/prod/tfls/t_sp_doo_osdi_2ref.sas 19AUG2025 08:29

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0003205
Summary of Duration of Observation for EQ-5D-3L VAS -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Observation for EQ-5D-3L VAS (Months) [1]	n	28	33
	Mean	17.86	12.59
	SD	15.929	14.022
	Median	11.84	6.67
	Min.	0.0	0.0
	Max.	45.6	48.9

[1] Time from the start of the first dose of study medication until the date the patients filled out last EQ-5D-3L VAS questionnaire.
/mnt/code/sSAP/sSAP02/prod/tfls/t_sp_doo_eq5d3l_2ref.sas 19AUG2025 08:29

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0003305
Summary of Duration of Observation for PGIS -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Observation for PGIS (Months) [1]	n	28	33
	Mean	15.39	9.92
	SD	14.739	11.634
	Median	9.77	5.49
	Min.	0.0	0.0
	Max.	46.0	46.0

[1] Time from the start of the first dose of study medication until the date the patients filled out last PGIS questionnaire.
/mnt/code/sSAP/sSAP02/prod/tfls/t_sp_doo_pgis_2ref.sas 19AUG2025 08:29

Protocol: 207499 Page 1 of 1
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0003405
Summary of Duration of Observation for PGIC -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Duration of Observation for PGIC (Months) [1]	n	26	31
	Mean	16.57	10.56
	SD	14.636	11.722
	Median	11.27	6.28
	Min.	0.9	0.8
	Max.	46.0	46.0

[1] Time from the start of the first dose of study medication until the date the patients filled out last PGIC questionnaire.
/mnt/code/sSAP/sSAP02/prod/tfls/t_sp_doo_pgic_2ref.sas 19AUG2025 08:29

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0003505
Summary of Duration of Observation for FACT-GP5 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Duration of Observation for FACT-GP5 (Months) [1]	n	28	33
	Mean	14.87	9.92
	SD	14.647	11.634
	Median	9.77	5.49
	Min.	0.0	0.0
	Max.	46.0	46.0

[1] Time from the start of the first dose of study medication until the date the patients filled out last FACT-GP5 questionnaire.
/mnt/code/sSAP/sSAP02/prod/tfls/t_sp_doo_factgp5_2ref.sas 19AUG2025 08:29

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0003605
Summary of Duration of Observation for PRO-CTCAE -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Duration of Observation for PRO-CTCAE (Months) [1]	n	28	33
	Mean	14.87	9.98
	SD	14.647	11.609
	Median	9.77	5.49
	Min.	0.0	0.0
	Max.	46.0	46.0

[1] Time from the start of the first dose of study medication until the date the patients filled out last PRO-CTCAE questionnaire.
/mnt/code/sSAP/sSAP02/prod/tfls/t_sp_doo_ctcae_2ref.sas 19AUG2025 08:29

1.3.1.10 Rücklaufquoten

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Baseline	# of subjects with PRO-CTCAE score (%)	27 (90%)	32 (97%)
	# of subjects with OSDI summary score (%)	27 (90%)	32 (97%)
	# of subjects with QLQ-C30 summary score (%)	27 (90%)	32 (97%)
	# of subjects with QLQ-MY20 domain score (%)	10 (33%)	12 (36%)
	# of subjects with QLQ-IL52 domain score (%)	26 (87%)	32 (97%)
	# of subjects with FACT-GP5 score (%)	27 (90%)	32 (97%)
	# of subjects with EQ-5D-3L VAS score (%)	27 (90%)	32 (97%)
	# of subjects with PGIS score (%)	27 (90%)	32 (97%)
Week 5	# of subjects with PRO-CTCAE score (%)	25 (83%)	29 (88%)
	# of subjects with OSDI summary score (%)	25 (83%)	29 (88%)
	# of subjects with QLQ-C30 summary score (%)	25 (83%)	29 (88%)
	# of subjects with QLQ-MY20 domain score (%)	9 (30%)	9 (27%)
	# of subjects with QLQ-IL52 domain score (%)	25 (83%)	29 (88%)
	# of subjects with FACT-GP5 score (%)	25 (83%)	29 (88%)
	# of subjects with EQ-5D-3L VAS score (%)	25 (83%)	29 (88%)
	# of subjects with PGIC score (%)	25 (83%)	29 (88%)
	# of subjects with PGIS score (%)	25 (83%)	29 (88%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 9	# of subjects with PRO-CTCAE score (%)	24 (80%)	27 (82%)
	# of subjects with OSDI summary score (%)	24 (80%)	26 (79%)
	# of subjects with QLQ-C30 summary score (%)	24 (80%)	27 (82%)
	# of subjects with QLQ-MY20 domain score (%)	10 (33%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	24 (80%)	25 (76%)
	# of subjects with FACT-GP5 score (%)	24 (80%)	27 (82%)
	# of subjects with PGIC score (%)	24 (80%)	27 (82%)
	# of subjects with PGIS score (%)	24 (80%)	27 (82%)
Week 13	# of subjects with PRO-CTCAE score (%)	23 (77%)	27 (82%)
	# of subjects with OSDI summary score (%)	23 (77%)	27 (82%)
	# of subjects with QLQ-C30 summary score (%)	23 (77%)	26 (79%)
	# of subjects with QLQ-MY20 domain score (%)	9 (30%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	23 (77%)	26 (79%)
	# of subjects with FACT-GP5 score (%)	23 (77%)	27 (82%)
	# of subjects with EQ-5D-3L VAS score (%)	23 (77%)	27 (82%)
	# of subjects with PGIC score (%)	23 (77%)	27 (82%)
	# of subjects with PGIS score (%)	23 (77%)	27 (82%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 17	# of subjects with PRO-CTCAE score (%)	22 (73%)	25 (76%)
	# of subjects with OSDI summary score (%)	22 (73%)	24 (73%)
	# of subjects with QLQ-C30 summary score (%)	22 (73%)	25 (76%)
	# of subjects with QLQ-MY20 domain score (%)	8 (27%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	22 (73%)	24 (73%)
	# of subjects with FACT-GP5 score (%)	22 (73%)	24 (73%)
	# of subjects with PGIC score (%)	22 (73%)	24 (73%)
	# of subjects with PGIS score (%)	22 (73%)	24 (73%)
Week 21	# of subjects with PRO-CTCAE score (%)	17 (57%)	19 (58%)
	# of subjects with OSDI summary score (%)	16 (53%)	18 (55%)
	# of subjects with QLQ-C30 summary score (%)	17 (57%)	19 (58%)
	# of subjects with QLQ-MY20 domain score (%)	7 (23%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	17 (57%)	19 (58%)
	# of subjects with FACT-GP5 score (%)	17 (57%)	19 (58%)
	# of subjects with EQ-5D-3L VAS score (%)	19 (63%)	20 (61%)
	# of subjects with PGIC score (%)	17 (57%)	19 (58%)
	# of subjects with PGIS score (%)	17 (57%)	19 (58%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 25	# of subjects with PRO-CTCAE score (%)	17 (57%)	15 (45%)
	# of subjects with QLQ-C30 summary score (%)	18 (60%)	16 (48%)
	# of subjects with QLQ-MY20 domain score (%)	7 (23%)	4 (12%)
	# of subjects with QLQ-IL52 domain score (%)	18 (60%)	16 (48%)
	# of subjects with FACT-GP5 score (%)	17 (57%)	15 (45%)
	# of subjects with PGIC score (%)	17 (57%)	14 (42%)
	# of subjects with PGIS score (%)	17 (57%)	15 (45%)
Week 29	# of subjects with PRO-CTCAE score (%)	14 (47%)	15 (45%)
	# of subjects with OSDI summary score (%)	17 (57%)	15 (45%)
	# of subjects with QLQ-C30 summary score (%)	15 (50%)	17 (52%)
	# of subjects with QLQ-MY20 domain score (%)	6 (20%)	5 (15%)
	# of subjects with QLQ-IL52 domain score (%)	15 (50%)	17 (52%)
	# of subjects with FACT-GP5 score (%)	14 (47%)	15 (45%)
	# of subjects with EQ-5D-3L VAS score (%)	17 (57%)	18 (55%)
	# of subjects with PGIC score (%)	14 (47%)	15 (45%)
	# of subjects with PGIS score (%)	14 (47%)	15 (45%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 33	# of subjects with PRO-CTCAE score (%)	16 (53%)	12 (36%)
	# of subjects with QLQ-C30 summary score (%)	16 (53%)	12 (36%)
	# of subjects with QLQ-MY20 domain score (%)	6 (20%)	3 (9%)
	# of subjects with QLQ-IL52 domain score (%)	16 (53%)	12 (36%)
	# of subjects with FACT-GP5 score (%)	16 (53%)	11 (33%)
	# of subjects with PGIC score (%)	15 (50%)	11 (33%)
	# of subjects with PGIS score (%)	15 (50%)	11 (33%)
Week 37	# of subjects with PRO-CTCAE score (%)	14 (47%)	9 (27%)
	# of subjects with OSDI summary score (%)	16 (53%)	10 (30%)
	# of subjects with QLQ-C30 summary score (%)	14 (47%)	9 (27%)
	# of subjects with QLQ-MY20 domain score (%)	4 (13%)	2 (6%)
	# of subjects with QLQ-IL52 domain score (%)	14 (47%)	9 (27%)
	# of subjects with FACT-GP5 score (%)	14 (47%)	9 (27%)
	# of subjects with EQ-5D-3L VAS score (%)	16 (53%)	10 (30%)
	# of subjects with PGIC score (%)	14 (47%)	9 (27%)
	# of subjects with PGIS score (%)	14 (47%)	9 (27%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 41	# of subjects with PRO-CTCAE score (%)	12 (40%)	9 (27%)
	# of subjects with QLQ-C30 summary score (%)	14 (47%)	12 (36%)
	# of subjects with QLQ-MY20 domain score (%)	5 (17%)	2 (6%)
	# of subjects with QLQ-IL52 domain score (%)	13 (43%)	12 (36%)
	# of subjects with FACT-GP5 score (%)	12 (40%)	9 (27%)
	# of subjects with PGIC score (%)	12 (40%)	9 (27%)
	# of subjects with PGIS score (%)	12 (40%)	9 (27%)
Week 45	# of subjects with PRO-CTCAE score (%)	14 (47%)	9 (27%)
	# of subjects with OSDI summary score (%)	13 (43%)	9 (27%)
	# of subjects with QLQ-C30 summary score (%)	15 (50%)	10 (30%)
	# of subjects with QLQ-MY20 domain score (%)	5 (17%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	15 (50%)	10 (30%)
	# of subjects with FACT-GP5 score (%)	14 (47%)	9 (27%)
	# of subjects with EQ-5D-3L VAS score (%)	13 (43%)	13 (39%)
	# of subjects with PGIC score (%)	14 (47%)	9 (27%)
	# of subjects with PGIS score (%)	14 (47%)	9 (27%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 49	# of subjects with PRO-CTCAE score (%)	11 (37%)	9 (27%)
	# of subjects with QLQ-C30 summary score (%)	11 (37%)	9 (27%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	11 (37%)	9 (27%)
	# of subjects with FACT-GP5 score (%)	11 (37%)	9 (27%)
	# of subjects with PGIC score (%)	11 (37%)	9 (27%)
	# of subjects with PGIS score (%)	11 (37%)	9 (27%)
Week 53	# of subjects with PRO-CTCAE score (%)	10 (33%)	9 (27%)
	# of subjects with OSDI summary score (%)	11 (37%)	8 (24%)
	# of subjects with QLQ-C30 summary score (%)	9 (30%)	11 (33%)
	# of subjects with QLQ-MY20 domain score (%)	4 (13%)	2 (6%)
	# of subjects with QLQ-IL52 domain score (%)	9 (30%)	11 (33%)
	# of subjects with FACT-GP5 score (%)	10 (33%)	9 (27%)
	# of subjects with EQ-5D-3L VAS score (%)	11 (37%)	11 (33%)
	# of subjects with PGIC score (%)	10 (33%)	9 (27%)
	# of subjects with PGIS score (%)	10 (33%)	9 (27%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 57	# of subjects with PRO-CTCAE score (%)	11 (37%)	7 (21%)
	# of subjects with QLQ-C30 summary score (%)	11 (37%)	9 (27%)
	# of subjects with QLQ-MY20 domain score (%)	5 (17%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	11 (37%)	9 (27%)
	# of subjects with FACT-GP5 score (%)	11 (37%)	7 (21%)
	# of subjects with PGIC score (%)	10 (33%)	7 (21%)
	# of subjects with PGIS score (%)	10 (33%)	7 (21%)
Week 61	# of subjects with PRO-CTCAE score (%)	9 (30%)	6 (18%)
	# of subjects with OSDI summary score (%)	10 (33%)	6 (18%)
	# of subjects with QLQ-C30 summary score (%)	11 (37%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	4 (13%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	11 (37%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	9 (30%)	6 (18%)
	# of subjects with EQ-5D-3L VAS score (%)	11 (37%)	7 (21%)
	# of subjects with PGIC score (%)	9 (30%)	6 (18%)
	# of subjects with PGIS score (%)	9 (30%)	6 (18%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 65	# of subjects with PRO-CTCAE score (%)	9 (30%)	6 (18%)
	# of subjects with QLQ-C30 summary score (%)	10 (33%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	5 (17%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	11 (37%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	9 (30%)	6 (18%)
	# of subjects with PGIC score (%)	9 (30%)	6 (18%)
	# of subjects with PGIS score (%)	9 (30%)	6 (18%)
Week 69	# of subjects with PRO-CTCAE score (%)	9 (30%)	6 (18%)
	# of subjects with OSDI summary score (%)	11 (37%)	6 (18%)
	# of subjects with QLQ-C30 summary score (%)	9 (30%)	7 (21%)
	# of subjects with QLQ-MY20 domain score (%)	4 (13%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	9 (30%)	7 (21%)
	# of subjects with FACT-GP5 score (%)	9 (30%)	6 (18%)
	# of subjects with EQ-5D-3L VAS score (%)	11 (37%)	7 (21%)
	# of subjects with PGIC score (%)	9 (30%)	6 (18%)
	# of subjects with PGIS score (%)	9 (30%)	6 (18%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Protocol: 207499 Page 10 of 29
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004205
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 73	# of subjects with PRO-CTCAE score (%)	9 (30%)	6 (18%)
	# of subjects with QLQ-C30 summary score (%)	10 (33%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	4 (13%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	10 (33%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	9 (30%)	6 (18%)
	# of subjects with PGIC score (%)	9 (30%)	6 (18%)
	# of subjects with PGIS score (%)	9 (30%)	6 (18%)
Week 77	# of subjects with PRO-CTCAE score (%)	7 (23%)	5 (15%)
	# of subjects with OSDI summary score (%)	8 (27%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (23%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	7 (23%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	7 (23%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	9 (30%)	6 (18%)
	# of subjects with PGIC score (%)	7 (23%)	5 (15%)
	# of subjects with PGIS score (%)	7 (23%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 81	# of subjects with PRO-CTCAE score (%)	7 (23%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (23%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	0
	# of subjects with QLQ-IL52 domain score (%)	7 (23%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	7 (23%)	5 (15%)
	# of subjects with PGIC score (%)	7 (23%)	5 (15%)
	# of subjects with PGIS score (%)	7 (23%)	5 (15%)
Week 85	# of subjects with PRO-CTCAE score (%)	7 (23%)	4 (12%)
	# of subjects with OSDI summary score (%)	7 (23%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	8 (27%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	4 (13%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (27%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	7 (23%)	4 (12%)
	# of subjects with EQ-5D-3L VAS score (%)	8 (27%)	6 (18%)
	# of subjects with PGIC score (%)	7 (23%)	4 (12%)
	# of subjects with PGIS score (%)	7 (23%)	4 (12%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 89	# of subjects with PRO-CTCAE score (%)	7 (23%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	8 (27%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (27%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	7 (23%)	5 (15%)
	# of subjects with PGIC score (%)	8 (27%)	5 (15%)
	# of subjects with PGIS score (%)	8 (27%)	5 (15%)
Week 93	# of subjects with PRO-CTCAE score (%)	7 (23%)	5 (15%)
	# of subjects with OSDI summary score (%)	8 (27%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	8 (27%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	4 (13%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (27%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	7 (23%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	9 (30%)	5 (15%)
	# of subjects with PGIC score (%)	8 (27%)	5 (15%)
	# of subjects with PGIS score (%)	8 (27%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 97	# of subjects with PRO-CTCAE score (%)	6 (20%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	8 (27%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (27%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	6 (20%)	5 (15%)
	# of subjects with PGIC score (%)	7 (23%)	5 (15%)
	# of subjects with PGIS score (%)	7 (23%)	5 (15%)
Week 101	# of subjects with PRO-CTCAE score (%)	7 (23%)	5 (15%)
	# of subjects with OSDI summary score (%)	6 (20%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (23%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	8 (27%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	7 (23%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	7 (23%)	6 (18%)
	# of subjects with PGIC score (%)	6 (20%)	5 (15%)
	# of subjects with PGIS score (%)	7 (23%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 105	# of subjects with PRO-CTCAE score (%)	6 (20%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	6 (20%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (20%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	6 (20%)	4 (12%)
	# of subjects with PGIC score (%)	6 (20%)	4 (12%)
	# of subjects with PGIS score (%)	6 (20%)	4 (12%)
Week 109	# of subjects with PRO-CTCAE score (%)	7 (23%)	5 (15%)
	# of subjects with OSDI summary score (%)	7 (23%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (23%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	0
	# of subjects with QLQ-IL52 domain score (%)	7 (23%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	7 (23%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	8 (27%)	6 (18%)
	# of subjects with PGIC score (%)	7 (23%)	5 (15%)
	# of subjects with PGIS score (%)	7 (23%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Protocol: 207499 Page 15 of 29
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004205
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 113	# of subjects with PRO-CTCAE score (%)	7 (23%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	8 (27%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (27%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	7 (23%)	5 (15%)
	# of subjects with PGIC score (%)	7 (23%)	5 (15%)
	# of subjects with PGIS score (%)	7 (23%)	5 (15%)
Week 117	# of subjects with PRO-CTCAE score (%)	6 (20%)	4 (12%)
	# of subjects with OSDI summary score (%)	6 (20%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	6 (20%)	4 (12%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (20%)	4 (12%)
	# of subjects with FACT-GP5 score (%)	6 (20%)	4 (12%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (20%)	4 (12%)
	# of subjects with PGIC score (%)	6 (20%)	4 (12%)
	# of subjects with PGIS score (%)	6 (20%)	4 (12%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 121	# of subjects with PRO-CTCAE score (%)	5 (17%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	5 (17%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (17%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	5 (15%)
	# of subjects with PGIC score (%)	5 (17%)	5 (15%)
	# of subjects with PGIS score (%)	5 (17%)	5 (15%)
Week 125	# of subjects with PRO-CTCAE score (%)	5 (17%)	5 (15%)
	# of subjects with OSDI summary score (%)	6 (20%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (23%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	7 (23%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (20%)	5 (15%)
	# of subjects with PGIC score (%)	5 (17%)	5 (15%)
	# of subjects with PGIS score (%)	5 (17%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Protocol: 207499 Page 17 of 29
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004205
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 129	# of subjects with PRO-CTCAE score (%)	5 (17%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	6 (20%)	4 (12%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (20%)	4 (12%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	4 (12%)
	# of subjects with PGIC score (%)	5 (17%)	4 (12%)
	# of subjects with PGIS score (%)	5 (17%)	4 (12%)
Week 133	# of subjects with PRO-CTCAE score (%)	4 (13%)	4 (12%)
	# of subjects with OSDI summary score (%)	5 (17%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	4 (13%)	4 (12%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	4 (13%)	4 (12%)
	# of subjects with FACT-GP5 score (%)	4 (13%)	4 (12%)
	# of subjects with EQ-5D-3L VAS score (%)	5 (17%)	4 (12%)
	# of subjects with PGIC score (%)	4 (13%)	4 (12%)
	# of subjects with PGIS score (%)	4 (13%)	4 (12%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 137	# of subjects with PRO-CTCAE score (%)	5 (17%)	3 (9%)
	# of subjects with QLQ-C30 summary score (%)	5 (17%)	3 (9%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (17%)	3 (9%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	3 (9%)
	# of subjects with PGIC score (%)	5 (17%)	3 (9%)
	# of subjects with PGIS score (%)	5 (17%)	3 (9%)
Week 141	# of subjects with PRO-CTCAE score (%)	5 (17%)	2 (6%)
	# of subjects with OSDI summary score (%)	6 (20%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	6 (20%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (20%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	2 (6%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (20%)	3 (9%)
	# of subjects with PGIC score (%)	5 (17%)	2 (6%)
	# of subjects with PGIS score (%)	5 (17%)	2 (6%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Protocol: 207499 Page 19 of 29
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004205
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 145	# of subjects with PRO-CTCAE score (%)	5 (17%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	5 (17%)	3 (9%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (17%)	3 (9%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	2 (6%)
	# of subjects with PGIC score (%)	5 (17%)	2 (6%)
	# of subjects with PGIS score (%)	5 (17%)	2 (6%)
Week 149	# of subjects with PRO-CTCAE score (%)	5 (17%)	2 (6%)
	# of subjects with OSDI summary score (%)	5 (17%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	6 (20%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (20%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	2 (6%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (20%)	2 (6%)
	# of subjects with PGIC score (%)	5 (17%)	2 (6%)
	# of subjects with PGIS score (%)	5 (17%)	2 (6%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 153	# of subjects with PRO-CTCAE score (%)	4 (13%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	4 (13%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	4 (13%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	4 (13%)	2 (6%)
	# of subjects with PGIC score (%)	3 (10%)	2 (6%)
	# of subjects with PGIS score (%)	3 (10%)	2 (6%)
Week 157	# of subjects with PRO-CTCAE score (%)	5 (17%)	2 (6%)
	# of subjects with OSDI summary score (%)	5 (17%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	5 (17%)	3 (9%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (17%)	3 (9%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	2 (6%)
	# of subjects with EQ-5D-3L VAS score (%)	5 (17%)	3 (9%)
	# of subjects with PGIC score (%)	5 (17%)	2 (6%)
	# of subjects with PGIS score (%)	5 (17%)	2 (6%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Protocol: 207499 Page 21 of 29
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004205
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 161	# of subjects with PRO-CTCAE score (%)	5 (17%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	6 (20%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (20%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	1 (3%)
	# of subjects with PGIC score (%)	5 (17%)	1 (3%)
	# of subjects with PGIS score (%)	5 (17%)	1 (3%)
Week 165	# of subjects with PRO-CTCAE score (%)	5 (17%)	2 (6%)
	# of subjects with OSDI summary score (%)	7 (23%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	5 (17%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (17%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	2 (6%)
	# of subjects with EQ-5D-3L VAS score (%)	7 (23%)	2 (6%)
	# of subjects with PGIC score (%)	5 (17%)	2 (6%)
	# of subjects with PGIS score (%)	5 (17%)	2 (6%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 169	# of subjects with PRO-CTCAE score (%)	5 (17%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	6 (20%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (20%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	1 (3%)
	# of subjects with PGIC score (%)	5 (17%)	1 (3%)
	# of subjects with PGIS score (%)	5 (17%)	1 (3%)
Week 173	# of subjects with PRO-CTCAE score (%)	5 (17%)	1 (3%)
	# of subjects with OSDI summary score (%)	4 (13%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	5 (17%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (3%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (17%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	5 (17%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	4 (13%)	1 (3%)
	# of subjects with PGIC score (%)	5 (17%)	1 (3%)
	# of subjects with PGIS score (%)	5 (17%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 177	# of subjects with PRO-CTCAE score (%)	3 (10%)	1 (3%)
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	3 (10%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	3 (10%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	3 (10%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	3 (10%)	1 (3%)
	# of subjects with PGIS score (%)	3 (10%)	1 (3%)
Week 181	# of subjects with PRO-CTCAE score (%)	3 (10%)	1 (3%)
	# of subjects with OSDI summary score (%)	3 (10%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	3 (10%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	3 (10%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	3 (10%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	3 (10%)	2 (6%)
	# of subjects with PGIC score (%)	3 (10%)	1 (3%)
	# of subjects with PGIS score (%)	3 (10%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 185	# of subjects with PRO-CTCAE score (%)	2 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	3 (10%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	3 (10%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	2 (7%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	2 (7%)	1 (3%)
	# of subjects with PGIS score (%)	2 (7%)	1 (3%)
Week 189	# of subjects with PRO-CTCAE score (%)	1 (3%)	1 (3%)
	# of subjects with OSDI summary score (%)	3 (10%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (3%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (3%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	1 (3%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	3 (10%)	2 (6%)
	# of subjects with PGIC score (%)	1 (3%)	1 (3%)
	# of subjects with PGIS score (%)	1 (3%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 193	# of subjects with PRO-CTCAE score (%)	2 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	2 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	2 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	2 (7%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	2 (7%)	1 (3%)
	# of subjects with PGIS score (%)	2 (7%)	1 (3%)
Week 197	# of subjects with PRO-CTCAE score (%)	1 (3%)	1 (3%)
	# of subjects with OSDI summary score (%)	2 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (3%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (3%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (3%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	2 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (3%)	1 (3%)
	# of subjects with PGIS score (%)	1 (3%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Protocol: 207499 Page 26 of 29
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004205
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 201	# of subjects with PRO-CTCAE score (%)	1 (3%)	1 (3%)
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	2 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	2 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (3%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	1 (3%)	1 (3%)
	# of subjects with PGIS score (%)	1 (3%)	1 (3%)
Week 205	# of subjects with PRO-CTCAE score (%)	0	0
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	0	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	0	1 (3%)
	# of subjects with FACT-GP5 score (%)	0	0
	# of subjects with EQ-5D-3L VAS score (%)	0	1 (3%)
	# of subjects with PGIC score (%)	0	0
	# of subjects with PGIS score (%)	0	0

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Protocol: 207499 Page 27 of 29
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004205
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
Week 213	# of subjects with PRO-CTCAE score (%)	0	0
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	0	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	0	1 (3%)
	# of subjects with FACT-GP5 score (%)	0	0
	# of subjects with EQ-5D-3L VAS score (%)	0	1 (3%)
	# of subjects with PGIC score (%)	0	0
	# of subjects with PGIS score (%)	0	0
End of Treatment	# of subjects with PRO-CTCAE score (%)	18 (60%)	21 (64%)
	# of subjects with OSDI summary score (%)	18 (60%)	20 (61%)
	# of subjects with QLQ-C30 summary score (%)	18 (60%)	22 (67%)
	# of subjects with QLQ-MY20 domain score (%)	7 (23%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	18 (60%)	21 (64%)
	# of subjects with FACT-GP5 score (%)	18 (60%)	20 (61%)
	# of subjects with EQ-5D-3L VAS score (%)	18 (60%)	20 (61%)
	# of subjects with PGIC score (%)	18 (60%)	20 (61%)
	# of subjects with PGIS score (%)	18 (60%)	20 (61%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
PFS FOLLOW-UP 3	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	0	0
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (3%)	0
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	0	0
	# of subjects with PGIS score (%)	0	0
PFS FOLLOW-UP 8	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	1 (3%)	0
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (3%)	0
	# of subjects with EQ-5D-3L VAS score (%)	1 (3%)	0
	# of subjects with PGIC score (%)	1 (3%)	0
	# of subjects with PGIS score (%)	1 (3%)	0
PFS FOLLOW-UP 10	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	1 (3%)	0
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (3%)	0
	# of subjects with EQ-5D-3L VAS score (%)	1 (3%)	0
	# of subjects with PGIC score (%)	1 (3%)	0
	# of subjects with PGIS score (%)	1 (3%)	0

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004205

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (ITT Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=30)	POM + BOR/DEX (N=33)
EPRO SURVIVAL FOLLOW-UP 1	# of subjects with OSDI summary score (%)	6 (20%)	0
	# of subjects with QLQ-C30 summary score (%)	9 (30%)	8 (24%)
	# of subjects with QLQ-MY20 domain score (%)	5 (17%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	9 (30%)	8 (24%)
	# of subjects with EQ-5D-3L VAS score (%)	9 (30%)	8 (24%)
EPRO SURVIVAL FOLLOW-UP 2	# of subjects with OSDI summary score (%)	5 (17%)	0
	# of subjects with QLQ-C30 summary score (%)	7 (23%)	7 (21%)
	# of subjects with QLQ-MY20 domain score (%)	3 (10%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	7 (23%)	7 (21%)
	# of subjects with EQ-5D-3L VAS score (%)	7 (23%)	7 (21%)
EPRO SURVIVAL FOLLOW-UP 3	# of subjects with OSDI summary score (%)	3 (10%)	0
	# of subjects with QLQ-C30 summary score (%)	6 (20%)	7 (21%)
	# of subjects with QLQ-MY20 domain score (%)	4 (13%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	6 (20%)	7 (21%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (20%)	7 (21%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/prod/tfls/t_pro_rr_itt_2ref.sas 09OCT2025 10:23

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Baseline	# of subjects with PRO-CTCAE score (%)	27 (96%)	32 (97%)
	# of subjects with OSDI summary score (%)	27 (96%)	32 (97%)
	# of subjects with QLQ-C30 summary score (%)	27 (96%)	32 (97%)
	# of subjects with QLQ-MY20 domain score (%)	10 (36%)	12 (36%)
	# of subjects with QLQ-IL52 domain score (%)	26 (93%)	32 (97%)
	# of subjects with FACT-GP5 score (%)	27 (96%)	32 (97%)
	# of subjects with EQ-5D-3L VAS score (%)	27 (96%)	32 (97%)
	# of subjects with PGIS score (%)	27 (96%)	32 (97%)
Week 5	# of subjects with PRO-CTCAE score (%)	25 (89%)	29 (88%)
	# of subjects with OSDI summary score (%)	25 (89%)	29 (88%)
	# of subjects with QLQ-C30 summary score (%)	25 (89%)	29 (88%)
	# of subjects with QLQ-MY20 domain score (%)	9 (32%)	9 (27%)
	# of subjects with QLQ-IL52 domain score (%)	25 (89%)	29 (88%)
	# of subjects with FACT-GP5 score (%)	25 (89%)	29 (88%)
	# of subjects with EQ-5D-3L VAS score (%)	25 (89%)	29 (88%)
	# of subjects with PGIC score (%)	25 (89%)	29 (88%)
	# of subjects with PGIS score (%)	25 (89%)	29 (88%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 9	# of subjects with PRO-CTCAE score (%)	24 (86%)	27 (82%)
	# of subjects with OSDI summary score (%)	24 (86%)	26 (79%)
	# of subjects with QLQ-C30 summary score (%)	24 (86%)	27 (82%)
	# of subjects with QLQ-MY20 domain score (%)	10 (36%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	24 (86%)	25 (76%)
	# of subjects with FACT-GP5 score (%)	24 (86%)	27 (82%)
	# of subjects with PGIC score (%)	24 (86%)	27 (82%)
	# of subjects with PGIS score (%)	24 (86%)	27 (82%)
Week 13	# of subjects with PRO-CTCAE score (%)	23 (82%)	27 (82%)
	# of subjects with OSDI summary score (%)	23 (82%)	27 (82%)
	# of subjects with QLQ-C30 summary score (%)	23 (82%)	26 (79%)
	# of subjects with QLQ-MY20 domain score (%)	9 (32%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	23 (82%)	26 (79%)
	# of subjects with FACT-GP5 score (%)	23 (82%)	27 (82%)
	# of subjects with EQ-5D-3L VAS score (%)	23 (82%)	27 (82%)
	# of subjects with PGIC score (%)	23 (82%)	27 (82%)
	# of subjects with PGIS score (%)	23 (82%)	27 (82%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 17	# of subjects with PRO-CTCAE score (%)	22 (79%)	25 (76%)
	# of subjects with OSDI summary score (%)	22 (79%)	24 (73%)
	# of subjects with QLQ-C30 summary score (%)	22 (79%)	25 (76%)
	# of subjects with QLQ-MY20 domain score (%)	8 (29%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	22 (79%)	24 (73%)
	# of subjects with FACT-GP5 score (%)	22 (79%)	24 (73%)
	# of subjects with PGIC score (%)	22 (79%)	24 (73%)
	# of subjects with PGIS score (%)	22 (79%)	24 (73%)
Week 21	# of subjects with PRO-CTCAE score (%)	17 (61%)	19 (58%)
	# of subjects with OSDI summary score (%)	16 (57%)	18 (55%)
	# of subjects with QLQ-C30 summary score (%)	17 (61%)	19 (58%)
	# of subjects with QLQ-MY20 domain score (%)	7 (25%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	17 (61%)	19 (58%)
	# of subjects with FACT-GP5 score (%)	17 (61%)	19 (58%)
	# of subjects with EQ-5D-3L VAS score (%)	19 (68%)	20 (61%)
	# of subjects with PGIC score (%)	17 (61%)	19 (58%)
	# of subjects with PGIS score (%)	17 (61%)	19 (58%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 25	# of subjects with PRO-CTCAE score (%)	17 (61%)	15 (45%)
	# of subjects with QLQ-C30 summary score (%)	18 (64%)	16 (48%)
	# of subjects with QLQ-MY20 domain score (%)	7 (25%)	4 (12%)
	# of subjects with QLQ-IL52 domain score (%)	18 (64%)	16 (48%)
	# of subjects with FACT-GP5 score (%)	17 (61%)	15 (45%)
	# of subjects with PGIC score (%)	17 (61%)	14 (42%)
	# of subjects with PGIS score (%)	17 (61%)	15 (45%)
Week 29	# of subjects with PRO-CTCAE score (%)	14 (50%)	15 (45%)
	# of subjects with OSDI summary score (%)	17 (61%)	15 (45%)
	# of subjects with QLQ-C30 summary score (%)	15 (54%)	17 (52%)
	# of subjects with QLQ-MY20 domain score (%)	6 (21%)	5 (15%)
	# of subjects with QLQ-IL52 domain score (%)	15 (54%)	17 (52%)
	# of subjects with FACT-GP5 score (%)	14 (50%)	15 (45%)
	# of subjects with EQ-5D-3L VAS score (%)	17 (61%)	18 (55%)
	# of subjects with PGIC score (%)	14 (50%)	15 (45%)
	# of subjects with PGIS score (%)	14 (50%)	15 (45%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 33	# of subjects with PRO-CTCAE score (%)	16 (57%)	12 (36%)
	# of subjects with QLQ-C30 summary score (%)	16 (57%)	12 (36%)
	# of subjects with QLQ-MY20 domain score (%)	6 (21%)	3 (9%)
	# of subjects with QLQ-IL52 domain score (%)	16 (57%)	12 (36%)
	# of subjects with FACT-GP5 score (%)	16 (57%)	11 (33%)
	# of subjects with PGIC score (%)	15 (54%)	11 (33%)
	# of subjects with PGIS score (%)	15 (54%)	11 (33%)
Week 37	# of subjects with PRO-CTCAE score (%)	14 (50%)	9 (27%)
	# of subjects with OSDI summary score (%)	16 (57%)	10 (30%)
	# of subjects with QLQ-C30 summary score (%)	14 (50%)	9 (27%)
	# of subjects with QLQ-MY20 domain score (%)	4 (14%)	2 (6%)
	# of subjects with QLQ-IL52 domain score (%)	14 (50%)	9 (27%)
	# of subjects with FACT-GP5 score (%)	14 (50%)	9 (27%)
	# of subjects with EQ-5D-3L VAS score (%)	16 (57%)	10 (30%)
	# of subjects with PGIC score (%)	14 (50%)	9 (27%)
	# of subjects with PGIS score (%)	14 (50%)	9 (27%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 41	# of subjects with PRO-CTCAE score (%)	12 (43%)	9 (27%)
	# of subjects with QLQ-C30 summary score (%)	14 (50%)	12 (36%)
	# of subjects with QLQ-MY20 domain score (%)	5 (18%)	2 (6%)
	# of subjects with QLQ-IL52 domain score (%)	13 (46%)	12 (36%)
	# of subjects with FACT-GP5 score (%)	12 (43%)	9 (27%)
	# of subjects with PGIC score (%)	12 (43%)	9 (27%)
	# of subjects with PGIS score (%)	12 (43%)	9 (27%)
Week 45	# of subjects with PRO-CTCAE score (%)	14 (50%)	9 (27%)
	# of subjects with OSDI summary score (%)	13 (46%)	9 (27%)
	# of subjects with QLQ-C30 summary score (%)	15 (54%)	10 (30%)
	# of subjects with QLQ-MY20 domain score (%)	5 (18%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	15 (54%)	10 (30%)
	# of subjects with FACT-GP5 score (%)	14 (50%)	9 (27%)
	# of subjects with EQ-5D-3L VAS score (%)	13 (46%)	13 (39%)
	# of subjects with PGIC score (%)	14 (50%)	9 (27%)
	# of subjects with PGIS score (%)	14 (50%)	9 (27%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 49	# of subjects with PRO-CTCAE score (%)	11 (39%)	9 (27%)
	# of subjects with QLQ-C30 summary score (%)	11 (39%)	9 (27%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	11 (39%)	9 (27%)
	# of subjects with FACT-GP5 score (%)	11 (39%)	9 (27%)
	# of subjects with PGIC score (%)	11 (39%)	9 (27%)
	# of subjects with PGIS score (%)	11 (39%)	9 (27%)
Week 53	# of subjects with PRO-CTCAE score (%)	10 (36%)	9 (27%)
	# of subjects with OSDI summary score (%)	11 (39%)	8 (24%)
	# of subjects with QLQ-C30 summary score (%)	9 (32%)	11 (33%)
	# of subjects with QLQ-MY20 domain score (%)	4 (14%)	2 (6%)
	# of subjects with QLQ-IL52 domain score (%)	9 (32%)	11 (33%)
	# of subjects with FACT-GP5 score (%)	10 (36%)	9 (27%)
	# of subjects with EQ-5D-3L VAS score (%)	11 (39%)	11 (33%)
	# of subjects with PGIC score (%)	10 (36%)	9 (27%)
	# of subjects with PGIS score (%)	10 (36%)	9 (27%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 57	# of subjects with PRO-CTCAE score (%)	11 (39%)	7 (21%)
	# of subjects with QLQ-C30 summary score (%)	11 (39%)	9 (27%)
	# of subjects with QLQ-MY20 domain score (%)	5 (18%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	11 (39%)	9 (27%)
	# of subjects with FACT-GP5 score (%)	11 (39%)	7 (21%)
	# of subjects with PGIC score (%)	10 (36%)	7 (21%)
	# of subjects with PGIS score (%)	10 (36%)	7 (21%)
Week 61	# of subjects with PRO-CTCAE score (%)	9 (32%)	6 (18%)
	# of subjects with OSDI summary score (%)	10 (36%)	6 (18%)
	# of subjects with QLQ-C30 summary score (%)	11 (39%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	4 (14%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	11 (39%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	9 (32%)	6 (18%)
	# of subjects with EQ-5D-3L VAS score (%)	11 (39%)	7 (21%)
	# of subjects with PGIC score (%)	9 (32%)	6 (18%)
	# of subjects with PGIS score (%)	9 (32%)	6 (18%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 65	# of subjects with PRO-CTCAE score (%)	9 (32%)	6 (18%)
	# of subjects with QLQ-C30 summary score (%)	10 (36%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	5 (18%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	11 (39%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	9 (32%)	6 (18%)
	# of subjects with PGIC score (%)	9 (32%)	6 (18%)
	# of subjects with PGIS score (%)	9 (32%)	6 (18%)
Week 69	# of subjects with PRO-CTCAE score (%)	9 (32%)	6 (18%)
	# of subjects with OSDI summary score (%)	11 (39%)	6 (18%)
	# of subjects with QLQ-C30 summary score (%)	9 (32%)	7 (21%)
	# of subjects with QLQ-MY20 domain score (%)	4 (14%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	9 (32%)	7 (21%)
	# of subjects with FACT-GP5 score (%)	9 (32%)	6 (18%)
	# of subjects with EQ-5D-3L VAS score (%)	11 (39%)	7 (21%)
	# of subjects with PGIC score (%)	9 (32%)	6 (18%)
	# of subjects with PGIS score (%)	9 (32%)	6 (18%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 73	# of subjects with PRO-CTCAE score (%)	9 (32%)	6 (18%)
	# of subjects with QLQ-C30 summary score (%)	10 (36%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	4 (14%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	10 (36%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	9 (32%)	6 (18%)
	# of subjects with PGIC score (%)	9 (32%)	6 (18%)
	# of subjects with PGIS score (%)	9 (32%)	6 (18%)
Week 77	# of subjects with PRO-CTCAE score (%)	7 (25%)	5 (15%)
	# of subjects with OSDI summary score (%)	8 (29%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (25%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	7 (25%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	7 (25%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	9 (32%)	6 (18%)
	# of subjects with PGIC score (%)	7 (25%)	5 (15%)
	# of subjects with PGIS score (%)	7 (25%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 81	# of subjects with PRO-CTCAE score (%)	7 (25%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (25%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	0
	# of subjects with QLQ-IL52 domain score (%)	7 (25%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	7 (25%)	5 (15%)
	# of subjects with PGIC score (%)	7 (25%)	5 (15%)
	# of subjects with PGIS score (%)	7 (25%)	5 (15%)
Week 85	# of subjects with PRO-CTCAE score (%)	7 (25%)	4 (12%)
	# of subjects with OSDI summary score (%)	7 (25%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	8 (29%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	4 (14%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (29%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	7 (25%)	4 (12%)
	# of subjects with EQ-5D-3L VAS score (%)	8 (29%)	6 (18%)
	# of subjects with PGIC score (%)	7 (25%)	4 (12%)
	# of subjects with PGIS score (%)	7 (25%)	4 (12%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 89	# of subjects with PRO-CTCAE score (%)	7 (25%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	8 (29%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (29%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	7 (25%)	5 (15%)
	# of subjects with PGIC score (%)	8 (29%)	5 (15%)
	# of subjects with PGIS score (%)	8 (29%)	5 (15%)
Week 93	# of subjects with PRO-CTCAE score (%)	7 (25%)	5 (15%)
	# of subjects with OSDI summary score (%)	8 (29%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	8 (29%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	4 (14%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (29%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	7 (25%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	9 (32%)	5 (15%)
	# of subjects with PGIC score (%)	8 (29%)	5 (15%)
	# of subjects with PGIS score (%)	8 (29%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 97	# of subjects with PRO-CTCAE score (%)	6 (21%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	8 (29%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (29%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	6 (21%)	5 (15%)
	# of subjects with PGIC score (%)	7 (25%)	5 (15%)
	# of subjects with PGIS score (%)	7 (25%)	5 (15%)
Week 101	# of subjects with PRO-CTCAE score (%)	7 (25%)	5 (15%)
	# of subjects with OSDI summary score (%)	6 (21%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (25%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	8 (29%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	7 (25%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	7 (25%)	6 (18%)
	# of subjects with PGIC score (%)	6 (21%)	5 (15%)
	# of subjects with PGIS score (%)	7 (25%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 105	# of subjects with PRO-CTCAE score (%)	6 (21%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	6 (21%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (21%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	6 (21%)	4 (12%)
	# of subjects with PGIC score (%)	6 (21%)	4 (12%)
	# of subjects with PGIS score (%)	6 (21%)	4 (12%)
Week 109	# of subjects with PRO-CTCAE score (%)	7 (25%)	5 (15%)
	# of subjects with OSDI summary score (%)	7 (25%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (25%)	6 (18%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	0
	# of subjects with QLQ-IL52 domain score (%)	7 (25%)	6 (18%)
	# of subjects with FACT-GP5 score (%)	7 (25%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	8 (29%)	6 (18%)
	# of subjects with PGIC score (%)	7 (25%)	5 (15%)
	# of subjects with PGIS score (%)	7 (25%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 113	# of subjects with PRO-CTCAE score (%)	7 (25%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	8 (29%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	0
	# of subjects with QLQ-IL52 domain score (%)	8 (29%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	7 (25%)	5 (15%)
	# of subjects with PGIC score (%)	7 (25%)	5 (15%)
	# of subjects with PGIS score (%)	7 (25%)	5 (15%)
Week 117	# of subjects with PRO-CTCAE score (%)	6 (21%)	4 (12%)
	# of subjects with OSDI summary score (%)	6 (21%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	6 (21%)	4 (12%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (21%)	4 (12%)
	# of subjects with FACT-GP5 score (%)	6 (21%)	4 (12%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (21%)	4 (12%)
	# of subjects with PGIC score (%)	6 (21%)	4 (12%)
	# of subjects with PGIS score (%)	6 (21%)	4 (12%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 121	# of subjects with PRO-CTCAE score (%)	5 (18%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	5 (18%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (18%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	5 (15%)
	# of subjects with PGIC score (%)	5 (18%)	5 (15%)
	# of subjects with PGIS score (%)	5 (18%)	5 (15%)
Week 125	# of subjects with PRO-CTCAE score (%)	5 (18%)	5 (15%)
	# of subjects with OSDI summary score (%)	6 (21%)	5 (15%)
	# of subjects with QLQ-C30 summary score (%)	7 (25%)	5 (15%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	7 (25%)	5 (15%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	5 (15%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (21%)	5 (15%)
	# of subjects with PGIC score (%)	5 (18%)	5 (15%)
	# of subjects with PGIS score (%)	5 (18%)	5 (15%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Protocol: 207499 Page 17 of 29
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 129	# of subjects with PRO-CTCAE score (%)	5 (18%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	6 (21%)	4 (12%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (21%)	4 (12%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	4 (12%)
	# of subjects with PGIC score (%)	5 (18%)	4 (12%)
	# of subjects with PGIS score (%)	5 (18%)	4 (12%)
Week 133	# of subjects with PRO-CTCAE score (%)	4 (14%)	4 (12%)
	# of subjects with OSDI summary score (%)	5 (18%)	4 (12%)
	# of subjects with QLQ-C30 summary score (%)	4 (14%)	4 (12%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	4 (14%)	4 (12%)
	# of subjects with FACT-GP5 score (%)	4 (14%)	4 (12%)
	# of subjects with EQ-5D-3L VAS score (%)	5 (18%)	4 (12%)
	# of subjects with PGIC score (%)	4 (14%)	4 (12%)
	# of subjects with PGIS score (%)	4 (14%)	4 (12%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 137	# of subjects with PRO-CTCAE score (%)	5 (18%)	3 (9%)
	# of subjects with QLQ-C30 summary score (%)	5 (18%)	3 (9%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (18%)	3 (9%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	3 (9%)
	# of subjects with PGIC score (%)	5 (18%)	3 (9%)
	# of subjects with PGIS score (%)	5 (18%)	3 (9%)
Week 141	# of subjects with PRO-CTCAE score (%)	5 (18%)	2 (6%)
	# of subjects with OSDI summary score (%)	6 (21%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	6 (21%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (21%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	2 (6%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (21%)	3 (9%)
	# of subjects with PGIC score (%)	5 (18%)	2 (6%)
	# of subjects with PGIS score (%)	5 (18%)	2 (6%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Protocol: 207499 Page 19 of 29
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 145	# of subjects with PRO-CTCAE score (%)	5 (18%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	5 (18%)	3 (9%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (18%)	3 (9%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	2 (6%)
	# of subjects with PGIC score (%)	5 (18%)	2 (6%)
	# of subjects with PGIS score (%)	5 (18%)	2 (6%)
Week 149	# of subjects with PRO-CTCAE score (%)	5 (18%)	2 (6%)
	# of subjects with OSDI summary score (%)	5 (18%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	6 (21%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (21%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	2 (6%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (21%)	2 (6%)
	# of subjects with PGIC score (%)	5 (18%)	2 (6%)
	# of subjects with PGIS score (%)	5 (18%)	2 (6%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Protocol: 207499 Page 20 of 29
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 153	# of subjects with PRO-CTCAE score (%)	4 (14%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	4 (14%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	4 (14%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	4 (14%)	2 (6%)
	# of subjects with PGIC score (%)	3 (11%)	2 (6%)
	# of subjects with PGIS score (%)	3 (11%)	2 (6%)
Week 157	# of subjects with PRO-CTCAE score (%)	5 (18%)	2 (6%)
	# of subjects with OSDI summary score (%)	5 (18%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	5 (18%)	3 (9%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (18%)	3 (9%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	2 (6%)
	# of subjects with EQ-5D-3L VAS score (%)	5 (18%)	3 (9%)
	# of subjects with PGIC score (%)	5 (18%)	2 (6%)
	# of subjects with PGIS score (%)	5 (18%)	2 (6%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 161	# of subjects with PRO-CTCAE score (%)	5 (18%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	6 (21%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (21%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	1 (3%)
	# of subjects with PGIC score (%)	5 (18%)	1 (3%)
	# of subjects with PGIS score (%)	5 (18%)	1 (3%)
Week 165	# of subjects with PRO-CTCAE score (%)	5 (18%)	2 (6%)
	# of subjects with OSDI summary score (%)	7 (25%)	2 (6%)
	# of subjects with QLQ-C30 summary score (%)	5 (18%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (18%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	2 (6%)
	# of subjects with EQ-5D-3L VAS score (%)	7 (25%)	2 (6%)
	# of subjects with PGIC score (%)	5 (18%)	2 (6%)
	# of subjects with PGIS score (%)	5 (18%)	2 (6%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 169	# of subjects with PRO-CTCAE score (%)	5 (18%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	6 (21%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	2 (7%)	0
	# of subjects with QLQ-IL52 domain score (%)	6 (21%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	1 (3%)
	# of subjects with PGIC score (%)	5 (18%)	1 (3%)
	# of subjects with PGIS score (%)	5 (18%)	1 (3%)
Week 173	# of subjects with PRO-CTCAE score (%)	5 (18%)	1 (3%)
	# of subjects with OSDI summary score (%)	4 (14%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	5 (18%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (4%)	0
	# of subjects with QLQ-IL52 domain score (%)	5 (18%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	5 (18%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	4 (14%)	1 (3%)
	# of subjects with PGIC score (%)	5 (18%)	1 (3%)
	# of subjects with PGIS score (%)	5 (18%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305
Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 177	# of subjects with PRO-CTCAE score (%)	3 (11%)	1 (3%)
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	3 (11%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	3 (11%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	3 (11%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	3 (11%)	1 (3%)
	# of subjects with PGIS score (%)	3 (11%)	1 (3%)
Week 181	# of subjects with PRO-CTCAE score (%)	3 (11%)	1 (3%)
	# of subjects with OSDI summary score (%)	3 (11%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	3 (11%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	3 (11%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	3 (11%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	3 (11%)	2 (6%)
	# of subjects with PGIC score (%)	3 (11%)	1 (3%)
	# of subjects with PGIS score (%)	3 (11%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 185	# of subjects with PRO-CTCAE score (%)	2 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	3 (11%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	3 (11%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	2 (7%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	2 (7%)	1 (3%)
	# of subjects with PGIS score (%)	2 (7%)	1 (3%)
Week 189	# of subjects with PRO-CTCAE score (%)	1 (4%)	1 (3%)
	# of subjects with OSDI summary score (%)	3 (11%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (4%)	2 (6%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (4%)	2 (6%)
	# of subjects with FACT-GP5 score (%)	1 (4%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	3 (11%)	2 (6%)
	# of subjects with PGIC score (%)	1 (4%)	1 (3%)
	# of subjects with PGIS score (%)	1 (4%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 193	# of subjects with PRO-CTCAE score (%)	2 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	2 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	2 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	2 (7%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	2 (7%)	1 (3%)
	# of subjects with PGIS score (%)	2 (7%)	1 (3%)
Week 197	# of subjects with PRO-CTCAE score (%)	1 (4%)	1 (3%)
	# of subjects with OSDI summary score (%)	2 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (4%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (4%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (4%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	2 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (4%)	1 (3%)
	# of subjects with PGIS score (%)	1 (4%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 201	# of subjects with PRO-CTCAE score (%)	1 (4%)	1 (3%)
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	2 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	2 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (4%)	1 (3%)
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	1 (4%)	1 (3%)
	# of subjects with PGIS score (%)	1 (4%)	1 (3%)
Week 205	# of subjects with PRO-CTCAE score (%)	0	0
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	0	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	0	1 (3%)
	# of subjects with FACT-GP5 score (%)	0	0
	# of subjects with EQ-5D-3L VAS score (%)	0	1 (3%)
	# of subjects with PGIC score (%)	0	0
	# of subjects with PGIS score (%)	0	0

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Week 213	# of subjects with PRO-CTCAE score (%)	0	0
	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	0	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	0	1 (3%)
	# of subjects with FACT-GP5 score (%)	0	0
	# of subjects with EQ-5D-3L VAS score (%)	0	1 (3%)
	# of subjects with PGIC score (%)	0	0
	# of subjects with PGIS score (%)	0	0
End of Treatment	# of subjects with PRO-CTCAE score (%)	18 (64%)	21 (64%)
	# of subjects with OSDI summary score (%)	18 (64%)	20 (61%)
	# of subjects with QLQ-C30 summary score (%)	18 (64%)	22 (67%)
	# of subjects with QLQ-MY20 domain score (%)	7 (25%)	7 (21%)
	# of subjects with QLQ-IL52 domain score (%)	18 (64%)	21 (64%)
	# of subjects with FACT-GP5 score (%)	18 (64%)	20 (61%)
	# of subjects with EQ-5D-3L VAS score (%)	18 (64%)	20 (61%)
	# of subjects with PGIC score (%)	18 (64%)	20 (61%)
	# of subjects with PGIS score (%)	18 (64%)	20 (61%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
PFS FOLLOW-UP 3	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	0	0
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (4%)	0
	# of subjects with EQ-5D-3L VAS score (%)	0	0
	# of subjects with PGIC score (%)	0	0
	# of subjects with PGIS score (%)	0	0
PFS FOLLOW-UP 8	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	1 (4%)	0
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (4%)	0
	# of subjects with EQ-5D-3L VAS score (%)	1 (4%)	0
	# of subjects with PGIC score (%)	1 (4%)	0
	# of subjects with PGIS score (%)	1 (4%)	0
PFS FOLLOW-UP 10	# of subjects with OSDI summary score (%)	0	0
	# of subjects with QLQ-C30 summary score (%)	1 (4%)	0
	# of subjects with QLQ-MY20 domain score (%)	0	0
	# of subjects with QLQ-IL52 domain score (%)	1 (4%)	0
	# of subjects with EQ-5D-3L VAS score (%)	1 (4%)	0
	# of subjects with PGIC score (%)	1 (4%)	0
	# of subjects with PGIS score (%)	1 (4%)	0

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

Table 4.0004305

Summary of Return Rates of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L VAS, FACT-GP5, PGIS and PGIC by Visit (Safety Population) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Timepoint		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
EPRO SURVIVAL FOLLOW-UP 1	# of subjects with OSDI summary score (%)	6 (21%)	0
	# of subjects with QLQ-C30 summary score (%)	9 (32%)	8 (24%)
	# of subjects with QLQ-MY20 domain score (%)	5 (18%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	9 (32%)	8 (24%)
	# of subjects with EQ-5D-3L VAS score (%)	9 (32%)	8 (24%)
EPRO SURVIVAL FOLLOW-UP 2	# of subjects with OSDI summary score (%)	5 (18%)	0
	# of subjects with QLQ-C30 summary score (%)	7 (25%)	7 (21%)
	# of subjects with QLQ-MY20 domain score (%)	3 (11%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	7 (25%)	7 (21%)
	# of subjects with EQ-5D-3L VAS score (%)	7 (25%)	7 (21%)
EPRO SURVIVAL FOLLOW-UP 3	# of subjects with OSDI summary score (%)	3 (11%)	0
	# of subjects with QLQ-C30 summary score (%)	6 (21%)	7 (21%)
	# of subjects with QLQ-MY20 domain score (%)	4 (14%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	6 (21%)	7 (21%)
	# of subjects with EQ-5D-3L VAS score (%)	6 (21%)	7 (21%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter. EQ-5D-3L VAS assessments are performed every 8 weeks. PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, FACT-GP5, PGIS, and PGIC assessments are performed every 4 weeks.
Note: For the MY20, only subjects enrolled following PA1 will be included.
/mnt/code/sSAP/sSAP02/prod/tfls/t_pro_rr_saf_2ref.sas 09OCT2025 10:24

1.3.2 Graphische Darstellungen – Ergebnisse für Patient Reported Outcomes

1.3.2.1 OSDI

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000105

Plot of Change from Baseline and Confidence Interval of OSDI Total Score by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation



BPd - n	27	24	23	22	21	15	16	15	13	10	10	11	8	7	8	6	7	6	6	5	6	5	5	7	4	3	3	2	17	6	25
PVd - n	32	28	25	27	24	18	15	10	9	8	6	6	5	4	5	5	5	4	5	4	2	2	2	2	1	1	1	1	20	0	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter.
/mnt/code/prod/sSAP/sSAP02/tfls/f_pro_chg_osdi_tot_2ref.sas 14OCT2025 13:53

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000305

Plot of Change from Baseline and Confidence Interval of OSDI Vision-Related Function Subscale Score by Analysis Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation



BPd - n	27	24	23	22	21	15	16	15	13	10	10	11	8	7	8	6	7	6	6	5	6	5	5	7	4	3	3	2	17	6	25
PVd - n	32	28	25	27	24	18	15	10	9	8	6	6	5	4	5	5	5	4	5	4	2	2	2	2	1	1	1	1	20	0	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_osdi_vis_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000505

Plot of Change from Baseline and Confidence Interval of OSDI Ocular Symptoms Subscale Score by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation



BPd - n	27	24	23	22	21	15	16	15	13	10	10	11	8	7	8	6	7	6	6	5	6	5	5	7	4	3	3	2	17	6	25
PVd - n	32	28	25	27	24	18	15	10	9	8	6	6	5	4	5	5	5	4	5	4	2	2	2	2	1	1	1	1	20	0	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_osdi_oc_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000705

Plot of Change from Baseline and Confidence Interval of OSDI Environmental Triggers Subscale Score by Analysis Timepoint

-

Lenalidomide and Anti-CD38 Refractory Subpopulation



BPd - n	18	13	13	13	13	9	8	10	8	6	5	7	4	3	4	3	3	3	2	3	3	2	2	3	2	1	2	2	9	4	17
PVd - n	28	22	17	16	16	13	10	8	6	5	3	4	4	3	3	4	4	3	4	3	2	1	1	1	1	1	1	1	13	0	25

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
Note: OSDI assessments are performed every 4 weeks up to Week 21 and every 8 weeks thereafter.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_osdi_env_2ref.sas 14OCT2025 13:53

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000905

Graph of Kaplan Meier Curves of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score



/mnt/code/prod/tfls/f_pro_osdi_ttd_fu_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000905

Graph of Kaplan Meier Curves of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms



/mnt/code/prod/tfls/f_pro_osdi_ttd_fu_2ref.sas 14OCT2025 13:54

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000905
Graph of Kaplan Meier Curves of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation
Item Score: Vision-related Function



/mnt/code/prod/tfls/f_pro_osdi_ttd_fu_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000905

Graph of Kaplan Meier Curves of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers



/mnt/code/prod/tfls/f_pro_osdi_ttd_fu_2ref.sas 14OCT2025 13:54

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000945
Graph of Kaplan Meier Curves of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation
Item Score: Vision-related Function

ISS Stage: I



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_osdi_ttd_fu_2ref_iss.sas 14OCT2025 13:55

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0000945

Graph of Kaplan Meier Curves of OSDI Time to First Deterioration (Up to and Including Last Follow-Up) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function

ISS Stage: II/III



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_osdi_ttd_fu_2ref_iss.sas 14OCT2025 13:55

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001105

Graph of Kaplan Meier Curves of OSDI Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Total Score



/mnt/code/prod/tfls/f_pro_osdi_tti_fu_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001105

Graph of Kaplan Meier Curves of OSDI Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Ocular Symptoms



/mnt/code/prod/tfls/f_pro_osdi_tti_fu_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001105

Graph of Kaplan Meier Curves of OSDI Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Vision-related Function



/mnt/code/prod/tfls/f_pro_osdi_tti_fu_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001105

Graph of Kaplan Meier Curves of OSDI Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Environmental Triggers



/mnt/code/prod/tfls/f_pro_osdi_tti_fu_2ref.sas 14OCT2025 13:55

1.3.2.2 EORTC QLQ-C30

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Global Health Status



BPd - n	27	24	23	22	21	16	17	14	15	13	13	14	11	9	11	11	10	9	10	7	7	8
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Global Health Status



BPd - n	7	8	7	7	6	7	7	6	5	6	6	4	5	6	5	5	4	5	6	5	6	5	3	3	3	1	2	1	2	0	0	18	7	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Figure 4.0001305
Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation
Domain Score: Physical Functioning



BPd - n	27	24	23	22	21	16	16	14	14	13	13	13	11	8	11	11	10	9	10	7	7	8
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Physical Functioning



BPd - n	7	8	7	7	6	7	7	6	5	6	6	4	5	6	5	5	4	5	6	5	6	5	3	3	3	1	2	1	2	0	0	18	7	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Role Functioning



BPd - n	27	24	23	21	21	16	17	14	13	13	13	14	11	9	11	11	10	9	10	7	7	8
PVd - n	31	27	25	25	24	18	15	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Role Functioning



BPd - n	7	8	7	7	6	7	7	6	5	6	6	4	5	6	4	5	4	5	6	5	6	5	3	3	3	1	2	1	2	0	0	18	7	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	29

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Emotional Functioning



BPd - n	26	23	22	21	20	15	16	13	14	12	12	13	10	8	10	10	9	8	9	6	6	7
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Emotional Functioning



BPd - n	6	7	6	6	5	6	6	5	5	6	5	4	5	5	5	5	4	5	6	5	5	5	3	3	3	1	2	1	2	0	0	17	6	24
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Cognitive Functioning



BPd - n	26	23	22	21	20	15	16	13	14	12	12	13	10	8	10	10	9	8	9	6	6	7
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Cognitive Functioning



BPd - n	6	7	6	6	5	6	6	5	5	6	5	4	5	5	5	5	4	5	6	5	5	5	3	3	3	1	2	1	2	0	0	17	6	24
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Figure 4.0001305
Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation
Domain Score: Social Functioning



BPd - n	27	24	23	22	21	16	17	14	15	13	13	14	11	9	11	11	10	9	10	7	7	8
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	8	11	8	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Social Functioning



BPd - n	7	8	7	7	6	7	7	6	4	6	6	4	5	6	5	5	4	5	6	5	6	5	3	3	3	1	2	1	2	0	0	18	7	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Fatigue



BPd - n	27	24	23	22	21	16	16	14	15	13	13	14	11	9	11	11	10	9	10	7	7	8
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Fatigue



BPd - n	7	8	7	7	6	7	7	6	5	6	6	4	5	6	5	5	3	5	6	5	5	5	3	3	3	1	2	1	2	0	0	18	8	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Figure 4.0001305
Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation
Domain Score: Nausea and Vomiting



BPd - n	26	23	21	21	20	15	15	13	14	12	11	13	10	8	10	10	9	8	9	6	6	7
PVd - n	31	27	25	25	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Nausea and Vomiting



BPd - n	6	7	6	6	5	6	6	4	4	5	5	3	4	5	4	4	3	4	5	4	5	4	2	2	2	0	1	0	1	0	0	18	7	24
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	21	9	29

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Pain



BPd - n	27	24	23	22	21	16	17	14	15	13	13	14	11	9	11	11	10	9	10	7	7	8
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Pain



BPd - n	7	8	7	7	6	7	7	6	5	6	6	4	5	6	5	5	3	5	6	5	6	5	3	3	3	1	2	1	2	0	0	18	8	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Dyspnea



BPd - n	27	24	23	21	21	16	17	14	13	13	13	14	11	9	11	11	10	9	10	7	7	8
PVd - n	31	27	25	25	24	18	15	16	12	9	12	10	9	11	9	6	6	7	5	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Dyspnea



BPd - n	7	8	7	7	6	7	7	6	5	6	6	4	5	6	4	5	4	5	6	5	6	5	3	3	3	1	2	1	2	0	0	18	7	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	29

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Insomnia



BPd - n	27	24	23	22	21	16	16	14	15	13	13	14	11	9	11	11	10	9	10	7	7	8
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Insomnia



BPd - n	7	8	7	7	6	7	7	6	5	6	6	4	5	6	5	5	3	5	6	5	6	5	3	3	3	1	2	1	2	0	0	18	7	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Appetite Loss



BPd - n	26	23	21	21	20	15	15	13	14	12	11	13	10	8	10	10	9	8	9	6	6	7
PVd - n	31	27	25	25	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Appetite Loss



BPd - n	6	7	6	6	5	6	6	4	4	5	5	3	4	5	4	4	3	4	5	4	5	4	2	2	2	0	1	0	1	0	0	18	7	24
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	21	9	29

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Constipation



BPd - n	26	23	21	21	20	15	15	13	14	12	11	13	10	8	10	10	9	8	9	6	6	7
PVd - n	31	27	25	25	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Constipation



BPd - n	6	7	6	6	5	6	6	4	4	5	5	3	4	5	4	4	3	4	5	4	5	4	2	2	2	0	1	0	1	0	0	18	7	24
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	21	9	29

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Diarrhea



BPd - n	27	23	23	22	21	16	16	14	15	13	13	13	11	9	11	10	10	9	10	7	7	8
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Diarrhea



BPd - n	7	8	7	7	6	7	6	6	5	5	6	4	5	6	5	5	3	5	6	5	5	5	3	3	3	1	2	1	2	0	0	18	7	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Financial Difficulties



BPd - n	26	23	22	21	20	16	17	14	15	13	13	14	11	9	11	11	10	9	10	7	7	8
PVd - n	32	28	26	26	25	19	16	17	12	9	12	10	8	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001305

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-C30 Domain Scores by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation

Domain Score: Financial Difficulties



BPd - n	7	8	7	7	6	7	7	6	4	6	6	4	5	6	5	5	3	5	6	5	6	5	3	3	3	1	2	1	2	0	0	17	7	24
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	22	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_qlq30_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score


Treatment
Belamaf 2.5/1.9 mg/kg + POM/DEX
POM + BOR/DEX
Proportion Without Deterioration
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48
Time (Months)
Number at Risk
(Number of Events)
BPd 30 (0) 22 (3) 21 (4) 18 (5) 15 (8) 13 (8) 11 (10) 10 (10) 8 (10) 7 (11) 7 (11) 7 (11) 7 (11) 7 (11) 6 (12) 5 (13) 4 (13) 4 (13) 4 (13) 4 (13) 4 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 3 (13) 2 (13) 2 (13) 2 (13) 1 (13) 1 (13) 0 (13) 0 (13) 0 (13)
PVd 33 (0) 26 (2) 21 (7) 18 (9) 13 (12) 10 (13) 10 (13) 7 (14) 6 (14) 6 (14) 6 (14) 6 (14) 6 (14) 4 (15) 4 (15) 4 (15) 4 (15) 3 (15) 3 (15) 2 (16) 2 (16) 2 (16) 2 (16) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 1 (17) 0 (17) 0 (17) 0

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score


Treatment
Belamaf 2.5/1.9 mg/kg + POM/DEX
POM + BOR/DEX
Proportion Without Deterioration
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48
Time (Months)
Number at Risk
(Number of Events)
BPd 30 (0) 22 (3) 17 (7) 13 (10) 10 (13) 9 (13) 6 (16) 5 (16) 4 (16) 4 (16) 4 (16) 4 (16) 2 (18) 2 (18) 2 (18) 1 (18) 1 (18) 0 (18) 0 (18) 0

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score


Treatment
Belamaf 2.5/1.9 mg/kg + POM/DEX
POM + BOR/DEX
Proportion Without Deterioration
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48
Time (Months)
Number at Risk
(Number of Events)
BPd 30 (0) 23 (1) 21 (2) 19 (3) 18 (3) 13 (6) 13 (6) 12 (6) 10 (6) 10 (6) 10 (6) 7 (8) 6 (8) 6 (8) 6 (8) 5 (9) 4 (9) 3 (10) 3 (10) 2 (10) 2 (10) 2 (10) 1 (10) 0 (10) 0 (10) 0 (10) 0 (10)
PVd 33 (0) 27 (0) 24 (3) 21 (6) 18 (8) 16 (9) 12 (11) 8 (14) 7 (14) 6 (15) 5 (16) 5 (16) 4 (16) 3 (16) 3 (16) 3 (16) 3 (16) 2 (16) 2 (16) 2 (16) 1 (16) 1 (16) 1 (16) 0 (17) 0 (17) 0 (17

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001405

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score



/mnt/code/prod/tfls/f_pro_c30_ttd_2ref.sas 14OCT2025 13:54

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001425

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Gender: Female



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_c30_ttd_2ref_gen.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001425

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score

Gender: Male



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_c30_ttd_2ref_gen.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001445

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

ISS Stage: I



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_c30_ttd_2ref_iss.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001445

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Deterioration (Up to and Including Last Follow-Up) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score

ISS Stage: II/III


Treatment
Belamaf 2.5/1.9 mg/kg + POM/DEX
POM + BOR/DEX
Proportion without Deterioration
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44
Time (Months)
Number at Risk
(Number of Events)
BPd 12 (0) 8 (0) 7 (1) 6 (1) 5 (1) 3 (2) 3 (2) 3 (2) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 1 (3) 0 (3) 0 (3) 0 (3) 0 (3) 0 (3) 0 (3) 0 (3)
PVd 18 (0) 11 (2) 5 (8) 4 (9) 4 (9) 2 (10) 1 (10) 0 (11) 0 (11) 0 (11

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Global Health Status Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Physical Functioning Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Role Functioning Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Cognitive Functioning Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Social Functioning Domain Score

Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score


Treatment
Belamaf 2.5/1.9 mg/kg + POM/DEX
POM + BOR/DEX
Proportion Without Improvement
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48
Time (Months)
Number at Risk
(Number of Events)
BPd 30 (0) 20 (5) 11 (13) 9 (15) 8 (15) 8 (15) 8 (15) 7 (16) 7 (16) 6 (16) 6 (16) 5 (16) 4 (16) 4 (16) 4 (16) 3 (17) 2 (17) 2 (17) 2 (17) 2 (17) 2 (17) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 1 (18) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19) 0 (19)
PVd 33 (0) 21 (7) 16 (12) 12 (16) 10 (18) 9 (18) 6 (19) 6 (19) 4 (19) 4 (19) 3 (20) 3 (20) 2 (20) 1 (20) 1 (20) 1 (20) 1 (20) 1 (20) 1 (20) 1 (20) 1 (20) 1 (20) 1 (20) 1 (20) 1 (20) 0 (20) 0 (20) 0

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Nausea and Vomiting Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Pain Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Dyspnoea Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Insomnia Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Appetite Loss Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Constipation Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Diarrhoea Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001505

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Financial Difficulties Domain Score



/mnt/code/prod/tfls/f_pro_c30_tti_2ref.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001525

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Gender: Female



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_c30_tti_2ref_gen.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001525

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Fatigue Domain Score

Gender: Male



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_c30_tti_2ref_gen.sas 14OCT2025 13:55

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001575

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Prior Lines of Therapy: 1/2/3



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_c30_tti_2ref_line2.sas 14OCT2025 13:56

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001575

Graph of Kaplan Meier Curves of EORTC QLQ-C30 Time to First Improvement (Up to and Including Last Follow-Up) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Emotional Functioning Domain Score

Prior Lines of Therapy: >=4



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_c30_tti_2ref_line2.sas 14OCT2025 13:56

1.3.2.3 EORTC-IL52

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003005

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-IL52 by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation



BPd - n	26	24	23	22	21	16	17	14	15	13	12	14	11	9	11	11	10	9	10	7	7	8
PVd - n	32	28	25	26	24	19	16	17	12	9	12	10	9	11	9	6	6	7	6	6	5	6

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_il52_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003005

Plot of Change from Baseline and Confidence Interval of EORTC QLQ-IL52 by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation



BPd - n	7	8	7	8	6	7	7	6	5	6	6	4	5	6	5	5	4	5	6	5	6	5	3	3	3	1	2	1	2	0	0	18	8	25
PVd - n	5	5	5	6	5	6	5	4	5	5	4	4	3	2	3	2	2	3	1	2	1	1	2	1	1	2	1	1	1	1	1	21	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_il52_2ref.sas 14OCT2025 13:59

Protocol: 207499 **Page 1 of 1**

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003105

Graph of Kaplan Meier Curves of EORTC QLQ-IL52 Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score



/mnt/code/prod/tfls/f_pro_il52_ttd_2ref.sas 14OCT2025 14:00

Protocol: 207499 **Page 1 of 1**

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003205

Graph of Kaplan Meier Curves of EORTC QLQ-IL52 Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: Disease Symptoms Domain Score



/mnt/code/prod/tfls/f_pro_il52_tti_2ref.sas 14OCT2025 13:59

1.3.2.4 EQ-5D VAS

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0001905

Plot of Change from Baseline and Confidence Interval of EQ-5D-3L VAS by Analysis Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation



BPd - n	27	24	22	18	16	15	13	10	11	11	9	7	8	7	7	6	5	5	6	5	5	7	4	3	3	2	0	0	17	8	25
PVd - n	32	28	27	20	18	10	13	11	7	7	6	6	5	6	6	4	5	4	3	2	3	2	1	2	2	1	1	1	20	9	30

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: BSLN = "Baseline", EOT = "End of Treatment", LFU = "Last Follow-Up", WCPB = "Worst Case Post-Baseline".
Note: Confidence limits are only populated if n >= 3.
Note: Data collected at the End of Treatment (EOT) visit is summarized under both the EOT visit and the nearest scheduled "Week X" visit.
/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_chg_vas_2ref.sas 14OCT2025 13:56

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002005

Graph of Kaplan Meier Curves of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale



/mnt/code/prod/tfls/f_pro_eq5d3l_ttd_2ref.sas 14OCT2025 13:57

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002035

Graph of Kaplan Meier Curves of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Region: Europe



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_eq5d3l_ttd_2ref_reg.sas 14OCT2025 13:57

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002035

Graph of Kaplan Meier Curves of EQ-5D-3L VAS Time to First Deterioration (Up to and Including Last Follow-Up) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale

Region: Non-Europe



/mnt/code/sSAP/sSAP02/prod/tfls/f_pro_eq5d3l_ttd_2ref_reg.sas 14OCT2025 13:57

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002105

Graph of Kaplan Meier Curves of EQ-5D-3L VAS Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: EQ-5D-3L VAS Subscale



/mnt/code/prod/tfls/f_pro_eq5d3l_tti_2ref.sas 14OCT2025 13:57

1.3.2.5 FACT-GP5

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.)

Data as of 07JUL2025

Figure 4.0002205
Stacked Bar Chart of FACT-GP5 by Timepoint -
Lenalidomide and Anti-CD38 Refractory Subpopulation



/mnt/code/prod/tfls/f_pro_factgp5_2ref.sas 14OCT2025 13:58

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002305

Graph of Kaplan Meier Curves of FACT-GP5 Time to First Deterioration (Up to and Including End of Treatment) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: FACT-GP5



/mnt/code/prod/tfls/f_pro_factgp5_ttd_2ref.sas 14OCT2025 13:58

1.3.2.6 PGIC

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.)

Data as of 07JUL2025

Figure 4.0002405
Stacked Bar Chart of PGIC Scores by Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation



/mnt/code/prod/tfls/f_pro_pgic_2ref.sas 14OCT2025 13:57

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002505

Graph of Kaplan Meier Curves of PGIC Time to First Negative Responder (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIC



/mnt/code/prod/tfls/f_pro_pgic_ttfneg_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002605

Graph of Kaplan Meier Curves of PGIC Time to First Positive Responder (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIC



/mnt/code/prod/tfls/f_pro_pgic_ttfpos_2ref.sas 14OCT2025 13:58

1.3.2.7 PGIS

Protocol: 207499
Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.)

Data as of 07JUL2025

Figure 4.0002705
Stacked Bar Chart of PGIS Scores by Timepoint - Lenalidomide and Anti-CD38 Refractory Subpopulation



/mnt/code/prod/tfls/f_pro_pgis_2ref.sas 14OCT2025 13:58

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002805

Graph of Kaplan Meier Curves of PGIS Time to First Deterioration (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS



/mnt/code/prod/tfls/f_pro_pgis_ttd_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Intent-to-Treat - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0002905

Graph of Kaplan Meier Curves of PGIS Time to First Improvement (Up to and Including Last Follow-Up) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Item Score: PGIS



/mnt/code/prod/tfls/f_pro_pgis_tti_2ref.sas 14OCT2025 13:59

1.3.2.8 PRO-CTCAE

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003305
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit (Yes/No Responses) - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Bruise Easily - Occurrence



/mnt/code/prod/tfls/f_pro_ctcae_yn_2ref.sas 14OCT2025 14:00

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003305
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit (Yes/No Responses) - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Flashing Light Front Eyes - Occurrence



/mnt/code/prod/tfls/f_pro_ctcae_yn_2ref.sas 14OCT2025 14:00

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003305
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit (Yes/No Responses) - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Hives - Occurrence



/mnt/code/prod/tfls/f_pro_ctcae_yn_2ref.sas 14OCT2025 14:00

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003305
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit (Yes/No Responses) - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Spots/Lines Front Of Eyes - Occurrence



/mnt/code/prod/tfls/f_pro_ctcae_yn_2ref.sas 14OCT2025 14:00

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Blurred Vision - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Blurred Vision - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Constipation - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Cough - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Cough - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Decreased Appetite - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Decreased Appetite - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Fatigue - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Fatigue - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Itchy - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Loose/Watery Stools - Frequency Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Mouth/Throat Sores - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Mouth/Throat Sores - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Nausea - Frequency Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Nausea - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Nosebleeds - Frequency Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Nosebleeds - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Numb/Tingling Hands/Feet - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Numb/Tingling Hands/Feet - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Pain/Burning Urination - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Problems Tasting Food/Drink - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Shivering/Shaking Chills - Frequency Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Shivering/Shaking Chills - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Shortness Of Breath - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Shortness Of Breath - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Vomiting - Frequency Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Vomiting - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Watery Eyes - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Watery Eyes - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Pain In The Abdomen (Belly Area) - Frequency Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Pain In The Abdomen (Belly Area) - Severity Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 4.0003405
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit - Lenalidomide and Anti-CD38 Refractory Subpopulation
Parameter: Pain In The Abdomen (Belly Area) - Interference Scale



/mnt/code/prod/tfls/f_pro_ctcae_max_2ref.sas 14OCT2025 13:59

1.4 Endpunkte zur Sicherheit

1.4.1 Tabellen – Ergebnisse für Endpunkte zur Sicherheit

1.4.1.1 UE jeglichen Schweregrades – Gesamtraten

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010505
Time to First Treatment Emergent Adverse Event -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	27 (96%)	32 (97%)
Censored	1 (4%)	1 (3%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.1 (0.0, 0.3)	0.1 (0.0, 0.1)
Median (95% CI)	0.3 (0.1, 0.6)	0.2 (0.1, 0.3)
3rd Quartile (95% CI)	0.8 (0.3, 1.9)	0.6 (0.3, 1.6)
Log-Rank P-value [2]	0.59361	
Hazard Ratio (95% CI) [3]	0.88 (0.53, 1.47)	
P-value [3]	0.62501	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_2ref.sas 01OCT2025 10:07

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010515
Time to First Treatment Emergent Adverse Event by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	10 (91%)	7 (100%)
	Censored	1 (9%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.5)	0.1 (0.1, 1.0)
	Median (95% CI)	0.5 (0.0, 1.0)	1.0 (0.1, 1.6)
	3rd Quartile (95% CI)	1.0 (0.5, -)	1.6 (0.3, -)
	Log-Rank P-value [2]	0.96059	
	Hazard Ratio (95% CI) [3]	0.97 (0.36, 2.62)	
	P-value [3]	0.95094	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_age.sas 01OCT2025 10:07

Table 3.0010515
Time to First Treatment Emergent Adverse Event by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	14 (100%)	14 (93%)
	Censored	0	1 (7%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.3)	0.0 (0.0, 0.2)
	Median (95% CI)	0.3 (0.0, 0.6)	0.2 (0.0, 0.4)
	3rd Quartile (95% CI)	0.6 (0.3, -)	0.5 (0.2, -)
	Log-Rank P-value [2]	0.90290	
	Hazard Ratio (95% CI) [3]	1.09 (0.51, 2.32)	
	P-value [3]	0.83292	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_age.sas 01OCT2025 10:07

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010515
Time to First Treatment Emergent Adverse Event by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	3 (100%)	11 (100%)
	Censored	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.1, -)	0.0 (0.0, 0.1)
	Median (95% CI)	0.1 (0.1, -)	0.1 (0.0, 0.3)
	3rd Quartile (95% CI)	1.9 (0.1, -)	0.3 (0.1, -)
	Log-Rank P-value [2]	0.23267	
	Hazard Ratio (95% CI) [3]	0.41 (0.09, 1.87)	
	P-value [3]	0.24753	
Interaction Test	P-value [4]	0.51659	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_age.sas 01OCT2025 10:07

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010525
Time to First Treatment Emergent Adverse Event by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	11 (92%)	15 (94%)
	Censored	1 (8%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.3)	0.1 (0.0, 0.3)
	Median (95% CI)	0.3 (0.1, 0.8)	0.3 (0.1, 0.7)
	3rd Quartile (95% CI)	0.7 (0.3, -)	0.8 (0.3, 1.8)
	Log-Rank P-value [2]	0.73624	
	Hazard Ratio (95% CI) [3]	0.89 (0.41, 1.95)	
	P-value [3]	0.77406	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_gen.sas 01OCT2025 10:08

Table 3.0010525
Time to First Treatment Emergent Adverse Event by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	16 (100%)	17 (100%)
	Censored	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.3)	0.0 (0.0, 0.1)
	Median (95% CI)	0.3 (0.0, 0.8)	0.1 (0.0, 0.5)
	3rd Quartile (95% CI)	0.8 (0.3, 1.0)	0.5 (0.1, 1.0)
	Log-Rank P-value [2]	0.50480	
	Hazard Ratio (95% CI) [3]	0.79 (0.39, 1.59)	
	P-value [3]	0.50801	
Interaction Test	P-value [4]	0.78831	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_gen.sas 01OCT2025 10:08

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010535
Time to First Treatment Emergent Adverse Event by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	17 (94%)	23 (96%)
	Censored	1 (6%)	1 (4%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.3)	0.1 (0.0, 0.1)
	Median (95% CI)	0.4 (0.1, 0.8)	0.3 (0.1, 0.5)
	3rd Quartile (95% CI)	0.8 (0.5, 2.7)	0.8 (0.3, 1.6)
	Log-Rank P-value [2]	0.64718	
	Hazard Ratio (95% CI) [3]	0.88 (0.47, 1.66)	
	P-value [3]	0.68839	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_reg.sas 01OCT2025 10:07

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010535
Time to First Treatment Emergent Adverse Event by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	10 (100%)	9 (100%)
	Censored	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.1)	0.0 (0.0, 0.1)
	Median (95% CI)	0.1 (0.0, 0.5)	0.1 (0.0, 0.7)
	3rd Quartile (95% CI)	0.5 (0.1, -)	0.3 (0.1, -)
	Log-Rank P-value [2]	0.61926	
	Hazard Ratio (95% CI) [3]	0.80 (0.32, 2.03)	
	P-value [3]	0.64526	
Interaction Test	P-value [4]	0.97994	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_reg.sas 01OCT2025 10:07

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010545
Time to First Treatment Emergent Adverse Event by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	18 (100%)	15 (100%)
	Censored	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.3)	0.2 (0.0, 0.3)
	Median (95% CI)	0.3 (0.1, 0.6)	0.5 (0.1, 1.0)
	3rd Quartile (95% CI)	0.6 (0.3, 1.0)	1.0 (0.5, -)
	Log-Rank P-value [2]	0.16865	
	Hazard Ratio (95% CI) [3]	1.66 (0.81, 3.37)	
	P-value [3]	0.16310	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_iss.sas 01OCT2025 10:07

Table 3.0010545
Time to First Treatment Emergent Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	9 (90%)	17 (94%)
	Censored	1 (10%)	1 (6%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.5)	0.0 (0.0, 0.1)
	Median (95% CI)	0.4 (0.0, 0.9)	0.1 (0.0, 0.2)
	3rd Quartile (95% CI)	0.9 (0.3, -)	0.3 (0.1, 0.7)
	Log-Rank P-value [2]	0.06652	
	Hazard Ratio (95% CI) [3]	0.47 (0.20, 1.07)	
	P-value [3]	0.07219	
Interaction Test	P-value [4]	0.02118	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_iss.sas 01OCT2025 10:07

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010555
Time to First Treatment Emergent Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	7 (100%)	6 (100%)
	Censored	0	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.0 (0.0, 0.1)	0.2 (0.0, 0.5)
	Median (95% CI)	0.1 (0.0, 0.3)	0.4 (0.0, -)
	3rd Quartile (95% CI)	0.3 (0.1, -)	0.7 (0.2, -)
	Log-Rank P-value [2]	0.35341	
	Hazard Ratio (95% CI) [3]	1.79 (0.56, 5.76)	
	P-value [3]	0.32583	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_line.sas 01OCT2025 10:08

Table 3.0010555
Time to First Treatment Emergent Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	12 (92%)	14 (100%)
	Censored	1 (8%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.3)	0.1 (0.0, 0.1)
	Median (95% CI)	0.3 (0.1, 0.6)	0.2 (0.0, 0.4)
	3rd Quartile (95% CI)	0.6 (0.3, -)	0.4 (0.1, -)
	Log-Rank P-value [2]	0.26626	
	Hazard Ratio (95% CI) [3]	0.65 (0.30, 1.44)	
	P-value [3]	0.29260	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_line.sas 01OCT2025 10:08

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010555
Time to First Treatment Emergent Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	8 (100%)	12 (92%)
	Censored	0	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.8)	0.0 (0.0, 0.1)
	Median (95% CI)	0.6 (0.0, 0.9)	0.1 (0.0, 0.6)
	3rd Quartile (95% CI)	0.9 (0.1, -)	0.6 (0.1, -)
	Log-Rank P-value [2]	0.90977	
	Hazard Ratio (95% CI) [3]	0.92 (0.37, 2.32)	
	P-value [3]	0.86689	
Interaction Test	P-value [4]	0.33584	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_line.sas 01OCT2025 10:08

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010575
Time to First Treatment Emergent Adverse Event by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	19 (95%)	20 (100%)
	Censored	1 (5%)	0
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.3)	0.1 (0.0, 0.2)
	Median (95% CI)	0.3 (0.1, 0.6)	0.2 (0.1, 0.5)
	3rd Quartile (95% CI)	0.6 (0.3, 2.7)	0.6 (0.3, 1.6)
	Log-Rank P-value [2]	0.61731	
	Hazard Ratio (95% CI) [3]	0.88 (0.47, 1.67)	
	P-value [3]	0.69949	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_line2.sas 01OCT2025 10:08

Table 3.0010575

Time to First Treatment Emergent Adverse Event by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	8 (100%)	12 (92%)
	Censored	0	1 (8%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.0, 0.8)	0.0 (0.0, 0.1)
	Median (95% CI)	0.6 (0.0, 0.9)	0.1 (0.0, 0.6)
	3rd Quartile (95% CI)	0.9 (0.1, -)	0.6 (0.1, -)
	Log-Rank P-value [2]	0.90977	
	Hazard Ratio (95% CI) [3]	0.92 (0.37, 2.32)	
	P-value [3]	0.86689	
Interaction Test	P-value [4]	0.98374	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_2ref_line2.sas 01OCT2025 10:08

1.4.1.2 UE jeglichen Schweregrades nach SOC und PT

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	14 (50%)	20 (61%)
Censored	14 (50%)	13 (39%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.3 (0.1, 8.4)	0.3 (0.0, 0.7)
Median (95% CI)	9.6 (0.3, -)	1.4 (0.4, -)
3rd Quartile (95% CI)	- (9.7, -)	19.4 (8.3, -)
Log-Rank P-value [2]	0.17226	
Hazard Ratio (95% CI) [3]	0.63 (0.32, 1.27)	
P-value [3]	0.19618	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	24 (86%)	11 (33%)
Censored	4 (14%)	22 (67%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.9 (0.7, 0.9)	5.8 (3.0, 16.0)
Median (95% CI)	0.9 (0.9, 1.6)	16.0 (5.8, -)
3rd Quartile (95% CI)	1.9 (1.0, -)	18.0 (16.0, -)
Log-Rank P-value [2]	<0.00001	
Hazard Ratio (95% CI) [3]	18.23 (6.08, 54.65)	
P-value [3]	<0.00001	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	10 (36%)	16 (48%)
Censored	18 (64%)	17 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.1 (0.1, 22.3)	0.9 (0.3, 1.6)
Median (95% CI)	36.4 (9.1, -)	4.1 (1.0, -)
3rd Quartile (95% CI)	- (22.3, -)	- (-, -)
Log-Rank P-value [2]	0.07737	
Hazard Ratio (95% CI) [3]	0.48 (0.21, 1.10)	
P-value [3]	0.08293	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Protocol: 207499 Page 4 of 15
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	13 (46%)	16 (48%)
Censored	15 (54%)	17 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.6 (0.0, 15.1)	0.4 (0.1, 0.8)
Median (95% CI)	23.3 (4.1, 41.7)	5.7 (0.5, -)
3rd Quartile (95% CI)	41.7 (23.3, -)	- (-, -)
Log-Rank P-value [2]	0.23123	
Hazard Ratio (95% CI) [3]	0.63 (0.29, 1.37)	
P-value [3]	0.24171	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Protocol: 207499 Page 5 of 15
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	18 (64%)	21 (64%)
Censored	10 (36%)	12 (36%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.9 (0.5, 2.7)	1.9 (0.3, 3.5)
Median (95% CI)	4.5 (2.1, 16.2)	4.2 (2.0, 7.2)
3rd Quartile (95% CI)	16.2 (11.1, -)	10.6 (6.0, -)
Log-Rank P-value [2]	0.56960	
Hazard Ratio (95% CI) [3]	0.83 (0.44, 1.57)	
P-value [3]	0.56664	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Injury, poisoning and procedural complications

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	3 (9%)
Censored	25 (89%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.1, -)	- (9.4, -)
Median (95% CI)	- (-, -)	- (9.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.78326	
Hazard Ratio (95% CI) [3]	0.80 (0.16, 4.04)	
P-value [3]	0.78368	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	15 (54%)	9 (27%)
Censored	13 (46%)	24 (73%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.4 (0.3, 1.0)	4.8 (0.3, -)
Median (95% CI)	9.5 (0.5, -)	- (4.9, -)
3rd Quartile (95% CI)	- (15.2, -)	- (-, -)
Log-Rank P-value [2]	0.06288	
Hazard Ratio (95% CI) [3]	2.20 (0.96, 5.06)	
P-value [3]	0.06273	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Metabolism and nutrition disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	7 (21%)
Censored	24 (86%)	26 (79%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	30.5 (0.3, -)	15.5 (2.3, -)
Median (95% CI)	- (30.5, -)	31.1 (15.5, -)
3rd Quartile (95% CI)	- (30.5, -)	- (31.1, -)
Log-Rank P-value [2]	0.32530	
Hazard Ratio (95% CI) [3]	0.54 (0.16, 1.87)	
P-value [3]	0.33253	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	8 (29%)	14 (42%)
Censored	20 (71%)	19 (58%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	6.2 (0.5, -)	2.4 (1.5, 6.0)
Median (95% CI)	- (6.2, -)	9.2 (4.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.2, -)
Log-Rank P-value [2]	0.12284	
Hazard Ratio (95% CI) [3]	0.51 (0.21, 1.22)	
P-value [3]	0.12895	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	8 (29%)	16 (48%)
Censored	20 (71%)	17 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.3 (0.7, -)	1.1 (0.0, 3.0)
Median (95% CI)	- (8.3, -)	6.8 (1.7, -)
3rd Quartile (95% CI)	- (-, -)	15.4 (6.8, -)
Log-Rank P-value [2]	0.00973	
Hazard Ratio (95% CI) [3]	0.33 (0.13, 0.79)	
P-value [3]	0.01360	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Psychiatric disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	3 (9%)
Censored	24 (86%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (1.6, -)
Median (95% CI)	- (15.5, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.62326	
Hazard Ratio (95% CI) [3]	1.45 (0.32, 6.50)	
P-value [3]	0.62525	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Renal and urinary disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	4 (12%)
Censored	25 (89%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.1, -)	- (1.5, -)
Median (95% CI)	- (24.8, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.63370	
Hazard Ratio (95% CI) [3]	0.69 (0.15, 3.14)	
P-value [3]	0.63548	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Respiratory, thoracic and mediastinal disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	6 (21%)	7 (21%)
Censored	22 (79%)	26 (79%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	41.7 (0.3, -)	28.8 (0.6, -)
Median (95% CI)	41.7 (41.7, -)	- (28.8, -)
3rd Quartile (95% CI)	- (41.7, -)	- (-, -)
Log-Rank P-value [2]	0.77550	
Hazard Ratio (95% CI) [3]	0.85 (0.28, 2.56)	
P-value [3]	0.77619	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Skin and subcutaneous tissue disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	5 (18%)	5 (15%)
Censored	23 (82%)	28 (85%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.1, -)	16.3 (1.4, -)
Median (95% CI)	- (-, -)	41.0 (16.3, -)
3rd Quartile (95% CI)	- (-, -)	41.0 (16.3, -)
Log-Rank P-value [2]	0.99095	
Hazard Ratio (95% CI) [3]	1.00 (0.28, 3.53)	
P-value [3]	0.99663	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Table 3.0010605
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	5 (15%)
Censored	26 (93%)	28 (85%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.6, -)	17.3 (3.7, -)
Median (95% CI)	- (-, -)	- (17.3, -)
3rd Quartile (95% CI)	- (-, -)	- (26.5, -)
Log-Rank P-value [2]	0.24375	
Hazard Ratio (95% CI) [3]	0.39 (0.07, 2.02)	
P-value [3]	0.26070	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_soc_2ref.sas 01OCT2025 10:09

Protocol: 207499 Page 1 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010615
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	8 (73%)	3 (43%)
	Censored	3 (27%)	4 (57%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.6, 1.8)	16.0 (1.6, -)
	Median (95% CI)	1.7 (0.6, -)	16.0 (1.6, -)
	3rd Quartile (95% CI)	5.5 (1.6, -)	18.0 (16.0, -)
	Log-Rank P-value [2]	0.01950	
	Hazard Ratio (95% CI) [3]	8.50 (1.03, 70.30)	
	P-value [3]	0.04705	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_age.sas 01OCT2025 10:11

Table 3.0010615

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	13 (93%)	3 (20%)
	Censored	1 (7%)	12 (80%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.8 (0.7, 0.9)	19.4 (3.0, -)
	Median (95% CI)	0.9 (0.7, 0.9)	19.4 (6.1, -)
	3rd Quartile (95% CI)	0.9 (0.9, -)	19.4 (-, -)
	Log-Rank P-value [2]	<0.00001	
	Hazard Ratio (95% CI) [3]	37.67 (4.73, 299.97)	
	P-value [3]	0.00061	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_age.sas 01OCT2025 10:11

Table 3.0010615

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	3 (100%)	5 (45%)
	Censored	0	6 (55%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.9, -)	5.6 (2.4, 6.9)
	Median (95% CI)	1.0 (0.9, -)	6.9 (2.4, -)
	3rd Quartile (95% CI)	1.9 (0.9, -)	- (5.8, -)
	Log-Rank P-value [2]	0.00007	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99578	
Interaction Test	P-value [4]	0.14332	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_age.sas 01OCT2025 10:11

Table 3.0010615

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	2 (18%)	3 (43%)
	Censored	9 (82%)	4 (57%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	9.9 (0.7, -)	3.0 (1.0, -)
	Median (95% CI)	- (0.7, -)	15.4 (1.0, -)
	3rd Quartile (95% CI)	- (9.9, -)	15.4 (3.0, -)
	Log-Rank P-value [2]	0.26309	
	Hazard Ratio (95% CI) [3]	0.36 (0.06, 2.30)	
	P-value [3]	0.28058	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_age.sas 01OCT2025 10:11

Protocol: 207499 Page 5 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010615
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	5 (36%)	5 (33%)
	Censored	9 (64%)	10 (67%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	8.3 (0.0, -)	2.7 (0.0, -)
	Median (95% CI)	9.9 (1.9, -)	- (1.7, -)
	3rd Quartile (95% CI)	- (9.9, -)	- (6.8, -)
	Log-Rank P-value [2]	0.62584	
	Hazard Ratio (95% CI) [3]	0.73 (0.20, 2.61)	
	P-value [3]	0.62868	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_age.sas 01OCT2025 10:11

Protocol: 207499 Page 6 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010615
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	1 (33%)	8 (73%)
	Censored	2 (67%)	3 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	7.4 (7.4, -)	0.3 (0.0, 1.7)
	Median (95% CI)	- (7.4, -)	1.7 (0.0, 4.4)
	3rd Quartile (95% CI)	- (7.4, -)	4.4 (1.1, -)
	Log-Rank P-value [2]	0.03360	
	Hazard Ratio (95% CI) [3]	0.00 (0.00, -)	
	P-value [3]	0.99588	
Interaction Test	P-value [4]	0.29702	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_age.sas 01OCT2025 10:11

Protocol: 207499 Page 1 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010625
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	9 (75%)	5 (31%)
	Censored	3 (25%)	11 (69%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.8 (0.7, 1.0)	5.8 (1.6, -)
	Median (95% CI)	1.4 (0.7, -)	19.4 (4.4, -)
	3rd Quartile (95% CI)	5.5 (1.0, -)	19.4 (6.9, -)
	Log-Rank P-value [2]	0.00025	
	Hazard Ratio (95% CI) [3]	11.00 (2.30, 52.58)	
	P-value [3]	0.00265	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_gen.sas 01OCT2025 10:11

Protocol: 207499 Page 2 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010625
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	15 (94%)	6 (35%)
	Censored	1 (6%)	11 (65%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.6, 0.9)	6.1 (2.4, 16.0)
	Median (95% CI)	0.9 (0.8, 1.0)	16.0 (5.6, -)
	3rd Quartile (95% CI)	1.6 (0.9, -)	18.0 (16.0, -)
	Log-Rank P-value [2]	<0.00001	
	Hazard Ratio (95% CI) [3]	27.53 (5.91, 128.15)	
	P-value [3]	0.00002	
Interaction Test	P-value [4]	0.41630	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_gen.sas 01OCT2025 10:11

Protocol: 207499 Page 3 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010625
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	3 (25%)	8 (50%)
	Censored	9 (75%)	8 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	9.9 (1.8, -)	1.7 (0.3, 4.4)
	Median (95% CI)	- (7.4, -)	6.8 (1.1, -)
	3rd Quartile (95% CI)	- (9.9, -)	- (4.4, -)
	Log-Rank P-value [2]	0.01650	
	Hazard Ratio (95% CI) [3]	0.17 (0.03, 0.84)	
	P-value [3]	0.03048	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_gen.sas 01OCT2025 10:11

Protocol: 207499 Page 4 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010625
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	5 (31%)	8 (47%)
	Censored	11 (69%)	9 (53%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	8.3 (0.0, -)	1.1 (0.0, -)
	Median (95% CI)	- (1.9, -)	15.4 (0.8, -)
	3rd Quartile (95% CI)	- (9.9, -)	15.4 (-, -)
	Log-Rank P-value [2]	0.18450	
	Hazard Ratio (95% CI) [3]	0.47 (0.15, 1.47)	
	P-value [3]	0.19197	
Interaction Test	P-value [4]	0.56716	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_gen.sas 01OCT2025 10:11

Protocol: 207499 Page 1 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010635
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	14 (78%)	6 (25%)
	Censored	4 (22%)	18 (75%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.8 (0.6, 0.9)	6.9 (1.6, -)
	Median (95% CI)	0.9 (0.8, 3.7)	16.0 (5.8, -)
	3rd Quartile (95% CI)	3.7 (0.9, -)	19.4 (16.0, -)
	Log-Rank P-value [2]	<0.00001	
	Hazard Ratio (95% CI) [3]	19.47 (4.30, 88.05)	
	P-value [3]	0.00012	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_reg.sas 01OCT2025 10:12

Table 3.0010635
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	10 (100%)	5 (56%)
	Censored	0	4 (44%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.7, 1.0)	5.0 (2.4, -)
	Median (95% CI)	0.9 (0.7, 1.0)	12.1 (2.4, -)
	3rd Quartile (95% CI)	1.0 (0.9, -)	18.0 (5.6, -)
	Log-Rank P-value [2]	0.00002	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99495	
Interaction Test	P-value [4]	0.94825	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_reg.sas 01OCT2025 10:12

Protocol: 207499 Page 3 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010635
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	3 (17%)	10 (42%)
	Censored	15 (83%)	14 (58%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	9.9 (8.3, -)	1.7 (0.0, 6.8)
	Median (95% CI)	- (8.3, -)	15.4 (1.7, -)
	3rd Quartile (95% CI)	- (9.9, -)	15.4 (-, -)
	Log-Rank P-value [2]	0.01124	
	Hazard Ratio (95% CI) [3]	0.21 (0.06, 0.79)	
	P-value [3]	0.02143	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_reg.sas 01OCT2025 10:12

Protocol: 207499 Page 4 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010635
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	5 (50%)	6 (67%)
	Censored	5 (50%)	3 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.8 (0.0, -)	0.8 (0.0, 3.0)
	Median (95% CI)	- (0.0, -)	3.0 (0.0, -)
	3rd Quartile (95% CI)	- (7.4, -)	- (2.7, -)
	Log-Rank P-value [2]	0.24955	
	Hazard Ratio (95% CI) [3]	0.48 (0.14, 1.71)	
	P-value [3]	0.25900	
Interaction Test	P-value [4]	0.81283	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_reg.sas 01OCT2025 10:12

Protocol: 207499 Page 1 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010645
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	16 (89%)	7 (47%)
	Censored	2 (11%)	8 (53%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.6, 0.9)	6.1 (1.6, 16.0)
	Median (95% CI)	0.9 (0.9, 1.6)	16.0 (5.8, -)
	3rd Quartile (95% CI)	1.8 (1.0, -)	18.0 (6.9, -)
	Log-Rank P-value [2]	<0.00001	
	Hazard Ratio (95% CI) [3]	17.49 (3.80, 80.50)	
	P-value [3]	0.00024	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_iss.sas 01OCT2025 10:12

Table 3.0010645

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	8 (80%)	4 (22%)
	Censored	2 (20%)	14 (78%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.7, 0.9)	5.6 (2.4, -)
	Median (95% CI)	0.9 (0.7, -)	19.4 (5.6, -)
	3rd Quartile (95% CI)	2.7 (0.9, -)	19.4 (-, -)
	Log-Rank P-value [2]	0.00002	
	Hazard Ratio (95% CI) [3]	14.97 (3.10, 72.25)	
	P-value [3]	0.00076	
Interaction Test	P-value [4]	0.63363	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_iss.sas 01OCT2025 10:12

Table 3.0010645

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	7 (39%)	7 (47%)
	Censored	11 (61%)	8 (53%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	8.3 (0.0, 9.9)	1.7 (0.0, -)
	Median (95% CI)	9.9 (7.4, -)	15.4 (1.0, -)
	3rd Quartile (95% CI)	- (9.9, -)	15.4 (-, -)
	Log-Rank P-value [2]	0.31981	
	Hazard Ratio (95% CI) [3]	0.59 (0.20, 1.74)	
	P-value [3]	0.34089	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_iss.sas 01OCT2025 10:12

Protocol: 207499 Page 4 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010645
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	1 (10%)	9 (50%)
	Censored	9 (90%)	9 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (1.9, -)	1.1 (0.0, 4.4)
	Median (95% CI)	- (1.9, -)	4.4 (1.1, -)
	3rd Quartile (95% CI)	- (-, -)	6.8 (4.4, -)
	Log-Rank P-value [2]	0.02328	
	Hazard Ratio (95% CI) [3]	0.13 (0.02, 1.03)	
	P-value [3]	0.05314	
Interaction Test	P-value [4]	0.09806	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_iss.sas 01OCT2025 10:12

Protocol: 207499 Page 1 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010655
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	6 (86%)	1 (17%)
	Censored	1 (14%)	5 (83%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.8, 0.9)	- (6.1, -)
	Median (95% CI)	0.9 (0.8, 1.8)	- (6.1, -)
	3rd Quartile (95% CI)	1.8 (0.9, -)	- (-, -)
	Log-Rank P-value [2]	0.00274	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99607	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line.sas 01OCT2025 10:12

Table 3.0010655

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	11 (85%)	6 (43%)
	Censored	2 (15%)	8 (57%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.6, 1.0)	5.6 (1.6, 6.9)
	Median (95% CI)	1.0 (0.7, 3.7)	5.8 (4.4, -)
	3rd Quartile (95% CI)	3.7 (1.0, -)	6.9 (5.6, -)
	Log-Rank P-value [2]	0.00012	
	Hazard Ratio (95% CI) [3]	12.43 (2.61, 59.24)	
	P-value [3]	0.00156	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line.sas 01OCT2025 10:12

Protocol: 207499 Page 3 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010655
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	7 (88%)	4 (31%)
	Censored	1 (13%)	9 (69%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.8 (0.7, 0.9)	18.0 (2.4, -)
	Median (95% CI)	0.9 (0.7, 1.0)	18.0 (3.0, -)
	3rd Quartile (95% CI)	1.0 (0.9, -)	19.4 (18.0, -)
	Log-Rank P-value [2]	<0.00001	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99539	
Interaction Test	P-value [4]	0.04240	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line.sas 01OCT2025 10:12

Protocol: 207499 Page 4 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010655
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	5 (71%)	3 (50%)
	Censored	2 (29%)	3 (50%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line.sas 01OCT2025 10:12

Protocol: 207499 Page 5 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010655
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	2 (15%)	6 (43%)
	Censored	11 (85%)	8 (57%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line.sas 01OCT2025 10:12

Protocol: 207499 Page 6 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010655

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	7 (54%)
	Censored	7 (88%)	6 (46%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line.sas 01OCT2025 10:12

Protocol: 207499 Page 1 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	17 (85%)	7 (35%)
	Censored	3 (15%)	13 (65%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.6, 0.9)	5.8 (1.6, -)
	Median (95% CI)	1.0 (0.9, 2.7)	16.0 (5.6, -)
	3rd Quartile (95% CI)	3.2 (1.0, -)	16.0 (6.9, -)
	Log-Rank P-value [2]	<0.00001	
	Hazard Ratio (95% CI) [3]	19.63 (4.30, 89.63)	
	P-value [3]	0.00012	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line2.sas 01OCT2025 10:12

Table 3.0010675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	7 (88%)	4 (31%)
	Censored	1 (13%)	9 (69%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.8 (0.7, 0.9)	18.0 (2.4, -)
	Median (95% CI)	0.9 (0.7, 1.0)	18.0 (3.0, -)
	3rd Quartile (95% CI)	1.0 (0.9, -)	19.4 (18.0, -)
	Log-Rank P-value [2]	<0.00001	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99539	
Interaction Test	P-value [4]	0.08512	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line2.sas 01OCT2025 10:12

Protocol: 207499 Page 3 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	7 (35%)	9 (45%)
	Censored	13 (65%)	11 (55%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	8.3 (0.0, 9.9)	1.7 (0.3, 4.4)
	Median (95% CI)	- (8.3, -)	15.4 (1.7, -)
	3rd Quartile (95% CI)	- (9.9, -)	15.4 (-, -)
	Log-Rank P-value [2]	0.10903	
	Hazard Ratio (95% CI) [3]	0.45 (0.16, 1.24)	
	P-value [3]	0.12132	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line2.sas 01OCT2025 10:12

Protocol: 207499 Page 4 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	7 (54%)
	Censored	7 (88%)	6 (46%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	- (0.7, -)	1.0 (0.0, 3.0)
	Median (95% CI)	- (0.7, -)	6.8 (0.0, -)
	3rd Quartile (95% CI)	- (-, -)	6.8 (3.0, -)
	Log-Rank P-value [2]	0.05568	
	Hazard Ratio (95% CI) [3]	0.15 (0.02, 1.33)	
	P-value [3]	0.08880	
Interaction Test	P-value [4]	0.24734	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_soc_2ref_line2.sas 01OCT2025 10:12

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	6 (21%)	13 (39%)
Censored	22 (79%)	20 (61%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	12.8 (0.1, -)	0.5 (0.0, 28.8)
Median (95% CI)	- (12.8, -)	28.8 (1.4, -)
3rd Quartile (95% CI)	- (-, -)	29.7 (28.8, -)
Log-Rank P-value [2]	0.05585	
Hazard Ratio (95% CI) [3]	0.40 (0.15, 1.06)	
P-value [3]	0.06606	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	12 (43%)	11 (33%)
Censored	16 (57%)	22 (67%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.4 (0.6, 9.7)	0.8 (0.7, 19.4)
Median (95% CI)	18.8 (3.3, -)	19.4 (8.3, -)
3rd Quartile (95% CI)	- (18.8, -)	- (19.4, -)
Log-Rank P-value [2]	0.78779	
Hazard Ratio (95% CI) [3]	1.12 (0.49, 2.56)	
P-value [3]	0.78442	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	8 (29%)	9 (27%)
Censored	20 (71%)	24 (73%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.5 (0.3, -)	0.8 (0.3, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.98312	
Hazard Ratio (95% CI) [3]	1.04 (0.40, 2.70)	
P-value [3]	0.93110	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Cataract

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	7 (25%)	5 (15%)
Censored	21 (75%)	28 (85%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	28.3 (0.9, -)	16.0 (6.1, 25.3)
Median (95% CI)	- (28.3, -)	25.3 (9.3, -)
3rd Quartile (95% CI)	- (-, -)	- (16.0, -)
Log-Rank P-value [2]	0.63368	
Hazard Ratio (95% CI) [3]	1.33 (0.41, 4.27)	
P-value [3]	0.63470	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	8 (29%)	0
Censored	20 (71%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.8 (0.9, -)	- (-, -)
Median (95% CI)	- (2.7, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.00124	
Hazard Ratio (95% CI) [3]	22.02 (2.74, >999.99)	
P-value [3]	0.04526	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal opacity

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	0
Censored	25 (89%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.05816	
Hazard Ratio (95% CI) [3]	8.38 (0.81, >999.99)	
P-value [3]	0.22343	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	10 (36%)	3 (9%)
Censored	18 (64%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.5 (0.9, 16.6)	18.0 (5.6, -)
Median (95% CI)	16.6 (3.7, -)	- (11.3, -)
3rd Quartile (95% CI)	- (16.6, -)	- (18.0, -)
Log-Rank P-value [2]	0.01148	
Hazard Ratio (95% CI) [3]	4.58 (1.26, 16.69)	
P-value [3]	0.02104	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	10 (36%)	1 (3%)
Censored	18 (64%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.0 (0.9, -)	- (5.6, -)
Median (95% CI)	- (2.1, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.00097	
Hazard Ratio (95% CI) [3]	13.96 (1.79, 109.21)	
P-value [3]	0.01200	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	1 (3%)
Censored	24 (86%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.6, -)	- (25.3, -)
Median (95% CI)	- (-, -)	- (25.3, -)
3rd Quartile (95% CI)	- (-, -)	- (25.3, -)
Log-Rank P-value [2]	0.18512	
Hazard Ratio (95% CI) [3]	3.95 (0.44, 35.52)	
P-value [3]	0.21964	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Protocol: 207499 Page 10 of 40
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	14 (50%)	2 (6%)
Censored	14 (50%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.8 (1.0, 5.6)	25.3 (5.6, -)
Median (95% CI)	16.6 (1.8, -)	- (25.3, -)
3rd Quartile (95% CI)	17.5 (16.6, -)	- (25.3, -)
Log-Rank P-value [2]	0.00012	
Hazard Ratio (95% CI) [3]	10.73 (2.41, 47.77)	
P-value [3]	0.00185	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Keratopathy

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	0
Censored	25 (89%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.9, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.05825	
Hazard Ratio (95% CI) [3]	8.28 (0.80, >999.99)	
P-value [3]	0.22616	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	6 (21%)	1 (3%)
Censored	22 (79%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	6.5 (1.9, -)	- (24.0, -)
Median (95% CI)	- (6.5, -)	- (24.0, -)
3rd Quartile (95% CI)	- (-, -)	- (24.0, -)
Log-Rank P-value [2]	0.03529	
Hazard Ratio (95% CI) [3]	7.03 (0.85, 58.42)	
P-value [3]	0.07100	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	6 (21%)	1 (3%)
Censored	22 (79%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.8, -)	- (5.6, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.02842	
Hazard Ratio (95% CI) [3]	7.48 (0.90, 62.17)	
P-value [3]	0.06239	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	17 (61%)	4 (12%)
Censored	11 (39%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.6 (0.8, 1.8)	17.3 (11.3, -)
Median (95% CI)	2.3 (1.7, -)	- (11.3, -)
3rd Quartile (95% CI)	- (3.6, -)	- (17.3, -)
Log-Rank P-value [2]	<0.00001	
Hazard Ratio (95% CI) [3]	9.53 (3.11, 29.20)	
P-value [3]	0.00008	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Protocol: 207499 Page 15 of 40
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual acuity reduced

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	2 (6%)
Censored	24 (86%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	17.3 (6.9, -)
Median (95% CI)	- (-, -)	- (17.3, -)
3rd Quartile (95% CI)	- (-, -)	- (17.3, -)
Log-Rank P-value [2]	0.37915	
Hazard Ratio (95% CI) [3]	2.12 (0.38, 11.67)	
P-value [3]	0.38986	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	5 (18%)	0
Censored	23 (82%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.01380	
Hazard Ratio (95% CI) [3]	13.35 (1.51, >999.99)	
P-value [3]	0.10932	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	8 (24%)
Censored	26 (93%)	25 (76%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.6, -)	5.4 (0.4, -)
Median (95% CI)	- (-, -)	- (5.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.03520	
Hazard Ratio (95% CI) [3]	0.21 (0.04, 1.03)	
P-value [3]	0.05385	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Diarrhoea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	9 (27%)
Censored	24 (86%)	24 (73%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	36.4 (0.1, -)	3.6 (1.0, -)
Median (95% CI)	- (36.4, -)	- (6.6, -)
3rd Quartile (95% CI)	- (36.4, -)	- (-, -)
Log-Rank P-value [2]	0.13785	
Hazard Ratio (95% CI) [3]	0.41 (0.12, 1.38)	
P-value [3]	0.14962	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Protocol: 207499 Page 19 of 40
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Nausea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	5 (15%)
Censored	24 (86%)	28 (85%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	25.4 (0.3, -)	- (0.9, -)
Median (95% CI)	- (25.4, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.75751	
Hazard Ratio (95% CI) [3]	0.81 (0.22, 3.04)	
P-value [3]	0.75429	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Asthenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	5 (15%)
Censored	27 (96%)	28 (85%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.4, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.12187	
Hazard Ratio (95% CI) [3]	0.21 (0.03, 1.84)	
P-value [3]	0.15980	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Protocol: 207499 Page 21 of 40
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Fatigue

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	5 (15%)
Censored	24 (86%)	28 (85%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.6, -)	- (0.3, -)
Median (95% CI)	- (23.3, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.69717	
Hazard Ratio (95% CI) [3]	0.76 (0.20, 2.93)	
P-value [3]	0.69448	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Oedema peripheral

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	5 (18%)	6 (18%)
Censored	23 (82%)	27 (82%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	39.1 (1.6, -)	- (0.8, -)
Median (95% CI)	- (15.1, -)	- (-, -)
3rd Quartile (95% CI)	- (39.1, -)	- (-, -)
Log-Rank P-value [2]	0.45665	
Hazard Ratio (95% CI) [3]	0.62 (0.17, 2.22)	
P-value [3]	0.45803	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Pyrexia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	5 (18%)	4 (12%)
Censored	23 (82%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	41.7 (1.7, -)	- (4.8, -)
Median (95% CI)	41.7 (41.7, -)	- (-, -)
3rd Quartile (95% CI)	- (41.7, -)	- (-, -)
Log-Rank P-value [2]	0.99499	
Hazard Ratio (95% CI) [3]	1.00 (0.25, 4.00)	
P-value [3]	0.99499	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Bronchitis

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	1 (3%)
Censored	25 (89%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.3, -)	- (5.0, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.34383	
Hazard Ratio (95% CI) [3]	2.86 (0.29, 27.80)	
P-value [3]	0.36508	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	6 (21%)	7 (21%)
Censored	22 (79%)	26 (79%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.8 (4.7, -)	9.0 (3.5, 20.5)
Median (95% CI)	- (9.8, -)	20.5 (9.0, -)
3rd Quartile (95% CI)	- (-, -)	- (20.5, -)
Log-Rank P-value [2]	0.61200	
Hazard Ratio (95% CI) [3]	0.75 (0.25, 2.25)	
P-value [3]	0.61316	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Protocol: 207499 Page 26 of 40
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	4 (12%)
Censored	24 (86%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.1, -)	- (6.5, -)
Median (95% CI)	- (16.3, -)	- (10.6, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.95510	
Hazard Ratio (95% CI) [3]	0.96 (0.24, 3.89)	
P-value [3]	0.95510	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Upper respiratory tract infection

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	9 (32%)	3 (9%)
Censored	19 (68%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	10.7 (1.7, 21.7)	27.5 (4.1, -)
Median (95% CI)	21.7 (10.7, -)	- (27.5, -)
3rd Quartile (95% CI)	- (21.7, -)	- (27.5, -)
Log-Rank P-value [2]	0.06442	
Hazard Ratio (95% CI) [3]	3.23 (0.87, 12.02)	
P-value [3]	0.07999	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Urinary tract infection

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	2 (6%)
Censored	24 (86%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	34.6 (10.1, -)	33.5 (33.5, -)
Median (95% CI)	- (14.0, -)	33.5 (33.5, -)
3rd Quartile (95% CI)	- (34.6, -)	- (33.5, -)
Log-Rank P-value [2]	0.70105	
Hazard Ratio (95% CI) [3]	1.40 (0.25, 8.00)	
P-value [3]	0.70226	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Protocol: 207499 Page 29 of 40
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	7 (25%)	1 (3%)
Censored	21 (75%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (0.3, -)	- (-, -)
Median (95% CI)	- (16.2, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.02714	
Hazard Ratio (95% CI) [3]	7.51 (0.92, 61.27)	
P-value [3]	0.05981	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Protocol: 207499 Page 30 of 40
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Aspartate aminotransferase increased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	1 (3%)
Censored	24 (86%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.13948	
Hazard Ratio (95% CI) [3]	4.51 (0.50, 40.38)	
P-value [3]	0.17799	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Blood alkaline phosphatase increased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	1 (3%)
Censored	25 (89%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.2, -)	- (-, -)
Median (95% CI)	- (24.8, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.31327	
Hazard Ratio (95% CI) [3]	3.04 (0.31, 29.42)	
P-value [3]	0.33739	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Gamma-glutamyltransferase increased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	0
Censored	25 (89%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	24.8 (17.2, -)	- (-, -)
Median (95% CI)	- (17.2, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.11655	
Hazard Ratio (95% CI) [3]	5.86 (0.55, 793.52)	
P-value [3]	0.31558	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	7 (25%)	3 (9%)
Censored	21 (75%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	15.2 (0.7, -)	24.2 (6.1, -)
Median (95% CI)	- (15.2, -)	- (24.2, -)
3rd Quartile (95% CI)	- (30.5, -)	- (-, -)
Log-Rank P-value [2]	0.19766	
Hazard Ratio (95% CI) [3]	2.38 (0.61, 9.26)	
P-value [3]	0.21131	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Platelet count decreased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	7 (25%)	4 (12%)
Censored	21 (75%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.6 (0.3, -)	28.8 (1.1, -)
Median (95% CI)	- (-, -)	- (28.8, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.22110	
Hazard Ratio (95% CI) [3]	2.16 (0.63, 7.40)	
P-value [3]	0.22021	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Urine albumin/creatinine ratio increased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	0
Censored	25 (89%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.05961	
Hazard Ratio (95% CI) [3]	8.28 (0.80, >999.99)	
P-value [3]	0.22595	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Arthralgia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	4 (12%)
Censored	27 (96%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (12.7, -)	34.1 (4.1, -)
Median (95% CI)	- (-, -)	34.1 (34.1, -)
3rd Quartile (95% CI)	- (-, -)	- (34.1, -)
Log-Rank P-value [2]	0.09112	
Hazard Ratio (95% CI) [3]	0.18 (0.02, 1.65)	
P-value [3]	0.12895	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	7 (21%)
Censored	27 (96%)	26 (79%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.9, -)	24.2 (1.5, 25.8)
Median (95% CI)	- (-, -)	25.8 (9.6, -)
3rd Quartile (95% CI)	- (-, -)	- (24.2, -)
Log-Rank P-value [2]	0.01795	
Hazard Ratio (95% CI) [3]	0.12 (0.01, 0.98)	
P-value [3]	0.04734	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Protocol: 207499 Page 38 of 40
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders
Preferred Term: Neuropathy peripheral

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	4 (12%)
Censored	26 (93%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	24.8 (18.7, -)	- (4.4, -)
Median (95% CI)	- (18.7, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.17214	
Hazard Ratio (95% CI) [3]	0.31 (0.05, 1.80)	
P-value [3]	0.19179	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by
System Organ Class (SOC) and Preferred Term (PT) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Dyspnoea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	3 (9%)
Censored	25 (89%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (5.9, -)	- (3.5, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.98443	
Hazard Ratio (95% CI) [3]	0.98 (0.20, 4.91)	
P-value [3]	0.98443	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010705
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders
Preferred Term: Hypertension

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	4 (12%)
Censored	27 (96%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	26.5 (17.3, -)
Median (95% CI)	- (-, -)	- (17.3, -)
3rd Quartile (95% CI)	- (-, -)	- (26.5, -)
Log-Rank P-value [2]	0.13071	
Hazard Ratio (95% CI) [3]	0.21 (0.02, 1.93)	
P-value [3]	0.16846	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref.sas 01OCT2025 10:08

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	3 (27%)	0
	Censored	8 (73%)	7 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	4 (29%)	0
	Censored	10 (71%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	1 (33%)	0
	Censored	2 (67%)	11 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	5 (45%)	1 (14%)
	Censored	6 (55%)	6 (86%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	4 (29%)	0
	Censored	10 (71%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	1 (33%)	2 (18%)
	Censored	2 (67%)	9 (82%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	5 (45%)	0
	Censored	6 (55%)	7 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	4 (29%)	0
	Censored	10 (71%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Protocol: 207499 Page 9 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	1 (33%)	1 (9%)
	Censored	2 (67%)	10 (91%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	5 (45%)	0
	Censored	6 (55%)	7 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	7 (50%)	1 (7%)
	Censored	7 (50%)	14 (93%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	2 (67%)	1 (9%)
	Censored	1 (33%)	10 (91%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	3 (27%)	1 (14%)
	Censored	8 (73%)	6 (86%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	2 (14%)	0
	Censored	12 (86%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	1 (33%)	0
	Censored	2 (67%)	11 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	2 (18%)	0
	Censored	9 (82%)	7 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	3 (21%)	0
	Censored	11 (79%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	1 (33%)	1 (9%)
	Censored	2 (67%)	10 (91%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	5 (45%)	0
	Censored	6 (55%)	7 (100%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.3 (1.0, 4.4)	- (-, -)
	Median (95% CI)	4.4 (1.0, -)	- (-, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (-, -)
	Log-Rank P-value [2]	0.02693	
	Hazard Ratio (95% CI) [3]	11.16 (1.23, >999.99)	
	P-value [3]	0.14043	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	9 (64%)	2 (13%)
	Censored	5 (36%)	13 (87%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.7, 1.7)	19.4 (3.0, -)
	Median (95% CI)	1.7 (0.9, -)	19.4 (-, -)
	3rd Quartile (95% CI)	- (1.7, -)	19.4 (-, -)
	Log-Rank P-value [2]	0.00423	
	Hazard Ratio (95% CI) [3]	7.07 (1.51, 33.06)	
	P-value [3]	0.01300	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	3 (100%)	2 (18%)
	Censored	0	9 (82%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.7 (1.7, -)	14.3 (11.3, -)
	Median (95% CI)	1.8 (1.7, -)	17.3 (11.3, -)
	3rd Quartile (95% CI)	3.6 (1.7, -)	- (11.3, -)
	Log-Rank P-value [2]	0.00009	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99722	
Interaction Test	P-value [4]	0.87412	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	1 (9%)	0
	Censored	10 (91%)	7 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	2 (14%)	0
	Censored	12 (86%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	2 (67%)	0
	Censored	1 (33%)	11 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	0	2 (29%)
	Censored	11 (100%)	5 (71%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	2 (14%)	3 (20%)
	Censored	12 (86%)	12 (80%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Protocol: 207499 Page 27 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	0	3 (27%)
	Censored	3 (100%)	8 (73%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	2 (18%)	1 (14%)
	Censored	9 (82%)	6 (86%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	4 (29%)	0
	Censored	10 (71%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Protocol: 207499 Page 30 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	1 (33%)	0
	Censored	2 (67%)	11 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	1 (9%)	2 (29%)
	Censored	10 (91%)	5 (71%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	0	2 (13%)
	Censored	14 (100%)	13 (87%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Protocol: 207499 Page 33 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010715
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	0	3 (27%)
	Censored	3 (100%)	8 (73%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_age.sas 01OCT2025 10:11

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	3 (25%)	0
	Censored	9 (75%)	16 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	5 (31%)	0
	Censored	11 (69%)	17 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	3 (25%)	0
	Censored	9 (75%)	16 (100%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.5 (1.0, -)	- (-, -)
	Median (95% CI)	- (3.5, -)	- (-, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.06001	
	Hazard Ratio (95% CI) [3]	8.29 (0.80, >999.99)	
	P-value [3]	0.22640	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	7 (44%)	3 (18%)
	Censored	9 (56%)	14 (82%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.6, 16.6)	18.0 (5.6, -)
	Median (95% CI)	16.6 (0.9, -)	18.0 (11.3, -)
	3rd Quartile (95% CI)	- (16.6, -)	- (18.0, -)
	Log-Rank P-value [2]	0.05442	
	Hazard Ratio (95% CI) [3]	3.54 (0.90, 13.84)	
	P-value [3]	0.06975	
Interaction Test	P-value [4]	0.60039	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	3 (25%)	0
	Censored	9 (75%)	16 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	7 (44%)	1 (6%)
	Censored	9 (56%)	16 (94%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	5 (42%)	1 (6%)
	Censored	7 (58%)	15 (94%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.0 (1.0, -)	25.3 (25.3, -)
	Median (95% CI)	17.5 (1.7, -)	- (25.3, -)
	3rd Quartile (95% CI)	17.5 (-, -)	- (25.3, -)
	Log-Rank P-value [2]	0.01172	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99642	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	9 (56%)	1 (6%)
	Censored	7 (44%)	16 (94%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.7 (0.6, 2.1)	- (5.6, -)
	Median (95% CI)	5.6 (1.6, -)	- (-, -)
	3rd Quartile (95% CI)	16.6 (2.1, -)	- (-, -)
	Log-Rank P-value [2]	0.00202	
	Hazard Ratio (95% CI) [3]	12.68 (1.60, 100.52)	
	P-value [3]	0.01621	
Interaction Test	P-value [4]	0.69877	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	1 (8%)	0
	Censored	11 (92%)	16 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	5 (31%)	1 (6%)
	Censored	11 (69%)	16 (94%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	2 (17%)	0
	Censored	10 (83%)	16 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	4 (25%)	1 (6%)
	Censored	12 (75%)	16 (94%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	7 (58%)	1 (6%)
	Censored	5 (42%)	15 (94%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.7 (0.8, 2.3)	19.4 (19.4, -)
	Median (95% CI)	2.9 (1.7, -)	- (19.4, -)
	3rd Quartile (95% CI)	- (2.3, -)	- (19.4, -)
	Log-Rank P-value [2]	0.00054	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99586	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	10 (63%)	3 (18%)
	Censored	6 (38%)	14 (82%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.7, 1.7)	17.3 (3.0, -)
	Median (95% CI)	1.9 (0.9, -)	- (11.3, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (17.3, -)
	Log-Rank P-value [2]	0.00116	
	Hazard Ratio (95% CI) [3]	6.91 (1.84, 26.03)	
	P-value [3]	0.00424	
Interaction Test	P-value [4]	0.52315	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	3 (25%)	0
	Censored	9 (75%)	16 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	2 (13%)	0
	Censored	14 (88%)	17 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	1 (8%)	2 (13%)
	Censored	11 (92%)	14 (88%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	1 (6%)	6 (35%)
	Censored	15 (94%)	11 (65%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	4 (33%)	0
	Censored	8 (67%)	16 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	3 (19%)	1 (6%)
	Censored	13 (81%)	16 (94%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	0	2 (13%)
	Censored	12 (100%)	14 (88%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010725
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	1 (6%)	5 (29%)
	Censored	15 (94%)	12 (71%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_gen.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	4 (22%)	0
	Censored	14 (78%)	24 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	4 (40%)	0
	Censored	6 (60%)	9 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	5 (28%)	0
	Censored	13 (72%)	24 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	5 (50%)	3 (33%)
	Censored	5 (50%)	6 (67%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	5 (28%)	0
	Censored	13 (72%)	24 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	5 (50%)	1 (11%)
	Censored	5 (50%)	8 (89%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	8 (44%)	1 (4%)
	Censored	10 (56%)	23 (96%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	6 (60%)	1 (11%)
	Censored	4 (40%)	8 (89%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	2 (11%)	0
	Censored	16 (89%)	24 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	4 (40%)	1 (11%)
	Censored	6 (60%)	8 (89%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	1 (6%)	0
	Censored	17 (94%)	24 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	5 (50%)	1 (11%)
	Censored	5 (50%)	8 (89%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	8 (44%)	2 (8%)
	Censored	10 (56%)	22 (92%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.7 (0.7, 4.4)	19.4 (3.0, -)
	Median (95% CI)	4.4 (1.7, -)	- (19.4, -)
	3rd Quartile (95% CI)	- (4.4, -)	- (19.4, -)
	Log-Rank P-value [2]	0.00257	
	Hazard Ratio (95% CI) [3]	7.68 (1.62, 36.45)	
	P-value [3]	0.01029	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	9 (90%)	2 (22%)
	Censored	1 (10%)	7 (78%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.0 (0.9, 1.8)	17.3 (11.3, -)
	Median (95% CI)	1.7 (0.9, 3.6)	17.3 (11.3, -)
	3rd Quartile (95% CI)	3.6 (1.7, -)	- (11.3, -)
	Log-Rank P-value [2]	0.00019	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99519	
Interaction Test	P-value [4]	0.68980	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	2 (11%)	0
	Censored	16 (89%)	24 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	3 (30%)	0
	Censored	7 (70%)	9 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	0	4 (17%)
	Censored	18 (100%)	20 (83%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	2 (20%)	4 (44%)
	Censored	8 (80%)	5 (56%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	3 (17%)	1 (4%)
	Censored	15 (83%)	23 (96%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	4 (40%)	0
	Censored	6 (60%)	9 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	0	3 (13%)
	Censored	18 (100%)	21 (88%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Protocol: 207499 Page 22 of 22
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010735
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	1 (10%)	4 (44%)
	Censored	9 (90%)	5 (56%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_reg.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	6 (33%)	0
	Censored	12 (67%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	2 (20%)	0
	Censored	8 (80%)	18 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	8 (44%)	1 (7%)
	Censored	10 (56%)	14 (93%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	2 (20%)	2 (11%)
	Censored	8 (80%)	16 (89%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	7 (39%)	0
	Censored	11 (61%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	3 (30%)	1 (6%)
	Censored	7 (70%)	17 (94%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	9 (50%)	0
	Censored	9 (50%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	5 (50%)	2 (11%)
	Censored	5 (50%)	16 (89%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	5 (28%)	1 (7%)
	Censored	13 (72%)	14 (93%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	1 (10%)	0
	Censored	9 (90%)	18 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	6 (33%)	0
	Censored	12 (67%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	0	1 (6%)
	Censored	10 (100%)	17 (94%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	12 (67%)	0
	Censored	6 (33%)	15 (100%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.7 (0.7, 1.8)	- (-, -)
	Median (95% CI)	1.9 (1.7, -)	- (-, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (-, -)
	Log-Rank P-value [2]	0.00007	
	Hazard Ratio (95% CI) [3]	34.76 (4.49, >999.99)	
	P-value [3]	0.01918	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	5 (50%)	4 (22%)
	Censored	5 (50%)	14 (78%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.8, 4.4)	11.3 (3.0, 17.3)
	Median (95% CI)	4.4 (0.8, -)	17.3 (11.3, -)
	3rd Quartile (95% CI)	- (1.7, -)	19.4 (11.3, -)
	Log-Rank P-value [2]	0.00354	
	Hazard Ratio (95% CI) [3]	12.45 (1.44, 107.36)	
	P-value [3]	0.02175	
Interaction Test	P-value [4]	0.15950	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	3 (17%)	0
	Censored	15 (83%)	15 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	2 (20%)	0
	Censored	8 (80%)	18 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	1 (6%)	4 (27%)
	Censored	17 (94%)	11 (73%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	1 (10%)	4 (22%)
	Censored	9 (90%)	14 (78%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	4 (22%)	1 (7%)
	Censored	14 (78%)	14 (93%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	3 (30%)	0
	Censored	7 (70%)	18 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	1 (6%)	3 (20%)
	Censored	17 (94%)	12 (80%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Protocol: 207499 Page 22 of 22
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010745
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	0	4 (22%)
	Censored	10 (100%)	14 (78%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_iss.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	2 (29%)	0
	Censored	5 (71%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	4 (31%)	0
	Censored	9 (69%)	14 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	2 (25%)	0
	Censored	6 (75%)	13 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 4 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	1 (14%)	0
	Censored	6 (86%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	6 (46%)	1 (7%)
	Censored	7 (54%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 6 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	2 (15%)
	Censored	5 (63%)	11 (85%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	0	0
	Censored	7 (100%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	7 (54%)	1 (7%)
	Censored	6 (46%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	0
	Censored	5 (63%)	13 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	2 (29%)	0
	Censored	5 (71%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	8 (62%)	1 (7%)
	Censored	5 (38%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755

Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	4 (50%)	1 (8%)
	Censored	4 (50%)	12 (92%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	0	0
	Censored	7 (100%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	3 (23%)	0
	Censored	10 (77%)	14 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	1 (8%)
	Censored	5 (63%)	12 (92%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	1 (14%)	0
	Censored	6 (86%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 17 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	3 (23%)	1 (7%)
	Censored	10 (77%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 18 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	2 (25%)	0
	Censored	6 (75%)	13 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	5 (71%)	0
	Censored	2 (29%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	7 (54%)	1 (7%)
	Censored	6 (46%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 21 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	5 (63%)	3 (23%)
	Censored	3 (38%)	10 (77%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 22 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	2 (29%)	0
	Censored	5 (71%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 23 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	2 (15%)	0
	Censored	11 (85%)	14 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 24 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	0
	Censored	7 (88%)	13 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	1 (14%)	2 (33%)
	Censored	6 (86%)	4 (67%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 26 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	1 (8%)	2 (14%)
	Censored	12 (92%)	12 (86%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 27 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	0	4 (31%)
	Censored	8 (100%)	9 (69%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	3 (43%)	0
	Censored	4 (57%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 29 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	3 (23%)	1 (7%)
	Censored	10 (77%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 30 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	0
	Censored	7 (88%)	13 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 31 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	0	3 (50%)
	Censored	7 (100%)	3 (50%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 32 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	0	2 (14%)
	Censored	13 (100%)	12 (86%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Protocol: 207499 Page 33 of 33
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0010755
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	2 (15%)
	Censored	7 (88%)	11 (85%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	6 (30%)	0
	Censored	14 (70%)	20 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	2 (25%)	0
	Censored	6 (75%)	13 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	7 (35%)	1 (5%)
	Censored	13 (65%)	19 (95%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	2 (15%)
	Censored	5 (63%)	11 (85%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	7 (35%)	1 (5%)
	Censored	13 (65%)	19 (95%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	0
	Censored	5 (63%)	13 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	10 (50%)	1 (5%)
	Censored	10 (50%)	19 (95%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (0.6, 16.6)	- (5.6, -)
	Median (95% CI)	16.6 (1.8, -)	- (-, -)
	3rd Quartile (95% CI)	17.5 (16.6, -)	- (-, -)
	Log-Rank P-value [2]	0.00834	
	Hazard Ratio (95% CI) [3]	9.64 (1.23, 75.66)	
	P-value [3]	0.03106	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	4 (50%)	1 (8%)
	Censored	4 (50%)	12 (92%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.7 (1.0, 2.0)	25.3 (25.3, -)
	Median (95% CI)	2.0 (1.0, -)	- (25.3, -)
	3rd Quartile (95% CI)	- (1.8, -)	- (25.3, -)
	Log-Rank P-value [2]	0.00132	
	Hazard Ratio (95% CI) [3]	>999.99 (0.00, -)	
	P-value [3]	0.99729	
Interaction Test	P-value [4]	0.78085	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	3 (15%)	0
	Censored	17 (85%)	20 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	1 (8%)
	Censored	5 (63%)	12 (92%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	4 (20%)	1 (5%)
	Censored	16 (80%)	19 (95%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	2 (25%)	0
	Censored	6 (75%)	13 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	12 (60%)	1 (5%)
	Censored	8 (40%)	19 (95%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.7 (0.8, 1.9)	17.3 (17.3, -)
	Median (95% CI)	3.0 (1.7, -)	- (17.3, -)
	3rd Quartile (95% CI)	- (3.7, -)	- (17.3, -)
	Log-Rank P-value [2]	0.00017	
	Hazard Ratio (95% CI) [3]	18.06 (2.32, 140.57)	
	P-value [3]	0.00572	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	5 (63%)	3 (23%)
	Censored	3 (38%)	10 (77%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.9 (0.7, 1.7)	11.3 (3.0, -)
	Median (95% CI)	1.7 (0.7, -)	19.4 (11.3, -)
	3rd Quartile (95% CI)	3.6 (1.0, -)	- (11.3, -)
	Log-Rank P-value [2]	0.00099	
	Hazard Ratio (95% CI) [3]	15.93 (1.82, 139.54)	
	P-value [3]	0.01243	
Interaction Test	P-value [4]	0.54909	

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	4 (20%)	0
	Censored	16 (80%)	20 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	0
	Censored	7 (88%)	13 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	2 (10%)	4 (20%)
	Censored	18 (90%)	16 (80%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	0	4 (31%)
	Censored	8 (100%)	9 (69%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	6 (30%)	1 (5%)
	Censored	14 (70%)	19 (95%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	0
	Censored	7 (88%)	13 (100%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	0	5 (25%)
	Censored	20 (100%)	15 (75%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

Table 3.0011675
Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	2 (15%)
	Censored	7 (88%)	11 (85%)

Note: n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date. SOCs (PTs) that have a p-value <0.05 in the main analysis are included. [1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method. [2] Two-sided p-value obtained from unstratified log-rank test. [3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, applicable subgroup, and treatment x subgroup interaction included as covariates in the model.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_socpt_2ref_line2.sas 01OCT2025 10:13

1.4.1.3 Schwere UE (CTCAE-Grad ≥ 3) – Gesamtraten

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011105
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	26 (93%)	25 (76%)
Censored	2 (7%)	8 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.3 (0.1, 0.3)	0.3 (0.0, 0.7)
Median (95% CI)	0.5 (0.3, 1.3)	1.8 (0.7, 6.1)
3rd Quartile (95% CI)	1.8 (0.5, -)	6.2 (3.7, -)
Log-Rank P-value [2]	0.02885	
Hazard Ratio (95% CI) [3]	1.90 (1.08, 3.36)	
P-value [3]	0.02611	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref.sas 01OCT2025 10:15

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011115
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	10 (91%)	4 (57%)
	Censored	1 (9%)	3 (43%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.3, 1.3)	3.7 (0.1, 6.5)
	Median (95% CI)	1.3 (0.3, 2.1)	6.5 (0.1, -)
	3rd Quartile (95% CI)	2.1 (0.7, -)	- (3.7, -)
	Log-Rank P-value [2]	0.10979	
	Hazard Ratio (95% CI) [3]	2.71 (0.78, 9.47)	
	P-value [3]	0.11759	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_age.sas 01OCT2025 10:16

Table 3.0011115

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	13 (93%)	11 (73%)
	Censored	1 (7%)	4 (27%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.1, 0.3)	0.3 (0.0, 1.4)
	Median (95% CI)	0.3 (0.3, 0.6)	3.7 (0.1, 6.1)
	3rd Quartile (95% CI)	0.6 (0.3, -)	6.1 (3.7, -)
	Log-Rank P-value [2]	0.06634	
	Hazard Ratio (95% CI) [3]	2.23 (0.96, 5.18)	
	P-value [3]	0.06122	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_age.sas 01OCT2025 10:16

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011115

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	3 (100%)	10 (91%)
	Censored	0	1 (9%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.1, -)	0.3 (0.0, 0.7)
	Median (95% CI)	0.2 (0.1, -)	0.7 (0.1, 1.8)
	3rd Quartile (95% CI)	1.9 (0.1, -)	1.8 (0.7, -)
	Log-Rank P-value [2]	0.59733	
	Hazard Ratio (95% CI) [3]	1.42 (0.38, 5.35)	
	P-value [3]	0.60740	
Interaction Test	P-value [4]	0.92951	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_age.sas 01OCT2025 10:16

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011125
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	11 (92%)	13 (81%)
	Censored	1 (8%)	3 (19%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.1, 0.3)	0.2 (0.0, 1.0)
	Median (95% CI)	0.4 (0.2, 1.9)	1.2 (0.1, 3.7)
	3rd Quartile (95% CI)	1.6 (0.3, -)	4.9 (1.0, -)
	Log-Rank P-value [2]	0.19359	
	Hazard Ratio (95% CI) [3]	1.80 (0.76, 4.27)	
	P-value [3]	0.18401	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_gen.sas 01OCT2025 10:16

Table 3.0011125

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	15 (94%)	12 (71%)
	Censored	1 (6%)	5 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.1, 0.5)	0.7 (0.0, 3.7)
	Median (95% CI)	0.5 (0.3, 1.8)	3.9 (0.3, 6.5)
	3rd Quartile (95% CI)	1.9 (0.5, -)	6.5 (3.9, -)
	Log-Rank P-value [2]	0.06433	
	Hazard Ratio (95% CI) [3]	2.09 (0.96, 4.55)	
	P-value [3]	0.06309	
Interaction Test	P-value [4]	0.73622	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_gen.sas 01OCT2025 10:16

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011135
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	16 (89%)	18 (75%)
	Censored	2 (11%)	6 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.3, 0.5)	0.3 (0.0, 0.7)
	Median (95% CI)	0.6 (0.3, 1.8)	2.5 (0.3, 6.1)
	3rd Quartile (95% CI)	2.8 (0.6, -)	6.5 (3.7, -)
	Log-Rank P-value [2]	0.25190	
	Hazard Ratio (95% CI) [3]	1.53 (0.77, 3.06)	
	P-value [3]	0.22869	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_reg.sas 01OCT2025 10:16

Table 3.0011135

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	10 (100%)	7 (78%)
	Censored	0	2 (22%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.2 (0.1, 0.3)	0.7 (0.0, 1.8)
	Median (95% CI)	0.3 (0.1, 0.7)	1.8 (0.0, 6.2)
	3rd Quartile (95% CI)	0.7 (0.3, -)	6.2 (0.7, -)
	Log-Rank P-value [2]	0.03656	
	Hazard Ratio (95% CI) [3]	3.10 (1.04, 9.22)	
	P-value [3]	0.04242	
Interaction Test	P-value [4]	0.28128	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_reg.sas 01OCT2025 10:16

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011145
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	18 (100%)	10 (67%)
	Censored	0	5 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.1, 0.3)	1.8 (0.1, 3.7)
	Median (95% CI)	0.4 (0.3, 1.3)	6.1 (0.7, -)
	3rd Quartile (95% CI)	1.4 (0.5, 2.1)	- (6.1, -)
	Log-Rank P-value [2]	0.00001	
	Hazard Ratio (95% CI) [3]	8.62 (2.77, 26.81)	
	P-value [3]	0.00020	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_iss.sas 01OCT2025 10:16

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011145
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	8 (80%)	15 (83%)
	Censored	2 (20%)	3 (17%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.1, 0.5)	0.1 (0.0, 0.4)
	Median (95% CI)	0.5 (0.1, -)	0.7 (0.1, 1.4)
	3rd Quartile (95% CI)	8.5 (0.5, -)	1.4 (0.7, -)
	Log-Rank P-value [2]	0.39469	
	Hazard Ratio (95% CI) [3]	0.70 (0.28, 1.73)	
	P-value [3]	0.43897	
Interaction Test	P-value [4]	0.00175	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_iss.sas 01OCT2025 10:16

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011155
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	7 (100%)	4 (67%)
	Censored	0	2 (33%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.1 (0.1, 0.3)	0.7 (0.3, 6.1)
	Median (95% CI)	0.3 (0.1, 1.4)	6.1 (0.3, -)
	3rd Quartile (95% CI)	1.4 (0.3, -)	- (0.7, -)
	Log-Rank P-value [2]	0.01269	
	Hazard Ratio (95% CI) [3]	6.05 (1.22, 30.00)	
	P-value [3]	0.02766	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_line.sas 01OCT2025 10:16

Table 3.0011155

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	12 (92%)	11 (79%)
	Censored	1 (8%)	3 (21%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.2, 0.5)	0.1 (0.0, 0.8)
	Median (95% CI)	0.5 (0.3, 1.8)	0.8 (0.1, 3.6)
	3rd Quartile (95% CI)	1.8 (0.3, -)	3.6 (0.8, -)
	Log-Rank P-value [2]	0.77127	
	Hazard Ratio (95% CI) [3]	1.18 (0.51, 2.76)	
	P-value [3]	0.69570	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_line.sas 01OCT2025 10:16

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011155
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	7 (88%)	10 (77%)
	Censored	1 (13%)	3 (23%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.4 (0.3, 1.3)	0.7 (0.0, 3.7)
	Median (95% CI)	1.0 (0.3, 2.8)	3.7 (0.3, 6.2)
	3rd Quartile (95% CI)	2.3 (0.5, -)	6.2 (1.4, -)
	Log-Rank P-value [2]	0.34851	
	Hazard Ratio (95% CI) [3]	1.61 (0.60, 4.34)	
	P-value [3]	0.34520	
Interaction Test	P-value [4]	0.20000	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_line.sas 01OCT2025 10:16

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011175
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	19 (95%)	15 (75%)
	Censored	1 (5%)	5 (25%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.3 (0.1, 0.3)	0.3 (0.0, 0.8)
	Median (95% CI)	0.3 (0.3, 1.4)	1.0 (0.3, 6.1)
	3rd Quartile (95% CI)	1.6 (0.3, -)	6.5 (1.8, -)
	Log-Rank P-value [2]	0.07533	
	Hazard Ratio (95% CI) [3]	1.92 (0.95, 3.88)	
	P-value [3]	0.06746	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_line2.sas 01OCT2025 10:17

Table 3.0011175

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	7 (88%)	10 (77%)
	Censored	1 (13%)	3 (23%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	0.4 (0.3, 1.3)	0.7 (0.0, 3.7)
	Median (95% CI)	1.0 (0.3, 2.8)	3.7 (0.3, 6.2)
	3rd Quartile (95% CI)	2.3 (0.5, -)	6.2 (1.4, -)
	Log-Rank P-value [2]	0.34851	
	Hazard Ratio (95% CI) [3]	1.61 (0.60, 4.34)	
	P-value [3]	0.34520	
Interaction Test	P-value [4]	0.62500	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_gr3_2ref_line2.sas 01OCT2025 10:17

1.4.1.4 Schwere UE (CTCAE-Grad ≥ 3) nach SOC und PT

Table 3.0011205

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	13 (46%)	16 (48%)
Censored	15 (54%)	17 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.4 (0.2, 8.4)	0.7 (0.0, 1.8)
Median (95% CI)	9.7 (0.7, -)	19.4 (0.7, -)
3rd Quartile (95% CI)	- (-, -)	28.8 (19.4, -)
Log-Rank P-value [2]	0.51212	
Hazard Ratio (95% CI) [3]	0.79 (0.38, 1.66)	
P-value [3]	0.53731	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Table 3.0011205
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	11 (39%)	4 (12%)
Censored	17 (61%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.3 (0.9, 8.5)	25.3 (5.6, -)
Median (95% CI)	- (2.8, -)	- (9.3, -)
3rd Quartile (95% CI)	- (-, -)	- (25.3, -)
Log-Rank P-value [2]	0.01111	
Hazard Ratio (95% CI) [3]	4.04 (1.27, 12.86)	
P-value [3]	0.01818	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Table 3.0011205
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	3 (9%)
Censored	27 (96%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (10.5, -)	- (3.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.25383	
Hazard Ratio (95% CI) [3]	0.29 (0.03, 2.80)	
P-value [3]	0.28310	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Table 3.0011205

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	6 (18%)
Censored	28 (100%)	27 (82%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.8, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.01616	
Hazard Ratio (95% CI) [3]	0.08 (0.00, 0.67)	
P-value [3]	0.11055	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Table 3.0011205

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	8 (29%)	9 (27%)
Censored	20 (71%)	24 (73%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	10.7 (1.3, -)	10.6 (4.2, 19.3)
Median (95% CI)	- (10.7, -)	19.3 (10.6, -)
3rd Quartile (95% CI)	- (-, -)	- (19.3, -)
Log-Rank P-value [2]	0.75478	
Hazard Ratio (95% CI) [3]	0.86 (0.33, 2.24)	
P-value [3]	0.75520	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Table 3.0011205

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	10 (36%)	4 (12%)
Censored	18 (64%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.5 (0.3, 25.6)	24.2 (0.7, -)
Median (95% CI)	25.6 (15.2, -)	- (24.2, -)
3rd Quartile (95% CI)	- (25.6, -)	- (-, -)
Log-Rank P-value [2]	0.05535	
Hazard Ratio (95% CI) [3]	2.99 (0.94, 9.57)	
P-value [3]	0.06467	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Table 3.0011205
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Metabolism and nutrition disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	2 (6%)
Censored	28 (100%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (6.2, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.16231	
Hazard Ratio (95% CI) [3]	0.20 (0.00, 2.52)	
P-value [3]	0.40328	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Table 3.0011205

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	4 (12%)
Censored	28 (100%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	24.2 (12.5, -)
Median (95% CI)	- (-, -)	- (12.5, -)
3rd Quartile (95% CI)	- (-, -)	- (24.2, -)
Log-Rank P-value [2]	0.02444	
Hazard Ratio (95% CI) [3]	0.09 (0.00, 0.82)	
P-value [3]	0.14377	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Protocol: 207499 Page 9 of 10
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011205
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Respiratory, thoracic and mediastinal disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	2 (6%)
Censored	26 (93%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (16.4, -)	- (-, -)
Median (95% CI)	- (16.4, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.95580	
Hazard Ratio (95% CI) [3]	0.95 (0.13, 6.86)	
P-value [3]	0.95579	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Protocol: 207499 Page 10 of 10
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011205
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	3 (9%)
Censored	27 (96%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	17.3 (3.7, -)
Median (95% CI)	- (-, -)	- (17.3, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.28369	
Hazard Ratio (95% CI) [3]	0.31 (0.03, 3.01)	
P-value [3]	0.30980	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref.sas 01OCT2025 10:17

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	4 (36%)	0
	Censored	7 (64%)	7 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	4 (29%)	2 (13%)
	Censored	10 (71%)	13 (87%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	3 (100%)	2 (18%)
	Censored	0	9 (82%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Protocol: 207499 Page 4 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	0	1 (14%)
	Censored	11 (100%)	6 (86%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	0	3 (20%)
	Censored	14 (100%)	12 (80%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	0	2 (18%)
	Censored	3 (100%)	9 (82%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	0	2 (29%)
	Censored	11 (100%)	5 (71%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	0	2 (13%)
	Censored	14 (100%)	13 (87%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Table 3.0011215
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	0	0
	Censored	3 (100%)	11 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_age.sas 01OCT2025 10:19

Protocol: 207499 Page 1 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011225
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	6 (50%)	1 (6%)
	Censored	6 (50%)	15 (94%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_gen.sas 01OCT2025 10:19

Table 3.0011225
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	5 (31%)	3 (18%)
	Censored	11 (69%)	14 (82%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_gen.sas 01OCT2025 10:19

Table 3.0011225
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	0	4 (25%)
	Censored	12 (100%)	12 (75%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_gen.sas 01OCT2025 10:19

Table 3.0011225
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	0	2 (12%)
	Censored	16 (100%)	15 (88%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_gen.sas 01OCT2025 10:19

Table 3.0011225
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	0	1 (6%)
	Censored	12 (100%)	15 (94%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_gen.sas 01OCT2025 10:19

Protocol: 207499 Page 6 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011225
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	0	3 (18%)
	Censored	16 (100%)	14 (82%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_gen.sas 01OCT2025 10:19

Protocol: 207499 Page 1 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011235
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	6 (33%)	1 (4%)
	Censored	12 (67%)	23 (96%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_reg.sas 01OCT2025 10:20

Table 3.0011235
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	5 (50%)	3 (33%)
	Censored	5 (50%)	6 (67%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_reg.sas 01OCT2025 10:20

Table 3.0011235
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	0	5 (21%)
	Censored	18 (100%)	19 (79%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_reg.sas 01OCT2025 10:20

Protocol: 207499 Page 4 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011235
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	0	1 (11%)
	Censored	10 (100%)	8 (89%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_reg.sas 01OCT2025 10:20

Table 3.0011235
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	0	2 (8%)
	Censored	18 (100%)	22 (92%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_reg.sas 01OCT2025 10:20

Protocol: 207499 Page 6 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011235
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	0	2 (22%)
	Censored	10 (100%)	7 (78%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_reg.sas 01OCT2025 10:20

Protocol: 207499 Page 1 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011245
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	8 (44%)	1 (7%)
	Censored	10 (56%)	14 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_iss.sas 01OCT2025 10:20

Table 3.0011245
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	3 (30%)	3 (17%)
	Censored	7 (70%)	15 (83%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_iss.sas 01OCT2025 10:20

Table 3.0011245
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	0	1 (7%)
	Censored	18 (100%)	14 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_iss.sas 01OCT2025 10:20

Table 3.0011245
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	0	5 (28%)
	Censored	10 (100%)	13 (72%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_iss.sas 01OCT2025 10:20

Protocol: 207499 Page 5 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011245
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	0	3 (20%)
	Censored	18 (100%)	12 (80%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_iss.sas 01OCT2025 10:20

Protocol: 207499 Page 6 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011245
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	0	1 (6%)
	Censored	10 (100%)	17 (94%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_iss.sas 01OCT2025 10:20

Protocol: 207499 Page 1 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011255
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	4 (57%)	1 (17%)
	Censored	3 (43%)	5 (83%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Table 3.0011255
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	4 (31%)	1 (7%)
	Censored	9 (69%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Table 3.0011255
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	2 (15%)
	Censored	5 (63%)	11 (85%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Protocol: 207499 Page 4 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011255
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	0	1 (17%)
	Censored	7 (100%)	5 (83%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Protocol: 207499 Page 5 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011255
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	0	4 (29%)
	Censored	13 (100%)	10 (71%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Table 3.0011255

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	0	1 (8%)
	Censored	8 (100%)	12 (92%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Table 3.0011255
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	0	1 (17%)
	Censored	7 (100%)	5 (83%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Protocol: 207499 Page 8 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011255
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	0	1 (7%)
	Censored	13 (100%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Protocol: 207499 Page 9 of 9
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011255
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	0	2 (15%)
	Censored	8 (100%)	11 (85%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line.sas 01OCT2025 10:20

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011275
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	8 (40%)	2 (10%)
	Censored	12 (60%)	18 (90%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.0 (0.9, 8.5)	- (5.6, -)
	Median (95% CI)	- (2.3, -)	- (6.1, -)
	3rd Quartile (95% CI)	- (-, -)	- (-, -)
	Log-Rank P-value [2]	0.04333	
	Hazard Ratio (95% CI) [3]	4.35 (0.92, 20.64)	
	P-value [3]	0.06396	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line2.sas 01OCT2025 10:20

Table 3.0011275
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	2 (15%)
	Censored	5 (63%)	11 (85%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (1.0, -)	25.3 (9.3, -)
	Median (95% CI)	- (1.0, -)	25.3 (9.3, -)
	3rd Quartile (95% CI)	- (1.9, -)	- (9.3, -)
	Log-Rank P-value [2]	0.04839	
	Hazard Ratio (95% CI) [3]	7.10 (0.74, 68.50)	
	P-value [3]	0.09030	
Interaction Test	P-value [4]	0.92113	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line2.sas 01OCT2025 10:20

Table 3.0011275

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	0	5 (25%)
	Censored	20 (100%)	15 (75%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line2.sas 01OCT2025 10:20

Table 3.0011275

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	0	1 (8%)
	Censored	8 (100%)	12 (92%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line2.sas 01OCT2025 10:20

Table 3.0011275
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	0	2 (10%)
	Censored	20 (100%)	18 (90%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line2.sas 01OCT2025 10:20

Protocol: 207499 Page 6 of 6
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011275
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	0	2 (15%)
	Censored	8 (100%)	11 (85%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_soc_2ref_line2.sas 01OCT2025 10:20

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	9 (27%)
Censored	25 (89%)	24 (73%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.3, -)	28.8 (0.1, 29.7)
Median (95% CI)	- (-, -)	29.7 (28.8, -)
3rd Quartile (95% CI)	- (-, -)	- (28.8, -)
Log-Rank P-value [2]	0.07549	
Hazard Ratio (95% CI) [3]	0.33 (0.09, 1.21)	
P-value [3]	0.09420	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Lymphopenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	2 (6%)
Censored	27 (96%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.64704	
Hazard Ratio (95% CI) [3]	0.57 (0.05, 6.34)	
P-value [3]	0.65126	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	10 (36%)	11 (33%)
Censored	18 (64%)	22 (67%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.3 (0.6, -)	0.8 (0.7, 19.4)
Median (95% CI)	- (3.9, -)	19.4 (8.3, -)
3rd Quartile (95% CI)	- (-, -)	- (19.4, -)
Log-Rank P-value [2]	0.83304	
Hazard Ratio (95% CI) [3]	0.91 (0.38, 2.17)	
P-value [3]	0.83488	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	6 (21%)	8 (24%)
Censored	22 (79%)	25 (76%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.3, -)	2.2 (0.3, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.76751	
Hazard Ratio (95% CI) [3]	0.87 (0.30, 2.50)	
P-value [3]	0.79068	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Cataract

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	3 (9%)
Censored	27 (96%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	25.3 (6.1, -)
Median (95% CI)	- (-, -)	- (9.3, -)
3rd Quartile (95% CI)	- (-, -)	- (25.3, -)
Log-Rank P-value [2]	0.25144	
Hazard Ratio (95% CI) [3]	0.29 (0.03, 2.79)	
P-value [3]	0.28106	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	0
Censored	26 (93%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.7, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.12921	
Hazard Ratio (95% CI) [3]	5.75 (0.47, 793.74)	
P-value [3]	0.35637	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	0
Censored	26 (93%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.17527	
Hazard Ratio (95% CI) [3]	4.63 (0.37, 641.14)	
P-value [3]	0.42114	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	0
Censored	26 (93%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.7, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.15677	
Hazard Ratio (95% CI) [3]	5.04 (0.41, 696.07)	
P-value [3]	0.39525	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	0
Censored	26 (93%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (5.6, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.17622	
Hazard Ratio (95% CI) [3]	4.57 (0.37, 631.05)	
P-value [3]	0.42302	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	0
Censored	25 (89%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.8, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.05789	
Hazard Ratio (95% CI) [3]	8.40 (0.81, >999.99)	
P-value [3]	0.22296	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual acuity reduced

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	0
Censored	25 (89%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.05961	
Hazard Ratio (95% CI) [3]	8.28 (0.80, >999.99)	
P-value [3]	0.22595	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Protocol: 207499 Page 12 of 19
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	4 (14%)	0
Censored	24 (86%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.9, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.04267	
Hazard Ratio (95% CI) [3]	9.32 (0.99, >999.99)	
P-value [3]	0.18174	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Diarrhoea

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	3 (9%)
Censored	28 (100%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (3.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.08436	
Hazard Ratio (95% CI) [3]	0.14 (0.00, 1.48)	
P-value [3]	0.26662	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Asthenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	2 (6%)
Censored	28 (100%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (6.1, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.16195	
Hazard Ratio (95% CI) [3]	0.20 (0.00, 2.52)	
P-value [3]	0.40278	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	3 (9%)
Censored	26 (93%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.3, -)	- (6.5, -)
Median (95% CI)	- (-, -)	- (10.6, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.67431	
Hazard Ratio (95% CI) [3]	0.68 (0.11, 4.11)	
P-value [3]	0.67613	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	6 (21%)	2 (6%)
Censored	22 (79%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	15.2 (0.7, -)	- (24.2, -)
Median (95% CI)	- (15.2, -)	- (24.2, -)
3rd Quartile (95% CI)	- (-, -)	- (24.2, -)
Log-Rank P-value [2]	0.14034	
Hazard Ratio (95% CI) [3]	3.15 (0.63, 15.67)	
P-value [3]	0.16193	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Platelet count decreased

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	7 (25%)	3 (9%)
Censored	21 (75%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.6 (0.3, -)	- (28.8, -)
Median (95% CI)	- (-, -)	- (28.8, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.12081	
Hazard Ratio (95% CI) [3]	2.83 (0.73, 10.99)	
P-value [3]	0.13170	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Metabolism and nutrition disorders
Preferred Term: Hypokalaemia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	2 (6%)
Censored	28 (100%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (6.2, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.16231	
Hazard Ratio (95% CI) [3]	0.20 (0.00, 2.52)	
P-value [3]	0.40328	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Table 3.0011305
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders
Preferred Term: Hypertension

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	2 (6%)
Censored	27 (96%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (17.3, -)
Median (95% CI)	- (-, -)	- (17.3, -)
3rd Quartile (95% CI)	- (-, -)	- (17.3, -)
Log-Rank P-value [2]	0.48808	
Hazard Ratio (95% CI) [3]	0.43 (0.04, 4.92)	
P-value [3]	0.49970	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref.sas 01OCT2025 10:19

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011315
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	1 (9%)	0
	Censored	10 (91%)	7 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_age.sas 01OCT2025 10:22

Table 3.0011315
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	1 (7%)	0
	Censored	13 (93%)	15 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_age.sas 01OCT2025 10:22

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011315
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	2 (67%)	0
	Censored	1 (33%)	11 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_age.sas 01OCT2025 10:22

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011325
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	3 (25%)	0
	Censored	9 (75%)	16 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_gen.sas 01OCT2025 10:22

Table 3.0011325
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	1 (6%)	0
	Censored	15 (94%)	17 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_gen.sas 01OCT2025 10:22

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011335
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	2 (11%)	0
	Censored	16 (89%)	24 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_reg.sas 01OCT2025 10:21

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011335
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	2 (20%)	0
	Censored	8 (80%)	9 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_reg.sas 01OCT2025 10:21

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011345
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	2 (11%)	0
	Censored	16 (89%)	15 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_iss.sas 01OCT2025 10:22

Table 3.0011345
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	2 (20%)	0
	Censored	8 (80%)	18 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_iss.sas 01OCT2025 10:22

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011355
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	1 (14%)	0
	Censored	6 (86%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_line.sas 01OCT2025 10:22

Protocol: 207499 Page 2 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011355
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	2 (15%)	0
	Censored	11 (85%)	14 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_line.sas 01OCT2025 10:22

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011355
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	0
	Censored	7 (88%)	13 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_line.sas 01OCT2025 10:22

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011375
Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event
by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	3 (15%)	0
	Censored	17 (85%)	20 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_line2.sas 01OCT2025 10:22

Table 3.0011375

Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	1 (13%)	0
	Censored	7 (88%)	13 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
SOCs (PTs) that have a p-value <0.05 in the main analysis are included.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_gr3_socpt_2ref_line2.sas 01OCT2025 10:22

1.4.1.5 SUE – Gesamtraten

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011405
Time to First Treatment Emergent Serious Adverse Event -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	14 (50%)	18 (55%)
Censored	14 (50%)	15 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.6 (0.5, 8.1)	3.3 (0.3, 6.1)
Median (95% CI)	10.5 (3.3, -)	10.6 (3.7, 25.8)
3rd Quartile (95% CI)	41.7 (10.7, -)	25.8 (10.6, -)
Log-Rank P-value [2]	0.38878	
Hazard Ratio (95% CI) [3]	0.73 (0.36, 1.49)	
P-value [3]	0.38935	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_2ref.sas 01OCT2025 10:19

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011415
Time to First Treatment Emergent Serious Adverse Event by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	6 (55%)	4 (57%)
	Censored	5 (45%)	3 (43%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (0.5, 4.6)	3.7 (1.4, -)
	Median (95% CI)	4.6 (0.5, -)	6.5 (1.4, -)
	3rd Quartile (95% CI)	8.1 (4.6, -)	28.6 (3.7, -)
	Log-Rank P-value [2]	0.75036	
	Hazard Ratio (95% CI) [3]	1.23 (0.34, 4.44)	
	P-value [3]	0.75076	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_age.sas 01OCT2025 10:19

Table 3.0011415
Time to First Treatment Emergent Serious Adverse Event by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	7 (50%)	8 (53%)
	Censored	7 (50%)	7 (47%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	3.3 (0.1, 10.7)	1.9 (0.3, 10.6)
	Median (95% CI)	10.7 (2.6, -)	10.6 (0.8, -)
	3rd Quartile (95% CI)	- (10.5, -)	25.8 (6.1, -)
	Log-Rank P-value [2]	0.59031	
	Hazard Ratio (95% CI) [3]	0.76 (0.27, 2.10)	
	P-value [3]	0.59146	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_age.sas 01OCT2025 10:19

Table 3.0011415
Time to First Treatment Emergent Serious Adverse Event by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	1 (33%)	6 (55%)
	Censored	2 (67%)	5 (45%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	41.7 (-, -)	0.5 (0.1, 19.3)
	Median (95% CI)	41.7 (-, -)	19.3 (0.3, -)
	3rd Quartile (95% CI)	41.7 (-, -)	- (4.2, -)
	Log-Rank P-value [2]	0.10070	
	Hazard Ratio (95% CI) [3]	0.00 (0.00, -)	
	P-value [3]	0.99661	
Interaction Test	P-value [4]	0.46184	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_age.sas 01OCT2025 10:19

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011425
Time to First Treatment Emergent Serious Adverse Event by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	6 (50%)	6 (38%)
	Censored	6 (50%)	10 (63%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.7 (0.6, 10.5)	2.8 (0.1, 25.8)
	Median (95% CI)	10.5 (1.9, -)	25.8 (1.9, -)
	3rd Quartile (95% CI)	41.7 (10.5, -)	- (25.8, -)
	Log-Rank P-value [2]	0.75710	
	Hazard Ratio (95% CI) [3]	0.83 (0.25, 2.77)	
	P-value [3]	0.75742	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_gen.sas 01OCT2025 10:21

Table 3.0011425
Time to First Treatment Emergent Serious Adverse Event by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	8 (50%)	12 (71%)
	Censored	8 (50%)	5 (29%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.1 (0.1, 5.2)	2.3 (0.3, 6.1)
	Median (95% CI)	10.7 (2.1, -)	6.1 (1.4, 19.3)
	3rd Quartile (95% CI)	- (5.2, -)	19.3 (6.1, -)
	Log-Rank P-value [2]	0.41537	
	Hazard Ratio (95% CI) [3]	0.69 (0.28, 1.70)	
	P-value [3]	0.41796	
Interaction Test	P-value [4]	0.61381	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_gen.sas 01OCT2025 10:21

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011435
Time to First Treatment Emergent Serious Adverse Event by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	8 (44%)	13 (54%)
	Censored	10 (56%)	11 (46%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	4.6 (0.6, 8.1)	1.7 (0.1, 4.2)
	Median (95% CI)	8.1 (3.3, -)	6.5 (1.9, 25.8)
	3rd Quartile (95% CI)	- (8.1, -)	25.8 (6.5, -)
	Log-Rank P-value [2]	0.42211	
	Hazard Ratio (95% CI) [3]	0.70 (0.29, 1.69)	
	P-value [3]	0.42457	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_reg.sas 01OCT2025 10:21

Table 3.0011435
Time to First Treatment Emergent Serious Adverse Event by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	6 (60%)	5 (56%)
	Censored	4 (40%)	4 (44%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.1 (0.1, 10.5)	4.7 (0.3, 19.3)
	Median (95% CI)	10.5 (0.1, -)	19.3 (0.3, -)
	3rd Quartile (95% CI)	41.7 (10.5, -)	28.6 (6.1, -)
	Log-Rank P-value [2]	0.80023	
	Hazard Ratio (95% CI) [3]	0.85 (0.24, 2.96)	
	P-value [3]	0.80043	
Interaction Test	P-value [4]	0.65336	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_reg.sas 01OCT2025 10:21

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011445
Time to First Treatment Emergent Serious Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	11 (61%)	8 (53%)
	Censored	7 (39%)	7 (47%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.1 (0.5, 5.2)	3.7 (0.3, 6.5)
	Median (95% CI)	10.5 (2.1, -)	28.6 (1.4, -)
	3rd Quartile (95% CI)	41.7 (10.5, -)	- (6.5, -)
	Log-Rank P-value [2]	0.88554	
	Hazard Ratio (95% CI) [3]	1.07 (0.42, 2.72)	
	P-value [3]	0.88590	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_iss.sas 01OCT2025 10:22

Table 3.0011445
Time to First Treatment Emergent Serious Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	3 (30%)	10 (56%)
	Censored	7 (70%)	8 (44%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	8.1 (0.1, -)	1.9 (0.1, 10.6)
	Median (95% CI)	- (0.1, -)	10.6 (0.8, -)
	3rd Quartile (95% CI)	- (8.1, -)	19.3 (10.6, -)
	Log-Rank P-value [2]	0.21119	
	Hazard Ratio (95% CI) [3]	0.45 (0.12, 1.63)	
	P-value [3]	0.22320	
Interaction Test	P-value [4]	0.20000	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_iss.sas 01OCT2025 10:22

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011455
Time to First Treatment Emergent Serious Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	4 (57%)	3 (50%)
	Censored	3 (43%)	3 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.9 (0.1, 3.3)	4.2 (1.9, -)
	Median (95% CI)	3.3 (0.1, -)	- (1.9, -)
	3rd Quartile (95% CI)	- (2.6, -)	- (4.2, -)
	Log-Rank P-value [2]	0.51236	
	Hazard Ratio (95% CI) [3]	1.65 (0.36, 7.48)	
	P-value [3]	0.51650	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_line.sas 01OCT2025 10:23

Table 3.0011455
Time to First Treatment Emergent Serious Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	7 (54%)	7 (50%)
	Censored	6 (46%)	7 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	5.2 (0.6, 10.5)	0.5 (0.1, 6.5)
	Median (95% CI)	10.5 (4.6, -)	6.5 (0.3, -)
	3rd Quartile (95% CI)	41.7 (8.1, -)	19.3 (6.5, -)
	Log-Rank P-value [2]	0.32141	
	Hazard Ratio (95% CI) [3]	0.57 (0.19, 1.73)	
	P-value [3]	0.32281	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_line.sas 01OCT2025 10:23

Table 3.0011455
Time to First Treatment Emergent Serious Adverse Event by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	8 (62%)
	Censored	5 (63%)	5 (38%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.3 (0.5, -)	3.7 (0.7, 10.6)
	Median (95% CI)	10.7 (0.5, -)	10.6 (3.3, -)
	3rd Quartile (95% CI)	- (10.7, -)	25.8 (10.6, -)
	Log-Rank P-value [2]	0.91064	
	Hazard Ratio (95% CI) [3]	0.92 (0.23, 3.70)	
	P-value [3]	0.91066	
Interaction Test	P-value [4]	0.79987	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_line.sas 01OCT2025 10:23

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011475
Time to First Treatment Emergent Serious Adverse Event by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	11 (55%)	10 (50%)
	Censored	9 (45%)	10 (50%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	2.9 (0.1, 8.1)	1.4 (0.1, 6.1)
	Median (95% CI)	10.5 (2.6, -)	6.5 (1.4, -)
	3rd Quartile (95% CI)	41.7 (10.5, -)	19.3 (6.5, -)
	Log-Rank P-value [2]	0.58003	
	Hazard Ratio (95% CI) [3]	0.78 (0.32, 1.88)	
	P-value [3]	0.57708	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_line2.sas 01OCT2025 10:23

Table 3.0011475

Time to First Treatment Emergent Serious Adverse Event by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	3 (38%)	8 (62%)
	Censored	5 (63%)	5 (38%)
	Estimates for Time Variable (Months) [1]		
	1st Quartile (95% CI)	1.3 (0.5, -)	3.7 (0.7, 10.6)
	Median (95% CI)	10.7 (0.5, -)	10.6 (3.3, -)
	3rd Quartile (95% CI)	- (10.7, -)	25.8 (10.6, -)
	Log-Rank P-value [2]	0.91064	
	Hazard Ratio (95% CI) [3]	0.92 (0.23, 3.70)	
	P-value [3]	0.91066	
Interaction Test	P-value [4]	0.99064	

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. [4] p-value of the interaction test based on a Cox Proportional Hazards model (Firth correction as applicable) with treatment, subgroup, and treatment x subgroup interaction included as covariates in the model.
/mnt/code/prod/tfls/t_s_aette_ser_2ref_line2.sas 01OCT2025 10:23

1.4.1.6 SUE nach SOC und PT

Protocol: 207499 Page 1 of 7
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011505
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	4 (12%)
Censored	27 (96%)	29 (88%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.4, -)	19.4 (1.5, -)
Median (95% CI)	- (-, -)	- (19.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.14175	
Hazard Ratio (95% CI) [3]	0.22 (0.02, 2.00)	
P-value [3]	0.17932	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref.sas 01OCT2025 10:23

Table 3.0011505

Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	2 (6%)
Censored	26 (93%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	41.7 (41.7, -)	- (-, -)
Median (95% CI)	41.7 (41.7, -)	- (-, -)
3rd Quartile (95% CI)	- (41.7, -)	- (-, -)
Log-Rank P-value [2]	0.95410	
Hazard Ratio (95% CI) [3]	0.94 (0.13, 6.91)	
P-value [3]	0.95409	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref.sas 01OCT2025 10:23

Table 3.0011505

Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	9 (32%)	10 (30%)
Censored	19 (68%)	23 (70%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.2 (0.6, -)	6.5 (2.2, 19.3)
Median (95% CI)	- (10.7, -)	19.3 (6.5, -)
3rd Quartile (95% CI)	- (-, -)	- (19.3, -)
Log-Rank P-value [2]	0.84877	
Hazard Ratio (95% CI) [3]	0.92 (0.37, 2.27)	
P-value [3]	0.84898	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref.sas 01OCT2025 10:23

Table 3.0011505
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	2 (6%)
Censored	28 (100%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (28.8, -)
Median (95% CI)	- (-, -)	- (28.8, -)
3rd Quartile (95% CI)	- (-, -)	- (28.8, -)
Log-Rank P-value [2]	0.15146	
Hazard Ratio (95% CI) [3]	0.19 (0.00, 2.40)	
P-value [3]	0.38749	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref.sas 01OCT2025 10:23

Protocol: 207499 Page 5 of 7
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011505
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	2 (6%)
Censored	28 (100%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (25.8, -)
Median (95% CI)	- (-, -)	- (25.8, -)
3rd Quartile (95% CI)	- (-, -)	- (25.8, -)
Log-Rank P-value [2]	0.15000	
Hazard Ratio (95% CI) [3]	0.19 (0.00, 2.38)	
P-value [3]	0.38548	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref.sas 01OCT2025 10:23

Protocol: 207499 Page 6 of 7
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011505
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Respiratory, thoracic and mediastinal disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	3 (11%)	1 (3%)
Censored	25 (89%)	32 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	41.7 (16.4, -)	- (-, -)
Median (95% CI)	41.7 (16.4, -)	- (-, -)
3rd Quartile (95% CI)	- (41.7, -)	- (-, -)
Log-Rank P-value [2]	0.43498	
Hazard Ratio (95% CI) [3]	2.43 (0.24, 24.10)	
P-value [3]	0.44857	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref.sas 01OCT2025 10:23

Table 3.0011505
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	2 (6%)
Censored	28 (100%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (3.7, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.18084	
Hazard Ratio (95% CI) [3]	0.22 (0.00, 2.75)	
P-value [3]	0.42956	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref.sas 01OCT2025 10:23

Table 3.0011515

Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No SOCs have p-value < 0.05 treatment effect on SOC level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref_age.sas 01OCT2025 10:25

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011525

Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) by Gender - Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No SOCs have p-value < 0.05 treatment effect on SOC level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref_gen.sas 01OCT2025 10:25

Table 3.0011535

Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) by Region - Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No SOCs have p-value < 0.05 treatment effect on SOC level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref_reg.sas 01OCT2025 10:26

Table 3.0011545

Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No SOCs have p-value < 0.05 treatment effect on SOC level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref_iss.sas 01OCT2025 10:26

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011555
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC)
by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No SOCs have p-value < 0.05 treatment effect on SOC level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref_line.sas 01OCT2025 10:26

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011575
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC)
by Prior Lines of Therapy 2 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No SOCs have p-value < 0.05 treatment effect on SOC level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_soc_2ref_line2.sas 01OCT2025 10:26

Table 3.0011605
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	3 (9%)
Censored	28 (100%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	19.4 (19.4, -)
Median (95% CI)	- (-, -)	- (19.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.07542	
Hazard Ratio (95% CI) [3]	0.13 (0.00, 1.40)	
P-value [3]	0.25149	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref.sas 01OCT2025 10:23

Table 3.0011605
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	0	2 (6%)
Censored	28 (100%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.17932	
Hazard Ratio (95% CI) [3]	0.22 (0.00, 2.73)	
P-value [3]	0.42742	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref.sas 01OCT2025 10:23

Table 3.0011605
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	1 (4%)	2 (6%)
Censored	27 (96%)	31 (94%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (5.2, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.57967	
Hazard Ratio (95% CI) [3]	0.51 (0.05, 5.69)	
P-value [3]	0.58660	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref.sas 01OCT2025 10:23

Table 3.0011605
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	3 (9%)
Censored	26 (93%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.3, -)	- (6.5, -)
Median (95% CI)	- (-, -)	- (10.6, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.67431	
Hazard Ratio (95% CI) [3]	0.68 (0.11, 4.11)	
P-value [3]	0.67613	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref.sas 01OCT2025 10:23

Protocol: 207499 Page 5 of 5
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011605
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Upper respiratory tract infection

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	2 (7%)	0
Censored	26 (93%)	33 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (12.1, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.16228	
Hazard Ratio (95% CI) [3]	4.92 (0.40, 681.73)	
P-value [3]	0.40277	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref.sas 01OCT2025 10:23

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011615
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Age (years) - Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No PTs have p-value < 0.05 treatment effect on SOC and PT level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref_age.sas 01OCT2025 10:26

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011625
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No PTs have p-value < 0.05 treatment effect on SOC and PT level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref_gen.sas 01OCT2025 10:26

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011635
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No PTs have p-value < 0.05 treatment effect on SOC and PT level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref_reg.sas 01OCT2025 10:27

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011645
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC)
and Preferred Term (PT) by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No PTs have p-value < 0.05 treatment effect on SOC and PT level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref_iss.sas 01OCT2025 10:27

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011655
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No PTs have p-value < 0.05 treatment effect on SOC and PT level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref_line.sas 01OCT2025 10:28

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011675
Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

No data to report. No PTs have p-value < 0.05 treatment effect on SOC and PT level in main analysis

/mnt/code/prod/tfls/t_s_aette_ser_socpt_2ref_line2.sas 01OCT2025 10:27

1.4.1.7 UE, die zum Therapieabbruch führen – Gesamtraten

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011705
Time to First Treatment Emergent Adverse Event Leading to Permanent Discontinuation of Study Treatment - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Subjects		
Event	7 (25%)	3 (9%)
Censored	21 (75%)	30 (91%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	11.3 (4.6, -)	- (30.4, -)
Median (95% CI)	- (11.3, -)	- (30.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]	0.22094	
Hazard Ratio (95% CI) [3]	2.28 (0.59, 8.87)	
P-value [3]	0.23371	

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from unstratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the unstratified Cox Proportional Hazards model (Firth correction as applicable) with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with POM+BOR/DEX.
/mnt/code/prod/tfls/t_s_aette_des_2ref.sas 01OCT2025 10:24

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011715
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
18 to <65	Number of subjects in subgroup, n*(%)	11 (39%)	7 (21%)
	Number of Subjects		
	Event	2 (18%)	1 (14%)
	Censored	9 (82%)	6 (86%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_age.sas 01OCT2025 10:24

Protocol: 207499 Page 2 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011715
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
65 to <75	Number of subjects in subgroup, n*(%)	14 (50%)	15 (45%)
	Number of Subjects		
	Event	5 (36%)	1 (7%)
	Censored	9 (64%)	14 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_age.sas 01OCT2025 10:24

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011715
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Age (years) -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=75	Number of subjects in subgroup, n*(%)	3 (11%)	11 (33%)
	Number of Subjects		
	Event	0	1 (9%)
	Censored	3 (100%)	10 (91%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_age.sas 01OCT2025 10:24

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011725
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Female	Number of subjects in subgroup, n*(%)	12 (43%)	16 (48%)
	Number of Subjects		
	Event	1 (8%)	1 (6%)
	Censored	11 (92%)	15 (94%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_gen.sas 01OCT2025 10:24

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011725
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Gender -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Male	Number of subjects in subgroup, n*(%)	16 (57%)	17 (52%)
	Number of Subjects		
	Event	6 (38%)	2 (12%)
	Censored	10 (63%)	15 (88%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_gen.sas 01OCT2025 10:24

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011735
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Europe	Number of subjects in subgroup, n*(%)	18 (64%)	24 (73%)
	Number of Subjects		
	Event	4 (22%)	2 (8%)
	Censored	14 (78%)	22 (92%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_reg.sas 01OCT2025 10:25

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011735
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Region -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Non-Europe	Number of subjects in subgroup, n*(%)	10 (36%)	9 (27%)
	Number of Subjects		
	Event	3 (30%)	1 (11%)
	Censored	7 (70%)	8 (89%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_reg.sas 01OCT2025 10:25

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011745
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
I	Number of subjects in subgroup, n*(%)	18 (64%)	15 (45%)
	Number of Subjects		
	Event	7 (39%)	2 (13%)
	Censored	11 (61%)	13 (87%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_iss.sas 01OCT2025 10:24

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011745
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by ISS Stage -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
II/III	Number of subjects in subgroup, n*(%)	10 (36%)	18 (55%)
	Number of Subjects		
	Event	0	1 (6%)
	Censored	10 (100%)	17 (94%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_iss.sas 01OCT2025 10:24

Protocol: 207499 Page 1 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011755
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1	Number of subjects in subgroup, n*(%)	7 (25%)	6 (18%)
	Number of Subjects		
	Event	1 (14%)	0
	Censored	6 (86%)	6 (100%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_line.sas 01OCT2025 10:25

Protocol: 207499 Page 2 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011755
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
2 or 3	Number of subjects in subgroup, n*(%)	13 (46%)	14 (42%)
	Number of Subjects		
	Event	4 (31%)	1 (7%)
	Censored	9 (69%)	13 (93%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_line.sas 01OCT2025 10:25

Protocol: 207499 Page 3 of 3
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011755
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Prior Lines of Therapy -
Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	2 (25%)	2 (15%)
	Censored	6 (75%)	11 (85%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_line.sas 01OCT2025 10:25

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011775
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
1/2/3	Number of subjects in subgroup, n*(%)	20 (71%)	20 (61%)
	Number of Subjects		
	Event	5 (25%)	1 (5%)
	Censored	15 (75%)	19 (95%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_line2.sas 01OCT2025 10:25

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0011775
Time to First Treatment Emergent Adverse Event
Leading to Permanent Discontinuation of Study Treatment by Prior Lines of Therapy 2 - Lenalidomide and Anti-CD38 Refractory Subpopulation

Subgroup		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
>=4	Number of subjects in subgroup, n*(%)	8 (29%)	13 (39%)
	Number of Subjects		
	Event	2 (25%)	2 (15%)
	Censored	6 (75%)	11 (85%)

Note: The percentage for n* is calculated by taking N as denominator. For all subsequent rows, n* is used as denominator for percentage calculation. Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
Note: Subgroup analysis was not performed because the subgroup analysis rules were not met.
/mnt/code/prod/tfls/t_s_aette_des_2ref_line2.sas 01OCT2025 10:25

1.4.1.8 UE, die zum Therapieabbruch führen, nach SOC und PT

Protocol: 207499 Page 1 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0008405

Treatment Emergent Adverse Events Leading to Permanent Discontinuation of Study Treatment Summary by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class Preferred Term	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
ANY EVENT	7 (25%)	3 (9%)
Infections and infestations		
Any Event	3 (11%)	0
Encephalitis herpes	1 (4%)	0
Pneumonia aspiration	1 (4%)	0
Visceral leishmaniasis	1 (4%)	0
Nervous system disorders		
Any Event	2 (7%)	0
Neuralgia	1 (4%)	0
Presyncope	1 (4%)	0
Hepatobiliary disorders		
Any Event	1 (4%)	0
Cholecystitis acute	1 (4%)	0
Musculoskeletal and connective tissue disorders		
Any Event	1 (4%)	0
Muscular weakness	1 (4%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Any Event	1 (4%)	1 (3%)
Gastrointestinal cancer metastatic	1 (4%)	0
Acute myeloid leukaemia	0	1 (3%)

Note: Includes all treatment-emergent adverse events.
/mnt/code/sSAP/sSAP02/prod/tfls/t_s_ae_disc_socpt_2ref.sas 01OCT2025 10:05

Protocol: 207499 Page 2 of 2
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0008405

Treatment Emergent Adverse Events Leading to Permanent Discontinuation of Study Treatment Summary by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class Preferred Term	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Psychiatric disorders		
Any Event	1 (4%)	0
Mood altered	1 (4%)	0
Respiratory, thoracic and mediastinal disorders		
Any Event	1 (4%)	0
Dyspnoea	1 (4%)	0
Pneumonitis	1 (4%)	0
General disorders and administration site conditions		
Any Event	0	1 (3%)
Death	0	1 (3%)
Investigations		
Any Event	0	1 (3%)
Oxygen saturation decreased	0	1 (3%)

Note: Includes all treatment-emergent adverse events.
/mnt/code/sSAP/sSAP02/prod/tfls/t_s_ae_disc_socpt_2ref.sas 01OCT2025 10:05

1.4.1.9 Beobachtungsdauer

Protocol: 207499 Page 1 of 1
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 1.0002805
Summary of Duration of Observation for Adverse Events -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Duration of Observation for AE (Months) [1]	n	28	33
	Mean	15.69	10.72
	SD	14.256	11.711
	Median	10.79	6.28
	Min.	0.4	0.0
	Max.	46.7	46.5

[1] Duration of Adverse Event is defined as the time from the first dose of study medication until 70 days after last dose of study treatment, withdrawn consent, start of subsequent anti myeloma therapy or death whichever occurs first.
/mnt/code/prod/tfls/t_sp_doo_ae_2ref.sas 19AUG2025 08:29

1.4.1.10 Behandlungsdauer

Table 3.0000105
Total Exposure Across All Components -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Cycles [1]	n	28	33
	Mean	15.2	14.2
	SD	14.89	15.78
	Median	10.0	8.0
	Min.	1	1
	Max.	51	62
Number of Cycles With at Least One Dose Reduction [2]	n	28	33
	Mean	1.9	0.8
	SD	2.30	1.15
	Median	1.0	1.0
	Min.	0	0
	Max.	7	5
	0	11 (39%)	16 (48%)
	1	6 (21%)	11 (33%)
	2	2 (7%)	3 (9%)
	>=3	9 (32%)	3 (9%)

[1] Number of cycles includes all cycles where at least one component was administered.
[2] Includes modification of any component. All CRF dose modifications are considered.
These include dose delay, escalation, interruption and reduction.
[3] Total duration of exposure=[(Overall study treatment end date) -
(Overall study treatment start date) + 1]
[4] Total duration of exposure (based on date of decision to discontinue treatment) =
[(latest of [overall study treatment end date, latest date of decision to discontinue treatment])
- (Overall study treatment start date) + 1]
Note: Cycle numbers are based on actual dosed cycle number (any component).
/mnt/code/prod/tfls/t_s_all_exp_2ref.sas 01OCT2025 09:51

Table 3.0000105
Total Exposure Across All Components -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Cycles With at Least One Dose Delay [2]	n	28	33
	Mean	8.7	4.3
	SD	9.50	5.22
	Median	4.5	3.0
	Min.	0	0
	Max.	30	28
	0	2 (7%)	4 (12%)
	1	7 (25%)	5 (15%)
	2	1 (4%)	5 (15%)
	>=3	18 (64%)	19 (58%)

[1] Number of cycles includes all cycles where at least one component was administered.
[2] Includes modification of any component. All CRF dose modifications are considered.
These include dose delay, escalation, interruption and reduction.
[3] Total duration of exposure=[(Overall study treatment end date) -
(Overall study treatment start date) + 1]
[4] Total duration of exposure (based on date of decision to discontinue treatment) =
[(latest of [overall study treatment end date, latest date of decision to discontinue treatment])
- (Overall study treatment start date) + 1]
Note: Cycle numbers are based on actual dosed cycle number (any component).
/mnt/code/prod/tfls/t_s_all_exp_2ref.sas 01OCT2025 09:51

Table 3.0000105
Total Exposure Across All Components -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Number of Cycles With at Least One Dose Modification [2]	n	28	33
	Mean	9.6	4.8
	SD	10.33	5.43
	Median	5.0	3.0
	Min.	0	0
	Max.	32	29
	0	2 (7%)	4 (12%)
	1	7 (25%)	3 (9%)
	2	0	5 (15%)
	>=3	19 (68%)	21 (64%)
Overall Total Duration of Exposure (Months) [3]	n	28	33
	Mean	14.882	10.137
	SD	14.6540	11.6622
	Median	9.610	5.487
	Min.	0.92	0.30
	Max.	46.92	46.46

[1] Number of cycles includes all cycles where at least one component was administered.
[2] Includes modification of any component. All CRF dose modifications are considered. These include dose delay, escalation, interruption and reduction.
[3] Total duration of exposure=[(Overall study treatment end date) - (Overall study treatment start date) + 1]
[4] Total duration of exposure (based on date of decision to discontinue treatment) = [(latest of [overall study treatment end date, latest date of decision to discontinue treatment]) - (Overall study treatment start date) + 1]
Note: Cycle numbers are based on actual dosed cycle number (any component).
/mnt/code/prod/tfls/t_s_all_exp_2ref.sas 01OCT2025 09:51

Table 3.0000105
Total Exposure Across All Components -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Cycle 1 Duration of Exposure (Months) [3]	n	28	33
	Mean	0.979	0.670
	SD	0.1704	0.0841
	Median	0.920	0.690
	Min.	0.82	0.30
	Max.	1.64	0.82
Cycles 2-8 Duration of Exposure (Months) [3]	n	26	29
	Mean	5.398	4.220
	SD	1.9737	1.3451
	Median	6.439	4.797
	Min.	0.92	0.56
	Max.	7.89	6.47

[1] Number of cycles includes all cycles where at least one component was administered.
[2] Includes modification of any component. All CRF dose modifications are considered.
These include dose delay, escalation, interruption and reduction.
[3] Total duration of exposure=[(Overall study treatment end date) -
(Overall study treatment start date) + 1]
[4] Total duration of exposure (based on date of decision to discontinue treatment) =
[(latest of [overall study treatment end date, latest date of decision to discontinue treatment])
- (Overall study treatment start date) + 1]
Note: Cycle numbers are based on actual dosed cycle number (any component).
/mnt/code/prod/tfls/t_s_all_exp_2ref.sas 01OCT2025 09:51

Table 3.0000105
Total Exposure Across All Components -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Cycles 9+ Duration of Exposure (Months) [3]	n	15	15
	Mean	16.598	12.669
	SD	14.4827	13.0576
	Median	9.232	7.392
	Min.	0.92	0.69
	Max.	39.29	40.48
Overall Total Duration of Exposure (Based on Date of Decision to Discontinue) (Months) [4]	n	28	33
	Mean	15.234	10.468
	SD	14.6905	11.6193
	Median	9.610	6.012
	Min.	0.92	0.30
	Max.	46.92	46.46

[1] Number of cycles includes all cycles where at least one component was administered.
[2] Includes modification of any component. All CRF dose modifications are considered.
These include dose delay, escalation, interruption and reduction.
[3] Total duration of exposure=[(Overall study treatment end date) -
(Overall study treatment start date) + 1]
[4] Total duration of exposure (based on date of decision to discontinue treatment) =
[(latest of [overall study treatment end date, latest date of decision to discontinue treatment])
- (Overall study treatment start date) + 1]
Note: Cycle numbers are based on actual dosed cycle number (any component).
/mnt/code/prod/tfls/t_s_all_exp_2ref.sas 01OCT2025 09:51

Table 3.0000105
Total Exposure Across All Components -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Cycle 1 Duration of Exposure (Based on Date of Decision to Discontinue) (Months) [4]	n	28	33
	Mean	1.054	0.730
	SD	0.4217	0.3402
	Median	0.920	0.690
	Min.	0.82	0.30
	Max.	3.02	2.56
Cycles 2-8 Duration of Exposure (Based on Date of Decision to Discontinue) (Months) [4]	n	26	29
	Mean	5.484	4.384
	SD	1.9802	1.1133
	Median	6.439	4.830
	Min.	0.92	2.10
	Max.	7.89	6.47

[1] Number of cycles includes all cycles where at least one component was administered.
[2] Includes modification of any component. All CRF dose modifications are considered.
These include dose delay, escalation, interruption and reduction.
[3] Total duration of exposure=[(Overall study treatment end date) -
(Overall study treatment start date) + 1]
[4] Total duration of exposure (based on date of decision to discontinue treatment) =
[(latest of [overall study treatment end date, latest date of decision to discontinue treatment])
- (Overall study treatment start date) + 1]
Note: Cycle numbers are based on actual dosed cycle number (any component).
/mnt/code/prod/tfls/t_s_all_exp_2ref.sas 01OCT2025 09:51

Table 3.0000105
Total Exposure Across All Components -
Lenalidomide and Anti-CD38 Refractory Subpopulation

		Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Cycles 9+ Duration of Exposure (Based on Date of Decision to Discontinue) (Months) [4]	n	15	15
	Mean	16.966	12.947
	SD	14.5323	13.0627
	Median	9.823	7.392
	Min.	0.92	0.69
	Max.	39.29	40.48

[1] Number of cycles includes all cycles where at least one component was administered.
[2] Includes modification of any component. All CRF dose modifications are considered.
These include dose delay, escalation, interruption and reduction.
[3] Total duration of exposure=[(Overall study treatment end date) -
(Overall study treatment start date) + 1]
[4] Total duration of exposure (based on date of decision to discontinue treatment) =
[(latest of [overall study treatment end date, latest date of decision to discontinue treatment])
- (Overall study treatment start date) + 1]
Note: Cycle numbers are based on actual dosed cycle number (any component).
/mnt/code/prod/tfls/t_s_all_exp_2ref.sas 01OCT2025 09:51

1.4.1.11 Dosisanpassungen

Table 3.0000405
Summary of Dose Reductions of GSK2857916 and Bortezomib - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Subjects with Any Reduction	11	(39%)	13	(39%)
Total Number of Dose Reductions	13		16	
Total Number of Cycles with at Least One Dose Reduction	13		16	
Number of Dose Reductions				
0	15	(54%)	19	(58%)
1	9	(32%)	10	(30%)
2	2	(7%)	3	(9%)
>=3	0		0	
Not Evaluable [1]	2	(7%)	1	(3%)
Number of Cycles with a Dose Reduction				
0	15	(54%)	19	(58%)
1	9	(32%)	10	(30%)
2	2	(7%)	3	(9%)
>=3	0		0	
Not Evaluable [1]	2	(7%)	1	(3%)

[1] Not evaluable means the subject did not receive any drug in any succeeding time period after the first dose.
[2] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.
[3] Denominators are calculated as the number of subjects with a dose record at the planned visit (including records where no dose was administered). Only planned visits where at least one reduction occurred in either treatment arm is presented.
Note: Protocol-mandated reduction (e.g., reduction of belantamab mafodotin at Cycle 2 Day 1) will not be counted as reduction. Reductions reflect a reduction in dose or frequency.
/mnt/code/prod/tfls/t_s_dosred_gsk_bor_2ref.sas 01OCT2025 09:52

Table 3.0000405
Summary of Dose Reductions of GSK2857916 and Bortezomib - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Reasons for Reduction [2]				
n	13		16	
Adverse Event	0		16	(100%)
Adverse Event Resolved	0		0	
Corneal Exam Findings	13	(100%)	0	
Subject Non-Compliance	0		0	
Other	0		0	

[1] Not evaluable means the subject did not receive any drug in any succeeding time period after the first dose.
[2] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.
[3] Denominators are calculated as the number of subjects with a dose record at the planned visit (including records where no dose was administered). Only planned visits where at least one reduction occurred in either treatment arm is presented.
Note: Protocol-mandated reduction (e.g., reduction of belantamab mafodotin at Cycle 2 Day 1) will not be counted as reduction. Reductions reflect a reduction in dose or frequency.
/mnt/code/prod/tfls/t_s_dosred_gsk_bor_2ref.sas 01OCT2025 09:52

Table 3.0000405
Summary of Dose Reductions of GSK2857916 and Bortezomib - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)		POM + BOR/DEX (N=33)	
Number of Subjects with Dose Reduction by Planned Visit [3]				
Cycle 1 Day 11			1/32	(3%)
Cycle 2 Day 1	0/27		1/30	(3%)
Cycle 3 Day 1	0/26		1/29	(3%)
Cycle 3 Day 11			1/28	(4%)
Cycle 4 Day 1	0/25		2/29	(7%)
Cycle 5 Day 1	2/21	(10%)	2/27	(7%)
Cycle 5 Day 8			1/24	(4%)
Cycle 6 Day 1	0/18		1/24	(4%)
Cycle 7 Day 1	1/18	(6%)	1/21	(5%)
Cycle 7 Day 11			1/16	(6%)
Cycle 8 Day 1	1/17	(6%)	0/17	
Cycle 8 Day 8			1/17	(6%)
Cycle 9 Day 1	1/16	(6%)	0/17	
Cycle 10 Day 1	1/14	(7%)	0/14	
Cycle 11 Day 1	1/14	(7%)	1/13	(8%)
Cycle 12 Day 1	0/14		1/11	(9%)
Cycle 14 Day 1	2/10	(20%)	0/10	
Cycle 15 Day 1	1/ 9	(11%)	0/10	
Cycle 20 Day 1	1/ 7	(14%)	0/ 6	

[1] Not evaluable means the subject did not receive any drug in any succeeding time period after the first dose.
[2] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.
[3] Denominators are calculated as the number of subjects with a dose record at the planned visit (including records where no dose was administered). Only planned visits where at least one reduction occurred in either treatment arm is presented.
Note: Protocol-mandated reduction (e.g., reduction of belantamab mafodotin at Cycle 2 Day 1) will not be counted as reduction. Reductions reflect a reduction in dose or frequency.
/mnt/code/prod/tfls/t_s_dosred_gsk_bor_2ref.sas 01OCT2025 09:52

Protocol: 207499 Page 4 of 4
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) Data as of 07JUL2025

Table 3.0000405
Summary of Dose Reductions of GSK2857916 and Bortezomib - Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)	POM + BOR/DEX (N=33)
Cycle 22 Day 1	1/ 7 (14%)	0/ 6
Cycle 42 Day 1	1/ 5 (20%)	0/ 5
Cycle 49 Day 1	0/ 2	1/ 2 (50%)

[1] Not evaluable means the subject did not receive any drug in any succeeding time period after the first dose.
[2] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.
[3] Denominators are calculated as the number of subjects with a dose record at the planned visit (including records where no dose was administered). Only planned visits where at least one reduction occurred in either treatment arm is presented.
Note: Protocol-mandated reduction (e.g., reduction of belantamab mafodotin at Cycle 2 Day 1) will not be counted as reduction. Reductions reflect a reduction in dose or frequency.
/mnt/code/prod/tfls/t_s_dosred_gsk_bor_2ref.sas 01OCT2025 09:52

Table 3.0000705
Summary of Dose Delays of GSK2857916 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)
Subjects with Any Dose Delay	21 (75%)
Total Number of Dose Delays [1]	92
Total Number of Cycles with at Least One Dose Delay	205
Number of Dose Delays	
0	7 (25%)
1	7 (25%)
2	3 (11%)
>=3	11 (39%)
Number of Cycles with a Dose Delay	
0	7 (25%)
1	2 (7%)
2	3 (11%)
>=3	16 (57%)

[1] A single dose delay will be reported when consecutive planned dosing dates
are missed/skipped/no dose is administered when planned.
[2] Duration of delay is defined as period from the expected start date of dose to subsequent
actual dosing date following dose delay. Duration of delay will be missing if dosing did not resume
prior to data cut off, i.e., if the delay was ongoing or subject subsequently discontinued treatment.
[3] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple
delays for the same reason. Consecutive dose delays are only considered as a single delay
but the reasons for each of these are summarised.
Note: Delays where no dose was administered are included.
/mnt/code/prod/tfls/t_s_dosdel_gsk_2ref.sas 01OCT2025 09:53

Table 3.0000705
Summary of Dose Delays of GSK2857916 -
Lenalidomide and Anti-CD38 Refractory Subpopulation

	Belamaf 2.5/1.9 mg/kg + POM/DEX (N=28)
Delay Duration (days) [2]	
n	77
1-21	1 (1%)
22-28	5 (6%)
29-42	21 (27%)
43-56	3 (4%)
>56	47 (61%)
Reasons for Delay [3]	
n	205
Adverse Event	27 (13%)
Adverse Event Resolved	0
Corneal Exam Findings	174 (85%)
Subject Non-Compliance	0
Other	4 (2%)

[1] A single dose delay will be reported when consecutive planned dosing dates
are missed/skipped/no dose is administered when planned.
[2] Duration of delay is defined as period from the expected start date of dose to subsequent
actual dosing date following dose delay. Duration of delay will be missing if dosing did not resume
prior to data cut off, i.e., if the delay was ongoing or subject subsequently discontinued treatment.
[3] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple
delays for the same reason. Consecutive dose delays are only considered as a single delay
but the reasons for each of these are summarised.
Note: Delays where no dose was administered are included.
/mnt/code/prod/tfls/t_s_dosdel_gsk_2ref.sas 01OCT2025 09:53

1.4.2 Graphische Darstellungen – Ergebnisse für Endpunkte zur Sicherheit

1.4.2.1 UE jeglichen Schweregrades – Gesamtraten

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000105
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event - Lenalidomide and Anti-CD38 Refractory Subpopulation



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/sSAP/sSAP02/tfls/f_s_aette_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000145

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage: I



Number at Risk (Number of Events)						
BPd	18	2	0	0	0	0
	(0)	(16)	(18)	(18)	(18)	(18)
PVd	15	4	1	0	0	0
	(0)	(11)	(14)	(15)	(15)	(15)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/sSAP/sSAP02/prod/tfls/f_s_aette_2ref_iss.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000145

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage: II/III



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/sSAP/sSAP02/prod/tfls/f_s_aette_2ref_iss.sas 14OCT2025 13:43

1.4.2.2 UE jeglichen Schweregrades nach SOC und PT

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders


Treatment
Belamaf 2.5/1.9 mg/kg + POM/DEX
POM + BOR/DEX
Proportion without Adverse Event
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48
Time Since Treatment Initiation (Months)
Number at Risk
(Number of Events)
BPd 28 11 6 4 2 1 0 0 0

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Injury, poisoning and procedural complications



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Metabolism and nutrition disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Psychiatric disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Renal and urinary disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Respiratory, thoracic and mediastinal disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Skin and subcutaneous tissue disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000205

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_soc_2ref.sas 14OCT2025 16:07

Protocol: 207499
Population: Safety - Global Cohort **Data as of 07JUL2025**

Figure 3.0000255
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation
System Organ Class: Eye disorders
Prior Lines of Therapy : 1



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_soc_2ref_line.sas 14OCT2025 13:43

Protocol: 207499
Population: Safety - Global Cohort **Data as of 07JUL2025**

Figure 3.0000255
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation
System Organ Class: Eye disorders
Prior Lines of Therapy : 2 or 3



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_soc_2ref_line.sas 14OCT2025 13:43

Protocol: 207499
Population: Safety - Global Cohort **Data as of 07JUL2025**

Figure 3.0000255
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) by Prior Lines of Therapy - Lenalidomide and Anti-CD38 Refractory Subpopulation
System Organ Class: Eye disorders
Prior Lines of Therapy : >=4



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_soc_2ref_line.sas 14OCT2025 13:43

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Cataract



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal opacity



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	22 (5)	20 (6)	19 (6)	14 (8)	13 (8)	10 (9)	9 (9)	8 (9)	7 (9)	6 (9)	5 (9)	4 (9)	4 (9)	4 (9)	4 (9)	4 (9)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	2 (10)	2 (10)	2 (10)	2 (10)	2 (10)	2 (10)	2 (10)	2 (10)	1 (10)	1 (10)	0 (10)	0 (10)	0 (10)	0 (10)	0 (10)	0 (10)	0 (10)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	17 (1)	13 (1)	10 (1)	9 (1)	9 (1)	9 (1)	7 (2)	6 (2)	6 (2)	6 (2)	4 (2)	4 (2)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	2 (3)	2 (3)	2 (3)	2 (3)	2 (3)	2 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	0 (3)	0 (3)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	23 (4)	19 (7)	17 (8)	14 (9)	13 (9)	10 (10)	9 (10)	8 (10)	7 (10)	6 (10)	6 (10)	5 (10)	5 (10)	5 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	4 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	2 (10)	2 (10)	1 (10)	1 (10)	1 (10)	1 (10)	1 (10)	0 (10)	0 (10)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	17 (1)	13 (1)	10 (1)	9 (1)	9 (1)	9 (1)	8 (1)	6 (1)	6 (1)	6 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	2 (1)	2 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye pain



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	25 (1)	23 (2)	20 (2)	19 (2)	16 (3)	15 (3)	14 (3)	13 (3)	13 (3)	12 (3)	11 (3)	10 (4)	9 (4)	9 (4)	8 (4)	8 (4)	7 (4)	6 (4)	6 (4)	6 (4)	6 (4)	6 (4)	6 (4)	6 (4)	5 (4)	5 (4)	5 (4)	5 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	3 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	18 (0)	14 (0)	11 (0)	10 (0)	10 (0)	10 (0)	9 (0)	7 (0)	7 (0)	7 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	24 (3)	17 (9)	15 (10)	14 (10)	13 (10)	11 (11)	10 (11)	9 (11)	7 (12)	7 (12)	6 (12)	5 (12)	5 (12)	5 (12)	4 (12)	4 (12)	3 (13)	1 (14)	1 (14)	1 (14

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Keratopathy



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Photophobia



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	26 (1)	23 (3)	21 (4)	18 (4)	17 (4)	14 (5)	12 (6)	11 (6)	10 (6)	9 (6)	8 (6)	7 (6)	7 (6)	7 (6)	6 (6)	6 (6)	6 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	4 (6)	4 (6)	4 (6)	4 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	2 (6)	2 (6)	1 (6)	1 (6)	1 (6)	1 (6)	1 (6)	0 (6)	0 (6)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	18 (0)	14 (0)	11 (0)	10 (0)	10 (0)	10 (0)	9 (0)	7 (0)	7 (0)	7 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	2 (1)	2 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Punctate keratitis



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	23 (4)	20 (6)	19 (6)	17 (6)	16 (6)	14 (6)	13 (6)	12 (6)	11 (6)	11 (6)	10 (6)	9 (6)	9 (6)	8 (6)	7 (6)	7 (6)	7 (6)	6 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	4 (6)	4 (6)	4 (6)	4 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	2 (6)	2 (6)	1 (6)	1 (6)	1 (6)	1 (6)	1 (6)	0 (6)	0 (6)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	17 (1)	13 (1)	10 (1)	9 (1)	9 (1)	9 (1)	8 (1)	6 (1)	6 (1)	6 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	2 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual acuity reduced



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	25 (2)	22 (4)	21 (4)	18 (4)	16 (5)	14 (5)	13 (5)	12 (5)	12 (5)	11 (5)	10 (5)	9 (5)	9 (5)	8 (5)	7 (5)	6 (5)	6 (5)	5 (5)	4 (5)	4 (5)	4 (5)	4 (5)	4 (5)	4 (5)	4 (5)	3 (5)	3 (5)	3 (5)	3 (5)	3 (5)	3 (5)	3 (5)	3 (5)	3 (5)	3 (5)	2 (5)	1 (5)	1 (5)	0 (5)	0 (5)	0 (5)	0 (5)	0 (5)	0 (5)	0 (5)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	18 (0)	14 (0)	11 (0)	10 (0)	10 (0)	10 (0)	9 (0)	7 (0)	7 (0)	7 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	3 (0)	3 (0)	2 (0)	2 (0)	2 (0)	2 (0)	2 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	0 (0)	0 (0)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	26 (1)	25 (1)	24 (1)	21 (1)	20 (1)	19 (1)	18 (1)	17 (1)	15 (2)	14 (2)	13 (2)	11 (2)	11 (2)	10 (2)	9 (2)	8 (2)	8 (2)	8 (2)	7 (2)	7 (2)	7 (2)	7 (2)	7 (2)	7 (2)	7 (2)	6 (2)	6 (2)	6 (2)	6 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	4 (2)	3 (2)	3 (2)	2 (2)	2 (2)	1 (2)	1 (2)	1 (2)	0 (2)	0 (2)
PVd	33 (0)	28 (3)	25 (5)	24 (5)	18 (6)	13 (7)	12 (8)	8 (8)	5 (8)	5 (8)	5 (8)	5 (8)	5 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	4 (8)	3 (8)	3 (8)	2 (8)	2 (8)	2 (8)	1 (8)	1 (8)	1 (8)	1 (8)	1 (8)	1 (8)	1 (8)	0 (8)	0 (8)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Diarrhoea



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Nausea



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	25 (2)	24 (2)	23 (2)	20 (2)	19 (2)	18 (2)	17 (2)	16 (2)	15 (2)	14 (2)	12 (3)	10 (3)	10 (3)	10 (3)	9 (3)	8 (3)	8 (3)	8 (3)	7 (3)	7 (3)	7 (3)	7 (3)	7 (3)	7 (3)	5 (4)	5 (4)	5 (4)	5 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	3 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)
PVd	33 (0)	28 (3)	27 (3)	25 (4)	19 (5)	14 (5)	14 (5)	11 (5)	9 (5)	9 (5)	9 (5)	9 (5)	8 (5)	6 (5)	6 (5)	6 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	5 (5)	3 (5)	3 (5)	2 (5)	2 (5)	2 (5)	2 (5)	2 (5)	1 (5)	1 (5)	1 (5)	1 (5)	1 (5)	1 (5)	0 (5)	0 (5)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Asthenia



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Fatigue



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Oedema peripheral



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	26 (1)	24 (2)	23 (2)	20 (2)	19 (2)	17 (2)	16 (2)	16 (2)	15 (2)	13 (3)	12 (3)	10 (3)	10 (3)	10 (3)	9 (3)	7 (4)	7 (4)	7 (4)	6 (4)	6 (4)	6 (4)	6 (4)	6 (4)	6 (4)	6 (4)	5 (4)	5 (4)	5 (4)	5 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	3 (4)	2 (5)	2 (5)	2 (5)	2 (5)	1 (5)	1 (5)	1 (5)	0 (5)	0 (5)
PVd	33 (0)	28 (3)	25 (5)	24 (5)	19 (5)	15 (5)	14 (6)	10 (6)	8 (6)	7 (6)	7 (6)	7 (6)	6 (6)	5 (6)	5 (6)	5 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	3 (6)	2 (6)	2 (6)	1 (6)	1 (6)	1 (6)	1 (6)	0 (6)	0 (6)	0 (6)	0 (6)	0 (6)	0 (6)	0 (6)	0 (6)	0 (6)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Pyrexia



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	24 (2)	23 (2)	21 (2)	19 (3)	17 (3)	16 (3)	14 (4)	13 (4)	12 (4)	11 (4)	10 (4)	10 (4)	10 (4)	9 (4)	8 (4)	8 (4)	7 (4)	7 (4)	7 (4)	7 (4)	7 (4)	7 (4)	7 (4)	6 (4)	6 (4)	6 (4)	6 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	4 (4)	3 (4)	3 (4)	1 (5)	1 (5)	1 (5)	1 (5)	1 (5)	0 (5)	0 (5)
PVd	33 (0)	29 (2)	28 (2)	27 (2)	22 (2)	17 (3)	17 (3)	12 (4)	9 (4)	8 (4)	8 (4)	8 (4)	8 (4)	6 (4)	6 (4)	6 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Bronchitis



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: COVID-19



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	26 (1)	25 (1)	22 (1)	20 (2)	18 (2)	16 (3)	15 (3)	14 (3)	11 (5)	10 (5)	8 (6)	8 (6)	7 (6)	7 (6)	6 (6)	6 (6)	6 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	5 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	3 (6)	3 (6)	2 (6)	2 (6)	1 (6)	1 (6)	1 (6)	0 (6)	0 (6)
PVd	33 (0)	31 (0)	29 (1)	28 (1)	22 (2)	17 (3)	16 (4)	13 (4)	10 (4)	9 (5)	9 (5)	9 (5)	8 (5)	6 (5)	5 (6)	5 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	3 (7)	3 (7)	3 (7)	3 (7)	3 (7)	3 (7)	3 (7)	3 (7)	3 (7)	2 (7)	2 (7)	2 (7)	2 (7)	2 (7)	2 (7)	2 (7)	1 (7)	1 (7)	1 (7)	1 (7)	1 (7)	1 (7)	1 (7)	1 (7)	0 (7)	0 (7)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Pneumonia



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	25 (1)	23 (2)	19 (3)	19 (3)	17 (3)	16 (3)	15 (3)	14 (3)	13 (3)	12 (3)	10 (3)	10 (3)	9 (3)	8 (3)	8 (3)	7 (4)	6 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	5 (4)	4 (4)	3 (4)	3 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)
PVd	33 (0)	30 (1)	29 (1)	27 (2)	23 (2)	18 (2)	18 (2)	13 (3)	10 (3)	9 (3)	9 (3)	8 (4)	8 (4)	6 (4)	6 (4)	6 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	2 (4)	2 (4)	2 (4)	2 (4)	2 (4)	2 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Upper respiratory tract infection



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Urinary tract infection



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	26 (0)	24 (1)	21 (1)	20 (1)	18 (1)	17 (1)	16 (1)	15 (1)	14 (1)	12 (2)	10 (2)	10 (2)	8 (3)	8 (3)	7 (3)	7 (3)	7 (3)	6 (3)	6 (3)	6 (3)	6 (3)	6 (3)	6 (3)	6 (3)	5 (3)	5 (3)	5 (3)	5 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	3 (4)	3 (4)	3 (4)	3 (4)	2 (4)	2 (4)	2 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)
PVd	33 (0)	31 (0)	29 (1)	28 (1)	22 (1)	18 (1)	18 (1)	14 (1)	11 (1)	10 (1)	10 (1)	10 (1)	9 (1)	7 (1)	7 (1)	7 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	3 (1)	3 (1)	2 (1)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	0 (2)	0 (2)	0 (2)	0 (2)	0 (2)	0 (2)	0 (2)	0 (2)	0 (2)	0 (2)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Aspartate aminotransferase increased



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Blood alkaline phosphatase increased



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Gamma-glutamyltransferase increased



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Platelet count decreased



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	20 (7)	19 (7)	18 (7)	15 (7)	14 (7)	13 (7)	12 (7)	11 (7)	10 (7)	10 (7)	10 (7)	8 (7)	8 (7)	8 (7)	7 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	5 (7)	5 (7)	5 (7)	5 (7)	5 (7)	5 (7)	5 (7)	5 (7)	4 (7)	3 (7)	3 (7)	2 (7)	2 (7)	1 (7)	1 (7)	1 (7)	0 (7)	0 (7)
PVd	33 (0)	29 (2)	27 (3)	26 (3)	22 (3)	17 (3)	17 (3)	13 (3)	10 (3)	9 (3)	9 (3)	9 (3)	8 (3)	6 (3)	6 (3)	6 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	4 (4)	4 (4)	3 (4)	3 (4)	2 (4)	2 (4)	2 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Urine albumin/creatinine ratio increased



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Arthralgia



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	26 (0)	25 (0)	22 (0)	21 (0)	19 (0)	18 (0)	17 (0)	16 (0)	15 (0)	14 (0)	12 (0)	11 (1)	10 (1)	9 (1)	8 (1)	8 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	6 (1)	6 (1)	6 (1)	6 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)
PVd	33 (0)	30 (1)	29 (1)	27 (2)	21 (2)	16 (3)	16 (3)	12 (3)	9 (3)	8 (3)	8 (3)	8 (3)	7 (3)	5 (3)	5 (3)	5 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	3 (3)	2 (3)	2 (3)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	26 (0)	25 (0)	21 (1)	20 (1)	18 (1)	17 (1)	16 (1)	15 (1)	14 (1)	13 (1)	11 (1)	11 (1)	10 (1)	9 (1)	8 (1)	8 (1)	7 (1)	6 (1)	6 (1)	6 (1)	6 (1)	6 (1)	6 (1)
PVd	33 (0)	30 (1)	27 (3)	26 (3)	21 (3)	16 (3)	16 (3)	13 (4)	10 (4)	9 (4)	8 (5)	8 (5)	7 (5)	5 (5)	5 (5)	5 (5)	4 (5)	4 (5)	4 (5)	4 (5)	4 (5)	4 (5)	4 (5)	4 (5)	3 (6)

	5	5	5	5	4	4	4	4	4	4	4	4	4	4	3	3	2	2	1	1	1	0	0
BPd	5 (1)	5 (1)	5 (1)	5 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)
PVd	2 (7)	2 (7)	2 (7)	2 (7)	2 (7)	2 (7)	2 (7)	2 (7)	1 (7)	1 (7)	1 (7)	1 (7)	1 (7)	1 (7)	0 (7)	0 (7)	0 (7)	0 (7)	0 (7)	0 (7)	0 (7)	0 (7)	0 (7)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Nervous system disorders
Preferred Term: Neuropathy peripheral



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Dyspnoea



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	26 (0)	24 (1)	21 (1)	20 (1)	17 (2)	16 (2)	15 (2)	13 (3)	12 (3)	11 (3)	10 (3)	10 (3)	10 (3)	9 (3)	8 (3)	8 (3)	8 (3)	7 (3)	7 (3)	7 (3)	7 (3)	7 (3)	7 (3)	7 (3)	6 (3)	6 (3)	6 (3)	6 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	4 (3)	3 (3)	3 (3)	2 (3)	2 (3)	1 (3)	1 (3)	1 (3)	0 (3)	0 (3)
PVd	33 (0)	30 (1)	29 (1)	27 (2)	21 (3)	17 (3)	17 (3)	13 (3)	10 (3)	9 (3)	9 (3)	9 (3)	9 (3)	7 (3)	7 (3)	7 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	3 (3)	3 (3)	2 (3)	2 (3)	2 (3)	2 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	0 (3)	0 (3)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000305
Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders
Preferred Term: Hypertension



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	25 (1)	24 (1)	21 (1)	20 (1)	18 (1)	17 (1)	16 (1)	15 (1)	14 (1)	13 (1)	12 (1)	12 (1)	11 (1)	10 (1)	9 (1)	9 (1)	8 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	6 (1)	6 (1)	6 (1)	6 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)
PVd	33 (0)	29 (2)	28 (2)	27 (2)	22 (2)	18 (2)	18 (2)	14 (2)	11 (2)	10 (2)	10 (2)	10 (2)	9 (2)	7 (2)	7 (2)	7 (2)	5 (2)	5 (2)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	3 (4)	3 (4)	3 (4)	3 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_socpt_2ref.sas 14OCT2025 13:43

1.4.2.3 Schwere UE (CTCAE-Grad ≥3) – Gesamtraten

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001705
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event - Lenalidomide and Anti-CD38 Refractory Subpopulation



Number at Risk (Events)																	
BPd	28 (0)	10 (18)	6 (22)	4 (24)	2 (25)	2 (25)	2 (25)	1 (25)	1 (25)	0 (26)	0 (26)	0 (26)	0 (26)	0 (26)	0 (26)	0 (26)	0 (26)
PVd	33 (0)	18 (14)	15 (17)	15 (17)	11 (21)	9 (21)	9 (21)	4 (25)	2 (25)	2 (25)	2 (25)	2 (25)	2 (25)	1 (25)	1 (25)	1 (25)	0 (25)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_gr3_2ref.sas 14OCT2025 13:44

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001745

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage: I



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/sSAP/sSAP02/prod/tfls/f_s_aette_gr3_2ref_iss.sas 14OCT2025 13:45

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001745

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by ISS Stage - Lenalidomide and Anti-CD38 Refractory Subpopulation

ISS Stage: II/III



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/sSAP/sSAP02/prod/tfls/f_s_aette_gr3_2ref_iss.sas 14OCT2025 13:45

1.4.2.4 Schwere UE (CTCAE-Grad ≥3) nach SOC und PT

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	22 (5)	20 (6)	17 (8)	14 (9)	13 (9)	11 (10)	10 (10)	9 (10)	8 (11)	7 (11)	6 (11)	4 (11)	4 (11)	3 (11)	3 (11)	3 (11)	3 (11)	2 (11)	1 (11)	1 (11)	1 (11)	1 (11)	1 (11)	1 (11)	1 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)	0 (11)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	17 (1)	12 (2)	9 (2)	8 (2)	7 (3)	7 (3)	6 (3)	5 (3)	5 (3)	5 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	3 (4)	3 (4)	3 (4)	3 (4)	3 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)	0 (4)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_gr3_soc_2ref.sas 14OCT2025 16:41

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	26 (0)	25 (0)	22 (0)	21 (0)	19 (0)	18 (0)	17 (0)	16 (0)	15 (0)	13 (1)	11 (1)	11 (1)	10 (1)	9 (1)	8 (1)	8 (1)	8 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	6 (1)	6 (1)	6 (1)	6 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	21 (2)	15 (3)	15 (3)	11 (3)	9 (3)	8 (3)	8 (3)	8 (3)	8 (3)	6 (3)	6 (3)	6 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	2 (3)	2 (3)	1 (3)	1 (3)	1 (3)	1 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_gr3_soc_2ref.sas 14OCT2025 16:41

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	26 (1)	24 (3)	23 (4)	19 (5)	18 (5)	15 (6)	14 (6)	14 (6)	13 (6)	12 (6)	10 (7)	8 (7)	8 (7)	8 (7)	8 (7)	8 (7)	7 (8)	7 (8)	6 (8)	6 (8)	6 (8)	6 (8)	6 (8)	6 (8)	6 (8)	5 (8)	5 (8)	5 (8)	5 (8)	5 (8)	5 (8)	5 (8)	5 (8)	5 (8)	5 (8)	4 (8)	3 (8)	3 (8)	2 (8)	2 (8)	1 (8)	1 (8)	1 (8)	0 (8)	0 (8)
PVd	33 (0)	31 (0)	29 (1)	27 (2)	22 (2)	17 (3)	17 (3)	13 (5)	10 (5)	9 (5)	9 (5)	8 (6)	8 (6)	6 (7)	6 (7)	6 (7)	4 (7)	4 (7)	4 (7)	4 (7)	3 (8)	3 (8)	3 (8)	3 (8)	3 (8)	3 (8)	3 (8)	3 (8)	3 (8)	2 (9)	2 (9)	2 (9)	2 (9)	2 (9)	2 (9)	2 (9)	2 (9)	1 (9)	1 (9)	1 (9)	1 (9)	1 (9)	1 (9)	1 (9)	0 (9)	0 (9)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_gr3_soc_2ref.sas 14OCT2025 16:41

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	20 (7)	18 (8)	17 (8)	14 (8)	13 (8)	13 (8)	12 (8)	11 (8)	10 (8)	10 (8)	10 (8)	8 (8)	8 (8)	8 (8)	7 (8)	5 (9)	5 (9)	5 (9)	5 (9)	5 (9)	5 (9)	5 (9)	5 (9)	5 (9)	5 (9)	4 (10)	4 (10)	4 (10)	4 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	3 (10)	2 (10)	2 (10)	2 (10)	1 (10)	1 (10)	1 (10)	1 (10)	1 (10)	0 (10)	0 (10)
PVd	33 (0)	28 (3)	28 (3)	27 (3)	23 (3)	18 (3)	18 (3)	14 (3)	11 (3)	10 (3)	10 (3)	10 (3)	9 (3)	7 (3)	7 (3)	7 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	5 (3)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	4 (4)	3 (4)	3 (4)	2 (4)	2 (4)	2 (4)	2 (4)	2 (4)	2 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	1 (4)	0 (4)	0 (4)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_gr3_soc_2ref.sas 14OCT2025 16:41

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Metabolism and nutrition disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_gr3_soc_2ref.sas 14OCT2025 16:41

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_gr3_soc_2ref.sas 14OCT2025 16:41

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Respiratory, thoracic and mediastinal disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_gr3_soc_2ref.sas 14OCT2025 16:41

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001805

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	25 (1)	24 (1)	21 (1)	20 (1)	18 (1)	17 (1)	16 (1)	15 (1)	14 (1)	13 (1)	12 (1)	12 (1)	11 (1)	10 (1)	9 (1)	9 (1)	8 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	6 (1)	6 (1)	6 (1)	6 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)
PVd	33 (0)	30 (1)	29 (1)	28 (1)	22 (2)	18 (2)	18 (2)	14 (2)	11 (2)	10 (2)	10 (2)	10 (2)	9 (2)	7 (2)	7 (2)	7 (2)	5 (2)	5 (2)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	3 (3)	3 (3)	2 (3)	2 (3)	2 (3)	2 (3)	2 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	0 (3)	0 (3)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_gr3_soc_2ref.sas 14OCT2025 16:41

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Lymphopenia



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_gr3_socpt_2ref.sas 14OCT2025 13:45

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Cataract



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	26 (1)	25 (1)	24 (1)	21 (1)	20 (1)	18 (1)	17 (1)	16 (1)	15 (1)	14 (1)	13 (1)	11 (1)	11 (1)	10 (1)	9 (1)	8 (1)	8 (1)	7 (1)	6 (1)	6 (1)	6 (1)	6 (1)	6 (1)	6 (1)	6 (1)	5 (1)	5 (1)	5 (1)	5 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	4 (1)	3 (1)	3 (1)	3 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	18 (0)	13 (1)	10 (1)	9 (1)	8 (2)	8 (2)	7 (2)	6 (2)	6 (2)	6 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	2 (3)	2 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)	0 (3)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_gr3_socpt_2ref.sas 14OCT2025 13:45

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905

Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Corneal epithelial microcysts



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Dry eye



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Eye irritation



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	26 (0)	25 (0)	21 (1)	20 (1)	18 (1)	16 (2)	15 (2)	14 (2)	13 (2)	12 (2)	10 (2)	10 (2)	9 (2)	8 (2)	8 (2)	8 (2)	7 (2)	6 (2)	6 (2)	6 (2)	6 (2)	6 (2)	6 (2)	5 (2)	5 (2)	5 (2)	5 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	3 (2)	3 (2)	2 (2)	2 (2)	1 (2)	1 (2)	1 (2)	0 (2)	0 (2)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	18 (0)	14 (0)	11 (0)	10 (0)	10 (0)	10 (0)	9 (0)	7 (0)	7 (0)	7 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	3 (0)	3 (0)	2 (0)	2 (0)	2 (0)	2 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	0 (0)	0 (0)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_gr3_socpt_2ref.sas 14OCT2025 13:45

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Vision blurred



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual acuity reduced



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	25 (2)	24 (2)	22 (3)	20 (3)	19 (3)	18 (3)	17 (3)	16 (3)	15 (3)	14 (3)	13 (3)	11 (3)	11 (3)	10 (3)	9 (3)	8 (3)	8 (3)	7 (3)	6 (3)	6 (3)	6 (3)	6 (3)	6 (3)	6 (3)
PVd	33 (0)	31 (0)	30 (0)	29 (0)	23 (0)	18 (0)	18 (0)	14 (0)	11 (0)	10 (0)	10 (0)	10 (0)	9 (0)	7 (0)	7 (0)	7 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)

	6	5	5	5	5	4	4	4	4	4	4	4	4	4	3	2	2	2	2	1	1	1	0	0
BPd	6 (3)	5 (3)	5 (3)	5 (3)	5 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	4 (3)	3 (3)	2 (3)	2 (3)	2 (3)	2 (3)	1 (3)	1 (3)	1 (3)	0 (3)	0 (3)
PVd	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	3 (0)	3 (0)	2 (0)	2 (0)	2 (0)	2 (0)	2 (0)	2 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	1 (0)	0 (0)	0 (0)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_gr3_socpt_2ref.sas 14OCT2025 13:45

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Eye disorders
Preferred Term: Visual impairment



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Gastrointestinal disorders
Preferred Term: Diarrhoea



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions
Preferred Term: Asthenia



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Pneumonia



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	25 (2)	24 (2)	21 (4)	18 (4)	17 (4)	16 (4)	15 (4)	14 (4)	13 (4)	11 (5)	11 (5)	9 (5)	9 (5)	9 (5)	8 (5)	6 (6)	6 (6)	6 (6)	6 (6)	6 (6)	6 (6)	6 (6)	6 (6)	6 (6)	6 (6)	6 (6)	5 (6)	5 (6)	5 (6)	5 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	4 (6)	3 (6)	3 (6)	3 (6)	2 (6)	2 (6)	1 (6)	1 (6)	1 (6)	0 (6)	0 (6)
PVd	33 (0)	30 (1)	29 (1)	28 (1)	23 (1)	18 (1)	18 (1)	14 (1)	11 (1)	10 (1)	10 (1)	10 (1)	9 (1)	7 (1)	7 (1)	7 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	3 (2)	3 (2)	2 (2)	2 (2)	2 (2)	2 (2)	2 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	0 (2)	0 (2)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_gr3_socpt_2ref.sas 14OCT2025 13:45

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations
Preferred Term: Platelet count decreased



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	20 (7)	19 (7)	18 (7)	15 (7)	14 (7)	13 (7)	12 (7)	11 (7)	10 (7)	10 (7)	10 (7)	8 (7)	8 (7)	8 (7)	7 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	6 (7)	5 (7)	5 (7)	5 (7)	5 (7)	5 (7)	5 (7)	5 (7)	5 (7)	4 (7)	3 (7)	3 (7)	2 (7)	2 (7)	1 (7)	1 (7)	1 (7)	0 (7)	0 (7)
PVd	33 (0)	29 (2)	28 (2)	27 (2)	23 (2)	18 (2)	18 (2)	14 (2)	11 (2)	10 (2)	10 (2)	10 (2)	9 (2)	7 (2)	7 (2)	7 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	5 (2)	4 (3)	4 (3)	3 (3)	3 (3)	2 (3)	2 (3)	2 (3)	2 (3)	2 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	1 (3)	0 (3)	0 (3)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_gr3_socpt_2ref.sas 14OCT2025 13:45

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Metabolism and nutrition disorders
Preferred Term: Hypokalaemia



Number at Risk (Number of Events)

| | | |

Protocol: 207499
Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0001905
Graph of Kaplan Meier Curves of Time to First Maximum Grade 3 or Higher Treatment Emergent Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders
Preferred Term: Hypertension



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	25 (1)	24 (1)	21 (1)	20 (1)	18 (1)	17 (1)	16 (1)	15 (1)	14 (1)	13 (1)	12 (1)	12 (1)	11 (1)	10 (1)	9 (1)	9 (1)	8 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	7 (1)	6 (1)	6 (1)	6 (1)	6 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	4 (1)	3 (1)	3 (1)	2 (1)	2 (1)	1 (1)	1 (1)	1 (1)	0 (1)	0 (1)
PVd	33 (0)	30 (1)	29 (1)	28 (1)	22 (1)	18 (1)	18 (1)	14 (1)	11 (1)	10 (1)	10 (1)	10 (1)	9 (1)	7 (1)	7 (1)	7 (1)	5 (1)	5 (1)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	4 (2)	3 (2)	3 (2)	2 (2)	2 (2)	2 (2)	2 (2)	2 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	0 (2)	0 (2)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_gr3_socpt_2ref.sas 14OCT2025 13:45

1.4.2.5 SUE – Gesamtraten

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000605

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event - Lenalidomide and Anti-CD38 Refractory Subpopulation



Number at Risk (Events)

| | | |

1.4.2.6 SUE nach SOC und PT

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000705

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000705

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: General disorders and administration site conditions



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000705

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000705

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Investigations



Number at Risk (Number of Events)

	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48
BPd	28 (0)	27 (0)	26 (0)	25 (0)	22 (0)	21 (0)	19 (0)	18 (0)	17 (0)	16 (0)	15 (0)	14 (0)	12 (0)	12 (0)	11 (0)	10 (0)	9 (0)	9 (0)	8 (0)	7 (0)	7 (0)	7 (0)	7 (0)	7 (0)	7 (0)	6 (0)	6 (0)	6 (0)	6 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	5 (0)	4 (0)	3 (0)	3 (0)	2 (0)	2 (0)	1 (0)	1 (0)	1 (0)	0 (0)	0 (0)
PVd	33 (0)	30 (1)	30 (1)	29 (1)	23 (1)	18 (1)	18 (1)	14 (1)	11 (1)	10 (1)	10 (1)	10 (1)	9 (1)	7 (1)	7 (1)	7 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	5 (1)	4 (2)	4 (2)	3 (2)	3 (2)	2 (2)	2 (2)	2 (2)	2 (2)	2 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	1 (2)	0 (2)	0 (2)

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_ser_soc_2ref.sas 14OCT2025 13:46

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000705

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Musculoskeletal and connective tissue disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_ser_soc_2ref.sas 14OCT2025 13:46

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000705

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Respiratory, thoracic and mediastinal disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_ser_soc_2ref.sas 14OCT2025 13:46

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000705

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Vascular disorders



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.

/mnt/code/prod/tfls/f_s_aette_ser_soc_2ref.sas 14OCT2025 13:46

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000805

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia



Number at Risk (Number of Events)

| | | |

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000805

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_ser_socpt_2ref.sas 14OCT2025 13:46

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000805

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: COVID-19



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_ser_socpt_2ref.sas 14OCT2025 13:46

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000805

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Pneumonia



Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date, or last contact date.
/mnt/code/prod/tfls/f_s_aette_ser_socpt_2ref.sas 14OCT2025 13:46

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000805

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Serious Adverse Event by System Organ Class (SOC) and Preferred Term (PT) - Lenalidomide and Anti-CD38 Refractory Subpopulation

System Organ Class: Infections and infestations
Preferred Term: Upper respiratory tract infection



Number at Risk (Number of Events)

| | | |

1.4.2.7 UE, die zum Therapieabbruch führen – Gesamtraten

Protocol: 207499

Population: Safety - Global Cohort (Len. & anti-CD38 ref.) **Data as of 07JUL2025**

Figure 3.0000405

Graph of Kaplan Meier Curves of Time to First Treatment Emergent Adverse Event Leading to Permanent Discontinuation of Study Treatment - Lenalidomide and Anti-CD38 Refractory Subpopulation



Number at Risk (Events)

| | | |